{"PMC7320875": [["IntroductionThe novel coronavirus disease 2019 (COVID-19) is an RNA virus-based disease, which emerged in December of 2019 in Wuhan (China) and quickly spread worldwide.", [["coronavirus disease", "DISEASE", 22, 41], ["COVID-19", "CHEMICAL", 48, 56], ["coronavirus", "ORGANISM", 22, 33], ["COVID-19", "ORGANISM", 48, 56], ["coronavirus disease 2019 (COVID-19", "SPECIES", 22, 56], ["The novel coronavirus disease", "PROBLEM", 12, 41], ["COVID", "TEST", 48, 53], ["an RNA virus-based disease", "PROBLEM", 61, 87], ["coronavirus disease", "OBSERVATION", 22, 41], ["RNA virus", "OBSERVATION", 64, 73], ["disease", "OBSERVATION", 80, 87]]], ["Due to its high infectivity, the World Health Organization (WHO) declared it a pandemic on March 11, 2020.1 By April 1, 2020, there were nearly 800,000 confirmed cases in 205 countries and territories around the world and more than 37,000 deaths, according to the WHO reports.1 The mean mortality rate is approximately 3% in the general population but could be higher in elderly patients with chronic comorbidities, such as diabetes, hypertension, and respiratory diseases.2 In patients requiring mechanical ventilation, mortality could be up to 81%.1,2 In most COVID-19 cases, patients are asymptomatic.", [["respiratory", "ANATOMY", 452, 463], ["deaths", "DISEASE", 239, 245], ["diabetes", "DISEASE", 424, 432], ["hypertension", "DISEASE", 434, 446], ["respiratory diseases", "DISEASE", 452, 472], ["patients", "ORGANISM", 379, 387], ["patients", "ORGANISM", 478, 486], ["patients", "ORGANISM", 578, 586], ["patients", "SPECIES", 379, 387], ["patients", "SPECIES", 478, 486], ["patients", "SPECIES", 578, 586], ["its high infectivity", "PROBLEM", 7, 27], ["The mean mortality rate", "TEST", 278, 301], ["chronic comorbidities", "PROBLEM", 393, 414], ["diabetes", "PROBLEM", 424, 432], ["hypertension", "PROBLEM", 434, 446], ["respiratory diseases", "PROBLEM", 452, 472], ["mechanical ventilation", "TREATMENT", 497, 519], ["asymptomatic", "PROBLEM", 591, 603], ["high infectivity", "OBSERVATION", 11, 27], ["mean", "OBSERVATION_MODIFIER", 282, 286], ["higher", "OBSERVATION_MODIFIER", 361, 367], ["chronic", "OBSERVATION_MODIFIER", 393, 400], ["comorbidities", "OBSERVATION", 401, 414], ["diabetes", "OBSERVATION", 424, 432], ["hypertension", "OBSERVATION", 434, 446], ["respiratory diseases", "OBSERVATION", 452, 472], ["mechanical ventilation", "OBSERVATION", 497, 519], ["asymptomatic", "OBSERVATION", 591, 603]]], ["However, the most commonly reported symptoms are mild, ranging from fever (83-98%), cough (76-82%), and minimal respiratory distress to shortness of breath (31-55%), oxygen saturation <93%, and acute respiratory distress syndrome requiring mechanic ventilation.1, 2, 3", [["respiratory", "ANATOMY", 112, 123], ["respiratory", "ANATOMY", 200, 211], ["fever", "DISEASE", 68, 73], ["cough", "DISEASE", 84, 89], ["respiratory distress", "DISEASE", 112, 132], ["shortness of breath", "DISEASE", 136, 155], ["oxygen", "CHEMICAL", 166, 172], ["respiratory distress syndrome", "DISEASE", 200, 229], ["oxygen", "CHEMICAL", 166, 172], ["oxygen", "SIMPLE_CHEMICAL", 166, 172], ["symptoms", "PROBLEM", 36, 44], ["fever", "PROBLEM", 68, 73], ["cough", "PROBLEM", 84, 89], ["minimal respiratory distress", "PROBLEM", 104, 132], ["shortness of breath", "PROBLEM", 136, 155], ["oxygen saturation", "TEST", 166, 183], ["acute respiratory distress syndrome", "PROBLEM", 194, 229], ["mechanic ventilation", "TREATMENT", 240, 260], ["mild", "OBSERVATION_MODIFIER", 49, 53], ["ranging", "OBSERVATION_MODIFIER", 55, 62], ["minimal", "OBSERVATION_MODIFIER", 104, 111], ["respiratory distress", "OBSERVATION", 112, 132], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["respiratory distress", "OBSERVATION", 200, 220], ["syndrome", "OBSERVATION", 221, 229], ["mechanic ventilation", "OBSERVATION", 240, 260]]]], "PMC7148905": [["IntroductionTourism is a spatially selective activity that is clustered in relatively compact areas focused around shopping and business precincts or anchored by primary attractions (Tunbridge and Ashworth 1996).", [["spatially", "OBSERVATION_MODIFIER", 25, 34], ["selective", "OBSERVATION_MODIFIER", 35, 44], ["activity", "OBSERVATION_MODIFIER", 45, 53]]], ["The degree of spatial selectivity is especially noticeable in a place like Hong Kong, where the Special Administrative Region\u2019s (SAR) mountainous topography dictates that all development is concentrated tightly along the coastal fringes of Victoria Harbor, on reclaimed land, or in bedroom suburbs located in lowland areas of the New Territories (HKY 2001).", [["degree", "OBSERVATION_MODIFIER", 4, 10], ["spatial selectivity", "OBSERVATION", 14, 33], ["coastal fringes", "OBSERVATION", 221, 236], ["lowland", "ANATOMY_MODIFIER", 309, 316], ["New", "OBSERVATION_MODIFIER", 330, 333]]], ["While many people consider Hong Kong to be one of the world\u2019s most densely populated cities, in reality about three quarters of its 1,092 sq km landmass is undeveloped and almost 40% of it is gazetted as country park (AFCD 2004).", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17], ["densely", "OBSERVATION_MODIFIER", 67, 74], ["populated", "OBSERVATION", 75, 84]]], ["Most of the undeveloped land can be found in the New Territories or on outlying islands.IntroductionThese rural areas have largely missed out on the economic miracle that is Hong Kong, in general, and on the tourism miracle, in particular.", [["New", "OBSERVATION_MODIFIER", 49, 52], ["rural", "OBSERVATION_MODIFIER", 106, 111]]], ["Many of the villages in the New Territories have suffered depopulation and economic stagnation.", [["economic stagnation", "PROBLEM", 75, 94], ["New", "OBSERVATION_MODIFIER", 28, 31], ["Territories", "ANATOMY_MODIFIER", 32, 43], ["suffered", "OBSERVATION_MODIFIER", 49, 57], ["depopulation", "OBSERVATION", 58, 70], ["economic", "OBSERVATION_MODIFIER", 75, 83], ["stagnation", "OBSERVATION_MODIFIER", 84, 94]]], ["Within one generation, formerly vibrant fishing and farming communities settled by ethnic minority Hakka and Tanka people for more than 300 years have entered steep decline.", [["people", "SPECIES", 115, 121], ["vibrant", "OBSERVATION_MODIFIER", 32, 39], ["fishing", "OBSERVATION", 40, 47]]], ["Ghost towns, decaying villages occupied by remnant populations, and abandoned farmland and aquaculture operations are now the norm in many areas.", [["remnant populations", "PROBLEM", 43, 62], ["abandoned farmland", "TREATMENT", 68, 86], ["aquaculture operations", "TREATMENT", 91, 113], ["remnant", "OBSERVATION_MODIFIER", 43, 50], ["populations", "OBSERVATION_MODIFIER", 51, 62], ["aquaculture operations", "OBSERVATION", 91, 113]]], ["These areas have also undergone economic transformation to become part of the pleasure periphery, providing nature-based, camping, and small-scaled domestic tourism opportunities for city dwellers wishing to escape crowded urban conditions.IntroductionThis paper presents a study of those individuals who have chosen to remain on one such peripheral island, Tap Mun, and who now own and operate small businesses serving tourists.", [["economic transformation", "PROBLEM", 32, 55], ["economic transformation", "OBSERVATION", 32, 55], ["small", "OBSERVATION_MODIFIER", 135, 140], ["small", "OBSERVATION_MODIFIER", 395, 400], ["businesses", "OBSERVATION", 401, 411]]], ["Tap Mun is a small island (1.7 sq km) located off the northeast coast of Hong Kong (Figure 1).", [["Tap", "PROTEIN", 0, 3], ["a small island", "PROBLEM", 11, 25], ["Mun", "OBSERVATION_MODIFIER", 4, 7], ["small", "OBSERVATION_MODIFIER", 13, 18], ["island", "OBSERVATION_MODIFIER", 19, 25]]], ["However, it began to decline in the 60s as water pollution, a decline in farming, and few opportunities for young people saw its population drift into the city or emigrate overseas.", [["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120]]], ["Today, perhaps as few as 100 mostly elderly people live there permanently.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50]]], ["The island is a popular hiking and camping destination for Hong Kong residents.", [["island", "OBSERVATION_MODIFIER", 4, 10], ["popular", "OBSERVATION_MODIFIER", 16, 23]]], ["It is also a popular spot for charter tours that deposit upwards of 2,000 people on any given Sunday during the summer season for sightseeing and a seafood dinner.Study Method ::: Tourism and the peripheryA qualitative method was adopted, as it seeks to understand phenomena in context-specific settings and, in addition, seeks insights, understanding, and depth of knowledge Hoepfl, 1997, Walle, 1997.", [["people", "SPECIES", 74, 80]]], ["In order to capture the lived experience of participants, naturalistic inquiry using a series of semi-structured interviews was chosen, supplemented by site visits and field inspections.", [["participants", "SPECIES", 44, 56]]], ["Notes were transcribed into English.Study Method ::: Tourism and the peripheryDeveloping a relationship with study participants is essential in this type of study in order to break down barriers and gain deeper insights into lived experiences (Hannabuss 1996).", [["participants", "SPECIES", 115, 127]]], ["Sixteen individuals participated in the study.", [["the study", "TEST", 36, 45]]], ["Since the goal of the study was to examine residents involved in tourism, the authors purposefully did not interview any residents without an interest in visitation.", [["the study", "TEST", 18, 27]]], ["Notably, the names of respondents have been changed to ensure confidentiality.Study Method ::: Tourism and the peripheryBecause qualitative research by nature involves an emergent structure, the research design and questions evolved as the study progressed (Hoepfl 1997).", [["periphery", "ANATOMY", 111, 120], ["the study", "TEST", 236, 245], ["periphery", "ANATOMY_MODIFIER", 111, 120]]], ["The first round, for example, focused on gathering oral histories of the island, and understanding tourism activity and the individual\u2019s own involvement in this sector.", [["oral", "ANATOMY", 51, 55], ["oral", "ORGANISM_SUBDIVISION", 51, 55], ["tourism activity", "OBSERVATION", 99, 115]]], ["Subsequent interviews sought clarification and additional details about why residents remained on the islands, their reasons for becoming involved, and other relevant information.Study Method ::: Tourism and the peripheryThis style of inquiry relies on the subjective evaluation of spoken words and not on the quantitative evaluation of numbers.", [["periphery", "ANATOMY", 212, 221], ["the subjective evaluation", "TEST", 253, 278], ["the quantitative evaluation", "TEST", 306, 333], ["periphery", "ANATOMY_MODIFIER", 212, 221]]], ["In addition, there is a risk of cultural bias, especially when one of the authors comes from a different ethnic and cultural background than the study participants.", [["participants", "SPECIES", 151, 163], ["cultural bias", "PROBLEM", 32, 45], ["the study", "TEST", 141, 150]]], ["Importantly, as well, the stories told by participants were largely consistent, enabling cross-verification of ideas.", [["participants", "SPECIES", 42, 54]]], ["The inclusion of a local Hong Kong Chinese author helped minimize cultural bias.Tap Mun ::: Tourism and the peripheryTap Mun, located in the northeast of the New Territories, is a remote island accessible only by ferry or water-taxi (Figure 1).", [["Tap", "PROTEIN", 80, 83], ["the peripheryTap Mun", "TREATMENT", 104, 124], ["periphery", "OBSERVATION_MODIFIER", 108, 117], ["Tap Mun", "OBSERVATION", 117, 124], ["northeast", "ANATOMY_MODIFIER", 141, 150], ["New", "OBSERVATION_MODIFIER", 158, 161], ["Territories", "OBSERVATION_MODIFIER", 162, 173], ["remote", "OBSERVATION_MODIFIER", 180, 186], ["island", "OBSERVATION", 187, 193]]], ["People living here are either of Tanka or Hakka descent.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The Tanka are thought to be descended from the original inhabitants of Hong Kong Rodwell, 1992, Lee and DeStefano, 2002.", [["thought to be", "UNCERTAINTY", 14, 27]]], ["The influx of Punti people (the ancestors of the modern Cantonese) in the 1100s supplanted the Tanka and pushed them to the coastal margins.", [["Punti people", "ORGANISM", 14, 26], ["people", "SPECIES", 20, 26], ["coastal", "OBSERVATION_MODIFIER", 124, 131], ["margins", "OBSERVATION_MODIFIER", 132, 139]]], ["Now outnumbered and often scorned, they faded into Hong Kong\u2019s sea-hazed background (1995:30)\u201d.Tap Mun ::: Tourism and the peripheryThe situation remained unchanged until the invocation of two Coastal Evacuation Orders in 1661 and 1664, forced all inhabitants to be evacuated 50 km inland.", [["periphery", "ANATOMY", 123, 132], ["Tap", "PROTEIN", 95, 98], ["periphery", "ANATOMY_MODIFIER", 123, 132], ["unchanged", "OBSERVATION_MODIFIER", 155, 164]]], ["The coast became a desolate wasteland as it was turned into a military zone (Lee and DeStefano 2002).", [["a desolate wasteland", "TREATMENT", 17, 37]]], ["The order was rescinded in 1669, but because most of the evacuees had perished during their period of forced eviction, repopulation was slow and sporadic.", [["forced eviction", "PROBLEM", 102, 117], ["sporadic", "PROBLEM", 145, 153]]], ["In response the Manchu rulers invited people from outside the region to migrate and the Hakka, people who had moved from northern China some generations earlier, responded.", [["people", "ORGANISM", 38, 44], ["people", "ORGANISM", 95, 101], ["people", "SPECIES", 38, 44], ["people", "SPECIES", 95, 101]]], ["The term Hakka is somewhat derogatory and literally means \u201cguest family,\u201d in reference to their outcast status in their adopted homeland of Southern China.", [["Hakka", "CHEMICAL", 9, 14]]], ["According to Lee and DeStefano the Hakka were a \u201cpeople proud of their language and traditions [and] they did not assimilate themselves with the mainstream culture of Southern China.", [["people", "SPECIES", 49, 55]]], ["As a result \u201cpartly to preserve their own culture, but mainly to protect themselves from violent acts of xenophobia, the Hakka tended to live away from mainstream populations on poorer lands\u201d (2002:53).", [["xenophobia", "DISEASE", 105, 115], ["their own culture", "TEST", 32, 49], ["xenophobia", "PROBLEM", 105, 115]]], ["The only land available to them was found on hillsides and other marginal areas leased from the Cantonese (Hung 1998), placing them in a socially inferior position economically indebted to the dominant cultural community (Dudgeon and Corlett 1994).", [["marginal", "OBSERVATION_MODIFIER", 65, 73], ["areas", "OBSERVATION_MODIFIER", 74, 79]]], ["Thus, the Hakka and Tanka inhabitants found themselves relegated to the geographical, social, and political margins, where they coexisted with some enmity with the dominant Cantonese population (Welsh 1997), continuing to speak their own dialects and practicing their own traditions.", [["the Hakka and Tanka inhabitants", "PROBLEM", 6, 37]]], ["Many elderly Hakka and Tanka still speak their own dialects.Tap Mun ::: Tourism and the peripheryUntil the early 60s, Tap Mun was a vibrant fishing village with a population of 5,000 people.", [["periphery", "ANATOMY", 88, 97], ["people", "ORGANISM", 183, 189], ["Tap", "PROTEIN", 60, 63], ["Tap", "PROTEIN", 118, 121], ["people", "SPECIES", 183, 189], ["periphery", "ANATOMY_MODIFIER", 88, 97]]], ["It sold tools for fishing, food, and other stuffs that were needed by those fishing ships.\u201d", [["other stuffs", "TREATMENT", 37, 49]]], ["But the winds of social and economic change were blowing as Hong Kong modernized quickly in the 60s.", [["winds", "OBSERVATION_MODIFIER", 8, 13]]], ["Tap Mun, along with many other isolated islands, was on the cusp of rapid transformation leading to decline as traditional agriculture and fishing activities were abandoned while the region underwent its own industrial revolution.", [["Tap", "PROTEIN", 0, 3], ["Tap Mun", "TREATMENT", 0, 7], ["many other isolated islands", "PROBLEM", 20, 47], ["rapid transformation", "PROBLEM", 68, 88], ["Mun", "OBSERVATION_MODIFIER", 4, 7], ["isolated", "OBSERVATION_MODIFIER", 31, 39], ["islands", "OBSERVATION", 40, 47], ["rapid transformation", "OBSERVATION", 68, 88]]], ["Superficially, rural life seemed traditional \u2026 but the country was threatened as never before by the city\u2019s natural expansion\u201d (Stokes 1995:114).Tap Mun ::: Tourism and the peripheryDecline accelerated in the 70s as a combination of water pollution, emigration to the United Kingdom, and few opportunities for young people saw a massive outflow of residents.", [["periphery", "ANATOMY", 173, 182], ["people", "ORGANISM", 316, 322], ["Tap", "PROTEIN", 145, 148], ["people", "SPECIES", 316, 322], ["periphery", "ANATOMY_MODIFIER", 173, 182], ["water pollution", "OBSERVATION", 233, 248], ["massive", "OBSERVATION_MODIFIER", 329, 336], ["outflow", "OBSERVATION_MODIFIER", 337, 344]]], ["Development of new bedroom suburbs in the New Territories led to more outmigration as young people left to pursue their education and stayed to take up jobs in factories, while many of elderly people chose the more comfortable retirement setting of a modern urban city.Tap Mun ::: Tourism and the peripheryParticipants indicated that by the 70s the Hakka had stopped farming.", [["Hakka", "CHEMICAL", 349, 354], ["people", "ORGANISM", 92, 98], ["people", "ORGANISM", 193, 199], ["Tap", "PROTEIN", 269, 272], ["people", "SPECIES", 92, 98], ["people", "SPECIES", 193, 199], ["new", "OBSERVATION_MODIFIER", 15, 18], ["New", "OBSERVATION_MODIFIER", 42, 45]]], ["Most Tanka also stopped fishing due to the combination of a series of Red Tides and the introduction of deep sea commercial net fishing operations that depleted onshore fish stocks.", [["fish", "ORGANISM_SUBDIVISION", 169, 173], ["Red Tides", "TREATMENT", 70, 79], ["deep sea commercial net fishing operations", "TREATMENT", 104, 146]]], ["The New Fishermen\u2019s Village was established in 1964 by a group of villagers who migrated to New Zealand and remitted money.", [["New", "OBSERVATION_MODIFIER", 4, 7]]], ["Between then and now, buildings have been abandoned, and many have collapsed or are in a structurally unsound condition.Tap Mun ::: Tourism and the peripheryToday, Tap Mun is a quiet island with perhaps as few as 100 permanent residents.", [["periphery", "ANATOMY", 148, 157], ["Tap", "PROTEIN", 120, 123], ["Tap", "PROTEIN", 164, 167], ["collapsed", "OBSERVATION", 67, 76], ["periphery", "ANATOMY_MODIFIER", 148, 157]]], ["No one knows how many people live here exactly, as census data do not discriminate to such a small region.", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28], ["small", "OBSERVATION_MODIFIER", 93, 98]]], ["Most people live in the New Fishermen\u2019s Village or along Tap Mun Hoi Pong Street in the original village.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["Much of the rest of the structures are abandoned and decaying (Figure 2), which add to its appeal as a contrast to ultramodern, high-rise Hong Kong.", [["abandoned", "OBSERVATION", 39, 48]]], ["The primary school closed two to three years ago, there is no home postal delivery service, a floating medical clinic visits two mornings a week, the police post is manned only on weekends, and supplies must be boated in as there are no retail or large grocery stores.Why Residents Remain ::: Tourism and the peripherySense of kinship and the strong attachment to place are seen as traditional virtues among Chinese people.", [["periphery", "ANATOMY", 309, 318], ["people", "ORGANISM", 416, 422], ["people", "SPECIES", 416, 422], ["no", "UNCERTAINTY", 59, 61], ["large", "OBSERVATION_MODIFIER", 247, 252], ["grocery stores", "OBSERVATION", 253, 267], ["periphery", "ANATOMY_MODIFIER", 309, 318]]], ["One elderly Hakka women stated that her family has been living on the island for five generations, while the wife of a food stall owner traced her family tree back six generations.", [["women", "ORGANISM", 18, 23], ["women", "SPECIES", 18, 23]]], ["Mrs. Li a Tanka women of about 70 said that her family has lived on the island for 13 generations.", [["women", "ORGANISM", 16, 21], ["women", "SPECIES", 16, 21]]], ["Yet, this generation is the last one that has retained such a strong sense of place, for in each case, the children have either emigrated overseas or moved to suburbs in Kowloon or the New Territories.", [["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115]]], ["In spite of the strong Chinese tradition of children looking after their parents, few residents interviewed were interested in moving in with their families.", [["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52]]], ["The Lai couple is typical.", [["Lai", "OBSERVATION_MODIFIER", 4, 7]]], ["They visit for short periods of time, but become restless and complain of the lack of fresh air.", [["restless", "DISEASE", 49, 57], ["restless", "PROBLEM", 49, 57], ["fresh air", "PROBLEM", 86, 95]]], ["Another woman continues to stay on the island while her husband and daughters live in the New Territories.", [["woman", "ORGANISM", 8, 13], ["woman", "SPECIES", 8, 13]]], ["The husband of a water-taxi operator stated that they have chosen not to live with their children in a public housing estate because they are accustomed to the simple life of the island.", [["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97]]], ["Another woman added, \u201cit is just free and secure to live here, I can just wander around and leave my house open without any locks.", [["woman", "ORGANISM", 8, 13], ["woman", "SPECIES", 8, 13]]], ["I tried to live with my children for a few days, but I was just nervous and dared not to leave the house.", [["children", "ORGANISM", 24, 32], ["nervous", "ANATOMICAL_SYSTEM", 64, 71], ["children", "SPECIES", 24, 32]]], ["I have heard of too many cases about elderly people being cheated.\u201d", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["Another interviewee, who was sitting in the backyard talking to three other Hakka women, said, \u201cvillagers here are just nice and friendly.", [["women", "ORGANISM", 82, 87], ["women", "SPECIES", 82, 87]]], ["We can entertain ourselves here while when I was living outside with my children, I got a feeling of being caught in a cage.", [["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80]]], ["By staying, they can enjoy a relatively simple and stress free lifestyle.Tourism on Tap Mun ::: Tourism and the peripheryThe tranquility of Tap Mun is disrupted when public ferries and charter tour boats disgorge thousands of tourists on a busy weekend for hiking, camping, sightseeing, and a seafood meal.", [["periphery", "ANATOMY", 112, 121], ["Tap", "PROTEIN", 84, 87], ["Tap", "PROTEIN", 140, 143], ["periphery", "ANATOMY_MODIFIER", 112, 121], ["Tap Mun", "OBSERVATION_MODIFIER", 140, 147]]], ["No record of arrivals is kept, but on Sundays during the peak season, it is estimated that more 2,000 people visit.", [["people", "SPECIES", 102, 108]]], ["In addition, the regular ferry service frequency is doubled and the number of available water-taxis usually triples.Tourism on Tap Mun ::: Tourism and the peripheryTourism began in the late 70s, when newspapers started to publish articles about the outdoor recreational opportunities available here.", [["Tap", "PROTEIN", 127, 130], ["periphery", "OBSERVATION_MODIFIER", 155, 164], ["Tourism", "OBSERVATION_MODIFIER", 164, 171]]], ["Interest grew slowly and the island\u2019s economy evolved organically from one based on primary production to one reliant on tourism and recreation.", [["slowly", "OBSERVATION_MODIFIER", 14, 20]]], ["These tours are now marketed to residents of public housing estates, through district councilors or among some private organizations like aged-care centers.Tourism on Tap Mun ::: Tourism and the peripheryThe Hong Kong Tourism Board includes Tap Mun in its promotional literature targeted at the international marketplace, but places much more emphasis on other more accessible islands with better infrastructure that offer the tourist more activities.", [["Tap", "PROTEIN", 167, 170], ["Tap", "PROTEIN", 241, 244], ["Tap Mun", "TREATMENT", 241, 248], ["islands", "OBSERVATION", 377, 384]]], ["In fact, its website promoting outlying islands (HKTB 2005a) makes no mention of Tap Mun and instead encourages people to visit islands located a short ferry ride from central Hong Kong.", [["people", "ORGANISM", 112, 118], ["Tap", "PROTEIN", 81, 84], ["people", "SPECIES", 112, 118]]], ["A feature article on outer islands (HKTB nd) mentions it in passing but again encourages people to visit other islands, while the \u201cCity Gardens and Parks\u201d section (HKTB 2005b) indicates that a twice-daily 312 hour circular ferry route takes people to the island.Tourism on Tap Mun ::: Tourism and the peripherySome inbound tour operators have tried to offer day-hiking, kayaking, bird-watching, seafood tours, and even helicopter/bus tours but with limited success.", [["outer islands", "ANATOMY", 21, 34], ["periphery", "ANATOMY", 301, 310], ["people", "ORGANISM", 89, 95], ["people", "ORGANISM", 241, 247], ["Tap", "PROTEIN", 273, 276], ["people", "SPECIES", 89, 95], ["people", "SPECIES", 241, 247], ["circular ferry route", "TREATMENT", 214, 234], ["periphery", "ANATOMY_MODIFIER", 301, 310]]], ["One nature-based operator indicated he ran a \u201chand full\u201d of helicopter trips before abandoning the idea.", [["hand", "ANATOMY", 46, 50], ["helicopter trips", "TREATMENT", 60, 76]]], ["His kayak and coral trips were more popular, but catered to small numbers.", [["His kayak", "TEST", 0, 9]]], ["His capacity was a maximum of seven people per trip.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42]]], ["Another operator indicated that lack of demand led them to abandon their tours to Tap Mun.", [["Tap", "PROTEIN", 82, 85]]], ["Its remoteness, lack of infrastructure, and preponderance of other islands offering a better quality experience result in limited interest in the provision of commercial tours targeted at inbound tourists.Tourism on Tap Mun ::: Tourism and the peripheryHowever, thousands of local residents may visit on a Sunday, and hundreds of others will go camping.", [["Tap", "PROTEIN", 216, 219], ["infrastructure", "PROBLEM", 24, 38], ["remoteness", "OBSERVATION_MODIFIER", 4, 14], ["infrastructure", "OBSERVATION", 24, 38], ["periphery", "OBSERVATION_MODIFIER", 244, 253]]], ["Tour package prices range from US$10 to $15 (HK$80 to $120) per person.", [["person", "SPECIES", 64, 70]]], ["Most of the tour fee is retained by the tour operator or ferry company, with local restaurants receiving US$4 or less per capita for a meal that consists of fresh fish, prawns, calamari, shellfish, a vegetable dish, rice, and tea.", [["tea", "ANATOMY", 226, 229], ["vegetable dish, rice, and tea", "CHEMICAL", 200, 229], ["prawns", "ORGANISM_SUBDIVISION", 169, 175], ["rice", "ORGANISM_SUBDIVISION", 216, 220], ["tea", "ORGANISM_SUBDIVISION", 226, 229], ["rice", "SPECIES", 216, 220], ["rice", "SPECIES", 216, 220], ["calamari", "TREATMENT", 177, 185]]], ["Prices are kept low due to the combination of intense competition between tour operators, competition between islands seeking to attract groups, and a primary market comprised mostly of low income, public housing dwellers.", [["Prices", "TREATMENT", 0, 6]]], ["Narrow margins and low profitability dictate these businesses must survive on volume.Tourism on Tap Mun ::: Tourism and the peripheryThe offering of sightseeing tours targeted at local residents is a uniquely Hong Kong phenomenon.", [["periphery", "ANATOMY", 124, 133], ["Tap", "PROTEIN", 96, 99], ["Narrow margins and low profitability", "PROBLEM", 0, 36], ["margins", "OBSERVATION_MODIFIER", 7, 14], ["low profitability", "OBSERVATION_MODIFIER", 19, 36], ["periphery", "ANATOMY_MODIFIER", 124, 133]]], ["These tours have been available for many years but grew in popularity during the 2003 SARS (Severe Acute Respiratory Syndrome) crisis when inbound tour operators began to target local residents as a means of generating cash flow during a time when international arrivals collapsed.", [["SARS", "DISEASE", 86, 90], ["Acute Respiratory Syndrome", "DISEASE", 99, 125], ["Severe Acute Respiratory Syndrome)", "PROBLEM", 92, 126], ["crisis", "PROBLEM", 127, 133], ["Severe", "OBSERVATION_MODIFIER", 92, 98], ["Acute", "OBSERVATION_MODIFIER", 99, 104], ["Respiratory Syndrome", "OBSERVATION", 105, 125], ["collapsed", "OBSERVATION", 271, 280]]], ["Car ownership rates are low (less than six cars per 100 residents, compared with more than 60 cars per 100 US residents).", [["Car ownership rates", "TEST", 0, 19], ["low", "OBSERVATION_MODIFIER", 24, 27]]], ["In jurisdictions where car ownership rates are higher, people will self-drive to these attractions, but in Hong Kong, tour operators fill the niche.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61]]], ["Second, the HKSAR consists of Hong Kong Island, Kowloon, and the New Territories which are connected to the China Mainland and some 235 offshore islands.", [["HKSAR", "DNA", 12, 17], ["Kowloon", "TREATMENT", 48, 55], ["New", "OBSERVATION_MODIFIER", 65, 68], ["Territories", "ANATOMY_MODIFIER", 69, 80], ["China Mainland", "ANATOMY", 108, 122], ["235", "OBSERVATION_MODIFIER", 132, 135], ["offshore islands", "OBSERVATION", 136, 152]]], ["Many of these islands have remnant villages and restaurants or offer a variety of nature based recreational opportunities which are appealing to local residents wishing to escape high density, high rise urban landscapes.Tourism on Tap Mun ::: Tourism and the peripheryPackage and independent tourists behave differently and exert different impacts on the community.", [["periphery", "ANATOMY", 259, 268], ["Tap", "PROTEIN", 231, 234], ["high density", "PROBLEM", 179, 191], ["islands", "OBSERVATION_MODIFIER", 14, 21], ["remnant", "OBSERVATION_MODIFIER", 27, 34], ["villages", "OBSERVATION", 35, 43], ["high density", "OBSERVATION_MODIFIER", 179, 191], ["periphery", "ANATOMY_MODIFIER", 259, 268]]], ["Package tours include Tap Mun as one of two or three stops.", [["Tap", "PROTEIN", 22, 25], ["Tap Mun", "TREATMENT", 22, 29]]], ["The length of stay is short and focused around lunch.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The disembarking of chartered ferries results in crowding on the pier and along the narrow street running through the village, sometimes taking more than five minutes for a group to snake its way through the narrow streets.", [["ferries", "MULTI-TISSUE_STRUCTURE", 30, 37], ["crowding on the pier", "PROBLEM", 49, 69], ["crowding", "OBSERVATION", 49, 57], ["narrow", "OBSERVATION_MODIFIER", 84, 90]]], ["Kirby (2003) describes the scene he encountered during his visit:It was Sunday, and at Tap Mun (Grass Island), the loudhailers and pink flags were out in full force, flocks of quickie-style tourist groups arriving on quarter-hourly ferries.", [["the loudhailers", "TREATMENT", 111, 126], ["pink flags", "PROBLEM", 131, 141], ["pink flags", "OBSERVATION", 131, 141]]], ["We stopped for noodles, and then followed the friendly masses along concrete paths that wound through abandoned villages, past a refurbished temple and through groves of traditional jinta graves \u2026", [["wound", "ANATOMY", 88, 93], ["wound", "PATHOLOGICAL_FORMATION", 88, 93], ["the friendly masses", "PROBLEM", 42, 61], ["traditional jinta graves", "PROBLEM", 170, 194], ["masses", "OBSERVATION", 55, 61], ["wound", "ANATOMY", 88, 93]]]], "PMC7120566": [["IntroductionInfluenza viruses belong to the Orthomyxoviridae family, which is categorized into three genera, namely influenzavirus A, B, and C. Influenzavirus A comprise several subtypes based on the unique combination of two surface proteins, hemagglutinin (HA) and neuraminidase (NA).", [["surface", "ANATOMY", 226, 233], ["Influenza viruses", "DISEASE", 12, 29], ["Influenza viruses", "ORGANISM", 12, 29], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 44, 60], ["influenzavirus A", "ORGANISM", 116, 132], ["B", "GENE_OR_GENE_PRODUCT", 134, 135], ["C. Influenzavirus A", "ORGANISM", 141, 160], ["hemagglutinin (HA)", "GENE_OR_GENE_PRODUCT", 244, 262], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 267, 280], ["surface proteins", "PROTEIN", 226, 242], ["hemagglutinin", "PROTEIN", 244, 257], ["HA", "PROTEIN", 259, 261], ["neuraminidase", "PROTEIN", 267, 280], ["NA", "PROTEIN", 282, 284], ["C. Influenzavirus", "SPECIES", 141, 158], ["C. Influenzavirus A", "SPECIES", 141, 160], ["IntroductionInfluenza viruses", "PROBLEM", 0, 29], ["two surface proteins", "TREATMENT", 222, 242], ["hemagglutinin (HA)", "TREATMENT", 244, 262], ["neuraminidase (NA)", "TREATMENT", 267, 285]]], ["The seasonal influenza A virus infects millions of individuals each year, with the highest risk of complications occurring in young, elderly, and immunocompromised patients.", [["influenza A virus", "DISEASE", 13, 30], ["seasonal influenza A virus", "ORGANISM", 4, 30], ["patients", "ORGANISM", 164, 172], ["influenza A virus", "SPECIES", 13, 30], ["patients", "SPECIES", 164, 172], ["seasonal influenza A virus", "SPECIES", 4, 30], ["The seasonal influenza A virus", "PROBLEM", 0, 30], ["complications", "PROBLEM", 99, 112], ["seasonal", "OBSERVATION_MODIFIER", 4, 12], ["influenza", "OBSERVATION", 13, 22], ["complications", "OBSERVATION", 99, 112]]], ["For example, influenzavirus A can lead to fatal encephalopathy in infants and pneumonia in the elderly.", [["encephalopathy", "DISEASE", 48, 62], ["pneumonia", "DISEASE", 78, 87], ["influenzavirus A", "ORGANISM", 13, 29], ["infants", "ORGANISM", 66, 73], ["infants", "SPECIES", 66, 73], ["influenzavirus A", "PROBLEM", 13, 29], ["fatal encephalopathy in infants", "PROBLEM", 42, 73], ["pneumonia", "PROBLEM", 78, 87], ["fatal", "OBSERVATION_MODIFIER", 42, 47], ["encephalopathy", "OBSERVATION", 48, 62], ["pneumonia", "OBSERVATION", 78, 87]]]], "PMC7169265": [["IntroductionCiclosporin has been used for many years in the treatment of feline hypersensitivity dermatitis at various doses, generally ranging from 5 to 10 mg/kg.1, 2, 3, 4 The dose of 7 mg/kg given daily has recently been tested in a randomized, blinded parallel group, placebo\u2010controlled study and was shown to be efficacious and well tolerated.5 In cats with head and neck excoriations, self\u2010induced alopecia, eosinophilic plaque and/or miliary dermatitis, the administration of 7 mg/kg ciclosporin daily for 6 weeks resulted in a decrease in total lesion and owner\u2010assessed pruritus severity scores.", [["head", "ANATOMY", 363, 367], ["neck", "ANATOMY", 372, 376], ["eosinophilic plaque", "ANATOMY", 414, 433], ["lesion", "ANATOMY", 553, 559], ["IntroductionCiclosporin", "CHEMICAL", 0, 23], ["feline hypersensitivity dermatitis", "DISEASE", 73, 107], ["head and neck excoriations", "DISEASE", 363, 389], ["alopecia", "DISEASE", 404, 412], ["eosinophilic plaque", "DISEASE", 414, 433], ["miliary dermatitis", "DISEASE", 441, 459], ["ciclosporin", "CHEMICAL", 491, 502], ["pruritus", "DISEASE", 579, 587], ["IntroductionCiclosporin", "CHEMICAL", 0, 23], ["ciclosporin", "CHEMICAL", 491, 502], ["IntroductionCiclosporin", "SIMPLE_CHEMICAL", 0, 23], ["feline", "ORGANISM", 73, 79], ["cats", "ORGANISM", 353, 357], ["head", "ORGANISM_SUBDIVISION", 363, 367], ["neck", "ORGANISM_SUBDIVISION", 372, 376], ["eosinophilic plaque", "PATHOLOGICAL_FORMATION", 414, 433], ["ciclosporin", "SIMPLE_CHEMICAL", 491, 502], ["feline", "SPECIES", 73, 79], ["cats", "SPECIES", 353, 357], ["IntroductionCiclosporin", "TREATMENT", 0, 23], ["feline hypersensitivity dermatitis", "PROBLEM", 73, 107], ["placebo\u2010controlled study", "TEST", 272, 296], ["head and neck excoriations", "PROBLEM", 363, 389], ["self\u2010induced alopecia", "PROBLEM", 391, 412], ["eosinophilic plaque", "PROBLEM", 414, 433], ["miliary dermatitis", "PROBLEM", 441, 459], ["ciclosporin", "TREATMENT", 491, 502], ["a decrease in total lesion", "PROBLEM", 533, 559], ["owner\u2010assessed pruritus severity scores", "PROBLEM", 564, 603], ["feline hypersensitivity dermatitis", "OBSERVATION", 73, 107], ["head", "ANATOMY", 363, 367], ["neck", "ANATOMY", 372, 376], ["excoriations", "OBSERVATION", 377, 389], ["alopecia", "OBSERVATION", 404, 412], ["eosinophilic", "OBSERVATION_MODIFIER", 414, 426], ["plaque", "OBSERVATION", 427, 433], ["miliary", "OBSERVATION_MODIFIER", 441, 448], ["dermatitis", "OBSERVATION", 449, 459], ["decrease", "OBSERVATION_MODIFIER", 535, 543], ["total", "OBSERVATION_MODIFIER", 547, 552], ["lesion", "OBSERVATION", 553, 559]]], ["In cats receiving the 7 mg/kg daily dose, the most common adverse events were mild gastrointestinal disorders.", [["gastrointestinal", "ANATOMY", 83, 99], ["gastrointestinal disorders", "DISEASE", 83, 109], ["cats", "ORGANISM", 3, 7], ["gastrointestinal", "ORGANISM_SUBDIVISION", 83, 99], ["cats", "SPECIES", 3, 7], ["mild gastrointestinal disorders", "PROBLEM", 78, 109], ["mild", "OBSERVATION_MODIFIER", 78, 82], ["gastrointestinal", "ANATOMY", 83, 99], ["disorders", "OBSERVATION", 100, 109]]], ["That dose\u2010determination study was aimed at establishing an efficacious and safe dose.", [["That dose\u2010determination study", "TEST", 0, 29]]], ["Dosing duration was limited to 6 weeks and did not address the long\u2010term use of ciclosporin to treat feline hypersensitivity dermatitis.IntroductionIn cats, limited information is available about long\u2010term efficacy and safety of ciclosporin.", [["ciclosporin", "CHEMICAL", 80, 91], ["feline hypersensitivity dermatitis", "DISEASE", 101, 135], ["ciclosporin", "CHEMICAL", 229, 240], ["ciclosporin", "CHEMICAL", 80, 91], ["ciclosporin", "CHEMICAL", 229, 240], ["ciclosporin", "SIMPLE_CHEMICAL", 80, 91], ["feline", "ORGANISM", 101, 107], ["cats", "ORGANISM", 151, 155], ["ciclosporin", "SIMPLE_CHEMICAL", 229, 240], ["cats", "SPECIES", 151, 155], ["ciclosporin", "TREATMENT", 80, 91], ["feline hypersensitivity dermatitis", "PROBLEM", 101, 135], ["ciclosporin", "TREATMENT", 229, 240], ["hypersensitivity dermatitis", "OBSERVATION", 108, 135]]], ["Studies suggest that feline hypersensitivity dermatitis can be well controlled with dose tapering;2, 6 however, the frequency and response to dose tapering has not been documented in cats.", [["feline hypersensitivity dermatitis", "DISEASE", 21, 55], ["feline", "ORGANISM", 21, 27], ["cats", "ORGANISM", 183, 187], ["feline", "SPECIES", 21, 27], ["cats", "SPECIES", 183, 187], ["Studies", "TEST", 0, 7], ["feline hypersensitivity dermatitis", "PROBLEM", 21, 55], ["dose tapering", "TREATMENT", 84, 97], ["dose tapering", "TREATMENT", 142, 155], ["feline", "OBSERVATION_MODIFIER", 21, 27], ["hypersensitivity dermatitis", "OBSERVATION", 28, 55]]], ["The present study was designed to assess the clinical response to a dose\u2010tapering regimen and the tolerability to ciclosporin administered for up to 18 weeks.Study design ::: Materials and methodsThe study was conducted in two phases.", [["ciclosporin", "CHEMICAL", 114, 125], ["ciclosporin", "CHEMICAL", 114, 125], ["ciclosporin", "SIMPLE_CHEMICAL", 114, 125], ["The present study", "TEST", 0, 17], ["a dose\u2010tapering regimen", "TREATMENT", 66, 89], ["ciclosporin", "TREATMENT", 114, 125], ["The study", "TEST", 196, 205]]], ["The first phase established 7 mg/kg as an effective dose of ciclosporin for the treatment of hypersensitivity dermatitis.5 The present study presents the outcome of the second phase, in which a dose\u2010tapering regimen was examined.Study design ::: Materials and methodsBriefly, the Phase 1 study was a blinded, randomized, parallel group, placebo\u2010controlled study, in which ciclosporin dosed orally at 2.5 or 7 mg/kg administered daily for 6 weeks was compared with a placebo control for the treatment of hypersensitivity dermatitis.", [["ciclosporin", "CHEMICAL", 60, 71], ["hypersensitivity dermatitis", "DISEASE", 93, 120], ["ciclosporin", "CHEMICAL", 372, 383], ["hypersensitivity dermatitis", "DISEASE", 503, 530], ["ciclosporin", "CHEMICAL", 60, 71], ["ciclosporin", "CHEMICAL", 372, 383], ["ciclosporin", "SIMPLE_CHEMICAL", 60, 71], ["ciclosporin", "SIMPLE_CHEMICAL", 372, 383], ["ciclosporin", "TREATMENT", 60, 71], ["hypersensitivity dermatitis", "PROBLEM", 93, 120], ["The present study", "TEST", 123, 140], ["a dose\u2010tapering regimen", "TREATMENT", 192, 215], ["the Phase 1 study", "TEST", 276, 293], ["placebo\u2010controlled study", "TEST", 337, 361], ["ciclosporin", "TREATMENT", 372, 383], ["a placebo control", "TREATMENT", 464, 481], ["hypersensitivity dermatitis", "PROBLEM", 503, 530], ["hypersensitivity dermatitis", "OBSERVATION", 93, 120], ["hypersensitivity dermatitis", "OBSERVATION", 503, 530]]], ["The clinical response was assessed 3 and 6 weeks after the start of treatment.Study design ::: Materials and methodsThe Phase 2 study explored the effect of a dose\u2010tapering regimen on the clinical response to ciclosporin.", [["ciclosporin", "CHEMICAL", 209, 220], ["ciclosporin", "CHEMICAL", 209, 220], ["ciclosporin", "SIMPLE_CHEMICAL", 209, 220], ["treatment", "TREATMENT", 68, 77], ["The Phase 2 study", "TEST", 116, 133], ["a dose\u2010tapering regimen", "TREATMENT", 157, 180], ["ciclosporin", "TREATMENT", 209, 220]]], ["The open\u2010label study immediately followed the Phase 1 study and was not randomized nor blinded.", [["The open\u2010label study", "TEST", 0, 20], ["the Phase 1 study", "TEST", 42, 59]]], ["Clinical observations were made by investigators at the inclusion visit V1 (day 0 of Phase 2; the same day as the final visit for Phase 1) and at weeks 4 (28 \u00b1 3 days), 8 (56 \u00b1 3 days) and 12 (84 \u00b1 3 days).Study design ::: Materials and methodsPhase 1 and 2 studies were both multicentre, with sites located in the USA, France, the UK, Belgium and Switzerland.", [["2 studies", "TEST", 256, 265]]], ["They were conducted in accordance with the procedures and principles of Good Clinical Practice.", [["the procedures", "TREATMENT", 39, 53]]], ["Cat owners signed an informed consent for their cat to be included and were free to withdraw their animals at any point.Inclusion/exclusion criteria ::: Materials and methodsCats were included in Phase 1 after a diagnosis of hypersensitivity dermatitis was made by ruling out flea bite hypersensitivity, bacterial and fungal infections.", [["hypersensitivity dermatitis", "DISEASE", 225, 252], ["flea bite hypersensitivity", "DISEASE", 276, 302], ["bacterial and fungal infections", "DISEASE", 304, 335], ["Cat", "ORGANISM", 0, 3], ["cat", "ORGANISM", 48, 51], ["hypersensitivity dermatitis", "PROBLEM", 225, 252], ["flea bite hypersensitivity", "PROBLEM", 276, 302], ["bacterial and fungal infections", "PROBLEM", 304, 335], ["hypersensitivity dermatitis", "OBSERVATION", 225, 252], ["fungal infections", "OBSERVATION", 318, 335]]], ["Food allergies were also evaluated for case exclusion whenever possible.", [["Food allergies", "DISEASE", 0, 14], ["Food allergies", "PROBLEM", 0, 14]]], ["Cats were evaluated for feline leukaemia virus and feline immunodeficiency virus infections and excluded if found positive.", [["feline leukaemia virus", "DISEASE", 24, 46], ["feline immunodeficiency virus infections", "DISEASE", 51, 91], ["Cats", "ORGANISM", 0, 4], ["feline leukaemia virus", "ORGANISM", 24, 46], ["feline immunodeficiency virus", "ORGANISM", 51, 80], ["feline leukaemia virus", "SPECIES", 24, 46], ["feline immunodeficiency virus", "SPECIES", 51, 80], ["feline leukaemia virus", "SPECIES", 24, 46], ["feline immunodeficiency virus", "SPECIES", 51, 80], ["feline leukaemia virus", "PROBLEM", 24, 46], ["feline immunodeficiency virus infections", "PROBLEM", 51, 91], ["positive", "PROBLEM", 114, 122], ["leukaemia virus", "OBSERVATION", 31, 46]]], ["Toxoplasma serology status was assessed prior to inclusion.", [["Toxoplasma", "ORGANISM", 0, 10], ["Toxoplasma", "SPECIES", 0, 10], ["Toxoplasma serology status", "TEST", 0, 26]]], ["In the USA, cats with Toxoplasma positive serology titres were excluded.", [["Toxoplasma positive serology", "DISEASE", 22, 50], ["cats", "ORGANISM", 12, 16], ["Toxoplasma", "ORGANISM", 22, 32], ["cats", "SPECIES", 12, 16], ["Toxoplasma", "SPECIES", 22, 32], ["Toxoplasma positive serology titres", "TEST", 22, 57]]], ["In the EU sites, no exclusion was made based on Toxoplasma serology titres.Inclusion/exclusion criteria ::: Materials and methodsCats completing Phase 1, except those which exhibited an adverse event resulting in study withdrawal or where there was poor owner compliance, were eligible to participate in Phase 2.", [["Toxoplasma", "ORGANISM", 48, 58], ["Toxoplasma", "SPECIES", 48, 58], ["Toxoplasma serology titres", "TEST", 48, 74], ["an adverse event", "PROBLEM", 183, 199], ["study withdrawal", "PROBLEM", 213, 229], ["no", "UNCERTAINTY", 17, 19], ["exclusion", "OBSERVATION", 20, 29]]], ["To be included in the study, cats had to be a minimum of 6 months of age and \u22652 kg body weight.", [["body", "ANATOMY", 83, 87], ["cats", "ORGANISM", 29, 33], ["body", "ORGANISM_SUBDIVISION", 83, 87], ["cats", "SPECIES", 29, 33], ["the study", "TEST", 18, 27], ["weight", "TEST", 88, 94]]], ["Exclusion criteria included the following: breeding, pregnant or lactating cats; presence of an active systemic infection; evidence of or history of any type of malignancy; uncontrolled ectoparasite infestation, requirement for vaccination during the study; and feeding uncooked, home\u2010prepared diets.Assessment of the clinical response ::: Materials and methodsThe assessment to determine clinical effect for dose tapering was made by comparing the initial investigator examination (baseline of Phase 1; V1P) with the overall clinical improvement at each visit [visits 2 (V2) and 3 (V3)].", [["malignancy", "ANATOMY", 161, 171], ["systemic infection", "DISEASE", 103, 121], ["malignancy", "DISEASE", 161, 171], ["ectoparasite infestation", "DISEASE", 186, 210], ["cats", "ORGANISM", 75, 79], ["cats", "SPECIES", 75, 79], ["breeding", "PROBLEM", 43, 51], ["lactating cats", "TREATMENT", 65, 79], ["an active systemic infection", "PROBLEM", 93, 121], ["malignancy", "PROBLEM", 161, 171], ["uncontrolled ectoparasite infestation", "PROBLEM", 173, 210], ["vaccination", "TREATMENT", 228, 239], ["the study", "TEST", 247, 256], ["The assessment", "TEST", 361, 375], ["dose tapering", "TREATMENT", 409, 422], ["the initial investigator examination", "TEST", 445, 481], ["active", "OBSERVATION_MODIFIER", 96, 102], ["systemic", "OBSERVATION_MODIFIER", 103, 111], ["infection", "OBSERVATION", 112, 121], ["malignancy", "OBSERVATION", 161, 171]]], ["Clinical improvement was assessed as follows: 0, excellent (clinical signs observed during the first examination have completely disappeared); 1, good (clear amelioration of the clinical signs compared with initial examination); 2, acceptable (clinical improvement compared with initial examination but cat has responded only slightly to treatment); 3, poor (clinical status of the cat compared with initial examination has not changed); and 4, bad (clinical status of the cat compared with initial examination has deteriorated).Assessment of the clinical response ::: Materials and methodsThe same investigator evaluated the severity of the lesions and pruritus at every visit.", [["lesions", "ANATOMY", 642, 649], ["pruritus", "DISEASE", 654, 662], ["cat", "ORGANISM", 382, 385], ["cat", "ORGANISM", 473, 476], ["lesions", "PATHOLOGICAL_FORMATION", 642, 649], ["the first examination", "TEST", 91, 112], ["initial examination", "TEST", 207, 226], ["initial examination", "TEST", 279, 298], ["treatment", "TREATMENT", 338, 347], ["initial examination", "TEST", 400, 419], ["initial examination", "TEST", 491, 510], ["the lesions", "PROBLEM", 638, 649], ["pruritus", "PROBLEM", 654, 662], ["lesions", "OBSERVATION", 642, 649]]], ["The lesion severity was measured using SCORFAD (SCORing Feline Allergic Dermatitis), a scoring system previously described5 and partly validated.7 The SCORFAD is a numerical rating scoring system to assess the severity of excoriations, (Ex), self\u2010induced alopecia (SA), miliary dermatitis (MD) and eosinophilic granuloma (Eo) in 10 body areas, resulting in a Total Lesion Score (TLS) from 0 to 16.", [["lesion", "ANATOMY", 4, 10], ["eosinophilic granuloma", "ANATOMY", 298, 320], ["body areas", "ANATOMY", 332, 342], ["Feline Allergic Dermatitis", "DISEASE", 56, 82], ["alopecia", "DISEASE", 255, 263], ["SA", "DISEASE", 265, 267], ["miliary dermatitis", "DISEASE", 270, 288], ["MD", "DISEASE", 290, 292], ["eosinophilic granuloma", "DISEASE", 298, 320], ["eosinophilic granuloma", "PATHOLOGICAL_FORMATION", 298, 320], ["SCORFAD", "DNA", 151, 158], ["The lesion severity", "PROBLEM", 0, 19], ["SCORFAD (SCORing Feline Allergic Dermatitis", "PROBLEM", 39, 82], ["excoriations", "PROBLEM", 222, 234], ["self\u2010induced alopecia (SA)", "PROBLEM", 242, 268], ["miliary dermatitis", "PROBLEM", 270, 288], ["eosinophilic granuloma", "PROBLEM", 298, 320], ["a Total Lesion Score", "TEST", 357, 377], ["TLS", "TEST", 379, 382], ["lesion", "OBSERVATION", 4, 10], ["severity", "OBSERVATION_MODIFIER", 11, 19], ["Allergic Dermatitis", "OBSERVATION", 63, 82], ["excoriations", "OBSERVATION", 222, 234], ["alopecia", "OBSERVATION", 255, 263], ["miliary", "OBSERVATION_MODIFIER", 270, 277], ["dermatitis", "OBSERVATION", 278, 288], ["eosinophilic", "OBSERVATION_MODIFIER", 298, 310], ["granuloma", "OBSERVATION", 311, 320], ["10 body", "OBSERVATION_MODIFIER", 329, 336], ["Total", "OBSERVATION_MODIFIER", 359, 364], ["Lesion", "OBSERVATION", 365, 371]]], ["A visual analog scale was used to determine an Owner Pruritus Score (OPS) based on the owner's observations of their cat's behaviour during the previous 3 days.", [["Pruritus", "DISEASE", 53, 61], ["cat", "ORGANISM", 117, 120], ["A visual analog scale", "TEST", 0, 21], ["an Owner Pruritus Score", "TEST", 44, 67]]], ["A line was marked at one end of the scale to indicate that the cat \u2018was comfortable, with normal grooming behaviour\u2019 or at the other end to show that the cat \u2018was uncomfortable, and was grooming all the time\u2019.", [["cat", "ORGANISM", 63, 66], ["cat", "ORGANISM", 154, 157], ["A line", "TREATMENT", 0, 6], ["uncomfortable", "PROBLEM", 163, 176], ["line", "OBSERVATION", 2, 6], ["marked", "OBSERVATION_MODIFIER", 11, 17]]], ["In addition, a five\u2010point numerical rating scale from 0 to 4 was used to determine an Investigator Pruritus Score (IPS) as previously described.5 An overall assessment of the clinical response was made by the investigator and owner at each visit of the Phase 2 study.", [["Pruritus", "DISEASE", 99, 107], ["a five\u2010point numerical rating scale", "TEST", 13, 48], ["An overall assessment", "TEST", 146, 167], ["the Phase 2 study", "TEST", 249, 266]]], ["Assessments were scored from 0 to 4 like in phase 1 at each visit beginning on day 28 until study exit (day 84 of Phase 2 if the cat completed the study).Dosage and administration ::: Materials and methodsCiclosporin was provided by Novartis Animal Health (Basel, Switzerland) as a 100 mg/mL micro\u2010emulsion liquid formulation contained in a glass bottle.", [["Ciclosporin", "CHEMICAL", 205, 216], ["Ciclosporin", "CHEMICAL", 205, 216], ["Ciclosporin", "SIMPLE_CHEMICAL", 205, 216], ["Assessments", "TEST", 0, 11], ["the study", "TEST", 143, 152], ["methodsCiclosporin", "TREATMENT", 198, 216], ["a 100 mg/mL micro\u2010emulsion liquid formulation", "TREATMENT", 280, 325], ["a glass bottle", "TREATMENT", 339, 353]]], ["The dosage of ciclosporin was delivered either via a minipump device attached to the bottle that was activated manually or by using a syringe, both of which were calibrated to deliver the required volume of treatment with an accuracy of 5%.", [["ciclosporin", "CHEMICAL", 14, 25], ["ciclosporin", "CHEMICAL", 14, 25], ["ciclosporin", "SIMPLE_CHEMICAL", 14, 25], ["ciclosporin", "TREATMENT", 14, 25], ["a minipump device", "TREATMENT", 51, 68], ["the bottle", "TREATMENT", 81, 91], ["a syringe", "TREATMENT", 132, 141], ["volume of treatment", "TREATMENT", 197, 216], ["an accuracy", "TEST", 222, 233]]], ["The ciclosporin was administered to the cat either on the cat's food or directly into the cat's mouth.", [["mouth", "ANATOMY", 96, 101], ["ciclosporin", "CHEMICAL", 4, 15], ["ciclosporin", "CHEMICAL", 4, 15], ["ciclosporin", "SIMPLE_CHEMICAL", 4, 15], ["cat", "ORGANISM", 40, 43], ["cat", "ORGANISM", 58, 61], ["cat", "ORGANISM", 90, 93], ["mouth", "ORGANISM_SUBDIVISION", 96, 101], ["The ciclosporin", "TREATMENT", 0, 15], ["mouth", "ANATOMY", 96, 101]]], ["The owner was instructed to withdraw the cat's food for a sufficient period of time where possible to encourage the cat to eat the medicated food.", [["cat", "ORGANISM", 41, 44], ["cat", "ORGANISM", 116, 119]]], ["If the cat refused the treatment for two consecutive dose attempts when offered with food, the owner was instructed to administer the treatment directly into the cat's mouth immediately after feeding.Dosage and administration ::: Materials and methodsFrom inclusion to study day 28 (\u00b13 days), all cats were administered a once daily oral dose of 7 mg/kg ciclosporin, independent from the previous treatment received in Phase 1.", [["mouth", "ANATOMY", 168, 173], ["oral", "ANATOMY", 333, 337], ["ciclosporin", "CHEMICAL", 354, 365], ["ciclosporin", "CHEMICAL", 354, 365], ["cat", "ORGANISM", 7, 10], ["cat", "ORGANISM", 162, 165], ["mouth", "ORGANISM_SUBDIVISION", 168, 173], ["cats", "ORGANISM", 297, 301], ["oral", "ORGANISM_SUBDIVISION", 333, 337], ["ciclosporin", "SIMPLE_CHEMICAL", 354, 365], ["cats", "SPECIES", 297, 301], ["the treatment", "TREATMENT", 19, 32], ["two consecutive dose attempts", "TREATMENT", 37, 66], ["the treatment", "TREATMENT", 130, 143], ["study", "TEST", 269, 274], ["ciclosporin", "TREATMENT", 354, 365], ["the previous treatment", "TREATMENT", 384, 406]]], ["From day 28, dose tapering was determined according to the investigator overall assessment of clinical response in comparison to the first day of inclusion in the Phase 1 study (V1P).", [["the investigator overall assessment", "TEST", 55, 90]]], ["All animals received ciclosporin at a target dose of 7 mg/kg, but the frequency of dosing could be altered to every other day (EoD) or twice weekly (TW) as presented in Table 1.", [["ciclosporin", "CHEMICAL", 21, 32], ["ciclosporin", "CHEMICAL", 21, 32], ["ciclosporin", "SIMPLE_CHEMICAL", 21, 32], ["ciclosporin", "TREATMENT", 21, 32]]], ["The investigator could adjust the dose between visits back to the previous dose regimen at any time if deemed necessary.", [["the previous dose regimen", "TREATMENT", 62, 87]]], ["If an animal was returned to the previous dose regimen between visits, the animal was evaluated at the next scheduled visit and the dose regimen maintained or adjusted according to the clinical response as described above.Dosage and administration ::: Materials and methodsTreatment acceptance was evaluated by the owner during dose administration.Authorized and prohibited treatments ::: Materials and methodsThroughout the duration of the Phase 2 study, cats received flea adulticide treatment at regular intervals according to the manufacturer's recommendations, except at one site which was located in a geographical area considered flea free.", [["adulticide", "CHEMICAL", 475, 485], ["cats", "ORGANISM", 456, 460], ["cats", "SPECIES", 456, 460], ["the previous dose regimen", "TREATMENT", 29, 54], ["the dose regimen", "TREATMENT", 128, 144], ["the Phase 2 study", "TEST", 437, 454], ["flea adulticide treatment", "TREATMENT", 470, 495], ["flea free", "OBSERVATION", 637, 646]]], ["Medications or interventions likely to have a significant effect on the efficacy parameters, such as topical or systemic glucocorticosteroids (including ophthalmic preparations), megestrol acetate, antihistamines, clomipramine, amitriptyline and fluoxetine, topical calcineurin inhibitors and allergen\u2010specific immunotherapy, were prohibited during the study.", [["megestrol acetate", "CHEMICAL", 179, 196], ["clomipramine", "CHEMICAL", 214, 226], ["amitriptyline", "CHEMICAL", 228, 241], ["fluoxetine", "CHEMICAL", 246, 256], ["megestrol acetate", "CHEMICAL", 179, 196], ["clomipramine", "CHEMICAL", 214, 226], ["amitriptyline", "CHEMICAL", 228, 241], ["fluoxetine", "CHEMICAL", 246, 256], ["megestrol", "SIMPLE_CHEMICAL", 179, 188], ["acetate", "SIMPLE_CHEMICAL", 189, 196], ["antihistamines", "SIMPLE_CHEMICAL", 198, 212], ["clomipramine", "SIMPLE_CHEMICAL", 214, 226], ["amitriptyline", "SIMPLE_CHEMICAL", 228, 241], ["fluoxetine", "SIMPLE_CHEMICAL", 246, 256], ["calcineurin", "GENE_OR_GENE_PRODUCT", 266, 277], ["Medications", "TREATMENT", 0, 11], ["interventions", "TREATMENT", 15, 28], ["topical", "TREATMENT", 101, 108], ["systemic glucocorticosteroids", "TREATMENT", 112, 141], ["ophthalmic preparations", "TREATMENT", 153, 176], ["megestrol acetate", "TREATMENT", 179, 196], ["antihistamines", "TREATMENT", 198, 212], ["clomipramine", "TREATMENT", 214, 226], ["amitriptyline", "TREATMENT", 228, 241], ["fluoxetine", "TREATMENT", 246, 256], ["topical calcineurin inhibitors", "TREATMENT", 258, 288], ["allergen\u2010specific immunotherapy", "TREATMENT", 293, 324], ["the study", "TEST", 349, 358]]], ["Essential fatty acids and shampoos were authorized only if used before study initiation and maintained throughout the study.", [["fatty acids", "CHEMICAL", 10, 21], ["fatty acids", "CHEMICAL", 10, 21], ["Essential fatty acids", "SIMPLE_CHEMICAL", 0, 21], ["shampoos", "SIMPLE_CHEMICAL", 26, 34], ["Essential fatty acids", "TREATMENT", 0, 21], ["shampoos", "TREATMENT", 26, 34], ["the study", "TEST", 114, 123], ["fatty acids", "OBSERVATION", 10, 21]]], ["Drugs interfering with ciclosporin, such as ketoconazole, itraconazole, erythromycin and phenobarbital, were also prohibited if given continuously for \u22657 days.", [["ciclosporin", "CHEMICAL", 23, 34], ["ketoconazole", "CHEMICAL", 44, 56], ["itraconazole", "CHEMICAL", 58, 70], ["erythromycin", "CHEMICAL", 72, 84], ["phenobarbital", "CHEMICAL", 89, 102], ["ciclosporin", "CHEMICAL", 23, 34], ["ketoconazole", "CHEMICAL", 44, 56], ["itraconazole", "CHEMICAL", 58, 70], ["erythromycin", "CHEMICAL", 72, 84], ["phenobarbital", "CHEMICAL", 89, 102], ["ciclosporin", "SIMPLE_CHEMICAL", 23, 34], ["ketoconazole", "SIMPLE_CHEMICAL", 44, 56], ["itraconazole", "SIMPLE_CHEMICAL", 58, 70], ["erythromycin", "SIMPLE_CHEMICAL", 72, 84], ["phenobarbital", "SIMPLE_CHEMICAL", 89, 102], ["Drugs", "TREATMENT", 0, 5], ["ciclosporin", "TREATMENT", 23, 34], ["ketoconazole", "TREATMENT", 44, 56], ["itraconazole", "TREATMENT", 58, 70], ["erythromycin", "TREATMENT", 72, 84], ["phenobarbital", "TREATMENT", 89, 102]]], ["Any vaccinations were to be given prior to the study start in Phase 1.", [["Any vaccinations", "TREATMENT", 0, 16], ["the study", "TEST", 43, 52]]], ["Other concomitant medications or treatments such as gastrointestinal parasiticides and medications having therapeutic effects unrelated to the treated dermatological disease were allowed as long as strictly documented.", [["gastrointestinal", "ANATOMY", 52, 68], ["gastrointestinal parasiticides", "DISEASE", 52, 82], ["Other concomitant medications", "TREATMENT", 0, 29], ["treatments", "TREATMENT", 33, 43], ["gastrointestinal parasiticides", "TREATMENT", 52, 82], ["medications", "TREATMENT", 87, 98], ["therapeutic effects", "TREATMENT", 106, 125], ["the treated dermatological disease", "PROBLEM", 139, 173]]], ["In cases of severe facial/neck pruritus, at the discretion of the investigator, an Elizabethan collar could be used at the beginning of the study and for up to a maximum of 10 days thereafter.Housing and feeding ::: Materials and methodsCats remained with their owners in their usual home for the duration of the study.", [["facial", "ANATOMY", 19, 25], ["neck", "ANATOMY", 26, 30], ["pruritus", "DISEASE", 31, 39], ["facial", "ORGANISM_SUBDIVISION", 19, 25], ["neck", "ORGANISM_SUBDIVISION", 26, 30], ["severe facial/neck pruritus", "PROBLEM", 12, 39], ["an Elizabethan collar", "TREATMENT", 80, 101], ["the study", "TEST", 136, 145], ["the study", "TEST", 309, 318], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["facial", "ANATOMY", 19, 25], ["neck", "ANATOMY", 26, 30], ["pruritus", "OBSERVATION", 31, 39]]], ["Owners were instructed not to change the home management or diet of their cats during the study and to allow for the cat(s) to be fed separately from other animals in the household to ensure that nonstudy animals did not ingest the test material when administered on food.", [["cats", "ORGANISM", 74, 78], ["cat", "ORGANISM", 117, 120], ["cats", "SPECIES", 74, 78], ["the home management", "TREATMENT", 37, 56], ["the study", "TEST", 86, 95]]], ["Owners were encouraged to restrict their cats from hunting and scavenging, and to offer only a commercial or cooked diet for the duration of the study.Assessment of safety ::: Materials and methodsIn addition to a full physical examination and body weight determination at each visit, blood samples were collected for haematology and biochemistry at inclusion and at study end, and in cases of premature withdrawal.", [["body", "ANATOMY", 244, 248], ["blood samples", "ANATOMY", 285, 298], ["cats", "ORGANISM", 41, 45], ["body", "ORGANISM_SUBDIVISION", 244, 248], ["blood samples", "ORGANISM_SUBSTANCE", 285, 298], ["cats", "SPECIES", 41, 45], ["scavenging", "TREATMENT", 63, 73], ["a commercial or cooked diet", "TREATMENT", 93, 120], ["the study", "TEST", 141, 150], ["a full physical examination", "TEST", 212, 239], ["body weight determination", "TEST", 244, 269], ["blood samples", "TEST", 285, 298], ["premature withdrawal", "PROBLEM", 394, 414], ["premature", "OBSERVATION_MODIFIER", 394, 403], ["withdrawal", "OBSERVATION", 404, 414]]], ["Adverse events (AEs) were monitored by the owner and the investigator throughout the study.", [["Adverse events", "PROBLEM", 0, 14], ["the study", "TEST", 81, 90]]], ["An AE was considered to be any observation that was unfavourable or unintended and occurred after the administration of ciclosporin, whether or not considered to be related to treatment.", [["ciclosporin", "CHEMICAL", 120, 131], ["ciclosporin", "CHEMICAL", 120, 131], ["ciclosporin", "SIMPLE_CHEMICAL", 120, 131], ["ciclosporin", "TREATMENT", 120, 131], ["treatment", "TREATMENT", 176, 185]]], ["A serious AE was defined as an adverse reaction which resulted in death, was life threatening, resulted in significant disability or incapacity, or which resulted in permanent or prolonged signs.", [["death", "DISEASE", 66, 71], ["A serious AE", "PROBLEM", 0, 12], ["an adverse reaction", "PROBLEM", 28, 47], ["death", "PROBLEM", 66, 71], ["significant disability", "PROBLEM", 107, 129], ["incapacity", "PROBLEM", 133, 143], ["permanent or prolonged signs", "PROBLEM", 166, 194], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["disability", "OBSERVATION", 119, 129], ["incapacity", "OBSERVATION", 133, 143]]], ["A significant AE included those that required active medical intervention and were considered by the investigator to be clinically significant.Assessment of safety ::: Materials and methodsAll AEs, regardless of causality, were recorded during the study.Statistical analysis ::: Materials and methodsThe dose tapering was measured on the cat population present for a full period separating two visits in Phase 2.", [["cat", "ORGANISM", 338, 341], ["A significant AE", "PROBLEM", 0, 16], ["active medical intervention", "TREATMENT", 46, 73], ["the study", "TEST", 244, 253], ["The dose tapering", "TREATMENT", 300, 317], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["tapering", "OBSERVATION_MODIFIER", 309, 317]]], ["For summary statistics and mean profile plots, missing values were imputed using the last observation carried forward method in order to obtain (approximately) comparable data for those animals which had missing values.", [["mean profile plots", "TEST", 27, 45], ["missing values", "PROBLEM", 47, 61], ["missing values", "PROBLEM", 204, 218]]], ["Body weight was compared after and before the study using Student's paired t\u2010test within each subgroup.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["Body weight", "TEST", 0, 11], ["the study", "TEST", 42, 51]]], ["The influence of vomiting on body weight was assessed with a repeated\u2010measurements ANCOVA model, including subgroup, time, subgroup \u00d7 time interaction, age, baseline weight and vomiting.", [["body", "ANATOMY", 29, 33], ["vomiting", "DISEASE", 17, 25], ["vomiting", "DISEASE", 177, 185], ["body", "ORGANISM_SUBDIVISION", 29, 33], ["vomiting", "PROBLEM", 17, 25], ["body weight", "TEST", 29, 40], ["a repeated\u2010measurements ANCOVA model", "TREATMENT", 59, 95], ["vomiting", "PROBLEM", 177, 185]]], ["Haematology and clinical chemistry parameters were compared between subgroups in an ANCOVA model including the subgroup and the baseline value.", [["clinical chemistry parameters", "TEST", 16, 45], ["an ANCOVA model", "TEST", 81, 96]]], ["All statistical calculations were performed using the software SAS\u00ae, version 9.1.3, in particular using Proc Univariate and Proc Mixed (SAS Institute, Cary, NC, USA).Cat population and demographics ::: ResultsOf 100 cats participating in the Phase 1 study, 88 were eligible for inclusion into Phase 2.", [["cats", "ORGANISM", 216, 220], ["All statistical calculations", "TEST", 0, 28], ["the software SAS\u00ae", "TEST", 50, 67], ["version", "TEST", 69, 76], ["the Phase 1 study", "TEST", 238, 255]]], ["Sixty\u2010five cats completed the Phase 2 study; 23 withdrew during the study as shown in Figure 1.", [["cats", "ORGANISM", 11, 15], ["cats", "SPECIES", 11, 15], ["the Phase 2 study", "TEST", 26, 43], ["the study", "TEST", 64, 73]]], ["The cat population consisted of 38 male and 50 female cats, aged from 1 to 17 years at the time of enrolment, with a mean age (\u00b1SD) of 6.7 \u00b1 3.8 years.", [["cat", "ORGANISM", 4, 7], ["cats", "ORGANISM", 54, 58], ["cats", "SPECIES", 54, 58]]], ["Mean body weight (\u00b1SD) was 5.03 \u00b1 1.48 kg, with a range of 2.3\u201310.4 kg.", [["body", "ANATOMY", 5, 9], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["Mean body weight", "TEST", 0, 16]]], ["Thirteen breeds were represented, where approximately 80% of the study animals were domestic short hair or European short hair.", [["hair", "ANATOMY", 99, 103], ["hair", "ANATOMY", 122, 126], ["hair", "MULTI-TISSUE_STRUCTURE", 99, 103], ["hair", "ORGAN", 122, 126], ["the study", "TEST", 61, 70]]], ["Ninety\u2010five per cent of the cats were receiving commercial food; 60% were living indoors only, while 39% were living indoor and outdoor, and only one cat was living outdoors.Treatment administration and dose\u2010tapering regimen ::: ResultsCiclosporin was administered directly into the mouth in 47 cats and was taken mixed with food in 34 cases.", [["mouth", "ANATOMY", 283, 288], ["ResultsCiclosporin", "CHEMICAL", 229, 247], ["cats", "ORGANISM", 28, 32], ["cat", "ORGANISM", 150, 153], ["ResultsCiclosporin", "SIMPLE_CHEMICAL", 229, 247], ["mouth", "ORGANISM_SUBDIVISION", 283, 288], ["cats", "ORGANISM", 295, 299], ["cats", "SPECIES", 28, 32], ["cat", "SPECIES", 150, 153], ["cats", "SPECIES", 295, 299], ["Treatment administration", "TREATMENT", 174, 198], ["dose\u2010tapering regimen", "TREATMENT", 203, 224], ["ResultsCiclosporin", "TREATMENT", 229, 247], ["mouth", "ANATOMY", 283, 288]]], ["In seven cases, mixed methods were used or the information was missing.Treatment administration and dose\u2010tapering regimen ::: ResultsThe dose could be tapered as shown in Table 2.", [["mixed methods", "TREATMENT", 16, 29], ["Treatment administration", "TREATMENT", 71, 95], ["dose\u2010tapering regimen", "TREATMENT", 100, 121]]], ["After the cats received a daily dose of 7 mg/kg ciclosporin for 28 days in Phase 2, the dose was administered EoD in 50 of 71 (70%) cats remaining in the study, representing 57% of the total cat population included in the study.", [["ciclosporin", "CHEMICAL", 48, 59], ["ciclosporin", "CHEMICAL", 48, 59], ["cats", "ORGANISM", 10, 14], ["ciclosporin", "SIMPLE_CHEMICAL", 48, 59], ["cats", "ORGANISM", 132, 136], ["cat", "ORGANISM", 191, 194], ["cats", "SPECIES", 10, 14], ["ciclosporin", "TREATMENT", 48, 59], ["the study", "TEST", 150, 159], ["the total cat population", "TEST", 181, 205], ["the study", "TEST", 218, 227]]], ["The interval between dose administration could be further extended to TW in 37 of 65 cats (57%) still in the study from day 56 to 84, representing 42% of the initial cat population.", [["cats", "ORGANISM", 85, 89], ["cat", "ORGANISM", 166, 169], ["The interval between dose administration", "TREATMENT", 0, 40], ["the study", "TEST", 105, 114]]], ["Only 25% of cats still in the study at V3 (18% of the initial population) remained on daily treatment at study end.", [["cats", "ORGANISM", 12, 16], ["the study", "TEST", 26, 35], ["daily treatment", "TREATMENT", 86, 101]]], ["In addition, the dose\u2010tapering regimen was similar regardless of observed lesion type at inclusion in the Phase 1 study.", [["lesion", "ANATOMY", 74, 80], ["the dose\u2010tapering regimen", "TREATMENT", 13, 38], ["lesion", "OBSERVATION", 74, 80]]], ["When considering cats still in the study between weeks 4 and 8 of Phase 2, the frequency of EoD treatment was 68, 70, 71 and 73% in cats with lesions of Eo, Ex, MD and SA, respectively.", [["lesions", "ANATOMY", 142, 149], ["cats", "ORGANISM", 17, 21], ["cats", "ORGANISM", 132, 136], ["lesions", "PATHOLOGICAL_FORMATION", 142, 149], ["the study", "TEST", 31, 40], ["EoD treatment", "TREATMENT", 92, 105], ["lesions of Eo", "PROBLEM", 142, 155], ["lesions", "OBSERVATION", 142, 149], ["Eo", "ANATOMY_MODIFIER", 153, 155], ["Ex", "ANATOMY_MODIFIER", 157, 159]]], ["Between weeks 8 and 12, ciclosporin was administered TW in cats presenting with Eo (56%), Ex (54%), MD(55%) and SA (61%) lesions.Response to therapy ::: ResultsFigure 2 shows that from inclusion in Phase 1 to week 4 in Phase 2, the mean (\u00b1SD) TLS decreased from 7.31 (\u00b13.52) to 2.28 (\u00b12.70), an improvement of 69% over Phase 1 baseline.", [["lesions", "ANATOMY", 121, 128], ["ciclosporin", "CHEMICAL", 24, 35], ["ciclosporin", "CHEMICAL", 24, 35], ["ciclosporin", "SIMPLE_CHEMICAL", 24, 35], ["cats", "ORGANISM", 59, 63], ["lesions", "PATHOLOGICAL_FORMATION", 121, 128], ["ciclosporin", "TREATMENT", 24, 35], ["Eo", "TEST", 80, 82], ["Ex", "TEST", 90, 92], ["MD", "TEST", 100, 102], ["SA", "TEST", 112, 114], ["(61%) lesions", "PROBLEM", 115, 128], ["TLS", "TEST", 243, 246], ["lesions", "OBSERVATION", 121, 128], ["improvement", "OBSERVATION_MODIFIER", 295, 306]]], ["During weeks 4\u201312 of Phase 2, the TLS score remained essentially stable.", [["the TLS score", "TEST", 30, 43], ["essentially", "OBSERVATION_MODIFIER", 53, 64], ["stable", "OBSERVATION", 65, 71]]], ["The mean (\u00b1SD) final TLS was 2.64 (\u00b13.18), a 64% improvement (P < 0.0001) over Phase 1 baseline.", [["The mean", "TEST", 0, 8], ["final TLS", "TEST", 15, 24], ["P", "TEST", 62, 63]]], ["The response was similar independent from the treatment received in Phase 1.Response to therapy ::: ResultsPruritus severity improved in a similar manner to TLS, as shown in Figure 3, illustrated by the owner assessment visual analog scale.", [["ResultsPruritus severity", "PROBLEM", 100, 124], ["TLS", "TEST", 157, 160], ["the owner assessment", "TEST", 199, 219]]], ["The Phase 1 mean (\u00b1SD) baseline score of 66.3 (\u00b123.2) decreased by week 4 of Phase 2 to 26.10 (\u00b128.90) and remained stable until study end.", [["The Phase", "TEST", 0, 9], ["baseline score", "TEST", 23, 37], ["Phase", "TEST", 77, 82], ["stable", "OBSERVATION_MODIFIER", 116, 122]]], ["At the final visit, the mean (\u00b1SD) OPS was 26.8 (\u00b132.0).", [["the mean (\u00b1SD) OPS", "TEST", 20, 38]]], ["Overall, the mean OPS score improved (P < 0.0001) by 61 and 60% by weeks 4 and 12, respectively.", [["the mean OPS score", "TEST", 9, 27]]], ["In addition, 59 of 88 (67%) cats were considered as grooming all the time or often and being agitated or nervous at enrolment in Phase 1, while only 16 of 88 (19%) were still behaving in this way at Phase 2 study end.", [["nervous", "ANATOMY", 105, 112], ["cats", "ORGANISM", 28, 32], ["cats", "SPECIES", 28, 32], ["being agitated", "PROBLEM", 87, 101]]], ["The proportion of cats grooming normally or grooming but being calm improved from eight of 88 (9%) to 57 of 88 (65%) from enrolment in Phase 1 to Phase 2 study end.Response to therapy ::: ResultsOverall, at study exit, there were no lesions or only mild lesions (TLS \u2264 1) in 50 of 88 (57%) cats.", [["lesions", "ANATOMY", 233, 240], ["lesions", "ANATOMY", 254, 261], ["cats", "ORGANISM", 18, 22], ["lesions", "PATHOLOGICAL_FORMATION", 233, 240], ["lesions", "PATHOLOGICAL_FORMATION", 254, 261], ["cats", "ORGANISM", 290, 294], ["cats", "SPECIES", 18, 22], ["cats", "SPECIES", 290, 294], ["lesions", "PROBLEM", 233, 240], ["mild lesions", "PROBLEM", 249, 261], ["TLS", "TEST", 263, 266], ["cats", "OBSERVATION", 18, 22], ["no", "UNCERTAINTY", 230, 232], ["lesions", "OBSERVATION", 233, 240], ["mild", "OBSERVATION_MODIFIER", 249, 253], ["lesions", "OBSERVATION", 254, 261]]], ["The frequency of complete resolution of lesions differed depending on the types of lesions initially observed at inclusion in Phase 1.", [["lesions", "ANATOMY", 40, 47], ["lesions", "ANATOMY", 83, 90], ["lesions", "PATHOLOGICAL_FORMATION", 40, 47], ["lesions", "PATHOLOGICAL_FORMATION", 83, 90], ["lesions", "PROBLEM", 40, 47], ["lesions", "PROBLEM", 83, 90], ["complete", "OBSERVATION_MODIFIER", 17, 25], ["resolution", "OBSERVATION_MODIFIER", 26, 36], ["lesions", "OBSERVATION", 40, 47], ["lesions", "OBSERVATION", 83, 90]]], ["There was a complete resolution of Eo, Ex, MD and SA lesions in 32 of 42 (76%), 44 of 68 (65%), 26 of 42 (62%) and 36 of 75 (48%) cats presenting with these respective lesions at inclusion in Phase 1.Response to therapy ::: ResultsAt study end, the investigator assessed the overall efficacy as excellent (45%), good (28%), acceptable (9%), poor (13%) or bad (5%).", [["SA lesions", "ANATOMY", 50, 60], ["lesions", "ANATOMY", 168, 175], ["SA lesions", "CANCER", 50, 60], ["cats", "ORGANISM", 130, 134], ["lesions", "PATHOLOGICAL_FORMATION", 168, 175], ["these respective lesions", "PROBLEM", 151, 175], ["complete", "OBSERVATION_MODIFIER", 12, 20], ["resolution", "OBSERVATION_MODIFIER", 21, 31], ["Eo", "OBSERVATION_MODIFIER", 35, 37], ["Ex", "OBSERVATION_MODIFIER", 39, 41], ["SA", "ANATOMY", 50, 52], ["lesions", "OBSERVATION", 53, 60], ["lesions", "OBSERVATION", 168, 175]]], ["A similar assessment was made by the owners (data not shown).Concomitant therapies ::: ResultsCiclosporin was used in conjunction with various medications, including macrocylic lactones and other antiparasitic agents, nutritional supplements, topical skin and otic cleansers, and antimicrobials.", [["skin", "ANATOMY", 251, 255], ["otic", "ANATOMY", 260, 264], ["ResultsCiclosporin", "CHEMICAL", 87, 105], ["macrocylic lactones", "CHEMICAL", 166, 185], ["macrocylic lactones", "CHEMICAL", 166, 185], ["ResultsCiclosporin", "SIMPLE_CHEMICAL", 87, 105], ["macrocylic lactones", "SIMPLE_CHEMICAL", 166, 185], ["skin", "ORGAN", 251, 255], ["A similar assessment", "TEST", 0, 20], ["ResultsCiclosporin", "TREATMENT", 87, 105], ["various medications", "TREATMENT", 135, 154], ["macrocylic lactones", "TREATMENT", 166, 185], ["other antiparasitic agents", "TREATMENT", 190, 216], ["nutritional supplements", "TREATMENT", 218, 241], ["topical skin and otic cleansers", "TREATMENT", 243, 274], ["antimicrobials", "TREATMENT", 280, 294], ["skin", "ANATOMY", 251, 255]]], ["Of the 88 cats that were treated with ciclosporin, 18 were on concurrent systemic antimicrobials.", [["ciclosporin", "CHEMICAL", 38, 49], ["ciclosporin", "CHEMICAL", 38, 49], ["cats", "ORGANISM", 10, 14], ["ciclosporin", "SIMPLE_CHEMICAL", 38, 49], ["cats", "SPECIES", 10, 14], ["ciclosporin", "TREATMENT", 38, 49], ["concurrent systemic antimicrobials", "TREATMENT", 62, 96]]], ["Twenty\u2010eight of the cats treated with ciclosporin received a macrocylic lactone.Tolerability ::: ResultsAdverse events were reported in 58 cats during the Phase 2 study.", [["ciclosporin", "CHEMICAL", 38, 49], ["macrocylic lactone", "CHEMICAL", 61, 79], ["ciclosporin", "CHEMICAL", 38, 49], ["macrocylic lactone", "CHEMICAL", 61, 79], ["cats", "ORGANISM", 20, 24], ["ciclosporin", "SIMPLE_CHEMICAL", 38, 49], ["macrocylic lactone", "SIMPLE_CHEMICAL", 61, 79], ["cats", "SPECIES", 20, 24], ["ciclosporin", "TREATMENT", 38, 49], ["a macrocylic lactone", "TREATMENT", 59, 79], ["the Phase 2 study", "TEST", 151, 168]]], ["Table 3 presents the AEs in cats with \u22655% frequency using system organ classification.", [["organ", "ANATOMY", 65, 70], ["cats", "ORGANISM", 28, 32], ["organ", "ORGAN", 65, 70]]], ["Digestive tract disorders were the most frequently reported AEs and included primarily vomiting (44% of cats with reported AEs) and diarrhoea (22% of cats with reported AEs).", [["Digestive tract", "ANATOMY", 0, 15], ["Digestive tract disorders", "DISEASE", 0, 25], ["vomiting", "DISEASE", 87, 95], ["diarrhoea", "DISEASE", 132, 141], ["Digestive tract", "ORGAN", 0, 15], ["cats", "ORGANISM", 104, 108], ["cats", "ORGANISM", 150, 154], ["Digestive tract disorders", "PROBLEM", 0, 25], ["primarily vomiting", "PROBLEM", 77, 95], ["diarrhoea", "PROBLEM", 132, 141], ["tract disorders", "OBSERVATION", 10, 25]]], ["There were also reports of anorexia, lethargy, sneezing and weight loss.", [["anorexia", "DISEASE", 27, 35], ["lethargy", "DISEASE", 37, 45], ["sneezing", "DISEASE", 47, 55], ["weight loss", "DISEASE", 60, 71], ["anorexia", "PROBLEM", 27, 35], ["lethargy", "PROBLEM", 37, 45], ["sneezing", "PROBLEM", 47, 55], ["weight loss", "PROBLEM", 60, 71], ["anorexia", "OBSERVATION", 27, 35], ["lethargy", "OBSERVATION", 37, 45], ["sneezing", "OBSERVATION", 47, 55], ["weight loss", "OBSERVATION", 60, 71]]], ["Eighty per cent of reported AEs occurred when cats were receiving a daily dose of ciclosporin.Tolerability ::: ResultsTwo cats had positive Toxoplasma gondii seroconversion during the study.", [["ciclosporin", "CHEMICAL", 82, 93], ["Toxoplasma gondii seroconversion", "DISEASE", 140, 172], ["ciclosporin", "CHEMICAL", 82, 93], ["cats", "ORGANISM", 46, 50], ["ciclosporin", "SIMPLE_CHEMICAL", 82, 93], ["cats", "ORGANISM", 122, 126], ["Toxoplasma gondii", "ORGANISM", 140, 157], ["cats", "SPECIES", 122, 126], ["Toxoplasma gondii", "SPECIES", 140, 157], ["Toxoplasma gondii", "SPECIES", 140, 157], ["ciclosporin", "TREATMENT", 82, 93], ["positive Toxoplasma gondii seroconversion", "PROBLEM", 131, 172], ["the study", "TEST", 180, 189], ["Toxoplasma gondii seroconversion", "OBSERVATION", 140, 172]]], ["In one case, a Toxoplasma titre was requested at study end because the cat was lethargic and had an elevation in creatinine phosphokinase; the cat remained clinically normal (IgG, 1:512; IgM negative).", [["Toxoplasma", "DISEASE", 15, 25], ["creatinine", "CHEMICAL", 113, 123], ["creatinine", "CHEMICAL", 113, 123], ["Toxoplasma", "ORGANISM", 15, 25], ["cat", "ORGANISM", 71, 74], ["creatinine phosphokinase", "GENE_OR_GENE_PRODUCT", 113, 137], ["cat", "ORGANISM", 143, 146], ["IgM", "GENE_OR_GENE_PRODUCT", 187, 190], ["creatinine phosphokinase", "PROTEIN", 113, 137], ["IgG", "PROTEIN", 175, 178], ["IgM", "PROTEIN", 187, 190], ["Toxoplasma", "SPECIES", 15, 25], ["a Toxoplasma titre", "TEST", 13, 31], ["lethargic", "PROBLEM", 79, 88], ["an elevation in creatinine phosphokinase", "PROBLEM", 97, 137], ["the cat", "TEST", 139, 146], ["IgG", "TEST", 175, 178], ["IgM", "TEST", 187, 190], ["elevation", "OBSERVATION", 100, 109], ["normal", "OBSERVATION", 167, 173]]], ["In the other case, Toxoplasma titres were measured during the course of the Phase 2 study because the cat was lethargic (IgG negative; IgM, 1:128).", [["Toxoplasma", "ORGANISM", 19, 29], ["cat", "ORGANISM", 102, 105], ["IgG", "PROTEIN", 121, 124], ["IgM", "PROTEIN", 135, 138], ["Toxoplasma", "SPECIES", 19, 29], ["Toxoplasma titres", "TEST", 19, 36], ["the Phase 2 study", "TEST", 72, 89], ["lethargic", "PROBLEM", 110, 119], ["IgG", "TEST", 121, 124], ["IgM", "TEST", 135, 138]]], ["In both cases, no signs other than lethargy and/or elevated values of creatinine phosphokinase were noted.", [["lethargy", "DISEASE", 35, 43], ["creatinine", "CHEMICAL", 70, 80], ["creatinine", "CHEMICAL", 70, 80], ["creatinine phosphokinase", "GENE_OR_GENE_PRODUCT", 70, 94], ["creatinine phosphokinase", "PROTEIN", 70, 94], ["signs", "PROBLEM", 18, 23], ["lethargy", "PROBLEM", 35, 43], ["elevated values of creatinine phosphokinase", "PROBLEM", 51, 94], ["no signs", "UNCERTAINTY", 15, 23]]], ["One other cat in the study was noted with anorexia and elevated liver enzymes (alanine aminotransferase and alkaline phosphatase).", [["liver", "ANATOMY", 64, 69], ["anorexia", "DISEASE", 42, 50], ["alanine", "CHEMICAL", 79, 86], ["alanine", "CHEMICAL", 79, 86], ["cat", "ORGANISM", 10, 13], ["liver", "ORGAN", 64, 69], ["alanine", "AMINO_ACID", 79, 86], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 87, 103], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 108, 128], ["liver enzymes", "PROTEIN", 64, 77], ["alanine aminotransferase", "PROTEIN", 79, 103], ["alkaline phosphatase", "PROTEIN", 108, 128], ["the study", "TEST", 17, 26], ["anorexia", "PROBLEM", 42, 50], ["elevated liver enzymes", "PROBLEM", 55, 77], ["alanine aminotransferase", "TEST", 79, 103], ["alkaline phosphatase", "TEST", 108, 128], ["anorexia", "OBSERVATION", 42, 50], ["elevated", "OBSERVATION", 55, 63], ["liver", "ANATOMY", 64, 69]]], ["The values for alanine aminotransferase improved from baseline (prior to Phase 1, 1076 IU/L) until exit in Phase 2 (1002 IU/L).", [["alanine", "CHEMICAL", 15, 22], ["alanine", "CHEMICAL", 15, 22], ["alanine", "AMINO_ACID", 15, 22], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 23, 39], ["alanine aminotransferase", "PROTEIN", 15, 39], ["The values", "TEST", 0, 10], ["alanine aminotransferase", "TEST", 15, 39], ["Phase", "TEST", 73, 78]]], ["Alkaline phosphatase values remained elevated (prestudy baseline, 116 IU/L; study exit in Phase 2, 195 IU/L).", [["Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 0, 20], ["Alkaline phosphatase", "PROTEIN", 0, 20], ["Alkaline phosphatase values", "TEST", 0, 27], ["elevated", "PROBLEM", 37, 45], ["study exit in Phase", "TEST", 76, 95]]], ["The cat was withdrawn and recovered.Tolerability ::: ResultsCats showed a trend for slight and temporary weight loss when on initial daily dosing at 7 mg/kg, as shown in Figure 4 in Phases 1 and 2.", [["weight loss", "DISEASE", 105, 116], ["cat", "ORGANISM", 4, 7], ["slight and temporary weight loss", "PROBLEM", 84, 116], ["initial daily dosing", "TREATMENT", 125, 145]]], ["In Phase 2, body weights for those animals that received any other dosing regimen than daily dosing showed no significant overall weight loss (P = 0.84).", [["body", "ANATOMY", 12, 16], ["weight loss", "DISEASE", 130, 141], ["body", "ORGANISM_SUBDIVISION", 12, 16], ["body weights", "TEST", 12, 24], ["any other dosing regimen", "TREATMENT", 57, 81], ["significant overall weight loss", "PROBLEM", 110, 141], ["P", "TEST", 143, 144], ["no", "UNCERTAINTY", 107, 109], ["significant", "OBSERVATION_MODIFIER", 110, 121], ["weight loss", "OBSERVATION", 130, 141]]], ["In addition, there were no correlations between body weight change and frequency of vomiting (P = 0.51).Tolerability ::: ResultsClinical chemistry and haematology values were evaluated prior to ciclosporin administration and at study end.", [["body", "ANATOMY", 48, 52], ["vomiting", "DISEASE", 84, 92], ["ciclosporin", "CHEMICAL", 194, 205], ["ciclosporin", "CHEMICAL", 194, 205], ["body", "ORGANISM_SUBDIVISION", 48, 52], ["ciclosporin", "SIMPLE_CHEMICAL", 194, 205], ["body weight change", "PROBLEM", 48, 66], ["vomiting", "PROBLEM", 84, 92], ["P", "TEST", 94, 95], ["haematology values", "TEST", 151, 169], ["ciclosporin administration", "TREATMENT", 194, 220]]], ["There were no significant differences noted in haematology.", [["significant differences", "PROBLEM", 14, 37], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["Mean alanine aminotransferase, alkaline phosphatase and albumin were significantly lower in animals treated daily with ciclosporin in comparison to animals on all other dosing regimens.", [["alanine", "CHEMICAL", 5, 12], ["ciclosporin", "CHEMICAL", 119, 130], ["alanine", "CHEMICAL", 5, 12], ["ciclosporin", "CHEMICAL", 119, 130], ["alanine", "AMINO_ACID", 5, 12], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 13, 29], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 31, 51], ["albumin", "GENE_OR_GENE_PRODUCT", 56, 63], ["ciclosporin", "SIMPLE_CHEMICAL", 119, 130], ["alanine aminotransferase", "PROTEIN", 5, 29], ["alkaline phosphatase", "PROTEIN", 31, 51], ["albumin", "PROTEIN", 56, 63], ["Mean alanine aminotransferase", "TEST", 0, 29], ["alkaline phosphatase", "TEST", 31, 51], ["albumin", "TEST", 56, 63], ["ciclosporin", "TREATMENT", 119, 130], ["all other dosing regimens", "TREATMENT", 159, 184]]], ["However, all mean parameter values remained within the normal reference ranges for cats (alanine aminotransferase, 34\u2013100 IU/L; alkaline phosphatase, 14\u2013102 IU/L; and albumin, 21\u201339 g/L).Tolerability ::: ResultsA total of six cats were withdrawn per study protocol due to the development of an AE.", [["alanine", "CHEMICAL", 89, 96], ["alanine", "CHEMICAL", 89, 96], ["cats", "ORGANISM", 83, 87], ["alanine", "AMINO_ACID", 89, 96], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 97, 113], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 128, 148], ["albumin", "GENE_OR_GENE_PRODUCT", 167, 174], ["cats", "ORGANISM", 226, 230], ["alanine aminotransferase", "PROTEIN", 89, 113], ["alkaline phosphatase", "PROTEIN", 128, 148], ["albumin", "PROTEIN", 167, 174], ["all mean parameter values", "TEST", 9, 34], ["cats", "TEST", 83, 87], ["alanine aminotransferase", "TEST", 89, 113], ["alkaline phosphatase", "TEST", 128, 148], ["IU/L", "TEST", 157, 161], ["albumin", "TEST", 167, 174], ["six cats", "TREATMENT", 222, 230], ["study protocol", "TEST", 250, 264], ["normal", "OBSERVATION", 55, 61], ["AE", "OBSERVATION", 294, 296]]], ["Clinical signs included diarrhoea, depression, lethargy, anorexia and vomiting.", [["diarrhoea", "DISEASE", 24, 33], ["depression", "DISEASE", 35, 45], ["lethargy", "DISEASE", 47, 55], ["anorexia", "DISEASE", 57, 65], ["vomiting", "DISEASE", 70, 78], ["diarrhoea", "PROBLEM", 24, 33], ["depression", "PROBLEM", 35, 45], ["lethargy", "PROBLEM", 47, 55], ["anorexia", "PROBLEM", 57, 65], ["vomiting", "PROBLEM", 70, 78], ["diarrhoea", "OBSERVATION", 24, 33], ["anorexia", "OBSERVATION", 57, 65]]], ["One case was subsequently diagnosed with feline infectious peritonitis and was euthanized, one was diagnosed with T. gondii infection and another one was diagnosed with hyperthyroidism.", [["feline infectious peritonitis", "DISEASE", 41, 70], ["T. gondii infection", "DISEASE", 114, 133], ["hyperthyroidism", "DISEASE", 169, 184], ["feline", "ORGANISM", 41, 47], ["T. gondii", "ORGANISM", 114, 123], ["feline", "SPECIES", 41, 47], ["T. gondii", "SPECIES", 114, 123], ["T. gondii", "SPECIES", 114, 123], ["feline infectious peritonitis", "PROBLEM", 41, 70], ["T. gondii infection", "PROBLEM", 114, 133], ["hyperthyroidism", "PROBLEM", 169, 184], ["feline", "OBSERVATION_MODIFIER", 41, 47], ["infectious", "OBSERVATION_MODIFIER", 48, 58], ["peritonitis", "OBSERVATION", 59, 70], ["gondii infection", "OBSERVATION", 117, 133], ["hyperthyroidism", "OBSERVATION", 169, 184]]], ["The cat diagnosed with hyperthyroidism was withdrawn from the study by the owner.", [["hyperthyroidism", "DISEASE", 23, 38], ["cat", "ORGANISM", 4, 7], ["hyperthyroidism", "PROBLEM", 23, 38], ["the study", "TEST", 58, 67], ["hyperthyroidism", "OBSERVATION", 23, 38]]], ["The owner elected not to treat, and the cat died from apparent uncontrolled hyperthyroidism after study exit.", [["hyperthyroidism", "DISEASE", 76, 91], ["cat", "ORGANISM", 40, 43], ["apparent uncontrolled hyperthyroidism", "PROBLEM", 54, 91], ["uncontrolled", "OBSERVATION_MODIFIER", 63, 75], ["hyperthyroidism", "OBSERVATION", 76, 91]]], ["All animals, with the exception of the feline infectious peritonitis and hyperthyroidism cases, recovered and remained clinically normal.DiscussionFollowing the daily administration of 7 mg/kg for a minimal duration of 4 weeks, the dose of ciclosporin could be tapered to EoD in up to 70% of cats remaining in the study.", [["peritonitis", "DISEASE", 57, 68], ["hyperthyroidism", "DISEASE", 73, 88], ["ciclosporin", "CHEMICAL", 240, 251], ["ciclosporin", "CHEMICAL", 240, 251], ["feline", "ORGANISM", 39, 45], ["ciclosporin", "SIMPLE_CHEMICAL", 240, 251], ["cats", "ORGANISM", 292, 296], ["feline", "SPECIES", 39, 45], ["the feline infectious peritonitis", "PROBLEM", 35, 68], ["hyperthyroidism cases", "PROBLEM", 73, 94], ["ciclosporin", "TREATMENT", 240, 251], ["the study", "TEST", 310, 319], ["feline", "OBSERVATION_MODIFIER", 39, 45], ["infectious", "OBSERVATION_MODIFIER", 46, 56], ["peritonitis", "OBSERVATION", 57, 68], ["hyperthyroidism", "OBSERVATION", 73, 88], ["normal", "OBSERVATION", 130, 136]]], ["It was possible to taper the dose further to TW in 57% of cats completing the study.", [["cats", "ORGANISM", 58, 62], ["TW", "TEST", 45, 47], ["the study", "TEST", 74, 83]]], ["A similar frequency of dose tapering was previously reported in cats suffering from idiopathic pruritus, eosinophilic plaque, indolent ulcer and/or linear granuloma.2 Vercelli et al.2 showed that following 8 weeks during which cats received an inducing dose of ciclosporin, the dose could be administered TW in 73% of the cats and EoD in 36% of the cats.DiscussionOverall, it would appear that the frequency of dose tapering is overestimated if based on the cat population remaining in the study, but underestimated if based on the initial population included into the study.", [["eosinophilic plaque", "ANATOMY", 105, 124], ["ulcer", "ANATOMY", 135, 140], ["granuloma", "ANATOMY", 155, 164], ["idiopathic pruritus", "DISEASE", 84, 103], ["eosinophilic plaque", "DISEASE", 105, 124], ["ulcer", "DISEASE", 135, 140], ["granuloma", "DISEASE", 155, 164], ["ciclosporin", "CHEMICAL", 261, 272], ["ciclosporin", "CHEMICAL", 261, 272], ["cats", "ORGANISM", 64, 68], ["eosinophilic plaque", "PATHOLOGICAL_FORMATION", 105, 124], ["ulcer", "PATHOLOGICAL_FORMATION", 135, 140], ["granuloma", "PATHOLOGICAL_FORMATION", 155, 164], ["cats", "ORGANISM", 227, 231], ["ciclosporin", "SIMPLE_CHEMICAL", 261, 272], ["cats", "ORGANISM", 322, 326], ["cats", "ORGANISM", 349, 353], ["cat", "ORGANISM", 458, 461], ["cats", "SPECIES", 64, 68], ["cats", "SPECIES", 227, 231], ["cats", "SPECIES", 349, 353], ["dose tapering", "TREATMENT", 23, 36], ["idiopathic pruritus", "PROBLEM", 84, 103], ["eosinophilic plaque", "PROBLEM", 105, 124], ["indolent ulcer", "PROBLEM", 126, 140], ["linear granuloma", "PROBLEM", 148, 164], ["ciclosporin", "TREATMENT", 261, 272], ["dose tapering", "TREATMENT", 411, 424], ["the study", "TEST", 486, 495], ["the study", "TEST", 565, 574], ["idiopathic", "OBSERVATION_MODIFIER", 84, 94], ["pruritus", "OBSERVATION", 95, 103], ["eosinophilic plaque", "OBSERVATION", 105, 124], ["indolent", "OBSERVATION_MODIFIER", 126, 134], ["ulcer", "OBSERVATION", 135, 140], ["linear", "OBSERVATION_MODIFIER", 148, 154], ["granuloma", "OBSERVATION", 155, 164]]], ["In a clinical study, the frequency of treatment interruption may be higher than in general practice conditions, because cats belonging to owners not complying with the protocol will be withdrawn.", [["cats", "ORGANISM", 120, 124], ["a clinical study", "TEST", 3, 19], ["treatment interruption", "TREATMENT", 38, 60], ["the protocol", "TREATMENT", 164, 176], ["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["Furthermore, it should be noted that the frequency of dose tapering observed in a clinical study may not predict precisely what will be observed in clinical practice.", [["dose tapering", "TREATMENT", 54, 67], ["a clinical study", "TEST", 80, 96]]], ["In a clinical trial, strict and standardized rules are given to taper the dose, while in clinical practice, dose adjustment may be based on various considerations, including but not limited to clinical improvement.", [["strict and standardized rules", "TREATMENT", 21, 50], ["dose adjustment", "TREATMENT", 108, 123]]], ["In addition, in this clinical trial, ciclosporin was generally used as monotherapy and the use of concomitant medications was restricted as much as possible.", [["ciclosporin", "CHEMICAL", 37, 48], ["ciclosporin", "CHEMICAL", 37, 48], ["ciclosporin", "SIMPLE_CHEMICAL", 37, 48], ["ciclosporin", "TREATMENT", 37, 48], ["monotherapy", "TREATMENT", 71, 82], ["concomitant medications", "TREATMENT", 98, 121]]], ["Cats treated in clinical practice may receive adjunct therapies that may contribute to clinical improvement.", [["adjunct therapies", "TREATMENT", 46, 63]]], ["It is also likely that owner compliance to treatment is better in a clinical trial compared with clinical practice, because owner compliance is regularly monitored and drug accountability assessed.", [["treatment", "TREATMENT", 43, 52], ["drug accountability", "TEST", 168, 187], ["also likely", "UNCERTAINTY", 6, 17]]], ["All these factors may contribute to the response to ciclosporin treatment and therefore affect the frequency of dose tapering.", [["ciclosporin", "CHEMICAL", 52, 63], ["ciclosporin", "CHEMICAL", 52, 63], ["ciclosporin", "SIMPLE_CHEMICAL", 52, 63], ["ciclosporin treatment", "TREATMENT", 52, 73], ["dose tapering", "TREATMENT", 112, 125]]], ["However, in a large proportion of cats in this study, the dose could be tapered to EoD and even TW without deterioration of the clinical response.", [["cats", "ORGANISM", 34, 38], ["this study", "TEST", 42, 52], ["large", "OBSERVATION_MODIFIER", 14, 19]]], ["In addition, a per protocol analysis was carried out to assess the influence of prohibited concurrent medications and noncompliance to the treatment administration or treatment regimen on the outcome.", [["a per protocol analysis", "TEST", 13, 36], ["concurrent medications", "TREATMENT", 91, 113], ["the treatment administration", "TREATMENT", 135, 163], ["treatment regimen", "TREATMENT", 167, 184]]], ["Cats wearing an Elizabethan collar for longer than the authorized 10 days or receiving systemic concomitant therapies, such as antibiotics for treatment of bacterial dermatitis (11 cats) or antihistamine (one cat), which might have contributed to the clinical improvement of some of the lesions, such as Eo,8, 9 were completely or partly excluded from this per protocol analysis.", [["lesions", "ANATOMY", 287, 294], ["bacterial dermatitis", "DISEASE", 156, 176], ["antihistamine", "CHEMICAL", 190, 203], ["antihistamine", "SIMPLE_CHEMICAL", 190, 203], ["cat", "ORGANISM", 209, 212], ["lesions", "PATHOLOGICAL_FORMATION", 287, 294], ["cats", "SPECIES", 181, 185], ["an Elizabethan collar", "TREATMENT", 13, 34], ["systemic concomitant therapies", "TREATMENT", 87, 117], ["antibiotics", "TREATMENT", 127, 138], ["bacterial dermatitis", "PROBLEM", 156, 176], ["antihistamine", "TREATMENT", 190, 203], ["the lesions", "PROBLEM", 283, 294], ["this per protocol analysis", "TEST", 352, 378], ["bacterial dermatitis", "OBSERVATION", 156, 176], ["lesions", "OBSERVATION", 287, 294]]], ["This analysis did not reveal any marked difference compared with the intent\u2010to\u2010treat analysis on dose tapering and clinical parameters, such as total lesion score and pruritus (data not shown), indicating a limited influence of compliance and concomitant therapies on the clinical outcome.DiscussionThe frequency and the extent of dose tapering appeared to be much higher in cats than in dogs.", [["lesion", "ANATOMY", 150, 156], ["pruritus", "DISEASE", 167, 175], ["cats", "ORGANISM", 375, 379], ["dogs", "ORGANISM", 388, 392], ["dogs", "SPECIES", 388, 392], ["This analysis", "TEST", 0, 13], ["the intent\u2010to\u2010treat analysis", "TEST", 65, 93], ["dose tapering", "TREATMENT", 97, 110], ["clinical parameters", "TEST", 115, 134], ["total lesion score", "PROBLEM", 144, 162], ["pruritus", "PROBLEM", 167, 175], ["concomitant therapies", "TREATMENT", 243, 264], ["marked", "OBSERVATION_MODIFIER", 33, 39], ["difference", "OBSERVATION", 40, 50]]], ["In a systematic review on clinical studies in dogs,10 the frequency of EoD treatment following a 4 week induction period was found to be generally close to 50% and, as a rule, no more than 20% of dogs could be dosed twice a week for maintenance.", [["EoD", "CHEMICAL", 71, 74], ["dogs", "ORGANISM", 46, 50], ["dogs", "ORGANISM", 196, 200], ["dogs", "SPECIES", 46, 50], ["dogs", "SPECIES", 196, 200], ["clinical studies", "TEST", 26, 42], ["EoD treatment", "TREATMENT", 71, 84], ["dogs", "TREATMENT", 196, 200]]], ["Different algorithms were used in clinical studies to decide on the change of dose in dogs and cats.", [["dogs", "ORGANISM", 86, 90], ["cats", "ORGANISM", 95, 99], ["dogs", "SPECIES", 86, 90], ["cats", "SPECIES", 95, 99], ["clinical studies", "TEST", 34, 50]]], ["In dogs, the change of dosing frequency was guided by the relative improvement of the Canine Atopic Dermatitis Extent and Severity Index11 lesion score over baseline, while in cats the change of dosing regimen was based on the overall clinical assessment made by the investigator.", [["Atopic Dermatitis", "DISEASE", 93, 110], ["dogs", "ORGANISM", 3, 7], ["cats", "ORGANISM", 176, 180], ["dogs", "SPECIES", 3, 7], ["cats", "SPECIES", 176, 180], ["the Canine Atopic Dermatitis", "PROBLEM", 82, 110], ["Severity Index11 lesion score", "PROBLEM", 122, 151], ["dosing regimen", "TREATMENT", 195, 209], ["the overall clinical assessment", "TEST", 223, 254], ["Canine", "OBSERVATION_MODIFIER", 86, 92], ["Atopic Dermatitis", "OBSERVATION", 93, 110]]], ["The dose could be tapered when a good or excellent response was obtained, which corresponds approximately to a 50% improvement of the lesion score and pruritus.7 The same threshold was selected in dog studies for changing the dosing regimen.12, 13 It could have been expected that the frequency of dose reduction would be lower in cats than in dogs.", [["lesion", "ANATOMY", 134, 140], ["pruritus", "DISEASE", 151, 159], ["dog", "ORGANISM", 197, 200], ["cats", "ORGANISM", 331, 335], ["dogs", "ORGANISM", 344, 348], ["dogs", "SPECIES", 344, 348], ["the lesion score", "PROBLEM", 130, 146], ["pruritus", "PROBLEM", 151, 159], ["dog studies", "TEST", 197, 208], ["changing the dosing regimen", "TREATMENT", 213, 240], ["dose reduction", "TREATMENT", 298, 312], ["lesion", "OBSERVATION", 134, 140]]], ["In cats, the dose could not be tapered when moderate or severe pruritus was still exhibited, whilst in dogs a reduction of the lesion score was sufficient for dose tapering even with persistent pruritus.", [["lesion", "ANATOMY", 127, 133], ["pruritus", "DISEASE", 63, 71], ["pruritus", "DISEASE", 194, 202], ["cats", "ORGANISM", 3, 7], ["dogs", "ORGANISM", 103, 107], ["cats", "SPECIES", 3, 7], ["moderate or severe pruritus", "PROBLEM", 44, 71], ["the lesion score", "PROBLEM", 123, 139], ["persistent pruritus", "PROBLEM", 183, 202], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["pruritus", "OBSERVATION", 63, 71], ["reduction", "OBSERVATION_MODIFIER", 110, 119], ["lesion", "OBSERVATION", 127, 133], ["persistent", "OBSERVATION_MODIFIER", 183, 193], ["pruritus", "OBSERVATION", 194, 202]]], ["Pharmacokinetic features of ciclosporin in dogs and cats may explain the difference in dose\u2010tapering frequency.", [["ciclosporin", "CHEMICAL", 28, 39], ["ciclosporin", "CHEMICAL", 28, 39], ["ciclosporin", "SIMPLE_CHEMICAL", 28, 39], ["dogs", "ORGANISM", 43, 47], ["cats", "ORGANISM", 52, 56], ["dogs", "SPECIES", 43, 47], ["cats", "SPECIES", 52, 56], ["ciclosporin in dogs", "TREATMENT", 28, 47], ["ciclosporin", "OBSERVATION_MODIFIER", 28, 39]]], ["In cats, blood concentrations at the same dose of ciclosporin tend to be comparatively higher than in dogs.14, 15 However, the concentration of ciclosporin needed to inhibit the expression of immunomodulatory cytokines, such as interleukin\u20102, interleukin\u20104 and interferon\u2010\u03b3, from peripheral blood mononuclear cell appears to be higher in cats than in dogs.16, 17 More information on the precise mode of action of ciclosporin in the skin and on the crucial target cells would be needed for the interpretation of this difference.DiscussionThe dose\u2010tapering regimen was, initially, similar for all four types of lesions observed, but the complete resolution of lesions was less frequent in cats suffering from self\u2010induced alopecia than other types of lesions.", [["blood", "ANATOMY", 9, 14], ["peripheral blood mononuclear cell", "ANATOMY", 280, 313], ["skin", "ANATOMY", 432, 436], ["cells", "ANATOMY", 463, 468], ["lesions", "ANATOMY", 609, 616], ["lesions", "ANATOMY", 658, 665], ["lesions", "ANATOMY", 749, 756], ["ciclosporin", "CHEMICAL", 50, 61], ["ciclosporin", "CHEMICAL", 144, 155], ["ciclosporin", "CHEMICAL", 413, 424], ["alopecia", "DISEASE", 720, 728], ["ciclosporin", "CHEMICAL", 50, 61], ["ciclosporin", "CHEMICAL", 144, 155], ["ciclosporin", "CHEMICAL", 413, 424], ["cats", "ORGANISM", 3, 7], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["ciclosporin", "SIMPLE_CHEMICAL", 50, 61], ["dogs", "ORGANISM", 102, 106], ["ciclosporin", "SIMPLE_CHEMICAL", 144, 155], ["interleukin\u20102", "GENE_OR_GENE_PRODUCT", 228, 241], ["interleukin\u20104", "GENE_OR_GENE_PRODUCT", 243, 256], ["interferon\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 261, 273], ["peripheral blood mononuclear cell", "CELL", 280, 313], ["cats", "ORGANISM", 338, 342], ["dogs", "ORGANISM", 351, 355], ["ciclosporin", "SIMPLE_CHEMICAL", 413, 424], ["skin", "ORGAN", 432, 436], ["cells", "CELL", 463, 468], ["lesions", "PATHOLOGICAL_FORMATION", 609, 616], ["lesions", "PATHOLOGICAL_FORMATION", 658, 665], ["cats", "ORGANISM", 687, 691], ["lesions", "PATHOLOGICAL_FORMATION", 749, 756], ["immunomodulatory cytokines", "PROTEIN", 192, 218], ["interleukin\u20102", "PROTEIN", 228, 241], ["interleukin\u20104", "PROTEIN", 243, 256], ["interferon\u2010\u03b3", "PROTEIN", 261, 273], ["peripheral blood mononuclear cell", "CELL_TYPE", 280, 313], ["target cells", "CELL_TYPE", 456, 468], ["cats", "SPECIES", 3, 7], ["dogs", "SPECIES", 102, 106], ["cats", "SPECIES", 338, 342], ["dogs", "SPECIES", 351, 355], ["blood concentrations", "TEST", 9, 29], ["ciclosporin", "TREATMENT", 50, 61], ["ciclosporin", "TREATMENT", 144, 155], ["immunomodulatory cytokines", "TREATMENT", 192, 218], ["interleukin\u20102", "TREATMENT", 228, 241], ["interleukin\u20104", "TREATMENT", 243, 256], ["interferon\u2010\u03b3", "TREATMENT", 261, 273], ["peripheral blood mononuclear cell", "TEST", 280, 313], ["ciclosporin", "TREATMENT", 413, 424], ["The dose\u2010tapering regimen", "TREATMENT", 537, 562], ["lesions", "PROBLEM", 609, 616], ["lesions", "PROBLEM", 658, 665], ["self\u2010induced alopecia", "PROBLEM", 707, 728], ["lesions", "PROBLEM", 749, 756], ["peripheral", "ANATOMY_MODIFIER", 280, 290], ["blood", "ANATOMY", 291, 296], ["mononuclear cell", "OBSERVATION", 297, 313], ["higher", "OBSERVATION_MODIFIER", 328, 334], ["skin", "ANATOMY", 432, 436], ["lesions", "OBSERVATION", 609, 616], ["resolution", "OBSERVATION_MODIFIER", 644, 654], ["lesions", "OBSERVATION", 658, 665], ["less frequent", "OBSERVATION_MODIFIER", 670, 683], ["lesions", "OBSERVATION", 749, 756]]], ["Slow hair regrowth, generally seen in winter when the follicle activity is low,18 is unlikely to explain the incomplete resolution of self\u2010 induced alopecia.", [["hair", "ANATOMY", 5, 9], ["follicle", "ANATOMY", 54, 62], ["alopecia", "DISEASE", 148, 156], ["hair", "MULTI-TISSUE_STRUCTURE", 5, 9], ["follicle", "MULTI-TISSUE_STRUCTURE", 54, 62], ["alopecia", "PATHOLOGICAL_FORMATION", 148, 156], ["Slow hair regrowth", "PROBLEM", 0, 18], ["the follicle activity", "TEST", 50, 71], ["self\u2010 induced alopecia", "PROBLEM", 134, 156], ["hair", "OBSERVATION_MODIFIER", 5, 9], ["regrowth", "OBSERVATION", 10, 18], ["alopecia", "OBSERVATION", 148, 156]]], ["The study was conducted in different geographical areas, climatic conditions and over several seasons.", [["The study", "TEST", 0, 9]]], ["It is possible that excessive grooming associated with behavioural disorders19, 20 may have contributed to the perpetuation of the alopecia.", [["alopecia", "DISEASE", 131, 139], ["alopecia", "PATHOLOGICAL_FORMATION", 131, 139], ["excessive grooming", "PROBLEM", 20, 38], ["behavioural disorders19", "PROBLEM", 55, 78], ["the alopecia", "PROBLEM", 127, 139], ["excessive", "OBSERVATION_MODIFIER", 20, 29], ["grooming", "OBSERVATION_MODIFIER", 30, 38], ["alopecia", "OBSERVATION", 131, 139]]], ["Severe prolonged pruritus can induce a state of anxiety and behavioural problems,21 forming a vicious cycle.", [["pruritus", "DISEASE", 17, 25], ["anxiety", "DISEASE", 48, 55], ["Severe prolonged pruritus", "PROBLEM", 0, 25], ["anxiety", "PROBLEM", 48, 55], ["behavioural problems", "PROBLEM", 60, 80], ["prolonged", "OBSERVATION_MODIFIER", 7, 16], ["pruritus", "OBSERVATION", 17, 25]]], ["The study may have included some cats with psychogenic alopecia, because a definitive diagnosis of psychogenic alopecia is difficult to make,19 and the anxious condition may not have resolved in spite of improvement in pruritus.DiscussionInterestingly, the duration of induction period at a starting dose of 7 mg/kg daily did not influence the clinical response at week 4.", [["psychogenic alopecia", "DISEASE", 43, 63], ["psychogenic alopecia", "DISEASE", 99, 119], ["pruritus", "DISEASE", 219, 227], ["cats", "ORGANISM", 33, 37], ["The study", "TEST", 0, 9], ["psychogenic alopecia", "PROBLEM", 43, 63], ["psychogenic alopecia", "PROBLEM", 99, 119], ["the anxious condition", "PROBLEM", 148, 169], ["pruritus", "PROBLEM", 219, 227], ["psychogenic", "OBSERVATION_MODIFIER", 99, 110], ["alopecia", "OBSERVATION", 111, 119], ["pruritus", "OBSERVATION", 219, 227]]], ["The total lesion score or pruritus severity was similar whether cats received ciclosporin for 4 weeks at 7 mg/kg (cats from the Phase 1 placebo group) or for 10 weeks (cats enrolled receiving the high dose in Phase 1).", [["lesion", "ANATOMY", 10, 16], ["pruritus", "DISEASE", 26, 34], ["ciclosporin", "CHEMICAL", 78, 89], ["ciclosporin", "CHEMICAL", 78, 89], ["cats", "ORGANISM", 64, 68], ["ciclosporin", "SIMPLE_CHEMICAL", 78, 89], ["cats", "ORGANISM", 168, 172], ["The total lesion score", "PROBLEM", 0, 22], ["pruritus severity", "PROBLEM", 26, 43], ["ciclosporin", "TREATMENT", 78, 89], ["the high dose in Phase", "TREATMENT", 192, 214], ["total", "OBSERVATION_MODIFIER", 4, 9], ["lesion", "OBSERVATION", 10, 16]]], ["This indicates that extending the duration of treatment with the inducing dose of 7 mg/kg daily is not likely to result in a better clinical response.", [["treatment", "TREATMENT", 46, 55], ["the inducing dose", "TREATMENT", 61, 78], ["not likely", "UNCERTAINTY", 99, 109]]], ["It is also noteworthy that the clinical response remained stable after dose tapering independent from the previous treatment received in Phase 1.", [["the previous treatment", "TREATMENT", 102, 124], ["stable", "OBSERVATION_MODIFIER", 58, 64]]], ["The study showed that the change of dosing regimen resulted in a stable response, and that dose adjustment to compensate for a deterioration of the disease was rarely needed.", [["The study", "TEST", 0, 9], ["dosing regimen", "TREATMENT", 36, 50], ["a deterioration of the disease", "PROBLEM", 125, 155], ["stable", "OBSERVATION_MODIFIER", 65, 71], ["disease", "OBSERVATION", 148, 155]]], ["A return to the previous dosing regimen between study visits was required in only 4% of the cats during Phase 2.DiscussionTreatment compliance was good, with only three cats being withdrawn during the study because the cat would not accept the medication either on food or dosed directly in the mouth.", [["mouth", "ANATOMY", 295, 300], ["cats", "ORGANISM", 92, 96], ["cats", "ORGANISM", 169, 173], ["cat", "ORGANISM", 219, 222], ["mouth", "ORGANISM_SUBDIVISION", 295, 300], ["the previous dosing regimen", "TREATMENT", 12, 39], ["the study", "TEST", 197, 206], ["the medication", "TREATMENT", 240, 254], ["mouth", "ANATOMY", 295, 300]]], ["Up to 39% of cats took the formulation mixed with food for the majority of the study duration.", [["cats", "ORGANISM", 13, 17], ["cats", "SPECIES", 13, 17]]], ["The volume of the formulation mixed with food was very small (0.07 mL/kg), so any potential taste of the product could be masked if mixed with a palatable food.DiscussionIn this study, 80% of reported AEs occurred during daily ciclosporin administration.", [["ciclosporin", "CHEMICAL", 227, 238], ["ciclosporin", "CHEMICAL", 227, 238], ["ciclosporin", "SIMPLE_CHEMICAL", 227, 238], ["this study", "TEST", 173, 183], ["reported AEs", "PROBLEM", 192, 204], ["daily ciclosporin administration", "TREATMENT", 221, 253], ["volume", "OBSERVATION_MODIFIER", 4, 10]]], ["The observed AEs were consistent with those already reported in cats receiving ciclosporin.6 Gastrointestinal AEs were the most frequently reported, with vomiting events seen in approximately 44% of the cases.", [["Gastrointestinal", "ANATOMY", 93, 109], ["ciclosporin", "CHEMICAL", 79, 90], ["vomiting", "DISEASE", 154, 162], ["ciclosporin", "CHEMICAL", 79, 90], ["cats", "ORGANISM", 64, 68], ["ciclosporin", "SIMPLE_CHEMICAL", 79, 90], ["The observed AEs", "PROBLEM", 0, 16], ["ciclosporin", "TREATMENT", 79, 90], ["vomiting events", "PROBLEM", 154, 169], ["consistent with", "UNCERTAINTY", 22, 37], ["Gastrointestinal", "ANATOMY", 93, 109]]], ["Vomiting tended to resolve without discontinuation of the treatment.", [["Vomiting", "DISEASE", 0, 8], ["Vomiting", "PROBLEM", 0, 8], ["the treatment", "TREATMENT", 54, 67]]], ["It is possible that some of the vomiting events were not related to ciclosporin, because vomiting was also observed in placebo\u2010treated cats enrolled in a previous study.5 Like vomiting, diarrhoea was generally mild and did not require medical intervention.DiscussionWeight loss was noted in cats treated daily with 2.5 and 7 mg/kg ciclosporin in the Phase 1 study and in those control cats (not previously exposed in Phase 1) when administered ciclosporin in the Phase 2 study.", [["vomiting", "DISEASE", 32, 40], ["ciclosporin", "CHEMICAL", 68, 79], ["vomiting", "DISEASE", 89, 97], ["vomiting", "DISEASE", 176, 184], ["diarrhoea", "DISEASE", 186, 195], ["DiscussionWeight loss", "DISEASE", 256, 277], ["ciclosporin", "CHEMICAL", 331, 342], ["ciclosporin", "CHEMICAL", 444, 455], ["ciclosporin", "CHEMICAL", 68, 79], ["ciclosporin", "CHEMICAL", 331, 342], ["ciclosporin", "CHEMICAL", 444, 455], ["ciclosporin", "SIMPLE_CHEMICAL", 68, 79], ["cats", "ORGANISM", 135, 139], ["cats", "ORGANISM", 291, 295], ["ciclosporin", "SIMPLE_CHEMICAL", 331, 342], ["cats", "ORGANISM", 385, 389], ["ciclosporin", "SIMPLE_CHEMICAL", 444, 455], ["cats", "SPECIES", 135, 139], ["cats", "SPECIES", 291, 295], ["cats", "SPECIES", 385, 389], ["the vomiting events", "PROBLEM", 28, 47], ["ciclosporin", "TREATMENT", 68, 79], ["vomiting", "PROBLEM", 89, 97], ["a previous study", "TEST", 152, 168], ["vomiting", "PROBLEM", 176, 184], ["diarrhoea", "PROBLEM", 186, 195], ["medical intervention", "TREATMENT", 235, 255], ["ciclosporin", "TREATMENT", 331, 342], ["ciclosporin", "TREATMENT", 444, 455], ["diarrhoea", "OBSERVATION", 186, 195], ["mild", "OBSERVATION_MODIFIER", 210, 214]]], ["No correlation was found between weight loss and frequency of vomiting events.", [["weight loss", "DISEASE", 33, 44], ["vomiting", "DISEASE", 62, 70], ["weight loss", "PROBLEM", 33, 44], ["vomiting events", "PROBLEM", 62, 77]]], ["The weight loss was most probably a result of the combination of ciclosporin\u2010related gastrointestinal disturbance and effects on food intake, because these elements were reduced with decreased dose frequency.", [["gastrointestinal", "ANATOMY", 85, 101], ["weight loss", "DISEASE", 4, 15], ["gastrointestinal disturbance", "DISEASE", 85, 113], ["gastrointestinal", "ORGANISM_SUBDIVISION", 85, 101], ["food", "ORGANISM_SUBDIVISION", 129, 133], ["The weight loss", "PROBLEM", 0, 15], ["ciclosporin\u2010related gastrointestinal disturbance", "PROBLEM", 65, 113], ["weight loss", "OBSERVATION", 4, 15], ["most probably", "UNCERTAINTY", 20, 33], ["gastrointestinal", "ANATOMY", 85, 101], ["disturbance", "OBSERVATION", 102, 113]]], ["The majority of cats with weight loss and treated with ciclosporin tended to regain weight, resulting in no overall weight loss at study end.DiscussionOf the cats diagnosed with serious AEs, feline infectious peritonitis was most probably a previously undiagnosed condition.", [["weight loss", "DISEASE", 26, 37], ["ciclosporin", "CHEMICAL", 55, 66], ["weight loss", "DISEASE", 116, 127], ["feline infectious peritonitis", "DISEASE", 191, 220], ["ciclosporin", "CHEMICAL", 55, 66], ["cats", "ORGANISM", 16, 20], ["ciclosporin", "SIMPLE_CHEMICAL", 55, 66], ["cats", "ORGANISM", 158, 162], ["feline", "ORGANISM", 191, 197], ["cats", "SPECIES", 16, 20], ["cats", "SPECIES", 158, 162], ["weight loss", "PROBLEM", 26, 37], ["ciclosporin", "TREATMENT", 55, 66], ["overall weight loss at study end", "PROBLEM", 108, 140], ["serious AEs", "PROBLEM", 178, 189], ["feline infectious peritonitis", "PROBLEM", 191, 220], ["a previously undiagnosed condition", "PROBLEM", 239, 273], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["cats", "OBSERVATION", 16, 20], ["weight loss", "OBSERVATION", 26, 37], ["no", "UNCERTAINTY", 105, 107], ["infectious", "OBSERVATION_MODIFIER", 198, 208], ["peritonitis", "OBSERVATION", 209, 220]]], ["Toxoplasmosis in association with ciclosporin monotherapy has been anecdotally reported.22, 23, 24, 25 Cats that are seronegative for T. gondii may be at risk of developing clinical toxoplasmosis if they become infected while undergoing treatment with ciclosporin.", [["Toxoplasmosis", "DISEASE", 0, 13], ["ciclosporin", "CHEMICAL", 34, 45], ["T. gondii", "DISEASE", 134, 143], ["toxoplasmosis", "DISEASE", 182, 195], ["ciclosporin", "CHEMICAL", 252, 263], ["ciclosporin", "CHEMICAL", 34, 45], ["ciclosporin", "CHEMICAL", 252, 263], ["ciclosporin", "SIMPLE_CHEMICAL", 34, 45], ["Cats", "ORGANISM", 103, 107], ["T. gondii", "ORGANISM", 134, 143], ["ciclosporin", "SIMPLE_CHEMICAL", 252, 263], ["T. gondii", "SPECIES", 134, 143], ["T. gondii", "SPECIES", 134, 143], ["Toxoplasmosis", "PROBLEM", 0, 13], ["ciclosporin monotherapy", "TREATMENT", 34, 57], ["T. gondii", "PROBLEM", 134, 143], ["developing clinical toxoplasmosis", "PROBLEM", 162, 195], ["treatment", "TREATMENT", 237, 246], ["ciclosporin", "TREATMENT", 252, 263], ["toxoplasmosis", "OBSERVATION", 182, 195], ["infected", "OBSERVATION", 211, 219]]], ["Potential exposure of seronegative cats or cats suspected to be seronegative to T. gondii should therefore be minimized (e.g. keep indoors, avoid feeding raw meat or scavenging).", [["meat", "ANATOMY", 158, 162], ["T. gondii", "DISEASE", 80, 89], ["cats", "ORGANISM", 35, 39], ["cats", "ORGANISM", 43, 47], ["T. gondii", "ORGANISM", 80, 89], ["meat", "ORGANISM_SUBDIVISION", 158, 162], ["cats", "SPECIES", 35, 39], ["cats", "SPECIES", 43, 47], ["T. gondii", "SPECIES", 80, 89], ["T. gondii", "SPECIES", 80, 89], ["seronegative cats", "PROBLEM", 22, 39], ["seronegative", "PROBLEM", 64, 76], ["T. gondii", "PROBLEM", 80, 89], ["seronegative cats", "OBSERVATION", 22, 39]]], ["The possible exacerbation of a pre\u2010existing serious systemic disease (e.g. feline infectious peritonitis) is consistent with the known pharmacology of this class of drug.", [["systemic disease", "DISEASE", 52, 68], ["feline infectious peritonitis", "DISEASE", 75, 104], ["feline", "ORGANISM", 75, 81], ["feline", "SPECIES", 75, 81], ["a pre\u2010existing serious systemic disease", "PROBLEM", 29, 68], ["e.g. feline infectious peritonitis", "PROBLEM", 70, 104], ["possible", "UNCERTAINTY", 4, 12], ["exacerbation", "OBSERVATION_MODIFIER", 13, 25], ["serious", "OBSERVATION_MODIFIER", 44, 51], ["systemic", "OBSERVATION_MODIFIER", 52, 60], ["disease", "OBSERVATION", 61, 68], ["infectious", "OBSERVATION_MODIFIER", 82, 92], ["peritonitis", "OBSERVATION", 93, 104], ["consistent with", "UNCERTAINTY", 109, 124]]], ["In cases of clinical toxoplasmosis or other serious systemic illness, treatment with ciclosporin should be withdrawn and appropriate therapy initiated.", [["toxoplasmosis", "DISEASE", 21, 34], ["systemic illness", "DISEASE", 52, 68], ["ciclosporin", "CHEMICAL", 85, 96], ["ciclosporin", "CHEMICAL", 85, 96], ["ciclosporin", "SIMPLE_CHEMICAL", 85, 96], ["clinical toxoplasmosis", "PROBLEM", 12, 34], ["other serious systemic illness", "PROBLEM", 38, 68], ["ciclosporin", "TREATMENT", 85, 96], ["appropriate therapy", "TREATMENT", 121, 140], ["toxoplasmosis", "OBSERVATION", 21, 34], ["serious", "OBSERVATION_MODIFIER", 44, 51], ["systemic", "OBSERVATION_MODIFIER", 52, 60], ["illness", "OBSERVATION", 61, 68]]], ["Ciclosporin is an inhibitor of the MDR1 P\u2010glycoprotein transporter.", [["Ciclosporin", "CHEMICAL", 0, 11], ["Ciclosporin", "CHEMICAL", 0, 11], ["Ciclosporin", "SIMPLE_CHEMICAL", 0, 11], ["MDR1", "GENE_OR_GENE_PRODUCT", 35, 39], ["MDR1 P\u2010glycoprotein transporter", "PROTEIN", 35, 66], ["Ciclosporin", "TREATMENT", 0, 11], ["an inhibitor", "TREATMENT", 15, 27], ["the MDR1 P\u2010glycoprotein transporter", "TREATMENT", 31, 66]]], ["Coadministration of ciclosporin with P\u2010glycoprotein substrates, such as macrocyclic lactones, could therefore potentially decrease the efflux of such drugs from blood\u2013brain barrier cells, potentially resulting in signs of central nervous system toxicity.", [["blood\u2013brain barrier cells", "ANATOMY", 161, 186], ["central nervous system", "ANATOMY", 222, 244], ["ciclosporin", "CHEMICAL", 20, 31], ["P\u2010glycoprotein", "CHEMICAL", 37, 51], ["macrocyclic lactones", "CHEMICAL", 72, 92], ["central nervous system toxicity", "DISEASE", 222, 253], ["ciclosporin", "CHEMICAL", 20, 31], ["P\u2010glycoprotein", "CHEMICAL", 37, 51], ["macrocyclic lactones", "CHEMICAL", 72, 92], ["ciclosporin", "SIMPLE_CHEMICAL", 20, 31], ["P\u2010glycoprotein", "SIMPLE_CHEMICAL", 37, 51], ["macrocyclic lactones", "SIMPLE_CHEMICAL", 72, 92], ["blood\u2013brain barrier cells", "CELL", 161, 186], ["central nervous system", "ANATOMICAL_SYSTEM", 222, 244], ["blood\u2013brain barrier cells", "CELL_TYPE", 161, 186], ["Coadministration", "TREATMENT", 0, 16], ["ciclosporin", "TREATMENT", 20, 31], ["P\u2010glycoprotein substrates", "TREATMENT", 37, 62], ["macrocyclic lactones", "TREATMENT", 72, 92], ["such drugs", "TREATMENT", 145, 155], ["blood\u2013brain barrier cells", "TREATMENT", 161, 186], ["central nervous system toxicity", "PROBLEM", 222, 253], ["barrier cells", "OBSERVATION", 173, 186], ["central nervous system toxicity", "OBSERVATION", 222, 253]]], ["In this study, cats were required to have been treated with a flea adulticide to rule out flea allergy as a cause of their allergic disease.", [["flea allergy", "DISEASE", 90, 102], ["allergic disease", "DISEASE", 123, 139], ["cats", "ORGANISM", 15, 19], ["cats", "SPECIES", 15, 19], ["this study", "TEST", 3, 13], ["a flea adulticide", "TREATMENT", 60, 77], ["flea allergy", "PROBLEM", 90, 102], ["their allergic disease", "PROBLEM", 117, 139], ["allergic disease", "OBSERVATION", 123, 139]]], ["Twenty\u2010eight cats that were subsequently treated with ciclosporin received concomitant treatment with a macrocyclic lactone (27 were treated with selamectin and one cat received milbemycin and praziquantel).", [["ciclosporin", "CHEMICAL", 54, 65], ["macrocyclic lactone", "CHEMICAL", 104, 123], ["selamectin", "CHEMICAL", 146, 156], ["milbemycin", "CHEMICAL", 178, 188], ["praziquantel", "CHEMICAL", 193, 205], ["ciclosporin", "CHEMICAL", 54, 65], ["macrocyclic lactone", "CHEMICAL", 104, 123], ["selamectin", "CHEMICAL", 146, 156], ["milbemycin", "CHEMICAL", 178, 188], ["praziquantel", "CHEMICAL", 193, 205], ["cats", "ORGANISM", 13, 17], ["ciclosporin", "SIMPLE_CHEMICAL", 54, 65], ["macrocyclic lactone", "SIMPLE_CHEMICAL", 104, 123], ["selamectin", "SIMPLE_CHEMICAL", 146, 156], ["cat", "ORGANISM", 165, 168], ["milbemycin", "SIMPLE_CHEMICAL", 178, 188], ["praziquantel", "SIMPLE_CHEMICAL", 193, 205], ["cats", "SPECIES", 13, 17], ["ciclosporin", "TREATMENT", 54, 65], ["concomitant treatment", "TREATMENT", 75, 96], ["a macrocyclic lactone", "TREATMENT", 102, 123], ["selamectin", "TREATMENT", 146, 156], ["milbemycin", "TREATMENT", 178, 188], ["praziquantel", "TREATMENT", 193, 205]]], ["Approximately 70% of these 28 cats experienced an AE (primarily digestive tract disorders).", [["digestive tract", "ANATOMY", 64, 79], ["digestive tract disorders", "DISEASE", 64, 89], ["cats", "ORGANISM", 30, 34], ["digestive tract", "ORGANISM_SUBDIVISION", 64, 79], ["cats", "SPECIES", 30, 34], ["an AE (primarily digestive tract disorders", "PROBLEM", 47, 89], ["digestive tract", "ANATOMY", 64, 79]]], ["One cat treated with selamectin was reported to have convulsions.", [["selamectin", "CHEMICAL", 21, 31], ["convulsions", "DISEASE", 53, 64], ["selamectin", "CHEMICAL", 21, 31], ["cat", "ORGANISM", 4, 7], ["selamectin", "SIMPLE_CHEMICAL", 21, 31], ["selamectin", "TREATMENT", 21, 31], ["convulsions", "PROBLEM", 53, 64], ["convulsions", "OBSERVATION", 53, 64]]], ["The convulsions were attributed to possible chronic renal disease, and the cat was continued with ciclosporin off study with no further reports.", [["renal", "ANATOMY", 52, 57], ["convulsions", "DISEASE", 4, 15], ["chronic renal disease", "DISEASE", 44, 65], ["ciclosporin", "CHEMICAL", 98, 109], ["ciclosporin", "CHEMICAL", 98, 109], ["renal", "ORGAN", 52, 57], ["cat", "ORGANISM", 75, 78], ["ciclosporin", "SIMPLE_CHEMICAL", 98, 109], ["The convulsions", "PROBLEM", 0, 15], ["chronic renal disease", "PROBLEM", 44, 65], ["ciclosporin", "TREATMENT", 98, 109], ["convulsions", "OBSERVATION", 4, 15], ["possible", "UNCERTAINTY", 35, 43], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["renal", "ANATOMY", 52, 57], ["disease", "OBSERVATION", 58, 65]]], ["While the number of animals on both ciclosporin and macrocyclic lactone therapy was limited and extrapolations should be made with caution, there did not appear to be an association between the concomitant use of these drugs and reports of neurological AEs.DiscussionIn conclusion, these results suggest that the inducing dose of 7 mg/kg ciclosporin can be tapered as soon as 4 weeks without deterioration of clinical response.", [["neurological", "ANATOMY", 240, 252], ["ciclosporin", "CHEMICAL", 36, 47], ["macrocyclic lactone", "CHEMICAL", 52, 71], ["ciclosporin", "CHEMICAL", 338, 349], ["ciclosporin", "CHEMICAL", 36, 47], ["macrocyclic lactone", "CHEMICAL", 52, 71], ["ciclosporin", "CHEMICAL", 338, 349], ["ciclosporin", "SIMPLE_CHEMICAL", 36, 47], ["macrocyclic lactone", "SIMPLE_CHEMICAL", 52, 71], ["ciclosporin", "SIMPLE_CHEMICAL", 338, 349], ["both ciclosporin", "TREATMENT", 31, 47], ["macrocyclic lactone therapy", "TREATMENT", 52, 79], ["these drugs", "TREATMENT", 213, 224], ["neurological AEs", "PROBLEM", 240, 256], ["ciclosporin", "TREATMENT", 338, 349]]], ["The dose regimen could be tapered to EoD or TW in greater than 53% of all cats entering the study.", [["cats", "ORGANISM", 74, 78], ["The dose regimen", "TREATMENT", 0, 16], ["TW", "TEST", 44, 46], ["the study", "TEST", 88, 97]]], ["Although ciclosporin treatment appears generally to be well tolerated, these data also suggest that establishing the lowest effective dose regimen of ciclosporin treatment will improve the safety profile of the drug.AcknowledgementsThe authors would like to thank all the study investigators who contributed cases: Luc Beco, Andrea Cannon, Paul Coward, Chris Dale, Claude Favrot, Eric Florant, Jacques Fontaine, Peter Forsythe, Cecilia Friberg, Thierry Hazan, Julie Henfrey, John Hutt, Jean\u2010Francois Jamet, Janet Littlewood, Linda Messinger, Neil McEwan, Donald MacTaggart, Tim Nuttall, Pascal Pr\u00e9laud, Tiffany Tapp, Randall Thomas and Patricia White.", [["ciclosporin", "CHEMICAL", 9, 20], ["ciclosporin", "CHEMICAL", 150, 161], ["ciclosporin", "CHEMICAL", 9, 20], ["ciclosporin", "CHEMICAL", 150, 161], ["ciclosporin", "SIMPLE_CHEMICAL", 9, 20], ["ciclosporin", "SIMPLE_CHEMICAL", 150, 161], ["ciclosporin treatment", "TREATMENT", 9, 30], ["the lowest effective dose regimen", "TREATMENT", 113, 146], ["ciclosporin treatment", "TREATMENT", 150, 171], ["Francois", "OBSERVATION", 491, 499]]], ["The authors would also like to thank the cat owners and the Atopica for Cat team at Novartis Animal Health.", [["cat", "ORGANISM", 41, 44]]]], "PMC7124124": [["IntroductionThe case studies in this volume have dug deep into the process of localization of the human security norm-complex in the 11 countries of East Asia.", [["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["The case studies", "TEST", 12, 28]]], ["As indicated in Chap.", [["Chap", "PROTEIN", 16, 20]]], ["10.1007/978-3-319-97247-3_1, there are three major characteristics that stand out in these case studies.", [["10.1007/978-3-319-97247-3_1", "CHEMICAL", 0, 27], ["these case studies", "TEST", 85, 103]]], ["First, the surveys uncover a wide variety of issues that are locally considered critical and pervasive threats to human security; political conflict and repression are included in this list, but we have found that the range of perceived human security threats is much wider than that.", [["human", "ORGANISM", 114, 119], ["human", "ORGANISM", 237, 242], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 237, 242]]], ["Second, human security consists of clusters of norms, and each component (freedom from fear and want, freedom to live in dignity, protection and empowerment) has been well understood , accepted, and put into practice in East Asian countries.", [["human", "ORGANISM", 8, 13], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13]]], ["Thus, the parts are already there, but another push seems necessary to elevate human security to a full-fledged international norm.IntroductionThird, in many countries, the national government is expected to assume the role of guarantor of human security.", [["human", "ORGANISM", 79, 84], ["human", "ORGANISM", 240, 245], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 240, 245]]], ["As meticulously discussed in the comparative analysis in Chap.", [["the comparative analysis", "TEST", 29, 53]]], ["10.1007/978-3-319-97247-3_13, this protective role of the state is generally appreciated by scholars and practitioners of human security in the region.", [["10.1007/978-3-319-97247-3_13", "CHEMICAL", 0, 28], ["human", "ORGANISM", 122, 127], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127]]], ["In fact, wedding the idea of human security to the expected functions of national governments may be the most salient feature of the localization of the human security norm in East Asia.", [["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 153, 158], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 153, 158]]], ["The same chapter also indicates that there is a shared perception that a host of serious human insecurities is caused by the process of rapid economic development in the region.", [["insecurities", "DISEASE", 95, 107], ["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["serious human insecurities", "PROBLEM", 81, 107], ["rapid economic development in the region", "PROBLEM", 136, 176], ["rapid", "OBSERVATION_MODIFIER", 136, 141], ["economic", "OBSERVATION_MODIFIER", 142, 150]]], ["It is imperative for us to pay closer attention to the quality of growth especially because the East Asian region is still a major engine of growth for the world economy.IntroductionBased on the findings in regionwide surveys and insightful comparison, this final chapter, a slightly long epilogue to the book, attempts to provide some food for thought not only for scholars but also for practitioners of human security and development in East Asia and worldwide.", [["human", "ORGANISM", 405, 410], ["human", "SPECIES", 405, 410], ["human", "SPECIES", 405, 410]]], ["While this book presents constructivist perspectives such as norm dynamics and security communities, its core message is meant to reach beyond the scholars of international relations (IR), as it is part of an endeavor to find the conditions to create a \u201ccommunity of practice\u201d (Wenger 1998; Adler 2005) of human security in the East Asian region.", [["human", "ORGANISM", 306, 311], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 306, 311]]], ["Such a community will provide the normative and epistemic grounds for concerted action to realize human security.IntroductionIn 2013, the United Nation Secretary General (UNSG) released a document on global human security practice, which is presented according to the three levels of governance: national (and sub-national), regional, and international (UNSG 2013).", [["human", "ORGANISM", 98, 103], ["human", "ORGANISM", 207, 212], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 207, 212]]], ["While the UNSG document was based on questionnaire surveys covering the broad UN member states, the present book complements it by advancing a focused inquiry targeting the East Asian region in more depth.", [["questionnaire surveys", "TEST", 37, 58], ["more depth", "OBSERVATION_MODIFIER", 194, 204]]], ["At the end of this book, we will return to the definition of human security and discuss why human security eventually had to be separated from its \u201csibling,\u201d the responsibility to protect (R2P).Empowerment and Capacity Development: The National DimensionHuman security is practiced by combining top-down protection with bottom-up empowerment.", [["human", "ORGANISM", 61, 66], ["human", "ORGANISM", 92, 97], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 92, 97], ["Capacity", "OBSERVATION_MODIFIER", 210, 218]]], ["Although people may empower themselves without waiting for intervention from domestic authorities or international donors, our comparative analysis (Chap.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["intervention", "TREATMENT", 59, 71], ["our comparative analysis", "TEST", 123, 147]]], ["10.1007/978-3-319-97247-3_13) argues that in East Asia, governments are widely expected to extend parental care and lead people to the right path; we may call this \u201cguided empowerment.\u201d", [["10.1007/978-3-319-97247-3_13", "CHEMICAL", 0, 28], ["people", "ORGANISM", 121, 127], ["people", "SPECIES", 121, 127], ["right", "ANATOMY_MODIFIER", 135, 140]]], ["Some case studies in this volume review this function in a positive light, while others envision the promotion of civil society that will act as a democratic counterbalance to authoritarian governments.", [["Some case studies", "TEST", 0, 17]]], ["Although empowering people while protecting them appears to be a contradiction, those holding power may practice both in the passage of time in a similar way to the process in which parents protect and bring up children: the young will eventually take control of their own life and may challenge, and even protect, their parents.", [["people", "ORGANISM", 20, 26], ["children", "ORGANISM", 211, 219], ["people", "SPECIES", 20, 26], ["children", "SPECIES", 211, 219]]], ["The notion of paternalism invites mixed, sometimes emotional reactions.1Empowerment and Capacity Development: The National DimensionBy definition, empowerment \u201caims at developing the capabilities of individuals and communities to make informed choices and to act on their own behalf.", [["paternalism", "OBSERVATION", 14, 25], ["Capacity", "OBSERVATION_MODIFIER", 88, 96]]], ["Empowering people not only enables them to develop their full potential, but it also allows them to find ways and to participate in solutions to ensure human security for themselves and others\u201d (UNHSU 2009, 7).", [["people", "ORGANISM", 11, 17], ["human", "ORGANISM", 152, 157], ["people", "SPECIES", 11, 17], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157]]], ["In short, empowered people will possess enhanced levels of problem-solving capacity.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["solving capacity", "PROBLEM", 67, 83]]], ["Then, if the capacity of the government to empower people is weak, deficiencies could be filled by means of international aid.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57]]], ["The practice of empowerment and that of capacity development are thus closely related.Empowerment and Capacity Development: The National DimensionThe concept of capacity development gained currency among international donors in the early 2000s (Fukuda-Parr et al. 2002).", [["donors", "ORGANISM", 218, 224], ["capacity development", "PROBLEM", 161, 181], ["capacity", "OBSERVATION_MODIFIER", 161, 169]]], ["Under the presidency of Sadako Ogata, the Japan International Cooperation Agency (JICA) took up the task of operationalizing capacity development at the same time as it absorbed the idea of human security.", [["human", "ORGANISM", 190, 195], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195]]], ["In its capacity assessment handbook, JICA distinguished three elements of capacity at each of the individual, organizational, and societal levels: the first element is the \u201ctechnical capacity,\u201d which takes the form of particular skills and knowledge (including tacit knowledge); the second is the \u201c core capacity,\u201d which refers to leadership capabilities and motivation to utilize the technical capacity; and the third is the \u201c enabling environment,\u201d which makes target organizations produce results with an increased capacity.", [["its capacity assessment", "TEST", 3, 26], ["an increased capacity", "PROBLEM", 505, 526], ["capacity", "OBSERVATION_MODIFIER", 7, 15], ["capacity", "OBSERVATION_MODIFIER", 74, 82]]], ["JICA emphasizes the significance of nurturing the core capacity at the organizational level, which is supposed to be the leverage point in many cases (JICA 2008, 14\u201322).", [["nurturing the core capacity", "PROBLEM", 36, 63]]], ["International donors including the World Bank, the Asian Development Bank, the United Nations Development Programme (UNDP), the European Commission , the Department for International Development (DfID), and Deutsche Gesellschaft f\u00fcr Internationale Zusammenarbeit (German Society for International Cooperation\u2014GIZ) GmbH have developed their principles and programs with regard to capacity development.Empowerment and Capacity Development: The National DimensionThe initiative to develop people\u2019s problem-solving capacity may be taken by national governments or international donors.", [["people", "ORGANISM", 486, 492], ["donors", "ORGANISM", 574, 580], ["people", "SPECIES", 486, 492], ["solving capacity", "PROBLEM", 503, 519]]], ["In any case, if citizens are sufficiently empowered, they may want to change their environments and courses of life from bottom up or begin to resolve local problems collectively by themselves.", [["local problems", "PROBLEM", 151, 165]]], ["In East Asia, the time of \u201coriental despotism,\u201d in which obedient rural subjects were mobilized from top down for public works (Wittfogel 1957) is definitely over, as people now think and act on their own.", [["despotism", "DISEASE", 36, 45], ["people", "SPECIES", 167, 173]]], ["Thus, the path of East Asia\u2019s further empowerment and democratization is not predetermined.Empowerment and Capacity Development: The National DimensionThe concept of freedom to live in dignity is related to the cultural aspect of human life.", [["human", "ORGANISM", 230, 235], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 230, 235], ["democratization", "TREATMENT", 54, 69]]], ["In the process of post-war decolonization, people in the newly independent nations called for the restoration of national dignity.", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["post-war decolonization", "TREATMENT", 18, 41]]], ["The prevalence of dignity in the culture of the UN is closely related to the expansion of the territories in which people are regarded as members of legitimate sovereign nations to which the sacred right of self-determination has been conferred.", [["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121], ["the culture", "TEST", 29, 40], ["dignity", "OBSERVATION", 18, 25], ["expansion", "OBSERVATION", 77, 86], ["territories", "ANATOMY_MODIFIER", 94, 105], ["right", "ANATOMY_MODIFIER", 198, 203]]], ["From the human security perspective, national dignity and individual dignity are both highly esteemed: human security requires international donors to pay respect to national self-determination and obliges national governments to respect the intrinsic value of individual citizens.", [["human", "ORGANISM", 9, 14], ["human", "ORGANISM", 103, 108], ["donors", "ORGANISM", 141, 147], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 103, 108]]], ["The principle of ownership has become part and parcel of human security practice by incorporating the concept of dignity into the norm-complex.Diversity of the\u00a0East Asian Nations: The Regional DimensionThe chapters of this volume have provided a comprehensive list of non-traditional and traditional threats: natural disasters (earthquakes and typhoons/cyclones), environmental pollution, climate change, epidemics, violent conflict, political repression, religious tensions, human trafficking, minority issues, unemployment , conditions of migrants, food crises, lingering poverty, and so on.", [["earthquakes", "DISEASE", 328, 339], ["food crises", "DISEASE", 551, 562], ["human", "ORGANISM", 57, 62], ["human", "ORGANISM", 476, 481], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 476, 481], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 476, 481], ["natural disasters", "PROBLEM", 309, 326], ["food crises", "PROBLEM", 551, 562]]], ["In a given country, people are exposed to a certain set of threats due to their geographic location, the state of economic development, and other unique factors.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["In terms of territory and population size, one may hesitate to lump China and Singapore together in the same category of nation states.", [["territory", "OBSERVATION_MODIFIER", 12, 21], ["population", "OBSERVATION_MODIFIER", 26, 36], ["size", "OBSERVATION_MODIFIER", 37, 41]]], ["In this region, presidential or parliamentary republics, constitutional monarchies, and communist regimes coexist side by side.", [["constitutional monarchies", "TREATMENT", 57, 82], ["communist regimes", "TREATMENT", 88, 105], ["parliamentary republics", "OBSERVATION", 32, 55]]], ["Before anthropologists discovered the notion of cultural relativism, East Asians were long accustomed to this way of thinking; the region has accommodated diverse indigenous and exogenous cultures and religions like Confucianism, Buddhism, Christianity, Islam as well as various sorts of animism.", [["animism", "DISEASE", 288, 295], ["cultural relativism", "PROBLEM", 48, 67], ["diverse indigenous and exogenous cultures", "PROBLEM", 155, 196], ["Confucianism", "PROBLEM", 216, 228], ["Buddhism", "PROBLEM", 230, 238], ["diverse", "OBSERVATION_MODIFIER", 155, 162], ["indigenous", "OBSERVATION_MODIFIER", 163, 173], ["exogenous cultures", "OBSERVATION", 178, 196]]], ["More than two decades after the publication of the , which attributed the rapid economic growth of the East Asian tigers to good education and appropriate industrial policies (World Bank 1993), most national economies continue growing with the strong backing of relatively efficient bureaucracies and capable administrations.", [["rapid", "OBSERVATION_MODIFIER", 74, 79], ["economic", "OBSERVATION_MODIFIER", 80, 88], ["growth", "OBSERVATION_MODIFIER", 89, 95]]], ["It is noteworthy that the capacity development of government institutions by means of knowledge transfer has always been an important component of Japan\u2019s development assistance.Diversity of the\u00a0East Asian Nations: The Regional DimensionIn the meantime, China has become the second largest economy in the world, and South Korea is now a member of the Organisation for Economic Co-operation and Development-Development Assistance Committee (OECD-DAC).", [["capacity", "OBSERVATION_MODIFIER", 26, 34]]], ["Despite the miraculous economic successes and deepening value chains in the region, a common security arrangement has not taken shape in East Asia, where sovereign nations still compete against each other openly.", [["the miraculous economic successes", "TREATMENT", 8, 41], ["deepening value chains in the region", "PROBLEM", 46, 82], ["chains", "OBSERVATION_MODIFIER", 62, 68], ["region", "ANATOMY_MODIFIER", 76, 82]]], ["Since the 1950s, the North Atlantic world have nurtured layers of regional organizations, called \u201csecurity communities\u201d by Karl Deutsch and his colleagues, in which all community members expect that disputes among the states will be settled in peaceful , non-military ways (Deutsch et al. 1957).", [["layers", "OBSERVATION_MODIFIER", 56, 62]]], ["Given that the emergence of such security communities followed the deepening of economic and cultural ties rather than the formation of military alliances (Ruggie 1996, 85), the time for a security community in East Asia where we witness a remarkable degree of economic integration may already be ripe.", [["economic integration", "TREATMENT", 261, 281]]], ["However, a political community that would share sovereignty is not preferred in this region, and as shown in the case study chapters and discussed later in this chapter, most are also skeptical about the R2P style intervention within the region.", [["the R2P style intervention", "TREATMENT", 200, 226]]], ["Nevertheless, in East Asia, it may not be difficult to reach a consensus to organize multiple cooperative platforms2 to address particular human security challenges, thereby building a pluralistic \u201chuman security community\u201d in which member states collaborate while retaining national sovereignty (Hernandez et al. 2018).Diversity of the\u00a0East Asian Nations: The Regional DimensionRegarding the prospect of the regional cooperation for human security, the Association of Southeast Asian Nations (ASEAN) stays one step ahead.", [["human", "ORGANISM", 139, 144], ["human", "ORGANISM", 198, 203], ["human", "ORGANISM", 434, 439], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 434, 439], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 434, 439], ["human security", "TREATMENT", 434, 448]]], ["Among the five world regions (Asia, Africa, Americas, Europe, and Oceania), from 2006 to 2015, 40 percent of natural disasters took place in Asia, and 51 percent of the related total casualties were people who lived in the region (IFRC 2016, 232\u20133).", [["people", "ORGANISM", 199, 205], ["people", "SPECIES", 199, 205]]], ["As Southeast Asia is a specifically disaster-prone area, ASEAN has advanced regional cooperation in disaster management in the framework of the ASEAN Agreement on Disaster Management and Emergency Response (AADMER), which is \u201ca legally-binding, regional multi-hazard and policy framework for cooperation, coordination, technical assistance, and resource mobilization\u201d (UNOCHA-ROAP 2013).", [["disaster management", "TREATMENT", 100, 119], ["Disaster Management", "TREATMENT", 163, 182]]], ["While Japan contributes to this initiative , ASEAN also succeeded in collaborating with China, with the support of the World Health Organization (WHO), when the Severe Acute Respiratory Syndrome (SARS) broke out.", [["Acute Respiratory Syndrome", "DISEASE", 168, 194], ["SARS", "DISEASE", 196, 200], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 157, 194], ["SARS", "PROBLEM", 196, 200], ["Severe", "OBSERVATION_MODIFIER", 161, 167], ["Acute", "OBSERVATION_MODIFIER", 168, 173], ["Respiratory Syndrome", "OBSERVATION", 174, 194]]], ["In responding to the SARS crisis, the ASEAN Plus Three ( China, Japan, and South Korea) framework was utilized (Acharya 2014, 217\u20138).Diversity of the\u00a0East Asian Nations: The Regional DimensionDepending on the choice of criteria, East Asian states can be classified into several groups with asymmetric power configurations.", [["SARS", "DISEASE", 21, 25], ["the SARS crisis", "PROBLEM", 17, 32], ["asymmetric", "OBSERVATION_MODIFIER", 290, 300], ["power configurations", "OBSERVATION", 301, 321]]], ["It is widely known that hierarchical regimes with centralized power structures historically developed in the plain regions of the Eurasian continent, while flexible, amorphous, and network-based polities prevailed largely in mountain areas as well as islands and archipelagoes in the Pacific (see, e.g., Geertz 1980; Scott 2009).", [["hierarchical regimes", "TREATMENT", 24, 44], ["centralized power structures", "TREATMENT", 50, 78], ["hierarchical", "OBSERVATION_MODIFIER", 24, 36], ["regimes", "OBSERVATION_MODIFIER", 37, 44], ["Eurasian continent", "OBSERVATION", 130, 148], ["Pacific", "ANATOMY_MODIFIER", 284, 291]]], ["The future of a human security community in East Asia hinges upon whether equal partnership can be matured between these two asymmetric powers, namely, between ASEAN and the \u201cPlus Three.\u201d", [["human", "ORGANISM", 16, 21], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21]]], ["A positive aspect is that, despite the political rivalry, a culture of mutual respect is gradually fostered, and there are active collaborative networks in civil society, business, and academia across the region.", [["a culture", "TEST", 58, 67], ["positive", "OBSERVATION", 2, 10], ["active", "OBSERVATION_MODIFIER", 123, 129], ["collaborative", "OBSERVATION_MODIFIER", 130, 143]]], ["If East Asia can sustain growth while assuming the responsibility to address global human security issues, the region may give rise to an Asian version of the OECD in the future.The Sustainable Development Goals (SDGs) and Human Security: The Global DimensionIt is very clear from the case studies that East Asian experts of human security share a view that multilateral assistance is much preferable to unilateral intervention.", [["human", "ORGANISM", 84, 89], ["Human", "ORGANISM", 223, 228], ["human", "ORGANISM", 325, 330], ["human", "SPECIES", 84, 89], ["Human", "SPECIES", 223, 228], ["human", "SPECIES", 325, 330], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 325, 330], ["global human security issues", "PROBLEM", 77, 105], ["multilateral assistance", "TREATMENT", 358, 381], ["unilateral intervention", "TREATMENT", 404, 427], ["very", "OBSERVATION_MODIFIER", 265, 269], ["clear", "OBSERVATION", 270, 275]]], ["Moreover, \u201cwhile the SDGs are not legally binding, governments are expected to take ownership and establish national frameworks for achievement of the 17 Goals.\u201d3 East Asian countries have already started to elaborate their own programs to meet these goals by 2030, and their efforts will be accelerated as the target year draws nearer.The Sustainable Development Goals (SDGs) and Human Security: The Global DimensionThere are two critical points that link the human security perspective with the practice to realize the SDGs.", [["Human", "ORGANISM", 381, 386], ["human", "ORGANISM", 461, 466], ["Human", "SPECIES", 381, 386], ["human", "SPECIES", 461, 466], ["human", "SPECIES", 461, 466], ["the SDGs", "PROBLEM", 517, 525]]], ["Second, the SDGs appear to pay less attention to risks and resilience that feature the discourses of human security, and this gap is expected to open a new field of complementary action.", [["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["new", "OBSERVATION_MODIFIER", 152, 155]]], ["As Fig. 14.1 shows, the process of human development cannot be a linear progress.", [["human", "ORGANISM", 35, 40], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["Fig.", "TEST", 3, 7]]], ["If development is the process of expanding people\u2019s freedom, human security aims at removing sources of people\u2019s unfreedom.", [["people", "ORGANISM", 43, 49], ["human", "ORGANISM", 61, 66], ["people", "ORGANISM", 104, 110], ["people", "SPECIES", 43, 49], ["human", "SPECIES", 61, 66], ["people", "SPECIES", 104, 110], ["human", "SPECIES", 61, 66]]], ["Calamities such as wars, armed conflicts, outbreaks of infectious diseases, and natural and human-made disasters pounce upon a wide swath of people at a time.", [["infectious diseases", "DISEASE", 55, 74], ["human", "ORGANISM", 92, 97], ["people", "ORGANISM", 141, 147], ["human", "SPECIES", 92, 97], ["people", "SPECIES", 141, 147], ["human", "SPECIES", 92, 97], ["infectious diseases", "PROBLEM", 55, 74], ["infectious", "OBSERVATION", 55, 65]]], ["The focus on these \u201cdownside risks\u201d is part of the theoretical underpinnings of the human security concept (Sen 2014).", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89]]], ["In the risk-prone societies of our time , even though both haves and have-nots are equally exposed to cross-border threats such as air pollution, multiple risks compel the most vulnerable people to suffer most, intensifying their insecurities (Beck 1992).", [["people", "ORGANISM", 188, 194], ["people", "SPECIES", 188, 194], ["air pollution", "OBSERVATION", 131, 144]]], ["These are the people who need to be protected and empowered most urgently.The Sustainable Development Goals (SDGs) and Human Security: The Global DimensionLet us use some illustrative examples .", [["people", "ORGANISM", 14, 20], ["Human", "ORGANISM", 119, 124], ["people", "SPECIES", 14, 20], ["Human", "SPECIES", 119, 124]]], ["In refugee camps, strong men often monopolize distributed foods and deprive women, children, and the weak of their food entitlements.", [["men", "ORGANISM", 25, 28], ["women", "ORGANISM", 76, 81], ["children", "ORGANISM", 83, 91], ["men", "SPECIES", 25, 28], ["women", "SPECIES", 76, 81], ["children", "SPECIES", 83, 91]]], ["The socially excluded persons living with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) may not have access to effective treatment even though the government provides such a service.", [["human immunodeficiency virus infection", "DISEASE", 42, 80], ["acquired immune deficiency syndrome", "DISEASE", 85, 120], ["HIV/AIDS", "DISEASE", 122, 130], ["persons", "ORGANISM", 22, 29], ["human immunodeficiency virus", "ORGANISM", 42, 70], ["persons", "SPECIES", 22, 29], ["human immunodeficiency virus", "SPECIES", 42, 70], ["human immunodeficiency virus", "SPECIES", 42, 70], ["HIV", "SPECIES", 122, 125], ["human immunodeficiency virus infection", "PROBLEM", 42, 80], ["acquired immune deficiency syndrome", "PROBLEM", 85, 120], ["HIV/AIDS", "PROBLEM", 122, 130], ["effective treatment", "TREATMENT", 155, 174], ["immune deficiency", "OBSERVATION", 94, 111]]], ["In debt-laden households, young voiceless children fall prey to human trafficking.", [["children", "ORGANISM", 42, 50], ["human", "ORGANISM", 64, 69], ["children", "SPECIES", 42, 50], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69]]], ["People who have no choice but to live in a wetland delta have their houses swept away by deluges caused by global climate change.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["global", "OBSERVATION_MODIFIER", 107, 113], ["climate", "OBSERVATION", 114, 121]]], ["People who cannot but choose the cheapest foods are exposed to the risks of dangerous food additives.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["These are all human security issues, and simultaneously, it is these sufferings that must be addressed by the SDGs.The Sustainable Development Goals (SDGs) and Human Security: The Global DimensionDownside risks, or critical and pervasive threats to human security, may hinder sustainable human development and exert grave impact on specific groups of vulnerable people.", [["human", "ORGANISM", 14, 19], ["Human", "ORGANISM", 160, 165], ["human", "ORGANISM", 249, 254], ["human", "ORGANISM", 288, 293], ["people", "ORGANISM", 362, 368], ["human", "SPECIES", 14, 19], ["Human", "SPECIES", 160, 165], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 288, 293], ["people", "SPECIES", 362, 368], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 288, 293]]], ["Traditionally, the UNSG regarded inter-state wars as the central threats to peace and security of the world, but the UN has already begun to discuss ways to address global risks other than classic wars, such as economic and social threats (including poverty, diseases, and environmental degradation), violent conflict within the nation, new weapons, terrorism, and transnational organized crime (UN 2004).", [["diseases", "PROBLEM", 259, 267]]], ["While the SDGs aim to reach a set of prescribed goals, human security strives to deal with the obstacles in the way of these shared goals and examines who are affected most adversely by those obstacles.", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60]]], ["Amartya Sen proposed a methodology of disaggregation in his Poverty and Famine, a classic analysis of famine crises in South Asia and Africa (Sen 1981): even when the total food supply seems to be sufficient in the nationally aggregated data, specific groups (including landless people) can starve to death, especially when they are wracked by ferocious market forces.", [["death", "DISEASE", 301, 306], ["people", "ORGANISM", 279, 285], ["people", "SPECIES", 279, 285], ["famine crises", "PROBLEM", 102, 115]]], ["Focusing attention on such variables as gender, generation, occupation, and geographic location, we should be able to clearly understand the differential vulnerability of particular communities and individuals to human security threats.4The Sustainable Development Goals (SDGs) and Human Security: The Global DimensionIn East Asia, people often refer to natural disasters, infectious diseases, and political conflict as typical human security issues.", [["infectious diseases", "DISEASE", 373, 392], ["human", "ORGANISM", 213, 218], ["Human", "ORGANISM", 282, 287], ["people", "ORGANISM", 332, 338], ["human", "ORGANISM", 428, 433], ["human", "SPECIES", 213, 218], ["Human", "SPECIES", 282, 287], ["people", "SPECIES", 332, 338], ["human", "SPECIES", 428, 433], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 428, 433], ["infectious", "OBSERVATION", 373, 383]]], ["In the list of the SDGs, these issues are featured in Goal 11 (Make cities and human settlements inclusive, safe, resilient, and sustainable), Goal 3 (Ensure healthy lives and promote well-being for all at all ages), and Goal 16 (Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels).", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84]]], ["We can also check how many times the keywords of human security such as want, fear, dignity, protection, and empowerment appear in the text of the SDGs; for example , empowerment is explicitly used in Goal 5 (Achieve gender equality and empower all women and girls).", [["human", "ORGANISM", 49, 54], ["women", "ORGANISM", 249, 254], ["human", "SPECIES", 49, 54], ["women", "SPECIES", 249, 254], ["girls", "SPECIES", 259, 264], ["human", "SPECIES", 49, 54]]], ["The idea and practice of human security have unique potential to contribute to the overall achievement of the SDGs through its focus on risks, vulnerability, and an ethical imperative of \u201cno one left behind\u201d as a global concern.Human Security and the\u00a0Responsibility to ProtectFinally, let us revisit the definition of the human security norm-complex.", [["human", "ORGANISM", 25, 30], ["Human", "ORGANISM", 228, 233], ["human", "ORGANISM", 322, 327], ["human security norm-complex", "PROTEIN", 322, 349], ["human", "SPECIES", 25, 30], ["Human", "SPECIES", 228, 233], ["human", "SPECIES", 322, 327], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 322, 327]]], ["In 2012, the United Nations General Assembly (UNGA) adopted a resolution on the definition of human security (UNGA 2012; see also Chap.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99]]], ["According to this document, a common understanding of human security includes: \u201cThe right of people to live in freedom and dignity, free from poverty and despair.", [["human", "ORGANISM", 54, 59], ["people", "ORGANISM", 93, 99], ["human", "SPECIES", 54, 59], ["people", "SPECIES", 93, 99], ["human", "SPECIES", 54, 59], ["right", "ANATOMY_MODIFIER", 84, 89]]], ["All individuals, in particular the vulnerable people, are entitled to freedom from fear and freedom from want, with an equal opportunity to enjoy all their rights and fully develop their human potential.\u201d", [["people", "ORGANISM", 46, 52], ["human", "ORGANISM", 187, 192], ["people", "SPECIES", 46, 52], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192]]], ["In this text, freedom is defined in terms of the duality of peace (absence of fear) and development (elimination of want), and juxtaposed with the right to live in dignity, with special emphasis given to the rights of vulnerable people.", [["people", "ORGANISM", 229, 235], ["people", "SPECIES", 229, 235], ["right", "ANATOMY_MODIFIER", 147, 152]]], ["Development of \u201chuman potential\u201d resonates with the idea of human development, which was originally defined as the process of enlarging people\u2019s choices.", [["human", "ORGANISM", 16, 21], ["human", "ORGANISM", 60, 65], ["people", "ORGANISM", 136, 142], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 60, 65], ["people", "SPECIES", 136, 142], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 60, 65], ["enlarging", "OBSERVATION_MODIFIER", 126, 135]]], ["The resolution fleshes out the concept further in subsequent paragraphs that begin with: \u201c(b) Human security calls for people-centred, comprehensive, context-specific and prevention-oriented responses that strengthen the protection and empowerment of all people and all communities.\u201dHuman Security and the\u00a0Responsibility to ProtectAs discussed in Chap.", [["Human", "ORGANISM", 94, 99], ["people", "ORGANISM", 255, 261], ["Human", "ORGANISM", 283, 288], ["Human", "SPECIES", 94, 99], ["people", "SPECIES", 119, 125], ["people", "SPECIES", 255, 261], ["Human", "SPECIES", 283, 288], ["resolution", "OBSERVATION_MODIFIER", 4, 14]]], ["10.1007/978-3-319-97247-3_1, human security is a norm-complex that consists of a cluster of related norms, and this hybridity allows for different interpretations of human security.", [["10.1007/978-3-319-97247-3_1", "CHEMICAL", 0, 27], ["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 166, 171], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 166, 171]]], ["This is one of the reasons why the title of this book is Human Security Norms in the plural, rather than the human security norm in the singular (the other reason lies in a variety of interpretations of the concept in different countries in East Asia).", [["Human", "ORGANISM", 57, 62], ["human", "ORGANISM", 109, 114], ["Human", "SPECIES", 57, 62], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["plural", "ANATOMY_MODIFIER", 85, 91]]], ["Since the introduction of the concept to the UN discourse around 1994, human security has been regarded by some as a sort of \u201cpatchwork\u201d of norms.", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76]]], ["Human security was criticized by Paris (2001) and others as a \u201cvague\u201d and \u201cuseless\u201d concept in a series of debates that largely took place in the North Atlantic region.5 The definition of human security in the 2012 UNGA resolution was agreed upon as a compromise among diplomats from the UN member states with starkly different backgrounds.", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 188, 193], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 188, 193], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 188, 193], ["North", "ANATOMY_MODIFIER", 146, 151], ["Atlantic", "ANATOMY_MODIFIER", 152, 160]]], ["As such, the latest definition also appears to remain elusive.Human Security and the\u00a0Responsibility to ProtectIn fact, however, the message of human security redefined in the 2012 UNGA resolution seems powerfully comprehensive and far from ambiguous.", [["Human", "ORGANISM", 62, 67], ["human", "ORGANISM", 143, 148], ["Human", "SPECIES", 62, 67], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148]]], ["The purport becomes clear when we contrast human security with its adversarial \u201csibling,\u201d the R2P , which was originally born as a sharp-edged, narrow interpretation of the human security concept (ICISS 2001).", [["human", "ORGANISM", 43, 48], ["human", "ORGANISM", 173, 178], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 173, 178], ["clear", "OBSERVATION", 20, 25]]], ["The UNGA resolution redefined human security as an opposite of the R2P approach: \u201c(d) The notion of human security is distinct from the responsibility to protect and its implementation.\u201d", [["human", "ORGANISM", 30, 35], ["human", "ORGANISM", 100, 105], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 100, 105]]], ["It also specifies the role of the state and international community engaged in assistance in case of humanitarian crises: \u201c(e) Human security does not entail the threat or the use of force or coercive measures.", [["Human", "ORGANISM", 127, 132], ["Human", "SPECIES", 127, 132], ["coercive measures", "TREATMENT", 192, 209]]], ["Human security does not replace State security.\u201d", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5]]], ["In addition, \u201c(f) Human security is based on national ownership (\u2026),\u201d and \u201c(g) Governments retain the primary role and responsibility for ensuring the survival, livelihood and dignity of their citizens.", [["Human", "ORGANISM", 18, 23], ["Human", "SPECIES", 18, 23]]], ["Human security requires greater collaboration and partnership (\u2026).\u201dHuman Security and the\u00a0Responsibility to ProtectWhen applied to a humanitarian emergency , the R2P approach is supposed to simplify the problem, react to the crisis, mobilize the military, enter the sovereign territory, and protect citizens.", [["Human", "ORGANISM", 0, 5], ["Human", "ORGANISM", 67, 72], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 67, 72], ["Human", "SPECIES", 0, 5], ["the R2P approach", "TREATMENT", 158, 174], ["the crisis", "PROBLEM", 221, 231]]], ["In contrast, the priority of the human security approach in the UN is now understood to contextualize the problem, prevent the crisis, coordinate activities of various actors, respect national sovereignty, and empower citizens from the bottom up.", [["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["the human security approach", "TREATMENT", 29, 56], ["the crisis", "PROBLEM", 123, 133]]], ["In every respect, human security as defined in the 2012 resolution is the antithesis of the conventional interpretation of the R2P .6 The action to address humanitarian crises has been discussed much in the analogy of medical practice such as \u201cdo no harm,\u201d a phrase in the Hippocratic Oath (M.B. Anderson 1999).", [["human", "ORGANISM", 18, 23], ["R2P", "DNA", 127, 130], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["the R2P", "TEST", 123, 130]]], ["While the R2P is like a \u201csurgical\u201d or \u201cinvasive\u201d therapy targeting troubled society, human security seems closer to an \u201cinternal\u201d or \u201coriental\u201d medicine designed to promote the resilience of an organism.", [["human", "ORGANISM", 85, 90], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["\u201cinvasive\u201d therapy", "TREATMENT", 38, 56], ["an organism", "PROBLEM", 191, 202]]], ["When multilateralism flourishes, the ideas of human security and the R2P , as well as their confrontation, complementarity and entanglements, attract keen public attention.", [["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51]]], ["However, when the enthusiasm for multilateral thinking recedes, it appears that both ideas tend to be sidelined.Human Security and the\u00a0Responsibility to ProtectStill, it is noteworthy that most respondents in our case studies did not confuse human security with the R2P , indicating that the comprehensive approach to human security is taking root in the region.", [["root", "ANATOMY", 343, 347], ["Human", "ORGANISM", 112, 117], ["human", "ORGANISM", 242, 247], ["human", "ORGANISM", 318, 323], ["root", "ORGANISM_SUBDIVISION", 343, 347], ["Human", "SPECIES", 112, 117], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 318, 323], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 318, 323], ["region", "ANATOMY_MODIFIER", 355, 361]]], ["In response, ASEAN\u2019s team of scholars headed by Surin Pitsuwan stated that the regional organization is \u201calready\u201d equipped with relevant mechanisms and instruments to carry out the R2P (High-Level Advisory Panel on the Responsibility to Protect in Southeast Asia 2014).", [["the R2P", "TEST", 177, 184]]], ["Given that human security challenges posed by nature and humans continue to confront the region and that East Asian people prefer the holistic approach to address them, the \u201coriental\u201d way of securing freedom will never cease to exist.", [["human", "ORGANISM", 11, 16], ["humans", "ORGANISM", 57, 63], ["people", "ORGANISM", 116, 122], ["human", "SPECIES", 11, 16], ["humans", "SPECIES", 57, 63], ["people", "SPECIES", 116, 122], ["human", "SPECIES", 11, 16], ["humans", "SPECIES", 57, 63]]]], "9205667cdec5ab68e043b62502652139f5418056": [["IntroductionAdult T-cell leukemiaelymphoma (ATL) is a kind of peripheral Tcell lymphoma caused by human T-cell lymphotropic virus type 1 (HTLV-1) [1] .", [["T-cell", "ANATOMY", 18, 24], ["ATL", "ANATOMY", 44, 47], ["peripheral Tcell lymphoma", "ANATOMY", 62, 87], ["ATL", "DISEASE", 44, 47], ["peripheral Tcell lymphoma", "DISEASE", 62, 87], ["IntroductionAdult T-cell leukemiaelymphoma", "CANCER", 0, 42], ["ATL", "CANCER", 44, 47], ["peripheral Tcell lymphoma", "CANCER", 62, 87], ["human T-cell lymphotropic virus type 1", "ORGANISM", 98, 136], ["HTLV-1", "ORGANISM", 138, 144], ["human", "SPECIES", 98, 103], ["lymphotropic virus type 1", "SPECIES", 111, 136], ["HTLV-1", "SPECIES", 138, 144], ["human T-cell lymphotropic virus type 1", "SPECIES", 98, 136], ["HTLV-1", "SPECIES", 138, 144], ["IntroductionAdult T-cell leukemiaelymphoma", "PROBLEM", 0, 42], ["peripheral Tcell lymphoma", "PROBLEM", 62, 87], ["human T-cell lymphotropic virus type", "PROBLEM", 98, 134], ["-cell leukemiaelymphoma", "OBSERVATION", 19, 42], ["peripheral", "ANATOMY_MODIFIER", 62, 72], ["Tcell lymphoma", "OBSERVATION", 73, 87]]], ["It is classified into four categories (acute, lymphoma, chronic, and smoldering types) depending on clinical features [2] .", [["lymphoma", "ANATOMY", 46, 54], ["lymphoma", "DISEASE", 46, 54], ["lymphoma", "CANCER", 46, 54], ["acute, lymphoma", "PROBLEM", 39, 54], ["four categories", "OBSERVATION_MODIFIER", 22, 37], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["lymphoma", "OBSERVATION", 46, 54], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["smoldering types", "OBSERVATION_MODIFIER", 69, 85]]], ["ATL is often resistant to chemotherapies, thus resulting in poor prognosis [3] .", [["ATL", "ANATOMY", 0, 3], ["ATL", "DISEASE", 0, 3], ["ATL", "CANCER", 0, 3], ["chemotherapies", "TREATMENT", 26, 40]]], ["Since ATL per se induces severe impairment of cellular immunity, ATL patients are susceptible to opportunistic infections by cytomegalovirus (CMV), candida, Pneumocystis jirovecci, and Strongyloides stercoralis [4] .", [["ATL", "ANATOMY", 6, 9], ["cellular", "ANATOMY", 46, 54], ["ATL", "ANATOMY", 65, 68], ["ATL", "DISEASE", 6, 9], ["impairment of cellular immunity", "DISEASE", 32, 63], ["ATL", "DISEASE", 65, 68], ["opportunistic infections by cytomegalovirus (CMV), candida", "DISEASE", 97, 155], ["Pneumocystis jirovecci", "DISEASE", 157, 179], ["Strongyloides stercoralis", "DISEASE", 185, 210], ["ATL", "CANCER", 6, 9], ["cellular", "CELL", 46, 54], ["ATL", "CANCER", 65, 68], ["patients", "ORGANISM", 69, 77], ["cytomegalovirus", "ORGANISM", 125, 140], ["CMV", "ORGANISM", 142, 145], ["candida", "ORGANISM", 148, 155], ["Pneumocystis jirovecci", "ORGANISM", 157, 179], ["Strongyloides stercoralis", "ORGANISM", 185, 210], ["patients", "SPECIES", 69, 77], ["Pneumocystis jirovecci", "SPECIES", 157, 179], ["Strongyloides stercoralis", "SPECIES", 185, 210], ["CMV", "SPECIES", 142, 145], ["Pneumocystis jirovecci", "SPECIES", 157, 179], ["Strongyloides stercoralis", "SPECIES", 185, 210], ["severe impairment of cellular immunity", "PROBLEM", 25, 63], ["opportunistic infections", "PROBLEM", 97, 121], ["cytomegalovirus (CMV)", "PROBLEM", 125, 146], ["candida", "PROBLEM", 148, 155], ["Pneumocystis jirovecci", "PROBLEM", 157, 179], ["Strongyloides stercoralis", "PROBLEM", 185, 210], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["impairment", "OBSERVATION", 32, 42], ["cellular immunity", "OBSERVATION", 46, 63], ["cytomegalovirus", "OBSERVATION", 125, 140], ["Pneumocystis jirovecci", "OBSERVATION", 157, 179], ["Strongyloides stercoralis", "OBSERVATION", 185, 210]]], ["Mogamulizumab is a promising, brand-new therapeutic option for ATL.", [["ATL", "ANATOMY", 63, 66], ["Mogamulizumab", "CHEMICAL", 0, 13], ["ATL", "DISEASE", 63, 66], ["Mogamulizumab", "CHEMICAL", 0, 13], ["Mogamulizumab", "SIMPLE_CHEMICAL", 0, 13], ["ATL", "CANCER", 63, 66], ["ATL", "PROBLEM", 63, 66]]], ["This agent binds CeC chemokine receptor 4 (CCR4) protein abundantly expressed in membrane surface of ATL cells, thereby activating natural killer cells in a manner of antibody-dependent cellular cytotoxicity [5] .", [["membrane surface", "ANATOMY", 81, 97], ["ATL cells", "ANATOMY", 101, 110], ["natural killer cells", "ANATOMY", 131, 151], ["cellular", "ANATOMY", 186, 194], ["CeC chemokine receptor 4", "GENE_OR_GENE_PRODUCT", 17, 41], ["CCR4", "GENE_OR_GENE_PRODUCT", 43, 47], ["membrane surface", "CELLULAR_COMPONENT", 81, 97], ["ATL cells", "CELL", 101, 110], ["natural killer cells", "CELL", 131, 151], ["cellular", "CELL", 186, 194], ["CeC chemokine receptor 4 (CCR4) protein", "PROTEIN", 17, 56], ["ATL cells", "CELL_LINE", 101, 110], ["natural killer cells", "CELL_TYPE", 131, 151], ["This agent binds CeC chemokine receptor 4 (CCR4) protein", "TREATMENT", 0, 56], ["ATL cells", "PROBLEM", 101, 110], ["activating natural killer cells", "TREATMENT", 120, 151], ["antibody", "TEST", 167, 175], ["dependent cellular cytotoxicity", "PROBLEM", 176, 207], ["membrane surface", "OBSERVATION_MODIFIER", 81, 97], ["ATL cells", "OBSERVATION", 101, 110], ["natural killer cells", "OBSERVATION", 131, 151], ["cellular cytotoxicity", "OBSERVATION", 186, 207]]], ["In patients treated with mogamulizumab, median progression-free survival and overall survival intervals were 5.2 and 13.7 months, respectively [5] .", [["mogamulizumab", "CHEMICAL", 25, 38], ["mogamulizumab", "CHEMICAL", 25, 38], ["patients", "ORGANISM", 3, 11], ["mogamulizumab", "SIMPLE_CHEMICAL", 25, 38], ["patients", "SPECIES", 3, 11], ["mogamulizumab", "TREATMENT", 25, 38]]], ["On the other hand, its profile of robust cytotoxicity would be problematic in some cases.", [["robust cytotoxicity", "PROBLEM", 34, 53]]], ["In fact, it has been suggested that mogamulizumab increases the risk of reactivation of CMV and hepatitis B virus [6, 7] .IntroductionCommunity respiratory viruses (CRVs) such as human rhinovirus and parainfluenza virus cause a common cold in healthy subjects.", [["mogamulizumab", "CHEMICAL", 36, 49], ["CMV and hepatitis B", "DISEASE", 88, 107], ["respiratory viruses", "DISEASE", 144, 163], ["human rhinovirus and parainfluenza virus", "DISEASE", 179, 219], ["mogamulizumab", "CHEMICAL", 36, 49], ["mogamulizumab", "SIMPLE_CHEMICAL", 36, 49], ["CMV", "ORGANISM", 88, 91], ["hepatitis B virus", "ORGANISM", 96, 113], ["IntroductionCommunity respiratory viruses", "ORGANISM", 122, 163], ["CRVs", "CANCER", 165, 169], ["human", "ORGANISM", 179, 184], ["rhinovirus", "ORGANISM", 185, 195], ["parainfluenza virus", "ORGANISM", 200, 219], ["hepatitis B virus", "SPECIES", 96, 113], ["human", "SPECIES", 179, 184], ["rhinovirus and parainfluenza virus", "SPECIES", 185, 219], ["CMV", "SPECIES", 88, 91], ["hepatitis B virus", "SPECIES", 96, 113], ["human rhinovirus", "SPECIES", 179, 195], ["parainfluenza virus", "SPECIES", 200, 219], ["mogamulizumab", "TREATMENT", 36, 49], ["CMV", "PROBLEM", 88, 91], ["hepatitis B virus", "PROBLEM", 96, 113], ["IntroductionCommunity respiratory viruses (CRVs)", "PROBLEM", 122, 170], ["human rhinovirus", "PROBLEM", 179, 195], ["parainfluenza virus", "PROBLEM", 200, 219], ["CMV", "OBSERVATION", 88, 91], ["respiratory viruses", "OBSERVATION", 144, 163]]], ["However, these viruses often cause severe pneumonia in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT) mainly through decreased T cell responses [8e10].IntroductionHere we report a case of fatal pneumonia and viremia due to human parainfluenza virus type 1 (HPIV-1) in a 65-year-old male patient with adult T-cell leukemiaelymphoma (ATL) treated with mogamulizumab.Case reportA 65-years-old male patient was diagnosed as having an acute type of ATL after eleven years of chronic phase, because the number of white blood cells (WBC) and lactate dehydrogenase (LDH) in the peripheral blood were markedly increased to 43,700/mL and 700 IU/ L, respectively.", [["leukemia", "ANATOMY", 69, 77], ["hematopoietic stem cell", "ANATOMY", 99, 122], ["T cell", "ANATOMY", 171, 177], ["adult T-cell leukemiaelymphoma", "ANATOMY", 344, 374], ["ATL", "ANATOMY", 376, 379], ["ATL", "ANATOMY", 488, 491], ["white blood cells", "ANATOMY", 551, 568], ["WBC", "ANATOMY", 570, 573], ["peripheral blood", "ANATOMY", 614, 630], ["pneumonia", "DISEASE", 42, 51], ["leukemia", "DISEASE", 69, 77], ["pneumonia", "DISEASE", 238, 247], ["viremia", "DISEASE", 252, 259], ["human parainfluenza virus", "DISEASE", 267, 292], ["adult T-cell leukemiaelymphoma", "DISEASE", 344, 374], ["ATL", "DISEASE", 376, 379], ["mogamulizumab", "CHEMICAL", 394, 407], ["ATL", "DISEASE", 488, 491], ["lactate", "CHEMICAL", 579, 586], ["mogamulizumab", "CHEMICAL", 394, 407], ["lactate", "CHEMICAL", 579, 586], ["patients", "ORGANISM", 55, 63], ["leukemia", "CANCER", 69, 77], ["hematopoietic stem cell", "CELL", 99, 122], ["T cell", "CELL", 171, 177], ["human", "ORGANISM", 267, 272], ["parainfluenza virus type 1", "ORGANISM", 273, 299], ["HPIV-1", "ORGANISM", 301, 307], ["patient", "ORGANISM", 331, 338], ["adult T-cell leukemiaelymphoma", "CANCER", 344, 374], ["ATL", "CANCER", 376, 379], ["mogamulizumab", "SIMPLE_CHEMICAL", 394, 407], ["patient", "ORGANISM", 439, 446], ["ATL", "CANCER", 488, 491], ["white blood cells", "CELL", 551, 568], ["WBC", "CELL", 570, 573], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 579, 600], ["LDH", "GENE_OR_GENE_PRODUCT", 602, 605], ["peripheral blood", "ORGANISM_SUBSTANCE", 614, 630], ["white blood cells", "CELL_TYPE", 551, 568], ["WBC", "CELL_TYPE", 570, 573], ["lactate dehydrogenase", "PROTEIN", 579, 600], ["LDH", "PROTEIN", 602, 605], ["patients", "SPECIES", 55, 63], ["human", "SPECIES", 267, 272], ["parainfluenza virus type 1", "SPECIES", 273, 299], ["patient", "SPECIES", 331, 338], ["patient", "SPECIES", 439, 446], ["human parainfluenza virus type 1 (HPIV-1", "SPECIES", 267, 307], ["these viruses", "PROBLEM", 9, 22], ["severe pneumonia", "PROBLEM", 35, 51], ["leukemia", "PROBLEM", 69, 77], ["hematopoietic stem cell transplantation", "TREATMENT", 99, 138], ["HSCT", "TEST", 140, 144], ["decreased T cell responses", "PROBLEM", 161, 187], ["fatal pneumonia", "PROBLEM", 232, 247], ["viremia", "PROBLEM", 252, 259], ["human parainfluenza virus type", "PROBLEM", 267, 297], ["adult T-cell leukemiaelymphoma", "PROBLEM", 344, 374], ["mogamulizumab", "TREATMENT", 394, 407], ["an acute type of ATL", "PROBLEM", 471, 491], ["chronic phase", "PROBLEM", 514, 527], ["white blood cells", "TEST", 551, 568], ["WBC", "TEST", 570, 573], ["lactate dehydrogenase", "TEST", 579, 600], ["LDH", "TEST", 602, 605], ["the peripheral blood", "TEST", 610, 630], ["viruses", "OBSERVATION", 15, 22], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["pneumonia", "OBSERVATION", 42, 51], ["leukemia", "OBSERVATION", 69, 77], ["hematopoietic stem cell transplantation", "OBSERVATION", 99, 138], ["fatal", "OBSERVATION_MODIFIER", 232, 237], ["pneumonia", "OBSERVATION", 238, 247], ["viremia", "OBSERVATION", 252, 259], ["cell leukemiaelymphoma", "OBSERVATION", 352, 374], ["acute", "OBSERVATION_MODIFIER", 474, 479], ["chronic phase", "OBSERVATION_MODIFIER", 514, 527], ["peripheral", "ANATOMY_MODIFIER", 614, 624], ["blood", "ANATOMY", 625, 630], ["markedly", "OBSERVATION_MODIFIER", 636, 644], ["increased", "OBSERVATION_MODIFIER", 645, 654]]], ["Therefore, combined regimens with VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone), AMP (doxorubicin, ranimustine, and prednisone), and VECP (vindesine, etoposide, carboplatin, and prednisone) were started as an induction chemotherapy.", [["VCAP", "CHEMICAL", 34, 38], ["vincristine", "CHEMICAL", 40, 51], ["cyclophosphamide", "CHEMICAL", 53, 69], ["doxorubicin", "CHEMICAL", 71, 82], ["prednisone", "CHEMICAL", 88, 98], ["AMP", "CHEMICAL", 101, 104], ["doxorubicin", "CHEMICAL", 106, 117], ["ranimustine", "CHEMICAL", 119, 130], ["prednisone", "CHEMICAL", 136, 146], ["VECP", "CHEMICAL", 153, 157], ["vindesine", "CHEMICAL", 159, 168], ["etoposide", "CHEMICAL", 170, 179], ["carboplatin", "CHEMICAL", 181, 192], ["prednisone", "CHEMICAL", 198, 208], ["VCAP", "CHEMICAL", 34, 38], ["vincristine", "CHEMICAL", 40, 51], ["cyclophosphamide", "CHEMICAL", 53, 69], ["doxorubicin", "CHEMICAL", 71, 82], ["prednisone", "CHEMICAL", 88, 98], ["AMP", "CHEMICAL", 101, 104], ["doxorubicin", "CHEMICAL", 106, 117], ["ranimustine", "CHEMICAL", 119, 130], ["prednisone", "CHEMICAL", 136, 146], ["VECP", "CHEMICAL", 153, 157], ["vindesine", "CHEMICAL", 159, 168], ["etoposide", "CHEMICAL", 170, 179], ["carboplatin", "CHEMICAL", 181, 192], ["prednisone", "CHEMICAL", 198, 208], ["VCAP", "SIMPLE_CHEMICAL", 34, 38], ["vincristine", "SIMPLE_CHEMICAL", 40, 51], ["cyclophosphamide", "SIMPLE_CHEMICAL", 53, 69], ["doxorubicin", "SIMPLE_CHEMICAL", 71, 82], ["prednisone", "SIMPLE_CHEMICAL", 88, 98], ["AMP", "SIMPLE_CHEMICAL", 101, 104], ["doxorubicin", "SIMPLE_CHEMICAL", 106, 117], ["ranimustine", "SIMPLE_CHEMICAL", 119, 130], ["prednisone", "SIMPLE_CHEMICAL", 136, 146], ["VECP", "SIMPLE_CHEMICAL", 153, 157], ["vindesine", "SIMPLE_CHEMICAL", 159, 168], ["etoposide", "SIMPLE_CHEMICAL", 170, 179], ["carboplatin", "SIMPLE_CHEMICAL", 181, 192], ["prednisone", "SIMPLE_CHEMICAL", 198, 208], ["combined regimens", "TREATMENT", 11, 28], ["VCAP (vincristine", "TREATMENT", 34, 51], ["cyclophosphamide", "TREATMENT", 53, 69], ["doxorubicin", "TREATMENT", 71, 82], ["prednisone", "TREATMENT", 88, 98], ["AMP", "TREATMENT", 101, 104], ["doxorubicin", "TREATMENT", 106, 117], ["ranimustine", "TREATMENT", 119, 130], ["prednisone", "TREATMENT", 136, 146], ["VECP", "TREATMENT", 153, 157], ["vindesine", "TREATMENT", 159, 168], ["etoposide", "TREATMENT", 170, 179], ["carboplatin", "TREATMENT", 181, 192], ["prednisone", "TREATMENT", 198, 208], ["an induction chemotherapy", "TREATMENT", 226, 251]]], ["Soon after the third course of VCAPeAMPeVECP therapies were finished, the number of circulating lymphocytes and ATL cells, LDH and soluble interleukin-2 receptor (sIL-2R) were unfortunately increased rapidly, suggesting that his status was turned to refractory phase.Case reportWe therefore introduced mogamulizumab at the dosage of 1 mg/kg per week as the salvage therapy based on the finding that positive ratio of the CCR4 antigen in ATL cells was 97%.", [["lymphocytes", "ANATOMY", 96, 107], ["ATL cells", "ANATOMY", 112, 121], ["ATL cells", "ANATOMY", 437, 446], ["VCAPeAMPeVECP", "CHEMICAL", 31, 44], ["mogamulizumab", "CHEMICAL", 302, 315], ["ATL", "DISEASE", 437, 440], ["VCAPeAMPeVECP", "CHEMICAL", 31, 44], ["mogamulizumab", "CHEMICAL", 302, 315], ["VCAPeAMPeVECP", "SIMPLE_CHEMICAL", 31, 44], ["lymphocytes", "CELL", 96, 107], ["ATL cells", "CELL", 112, 121], ["LDH", "GENE_OR_GENE_PRODUCT", 123, 126], ["interleukin-2 receptor", "GENE_OR_GENE_PRODUCT", 139, 161], ["sIL-2R", "GENE_OR_GENE_PRODUCT", 163, 169], ["mogamulizumab", "SIMPLE_CHEMICAL", 302, 315], ["CCR4 antigen", "GENE_OR_GENE_PRODUCT", 421, 433], ["ATL cells", "CELL", 437, 446], ["circulating lymphocytes", "CELL_TYPE", 84, 107], ["ATL cells", "CELL_TYPE", 112, 121], ["LDH", "PROTEIN", 123, 126], ["soluble interleukin-2 receptor", "PROTEIN", 131, 161], ["sIL", "PROTEIN", 163, 166], ["CCR4 antigen", "PROTEIN", 421, 433], ["ATL cells", "CELL_LINE", 437, 446], ["VCAPeAMPeVECP therapies", "TREATMENT", 31, 54], ["circulating lymphocytes", "TEST", 84, 107], ["ATL cells", "TEST", 112, 121], ["LDH", "TEST", 123, 126], ["soluble interleukin", "TEST", 131, 150], ["refractory phase", "PROBLEM", 250, 266], ["mogamulizumab", "TREATMENT", 302, 315], ["the salvage therapy", "TREATMENT", 353, 372], ["the CCR4 antigen", "TEST", 417, 433], ["ATL cells", "TEST", 437, 446], ["circulating lymphocytes", "OBSERVATION", 84, 107], ["ATL cells", "OBSERVATION", 112, 121]]], ["Before the treatment, the number of neutrophils, lymphocytes, and ATL cells in the peripheral blood was 2849/mL, 10,780/mL, and 847/mL, respectively.", [["neutrophils", "ANATOMY", 36, 47], ["lymphocytes", "ANATOMY", 49, 60], ["ATL cells", "ANATOMY", 66, 75], ["peripheral blood", "ANATOMY", 83, 99], ["neutrophils", "CELL", 36, 47], ["lymphocytes", "CELL", 49, 60], ["ATL cells", "CELL", 66, 75], ["peripheral blood", "ORGANISM_SUBSTANCE", 83, 99], ["neutrophils", "CELL_TYPE", 36, 47], ["lymphocytes", "CELL_TYPE", 49, 60], ["ATL cells", "CELL_TYPE", 66, 75], ["the treatment", "TREATMENT", 7, 20], ["neutrophils", "TEST", 36, 47], ["lymphocytes", "TEST", 49, 60], ["ATL cells", "TEST", 66, 75], ["lymphocytes", "ANATOMY", 49, 60], ["ATL cells", "OBSERVATION", 66, 75], ["peripheral", "ANATOMY_MODIFIER", 83, 93], ["blood", "ANATOMY", 94, 99]]], ["On day 2 after induction of mogamulizumab, ATL cells disappeared in the peripheral blood, and the number of lymphocytes was rapidly decreased to 460/mL, accompanied by the prolongation of severe lymphopenia (grade 3e4) (Fig. 1 ).", [["ATL cells", "ANATOMY", 43, 52], ["peripheral blood", "ANATOMY", 72, 88], ["lymphocytes", "ANATOMY", 108, 119], ["mogamulizumab", "CHEMICAL", 28, 41], ["ATL", "DISEASE", 43, 46], ["lymphopenia", "DISEASE", 195, 206], ["mogamulizumab", "CHEMICAL", 28, 41], ["mogamulizumab", "SIMPLE_CHEMICAL", 28, 41], ["ATL cells", "CELL", 43, 52], ["peripheral blood", "ORGANISM_SUBSTANCE", 72, 88], ["lymphocytes", "CELL", 108, 119], ["ATL cells", "CELL_LINE", 43, 52], ["lymphocytes", "CELL_TYPE", 108, 119], ["mogamulizumab", "TREATMENT", 28, 41], ["ATL cells", "PROBLEM", 43, 52], ["severe lymphopenia", "PROBLEM", 188, 206], ["ATL cells", "OBSERVATION", 43, 52], ["peripheral", "ANATOMY_MODIFIER", 72, 82], ["blood", "ANATOMY", 83, 88], ["lymphocytes", "OBSERVATION", 108, 119], ["decreased", "OBSERVATION_MODIFIER", 132, 141], ["prolongation", "OBSERVATION_MODIFIER", 172, 184], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["lymphopenia", "OBSERVATION", 195, 206]]], ["Despite prophylactic medication had been administered with levofloxacin (LVFX), itraconazole (ITCZ), sulfamethoxazole/trimethoprim (ST) and acyclovir (ACV), he suffered from infectious complications including CMV antigenemia, gram-negative bacterial sepsis, and aspergillosis during the clinical course.", [["levofloxacin", "CHEMICAL", 59, 71], ["LVFX", "CHEMICAL", 73, 77], ["itraconazole", "CHEMICAL", 80, 92], ["ITCZ), sulfamethoxazole/trimethoprim", "CHEMICAL", 94, 130], ["ST", "CHEMICAL", 132, 134], ["acyclovir", "CHEMICAL", 140, 149], ["ACV", "CHEMICAL", 151, 154], ["CMV antigenemia", "DISEASE", 209, 224], ["bacterial sepsis", "DISEASE", 240, 256], ["aspergillosis", "DISEASE", 262, 275], ["levofloxacin", "CHEMICAL", 59, 71], ["LVFX", "CHEMICAL", 73, 77], ["itraconazole", "CHEMICAL", 80, 92], ["ITCZ", "CHEMICAL", 94, 98], ["sulfamethoxazole", "CHEMICAL", 101, 117], ["trimethoprim", "CHEMICAL", 118, 130], ["acyclovir", "CHEMICAL", 140, 149], ["ACV", "CHEMICAL", 151, 154], ["levofloxacin", "SIMPLE_CHEMICAL", 59, 71], ["LVFX", "SIMPLE_CHEMICAL", 73, 77], ["itraconazole", "SIMPLE_CHEMICAL", 80, 92], ["ITCZ", "SIMPLE_CHEMICAL", 94, 98], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 101, 117], ["trimethoprim", "SIMPLE_CHEMICAL", 118, 130], ["ST", "SIMPLE_CHEMICAL", 132, 134], ["acyclovir", "SIMPLE_CHEMICAL", 140, 149], ["ACV", "SIMPLE_CHEMICAL", 151, 154], ["CMV", "ORGANISM", 209, 212], ["CMV", "SPECIES", 209, 212], ["prophylactic medication", "TREATMENT", 8, 31], ["levofloxacin", "TREATMENT", 59, 71], ["LVFX", "TREATMENT", 73, 77], ["itraconazole (ITCZ)", "TREATMENT", 80, 99], ["sulfamethoxazole", "TREATMENT", 101, 117], ["trimethoprim", "TREATMENT", 118, 130], ["acyclovir (ACV", "TREATMENT", 140, 154], ["infectious complications", "PROBLEM", 174, 198], ["CMV antigenemia", "PROBLEM", 209, 224], ["gram-negative bacterial sepsis", "PROBLEM", 226, 256], ["aspergillosis", "PROBLEM", 262, 275], ["infectious", "OBSERVATION_MODIFIER", 174, 184], ["CMV antigenemia", "OBSERVATION", 209, 224], ["negative bacterial sepsis", "OBSERVATION", 231, 256], ["aspergillosis", "OBSERVATION", 262, 275]]], ["Although these infections were well controlled by the broad spectrum antimicrobial treatment, multiple patchy ground-glass opacities in bilateral lungs, an atypical pattern of bacterial pneumonia, were appeared and gradually worsened.", [["lungs", "ANATOMY", 146, 151], ["infections", "DISEASE", 15, 25], ["bacterial pneumonia", "DISEASE", 176, 195], ["lungs", "ORGAN", 146, 151], ["these infections", "PROBLEM", 9, 25], ["the broad spectrum antimicrobial treatment", "TREATMENT", 50, 92], ["multiple patchy ground-glass opacities in bilateral lungs", "PROBLEM", 94, 151], ["bacterial pneumonia", "PROBLEM", 176, 195], ["infections", "OBSERVATION", 15, 25], ["multiple", "OBSERVATION_MODIFIER", 94, 102], ["patchy", "OBSERVATION_MODIFIER", 103, 109], ["ground-glass opacities", "OBSERVATION", 110, 132], ["bilateral", "ANATOMY_MODIFIER", 136, 145], ["lungs", "ANATOMY", 146, 151], ["atypical", "OBSERVATION_MODIFIER", 156, 164], ["pattern", "OBSERVATION_MODIFIER", 165, 172], ["bacterial", "OBSERVATION_MODIFIER", 176, 185], ["pneumonia", "OBSERVATION", 186, 195], ["gradually", "OBSERVATION_MODIFIER", 215, 224], ["worsened", "OBSERVATION_MODIFIER", 225, 233]]], ["Due to acute respiratory failure, he died on day 48 (Figs.", [["respiratory", "ANATOMY", 13, 24], ["respiratory failure", "DISEASE", 13, 32], ["acute respiratory failure", "PROBLEM", 7, 32], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory", "ANATOMY", 13, 24], ["failure", "OBSERVATION", 25, 32]]], ["Since chest CT showed typical patterns of viral pneumonia (Fig. 2) , the peripheral blood was collected premortally and examined with multiplex PCR kit (Seeplex RV15 OneStep ACE Detection, Seegene, South Korea), which can screen most CRVs including influenza virus A/B, human adenovirus, coronavirus, parainfluenza virus 1/2/3, rhinovirus A/B/C, respiratory syncytial (RS) virus A/B, bocavirus 1/2/3/4, metapneumovirus, and enterovirus [11] .", [["chest", "ANATOMY", 6, 11], ["peripheral blood", "ANATOMY", 73, 89], ["viral pneumonia", "DISEASE", 42, 57], ["parainfluenza virus", "DISEASE", 301, 320], ["respiratory syncytial (RS) virus", "DISEASE", 346, 378], ["peripheral blood", "ORGANISM_SUBSTANCE", 73, 89], ["influenza virus A/B", "ORGANISM", 249, 268], ["human adenovirus", "ORGANISM", 270, 286], ["coronavirus", "ORGANISM", 288, 299], ["parainfluenza virus 1/2/3", "ORGANISM", 301, 326], ["rhinovirus A/B/C", "ORGANISM", 328, 344], ["respiratory syncytial (RS) virus A/B", "ORGANISM", 346, 382], ["bocavirus 1/2/3/4", "ORGANISM", 384, 401], ["metapneumovirus", "ORGANISM", 403, 418], ["influenza virus", "SPECIES", 249, 264], ["human", "SPECIES", 270, 275], ["coronavirus", "SPECIES", 288, 299], ["parainfluenza virus", "SPECIES", 301, 320], ["human adenovirus", "SPECIES", 270, 286], ["parainfluenza virus", "SPECIES", 301, 320], ["rhinovirus A/B/C, respiratory syncytial (RS) virus", "SPECIES", 328, 378], ["chest CT", "TEST", 6, 14], ["viral pneumonia", "PROBLEM", 42, 57], ["the peripheral blood", "TEST", 69, 89], ["multiplex PCR kit", "TEST", 134, 151], ["ACE Detection", "TEST", 174, 187], ["CRVs", "TEST", 234, 238], ["influenza virus", "PROBLEM", 249, 264], ["human adenovirus", "PROBLEM", 270, 286], ["coronavirus", "PROBLEM", 288, 299], ["parainfluenza virus", "PROBLEM", 301, 320], ["rhinovirus A/B/C", "TEST", 328, 344], ["respiratory syncytial (RS) virus A/B", "PROBLEM", 346, 382], ["bocavirus", "PROBLEM", 384, 393], ["metapneumovirus", "PROBLEM", 403, 418], ["enterovirus", "PROBLEM", 424, 435], ["chest", "ANATOMY", 6, 11], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["pneumonia", "OBSERVATION", 48, 57], ["peripheral", "ANATOMY_MODIFIER", 73, 83], ["blood", "ANATOMY", 84, 89], ["respiratory syncytial", "ANATOMY", 346, 367], ["metapneumovirus", "ANATOMY", 403, 418]]], ["Consequently, RNA of HPIV-1 was detected in the blood and we diagnosed viremia due to HPIV-1.Case reportIn the autopsied lungs, cytoplasmic inclusion bodies and multinucleated syncytial giant cells were abundantly observed (Fig. 3) .", [["blood", "ANATOMY", 48, 53], ["lungs", "ANATOMY", 121, 126], ["cytoplasmic inclusion bodies", "ANATOMY", 128, 156], ["multinucleated syncytial giant cells", "ANATOMY", 161, 197], ["viremia", "DISEASE", 71, 78], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 21, 27], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 86, 92], ["lungs", "ORGAN", 121, 126], ["cytoplasmic", "ORGANISM_SUBSTANCE", 128, 139], ["syncytial giant cells", "CELL", 176, 197], ["HPIV", "PROTEIN", 21, 25], ["multinucleated syncytial giant cells", "CELL_TYPE", 161, 197], ["HPIV-1", "SPECIES", 21, 27], ["HPIV-1", "SPECIES", 86, 92], ["RNA of HPIV", "TEST", 14, 25], ["the blood", "TEST", 44, 53], ["viremia", "PROBLEM", 71, 78], ["HPIV", "PROBLEM", 86, 90], ["cytoplasmic inclusion bodies", "PROBLEM", 128, 156], ["multinucleated syncytial giant cells", "PROBLEM", 161, 197], ["blood", "ANATOMY", 48, 53], ["viremia", "OBSERVATION", 71, 78], ["lungs", "ANATOMY", 121, 126], ["cytoplasmic", "OBSERVATION_MODIFIER", 128, 139], ["inclusion bodies", "OBSERVATION", 140, 156], ["multinucleated", "OBSERVATION_MODIFIER", 161, 175], ["syncytial giant cells", "OBSERVATION", 176, 197]]], ["These findings are commonly observed in viral pneumonia and especially, the former finding strongly suggests RNA viral infection.", [["viral pneumonia", "DISEASE", 40, 55], ["viral infection", "DISEASE", 113, 128], ["viral pneumonia", "PROBLEM", 40, 55], ["RNA viral infection", "PROBLEM", 109, 128], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["pneumonia", "OBSERVATION", 46, 55], ["strongly suggests", "UNCERTAINTY", 91, 108], ["RNA", "OBSERVATION", 109, 112], ["viral infection", "OBSERVATION", 113, 128]]], ["Also, hyaline membrane formation reflecting diffuse alveolar damage was observed in the lung (Fig. 3) .", [["hyaline membrane", "ANATOMY", 6, 22], ["alveolar", "ANATOMY", 52, 60], ["lung", "ANATOMY", 88, 92], ["alveolar damage", "DISEASE", 52, 67], ["hyaline membrane", "CELLULAR_COMPONENT", 6, 22], ["alveolar", "TISSUE", 52, 60], ["lung", "ORGAN", 88, 92], ["hyaline membrane formation", "PROBLEM", 6, 32], ["diffuse alveolar damage", "PROBLEM", 44, 67], ["hyaline", "OBSERVATION_MODIFIER", 6, 13], ["membrane formation", "OBSERVATION", 14, 32], ["diffuse", "OBSERVATION_MODIFIER", 44, 51], ["alveolar", "ANATOMY_MODIFIER", 52, 60], ["damage", "OBSERVATION", 61, 67], ["lung", "ANATOMY", 88, 92]]], ["On the other hand, neutrophilic infiltration and microorganisms including bacteria and fungi were not observed.", [["neutrophilic", "ANATOMY", 19, 31], ["neutrophilic infiltration", "PROBLEM", 19, 44], ["microorganisms", "PROBLEM", 49, 63], ["bacteria", "PROBLEM", 74, 82], ["fungi", "PROBLEM", 87, 92], ["hand", "ANATOMY", 13, 17], ["neutrophilic infiltration", "OBSERVATION", 19, 44], ["bacteria", "OBSERVATION_MODIFIER", 74, 82]]], ["Also, CCR4 antigen-positive ATL cells were not detected at all in the lung and a variety of tissues, indicating that his ATL status was complete remission.", [["ATL cells", "ANATOMY", 28, 37], ["lung", "ANATOMY", 70, 74], ["tissues", "ANATOMY", 92, 99], ["ATL", "ANATOMY", 121, 124], ["ATL", "DISEASE", 121, 124], ["CCR4 antigen", "GENE_OR_GENE_PRODUCT", 6, 18], ["lung", "ORGAN", 70, 74], ["tissues", "TISSUE", 92, 99], ["ATL", "CANCER", 121, 124], ["CCR4 antigen", "PROTEIN", 6, 18], ["positive ATL cells", "CELL_TYPE", 19, 37], ["CCR4 antigen", "TEST", 6, 18], ["positive ATL cells", "PROBLEM", 19, 37], ["his ATL status", "PROBLEM", 117, 131], ["ATL cells", "OBSERVATION", 28, 37], ["lung", "ANATOMY", 70, 74]]], ["Taken together, we finally diagnosed that the cause of death was severe pneumonia due to HPIV-1 infection.DiscussionWe herein reported a case of fatal pneumonia and viremia due to HPIV-1 in a patient with ATL treated with mogamulizumab.", [["ATL", "ANATOMY", 205, 208], ["death", "DISEASE", 55, 60], ["pneumonia", "DISEASE", 72, 81], ["infection", "DISEASE", 96, 105], ["pneumonia", "DISEASE", 151, 160], ["viremia", "DISEASE", 165, 172], ["HPIV-1", "CHEMICAL", 180, 186], ["ATL", "DISEASE", 205, 208], ["mogamulizumab", "CHEMICAL", 222, 235], ["mogamulizumab", "CHEMICAL", 222, 235], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 89, 95], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 180, 186], ["patient", "ORGANISM", 192, 199], ["ATL", "CANCER", 205, 208], ["mogamulizumab", "SIMPLE_CHEMICAL", 222, 235], ["patient", "SPECIES", 192, 199], ["HPIV-1", "SPECIES", 89, 95], ["HPIV-1", "SPECIES", 180, 186], ["death", "PROBLEM", 55, 60], ["severe pneumonia", "PROBLEM", 65, 81], ["HPIV", "PROBLEM", 89, 93], ["1 infection", "PROBLEM", 94, 105], ["fatal pneumonia", "PROBLEM", 145, 160], ["viremia", "PROBLEM", 165, 172], ["HPIV", "PROBLEM", 180, 184], ["ATL", "TREATMENT", 205, 208], ["mogamulizumab", "TREATMENT", 222, 235], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["pneumonia", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 96, 105], ["fatal", "OBSERVATION_MODIFIER", 145, 150], ["pneumonia", "OBSERVATION", 151, 160], ["viremia", "OBSERVATION", 165, 172]]], ["There is only one report showing human parainfluenza virus type 2 (HPIV-2) viremia in a patient with acute myocarditis [12] .", [["parainfluenza virus", "DISEASE", 39, 58], ["viremia", "DISEASE", 75, 82], ["myocarditis", "DISEASE", 107, 118], ["human", "ORGANISM", 33, 38], ["parainfluenza virus type 2", "ORGANISM", 39, 65], ["HPIV-2", "ORGANISM", 67, 73], ["patient", "ORGANISM", 88, 95], ["human", "SPECIES", 33, 38], ["parainfluenza virus", "SPECIES", 39, 58], ["patient", "SPECIES", 88, 95], ["human parainfluenza virus", "SPECIES", 33, 58], ["human parainfluenza virus type 2", "PROBLEM", 33, 65], ["viremia", "PROBLEM", 75, 82], ["acute myocarditis", "PROBLEM", 101, 118], ["parainfluenza virus", "OBSERVATION", 39, 58], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["myocarditis", "OBSERVATION", 107, 118]]], ["To our knowledge, this case is the first report documenting viremia due to HPIV-1.DiscussionCRVs are widely known as causative pathogens of upper respiratory tract infection (URTI) in healthy subjects.", [["upper respiratory tract", "ANATOMY", 140, 163], ["viremia", "DISEASE", 60, 67], ["upper respiratory tract infection", "DISEASE", 140, 173], ["URTI", "DISEASE", 175, 179], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 75, 81], ["upper respiratory", "ORGANISM_SUBDIVISION", 140, 157], ["tract", "ORGANISM_SUBDIVISION", 158, 163], ["HPIV-1", "SPECIES", 75, 81], ["viremia", "PROBLEM", 60, 67], ["upper respiratory tract infection", "PROBLEM", 140, 173], ["viremia", "OBSERVATION", 60, 67], ["upper", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163], ["infection", "OBSERVATION", 164, 173]]], ["However, CRVs have also been recognized to cause lower respiratory tract infection (LRTI) with high mortality rate in patients with leukemia or recipients of HSCT [8,9,13e16] .", [["lower respiratory tract", "ANATOMY", 49, 72], ["leukemia", "ANATOMY", 132, 140], ["lower respiratory tract infection", "DISEASE", 49, 82], ["LRTI", "DISEASE", 84, 88], ["leukemia", "DISEASE", 132, 140], ["CRVs", "GENE_OR_GENE_PRODUCT", 9, 13], ["lower", "ORGANISM_SUBDIVISION", 49, 54], ["respiratory tract", "ORGANISM_SUBDIVISION", 55, 72], ["patients", "ORGANISM", 118, 126], ["leukemia", "CANCER", 132, 140], ["patients", "SPECIES", 118, 126], ["CRVs", "PROBLEM", 9, 13], ["lower respiratory tract infection", "PROBLEM", 49, 82], ["high mortality rate", "PROBLEM", 95, 114], ["leukemia", "PROBLEM", 132, 140], ["lower", "ANATOMY_MODIFIER", 49, 54], ["respiratory tract", "ANATOMY", 55, 72], ["infection", "OBSERVATION", 73, 82], ["leukemia", "OBSERVATION", 132, 140]]], ["LRTI due to HPIV occurred in 13%e43% in patients with leukemia and HSCT recipients, and its mortality rate was 12e50% [15] .", [["leukemia", "ANATOMY", 54, 62], ["LRTI", "DISEASE", 0, 4], ["HPIV", "DISEASE", 12, 16], ["leukemia", "DISEASE", 54, 62], ["patients", "ORGANISM", 40, 48], ["leukemia", "CANCER", 54, 62], ["patients", "SPECIES", 40, 48], ["HPIV", "SPECIES", 12, 16], ["LRTI", "PROBLEM", 0, 4], ["HPIV", "PROBLEM", 12, 16], ["leukemia", "PROBLEM", 54, 62], ["HSCT recipients", "TREATMENT", 67, 82], ["its mortality rate", "TEST", 88, 106], ["leukemia", "OBSERVATION", 54, 62]]], ["The most important risk factor for progression to LRTI is lymphopenia.", [["LRTI", "DISEASE", 50, 54], ["lymphopenia", "DISEASE", 58, 69], ["LRTI", "PROBLEM", 50, 54], ["lymphopenia", "PROBLEM", 58, 69], ["LRTI", "OBSERVATION", 50, 54], ["lymphopenia", "OBSERVATION", 58, 69]]], ["Although the thresholds vary according to studies, lymphocyte count less than 200/mL is accepted as the guideline [8, 13] .", [["lymphocyte", "ANATOMY", 51, 61], ["lymphocyte", "CELL", 51, 61], ["studies", "TEST", 42, 49], ["lymphocyte count", "TEST", 51, 67]]], ["In the present case, prolongation of severe lymphopenia less than 200/mL was considered as the possible main cause to develop fatal pneumonia and viremia due to HPIV-1.DiscussionChest CT images may help to differentiate between bacterial and viral pneumonia.", [["lymphopenia", "DISEASE", 44, 55], ["pneumonia", "DISEASE", 132, 141], ["viremia", "DISEASE", 146, 153], ["bacterial and viral pneumonia", "DISEASE", 228, 257], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 161, 167], ["HPIV-1", "SPECIES", 161, 167], ["severe lymphopenia", "PROBLEM", 37, 55], ["fatal pneumonia", "PROBLEM", 126, 141], ["viremia", "PROBLEM", 146, 153], ["HPIV", "PROBLEM", 161, 165], ["DiscussionChest CT images", "TEST", 168, 193], ["bacterial and viral pneumonia", "PROBLEM", 228, 257], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["lymphopenia", "OBSERVATION", 44, 55], ["fatal", "OBSERVATION_MODIFIER", 126, 131], ["pneumonia", "OBSERVATION", 132, 141], ["viremia", "OBSERVATION", 146, 153], ["bacterial", "OBSERVATION", 228, 237], ["viral", "OBSERVATION_MODIFIER", 242, 247], ["pneumonia", "OBSERVATION", 248, 257]]], ["Generally, interstitial infiltrates including multifocal distribution of ground-glass opacities suggest viral pneumonia [17e19].", [["interstitial infiltrates", "ANATOMY", 11, 35], ["viral pneumonia", "DISEASE", 104, 119], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 11, 35], ["interstitial infiltrates", "PROBLEM", 11, 35], ["ground-glass opacities", "PROBLEM", 73, 95], ["viral pneumonia", "PROBLEM", 104, 119], ["interstitial", "ANATOMY_MODIFIER", 11, 23], ["infiltrates", "OBSERVATION", 24, 35], ["multifocal", "OBSERVATION_MODIFIER", 46, 56], ["distribution", "OBSERVATION_MODIFIER", 57, 69], ["ground-glass opacities", "OBSERVATION", 73, 95], ["suggest", "UNCERTAINTY", 96, 103], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["pneumonia", "OBSERVATION", 110, 119]]], ["Regarding HPIV pneumonia, a recent study showed that tree-in-bud opacities reflecting bronchiolitis were the most common finding (67%) followed by bronchial wall thickening (38%) and ground-glass opacities (38%) [20] .", [["bud opacities", "ANATOMY", 61, 74], ["bronchial wall", "ANATOMY", 147, 161], ["pneumonia", "DISEASE", 15, 24], ["bronchiolitis", "DISEASE", 86, 99], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 147, 161], ["HPIV", "SPECIES", 10, 14], ["HPIV pneumonia", "PROBLEM", 10, 24], ["a recent study", "TEST", 26, 40], ["tree-in-bud opacities", "PROBLEM", 53, 74], ["bronchiolitis", "PROBLEM", 86, 99], ["bronchial wall thickening", "PROBLEM", 147, 172], ["ground-glass opacities", "PROBLEM", 183, 205], ["pneumonia", "OBSERVATION", 15, 24], ["tree", "OBSERVATION_MODIFIER", 53, 57], ["bud", "ANATOMY_MODIFIER", 61, 64], ["opacities", "OBSERVATION", 65, 74], ["bronchiolitis", "OBSERVATION", 86, 99], ["most common", "OBSERVATION_MODIFIER", 109, 120], ["bronchial", "ANATOMY", 147, 156], ["wall", "ANATOMY_MODIFIER", 157, 161], ["thickening", "OBSERVATION", 162, 172], ["ground", "OBSERVATION_MODIFIER", 183, 189], ["glass opacities", "OBSERVATION", 190, 205]]], ["Although the typical tree-inbud opacities were not observed in the present case, centrilobular nodules suggesting bronchiolitis were observed on day 32, and the findings were worsened to diffuse patchy ground-glass opacities over the clinical course (Fig. 2) .", [["centrilobular nodules", "ANATOMY", 81, 102], ["bronchiolitis", "DISEASE", 114, 127], ["tree-inbud opacities", "PATHOLOGICAL_FORMATION", 21, 41], ["centrilobular nodules", "PATHOLOGICAL_FORMATION", 81, 102], ["inbud opacities", "PROBLEM", 26, 41], ["centrilobular nodules", "PROBLEM", 81, 102], ["bronchiolitis", "PROBLEM", 114, 127], ["diffuse patchy ground-glass opacities", "PROBLEM", 187, 224], ["typical", "OBSERVATION_MODIFIER", 13, 20], ["tree", "OBSERVATION_MODIFIER", 21, 25], ["opacities", "OBSERVATION", 32, 41], ["not observed", "UNCERTAINTY", 47, 59], ["centrilobular", "OBSERVATION_MODIFIER", 81, 94], ["nodules", "OBSERVATION", 95, 102], ["suggesting", "UNCERTAINTY", 103, 113], ["bronchiolitis", "OBSERVATION", 114, 127], ["worsened", "OBSERVATION_MODIFIER", 175, 183], ["diffuse", "OBSERVATION_MODIFIER", 187, 194], ["patchy", "OBSERVATION_MODIFIER", 195, 201], ["ground-glass opacities", "OBSERVATION", 202, 224]]], ["Thus, CT images observed in this patient were consistent with the previous report of HPIV pneumonia.DiscussionIdeally, direct detection of virus from the lung is warranted to diagnose viral pneumonia.", [["lung", "ANATOMY", 154, 158], ["pneumonia", "DISEASE", 90, 99], ["pneumonia", "DISEASE", 190, 199], ["patient", "ORGANISM", 33, 40], ["lung", "ORGAN", 154, 158], ["patient", "SPECIES", 33, 40], ["HPIV", "SPECIES", 85, 89], ["CT images", "TEST", 6, 15], ["HPIV pneumonia", "PROBLEM", 85, 99], ["virus from the lung", "PROBLEM", 139, 158], ["diagnose viral pneumonia", "PROBLEM", 175, 199], ["HPIV", "ANATOMY", 85, 89], ["pneumonia", "OBSERVATION", 90, 99], ["virus", "OBSERVATION", 139, 144], ["lung", "ANATOMY", 154, 158], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["pneumonia", "OBSERVATION", 190, 199]]], ["Both immunostaining with anti-HPIV-1 antibodies and detection of HPIV-1 in the extraction liquid from lung tissue were attempted.", [["lung tissue", "ANATOMY", 102, 113], ["anti-HPIV-1", "GENE_OR_GENE_PRODUCT", 25, 36], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 65, 71], ["lung tissue", "TISSUE", 102, 113], ["anti-HPIV-1 antibodies", "PROTEIN", 25, 47], ["HPIV", "PROTEIN", 65, 69], ["HPIV-1", "SPECIES", 65, 71], ["anti-HPIV", "TEST", 25, 34], ["HPIV", "TEST", 65, 69], ["the extraction liquid", "TREATMENT", 75, 96], ["lung tissue", "ANATOMY", 102, 113]]], ["However, it was technically difficult to detect HPIV-1 in the lung because RNA is generally unstable and long-term fixation with formalin and paraffin should be cruel condition for RNA virus including HPIV-1.", [["lung", "ANATOMY", 62, 66], ["formalin", "CHEMICAL", 129, 137], ["formalin", "CHEMICAL", 129, 137], ["paraffin", "CHEMICAL", 142, 150], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 48, 54], ["lung", "ORGAN", 62, 66], ["formalin", "SIMPLE_CHEMICAL", 129, 137], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 201, 207], ["HPIV", "PROTEIN", 48, 52], ["HPIV-1", "SPECIES", 48, 54], ["HPIV-1", "SPECIES", 201, 207], ["HPIV", "TEST", 48, 52], ["long-term fixation with formalin", "TREATMENT", 105, 137], ["paraffin", "TREATMENT", 142, 150], ["RNA virus", "PROBLEM", 181, 190], ["lung", "ANATOMY", 62, 66], ["unstable", "OBSERVATION_MODIFIER", 92, 100]]], ["We finally diagnosed HPIV-1 pneumonia based on a line of evidence as listed below; 1) HPIV-1 was detected in the blood, 2) CT images were consistent with viral pneumonia, and 3) pathological findings suggested RNA viral infection in the lung.DiscussionUndoubtedly, mogamulizumab is a promising agent for the treatment of refractory ATL.", [["blood", "ANATOMY", 113, 118], ["lung", "ANATOMY", 237, 241], ["ATL", "ANATOMY", 332, 335], ["pneumonia", "DISEASE", 28, 37], ["viral pneumonia", "DISEASE", 154, 169], ["viral infection", "DISEASE", 214, 229], ["mogamulizumab", "CHEMICAL", 265, 278], ["ATL", "DISEASE", 332, 335], ["mogamulizumab", "CHEMICAL", 265, 278], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 86, 92], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["lung", "ORGAN", 237, 241], ["mogamulizumab", "SIMPLE_CHEMICAL", 265, 278], ["ATL", "CANCER", 332, 335], ["HPIV-1", "SPECIES", 21, 27], ["HPIV", "PROBLEM", 21, 25], ["1 pneumonia", "PROBLEM", 26, 37], ["HPIV", "TEST", 86, 90], ["CT images", "TEST", 123, 132], ["viral pneumonia", "PROBLEM", 154, 169], ["pathological findings", "TEST", 178, 199], ["RNA viral infection in the lung", "PROBLEM", 210, 241], ["refractory ATL", "PROBLEM", 321, 335], ["pneumonia", "OBSERVATION", 28, 37], ["blood", "ANATOMY", 113, 118], ["consistent with", "UNCERTAINTY", 138, 153], ["viral", "OBSERVATION_MODIFIER", 154, 159], ["pneumonia", "OBSERVATION", 160, 169], ["RNA", "OBSERVATION_MODIFIER", 210, 213], ["viral", "OBSERVATION_MODIFIER", 214, 219], ["infection", "OBSERVATION", 220, 229], ["lung", "ANATOMY", 237, 241], ["refractory", "OBSERVATION_MODIFIER", 321, 331], ["ATL", "OBSERVATION", 332, 335]]], ["However, its robust cytotoxicity may provoke life-threatening opportunistic infections as observed in the present case.", [["opportunistic infections", "DISEASE", 62, 86], ["life-threatening opportunistic infections", "PROBLEM", 45, 86], ["robust", "OBSERVATION_MODIFIER", 13, 19], ["cytotoxicity", "OBSERVATION", 20, 32], ["opportunistic", "OBSERVATION_MODIFIER", 62, 75], ["infections", "OBSERVATION", 76, 86]]], ["Although some reports showed ribavirin therapy with or without intravenous immunoglobulin (IVIG) was effective for the treatment of HPIV infection [9] , there is no established antiviral therapy for the treatment of HPIV infection.", [["intravenous", "ANATOMY", 63, 74], ["ribavirin", "CHEMICAL", 29, 38], ["HPIV infection", "DISEASE", 132, 146], ["infection", "DISEASE", 221, 230], ["ribavirin", "CHEMICAL", 29, 38], ["ribavirin", "SIMPLE_CHEMICAL", 29, 38], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 63, 89], ["IVIG", "SIMPLE_CHEMICAL", 91, 95], ["HPIV", "CANCER", 216, 220], ["intravenous immunoglobulin", "PROTEIN", 63, 89], ["HPIV", "SPECIES", 132, 136], ["HPIV", "SPECIES", 216, 220], ["ribavirin therapy", "TREATMENT", 29, 46], ["intravenous immunoglobulin (IVIG", "TREATMENT", 63, 95], ["HPIV infection", "PROBLEM", 132, 146], ["antiviral therapy", "TREATMENT", 177, 194], ["HPIV infection", "PROBLEM", 216, 230], ["ribavirin therapy", "OBSERVATION", 29, 46], ["infection", "OBSERVATION", 137, 146], ["no established", "UNCERTAINTY", 162, 176], ["antiviral therapy", "OBSERVATION", 177, 194], ["infection", "OBSERVATION", 221, 230]]], ["In this context, standard precaution is the most effective countermeasure to prevent the infection and spread of HPIV [8, 9] .DiscussionIn conclusion, we reported a case of fatal pneumonia and viremia due to HPIV-1 in a patient with ATL treated with mogamulizumab.", [["ATL", "ANATOMY", 233, 236], ["infection", "DISEASE", 89, 98], ["HPIV", "DISEASE", 113, 117], ["pneumonia", "DISEASE", 179, 188], ["viremia", "DISEASE", 193, 200], ["HPIV-1", "CHEMICAL", 208, 214], ["ATL", "DISEASE", 233, 236], ["mogamulizumab", "CHEMICAL", 250, 263], ["mogamulizumab", "CHEMICAL", 250, 263], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 208, 214], ["patient", "ORGANISM", 220, 227], ["ATL", "CANCER", 233, 236], ["mogamulizumab", "SIMPLE_CHEMICAL", 250, 263], ["patient", "SPECIES", 220, 227], ["HPIV", "SPECIES", 113, 117], ["HPIV-1", "SPECIES", 208, 214], ["standard precaution", "TREATMENT", 17, 36], ["the infection", "PROBLEM", 85, 98], ["fatal pneumonia", "PROBLEM", 173, 188], ["viremia", "PROBLEM", 193, 200], ["HPIV", "PROBLEM", 208, 212], ["ATL", "TREATMENT", 233, 236], ["mogamulizumab", "TREATMENT", 250, 263], ["infection", "OBSERVATION", 89, 98], ["fatal", "OBSERVATION_MODIFIER", 173, 178], ["pneumonia", "OBSERVATION", 179, 188], ["viremia", "OBSERVATION", 193, 200]]], ["The current case suggested that prolonged severe lymphopenia induced by mogamulizumab was most likely to let the patient susceptible to HPIV-1 infection.", [["lymphopenia", "DISEASE", 49, 60], ["mogamulizumab", "CHEMICAL", 72, 85], ["infection", "DISEASE", 143, 152], ["mogamulizumab", "CHEMICAL", 72, 85], ["mogamulizumab", "SIMPLE_CHEMICAL", 72, 85], ["patient", "ORGANISM", 113, 120], ["HPIV-1", "ORGANISM", 136, 142], ["patient", "SPECIES", 113, 120], ["HPIV-1", "SPECIES", 136, 142], ["prolonged severe lymphopenia", "PROBLEM", 32, 60], ["HPIV", "PROBLEM", 136, 140], ["1 infection", "PROBLEM", 141, 152], ["prolonged", "OBSERVATION_MODIFIER", 32, 41], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["lymphopenia", "OBSERVATION", 49, 60], ["infection", "OBSERVATION", 143, 152]]]], "42259965626fa14706d3f3c6881aaf082dadfb59": [["IntroductionThe miniaturization trend is being driven by portable devices development out of regard for reduction or elimination of reagents and assay time, more efficient analysis with lower energy consumption, and simplified operation.", [["reduction", "TREATMENT", 104, 113], ["reagents", "TREATMENT", 132, 140], ["lower energy consumption", "PROBLEM", 186, 210], ["simplified operation", "TREATMENT", 216, 236]]], ["Microfluidics is a powerful tool for downscaling devices, especially the flow-based ones, by providing an integrated platform including sample preparation, delivery and measurement with a high degree of automation, only small amounts of reagents and faster assay time (Chen et al., 2016; Mross et al., 2015; Sackmann et al., 2014; Streets and Huang, 2013) .", [["downscaling devices", "TREATMENT", 37, 56], ["sample preparation", "TREATMENT", 136, 154], ["delivery", "TREATMENT", 156, 164], ["measurement", "TEST", 169, 180], ["a high degree of automation", "PROBLEM", 186, 213], ["high degree", "OBSERVATION_MODIFIER", 188, 199], ["small", "OBSERVATION_MODIFIER", 220, 225]]], ["Therefore, microfluidic-based devices have grabbed considerable attention by researchers to produce point-of-care (POC) assays for a broad range of applications.", [["microfluidic-based devices", "TREATMENT", 11, 37], ["a broad range of applications", "TREATMENT", 131, 160]]], ["Microfluidic devices are usually characterized by low cost and simple fabrication process, thereby selection of available materials is extremely essential.", [["Microfluidic devices", "TREATMENT", 0, 20], ["low cost and simple fabrication process", "PROBLEM", 50, 89], ["low cost", "OBSERVATION", 50, 58], ["simple fabrication", "OBSERVATION", 63, 81]]], ["Conventional microfluidic devices are made of glass, silicon or polymer materials, such as polydimethylsiloxane (PDMS), polystyrene (PS), polycarbonate (PC), polymethyl methacrylate (PMMA), polyethylene terephthalate (PET) and polyvinyl chloride (PVC) (Dauson et al., 2016; Jackson et al., 2016; Kitsara and Ducr\u00e9e, 2013; Ogo\u0144czyk et al., 2010; Li et al., 2012; .", [["polydimethylsiloxane", "CHEMICAL", 91, 111], ["PDMS", "CHEMICAL", 113, 117], ["polystyrene", "CHEMICAL", 120, 131], ["PS", "CHEMICAL", 133, 135], ["polymethyl methacrylate", "CHEMICAL", 158, 181], ["PMMA", "CHEMICAL", 183, 187], ["polyethylene terephthalate", "CHEMICAL", 190, 216], ["PET", "CHEMICAL", 218, 221], ["polyvinyl chloride", "CHEMICAL", 227, 245], ["silicon", "CHEMICAL", 53, 60], ["polydimethylsiloxane", "CHEMICAL", 91, 111], ["PDMS", "CHEMICAL", 113, 117], ["polystyrene", "CHEMICAL", 120, 131], ["polycarbonate", "CHEMICAL", 138, 151], ["polymethyl methacrylate", "CHEMICAL", 158, 181], ["PMMA", "CHEMICAL", 183, 187], ["polyethylene terephthalate", "CHEMICAL", 190, 216], ["PET", "CHEMICAL", 218, 221], ["polyvinyl chloride", "CHEMICAL", 227, 245], ["PVC", "CHEMICAL", 247, 250], ["silicon", "SIMPLE_CHEMICAL", 53, 60], ["polydimethylsiloxane", "SIMPLE_CHEMICAL", 91, 111], ["polystyrene", "SIMPLE_CHEMICAL", 120, 131], ["PS", "SIMPLE_CHEMICAL", 133, 135], ["polycarbonate", "SIMPLE_CHEMICAL", 138, 151], ["PC", "SIMPLE_CHEMICAL", 153, 155], ["polymethyl methacrylate", "SIMPLE_CHEMICAL", 158, 181], ["PMMA", "SIMPLE_CHEMICAL", 183, 187], ["polyethylene terephthalate", "SIMPLE_CHEMICAL", 190, 216], ["PET", "SIMPLE_CHEMICAL", 218, 221], ["polyvinyl chloride", "SIMPLE_CHEMICAL", 227, 245], ["Conventional microfluidic devices", "TREATMENT", 0, 33], ["glass, silicon or polymer materials", "TREATMENT", 46, 81], ["polydimethylsiloxane (PDMS)", "TREATMENT", 91, 118], ["polystyrene (PS)", "TREATMENT", 120, 136], ["polycarbonate (PC), polymethyl methacrylate (PMMA), polyethylene terephthalate (PET) and polyvinyl chloride (PVC", "TREATMENT", 138, 250], ["microfluidic devices", "OBSERVATION", 13, 33]]], ["Although these materials are good for the fabrication and prototyping of microfluidic chips, they require sophisticated, expensive and timeconsuming fabrication processes without any exception, which limits their use in the development of microfluidic device towards low cost POC testing.", [["the fabrication", "TREATMENT", 38, 53], ["prototyping of microfluidic chips", "TREATMENT", 58, 91], ["expensive and timeconsuming fabrication processes", "TREATMENT", 121, 170], ["microfluidic device", "TREATMENT", 239, 258], ["POC testing", "TEST", 276, 287], ["good", "OBSERVATION_MODIFIER", 29, 33], ["microfluidic device", "OBSERVATION", 239, 258]]], ["In addition, the relative high manufacturing costs due to the materials and cleanliness requirements prevent to some extent the massive use of these devices worldwide.IntroductionPaper-based microfluidic analytical devices (\u03bcPADs) are emerged as an alternative to overcome the above limitations and was firstly proposed by the Whitesides' group in 2007 (Martinez et al., 2007) . \u03bcPADs introduce an innovative platform technology for fluid handling and analysis with wide range of applications including diagnostic biosensing, food safety and environmental monitoring (Tomazelli Coltro et al., 2014; Fernandes et al., 2017; Ghaderinezhad et al., 2017; K.etisen et al., 2013; Ma et al., 2018; Qi et al., 2017; Weng et al., 2018; Weng and Neethirajan, 2018a , 2017 Xia et al., 2016; , due to the advantages of portability, simplicity, economic affordability and minimal sample consumption (Akyazi et al., 2017; Cate et al., 2014; Gong and Sinton, 2017; He et al., 2016; Hu et al., 2014; Yamada et al., 2017) .", [["the relative high manufacturing costs", "PROBLEM", 13, 50], ["the materials", "TREATMENT", 58, 71], ["cleanliness requirements", "TREATMENT", 76, 100], ["these devices worldwide", "TREATMENT", 143, 166], ["IntroductionPaper", "TREATMENT", 167, 184], ["based microfluidic analytical devices (\u03bcPADs)", "TREATMENT", 185, 230], ["fluid handling", "TREATMENT", 433, 447], ["analysis", "TEST", 452, 460], ["diagnostic biosensing", "TEST", 503, 524], ["environmental monitoring", "TEST", 542, 566], ["high manufacturing", "OBSERVATION", 26, 44], ["massive", "OBSERVATION_MODIFIER", 128, 135]]], ["However, the low mechanical strength and surface tension as well as the requirement of hydrophobic barriers still limit their practical applications in making microfluidic analytical devices (Agustini et al., 2016; Akyazi et al., 2017; Dou et al., 2015; .IntroductionMore recently, thread substrate has been introduced into microfluidic devices, known as thread-based microfluidics, due to its features such as wide use, high availability, low cost, general hydrophilic nature, as well as the lightweight and easy biodegradability Gaines et al., 2018a Gaines et al., , 2018b Kabariya and Ramani, 2018; Ochiai et al., 2017; Chuan\u00e1Yeo and Teck\u00e1Lim, 2016) .", [["surface", "ANATOMY", 41, 48], ["the low mechanical strength", "PROBLEM", 9, 36], ["surface tension", "PROBLEM", 41, 56], ["hydrophobic barriers", "TREATMENT", 87, 107], ["microfluidic analytical devices", "TREATMENT", 159, 190], ["thread substrate", "TREATMENT", 282, 298], ["microfluidic devices", "TREATMENT", 324, 344], ["thread-based microfluidics", "TREATMENT", 355, 381], ["low mechanical strength", "OBSERVATION_MODIFIER", 13, 36], ["surface tension", "OBSERVATION", 41, 56], ["low cost", "OBSERVATION_MODIFIER", 440, 448], ["hydrophilic nature", "OBSERVATION_MODIFIER", 458, 476]]], ["Thread-based microfluidic devices utilize threads to construct fluidic channels to perform various analytical assays.", [["Thread-based microfluidic devices", "TREATMENT", 0, 33], ["various analytical assays", "TEST", 91, 116], ["microfluidic devices", "OBSERVATION", 13, 33]]], ["Thread refers to thin strand of cotton, nylon, or other fibers and the wicking property of which facilitates the fluidic flow without using an external pumping system.", [["fibers", "ANATOMY", 56, 62], ["fibers", "CELLULAR_COMPONENT", 56, 62], ["cotton, nylon, or other fibers", "TREATMENT", 32, 62], ["an external pumping system", "TREATMENT", 140, 166], ["fluidic flow", "OBSERVATION", 113, 125]]], ["In addition, the mechanical strength of thread is higher compared to paper even under wet condition.", [["mechanical strength", "OBSERVATION", 17, 36]]], ["Therefore, no hydrophobic barriers are required for the formation of microchannels, neither the mechanical pumps for the transportation of solutions.", [["hydrophobic barriers", "TREATMENT", 14, 34], ["the formation of microchannels", "TREATMENT", 52, 82], ["the mechanical pumps", "TREATMENT", 92, 112], ["the transportation of solutions", "TREATMENT", 117, 148], ["mechanical pumps", "OBSERVATION", 96, 112]]], ["Instead, in thread-based microfluidic devices, these may be achieved solely by the capillary force between fibers of the thread due to the high hydrophilic character (Berthier et al., 2017; Lu et al., 2015) .", [["capillary", "ANATOMY", 83, 92], ["fibers", "ANATOMY", 107, 113], ["capillary", "TISSUE", 83, 92], ["fibers", "CELLULAR_COMPONENT", 107, 113], ["thread-based microfluidic devices", "TREATMENT", 12, 45], ["the high hydrophilic character", "PROBLEM", 135, 165], ["microfluidic devices", "OBSERVATION", 25, 45], ["high", "OBSERVATION_MODIFIER", 139, 143], ["hydrophilic character", "OBSERVATION_MODIFIER", 144, 165]]], ["Other advantages of threads include the great capacity to be easily modified the properties of their fibers by immobilization or incorporation of chemicals to create reaction and detection regions and the less lost volume of unused volume of solution due to the better confinement of fluids.", [["fibers", "ANATOMY", 101, 107], ["fibers", "CELLULAR_COMPONENT", 101, 107], ["threads", "TREATMENT", 20, 27], ["the great capacity", "PROBLEM", 36, 54], ["immobilization", "TREATMENT", 111, 125], ["incorporation of chemicals", "TREATMENT", 129, 155], ["unused volume of solution", "TREATMENT", 225, 250], ["fluids", "OBSERVATION", 284, 290]]], ["Thread-based microfluidic devices have been found applications in portable diagnostic systems, smart bandages and even tissue engineering (Berthier et al., 2017) .", [["tissue", "ANATOMY", 119, 125], ["tissue", "TISSUE", 119, 125], ["Thread-based microfluidic devices", "TREATMENT", 0, 33], ["portable diagnostic systems", "TEST", 66, 93], ["smart bandages", "TREATMENT", 95, 109], ["microfluidic devices", "OBSERVATION", 13, 33], ["bandages", "OBSERVATION", 101, 109]]], ["There are a few reports demonstrating the capacity of threadbased microfluidics to be used in electrochemical detection Caetano et al., 2018; Carneiro et al., 2018; Song et al., 2017) , electrochemiluminescence detection Liu et al., 2016) , chemical sensing and synthesize (Banerjee et al., 2013; Cabot et al., 2018; Erenas et al., 2016; Li et al., 2017) , immunochromatographic assays Liu et al., 2017; Meng et al., 2017; Seth et al., 2018; Zhou et al., 2012) , capillary electrophoresis electrochemical (CE-EC) detection Wei et al., 2012) , pH sensing (Lyu et al., 2018; Punjiya et al., 2017) and cell culture .", [["cell", "ANATOMY", 599, 603], ["capillary", "TISSUE", 463, 472], ["cell", "CELL", 599, 603], ["threadbased microfluidics", "TREATMENT", 54, 79], ["immunochromatographic assays", "TEST", 357, 385], ["capillary electrophoresis", "TEST", 463, 488], ["pH sensing", "TEST", 543, 553], ["cell culture", "TEST", 599, 611]]], ["Threads hold a great promising potential for the development of wearable diagnostic devices by simply integrating with wearable materials (Derakhshandeh et al., 2018; Sadeqi et al., 2018) .IntroductionIn this review, we intend to give an overview of thread-based microfluidic platforms for a wide variety of applications.", [["wearable diagnostic devices", "TREATMENT", 64, 91], ["thread-based microfluidic platforms", "TREATMENT", 250, 285], ["a wide variety of applications", "TREATMENT", 290, 320]]], ["We focus on the primary advances reported in last 5 years with regard to fabrication methods, designs, diagnostic applications and performance of those thread-based microfluidic devices.", [["fabrication methods", "TREATMENT", 73, 92], ["those thread-based microfluidic devices", "TREATMENT", 146, 185], ["microfluidic devices", "OBSERVATION", 165, 185]]], ["Finally, a perspective on the future trends for the thread-based microfluidic devices is also given.Fabrication Techniques in Thread-based MicrofluidicsAs mentioned previously, the distinct characteristics of thread make it a useful material for the fabrication microfluidic devices, such as the simplicity, low cost, lightweight, easy access, functionality as well as suitability for mass fabrication methods like sewing or knitting (Li et al., 2009; Mross et al., 2015) .", [["the thread-based microfluidic devices", "TREATMENT", 48, 85], ["Fabrication Techniques", "TREATMENT", 100, 122], ["Thread-based MicrofluidicsAs", "TREATMENT", 126, 154], ["the fabrication microfluidic devices", "TREATMENT", 246, 282], ["mass fabrication methods", "TREATMENT", 385, 409], ["microfluidic devices", "OBSERVATION", 65, 85], ["microfluidic devices", "OBSERVATION", 262, 282]]], ["It also facilitates the fabrication of 3D structures and can be easily incorporated into garment due to its higher tensile strength than paper (Nilghaz et al., 2013) .", [["the fabrication of 3D structures", "TREATMENT", 20, 52]]], ["Typical thread materials used in making microfluidic devices are cotton Liu et al., 2017) , polyester (Adhikari et al., 2018; Jarujamrus et al., 2018; Nilghaz et al., 2016) , nylon Qiu et al., 2018) , acrylic (Cabot et al., 2018) , wool (Jeon et al., 2015a (Jeon et al., , 2015b or silk (Konwarh et al., 2016; Yan et al., 2015) .", [["polyester", "CHEMICAL", 92, 101], ["Typical thread materials", "TREATMENT", 0, 24], ["microfluidic devices", "TREATMENT", 40, 60]]], ["Usually, threads consist of fibers of natural origin such as cotton or cellulose, or of artificial origin such as polymers, aligned or twisted together.", [["fibers", "ANATOMY", 28, 34], ["fibers", "CELLULAR_COMPONENT", 28, 34], ["cellulose", "SIMPLE_CHEMICAL", 71, 80], ["cotton or cellulose", "TREATMENT", 61, 80], ["natural origin", "OBSERVATION_MODIFIER", 38, 52]]], ["The former being hydrophobic in its natural state and thus has to be treated (Li et al., 2009) or mercerized (Reches, 2013; Reches et al., 2010) in order to wick fluids.", [["hydrophobic", "OBSERVATION_MODIFIER", 17, 28]]], ["To obtain wicking of the fibers, wetting properties are necessary, including physical and chemical properties.", [["fibers", "ANATOMY", 25, 31], ["fibers", "CELLULAR_COMPONENT", 25, 31]]], ["In addition, the selection of threads for specific applications also depends on the microscale surface morphologies of different fibers (Nilghaz et al., 2014b) .Fabrication Techniques in Thread-based MicrofluidicsThe wicking of the liquid in thread relies on the twisted strands of cellulose fiber and the gap in between.", [["surface", "ANATOMY", 95, 102], ["fibers", "ANATOMY", 129, 135], ["fibers", "CELLULAR_COMPONENT", 129, 135], ["cellulose fiber", "CELLULAR_COMPONENT", 282, 297], ["specific applications", "TREATMENT", 42, 63], ["Fabrication Techniques", "TREATMENT", 161, 183], ["Thread-based Microfluidics", "TREATMENT", 187, 213], ["the twisted strands of cellulose fiber", "TREATMENT", 259, 297]]], ["The wicking capability enable the thread to push the liquid along the length without using any auxiliary pump, leading to simplifying the overall set-up significantly.", [["The wicking capability", "PROBLEM", 0, 22], ["any auxiliary pump", "TREATMENT", 91, 109]]], ["Therefore, wetting properties of the fibers are necessary.", [["fibers", "ANATOMY", 37, 43], ["fibers", "CELLULAR_COMPONENT", 37, 43], ["wetting properties of the fibers", "TREATMENT", 11, 43]]], ["Usually, thread needs to be undergone hydrophilically treatment to remove noncellulosic components in order to increase the wicking wettability, including plasma oxidation, chlorination, scouring with specific chemical solution (Erenas et al., 2016; Ulum et al., 2016; Wu et al., 2016) .", [["plasma", "ANATOMY", 155, 161], ["plasma", "ORGANISM_SUBSTANCE", 155, 161], ["hydrophilically treatment", "TREATMENT", 38, 63], ["noncellulosic components", "TREATMENT", 74, 98], ["the wicking wettability", "PROBLEM", 120, 143], ["plasma oxidation", "TREATMENT", 155, 171], ["chlorination", "TREATMENT", 173, 185]]], ["However, the modified hydrophilicity may reduce gradually with time, typically 24 h, due to the spontaneous reorientation of polar groups (Caschera et al., 2014) .", [["the modified hydrophilicity", "PROBLEM", 9, 36], ["hydrophilicity", "OBSERVATION", 22, 36]]], ["To maintain the wettability for a period of time is extremely important, especially for point-of-care testing (POCT) tools.", [["wettability", "OBSERVATION_MODIFIER", 16, 27]]], ["Li et al. (2018) utilized a biocompatible polymer, chitosan, to functionalize the cotton thread via electrostatic-interaction-mediated adsorption to prolong stable hydrophilicity.", [["chitosan", "CHEMICAL", 51, 59], ["chitosan", "SIMPLE_CHEMICAL", 51, 59], ["a biocompatible polymer, chitosan", "TREATMENT", 26, 59], ["the cotton thread", "TREATMENT", 78, 95], ["stable", "OBSERVATION_MODIFIER", 157, 163], ["hydrophilicity", "OBSERVATION", 164, 178]]], ["The results showed that the hydrophilicity of the chitosan functionalized cotton thread was stable even after storage for 3 months and it was able to increase the wicking rate.", [["chitosan", "CHEMICAL", 50, 58], ["chitosan", "SIMPLE_CHEMICAL", 50, 58], ["the chitosan functionalized cotton thread", "TREATMENT", 46, 87], ["hydrophilicity", "OBSERVATION_MODIFIER", 28, 42], ["stable", "OBSERVATION_MODIFIER", 92, 98]]], ["Berthier et al. (2017) investigated the flow patterns in different flow regimes for homogenous and heterogeneous fiber bundles by both theoretical and numerical analysis.", [["fiber bundles", "ANATOMY", 113, 126], ["fiber bundles", "CELLULAR_COMPONENT", 113, 126], ["the flow patterns", "TEST", 36, 53], ["different flow regimes", "TREATMENT", 57, 79], ["homogenous and heterogeneous fiber bundles", "PROBLEM", 84, 126], ["both theoretical and numerical analysis", "TEST", 130, 169], ["flow regimes", "OBSERVATION", 67, 79], ["heterogeneous", "OBSERVATION_MODIFIER", 99, 112], ["fiber bundles", "OBSERVATION", 113, 126]]], ["They drew a conclusion that a limited number of fibers was sufficient for thread-based capillary flows and various of flow patterns could occur in heterogeneous fiber bundles depending on the compactness and contact angles, allowing numerous of applications.", [["fibers", "ANATOMY", 48, 54], ["capillary", "ANATOMY", 87, 96], ["fiber bundles", "ANATOMY", 161, 174], ["fibers", "CELLULAR_COMPONENT", 48, 54], ["capillary", "TISSUE", 87, 96], ["fiber bundles", "CELLULAR_COMPONENT", 161, 174], ["thread-based capillary flows", "TEST", 74, 102], ["heterogeneous fiber bundles", "PROBLEM", 147, 174], ["capillary flows", "OBSERVATION", 87, 102], ["flow patterns", "OBSERVATION", 118, 131], ["heterogeneous", "OBSERVATION_MODIFIER", 147, 160], ["fiber bundles", "OBSERVATION", 161, 174], ["contact angles", "OBSERVATION", 208, 222]]], ["Jeon et al. (2015b) investigated the plasma treatments of wool fiber surface so as to changing the wettability of hydrophobic wool thread herein to control the flow rate of the thread-based microfluidic devices.", [["plasma", "ANATOMY", 37, 43], ["wool fiber surface", "ANATOMY", 58, 76], ["plasma", "ORGANISM_SUBSTANCE", 37, 43], ["the plasma treatments of wool fiber surface", "TREATMENT", 33, 76], ["hydrophobic wool thread herein", "TREATMENT", 114, 144], ["the thread-based microfluidic devices", "TREATMENT", 173, 210], ["microfluidic devices", "OBSERVATION", 190, 210]]], ["They reported that plasma treatment was able to improve the wettability due to the removal of the fatty acid layer on the surface.", [["plasma", "ANATOMY", 19, 25], ["surface", "ANATOMY", 122, 129], ["fatty acid", "CHEMICAL", 98, 108], ["fatty acid", "CHEMICAL", 98, 108], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["surface", "CELLULAR_COMPONENT", 122, 129], ["plasma treatment", "TREATMENT", 19, 35], ["the removal", "TREATMENT", 79, 90], ["the fatty acid layer", "PROBLEM", 94, 114], ["fatty acid", "OBSERVATION", 98, 108], ["layer", "OBSERVATION_MODIFIER", 109, 114], ["surface", "OBSERVATION_MODIFIER", 122, 129]]], ["Various gases (oxygen, argon, nitrogen and air), plasma treated wools had different flow rates and oxygen plasma was the most effective to change the wettability.", [["plasma", "ANATOMY", 49, 55], ["oxygen", "CHEMICAL", 15, 21], ["argon, nitrogen", "CHEMICAL", 23, 38], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 15, 21], ["argon", "CHEMICAL", 23, 28], ["nitrogen", "CHEMICAL", 30, 38], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["argon", "SIMPLE_CHEMICAL", 23, 28], ["nitrogen", "SIMPLE_CHEMICAL", 30, 38], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["plasma", "ORGANISM_SUBSTANCE", 106, 112], ["Various gases", "TEST", 0, 13], ["oxygen", "TREATMENT", 15, 21], ["argon", "TREATMENT", 23, 28], ["nitrogen", "TREATMENT", 30, 38], ["plasma", "TREATMENT", 49, 55], ["different flow rates", "PROBLEM", 74, 94], ["oxygen plasma", "TEST", 99, 112]]], ["As the treatment time increased, the wicking rate was found to increase, however, increasing time could damage the wool surface.", [["wool surface", "ANATOMY", 115, 127], ["wool surface", "CELLULAR_COMPONENT", 115, 127], ["the wicking rate", "TEST", 33, 49], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["wool", "OBSERVATION_MODIFIER", 115, 119], ["surface", "OBSERVATION_MODIFIER", 120, 127]]], ["Based on their findings, appropriate plasma treatments may used for different applications to acquire specific flow rate requirement in thread-base microfluidic devices.Fabrication Techniques in Thread-based MicrofluidicsIn a thread-based microfluidic device, the wicking of fluid depends on the passive capillary of the thread which is hardly controlled precisely due to formation of random orientation of cellulose fibers.", [["plasma", "ANATOMY", 37, 43], ["capillary", "ANATOMY", 304, 313], ["plasma", "ORGANISM_SUBSTANCE", 37, 43], ["capillary", "TISSUE", 304, 313], ["cellulose fibers", "CELLULAR_COMPONENT", 407, 423], ["Thread-based MicrofluidicsIn", "CELL_LINE", 195, 223], ["appropriate plasma treatments", "TREATMENT", 25, 54], ["different applications", "TREATMENT", 68, 90], ["specific flow rate requirement", "TREATMENT", 102, 132], ["thread-base microfluidic devices", "TREATMENT", 136, 168], ["Fabrication Techniques", "TREATMENT", 169, 191], ["a thread-based microfluidic device", "TREATMENT", 224, 258], ["the wicking of fluid", "TREATMENT", 260, 280], ["cellulose fibers", "TREATMENT", 407, 423], ["base", "ANATOMY_MODIFIER", 143, 147], ["microfluidic devices", "OBSERVATION", 148, 168], ["microfluidic device", "OBSERVATION", 239, 258], ["fluid", "OBSERVATION", 275, 280]]], ["To achieve a tunable hydrophobicity in a thread-based microfluidic device, Choi et al. (2018) used twelve-fold diluted polysiloxanes to partially change the hydrophilicity of the cotton thread to obtain desirable fluidic delay and optimum interaction between the antibody-functionalized gold nanoparticle probes and target antigen (Fig. 1) .", [["polysiloxanes", "CHEMICAL", 119, 132], ["polysiloxanes", "CHEMICAL", 119, 132], ["polysiloxanes", "SIMPLE_CHEMICAL", 119, 132], ["gold nanoparticle", "SIMPLE_CHEMICAL", 287, 304], ["antibody", "PROTEIN", 263, 271], ["target antigen", "PROTEIN", 316, 330], ["a tunable hydrophobicity", "TREATMENT", 11, 35], ["a thread-based microfluidic device", "TREATMENT", 39, 73], ["twelve-fold diluted polysiloxanes", "TREATMENT", 99, 132], ["the cotton thread", "TREATMENT", 175, 192], ["desirable fluidic delay", "PROBLEM", 203, 226], ["the antibody", "TEST", 259, 271], ["microfluidic device", "OBSERVATION", 54, 73]]], ["With the modification, more resultant complexes were generated and captured at the test zone thus enhanced the sensitivity (around 10-fold signal enhancement) significantly.", [["the sensitivity", "TEST", 107, 122]]], ["They detected Salmonella enterica serotype Enteritidis in PBS, spiked whole milk, juice and lettuce, detection limits of which were 500, 1000, 1000 and 5000 CFU/mL, respectively.", [["milk", "ANATOMY", 76, 80], ["juice", "ANATOMY", 82, 87], ["Salmonella enterica serotype Enteritidis", "ORGANISM", 14, 54], ["milk", "ORGANISM_SUBSTANCE", 76, 80], ["juice", "ORGANISM_SUBSTANCE", 82, 87], ["lettuce", "ORGANISM_SUBDIVISION", 92, 99], ["Salmonella", "SPECIES", 14, 24], ["enterica serotype Enteritidis", "SPECIES", 25, 54], ["milk", "SPECIES", 76, 80], ["juice", "SPECIES", 82, 87], ["Salmonella enterica serotype Enteritidis", "SPECIES", 14, 54], ["lettuce", "SPECIES", 92, 99], ["Salmonella enterica serotype Enteritidis", "PROBLEM", 14, 54], ["Salmonella", "OBSERVATION_MODIFIER", 14, 24], ["enterica", "OBSERVATION_MODIFIER", 25, 33], ["serotype Enteritidis", "OBSERVATION", 34, 54]]], ["The entire sample-to-answer assay needed only 10 min in comparison with several days required for a conventional bacterial plating assay. network to achieve mixing .", [["network", "MULTI-TISSUE_STRUCTURE", 138, 145], ["a conventional bacterial plating assay", "TEST", 98, 136]]], ["Recently, the use of the thread-based microfluidics has been applied to immunoassays Mao et al., 2015a; Song et al., 2017) , determination of nucleic acids , proteins Mao et al., 2015b; Nilghaz et al., 2014a; Ulum et al., 2016) , glucose Lee et al., 2018; Yang et al., 2014a) , virus (Weng and Neethirajan, 2018b) , small ions (Jarujamrus et al., 2018; Yan et al., 2015) , bacteria isolation and quantification , chemotaxis studies for cell culture systems Ramesan et al., 2016) , blood typing (Nilghaz et al., 2014b) , chemical synthesis (Banerjee et al., 2013) and metabolite analysis (Cabot et al., 2018) .", [["cell", "ANATOMY", 436, 440], ["blood", "ANATOMY", 481, 486], ["nucleic acids", "CHEMICAL", 142, 155], ["glucose", "CHEMICAL", 230, 237], ["glucose", "CHEMICAL", 230, 237], ["glucose", "SIMPLE_CHEMICAL", 230, 237], ["cell", "CELL", 436, 440], ["blood", "ORGANISM_SUBSTANCE", 481, 486], ["the thread-based microfluidics", "TREATMENT", 21, 51], ["nucleic acids", "TEST", 142, 155], ["virus", "PROBLEM", 278, 283], ["bacteria isolation", "PROBLEM", 373, 391], ["chemotaxis studies", "TEST", 413, 431], ["cell culture systems", "TEST", 436, 456], ["blood typing", "TEST", 481, 493], ["chemical synthesis", "TEST", 520, 538], ["metabolite analysis", "TEST", 567, 586]]], ["Typical thread-based microfluidic platforms are summarized in Table 1 .", [["Typical thread-based microfluidic platforms", "PROBLEM", 0, 43], ["thread", "OBSERVATION_MODIFIER", 8, 14], ["microfluidic platforms", "OBSERVATION", 21, 43]]], ["Details are demonstrated in the following sections.Colorimetric DetectionColorimetric enzyme-linked immunosorbent assay (ELISA) is a standard and reliable quantification method in laboratories.", [["sections", "ANATOMY", 42, 50], ["DetectionColorimetric enzyme", "PROTEIN", 64, 92], ["Colorimetric DetectionColorimetric enzyme-linked immunosorbent assay", "TEST", 51, 119]]], ["However, conventional ELISA is usually time consuming, labor-intensive and requires relative high sample/reagents consumption and bulky equipment.", [["labor", "PROBLEM", 55, 60], ["relative high sample/reagents consumption", "TREATMENT", 84, 125], ["bulky equipment", "TREATMENT", 130, 145]]], ["Thread-based microfluidics is a superior alternative to perform ELISA to overcome those shortcomings.", [["ELISA", "TEST", 64, 69], ["microfluidics", "OBSERVATION", 13, 26]]], ["In addition to the lower reagent consumption due to the small scale, the immobilization of probe is easier because of the high absorbability of the cotton compared to paper or other conventional materials for microfluidics.", [["the lower reagent consumption", "PROBLEM", 15, 44], ["the small scale", "TREATMENT", 52, 67], ["the immobilization of probe", "TREATMENT", 69, 96], ["the high absorbability of the cotton", "PROBLEM", 118, 154], ["small", "OBSERVATION_MODIFIER", 56, 61]]], ["Moreover, bulky and expensive equipment can be avoided (Bagherbaigi et al., 2014) .", [["bulky", "OBSERVATION_MODIFIER", 10, 15]]], ["Gonzalez et al. (2018b) reported ELISA on a thread for the quantitative detection of biotinylated goat anti-mouse IgG and rabbit IgG antibodies.", [["goat anti-mouse IgG", "GENE_OR_GENE_PRODUCT", 98, 117], ["rabbit", "ORGANISM", 122, 128], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 129, 143], ["biotinylated goat anti-mouse IgG", "PROTEIN", 85, 117], ["rabbit IgG antibodies", "PROTEIN", 122, 143], ["goat", "SPECIES", 98, 102], ["anti-mouse", "SPECIES", 103, 113], ["rabbit", "SPECIES", 122, 128], ["goat", "SPECIES", 98, 102], ["rabbit", "SPECIES", 122, 128], ["the quantitative detection", "TEST", 55, 81], ["biotinylated goat anti-mouse IgG", "TREATMENT", 85, 117], ["rabbit IgG antibodies", "TEST", 122, 143]]], ["The device was fabricated from a piece of nylon thread placed on top of Scotch packaging tape with the end trifurcated into three separate analysis sites, as shown in Fig. 2 .", [["Scotch packaging tape", "DNA", 72, 93], ["The device", "TREATMENT", 0, 10], ["a piece of nylon thread", "TREATMENT", 31, 54], ["Scotch packaging tape", "TREATMENT", 72, 93]]], ["The rabbit IgG was firstly spotted on the analysis sites and allowed to dry out.", [["rabbit", "ORGANISM", 4, 10], ["IgG", "GENE_OR_GENE_PRODUCT", 11, 14], ["rabbit IgG", "PROTEIN", 4, 14], ["rabbit", "SPECIES", 4, 10], ["rabbit", "SPECIES", 4, 10], ["The rabbit IgG", "TEST", 0, 14], ["rabbit", "OBSERVATION_MODIFIER", 4, 10], ["IgG", "OBSERVATION", 11, 14]]], ["The blocking buffer was then added on top of the antigen followed by adding secondary antibody.", [["secondary antibody", "PROTEIN", 76, 94], ["The blocking buffer", "TREATMENT", 0, 19], ["secondary antibody", "PROBLEM", 76, 94]]], ["After three washes by PBS running through the whole thread to soak up the excess wash buffer, a piece of cotton thread was positioned underneath the analysis sites.", [["cotton", "SPECIES", 105, 111], ["PBS", "TREATMENT", 22, 25], ["the excess wash buffer", "TREATMENT", 70, 92], ["a piece of cotton thread", "TREATMENT", 94, 118]]], ["The colorimetric solution was then added to the analysis sites and sit for 30 min followed by scanning to investigate the intensity of the purple color.", [["The colorimetric solution", "TREATMENT", 0, 25], ["scanning", "TEST", 94, 102], ["the purple color", "PROBLEM", 135, 151], ["purple color", "OBSERVATION", 139, 151]]], ["The sensitivity of the detection of femtomolar was133.8 fmol/zone.", [["femtomolar", "ANATOMY", 36, 46], ["the detection", "TEST", 19, 32], ["femtomolar", "TEST", 36, 46]]], ["Earlier, Gonzalez et al. (2017) utilized a similar nylon thread-based analytical device (\u00b5TAD) consisted of a nylon thread trifurcated into three channels terminating at open analysis sites at the end to assess the activity of acetylcholinesterase (AChE) via colorimetric analylsis.", [["acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 227, 247], ["AChE", "GENE_OR_GENE_PRODUCT", 249, 253], ["acetylcholinesterase", "PROTEIN", 227, 247], ["AChE", "PROTEIN", 249, 253], ["a similar nylon thread-based analytical device (\u00b5TAD)", "TREATMENT", 41, 94], ["a nylon thread", "TREATMENT", 108, 122], ["acetylcholinesterase (AChE", "TREATMENT", 227, 253], ["colorimetric analylsis", "TEST", 259, 281]]], ["As sample and indicator mixed together and traveled up to the analysis sites, an intense yellow color change then occurred indicating the presence of AChE.", [["sample", "ANATOMY", 3, 9], ["AChE", "GENE_OR_GENE_PRODUCT", 150, 154], ["AChE", "PROTEIN", 150, 154], ["the analysis sites", "TEST", 58, 76], ["an intense yellow color change", "PROBLEM", 78, 108], ["AChE", "PROBLEM", 150, 154], ["intense", "OBSERVATION_MODIFIER", 81, 88], ["yellow color", "OBSERVATION", 89, 101]]], ["An IC 50 value with a known inhibitor of neostigmine bromide (NB) was determined to be 1.74 nM.Colorimetric DetectionMao's group developed several cotton-based diagnosis devices for rapid detection of proteins for various immunochromatographic applications ( immunochromatographic assay on cotton thread for carcinoembryonic antigen (CEA) detection by using carbon nanotube/gold nanoparticles (CNT/GNPs) nanocomposite reporter probes.", [["neostigmine bromide", "CHEMICAL", 41, 60], ["NB", "CHEMICAL", 62, 64], ["carbon nanotube", "CHEMICAL", 358, 373], ["gold nanoparticles", "CHEMICAL", 374, 392], ["CNT", "CHEMICAL", 394, 397], ["neostigmine bromide", "CHEMICAL", 41, 60], ["carbon", "CHEMICAL", 358, 364], ["neostigmine bromide", "SIMPLE_CHEMICAL", 41, 60], ["NB", "SIMPLE_CHEMICAL", 62, 64], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 308, 332], ["CEA", "GENE_OR_GENE_PRODUCT", 334, 337], ["carbon nanotube", "SIMPLE_CHEMICAL", 358, 373], ["gold nanoparticles", "SIMPLE_CHEMICAL", 374, 392], ["GNPs", "SIMPLE_CHEMICAL", 398, 402], ["carcinoembryonic antigen", "PROTEIN", 308, 332], ["CEA", "PROTEIN", 334, 337], ["An IC", "TREATMENT", 0, 5], ["a known inhibitor of neostigmine bromide", "TREATMENT", 20, 60], ["Colorimetric Detection", "TEST", 95, 117], ["rapid detection", "TEST", 182, 197], ["various immunochromatographic applications", "TEST", 214, 256], ["immunochromatographic assay", "TEST", 259, 286], ["cotton thread", "TREATMENT", 290, 303], ["carcinoembryonic antigen", "TEST", 308, 332], ["carbon nanotube/gold nanoparticles (CNT/GNPs) nanocomposite reporter probes", "TREATMENT", 358, 433]]], ["As shown in Fig. 3(a) , the device consisted of a sample pad (glass fiber), an absorbent pad (filter paper strip) for outlet and a cotton thread formed channel in between.", [["the device", "TREATMENT", 24, 34], ["a sample pad (glass fiber", "TREATMENT", 48, 73], ["an absorbent pad (filter paper strip", "TREATMENT", 76, 112], ["outlet", "PROBLEM", 118, 124], ["a cotton thread", "TREATMENT", 129, 144]]], ["Pretreated cotton thread was immobilized with a certain concentration of CEA to form the test zone.", [["CEA", "GENE_OR_GENE_PRODUCT", 73, 76], ["CEA", "PROTEIN", 73, 76], ["cotton", "SPECIES", 11, 17], ["Pretreated cotton thread", "TREATMENT", 0, 24], ["a certain concentration of CEA", "TREATMENT", 46, 76], ["CEA", "OBSERVATION", 73, 76]]], ["In a typical assay, sample solution was added onto the sample pad followed by the running buffer to help the migration of sample on the thread.", [["sample", "ANATOMY", 122, 128], ["sample solution", "TREATMENT", 20, 35], ["the sample pad", "TREATMENT", 51, 65], ["the running buffer", "TREATMENT", 78, 96], ["the thread", "TREATMENT", 132, 142]]], ["The biosensor was able to detect CEA with a sensitivity of 2.32 ng/mL, which was 2-3 magnitudes superior than the traditional methods using solely gold nanoparticles (GNPs) or carbon nanotubes (CNTs) as reporter probes.", [["gold nanoparticles", "CHEMICAL", 147, 165], ["GNPs", "CHEMICAL", 167, 171], ["carbon nanotubes", "CHEMICAL", 176, 192], ["carbon", "CHEMICAL", 176, 182], ["CEA", "GENE_OR_GENE_PRODUCT", 33, 36], ["gold nanoparticles", "SIMPLE_CHEMICAL", 147, 165], ["GNPs", "SIMPLE_CHEMICAL", 167, 171], ["carbon nanotubes", "SIMPLE_CHEMICAL", 176, 192], ["CNTs", "SIMPLE_CHEMICAL", 194, 198], ["CEA", "PROTEIN", 33, 36], ["CEA", "TEST", 33, 36], ["a sensitivity", "TEST", 42, 55], ["solely gold nanoparticles (GNPs)", "TREATMENT", 140, 172], ["carbon nanotubes (CNTs", "TREATMENT", 176, 198]]], ["This biosensor provided a promising way for various protein biomarker tests in clinical diagnosis.", [["This biosensor", "TEST", 0, 14], ["various protein biomarker tests", "TEST", 44, 75]]], ["Liu et al. (2017) utilized a similar immunochromatograpgic assay on a cotton thread biosensor to detect a protein biomarker related to lung cancer, squamous cell carcinomaantigen (SCCA).", [["lung cancer", "ANATOMY", 135, 146], ["squamous cell", "ANATOMY", 148, 161], ["SCCA", "ANATOMY", 180, 184], ["lung cancer", "DISEASE", 135, 146], ["lung cancer", "CANCER", 135, 146], ["squamous cell carcinomaantigen", "CANCER", 148, 178], ["SCCA", "CANCER", 180, 184], ["a cotton thread biosensor", "TREATMENT", 68, 93], ["a protein biomarker", "TEST", 104, 123], ["lung cancer", "PROBLEM", 135, 146], ["squamous cell carcinomaantigen (SCCA)", "PROBLEM", 148, 185], ["lung", "ANATOMY", 135, 139], ["cancer", "OBSERVATION", 140, 146], ["squamous cell", "OBSERVATION", 148, 161]]], ["It obtained a superior sensitivity of 3.03 ng/mL, which was more sensitive (10 and 5000 folds) than previous reported CNT based lateral flow assays.", [["a superior sensitivity", "TEST", 12, 34], ["previous reported CNT based lateral flow assays", "TEST", 100, 147], ["lateral", "OBSERVATION_MODIFIER", 128, 135], ["flow", "OBSERVATION", 136, 140]]], ["With this method, Meng et al. (2017) successfully detected the human ferritin antigen with a detection limit of 50 ng/mL within 25 min without instrumentation.", [["human", "ORGANISM", 63, 68], ["ferritin antigen", "GENE_OR_GENE_PRODUCT", 69, 85], ["human ferritin antigen", "PROTEIN", 63, 85], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["the human ferritin antigen", "TEST", 59, 85], ["instrumentation", "TREATMENT", 143, 158]]], ["This sensitivity is nearly 500 folds lower than that of the similar report (Abera and Choi, 2010) .Colorimetric DetectionThe technique of thread-based microfluidics has distinct advantages over the colorimetric detection in traditional 96-well plates.", [["This sensitivity", "TEST", 0, 16], ["Colorimetric Detection", "TEST", 99, 121], ["thread-based microfluidics", "TREATMENT", 138, 164], ["the colorimetric detection", "TEST", 194, 220], ["distinct", "OBSERVATION_MODIFIER", 169, 177], ["advantages", "OBSERVATION_MODIFIER", 178, 188]]], ["It is apparent that small volumes of sample/reagents and short detection time are required due to the small scale of the thread devices and the superior probe absorbent capability with treatments.", [["sample/reagents", "TREATMENT", 37, 52], ["short detection time", "TEST", 57, 77], ["the thread devices", "TREATMENT", 117, 135], ["the superior probe absorbent capability", "TREATMENT", 140, 179], ["treatments", "TREATMENT", 185, 195], ["small", "OBSERVATION_MODIFIER", 20, 25], ["volumes", "OBSERVATION_MODIFIER", 26, 33], ["small", "OBSERVATION_MODIFIER", 102, 107], ["thread devices", "OBSERVATION", 121, 135], ["superior", "OBSERVATION_MODIFIER", 144, 152], ["absorbent capability", "OBSERVATION", 159, 179]]], ["In addition, the fabrication procedures and required equipment are much simpler and cost effective.", [["the fabrication procedures", "TREATMENT", 13, 39], ["equipment", "TREATMENT", 53, 62]]], ["Given the cost and efficiency by the thread-based microfluidics, it is a promising alternative to conventional ELISA and may become new diagnostic devices in the growing healthcare industry for probing a wide range of biological interactions.", [["the thread-based microfluidics", "TREATMENT", 33, 63], ["conventional ELISA", "TEST", 98, 116], ["new", "OBSERVATION_MODIFIER", 132, 135]]], ["Nilghaz et al. (2014a) reported a semi-quantitative thread-based analytical device by length measurement of color change on indicator treated threads using a printed ruler.", [["a semi-quantitative thread-based analytical device", "TREATMENT", 32, 82], ["color change", "PROBLEM", 108, 120], ["a printed ruler", "TREATMENT", 156, 171]]], ["The device was simply made of straight cotton/ polyester threads with a knot in the centre.", [["polyester", "CHEMICAL", 47, 56], ["The device", "TREATMENT", 0, 10], ["straight cotton/ polyester threads", "TREATMENT", 30, 64]]], ["The method utilized a specific colorimetric reaction between analyte molecules and indicator reagents, during which the resultant products underwent chromatographic elution and were driven by fixed volumes of sample as the aqueous carrier phase.", [["a specific colorimetric reaction", "PROBLEM", 20, 52], ["indicator reagents", "TREATMENT", 83, 101], ["chromatographic elution", "TREATMENT", 149, 172], ["the aqueous carrier phase", "TEST", 219, 244], ["chromatographic elution", "OBSERVATION", 149, 172]]], ["Samples of different analyte concentrations could result in specific lengths of color change on the thread, allowing the determination of the analyte concentration.", [["Samples", "ANATOMY", 0, 7], ["different analyte concentrations", "TREATMENT", 11, 43], ["color change", "PROBLEM", 80, 92], ["the analyte concentration", "TREATMENT", 138, 163]]], ["Protein and nitrite assays were successfully performed on the device and linear ranges of 0-1.5 mg/mL and 0-1000 \u00b5M were obtained, respectively.", [["nitrite", "CHEMICAL", 12, 19], ["nitrite", "CHEMICAL", 12, 19], ["nitrite", "SIMPLE_CHEMICAL", 12, 19], ["Protein", "TEST", 0, 7], ["nitrite assays", "TEST", 12, 26]]], ["Compared to other common used thread-based colorimetric methods, this length measurement method could be easily interpreted without the need of electronic equipment and trained professionals.", [["this length measurement method", "TEST", 65, 95], ["electronic equipment", "TREATMENT", 144, 164]]], ["Later, Nilghaz et al. .Table 1Summary of the typical thread-based microfluidic platforms reported in literatures.", [["microfluidic platforms", "OBSERVATION", 66, 88]]], ["Salmonella enterica serotype Enteritidis in phosphate buffered saline, spiked whole milk, juice and lettuce 500, 1000, 1000 and5000 CFU/mL, respectively Integrating polysiloxanes to obtain tunable hydrophobicity;Table 110-fold signal enhancement; Sample-to-answer process; Glucose linear dynamic range of 0-25 mM Eelectrodes made by painting nylon thread with layered silver/ carbon ink, silver/ silver chloride ink and carbon/graphite Electrochemical Nylon thread;Table 1Glucose and acetylthiocholineTable 1Linear dynamic detection range of 0-15 mM and 0-9.84 mg/mL Electrodes painted with conductive inks (continued on next page) X. Weng, et al. Biosensors and Bioelectronics 132 (2019) 171-185 (2014b) investigated the separation properties of cotton thread and silk fibers in blood typing analysis.", [["milk", "ANATOMY", 84, 88], ["juice", "ANATOMY", 90, 95], ["silk fibers", "ANATOMY", 765, 776], ["blood", "ANATOMY", 780, 785], ["phosphate", "CHEMICAL", 44, 53], ["Glucose", "CHEMICAL", 273, 280], ["silver", "CHEMICAL", 368, 374], ["carbon ink", "CHEMICAL", 376, 386], ["silver", "CHEMICAL", 388, 394], ["silver chloride", "CHEMICAL", 396, 411], ["carbon/graphite", "CHEMICAL", 420, 435], ["phosphate", "CHEMICAL", 44, 53], ["Glucose", "CHEMICAL", 273, 280], ["silver", "CHEMICAL", 368, 374], ["carbon", "CHEMICAL", 376, 382], ["silver", "CHEMICAL", 388, 394], ["silver chloride", "CHEMICAL", 396, 411], ["carbon", "CHEMICAL", 420, 426], ["graphite", "CHEMICAL", 427, 435], ["Salmonella enterica serotype Enteritidis", "ORGANISM", 0, 40], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 44, 69], ["milk", "ORGANISM_SUBSTANCE", 84, 88], ["juice", "ORGANISM_SUBSTANCE", 90, 95], ["polysiloxanes", "SIMPLE_CHEMICAL", 165, 178], ["Glucose", "SIMPLE_CHEMICAL", 273, 280], ["silver", "SIMPLE_CHEMICAL", 368, 374], ["carbon ink", "SIMPLE_CHEMICAL", 376, 386], ["silver", "SIMPLE_CHEMICAL", 388, 394], ["silver chloride ink", "SIMPLE_CHEMICAL", 396, 415], ["carbon", "SIMPLE_CHEMICAL", 420, 426], ["1Glucose", "SIMPLE_CHEMICAL", 471, 479], ["acetylthiocholineTable 1Linear", "SIMPLE_CHEMICAL", 484, 514], ["silk fibers", "CELL", 765, 776], ["blood", "ORGANISM_SUBSTANCE", 780, 785], ["Salmonella enterica serotype Enteritidis", "SPECIES", 0, 40], ["milk", "SPECIES", 84, 88], ["Salmonella enterica serotype Enteritidis", "SPECIES", 0, 40], ["lettuce", "SPECIES", 100, 107], ["Salmonella enterica serotype Enteritidis in phosphate buffered saline", "TREATMENT", 0, 69], ["tunable hydrophobicity", "TEST", 189, 211], ["signal enhancement", "TEST", 227, 245], ["Sample", "TEST", 247, 253], ["Glucose linear dynamic range", "TEST", 273, 301], ["painting nylon thread", "TREATMENT", 333, 354], ["layered silver/ carbon ink", "TREATMENT", 360, 386], ["silver/ silver chloride ink", "TREATMENT", 388, 415], ["carbon/graphite Electrochemical Nylon thread", "TREATMENT", 420, 464], ["conductive inks", "TREATMENT", 591, 606], ["Biosensors", "TEST", 648, 658], ["Bioelectronics", "TEST", 663, 677], ["cotton thread", "TREATMENT", 747, 760], ["blood typing analysis", "TEST", 780, 801], ["serotype Enteritidis", "OBSERVATION", 20, 40], ["cotton thread", "OBSERVATION", 747, 760]]], ["They used a fluorescent confocal microscopy to study the effect of the surface morphology of threads on the blood typing results.", [["surface", "ANATOMY", 71, 78], ["blood", "ANATOMY", 108, 113], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["a fluorescent confocal microscopy", "TEST", 10, 43], ["the blood typing", "TEST", 104, 120]]], ["Silk was found the more suitable substrate for blood typing purpose because the surface of which was smooth with no intrafiber gaps thus forming regular and continuous microfluidic channels.", [["blood", "ANATOMY", 47, 52], ["surface", "ANATOMY", 80, 87], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["blood typing purpose", "TEST", 47, 67], ["intrafiber gaps", "PROBLEM", 116, 131], ["no", "UNCERTAINTY", 113, 115], ["intrafiber gaps", "OBSERVATION", 116, 131], ["microfluidic channels", "OBSERVATION", 168, 189]]], ["Du et al. (2015) used a cotton thread device coupled with fluorescence method to quantitatively detect human genetic disease related DNA at room temperature.", [["human", "ORGANISM", 103, 108], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["a cotton thread device", "TREATMENT", 22, 44], ["fluorescence method", "TREATMENT", 58, 77], ["human genetic disease related DNA", "PROBLEM", 103, 136]]], ["The device (Fig. 3(b) ) was consisted of a single cotton thread strip positioned on two parallel double faced adhesive tapes and an absorbent pad at the downstream end.", [["The device (Fig. 3(b)", "TREATMENT", 0, 21], ["a single cotton thread strip", "TREATMENT", 41, 69], ["two parallel double faced adhesive tapes", "TREATMENT", 84, 124], ["an absorbent pad", "TREATMENT", 129, 145], ["adhesive tapes", "OBSERVATION", 110, 124], ["absorbent pad", "OBSERVATION", 132, 145]]], ["The glass fiber loading gold nanoparticle (AuNP) conjugates modified with adenosine based molecular beacon (ABMB) probes was attached to the other end of the thread.", [["gold nanoparticle", "CHEMICAL", 24, 41], ["AuNP", "CHEMICAL", 43, 47], ["adenosine", "CHEMICAL", 74, 83], ["adenosine", "CHEMICAL", 74, 83], ["gold nanoparticle", "SIMPLE_CHEMICAL", 24, 41], ["AuNP", "SIMPLE_CHEMICAL", 43, 47], ["adenosine", "SIMPLE_CHEMICAL", 74, 83], ["The glass fiber loading gold nanoparticle (AuNP) conjugates", "TREATMENT", 0, 59], ["adenosine based molecular beacon (ABMB) probes", "TREATMENT", 74, 120], ["glass fiber", "OBSERVATION", 4, 15]]], ["In an assay, a mixture solution of sample containing desired complementary and single base mismatched DNA sequences and AuNP-ABMB conjugates was added to the sample pad.", [["sample", "ANATOMY", 35, 41], ["AuNP", "CHEMICAL", 120, 124], ["ABMB", "CHEMICAL", 125, 129], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["AuNP-ABMB conjugates", "SIMPLE_CHEMICAL", 120, 140], ["complementary and single base mismatched DNA sequences", "DNA", 61, 115], ["a mixture solution of sample", "TREATMENT", 13, 41], ["single base mismatched DNA sequences", "TREATMENT", 79, 115], ["AuNP-ABMB conjugates", "TREATMENT", 120, 140], ["the sample pad", "TEST", 154, 168]]], ["In the presence of target DNA sequences, the hairpin structure of ABMB opened resulting in the release of the biotin group modified at one end of the DNA probes and reacting with the streptavidin immobilized on the test zone of the cotton thread.", [["ABMB", "CHEMICAL", 66, 70], ["biotin", "CHEMICAL", 110, 116], ["biotin", "CHEMICAL", 110, 116], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["ABMB", "GENE_OR_GENE_PRODUCT", 66, 70], ["biotin", "SIMPLE_CHEMICAL", 110, 116], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["streptavidin", "GENE_OR_GENE_PRODUCT", 183, 195], ["target DNA sequences", "DNA", 19, 39], ["ABMB", "PROTEIN", 66, 70], ["streptavidin", "PROTEIN", 183, 195], ["target DNA sequences", "TEST", 19, 39], ["the hairpin structure of ABMB", "PROBLEM", 41, 70], ["the biotin group", "TREATMENT", 106, 122], ["the DNA probes", "TREATMENT", 146, 160], ["the streptavidin", "TREATMENT", 179, 195], ["the cotton thread", "TREATMENT", 228, 245], ["hairpin structure", "OBSERVATION", 45, 62]]], ["A red band would then appear and quantitative measurements could be performed by analyzing the color intensity of the test zone with a scanner and \"ImageJ\" software.", [["A red band", "TREATMENT", 0, 10], ["quantitative measurements", "TEST", 33, 58]]], ["The device was able to discriminate the single based DNA related the disease hereditary tyrosinemia type I with a linear dynamic range of 2.5-100 nM.", [["hereditary tyrosinemia", "DISEASE", 77, 99], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["The device", "TREATMENT", 0, 10], ["the single based DNA", "PROBLEM", 36, 56], ["the disease hereditary tyrosinemia type I", "PROBLEM", 65, 106], ["disease", "OBSERVATION", 69, 76], ["tyrosinemia", "OBSERVATION", 88, 99]]], ["The distinguished advantage of this device is the roomtemperature detection capability with high sensitivity, which is much simpler and superior than those previous reports (Lin and Tseng, 2012) .Table 1Thread-based microfluidic devices may also apply for ion recognition.", [["this device", "TREATMENT", 31, 42], ["high sensitivity", "PROBLEM", 92, 108], ["1Thread-based microfluidic devices", "TREATMENT", 202, 236], ["high sensitivity", "OBSERVATION_MODIFIER", 92, 108]]], ["Erenas et al. (2016) demonstrated a cotton thread microfluidic colorimetric device of ionophore extraction chemistry for the optical recognition of potassium.", [["ionophore", "CHEMICAL", 86, 95], ["potassium", "CHEMICAL", 148, 157], ["ionophore", "CHEMICAL", 86, 95], ["potassium", "CHEMICAL", 148, 157], ["ionophore", "SIMPLE_CHEMICAL", 86, 95], ["potassium", "SIMPLE_CHEMICAL", 148, 157], ["a cotton thread microfluidic colorimetric device of ionophore extraction", "TREATMENT", 34, 106], ["potassium", "TEST", 148, 157]]], ["The device consisted of a 1 cm-long cotton thread sewn onto a piece of ethylene-vinyl acetate (EVA) foam.", [["ethylene-vinyl acetate", "CHEMICAL", 71, 93], ["ethylene-vinyl acetate", "CHEMICAL", 71, 93], ["EVA", "CHEMICAL", 95, 98], ["ethylene-vinyl acetate", "SIMPLE_CHEMICAL", 71, 93], ["EVA", "SIMPLE_CHEMICAL", 95, 98], ["The device", "TREATMENT", 0, 10], ["a 1 cm-long cotton thread sewn", "TREATMENT", 24, 54], ["a piece of ethylene-vinyl acetate (EVA) foam", "TREATMENT", 60, 104], ["1 cm", "OBSERVATION_MODIFIER", 26, 30]]], ["The natural waxes in the cotton thread was removed by scouring in Na 2 CO 3 .", [["Na", "CHEMICAL", 66, 68], ["Na 2 CO 3", "CHEMICAL", 66, 75], ["the cotton thread", "TREATMENT", 21, 38], ["natural", "OBSERVATION_MODIFIER", 4, 11], ["waxes", "OBSERVATION_MODIFIER", 12, 17]]], ["A stitch on the side of the foam served as the sampling zone while the thread on the top as the recognition zone.", [["A stitch on the side of the foam", "TREATMENT", 0, 32], ["stitch", "OBSERVATION", 2, 8], ["foam", "OBSERVATION", 28, 32]]], ["The potassium sensing solution containing ionophore extraction was firstly added to the recognition zone and dried out at room temperature for use.", [["potassium", "CHEMICAL", 4, 13], ["ionophore", "CHEMICAL", 42, 51], ["potassium", "CHEMICAL", 4, 13], ["ionophore", "CHEMICAL", 42, 51], ["potassium", "SIMPLE_CHEMICAL", 4, 13], ["ionophore", "SIMPLE_CHEMICAL", 42, 51], ["The potassium sensing solution", "TREATMENT", 0, 30], ["ionophore extraction", "TREATMENT", 42, 62]]], ["In an assay, sample was added into the thread and allowed to flow to the detection area followed by image capture and processing.", [["sample", "ANATOMY", 13, 19]]], ["The device was employed to analyze potassium in mineral waters and no significant statistical differences (95% confidence interval) were obtained compared to those by the atomic absorption spectrometry method.Table 1As mentioned above, most of current thread-based microfluidic devices with colorimetric detection used cotton materials as substrates, and treatment processes are usually required to cleanse the impurities on surface for acquiring wicking capabilities.", [["surface", "ANATOMY", 425, 432], ["potassium", "CHEMICAL", 35, 44], ["potassium", "CHEMICAL", 35, 44], ["potassium", "SIMPLE_CHEMICAL", 35, 44], ["The device", "TREATMENT", 0, 10], ["potassium in mineral waters", "TREATMENT", 35, 62], ["significant statistical differences", "PROBLEM", 70, 105], ["the atomic absorption spectrometry method", "TEST", 167, 208], ["current thread-based microfluidic devices", "TREATMENT", 244, 285], ["colorimetric detection", "TEST", 291, 313], ["cotton materials", "TREATMENT", 319, 335], ["treatment processes", "TREATMENT", 355, 374], ["no", "UNCERTAINTY", 67, 69], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["microfluidic devices", "OBSERVATION", 265, 285]]], ["These thread-based microfluidic devices with colorimetric detection either obtained qualitative results by naked eyes or semi-quantitative measurement by a scanner or digital camera followed by software analysis of the color intensity.", [["eyes", "ANATOMY", 113, 117], ["eyes", "ORGAN", 113, 117], ["These thread-based microfluidic devices", "TREATMENT", 0, 39], ["colorimetric detection", "TEST", 45, 67], ["semi-quantitative measurement", "TEST", 121, 150], ["digital camera", "TEST", 167, 181], ["software analysis", "TEST", 194, 211], ["microfluidic devices", "OBSERVATION", 19, 39]]], ["However, accurate color change is hardly to achieve due to the errors generated by different models of electronic devices or lightness, saturation and optical background noise.", [["the errors", "PROBLEM", 59, 69], ["electronic devices", "TREATMENT", 103, 121], ["saturation", "TEST", 136, 146]]], ["These may affect significantly the interpretations of the same colors resulting in reducing the sensitivity of the system.Electrochemical detectionFluid handling in microfluidic systems is a major challenge.", [["Electrochemical detection", "TEST", 122, 147], ["Fluid handling in microfluidic systems", "PROBLEM", 147, 185], ["microfluidic systems", "OBSERVATION", 165, 185]]], ["It relies on external pumps or micropumps which are usually difficult for integration.", [["external pumps", "TREATMENT", 13, 27], ["micropumps", "PROBLEM", 31, 41], ["external pumps", "OBSERVATION", 13, 27]]], ["To overcome the limitation, passive pumping is a good solution.", [["passive pumping", "TREATMENT", 28, 43]]], ["The use of paper is one of the alternative that transport fluid only by capillary force.", [["fluid", "ANATOMY", 58, 63], ["capillary", "ANATOMY", 72, 81], ["capillary", "TISSUE", 72, 81]]], ["However, significant reduction of the mechanical strength when transporting aqueous solutions is a concern.", [["the mechanical strength", "TREATMENT", 34, 57], ["transporting aqueous solutions", "TREATMENT", 63, 93], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["mechanical strength", "OBSERVATION", 38, 57]]], ["Compared to the paper-based microfluidic devices, cotton threads may overcome the limitations as they have relative high mechanical strength and no complicated microfabrication process is required when used in making microchannels (Li et al., 2009; Nilghaz et al., 2013) .", [["the paper-based microfluidic devices", "TREATMENT", 12, 48], ["cotton threads", "TREATMENT", 50, 64], ["relative high mechanical strength", "PROBLEM", 107, 140], ["complicated microfabrication process", "PROBLEM", 148, 184], ["high mechanical strength", "OBSERVATION", 116, 140], ["no", "UNCERTAINTY", 145, 147], ["complicated", "OBSERVATION_MODIFIER", 148, 159], ["microfabrication", "OBSERVATION", 160, 176]]], ["Agustini et al. (2016 Agustini et al. ( , 2017 made some efforts in making low-cost thread-based microfluidic devices for electroanalytical applications, such as a thread based device for micro flow injection analysis based on electrochemical technique.", [["low-cost thread-based microfluidic devices", "TREATMENT", 75, 117], ["electroanalytical applications", "TREATMENT", 122, 152], ["a thread based device", "TREATMENT", 162, 183], ["micro flow injection analysis", "TEST", 188, 217], ["electrochemical technique", "TREATMENT", 227, 252]]], ["They exclaimed that thread microchannels presented high polarity because no wax or other non-cellulosic substance coated on the threads, thus no need for any treatment before use.", [["thread microchannels", "TREATMENT", 20, 40], ["any treatment", "TREATMENT", 154, 167], ["high polarity", "OBSERVATION_MODIFIER", 51, 64]]], ["A relative high flow rate of 2.2 \u00b5L/s could be achieved.", [["A relative high flow rate", "TEST", 0, 25], ["high", "OBSERVATION_MODIFIER", 11, 15], ["flow", "OBSERVATION_MODIFIER", 16, 20]]], ["This presented that thread-based microfluidic channels could provide high polarity and flow rate without using external components, and showed good performance when used in an electroanalytical device for micro flow injection analysis.", [["thread-based microfluidic channels", "TREATMENT", 20, 54], ["flow rate", "TEST", 87, 96], ["an electroanalytical device", "TREATMENT", 173, 200], ["micro flow injection analysis", "TEST", 205, 234], ["microfluidic channels", "OBSERVATION", 33, 54], ["high polarity", "OBSERVATION_MODIFIER", 69, 82]]], ["They utilized a similar microfluidic thread based electroanalytical system to perform chromatographic separations which based on an ion exchange mechanism and detected by gold electrodes manufactured directly on the cotton threads.", [["chromatographic separations", "TREATMENT", 86, 113], ["an ion exchange mechanism", "TREATMENT", 129, 154], ["the cotton threads", "TREATMENT", 212, 230], ["gold electrodes", "OBSERVATION", 171, 186]]], ["Carneiro et al. (2018) presented a 3D printed microfluidic electroanalytical device boning with cotton threads for amperometric detection of antioxidant in wine samples.", [["wine samples", "ANATOMY", 156, 168], ["wine samples", "ORGANISM_SUBSTANCE", 156, 168], ["a 3D printed microfluidic electroanalytical device", "TREATMENT", 33, 83], ["cotton threads", "TREATMENT", 96, 110], ["amperometric detection", "TEST", 115, 137]]], ["The structure of the thread-based electroanalytical device (\u00b5TED) is shown in Fig. 4(a) .", [["the thread-based electroanalytical device (\u00b5TED)", "TREATMENT", 17, 65], ["electroanalytical device", "OBSERVATION", 34, 58]]], ["The SPCEs (working electrode, counter electrode and reference electrode) were manufactured by the micro DEK 1760RS printer.", [["DEK", "GENE_OR_GENE_PRODUCT", 104, 107], ["DEK", "PROTEIN", 104, 107], ["The SPCEs (working electrode, counter electrode and reference electrode", "TREATMENT", 0, 71]]], ["The device consisted of an inlet, outlet and the SPEs attached near to the outlet.", [["The device", "TREATMENT", 0, 10], ["an inlet, outlet and the SPEs", "TREATMENT", 24, 53], ["inlet", "OBSERVATION_MODIFIER", 27, 32], ["outlet", "OBSERVATION_MODIFIER", 34, 40], ["outlet", "ANATOMY_MODIFIER", 75, 81]]], ["Nine parallel threads without twisting were positioned throughout the inlet and outlet reservoirs to form the microchannels.", [["without", "UNCERTAINTY", 22, 29], ["twisting", "OBSERVATION_MODIFIER", 30, 38], ["outlet reservoirs", "OBSERVATION", 80, 97]]], ["The detection zone on the SPEs was filled with cotton thread to keep the entire electrode immersed in the flowing solution during amperometric measurements.", [["SPEs", "ANATOMY", 26, 30], ["cotton thread", "TREATMENT", 47, 60], ["amperometric measurements", "TEST", 130, 155], ["zone", "OBSERVATION_MODIFIER", 14, 18]]], ["The detection limits of the biosensor for gallic and caffeic acid were 1.5 \u00d7 10 \u22126 M and 8.0 \u00d7 10 \u22127 M, respectively.", [["gallic", "CHEMICAL", 42, 48], ["caffeic acid", "CHEMICAL", 53, 65], ["gallic and caffeic acid", "CHEMICAL", 42, 65], ["gallic", "SIMPLE_CHEMICAL", 42, 48], ["caffeic acid", "SIMPLE_CHEMICAL", 53, 65], ["the biosensor", "TEST", 24, 37], ["gallic", "TEST", 42, 48], ["caffeic acid", "TEST", 53, 65]]], ["Using the device, their group (Caetano et al., 2018) detected phenol in drinking water.", [["phenol", "CHEMICAL", 62, 68], ["phenol", "CHEMICAL", 62, 68], ["phenol", "SIMPLE_CHEMICAL", 62, 68], ["the device", "TREATMENT", 6, 16]]], ["It utilized both the capillary force and gravity along the thread to transport the fluid and electrochemical detection to analyze the results.", [["capillary", "ANATOMY", 21, 30], ["fluid", "ANATOMY", 83, 88], ["capillary", "TISSUE", 21, 30], ["the capillary force", "TREATMENT", 17, 36], ["electrochemical detection", "TEST", 93, 118], ["fluid", "OBSERVATION", 83, 88]]], ["This method achieved a low limit of detection of 2.91 nmol/L and superior sensitivity compared to other phenol sensors.", [["phenol", "CHEMICAL", 104, 110], ["phenol", "CHEMICAL", 104, 110], ["phenol", "SIMPLE_CHEMICAL", 104, 110], ["This method", "TEST", 0, 11], ["2.91 nmol/L and superior sensitivity", "PROBLEM", 49, 85], ["other phenol sensors", "TEST", 98, 118], ["low limit", "OBSERVATION_MODIFIER", 23, 32]]], ["Dossi et al. (2018) developed a cotton thread fluidic device coupled with paper-based wall-jet electrochemical detector.", [["a cotton thread fluidic device", "TREATMENT", 30, 60], ["wall", "ANATOMY_MODIFIER", 86, 90]]], ["Hydrophobic barriers were firstly patterned onto the filter paper by a permanent Lumocolar marker.", [["Hydrophobic barriers", "TREATMENT", 0, 20], ["a permanent Lumocolar marker", "TREATMENT", 69, 97], ["filter", "OBSERVATION", 53, 59]]], ["Then, a mechanical micro pencil was used to draw the working, counter and reference electrodes onto the paper under a pressure of 1.91 N at a writing speed of 3 cm/s.", [["a mechanical micro pencil", "TREATMENT", 6, 31], ["a pressure", "TEST", 116, 126]]], ["Afterwards, 7 cm long pieces of cotton thread with hydrophilicity improvement by NaOH were positioned horizontally on a Teflon support.", [["NaOH", "CHEMICAL", 81, 85], ["NaOH", "CHEMICAL", 81, 85], ["Teflon", "CHEMICAL", 120, 126], ["NaOH", "SIMPLE_CHEMICAL", 81, 85], ["7 cm long pieces of cotton thread", "TREATMENT", 12, 45], ["a Teflon support", "TREATMENT", 118, 134], ["7 cm", "OBSERVATION_MODIFIER", 12, 16], ["hydrophilicity", "OBSERVATION_MODIFIER", 51, 65], ["improvement", "OBSERVATION_MODIFIER", 66, 77]]], ["One end of the thread was immersed in the electrolyte solution while the other was in contact with the working electrode.", [["the electrolyte solution", "TREATMENT", 38, 62], ["the working electrode", "TREATMENT", 99, 120]]], ["To obtain good alignment, an X, Y, Z mechanical manipulator was used.", [["an X, Y, Z mechanical manipulator", "TREATMENT", 26, 59], ["good", "OBSERVATION_MODIFIER", 10, 14], ["alignment", "OBSERVATION_MODIFIER", 15, 24]]], ["A filter paper was attached to the rear face of the PED-PDE to drain the running buffer.", [["A filter paper", "TREATMENT", 0, 14], ["the running buffer", "TREATMENT", 69, 87], ["filter", "OBSERVATION", 2, 8], ["drain", "OBSERVATION", 63, 68]]], ["The device allowed the rapid and selective detection of hydrophilic orthodiphenols with a low enough detection limit of 2 mM.", [["orthodiphenols", "CHEMICAL", 68, 82], ["orthodiphenols", "CHEMICAL", 68, 82], ["orthodiphenols", "SIMPLE_CHEMICAL", 68, 82], ["The device", "TREATMENT", 0, 10], ["hydrophilic orthodiphenols", "PROBLEM", 56, 82], ["hydrophilic orthodiphenols", "OBSERVATION", 56, 82], ["low enough", "OBSERVATION_MODIFIER", 90, 100]]], ["Gaines et al. (2018a) reported a thread-based electrochemical sensor for the detection of glucose.", [["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 90, 97], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["glucose", "TEST", 90, 97]]], ["The device is shown in Fig. 4(b) , three thread electrodes were made by painting nylon thread with layered silver/ carbon ink, silver/ silver chloride ink and carbon/graphite ink to serve as working electrode (WE), reference electrode (RE) and the counter electrode (CE), respectively.", [["silver", "CHEMICAL", 107, 113], ["carbon ink", "CHEMICAL", 115, 125], ["silver", "CHEMICAL", 127, 133], ["silver chloride", "CHEMICAL", 135, 150], ["carbon/graphite", "CHEMICAL", 159, 174], ["silver", "CHEMICAL", 107, 113], ["carbon", "CHEMICAL", 115, 121], ["silver", "CHEMICAL", 127, 133], ["silver chloride", "CHEMICAL", 135, 150], ["carbon", "CHEMICAL", 159, 165], ["graphite", "CHEMICAL", 166, 174], ["silver", "SIMPLE_CHEMICAL", 107, 113], ["carbon ink", "SIMPLE_CHEMICAL", 115, 125], ["silver", "SIMPLE_CHEMICAL", 127, 133], ["silver chloride ink", "SIMPLE_CHEMICAL", 135, 154], ["carbon", "SIMPLE_CHEMICAL", 159, 165], ["The device", "TREATMENT", 0, 10], ["three thread electrodes", "TREATMENT", 35, 58], ["painting nylon thread", "TREATMENT", 72, 93], ["layered silver/ carbon ink", "TREATMENT", 99, 125], ["silver/ silver chloride ink", "TREATMENT", 127, 154], ["carbon/graphite ink", "TREATMENT", 159, 178], ["the counter electrode (CE)", "TREATMENT", 244, 270]]], ["The chip was made on a piece of fabric attached to the laminated adhesive plastic.", [["The chip", "TREATMENT", 0, 8], ["a piece of fabric attached to the laminated adhesive plastic", "TREATMENT", 21, 81], ["chip", "OBSERVATION", 4, 8], ["adhesive plastic", "OBSERVATION", 65, 81]]], ["Laser cutter was used to make holes for fixing the thread electrodes.", [["Laser cutter", "TREATMENT", 0, 12], ["the thread electrodes", "TREATMENT", 47, 68]]], ["A paraffin film was merged onto the back of the chip by a heat gun to prevent the leakage.", [["paraffin", "CHEMICAL", 2, 10], ["A paraffin film", "TEST", 0, 15], ["a heat gun", "TREATMENT", 56, 66], ["the leakage", "PROBLEM", 78, 89], ["leakage", "OBSERVATION", 82, 89]]], ["The overhanging thread outside the chip connected with the potentionstat for measurement.", [["potentionstat", "DNA", 59, 72], ["the chip", "TREATMENT", 31, 39], ["overhanging", "OBSERVATION_MODIFIER", 4, 15]]], ["Beewax was finally painted layer by layer onto the edges of the chip to form the barrier.", [["Beewax", "SIMPLE_CHEMICAL", 0, 6], ["barrier", "TISSUE", 81, 88], ["layer", "OBSERVATION_MODIFIER", 27, 32], ["layer", "OBSERVATION_MODIFIER", 36, 41]]], ["PBS solution containing glucose oxidase (GOx) (10 mg/mL), potassium ferricyanide (K 3 [Fe(CN) 6 ]) (10 mg/mL) served as the mediator, and glucose of concentrations ranging from 0 m to 25 mM were tested in this electrochemical sensor.", [["glucose", "CHEMICAL", 24, 31], ["GOx", "CHEMICAL", 41, 44], ["potassium ferricyanide", "CHEMICAL", 58, 80], ["K", "CHEMICAL", 82, 83], ["Fe", "CHEMICAL", 87, 89], ["glucose", "CHEMICAL", 138, 145], ["glucose", "CHEMICAL", 24, 31], ["potassium ferricyanide", "CHEMICAL", 58, 80], ["K 3 [Fe(CN) 6", "CHEMICAL", 82, 95], ["glucose", "CHEMICAL", 138, 145], ["glucose oxidase", "SIMPLE_CHEMICAL", 24, 39], ["GOx", "SIMPLE_CHEMICAL", 41, 44], ["potassium ferricyanide", "SIMPLE_CHEMICAL", 58, 80], ["K 3 [Fe(CN) 6 ]", "SIMPLE_CHEMICAL", 82, 97], ["glucose", "SIMPLE_CHEMICAL", 138, 145], ["glucose oxidase", "PROTEIN", 24, 39], ["PBS solution", "TREATMENT", 0, 12], ["glucose oxidase (GOx)", "TREATMENT", 24, 45], ["potassium ferricyanide (K 3 [Fe(CN)", "TREATMENT", 58, 93], ["glucose of concentrations", "TEST", 138, 163]]], ["The results of which presented good suitability.", [["good", "OBSERVATION_MODIFIER", 31, 35]]], ["By using thread-based electrodes and nylon thread, Gaines et al. (2018b) made another electrochemical sensor to detect glucose and acetylthiocholine.", [["glucose", "CHEMICAL", 119, 126], ["acetylthiocholine", "CHEMICAL", 131, 148], ["glucose", "CHEMICAL", 119, 126], ["acetylthiocholine", "CHEMICAL", 131, 148], ["glucose", "SIMPLE_CHEMICAL", 119, 126], ["acetylthiocholine", "SIMPLE_CHEMICAL", 131, 148], ["thread-based electrodes and nylon thread", "TREATMENT", 9, 49], ["glucose", "TEST", 119, 126], ["acetylthiocholine", "TREATMENT", 131, 148]]], ["As seen in Fig. 4(c) , the device consisted of three nylonbased electrodes painted with conductive inks and a piece of nylon thread wrapped around to hold the solution and connect the electrodes.", [["the device", "TREATMENT", 23, 33], ["three nylonbased electrodes", "TREATMENT", 47, 74], ["conductive inks", "TREATMENT", 88, 103], ["a piece of nylon thread", "TREATMENT", 108, 131], ["the solution", "TREATMENT", 155, 167], ["the electrodes", "TREATMENT", 180, 194], ["conductive inks", "OBSERVATION", 88, 103]]], ["Cyclic voltammetry measurement was conducted by this device on the detection of glucose (0-15 mM) and acetylthiocholine (ATC) (0-9.84 mg/mL), good linear regression line with R 2 values of 0.985 and 0.995 were achieved.", [["glucose", "CHEMICAL", 80, 87], ["acetylthiocholine", "CHEMICAL", 102, 119], ["ATC", "CHEMICAL", 121, 124], ["glucose", "CHEMICAL", 80, 87], ["acetylthiocholine", "CHEMICAL", 102, 119], ["glucose", "SIMPLE_CHEMICAL", 80, 87], ["acetylthiocholine", "SIMPLE_CHEMICAL", 102, 119], ["ATC", "SIMPLE_CHEMICAL", 121, 124], ["Cyclic voltammetry measurement", "TEST", 0, 30], ["glucose", "TEST", 80, 87], ["acetylthiocholine (ATC", "TREATMENT", 102, 124]]], ["This nylon-based electrochemical sensor is very simple and will find intensive applications in the development of POCT diagnostic devices for the resource-limited regions.Electrochemical detectionImplantable diagnostic devices and smart wearable systems provide significant and powerful tools for diagnostic analysis.", [["This nylon", "TREATMENT", 0, 10], ["intensive applications", "TREATMENT", 69, 91], ["POCT diagnostic devices", "TREATMENT", 114, 137], ["Electrochemical detectionImplantable diagnostic devices", "TREATMENT", 171, 226], ["smart wearable systems", "TEST", 231, 253], ["diagnostic analysis", "TEST", 297, 316]]], ["Selection of proper materials for fabricating these devices are extremely important as the risks of mismatch or incompatibility between the properties of the biological tissues and the semiconductor-based electronics.", [["tissues", "ANATOMY", 169, 176], ["tissues", "TISSUE", 169, 176], ["Selection of proper materials", "TREATMENT", 0, 29], ["fabricating these devices", "TREATMENT", 34, 59], ["mismatch or incompatibility", "PROBLEM", 100, 127], ["proper materials", "OBSERVATION", 13, 29], ["mismatch", "OBSERVATION", 100, 108], ["biological tissues", "ANATOMY", 158, 176]]], ["For instance, Polyimide13 and Parylene14 are two of the extensively used as the substrates for making such devices.", [["Polyimide13", "CHEMICAL", 14, 25], ["Parylene14", "CHEMICAL", 30, 40], ["Polyimide13", "CHEMICAL", 14, 25], ["Parylene14", "CHEMICAL", 30, 40], ["Polyimide13", "SIMPLE_CHEMICAL", 14, 25], ["Parylene14", "SIMPLE_CHEMICAL", 30, 40], ["Polyimide13", "TREATMENT", 14, 25], ["Parylene14", "TREATMENT", 30, 40], ["such devices", "TREATMENT", 102, 114]]], ["However, the microfabrication cost is high due to the complicated microfabrication procedures and the requirement of clean room facilities when using these materials.", [["the microfabrication cost", "PROBLEM", 9, 34], ["the complicated microfabrication procedures", "TREATMENT", 50, 93], ["complicated", "OBSERVATION_MODIFIER", 54, 65], ["microfabrication", "OBSERVATION", 66, 82]]], ["As mentioned previously, the degradation and mechanical properties of threads can be easily modified by selected various material composition, hence enable threads to be an excellent candidate for the development of implantable diagnostic devices and smart wearable systems.", [["the degradation", "PROBLEM", 25, 40], ["mechanical properties of threads", "TREATMENT", 45, 77], ["implantable diagnostic devices", "TREATMENT", 216, 246]]], ["Mostafalu et al. (2016) reported a thread-based microfluidic sensor for 3D tissue embedding to measure strain, gastric and subcutanceous pH in vitro and in vivo.", [["tissue", "ANATOMY", 75, 81], ["gastric", "ANATOMY", 111, 118], ["tissue", "TISSUE", 75, 81], ["gastric", "MULTI-TISSUE_STRUCTURE", 111, 118], ["a thread-based microfluidic sensor", "TREATMENT", 33, 67], ["3D tissue embedding", "TREATMENT", 72, 91], ["strain", "PROBLEM", 103, 109], ["gastric and subcutanceous pH in vitro", "PROBLEM", 111, 148], ["gastric", "ANATOMY", 111, 118]]], ["As shown in Fig. 4(d) , microfluidic channels were formed by the hydrophilic threads embroidered into the hydrophilic woven fabric to transport fluid to the testing zone.", [["microfluidic channels", "TREATMENT", 24, 45], ["the hydrophilic threads", "TREATMENT", 61, 84], ["hydrophilic woven", "OBSERVATION", 106, 123], ["transport fluid", "OBSERVATION", 134, 149]]], ["Conductive threads functionalized with nanomaterials served as electrodes for the in vitro and in vivo measurement of physiological properties.", [["Conductive threads functionalized", "TREATMENT", 0, 33], ["nanomaterials", "TREATMENT", 39, 52], ["physiological properties", "OBSERVATION", 118, 142]]], ["A smartphone was then connected the sensor via signal processing electronics and wireless communication.", [["signal processing electronics", "TREATMENT", 47, 76]]], ["They evaluated the performance of this integrated system and the results suggested that it was able to act as a part of human skin or clothing and even be implanted.", [["skin", "ANATOMY", 126, 130], ["human", "ORGANISM", 120, 125], ["skin", "ORGAN", 126, 130], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["clothing", "TREATMENT", 134, 142], ["skin", "ANATOMY", 126, 130]]], ["This method presents a promising pathway to make smart wearable equipment, such as smart bandages, smart sutures for point-of-care diagnostics, surgical implants or other applications.", [["smart wearable equipment", "TREATMENT", 49, 73], ["smart bandages", "TREATMENT", 83, 97], ["smart sutures", "TREATMENT", 99, 112], ["surgical implants", "TREATMENT", 144, 161], ["other applications", "TREATMENT", 165, 183], ["surgical implants", "OBSERVATION", 144, 161]]], ["Glavan et al. (2016) developed an electroanalytical device by using stainless steel pins as the electrodes and cotton thread and paper as the liquid support and substrate.", [["an electroanalytical device", "TREATMENT", 31, 58], ["stainless steel pins", "TREATMENT", 68, 88], ["the electrodes and cotton thread", "TREATMENT", 92, 124], ["the liquid support", "TREATMENT", 138, 156]]], ["A stainless steel pin coated with a graphite and carbon nanotube ink served as the working electrode (WE) while bare stainless steel pins served as the reference and counter electrodes (RE and CE) and with a distance of~2.53 mm away from one another.Electrochemical detectionIn an assay, a droplet of liquid was pipetted to the thread, allowing for wicking to the electrodes and followed by the cyclic voltammograms recorded at a scan rate of 100 mV/s in a 500 \u03bcM solution of FeCO 2 H in 1 \u00d7 PBS (pH 7.6).", [["graphite", "CHEMICAL", 36, 44], ["carbon nanotube", "CHEMICAL", 49, 64], ["FeCO 2 H", "CHEMICAL", 476, 484], ["graphite", "CHEMICAL", 36, 44], ["carbon", "CHEMICAL", 49, 55], ["FeCO 2 H", "CHEMICAL", 476, 484], ["FeCO 2 H", "SIMPLE_CHEMICAL", 476, 484], ["A stainless steel pin coated", "TREATMENT", 0, 28], ["a graphite and carbon nanotube ink", "TREATMENT", 34, 68], ["the working electrode", "TREATMENT", 79, 100], ["bare stainless steel pins", "TREATMENT", 112, 137], ["a droplet of liquid", "TREATMENT", 288, 307], ["the cyclic voltammograms", "TEST", 391, 415], ["a scan rate", "TEST", 428, 439], ["a 500 \u03bcM solution", "TREATMENT", 455, 472], ["FeCO", "TREATMENT", 476, 480], ["pH", "TEST", 497, 499], ["stainless", "OBSERVATION_MODIFIER", 2, 11], ["steel", "OBSERVATION_MODIFIER", 12, 17], ["pin", "OBSERVATION_MODIFIER", 18, 21], ["coated", "OBSERVATION_MODIFIER", 22, 28], ["steel pins", "OBSERVATION", 127, 137]]], ["Fig. 5 shows the variation in the CVs of the FeCO 2 H solution for seven different devices.", [["FeCO 2 H", "CHEMICAL", 45, 53], ["FeCO 2 H", "CHEMICAL", 45, 53], ["the FeCO 2 H solution", "TREATMENT", 41, 62], ["seven different devices", "TREATMENT", 67, 90], ["variation", "OBSERVATION_MODIFIER", 17, 26]]], ["They found the results did not vary with the tension of the thread hence enable to form a stable electrodeelectrolyte interface and stable current.", [["a stable electrodeelectrolyte interface", "PROBLEM", 88, 127], ["tension", "OBSERVATION", 45, 52], ["stable", "OBSERVATION_MODIFIER", 90, 96], ["electrodeelectrolyte interface", "OBSERVATION", 97, 127], ["stable", "OBSERVATION_MODIFIER", 132, 138]]], ["Their method provides a promising way for the development of portable, versatile, easily storable and low-cost electroanalytical devices for various applications, though the variation in terms of the relative standard deviation (RSD) need to be improved.", [["easily storable and low-cost electroanalytical devices", "TREATMENT", 82, 136], ["various applications", "TREATMENT", 141, 161], ["the relative standard deviation (RSD)", "PROBLEM", 196, 233]]], ["Song et al. (2017) demonstrated an electrochemical immunoassay device using natural cotton thread for human ferritin determination.", [["human", "ORGANISM", 102, 107], ["ferritin", "GENE_OR_GENE_PRODUCT", 108, 116], ["human ferritin", "PROTEIN", 102, 116], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["an electrochemical immunoassay device", "TREATMENT", 32, 69], ["natural cotton thread", "TREATMENT", 76, 97], ["human ferritin determination", "TEST", 102, 130]]], ["An enhanced sensitivity of 1.58 ng/mL ferritin was achieved by using the electroactive report probe gold nanorod (GNR) compared with the gold nanoparticle report probe.", [["gold nanorod", "CHEMICAL", 100, 112], ["ferritin", "GENE_OR_GENE_PRODUCT", 38, 46], ["gold nanorod", "SIMPLE_CHEMICAL", 100, 112], ["GNR", "SIMPLE_CHEMICAL", 114, 117], ["ferritin", "PROTEIN", 38, 46], ["An enhanced sensitivity", "TEST", 0, 23], ["ng/mL ferritin", "TEST", 32, 46]]], ["The principle and procedures of the nature cotton thread based immunoassay device was shown in Fig. 6 .", [["the nature cotton thread based immunoassay device", "TREATMENT", 32, 81]]], ["The GNR-antibody-Ferritin complex was added onto the sample pad to wick along the cotton thread to the test zone and then reacted with the preimmoblilized capture antibody (dAb).", [["sample", "ANATOMY", 53, 59], ["GNR-antibody", "GENE_OR_GENE_PRODUCT", 4, 16], ["Ferritin", "GENE_OR_GENE_PRODUCT", 17, 25], ["GNR-antibody", "PROTEIN", 4, 16], ["Ferritin complex", "PROTEIN", 17, 33], ["preimmoblilized capture antibody", "PROTEIN", 139, 171], ["dAb", "PROTEIN", 173, 176], ["The GNR-antibody", "TEST", 0, 16], ["Ferritin complex", "PROBLEM", 17, 33], ["GNR", "OBSERVATION", 4, 7]]], ["The resultant sandwich GNR-dAb-FerritincAb complexes would present a purple band on the thread due to the accumulation of the GNR.", [["GNR", "PROTEIN", 23, 26], ["dAb", "PROTEIN", 27, 30], ["FerritincAb complexes", "PROTEIN", 31, 52], ["The resultant sandwich GNR", "TEST", 0, 26], ["FerritincAb complexes", "PROBLEM", 31, 52], ["a purple band", "PROBLEM", 67, 80], ["the accumulation of the GNR", "PROBLEM", 102, 129], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["sandwich GNR", "OBSERVATION", 14, 26], ["purple band", "OBSERVATION_MODIFIER", 69, 80], ["GNR", "OBSERVATION", 126, 129]]], ["To achieve quantitative results, the test zone was transferred to an electrochemical cell containing 750 \u00b5L HBr-Br 2 (6.0 mol/L HBr-0.6 mol/L Br 2 ) solutions to dissolve the captured GNR to perform ASV detection.", [["cell", "ANATOMY", 85, 89], ["Br 2", "CHEMICAL", 112, 116], ["HBr", "CHEMICAL", 128, 131], ["Br 2", "CHEMICAL", 142, 146], ["cell", "CELL", 85, 89], ["GNR", "SIMPLE_CHEMICAL", 184, 187], ["the test zone", "TEST", 33, 46], ["HBr", "TEST", 128, 131], ["mol/L Br 2 ) solutions", "TREATMENT", 136, 158], ["ASV detection", "TEST", 199, 212], ["GNR", "OBSERVATION", 184, 187]]], ["The ASV detection had a dynamic range of 5-5000 ng/mL with a detection limit of 1.58 ng/mL and a total assay time of 30 min.", [["The ASV detection", "TEST", 0, 17], ["a total assay", "TEST", 95, 108]]], ["This method offers a great way for bioassay applications that have high sensitivity requirement.Electrochemical detectionThread-based electrochemical devices are of distinct advantages compared to those coupled with surface-plasmon resonance, fluorescence or chemiluminescence, including simple instrumentation and signal quantification, low cost of the entire assay, and potential for onsite detection.", [["bioassay applications", "TREATMENT", 35, 56], ["high sensitivity requirement", "PROBLEM", 67, 95], ["Electrochemical detectionThread-based electrochemical devices", "TREATMENT", 96, 157], ["surface-plasmon resonance", "TEST", 216, 241], ["chemiluminescence", "TEST", 259, 276], ["simple instrumentation", "TREATMENT", 288, 310], ["signal quantification", "TEST", 315, 336], ["onsite detection", "TEST", 386, 402], ["electrochemical devices", "OBSERVATION", 134, 157]]], ["Although high sensitivity may be obtained in comparison with thread-based devices with colorimetric detection, the fabrication of electrodes increases the complexity of the device.Other detection methodsThere are a few thread-based microfluidic devices coulped with some other detection methods.", [["thread-based devices", "TREATMENT", 61, 81], ["colorimetric detection", "TEST", 87, 109], ["the fabrication of electrodes", "TREATMENT", 111, 140], ["the device", "TREATMENT", 169, 179], ["a few thread-based microfluidic devices", "TREATMENT", 213, 252], ["electrodes", "OBSERVATION_MODIFIER", 130, 140], ["complexity", "OBSERVATION_MODIFIER", 155, 165], ["few", "OBSERVATION_MODIFIER", 215, 218], ["thread", "OBSERVATION_MODIFIER", 219, 225], ["microfluidic devices", "OBSERVATION", 232, 252]]], ["Jarujamrus et al. (2018) described a complexometric and argentometric titrations using microfluidic threadbased analytical device for Mg(II) determination in water, rubber latex samples and chloride ion in water and food seasoning samples by length measurement.", [["samples", "ANATOMY", 231, 238], ["Mg(II", "CHEMICAL", 134, 139], ["chloride", "CHEMICAL", 190, 198], ["Mg(II)", "CHEMICAL", 134, 140], ["chloride", "CHEMICAL", 190, 198], ["Mg(II)", "SIMPLE_CHEMICAL", 134, 140], ["water", "SIMPLE_CHEMICAL", 158, 163], ["chloride", "SIMPLE_CHEMICAL", 190, 198], ["a complexometric and argentometric titrations", "TREATMENT", 35, 80], ["microfluidic threadbased analytical device", "TREATMENT", 87, 129], ["rubber latex samples", "TREATMENT", 165, 185], ["chloride ion in water", "TREATMENT", 190, 211], ["length measurement", "TEST", 242, 260]]], ["The fabrication of the microfluidic thread-based analytical device for the complexometric titration is shown in Fig. 7(a) .", [["the microfluidic thread-based analytical device", "TREATMENT", 19, 66], ["the complexometric titration", "TREATMENT", 71, 99], ["microfluidic thread", "OBSERVATION", 23, 42]]], ["The analytical device was made from two 15 cm cotton pretreated thread tied together with a central knot and then immobilized onto a support to facilitate the sample loading with indicator solution.", [["sample", "ANATOMY", 159, 165], ["The analytical device", "TREATMENT", 0, 21], ["a central knot", "TREATMENT", 90, 104], ["a support", "TREATMENT", 131, 140], ["the sample loading with indicator solution", "TREATMENT", 155, 197], ["central knot", "OBSERVATION", 92, 104]]], ["After the reaction between the target and deposited indicator at the test zone, a color change occurred along the thread with different lengths depending on the concentration of the analyte.", [["the reaction", "PROBLEM", 6, 18], ["a color change", "PROBLEM", 80, 94], ["the analyte", "TREATMENT", 178, 189], ["color change", "OBSERVATION", 82, 94], ["lengths", "OBSERVATION_MODIFIER", 136, 143]]], ["The working concentration range of this device on Mg(II) determination and chloride ion were 25-1000 mg/L and 75-600 mg/L, respectively.", [["Mg(II", "CHEMICAL", 50, 55], ["chloride", "CHEMICAL", 75, 83], ["Mg(II)", "CHEMICAL", 50, 56], ["chloride", "CHEMICAL", 75, 83], ["Mg(II", "SIMPLE_CHEMICAL", 50, 55], ["chloride ion", "SIMPLE_CHEMICAL", 75, 87], ["this device", "TREATMENT", 35, 46], ["chloride ion", "TEST", 75, 87]]], ["This length measurement method on thread is vey simple and results can even been read by naked eye, which offers a cost-effective and convenient alternative tool for the conventional analytical chemistry or biochemistry.Other detection methodsIn addition, thread can also used for the applications of electrophoresis (Cabot et al., 2018; Yang et al., 2018 Yang et al., , 2014a Yang et al., , 2014b Yang et al., , 2014c .", [["eye", "ANATOMY", 95, 98], ["eye", "ORGAN", 95, 98], ["This length measurement", "TEST", 0, 23], ["eye", "ANATOMY", 95, 98]]], ["Usually, thread-based electrophoresis devices usually require plasmatreated threads to obtain greater currents than that on native threads (Wei et The schematic of cotton thread device for room temperature nucleic acid rapid detection based on adenosine-based molecular beacon probe .", [["nucleic acid", "CHEMICAL", 206, 218], ["adenosine", "CHEMICAL", 244, 253], ["adenosine", "CHEMICAL", 244, 253], ["adenosine", "SIMPLE_CHEMICAL", 244, 253], ["thread-based electrophoresis devices", "TREATMENT", 9, 45], ["plasmatreated threads", "TREATMENT", 62, 83], ["cotton thread device", "TREATMENT", 164, 184], ["room temperature nucleic acid rapid detection", "TEST", 189, 234], ["adenosine", "TREATMENT", 244, 253]]], ["Weng, et al. Biosensors and Bioelectronics 132 (2019) 171-185 microfluidic electrophoresis system to evaluate the zone electrophoresis upon 8 commercially available threads including 100% nylon bundle, 100% silk, 100% cotton, 100% polyester, 100% acrylic, 50% acrylic 50% nylon, 100% pure Merino wool and the waxed dental tape.", [["polyester", "CHEMICAL", 231, 240], ["Biosensors", "TEST", 13, 23], ["Bioelectronics", "TEST", 28, 42], ["microfluidic electrophoresis system", "TEST", 62, 97], ["the zone electrophoresis", "TEST", 110, 134], ["50% acrylic", "TREATMENT", 256, 267], ["the waxed dental tape", "TREATMENT", 305, 326]]], ["It was found that the synthetic threads presented higher EOF, with acrylic (cyanide based) provided the highest value, while nylon bundle presented higher resolution and lower solute dispersion and, whilst also helped to minimize the contribution of Joule heating.", [["cyanide", "CHEMICAL", 76, 83], ["cyanide", "CHEMICAL", 76, 83], ["cyanide", "SIMPLE_CHEMICAL", 76, 83], ["acrylic (cyanide", "TREATMENT", 67, 83], ["lower solute dispersion", "TREATMENT", 170, 193], ["Joule heating", "TREATMENT", 250, 263], ["higher", "OBSERVATION_MODIFIER", 50, 56], ["EOF", "OBSERVATION_MODIFIER", 57, 60], ["higher", "OBSERVATION_MODIFIER", 148, 154], ["resolution", "OBSERVATION_MODIFIER", 155, 165], ["lower", "OBSERVATION_MODIFIER", 170, 175], ["solute dispersion", "OBSERVATION", 176, 193]]], ["They quantified of low abundance metabolites, riboflavin in human urine, on the system.", [["urine", "ANATOMY", 66, 71], ["riboflavin", "CHEMICAL", 46, 56], ["riboflavin", "CHEMICAL", 46, 56], ["riboflavin", "SIMPLE_CHEMICAL", 46, 56], ["human", "ORGANISM", 60, 65], ["urine", "ORGANISM_SUBSTANCE", 66, 71], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["low abundance metabolites", "PROBLEM", 19, 44], ["riboflavin in human urine", "PROBLEM", 46, 71], ["low abundance", "OBSERVATION_MODIFIER", 19, 32]]], ["Results showed that the separation could be achieved in less than a minute and a linear working rang of 0.1-15 mg/mL was obtained.", [["a linear working rang", "TEST", 79, 100]]], ["Yang et al. (2014a) demonstrated an enzyme-doped thread-based device ( Fig. 7(b) ) on which liquid transportation, bio-reaction and capillary electrophoresis (CE) and electrochemical detection of urea and glucose could be simply achieved.", [["urea", "CHEMICAL", 196, 200], ["glucose", "CHEMICAL", 205, 212], ["urea", "CHEMICAL", 196, 200], ["glucose", "CHEMICAL", 205, 212], ["capillary", "TISSUE", 132, 141], ["urea", "SIMPLE_CHEMICAL", 196, 200], ["glucose", "SIMPLE_CHEMICAL", 205, 212], ["an enzyme", "TEST", 33, 42], ["doped thread-based device", "TREATMENT", 43, 68], ["capillary electrophoresis", "TEST", 132, 157], ["electrochemical detection of urea and glucose", "TEST", 167, 212]]], ["When used in urea and glucose samples detection, linear dynamic range of 0.1 mM~10.0 mM (R 2 =0.9850) and 0.1 mM~13.0 mM (R 2 =0.9668) were obtained, respectively, which were sufficient for blood urea nitrogen and serum glucose determination.", [["blood", "ANATOMY", 190, 195], ["serum", "ANATOMY", 214, 219], ["urea", "CHEMICAL", 13, 17], ["glucose", "CHEMICAL", 22, 29], ["blood urea nitrogen", "CHEMICAL", 190, 209], ["glucose", "CHEMICAL", 220, 227], ["urea", "CHEMICAL", 13, 17], ["glucose", "CHEMICAL", 22, 29], ["urea", "CHEMICAL", 196, 200], ["nitrogen", "CHEMICAL", 201, 209], ["glucose", "CHEMICAL", 220, 227], ["urea", "SIMPLE_CHEMICAL", 13, 17], ["glucose", "SIMPLE_CHEMICAL", 22, 29], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["urea", "SIMPLE_CHEMICAL", 196, 200], ["nitrogen", "SIMPLE_CHEMICAL", 201, 209], ["serum", "ORGANISM_SUBSTANCE", 214, 219], ["glucose", "SIMPLE_CHEMICAL", 220, 227], ["urea", "TEST", 13, 17], ["glucose samples detection", "TEST", 22, 47], ["linear dynamic range", "TEST", 49, 69], ["blood urea nitrogen", "TEST", 190, 209], ["serum glucose determination", "TEST", 214, 241]]], ["By using thread-based microfluidic devices for CE-EC detection, micromachining procedure can be avoid to fabricate the microfluidic channels.", [["EC", "CELL", 50, 52], ["thread-based microfluidic devices", "TREATMENT", 9, 42], ["CE-EC detection", "TREATMENT", 47, 62], ["micromachining procedure", "TREATMENT", 64, 88], ["microfluidic channels", "OBSERVATION", 119, 140]]], ["Therefore, flexible microfluidic configuration design can be easily achieved for a variety of bioanalysis.Other detection methodsLin and Lin (2016) developed a single polyester thread microfluidic X. Weng, et al. Biosensors and Bioelectronics 132 (2019) 171-185 Fig. 5.", [["polyester", "CHEMICAL", 167, 176], ["flexible microfluidic configuration", "TREATMENT", 11, 46], ["a single polyester thread microfluidic X.", "TREATMENT", 158, 199], ["Biosensors", "TEST", 213, 223], ["Bioelectronics", "TEST", 228, 242], ["flexible", "OBSERVATION", 11, 19], ["microfluidic configuration", "OBSERVATION", 20, 46]]], ["Schematic (A) and picture (B) of the electroanalytical device made by stainless steel pins and cotton thread and paper and the fabrication procedure.", [["the electroanalytical device", "TREATMENT", 33, 61], ["stainless steel pins and cotton thread", "TREATMENT", 70, 108], ["the fabrication procedure", "TREATMENT", 123, 148]]], ["(C) Cyclic voltammograms recorded in a 500 \u03bcM solution of FeCO 2 H in 1 \u00d7 PBS, pH 7.6 at a scan rate of 100 mV/s using seven independent thread-and-pin arrays (Glavan et al., 2016) .", [["FeCO 2 H", "CHEMICAL", 58, 66], ["FeCO 2 H", "CHEMICAL", 58, 66], ["FeCO 2 H", "SIMPLE_CHEMICAL", 58, 66], ["Cyclic voltammograms", "TEST", 4, 24], ["a 500 \u03bcM solution", "TREATMENT", 37, 54], ["FeCO", "TEST", 58, 62], ["PBS", "TEST", 74, 77], ["pH", "TEST", 79, 81], ["a scan rate", "TEST", 89, 100]]], ["X. Weng, et al. Biosensors and Bioelectronics 132 (2019) 171-185 system for rapid mass spectrometry detection of liquid food and medical samples.", [["Biosensors", "TEST", 16, 26], ["Bioelectronics", "TEST", 31, 45], ["rapid mass spectrometry", "TEST", 76, 99], ["medical samples", "TEST", 129, 144]]], ["The system was capable of sample loading and separation, pinch focusing and electrospray ionization.", [["sample", "ANATOMY", 26, 32], ["sample loading", "TREATMENT", 26, 40], ["separation", "TREATMENT", 45, 55], ["electrospray ionization", "TEST", 76, 99]]], ["It consisted of a two electrodes and a single polyester thread.", [["polyester", "CHEMICAL", 46, 55], ["a two electrodes", "TREATMENT", 16, 32], ["a single polyester thread", "TREATMENT", 37, 62], ["two electrodes", "OBSERVATION", 18, 32]]], ["The thread was fixed on a PMMA chip with one end immersed in a buffer well to keep it wet through capillary force.", [["capillary", "ANATOMY", 98, 107], ["PMMA", "CHEMICAL", 26, 30], ["capillary", "TISSUE", 98, 107], ["a PMMA chip", "TREATMENT", 24, 35], ["capillary force", "OBSERVATION", 98, 113]]], ["Electric fields were applied on the electrodes to achieve the CE separation and electrospray ionization during which two neighboring buffer drops were applied to pinch the sample band into smaller width.", [["Electric fields", "TREATMENT", 0, 15], ["the electrodes", "TREATMENT", 32, 46], ["the CE separation", "TREATMENT", 58, 75], ["electrospray ionization", "TREATMENT", 80, 103], ["two neighboring buffer drops", "TREATMENT", 117, 145], ["smaller", "OBSERVATION_MODIFIER", 189, 196], ["width", "OBSERVATION_MODIFIER", 197, 202]]], ["The other end of the thread was put 4-10 mm in front of the mass spectrometry inlet for analyzing.", [["end", "OBSERVATION_MODIFIER", 10, 13], ["mass", "OBSERVATION", 60, 64]]], ["This method is much simpler than conventional microfluidic electrophoresis chips.Thread /paper (PDMS) hybrid microfluidicsAs porous materials for fabrication of microfluidic devices, threads have many advantages over paper including stronger mechanical strength, surface tension, easy biodegradability and no requirement of hydrophobic barriers.", [["surface", "ANATOMY", 263, 270], ["conventional microfluidic electrophoresis chips", "TREATMENT", 33, 80], ["Thread /paper (PDMS) hybrid microfluidics", "TREATMENT", 81, 122], ["fabrication of microfluidic devices", "TREATMENT", 146, 181], ["surface tension", "PROBLEM", 263, 278], ["easy biodegradability", "PROBLEM", 280, 301], ["hydrophobic barriers", "TREATMENT", 324, 344], ["microfluidic devices", "OBSERVATION", 161, 181]]], ["Introduction of threads in paper-based microfluidic devices simplify the fabrication and enhances the performance (Neris et al., 2018) . utilized thread/paper hybrid analytical device for glucose detection through a colorimetric assay.", [["glucose", "CHEMICAL", 188, 195], ["glucose", "CHEMICAL", 188, 195], ["glucose", "SIMPLE_CHEMICAL", 188, 195], ["Introduction of threads in paper-based microfluidic devices", "TREATMENT", 0, 59], ["the fabrication", "TREATMENT", 69, 84], ["thread/paper hybrid analytical device", "TREATMENT", 146, 183], ["glucose detection", "TEST", 188, 205], ["a colorimetric assay", "TEST", 214, 234], ["microfluidic devices", "OBSERVATION", 39, 59]]], ["In the device, nylon thread was trifurcated three branches to serve as channels to dispense the glucose oxidase, horseradish peroxidase and potassium iodide solution to the analysis sites comprised of circular shaped chromatography paper.", [["glucose", "CHEMICAL", 96, 103], ["potassium iodide", "CHEMICAL", 140, 156], ["glucose", "CHEMICAL", 96, 103], ["potassium iodide", "CHEMICAL", 140, 156], ["glucose", "SIMPLE_CHEMICAL", 96, 103], ["oxidase", "GENE_OR_GENE_PRODUCT", 104, 111], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 113, 135], ["potassium iodide", "SIMPLE_CHEMICAL", 140, 156], ["glucose oxidase", "PROTEIN", 96, 111], ["horseradish peroxidase", "PROTEIN", 113, 135], ["horseradish", "SPECIES", 113, 124], ["the device, nylon thread", "TREATMENT", 3, 27], ["the glucose oxidase", "TREATMENT", 92, 111], ["horseradish peroxidase", "TREATMENT", 113, 135], ["potassium iodide solution", "TREATMENT", 140, 165], ["circular shaped chromatography paper", "TREATMENT", 201, 237], ["circular", "OBSERVATION_MODIFIER", 201, 209], ["shaped", "OBSERVATION_MODIFIER", 210, 216]]], ["The analysis sites were spotted with glucose of standard concentrations.", [["glucose", "CHEMICAL", 37, 44], ["glucose", "CHEMICAL", 37, 44], ["glucose", "SIMPLE_CHEMICAL", 37, 44], ["The analysis sites", "TEST", 0, 18]]], ["After loading sample, the yellowbrown color at the analysis sites could indicate the oxidation of iodide to iodine.", [["iodide", "CHEMICAL", 98, 104], ["iodine", "CHEMICAL", 108, 114], ["iodide", "CHEMICAL", 98, 104], ["iodine", "CHEMICAL", 108, 114], ["iodide", "SIMPLE_CHEMICAL", 98, 104], ["iodine", "SIMPLE_CHEMICAL", 108, 114], ["the yellowbrown color at the analysis sites", "PROBLEM", 22, 65], ["iodine", "TREATMENT", 108, 114]]], ["The intensities were then scanned with a Desktop Scanner to quantitate the glucose in sample.", [["glucose", "CHEMICAL", 75, 82], ["glucose", "CHEMICAL", 75, 82], ["glucose", "SIMPLE_CHEMICAL", 75, 82], ["a Desktop Scanner", "TEST", 39, 56], ["the glucose in sample", "TEST", 71, 92]]], ["The results showed good correlation in the detection of glucose in artificial urine.", [["urine", "ANATOMY", 78, 83], ["glucose", "CHEMICAL", 56, 63], ["glucose", "CHEMICAL", 56, 63], ["glucose", "SIMPLE_CHEMICAL", 56, 63], ["urine", "ORGANISM_SUBSTANCE", 78, 83], ["glucose in artificial urine", "PROBLEM", 56, 83]]], ["More recently, Gonzalez et al. (2018a) made another microfluidic thread/paper-based analytical device (\u00b5TPAD) for ELISA in detection of biotinylated goat anti-mouse IgG antibody.", [["goat", "ORGANISM", 149, 153], ["biotinylated goat anti-mouse IgG antibody", "PROTEIN", 136, 177], ["goat", "SPECIES", 149, 153], ["anti-mouse", "SPECIES", 154, 164], ["goat", "SPECIES", 149, 153], ["another microfluidic thread/paper", "TREATMENT", 44, 77], ["analytical device (\u00b5TPAD)", "TREATMENT", 84, 109], ["ELISA in detection", "TEST", 114, 132], ["biotinylated goat anti-mouse IgG antibody", "TEST", 136, 177]]], ["The \u00b5TPAD provided good R 2 value for the linear range and sensitivity.", [["\u00b5TPAD", "PROTEIN", 4, 9]]], ["Sateanchok et al. (2018) developed a simple cotton thread/paper based microfluidic device with mobile phone detector for antioxidant.", [["a simple cotton thread/paper based microfluidic device", "TREATMENT", 35, 89], ["microfluidic device", "OBSERVATION", 70, 89]]], ["As shown in Fig. 8(a) , a bunch of cotton thread were stuck on a plastic sheet to serve as microchannels to deliver solution to the paper band functionalized with reagents.", [["a bunch of cotton thread", "TREATMENT", 24, 48], ["a plastic sheet", "TREATMENT", 63, 78]]], ["After the reaction, the results could be observed on the cotton thread (total phenolic content assay) or paper strip (DPPH assay).", [["DPPH", "CHEMICAL", 118, 122], ["DPPH", "CHEMICAL", 118, 122], ["phenolic", "SIMPLE_CHEMICAL", 78, 86], ["DPPH", "SIMPLE_CHEMICAL", 118, 122], ["the cotton thread", "TEST", 53, 70], ["total phenolic content assay", "TEST", 72, 100], ["paper strip (DPPH assay", "TEST", 105, 128]]], ["Pictures of resultant cotton thread and paper strip were taken for further measurement by a mobile phone camera.", [["resultant cotton thread", "TREATMENT", 12, 35], ["paper strip", "TREATMENT", 40, 51], ["resultant", "OBSERVATION_MODIFIER", 12, 21], ["cotton thread", "OBSERVATION", 22, 35]]], ["The platform was used in green tea sample detection and the results obtained were found to highly agree with that of the standard methods.", [["tea sample", "ANATOMY", 31, 41], ["green tea", "CHEMICAL", 25, 34], ["green tea sample detection", "TEST", 25, 51]]], ["Weng, et al. Biosensors and Bioelectronics 132 (2019) 171-185 microfluidic device on a piezoelectric substrate.", [["Biosensors", "TEST", 13, 23], ["Bioelectronics", "TEST", 28, 42], ["microfluidic device", "TREATMENT", 62, 81], ["a piezoelectric substrate", "TREATMENT", 85, 110]]], ["A PDMS channel of 1 mm in diameter was filled with cotton thread and the terminal part of which was distributed on the PDMS surface equally.", [["PDMS", "CHEMICAL", 2, 6], ["A PDMS channel of 1 mm in diameter", "TREATMENT", 0, 34], ["cotton thread", "TREATMENT", 51, 64], ["PDMS", "OBSERVATION_MODIFIER", 2, 6], ["channel", "OBSERVATION_MODIFIER", 7, 14], ["1 mm", "OBSERVATION_MODIFIER", 18, 22], ["diameter", "OBSERVATION_MODIFIER", 26, 34], ["filled", "OBSERVATION", 39, 45], ["cotton thread", "OBSERVATION", 51, 64], ["terminal", "OBSERVATION_MODIFIER", 73, 81], ["distributed", "OBSERVATION_MODIFIER", 100, 111], ["PDMS", "OBSERVATION_MODIFIER", 119, 123], ["surface", "OBSERVATION_MODIFIER", 124, 131]]], ["A filter paper of 6 mm in diameter with dried reaction solution was then mounted on the cotton thread.", [["A filter paper of 6 mm in diameter with dried reaction solution", "TREATMENT", 0, 63], ["the cotton thread", "TREATMENT", 84, 101], ["filter", "OBSERVATION", 2, 8], ["6 mm", "OBSERVATION_MODIFIER", 18, 22], ["diameter", "OBSERVATION_MODIFIER", 26, 34], ["dried reaction", "OBSERVATION", 40, 54]]], ["This channel was located on a piezoelectric substrate which served as an interdigital transducer.", [["a piezoelectric substrate", "TREATMENT", 28, 53], ["an interdigital transducer", "TREATMENT", 70, 96]]], ["Surface acoustic wave was used in this study to transport solution to the target inlet zone of the device and then flew to the reaction zone via capillary force.", [["capillary", "ANATOMY", 145, 154], ["capillary", "TISSUE", 145, 154], ["Surface acoustic wave", "TEST", 0, 21], ["this study", "TEST", 34, 44], ["the device", "TREATMENT", 95, 105], ["capillary force", "OBSERVATION", 145, 160]]], ["A linear rate of fluidic transportation of 4.558 mm/s was achieved in the cotton thread.", [["fluidic transportation", "TEST", 17, 39], ["the cotton thread", "TREATMENT", 70, 87], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["fluidic", "OBSERVATION_MODIFIER", 17, 24]]], ["This method combines both advantages of paper and thread, no external driving force for loading sample solution into target testing zone is required but solely by controlling the electric signal applied to interdigital transducers.", [["loading sample solution", "TREATMENT", 88, 111], ["target testing zone", "TEST", 117, 136]]], ["Nilghaz et al. (2018) developed a three-dimensional cell culture system by stacking multiple layers of polydimethylsiloxane (PDMS) connected through thread ( Fig. 8(b) ).", [["cell", "ANATOMY", 52, 56], ["polydimethylsiloxane", "CHEMICAL", 103, 123], ["polydimethylsiloxane", "CHEMICAL", 103, 123], ["PDMS", "CHEMICAL", 125, 129], ["cell", "CELL", 52, 56], ["polydimethylsiloxane", "SIMPLE_CHEMICAL", 103, 123], ["stacking multiple layers of polydimethylsiloxane (PDMS)", "TREATMENT", 75, 130]]], ["The stacking layers of PDMS were embedded with the functionalized hydroxypropyl cellulose methacrylate (HPC-MA) scaffold as the cell adhesion structure while the cotton thread served as a readymade hydrophilic channel for liquid transportation.", [["cell", "ANATOMY", 128, 132], ["hydroxypropyl cellulose methacrylate", "CHEMICAL", 66, 102], ["HPC-MA", "CHEMICAL", 104, 110], ["PDMS", "CHEMICAL", 23, 27], ["hydroxypropyl cellulose methacrylate", "CHEMICAL", 66, 102], ["HPC-MA", "CHEMICAL", 104, 110], ["PDMS", "SIMPLE_CHEMICAL", 23, 27], ["hydroxypropyl cellulose methacrylate", "SIMPLE_CHEMICAL", 66, 102], ["HPC-MA", "SIMPLE_CHEMICAL", 104, 110], ["cell", "CELL", 128, 132], ["The stacking layers of PDMS", "TREATMENT", 0, 27], ["the functionalized hydroxypropyl cellulose methacrylate (HPC-MA) scaffold", "TREATMENT", 47, 120], ["the cell adhesion structure", "PROBLEM", 124, 151], ["the cotton thread", "TREATMENT", 158, 175], ["a readymade hydrophilic channel", "TREATMENT", 186, 217], ["liquid transportation", "TREATMENT", 222, 243], ["layers", "OBSERVATION_MODIFIER", 13, 19], ["cell adhesion", "OBSERVATION", 128, 141]]], ["The cotton thread was sewn into the four layers of PDMS and crossed the scaffolds.", [["PDMS", "CHEMICAL", 51, 55], ["The cotton thread", "TREATMENT", 0, 17], ["PDMS", "TREATMENT", 51, 55], ["the scaffolds", "TREATMENT", 68, 81], ["four", "OBSERVATION_MODIFIER", 36, 40], ["layers", "OBSERVATION_MODIFIER", 41, 47]]], ["The thread between the PDMS layers were well positioned into the channels to wick the cell culture media from the top to the growing cells into the scaffold hence avoided the requirement of either pump or external pressure.", [["cell", "ANATOMY", 86, 90], ["cells", "ANATOMY", 133, 138], ["PDMS", "CHEMICAL", 23, 27], ["cell", "CELL", 86, 90], ["cells", "CELL", 133, 138], ["growing cells", "CELL_TYPE", 125, 138], ["The thread between the PDMS layers", "TREATMENT", 0, 34], ["the cell culture media", "TEST", 82, 104], ["either pump", "TREATMENT", 190, 201], ["external pressure", "TREATMENT", 205, 222], ["PDMS", "OBSERVATION_MODIFIER", 23, 27], ["layers", "OBSERVATION_MODIFIER", 28, 34], ["external pressure", "OBSERVATION", 205, 222]]], ["An average thickness of 300 \u00b5m of the thread provided was tested to be able to provide sufficient rate to continuously transport he media.", [["the thread", "TREATMENT", 34, 44], ["average", "OBSERVATION_MODIFIER", 3, 10], ["thickness", "OBSERVATION_MODIFIER", 11, 20]]], ["COS-7 cells could proliferate over a period of 3-6 days with the present number present identical with that grown in the tissue culture dish and scaffold in a microwell plate.Thread /paper (PDMS) hybrid microfluidicsTo achieve high throughput detection, Seth et al. (2018) made a multi-channel immunochromatographic diagnostic device by using combination of polyester sewing thread and nitrocellulose membrane.", [["COS-7 cells", "ANATOMY", 0, 11], ["tissue culture dish", "ANATOMY", 121, 140], ["membrane", "ANATOMY", 401, 409], ["polyester", "CHEMICAL", 358, 367], ["nitrocellulose", "CHEMICAL", 386, 400], ["COS-7 cells", "CELL", 0, 11], ["tissue", "TISSUE", 121, 127], ["membrane", "CELLULAR_COMPONENT", 401, 409], ["COS-7 cells", "CELL_LINE", 0, 11], ["the tissue culture dish and scaffold in a microwell plate", "PROBLEM", 117, 174], ["Thread /paper (PDMS) hybrid microfluidics", "TREATMENT", 175, 216], ["a multi-channel immunochromatographic diagnostic device", "TREATMENT", 278, 333], ["polyester sewing thread and nitrocellulose membrane", "TREATMENT", 358, 409], ["7 cells", "OBSERVATION_MODIFIER", 4, 11], ["tissue", "ANATOMY", 121, 127], ["microwell plate", "OBSERVATION", 159, 174]]], ["As shown in Fig. 8(c) , the device had a plain paper disc in the centre as the sample pad and connected with nitrocellulose membrane strips of test zone.", [["membrane", "ANATOMY", 124, 132], ["nitrocellulose", "CHEMICAL", 109, 123], ["the device", "TREATMENT", 24, 34], ["a plain paper disc", "TREATMENT", 39, 57], ["the sample pad", "TREATMENT", 75, 89], ["nitrocellulose membrane strips", "TREATMENT", 109, 139], ["disc", "ANATOMY", 53, 57]]], ["Thread was sewn to connect the sample pad and the test zone strips.", [["sample pad", "ANATOMY", 31, 41], ["the sample pad", "TEST", 27, 41], ["the test zone strips", "TEST", 46, 66], ["sewn", "OBSERVATION", 11, 15]]], ["Absorbent pads were placed at the end of the membrane strips to facilitate the wicking and draining liquid.", [["membrane", "ANATOMY", 45, 53], ["Absorbent pads", "TREATMENT", 0, 14], ["the membrane strips", "TREATMENT", 41, 60], ["pads", "OBSERVATION", 10, 14]]], ["Gold conjugates were added on the glass fiber pad and dried out at room temperature for assembly.", [["Gold conjugates", "SIMPLE_CHEMICAL", 0, 15], ["Gold conjugates", "TREATMENT", 0, 15], ["the glass fiber pad", "TREATMENT", 30, 49], ["conjugates", "OBSERVATION", 5, 15]]], ["The test and control antibodies were dispensed onto the nitrocellulose membrane to make lines by a Lateral Flow Reagent Dispenser with a syringe pump.", [["membrane", "ANATOMY", 71, 79], ["nitrocellulose", "CHEMICAL", 56, 70], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["The test", "TEST", 0, 8], ["control antibodies", "TREATMENT", 13, 31], ["the nitrocellulose membrane", "TREATMENT", 52, 79], ["a Lateral Flow Reagent Dispenser", "TREATMENT", 97, 129], ["a syringe pump", "TREATMENT", 135, 149]]], ["To demonstrate the performance of the device, H. pylori, Hepatitis B and IgG antigens were detected.", [["H. pylori", "ORGANISM", 46, 55], ["Hepatitis B", "ORGANISM", 57, 68], ["IgG antigens", "GENE_OR_GENE_PRODUCT", 73, 85], ["Hepatitis B and IgG antigens", "PROTEIN", 57, 85], ["H. pylori", "SPECIES", 46, 55], ["H. pylori", "SPECIES", 46, 55], ["Hepatitis B", "SPECIES", 57, 68], ["the device", "TREATMENT", 34, 44], ["H. pylori", "PROBLEM", 46, 55], ["Hepatitis B and IgG antigens", "TEST", 57, 85]]], ["A test could be completed within 15 min with lowest detection limit within the range of 30-300 ng/mL which was comparable to other lateral flow tests (Jimenez et al., 2017) .", [["A test", "TEST", 0, 6], ["other lateral flow tests", "TEST", 125, 149]]], ["The device was capable of multiplexed testing, however, more efforts are required to further improve the sensitivity and make it work in practical diagnostic solution.", [["The device", "TREATMENT", 0, 10], ["multiplexed testing", "TEST", 26, 45]]], ["Lee et al. (2018) designed a microfluidic thread/paper based analytical device (\u00b5TPAD) combined with artificial neural networks to quantify glucose in artificial urine.", [["neural networks", "ANATOMY", 112, 127], ["urine", "ANATOMY", 162, 167], ["glucose", "CHEMICAL", 140, 147], ["glucose", "CHEMICAL", 140, 147], ["neural networks", "MULTI-TISSUE_STRUCTURE", 112, 127], ["glucose", "SIMPLE_CHEMICAL", 140, 147], ["urine", "ORGANISM_SUBSTANCE", 162, 167], ["a microfluidic thread/paper based analytical device (\u00b5TPAD)", "TREATMENT", 27, 86], ["artificial neural networks", "TREATMENT", 101, 127], ["glucose in artificial urine", "TEST", 140, 167]]], ["The schematic of the configuration is shown in Fig. 9 .", [["Fig", "OBSERVATION_MODIFIER", 47, 50]]], ["The device was made of five major layers: top layer single-sided tape with centre hole, topside double-sided tape and blank chromatography paper with centre and nine circle holes, bottom side double-sided tape with nine holes and bottom layer single-sided tape with nine circles hole.", [["The device", "TREATMENT", 0, 10], ["top layer single-sided tape", "TREATMENT", 42, 69], ["centre hole", "TREATMENT", 75, 86], ["topside double-sided tape and blank chromatography", "TREATMENT", 88, 138], ["centre and nine circle holes", "TREATMENT", 150, 178], ["bottom side double-sided tape", "TREATMENT", 180, 209], ["nine holes", "TREATMENT", 215, 225], ["bottom layer single-sided tape with nine circles hole", "TREATMENT", 230, 283], ["top", "OBSERVATION_MODIFIER", 42, 45], ["layer", "OBSERVATION_MODIFIER", 46, 51], ["sided", "ANATOMY_MODIFIER", 199, 204], ["nine holes", "OBSERVATION", 215, 225], ["bottom", "OBSERVATION_MODIFIER", 230, 236], ["layer", "OBSERVATION_MODIFIER", 237, 242], ["sided", "ANATOMY_MODIFIER", 250, 255], ["circles hole", "OBSERVATION", 271, 283]]], ["Three pieces of nylon thread were trifurcated on the bottom layer with single-sided tape.", [["nylon thread", "TREATMENT", 16, 28], ["single-sided tape", "TREATMENT", 71, 88], ["nylon thread", "OBSERVATION", 16, 28], ["bottom", "OBSERVATION_MODIFIER", 53, 59], ["layer", "OBSERVATION_MODIFIER", 60, 65], ["sided", "ANATOMY_MODIFIER", 78, 83], ["tape", "OBSERVATION", 84, 88]]], ["Increasing glucose concentrations or artificial urine with known glucose was pre-spotted on the chromatography paper circles to determine the target glucose.", [["urine", "ANATOMY", 48, 53], ["glucose", "CHEMICAL", 11, 18], ["glucose", "CHEMICAL", 65, 72], ["glucose", "CHEMICAL", 149, 156], ["glucose", "CHEMICAL", 11, 18], ["glucose", "CHEMICAL", 65, 72], ["glucose", "CHEMICAL", 149, 156], ["glucose", "SIMPLE_CHEMICAL", 11, 18], ["urine", "ORGANISM_SUBSTANCE", 48, 53], ["glucose", "SIMPLE_CHEMICAL", 65, 72], ["glucose", "SIMPLE_CHEMICAL", 149, 156], ["Increasing glucose concentrations", "PROBLEM", 0, 33], ["artificial urine", "PROBLEM", 37, 53], ["known glucose", "PROBLEM", 59, 72], ["the target glucose", "TEST", 138, 156], ["glucose concentrations", "OBSERVATION", 11, 33]]], ["A dynamic detection range of 0.5-15 mM was achieved.", [["A dynamic detection range", "TEST", 0, 25]]], ["They used an artificial neural networks trained on the four-channel CMYK color data from 54 \u00b5TPAD and the ANN to correctly classify 94.4% \u00b5TPAD analysis sites.Thread /paper (PDMS) hybrid microfluidicsFluorescence-based biosensors are the most popular category because they offer superior sensitivity in analysis .", [["neural networks", "ANATOMY", 24, 39], ["neural networks", "MULTI-TISSUE_STRUCTURE", 24, 39], ["Thread /paper (PDMS) hybrid microfluidics", "TREATMENT", 159, 200], ["Fluorescence", "TEST", 200, 212], ["superior sensitivity in analysis", "TEST", 279, 311]]], ["Our group (Weng and Neethirajan, 2018b ) utilized a cotton thread device in the application of avian coronavirus detection.", [["avian", "ORGANISM", 95, 100], ["coronavirus", "ORGANISM", 101, 112], ["avian coronavirus", "SPECIES", 95, 112], ["avian coronavirus", "SPECIES", 95, 112], ["a cotton thread device", "TREATMENT", 50, 72], ["avian coronavirus detection", "TREATMENT", 95, 122], ["avian coronavirus", "OBSERVATION", 95, 112]]], ["Usually, the concentration of the target virus is very low, therefore, the sensitivity of the biosensor is extremely important.", [["the target virus", "PROBLEM", 30, 46], ["the biosensor", "TEST", 90, 103], ["target", "OBSERVATION_MODIFIER", 34, 40], ["virus", "OBSERVATION", 41, 46], ["very", "OBSERVATION_MODIFIER", 50, 54], ["low", "OBSERVATION_MODIFIER", 55, 58]]], ["To achieve that, a nanomaterial, molybdenum disulfide (MoS 2 ) was used due to its distinct optical property.", [["molybdenum disulfide", "CHEMICAL", 33, 53], ["MoS 2", "CHEMICAL", 55, 60], ["molybdenum disulfide", "CHEMICAL", 33, 53], ["MoS 2", "CHEMICAL", 55, 60], ["molybdenum disulfide", "SIMPLE_CHEMICAL", 33, 53], ["MoS 2", "SIMPLE_CHEMICAL", 55, 60], ["a nanomaterial, molybdenum disulfide (MoS", "TREATMENT", 17, 58]]], ["In the work, we developed a single-step immunosensor on cotton thread with antibody-functionalized MoS 2 based on a homogeneous fluorescence resonance energy transfer (FRET) immunoassay.", [["MoS 2", "PROTEIN", 99, 104], ["cotton thread", "TREATMENT", 56, 69], ["antibody-functionalized MoS", "TREATMENT", 75, 102]]], ["The thread-based network interconnected by knots to achieve the fluid mixing and separation.", [["The thread-based network", "TREATMENT", 0, 24], ["the fluid mixing", "TREATMENT", 60, 76], ["fluid mixing", "OBSERVATION", 64, 76]]], ["Two individual thread for sample and probe reagent dispensing were split to two streams.", [["sample and probe reagent dispensing", "TREATMENT", 26, 61]]], ["One of the two stream was then recombined with knot for mixing and the other two streams were used for negative control and background testing.", [["mixing", "TREATMENT", 56, 62], ["background testing", "TEST", 124, 142]]], ["Spiked chicken blood sample were successfully detected with high specificity and a detection of limit of 4.6 \u00d7 10 2 EID 50 per mL.", [["blood sample", "ANATOMY", 15, 27], ["chicken", "ORGANISM", 7, 14], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["chicken", "SPECIES", 7, 14], ["chicken", "SPECIES", 7, 14], ["chicken blood sample", "TEST", 7, 27], ["a detection", "TEST", 81, 92]]], ["Our method presented many advantages over conventional immunological tests, such as rapidity, ease of local manufacture, small consumption and high sensitive.Other applicationsAlthough thread-based microfluidics offer a promising alternative to conventional microfluidic systems, it also has limitations (Chen et al., 2016) .", [["conventional immunological tests", "TEST", 42, 74], ["local manufacture", "TREATMENT", 102, 119], ["small consumption", "PROBLEM", 121, 138], ["conventional microfluidic systems", "TREATMENT", 245, 278], ["local manufacture", "OBSERVATION", 102, 119], ["small", "OBSERVATION_MODIFIER", 121, 126], ["high sensitive", "OBSERVATION_MODIFIER", 143, 157]]], ["By making thread network, it is able to achieve the complicated fluidic manipulation of transportation, separation, mixing and generating concentration gradients.", [["thread network", "MULTI-TISSUE_STRUCTURE", 10, 24], ["the complicated fluidic manipulation of transportation", "TREATMENT", 48, 102], ["mixing and generating concentration gradients", "TREATMENT", 116, 161]]], ["However, it depends on the passive capillary of the thread which is hardly controlled precisely due to the formation of random orientation of cellulose fibers.", [["capillary", "ANATOMY", 35, 44], ["capillary", "TISSUE", 35, 44], ["cellulose fibers", "CELLULAR_COMPONENT", 142, 158], ["cellulose fibers", "TREATMENT", 142, 158]]], ["To overcome this, Ramesan et al. (2016) utilized high frequency sound waves convective flow generator to realize rapid, precise and uniform flow control in the thread network as well as a continuous and stable concentration gradient of dilution.", [["high frequency sound waves convective flow generator", "TREATMENT", 49, 101], ["uniform", "OBSERVATION_MODIFIER", 132, 139], ["flow", "OBSERVATION", 140, 144], ["stable", "OBSERVATION_MODIFIER", 203, 209]]], ["The method could also do the dynamically regulation which was a distinct advantage over the passive capillary driving mode.", [["capillary", "ANATOMY", 100, 109], ["capillary", "TISSUE", 100, 109], ["the passive capillary driving mode", "TREATMENT", 88, 122], ["distinct", "OBSERVATION_MODIFIER", 64, 72], ["advantage", "OBSERVATION_MODIFIER", 73, 82]]], ["As shown in Fig. 10(a) , the time series images show that in the presence of SAW, it takes significantly shorter time for the dyes to go through the thread network and the mixing is much more uniform.", [["the time series images", "TEST", 25, 47], ["the dyes", "TREATMENT", 122, 130], ["the thread network", "TREATMENT", 145, 163], ["more uniform", "OBSERVATION_MODIFIER", 187, 199]]], ["They embedded this thread concentration gradient generator into a cell-laden 3D hydrogel component.", [["cell", "ANATOMY", 66, 70], ["cell", "CELL", 66, 70], ["this thread concentration gradient generator", "TREATMENT", 14, 58], ["a cell-laden 3D hydrogel component", "TREATMENT", 64, 98], ["hydrogel component", "OBSERVATION", 80, 98]]], ["Results presented that it was able to better mimic the in vivo tissue microenvironment than that by conventional 2D microchannel structure.Other applicationsElectrophoretic separation is another important application of thread-based microfluidics in chemistry and biology. reported a cross channel thread-based microfluidic device to conduct electrophoretic separation of mixed food dyes.", [["tissue", "ANATOMY", 63, 69], ["tissue", "TISSUE", 63, 69], ["Electrophoretic separation", "TREATMENT", 157, 183], ["a cross channel thread-based microfluidic device", "TREATMENT", 282, 330], ["mixed food dyes", "PROBLEM", 372, 387], ["microfluidic device", "OBSERVATION", 311, 330], ["mixed food dyes", "OBSERVATION", 372, 387]]], ["The device consisted of four micropipette tips fixed onto a glass slide as the reservoirs and a cross channel by threads sticking to the reservoirs ( Fig. 10(b) ).", [["The device", "TREATMENT", 0, 10], ["four micropipette tips", "TREATMENT", 24, 46], ["a glass slide", "TREATMENT", 58, 71], ["the reservoirs", "TREATMENT", 75, 89], ["a cross channel", "TREATMENT", 94, 109], ["micropipette", "OBSERVATION_MODIFIER", 29, 41], ["tips", "OBSERVATION_MODIFIER", 42, 46]]], ["Four platinum electrodes were inserted the reservoirs to provide electrical potential.", [["platinum", "CHEMICAL", 5, 13], ["platinum", "CHEMICAL", 5, 13], ["Four platinum electrodes", "TREATMENT", 0, 24], ["the reservoirs", "TREATMENT", 39, 53], ["platinum electrodes", "OBSERVATION", 5, 24]]], ["After wetting the thread with buffer solution, food dye was added and followed by applying potentials.", [["buffer solution", "TREATMENT", 30, 45], ["food dye", "TREATMENT", 47, 55]]], ["Desired voltages of different values were applied on the reservoirs at the steps of sample loading, injection, and separation.", [["sample", "ANATOMY", 84, 90], ["injection", "TREATMENT", 100, 109], ["separation", "TREATMENT", 115, 125], ["different", "OBSERVATION_MODIFIER", 20, 29], ["values", "OBSERVATION_MODIFIER", 30, 36]]], ["By controlling and adjusting the potentials on the inlets and outlets, the sample could be loaded, injected, and separated within 3.5 min.Other applicationsYan et al. (2015) reported a thread-based microfluidic device combining with thermal lens to determine Cu (II) and Zn (II) sequentially.", [["sample", "ANATOMY", 75, 81], ["Cu (II", "CHEMICAL", 259, 265], ["Zn", "CHEMICAL", 271, 273], ["Cu (II)", "CHEMICAL", 259, 266], ["Zn (II)", "CHEMICAL", 271, 278], ["Cu (II)", "SIMPLE_CHEMICAL", 259, 266], ["Zn (II", "SIMPLE_CHEMICAL", 271, 277], ["the inlets and outlets", "TREATMENT", 47, 69], ["a thread-based microfluidic device", "TREATMENT", 183, 217], ["thermal lens", "TREATMENT", 233, 245], ["Zn (II)", "TREATMENT", 271, 278], ["microfluidic device", "OBSERVATION", 198, 217]]], ["The device consisted of a U-shaped supporter and \"Y\" geometrics thread channels.", [["The device", "TREATMENT", 0, 10], ["a U-shaped supporter and \"Y\" geometrics thread channels", "TREATMENT", 24, 79]]], ["As shown in Fig. 10 (c), sample and reagent solution were loaded into the two inlet threads (A, B) and flew into the \"Y\" geometrics channel via micropipettes while the buffer thread channel (E) was immersed into the buffer solution inlet (D).", [["reagent solution", "TREATMENT", 36, 52], ["the buffer thread channel (E)", "TREATMENT", 164, 193]]], ["The flow in \"Y\" geometrics traveled faster than that in the buffer solution channel at a certain inclination angle, thus when solutions mixed, the Cu-zinxon complex could be formed and determined first.", [["Cu-zinxon", "CHEMICAL", 147, 156], ["Cu-zinxon", "CHEMICAL", 147, 156], ["Cu-zinxon", "SIMPLE_CHEMICAL", 147, 156], ["Cu-zinxon complex", "PROTEIN", 147, 164], ["The flow", "TEST", 0, 8], ["flow", "OBSERVATION_MODIFIER", 4, 8]]], ["With the buffer solution wicked into the \"Y\" geometrics channel, the Cu-zincon and Zn-zincon complex would be detected, thus the copper and zinc ions.", [["Cu-zincon", "CHEMICAL", 69, 78], ["Zn-zincon", "CHEMICAL", 83, 92], ["copper", "CHEMICAL", 129, 135], ["zinc", "CHEMICAL", 140, 144], ["Cu-zincon", "CHEMICAL", 69, 78], ["Zn-zincon", "CHEMICAL", 83, 92], ["copper", "CHEMICAL", 129, 135], ["zinc", "CHEMICAL", 140, 144], ["Cu-zincon", "SIMPLE_CHEMICAL", 69, 78], ["Zn-zincon", "SIMPLE_CHEMICAL", 83, 92], ["copper", "SIMPLE_CHEMICAL", 129, 135], ["zinc ions", "SIMPLE_CHEMICAL", 140, 149], ["Cu-zincon and Zn-zincon complex", "PROTEIN", 69, 100], ["the buffer solution", "TREATMENT", 5, 24], ["the Cu-zincon and Zn-zincon complex", "TREATMENT", 65, 100], ["the copper and zinc ions", "TREATMENT", 125, 149]]], ["Using this device, they determined Cu(II) and Zn(II) in hair samples and the results showed good agreement with those by the AAS method.", [["hair samples", "ANATOMY", 56, 68], ["Cu(II", "CHEMICAL", 35, 40], ["Zn", "CHEMICAL", 46, 48], ["Cu(II)", "CHEMICAL", 35, 41], ["Zn(II)", "CHEMICAL", 46, 52], ["Cu(II)", "SIMPLE_CHEMICAL", 35, 41], ["Zn(II", "SIMPLE_CHEMICAL", 46, 51], ["hair samples", "CANCER", 56, 68], ["this device", "TREATMENT", 6, 17], ["hair samples", "TEST", 56, 68]]], ["This study shows that thread is a good substrate for fluid transportation without any external power.", [["fluid", "ANATOMY", 53, 58], ["This study", "TEST", 0, 10], ["fluid transportation", "TREATMENT", 53, 73], ["fluid", "OBSERVATION", 53, 58]]], ["In addition, the transportation rate can be changed by adjusting the inclination angle of the thread channel network, which is crucial in many applications of chemistry, biochemistry, and biological samples detection.", [["the transportation rate", "TEST", 13, 36], ["biological samples detection", "TEST", 188, 216]]], ["Ulum et al. (2016) reported an ethylenediaminetetraacetic acid (EDTA)-functionalized \u03bcTAD for whole blood plasma separation assay.", [["blood plasma", "ANATOMY", 100, 112], ["ethylenediaminetetraacetic acid", "CHEMICAL", 31, 62], ["EDTA", "CHEMICAL", 64, 68], ["ethylenediaminetetraacetic acid", "CHEMICAL", 31, 62], ["EDTA", "CHEMICAL", 64, 68], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 31, 62], ["EDTA", "SIMPLE_CHEMICAL", 64, 68], ["\u03bcTAD", "SIMPLE_CHEMICAL", 85, 89], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["plasma", "ORGANISM_SUBSTANCE", 106, 112], ["an ethylenediaminetetraacetic acid (EDTA", "TREATMENT", 28, 68], ["whole blood plasma separation assay", "TEST", 94, 129]]], ["The thread-based device was simply fabricated by stretching the scouring treated cotton thread in a frame of glass slide with a paper support.", [["The thread-based device", "TREATMENT", 0, 23], ["the scouring treated cotton thread", "TREATMENT", 60, 94], ["a paper support", "TREATMENT", 126, 141], ["device", "OBSERVATION", 17, 23]]], ["Critical zone where significant color change occurs was selected to take images to perform the analysis.", [["significant color change", "PROBLEM", 20, 44], ["the analysis", "TEST", 91, 103], ["zone", "OBSERVATION_MODIFIER", 9, 13], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["color change", "OBSERVATION", 32, 44]]], ["They tested several cotton thread treatments and found that the cotton-thread without any treatment preventing the blood from wicking while that with EDTA functionalization followed by 60 min drying at refrigerated temperature presented excellent results in terms of the clearest separation boundary and longest wicking distance.", [["blood", "ANATOMY", 115, 120], ["EDTA", "CHEMICAL", 150, 154], ["EDTA", "CHEMICAL", 150, 154], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["EDTA", "SIMPLE_CHEMICAL", 150, 154], ["several cotton thread treatments", "TREATMENT", 12, 44], ["the cotton-thread", "TREATMENT", 60, 77], ["any treatment", "TREATMENT", 86, 99], ["the blood from wicking", "PROBLEM", 111, 133], ["EDTA functionalization", "TREATMENT", 150, 172]]], ["This cotton thread microfluidic device on albumin assay had a limit of detection of 114 mg/L \u22121 which was superior than conventional blood analysis and provided a promising strategy for combining separation and assay in a single device.Concluding remarksWe have described thread-based microfluidic diagnostic devices in terms of fabrication and various applications over the past few years.", [["blood", "ANATOMY", 133, 138], ["albumin", "GENE_OR_GENE_PRODUCT", 42, 49], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["This cotton thread microfluidic device", "TREATMENT", 0, 38], ["albumin assay", "TEST", 42, 55], ["conventional blood analysis", "TEST", 120, 147], ["a promising strategy", "TREATMENT", 161, 181], ["combining separation", "TREATMENT", 186, 206], ["a single device", "TREATMENT", 220, 235], ["thread-based microfluidic diagnostic devices", "TREATMENT", 272, 316], ["fabrication", "TREATMENT", 329, 340], ["thread", "OBSERVATION_MODIFIER", 272, 278], ["microfluidic diagnostic devices", "OBSERVATION", 285, 316]]], ["As an alternative porous material for microfluidic devices, thread-based microfluidics overcome the disadvantages of paper-based microfluidics, including the form of paper and the one-dimensional methods like litmus paper and lateral flow immunoassays (He et al., 2015) .Concluding remarksThread-based microfluidics, used in the development of POC X. Weng, et al. Biosensors and Bioelectronics 132 (2019) 171-185 diagnostic devices, meets the ASSURED (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverable to endusers) criterion for a number of reasons: light weight, available in various forms with diversity of properties and easily obtained, compatible with many biological samples, low-cost, and easy handling after use.", [["an alternative porous material", "TREATMENT", 3, 33], ["microfluidic devices", "TREATMENT", 38, 58], ["thread-based microfluidics", "TREATMENT", 60, 86], ["paper-based microfluidics", "TREATMENT", 117, 142], ["lateral flow immunoassays", "TEST", 226, 251], ["Thread-based microfluidics", "TREATMENT", 289, 315], ["Biosensors", "TEST", 364, 374], ["Bioelectronics", "TEST", 379, 393], ["diagnostic devices", "TEST", 413, 431], ["light weight", "TEST", 598, 610], ["microfluidic devices", "OBSERVATION", 38, 58], ["microfluidics", "OBSERVATION", 302, 315]]], ["While the field of thread-based microfluidics has expanded rapidly, there are many challenges that still need to be addressed.", [["microfluidics", "OBSERVATION", 32, 45], ["expanded", "OBSERVATION_MODIFIER", 50, 58], ["rapidly", "OBSERVATION_MODIFIER", 59, 66]]], ["For example, to obtain controllable flow rate on the thread so as to accurately manipulate the flow transportation.", [["controllable flow rate", "TEST", 23, 45], ["the flow transportation", "TEST", 91, 114], ["flow", "OBSERVATION", 95, 99]]], ["To develop complicated 3D thread devices that carry out multiplexed diagnostics in a simple-to-use format without any external reading equipment.", [["complicated 3D thread devices", "TREATMENT", 11, 40], ["multiplexed diagnostics", "TEST", 56, 79], ["thread devices", "OBSERVATION", 26, 40]]], ["In terms of the performance of current thread-based microfluidic devices, the sensitivity is relatively lower or comparable to conventional analytical techniques (Malon et al., 2017) due to the evaporation and water retention factor occurs during the fluid transportation.", [["fluid", "ANATOMY", 251, 256], ["current thread-based microfluidic devices", "TREATMENT", 31, 72], ["the sensitivity", "TEST", 74, 89], ["the evaporation", "TREATMENT", 190, 205], ["water retention factor", "PROBLEM", 210, 232], ["the fluid transportation", "TREATMENT", 247, 271], ["microfluidic devices", "OBSERVATION", 52, 72], ["water retention", "OBSERVATION", 210, 225], ["fluid", "OBSERVATION", 251, 256]]], ["Seeking biocompatible materials, i.e., flexible and stretchable fibers, for thread creation or functionalization and flexible electronic circuits is necessary and crucial if thread-based microfluidics want to find its applications in wearable or long-term implantable devices.", [["fibers", "ANATOMY", 64, 70], ["flexible and stretchable fibers", "TREATMENT", 39, 70], ["thread creation or functionalization", "TREATMENT", 76, 112], ["flexible electronic circuits", "TREATMENT", 117, 145], ["thread-based microfluidics", "TREATMENT", 174, 200], ["long-term implantable devices", "TREATMENT", 246, 275], ["long-term", "OBSERVATION_MODIFIER", 246, 255], ["implantable devices", "OBSERVATION", 256, 275]]], ["The requirement of the mass production of thread-based microfluidic devices necessitates the improvement in fabrication techniques.", [["the mass production", "TREATMENT", 19, 38], ["thread-based microfluidic devices", "TREATMENT", 42, 75], ["fabrication techniques", "TREATMENT", 108, 130], ["mass", "OBSERVATION", 23, 27], ["thread", "OBSERVATION_MODIFIER", 42, 48], ["microfluidic devices", "OBSERVATION", 55, 75], ["improvement", "OBSERVATION_MODIFIER", 93, 104]]], ["Currently, thread-based microfluidics is still in the laboratory research stage of development although many of thread-based microfluidic platforms demonstrated in this review present their potential to provide portable, low-cost and reliable diagnosis real life.", [["thread-based microfluidic platforms", "TEST", 112, 147], ["microfluidics", "OBSERVATION", 24, 37], ["microfluidic platforms", "OBSERVATION", 125, 147]]], ["Overall, improvements in terms of platform fabrication, analytical and detection techniques are required to enable them to be adapted and commercialized in practical applications in real world.", [["platform fabrication", "TREATMENT", 34, 54], ["improvements", "OBSERVATION_MODIFIER", 9, 21]]], ["Particularly in the fields where analytical measurements have traditionally been a cost limiting factor and the underdeveloped and resource limited regions due to the low cost and ease of use of threads.", [["analytical measurements", "TEST", 33, 56], ["a cost limiting factor", "PROBLEM", 81, 103], ["fields", "ANATOMY_MODIFIER", 20, 26]]]], "PMC4204940": [["IntroductionPorcine transmissible gastroenteritis coronavirus (TGEV) is an animal coronavirus that causes severe gastroenteritis in young TGEV-seronegative pigs.", [["transmissible gastroenteritis coronavirus", "DISEASE", 20, 61], ["TGEV", "DISEASE", 63, 67], ["animal coronavirus", "DISEASE", 75, 93], ["gastroenteritis", "DISEASE", 113, 128], ["IntroductionPorcine transmissible gastroenteritis coronavirus", "ORGANISM", 0, 61], ["TGEV", "ORGANISM", 63, 67], ["TGEV", "ORGANISM", 138, 142], ["pigs", "ORGANISM", 156, 160], ["transmissible gastroenteritis coronavirus", "SPECIES", 20, 61], ["TGEV", "SPECIES", 63, 67], ["coronavirus", "SPECIES", 82, 93], ["TGEV", "SPECIES", 138, 142], ["pigs", "SPECIES", 156, 160], ["transmissible gastroenteritis coronavirus", "SPECIES", 20, 61], ["TGEV", "SPECIES", 63, 67], ["TGEV", "SPECIES", 138, 142], ["IntroductionPorcine transmissible gastroenteritis coronavirus (TGEV", "PROBLEM", 0, 67], ["an animal coronavirus", "PROBLEM", 72, 93], ["severe gastroenteritis", "PROBLEM", 106, 128], ["seronegative pigs", "TREATMENT", 143, 160], ["gastroenteritis coronavirus", "OBSERVATION", 34, 61], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["gastroenteritis", "OBSERVATION", 113, 128], ["seronegative pigs", "OBSERVATION", 143, 160]]], ["Various breeds of pigs, regardless of age, are susceptible to TGEV; however, the mortality rate for piglets under 2 weeks of age is the highest, reaching almost 100%.", [["TGEV", "DISEASE", 62, 66], ["pigs", "ORGANISM", 18, 22], ["TGEV", "ORGANISM", 62, 66], ["piglets", "ORGANISM", 100, 107], ["pigs", "SPECIES", 18, 22], ["piglets", "SPECIES", 100, 107], ["pigs", "SPECIES", 18, 22], ["TGEV", "SPECIES", 62, 66], ["pigs", "TREATMENT", 18, 22], ["TGEV", "PROBLEM", 62, 66]]], ["Diseased pigs often present with vomiting, dehydration, and severe diarrhea.", [["vomiting", "DISEASE", 33, 41], ["dehydration", "DISEASE", 43, 54], ["diarrhea", "DISEASE", 67, 75], ["pigs", "ORGANISM", 9, 13], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["vomiting", "PROBLEM", 33, 41], ["dehydration", "PROBLEM", 43, 54], ["severe diarrhea", "PROBLEM", 60, 75], ["dehydration", "OBSERVATION", 43, 54], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["diarrhea", "OBSERVATION", 67, 75]]], ["Further, the disease is known to affect pigs in many countries throughout the world and an outbreak can cause enormous losses in the pig industry [1], [2].", [["pigs", "ORGANISM", 40, 44], ["pig", "ORGANISM", 133, 136], ["pigs", "SPECIES", 40, 44], ["pig", "SPECIES", 133, 136], ["pigs", "SPECIES", 40, 44], ["pig", "SPECIES", 133, 136], ["the disease", "PROBLEM", 9, 20], ["enormous losses", "PROBLEM", 110, 125], ["disease", "OBSERVATION", 13, 20]]], ["The pathogen, TGEV, which belongs to the Alphacoronavirus genus of the Coronavirinae subfamily within the family Coronaviridae, is an enveloped, non-segmented, single-stranded positive-sense RNA virus [3], [4].", [["TGEV", "ORGANISM", 14, 18], ["Alphacoronavirus genus", "ORGANISM", 41, 63], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 71, 84], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 113, 126], ["Coronavirinae subfamily", "PROTEIN", 71, 94], ["TGEV", "SPECIES", 14, 18], ["The pathogen", "PROBLEM", 0, 12], ["TGEV", "PROBLEM", 14, 18], ["stranded positive-sense RNA virus", "PROBLEM", 167, 200]]], ["The envelop, core, and nucleocapsid of the TGEV virion contain four major structural proteins: the nucleocapsid (N) protein, the membrane (M) glycoprotein, the small envelope (E) protein, and the spike (S) protein [5].", [["membrane", "ANATOMY", 129, 137], ["TGEV virion", "ORGANISM", 43, 54], ["nucleocapsid (N) protein", "GENE_OR_GENE_PRODUCT", 99, 123], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["(M) glycoprotein", "GENE_OR_GENE_PRODUCT", 138, 154], ["small envelope (E)", "GENE_OR_GENE_PRODUCT", 160, 178], ["spike (S)", "GENE_OR_GENE_PRODUCT", 196, 205], ["TGEV virion", "PROTEIN", 43, 54], ["structural proteins", "PROTEIN", 74, 93], ["nucleocapsid (N) protein", "PROTEIN", 99, 123], ["membrane (M) glycoprotein", "PROTEIN", 129, 154], ["small envelope (E) protein", "PROTEIN", 160, 186], ["spike (S) protein", "PROTEIN", 196, 213], ["TGEV", "SPECIES", 43, 47], ["TGEV", "SPECIES", 43, 47], ["the TGEV virion", "PROBLEM", 39, 54], ["the nucleocapsid (N) protein", "TEST", 95, 123], ["glycoprotein", "TEST", 142, 154], ["the small envelope (E) protein", "TEST", 156, 186], ["the spike (S) protein", "TEST", 192, 213], ["envelop", "OBSERVATION_MODIFIER", 4, 11]]], ["The tropism and pathogenicity of the virus are influenced by the S protein, which has four major antigenic sites, A, B, C, and D, with site A being the major inducer of antibody neutralization [3], [5].", [["B", "GENE_OR_GENE_PRODUCT", 117, 118], ["C", "GENE_OR_GENE_PRODUCT", 120, 121], ["D", "GENE_OR_GENE_PRODUCT", 127, 128], ["S protein", "PROTEIN", 65, 74], ["The tropism", "PROBLEM", 0, 11], ["the virus", "PROBLEM", 33, 42], ["the S protein", "TEST", 61, 74], ["A, B, C, and D, with site", "PROBLEM", 114, 139], ["tropism", "OBSERVATION_MODIFIER", 4, 11], ["virus", "OBSERVATION", 37, 42], ["major", "OBSERVATION_MODIFIER", 91, 96], ["antigenic sites", "OBSERVATION", 97, 112]]], ["The M protein, which plays a central role in virus assembly by interacting with viral ribonucleoprotein (RNP) and S glycoproteins [6], is embedded within the virus membrane and interacts with the nucleocapsid, forming the core of TGEV virion.", [["membrane", "ANATOMY", 164, 172], ["M protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["RNP", "CELLULAR_COMPONENT", 105, 108], ["S glycoproteins [6", "GENE_OR_GENE_PRODUCT", 114, 132], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["TGEV virion", "ORGANISM", 230, 241], ["M protein", "PROTEIN", 4, 13], ["viral ribonucleoprotein", "PROTEIN", 80, 103], ["RNP", "PROTEIN", 105, 108], ["S glycoproteins", "PROTEIN", 114, 129], ["TGEV virion", "PROTEIN", 230, 241], ["TGEV", "SPECIES", 230, 234], ["The M protein", "TEST", 0, 13], ["a central role in virus", "PROBLEM", 27, 50], ["TGEV virion", "TREATMENT", 230, 241], ["virus membrane", "OBSERVATION", 158, 172], ["TGEV virion", "OBSERVATION", 230, 241]]], ["In addition, the N-terminal domain of the M protein is essential for interferon alpha (IFN-\u03b1) induction [7], which is involved in the host\u2019s innate immune response.", [["N", "CHEMICAL", 17, 18], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 69, 85], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 87, 92], ["N-terminal domain", "PROTEIN", 17, 34], ["M protein", "PROTEIN", 42, 51], ["interferon alpha", "PROTEIN", 69, 85], ["IFN", "PROTEIN", 87, 90], ["the M protein", "TEST", 38, 51], ["interferon alpha (IFN-\u03b1) induction", "TREATMENT", 69, 103], ["essential for", "UNCERTAINTY", 55, 68]]], ["The E protein, a transmembrane protein that acts as a minor structural component in TGEV and affects virus morphogenesis, is essential for virion assembly and release [8].IntroductionTGEV RNA, along with the N protein, is infectious and invades the organism through the digestive and respiratory tracts, resulting in infection of the small intestinal enterocytes, villous atrophy, and severe watery diarrhea.", [["transmembrane", "ANATOMY", 17, 30], ["virion", "ANATOMY", 139, 145], ["digestive", "ANATOMY", 270, 279], ["respiratory tracts", "ANATOMY", 284, 302], ["small intestinal enterocytes", "ANATOMY", 334, 362], ["villous", "ANATOMY", 364, 371], ["infection", "DISEASE", 317, 326], ["villous atrophy", "DISEASE", 364, 379], ["watery diarrhea", "DISEASE", 392, 407], ["E protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["transmembrane", "CELLULAR_COMPONENT", 17, 30], ["TGEV", "ORGANISM", 84, 88], ["virion", "CELLULAR_COMPONENT", 139, 145], ["digestive", "ORGAN", 270, 279], ["respiratory tracts", "MULTI-TISSUE_STRUCTURE", 284, 302], ["intestinal enterocytes", "MULTI-TISSUE_STRUCTURE", 340, 362], ["villous", "MULTI-TISSUE_STRUCTURE", 364, 371], ["E protein", "PROTEIN", 4, 13], ["transmembrane protein", "PROTEIN", 17, 38], ["IntroductionTGEV RNA", "RNA", 171, 191], ["N protein", "PROTEIN", 208, 217], ["TGEV", "SPECIES", 84, 88], ["The E protein", "TEST", 0, 13], ["a transmembrane protein", "TEST", 15, 38], ["a minor structural component", "PROBLEM", 52, 80], ["TGEV", "PROBLEM", 84, 88], ["virus morphogenesis", "PROBLEM", 101, 120], ["virion assembly", "TREATMENT", 139, 154], ["IntroductionTGEV RNA", "PROBLEM", 171, 191], ["the N protein", "TEST", 204, 217], ["infectious", "PROBLEM", 222, 232], ["infection", "PROBLEM", 317, 326], ["the small intestinal enterocytes", "PROBLEM", 330, 362], ["villous atrophy", "PROBLEM", 364, 379], ["severe watery diarrhea", "PROBLEM", 385, 407], ["TGEV", "OBSERVATION", 84, 88], ["infectious", "OBSERVATION", 222, 232], ["digestive", "ANATOMY", 270, 279], ["respiratory tracts", "ANATOMY", 284, 302], ["infection", "OBSERVATION", 317, 326], ["small", "OBSERVATION_MODIFIER", 334, 339], ["intestinal enterocytes", "ANATOMY", 340, 362], ["villous atrophy", "OBSERVATION", 364, 379], ["severe", "OBSERVATION_MODIFIER", 385, 391], ["watery", "OBSERVATION_MODIFIER", 392, 398], ["diarrhea", "OBSERVATION", 399, 407]]], ["These changes in intestinal health are known to be important during the pathogenesis of TGEV infection [9].", [["intestinal", "ANATOMY", 17, 27], ["TGEV infection", "DISEASE", 88, 102], ["intestinal", "ORGAN", 17, 27], ["TGEV", "ORGANISM", 88, 92], ["TGEV", "SPECIES", 88, 92], ["TGEV infection", "PROBLEM", 88, 102], ["intestinal", "ANATOMY", 17, 27], ["infection", "OBSERVATION", 93, 102]]], ["Furthermore, corresponding to these pathologic changes observed in vivo, TGEV can also propagate and cause cytopathic effects (CPEs) in multiple types of cultured cells, such as swine testicular (ST) cells, PK-15 cells, and villous enterocytes.", [["cells", "ANATOMY", 163, 168], ["testicular (ST) cells", "ANATOMY", 184, 205], ["PK-15 cells", "ANATOMY", 207, 218], ["villous enterocytes", "ANATOMY", 224, 243], ["TGEV", "ORGANISM", 73, 77], ["cells", "CELL", 163, 168], ["swine", "ORGANISM", 178, 183], ["testicular (ST) cells", "CELL", 184, 205], ["PK-15 cells", "CELL", 207, 218], ["villous enterocytes", "CELL", 224, 243], ["cultured cells", "CELL_LINE", 154, 168], ["swine testicular (ST) cells", "CELL_TYPE", 178, 205], ["PK-15 cells", "CELL_LINE", 207, 218], ["villous enterocytes", "CELL_TYPE", 224, 243], ["swine", "SPECIES", 178, 183], ["TGEV", "SPECIES", 73, 77], ["swine", "SPECIES", 178, 183], ["these pathologic changes", "PROBLEM", 30, 54], ["TGEV", "PROBLEM", 73, 77], ["cytopathic effects (CPEs)", "PROBLEM", 107, 132], ["cultured cells", "PROBLEM", 154, 168], ["swine testicular (ST) cells", "PROBLEM", 178, 205], ["PK", "TEST", 207, 209], ["villous enterocytes", "PROBLEM", 224, 243], ["pathologic", "OBSERVATION", 36, 46], ["cytopathic", "OBSERVATION_MODIFIER", 107, 117], ["cultured cells", "OBSERVATION", 154, 168], ["testicular", "ANATOMY", 184, 194], ["villous enterocytes", "OBSERVATION", 224, 243]]], ["Notably, ST cells are more susceptible to TGEV, and higher levels of virus replication have been observed in this cell line [10], [11].IntroductionThe full RNA genome of TGEV is approximately 28.5 kb in length and has a 5\u2032-cap structure and a poly(A) tail at the 3\u2032 end.", [["ST cells", "ANATOMY", 9, 17], ["cell line", "ANATOMY", 114, 123], ["ST cells", "CELL", 9, 17], ["TGEV", "ORGANISM", 42, 46], ["cell line", "CELL", 114, 123], ["TGEV", "ORGANISM", 170, 174], ["ST cells", "CELL_TYPE", 9, 17], ["5\u2032-cap structure", "DNA", 220, 236], ["poly(A) tail", "PROTEIN", 243, 255], ["3\u2032 end", "DNA", 263, 269], ["TGEV", "SPECIES", 42, 46], ["TGEV", "SPECIES", 170, 174], ["ST cells", "PROBLEM", 9, 17], ["TGEV", "PROBLEM", 42, 46], ["higher levels of virus replication", "PROBLEM", 52, 86], ["length", "TEST", 203, 209], ["a 5\u2032-cap structure", "TREATMENT", 218, 236], ["a poly(A) tail at the 3\u2032 end", "TREATMENT", 241, 269], ["approximately", "OBSERVATION_MODIFIER", 178, 191], ["28.5 kb", "OBSERVATION_MODIFIER", 192, 199], ["5\u2032-cap structure", "OBSERVATION_MODIFIER", 220, 236], ["tail", "ANATOMY", 251, 255]]], ["The 9 open reading frame (ORF) genes included in the TGEV genome are arranged in the following order 5\u2032-la- lb-S-3a-3b-E-M-N-7-3\u2032.", [["5\u2032-la- lb-S-3a-3b-E-M-N-7-3", "CHEMICAL", 101, 128], ["TGEV", "ORGANISM", 53, 57], ["S-3a-3b-E-M-N-7-3\u2032", "SIMPLE_CHEMICAL", 111, 129], ["9 open reading frame", "DNA", 4, 24], ["ORF", "DNA", 26, 29], ["TGEV genome", "DNA", 53, 64], ["S-3a-3b-E-M", "DNA", 111, 122], ["N-7-3\u2032", "DNA", 123, 129], ["TGEV", "SPECIES", 53, 57], ["TGEV", "SPECIES", 53, 57], ["la", "TEST", 104, 106], ["S-3a-3b-E-M", "TEST", 111, 122]]], ["The first gene at the 5\u2032 end consists of two large ORFs, ORF la and ORF lb, which constitute the replicase gene, known for its RNA-dependent RNA-polymerase and helicase activities, as well as other enzymes, such as endoribonuclease, 3\u2032\u20135\u2032exoribonuclease, 2\u2032-O-ribose methyltransferase, ribose ADP 1\u201d phosphatase, etc. [12].", [["ADP", "CHEMICAL", 293, 296], ["2\u2032-O-ribose", "CHEMICAL", 255, 266], ["ribose ADP", "CHEMICAL", 286, 296], ["ORF lb", "GENE_OR_GENE_PRODUCT", 68, 74], ["endoribonuclease", "GENE_OR_GENE_PRODUCT", 215, 231], ["3\u2032\u20135\u2032exoribonuclease", "SIMPLE_CHEMICAL", 233, 253], ["2\u2032-O-ribose methyltransferase", "SIMPLE_CHEMICAL", 255, 284], ["ribose ADP 1\u201d phosphatase", "GENE_OR_GENE_PRODUCT", 286, 311], ["5\u2032 end", "DNA", 22, 28], ["ORFs", "DNA", 51, 55], ["ORF", "DNA", 57, 60], ["ORF lb", "DNA", 68, 74], ["replicase gene", "DNA", 97, 111], ["RNA-dependent RNA-polymerase", "PROTEIN", 127, 155], ["enzymes", "PROTEIN", 198, 205], ["endoribonuclease", "PROTEIN", 215, 231], ["3\u2032\u20135\u2032exoribonuclease, 2\u2032-O-ribose methyltransferase", "PROTEIN", 233, 284], ["ribose ADP 1\u201d phosphatase", "PROTEIN", 286, 311], ["two large ORFs", "PROBLEM", 41, 55], ["ORF la and ORF lb", "TEST", 57, 74], ["its RNA", "PROBLEM", 123, 130], ["dependent RNA-polymerase", "PROBLEM", 131, 155], ["helicase activities", "TEST", 160, 179], ["other enzymes", "TEST", 192, 205], ["endoribonuclease", "TEST", 215, 231], ["exoribonuclease", "TEST", 238, 253], ["ribose methyltransferase", "TREATMENT", 260, 284], ["ribose ADP", "TEST", 286, 296], ["phosphatase", "TEST", 300, 311], ["large", "OBSERVATION_MODIFIER", 45, 50], ["ORFs", "OBSERVATION", 51, 55]]], ["ORF2, ORF4, ORF5, and ORF6 encode the S, E, M, and N proteins, respectively, while ORF3a, ORF3b, and ORF7 encode non-structural proteins [13].", [["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF4", "GENE_OR_GENE_PRODUCT", 6, 10], ["ORF5", "GENE_OR_GENE_PRODUCT", 12, 16], ["ORF6", "GENE_OR_GENE_PRODUCT", 22, 26], ["E", "GENE_OR_GENE_PRODUCT", 41, 42], ["ORF3a", "GENE_OR_GENE_PRODUCT", 83, 88], ["ORF3b", "GENE_OR_GENE_PRODUCT", 90, 95], ["ORF7", "GENE_OR_GENE_PRODUCT", 101, 105], ["ORF2", "DNA", 0, 4], ["ORF4", "DNA", 6, 10], ["ORF5", "DNA", 12, 16], ["ORF6", "DNA", 22, 26], ["S, E, M, and N proteins", "PROTEIN", 38, 61], ["ORF3a", "PROTEIN", 83, 88], ["ORF3b", "DNA", 90, 95], ["ORF7", "DNA", 101, 105], ["non-structural proteins", "PROTEIN", 113, 136], ["ORF5", "TEST", 12, 16], ["the S, E, M, and N proteins", "TEST", 34, 61], ["ORF3b", "TEST", 90, 95]]], ["Some investigators have suggested that ORF3 may be related to viral virulence and pathogenesis [12], while ORF7 may interact with host cell proteins and play a role in TGEV replication [14].", [["cell", "ANATOMY", 135, 139], ["ORF3", "GENE_OR_GENE_PRODUCT", 39, 43], ["ORF7", "GENE_OR_GENE_PRODUCT", 107, 111], ["host cell", "CELL", 130, 139], ["TGEV", "ORGANISM", 168, 172], ["ORF3", "DNA", 39, 43], ["ORF7", "PROTEIN", 107, 111], ["host cell proteins", "PROTEIN", 130, 148], ["TGEV", "SPECIES", 168, 172], ["ORF3", "TREATMENT", 39, 43], ["viral virulence", "PROBLEM", 62, 77], ["host cell proteins", "TREATMENT", 130, 148]]], ["In fact, a recent study indicates that plasmid-transcribed small hairpin (sh) RNAs targeting the ORF7 gene of TGEV is capable of inhibiting virus replication and expression of the viral target gene in ST cells in vitro [15].", [["ST cells", "ANATOMY", 201, 209], ["ORF7", "GENE_OR_GENE_PRODUCT", 97, 101], ["TGEV", "ORGANISM", 110, 114], ["ST cells", "CELL", 201, 209], ["small hairpin (sh) RNAs", "RNA", 59, 82], ["ORF7 gene", "DNA", 97, 106], ["viral target gene", "DNA", 180, 197], ["ST cells", "CELL_TYPE", 201, 209], ["TGEV", "SPECIES", 110, 114], ["a recent study", "TEST", 9, 23], ["plasmid-transcribed small hairpin (sh) RNAs", "TREATMENT", 39, 82], ["TGEV", "PROBLEM", 110, 114], ["inhibiting virus replication", "TREATMENT", 129, 157], ["the viral target gene in ST cells", "PROBLEM", 176, 209], ["small", "OBSERVATION_MODIFIER", 59, 64], ["hairpin", "OBSERVATION", 65, 72]]], ["Although we have some knowledge concerning the translation and function of these viral proteins, the interactions that occur between these proteins and host cell proteins are not fully understood.IntroductionImportantly, recent advances in proteomic technology have allowed for more in depth investigation of virus-host interactions, and different techniques have been successfully applied to identify altered proteins in infected host cells and tissues.", [["cell", "ANATOMY", 157, 161], ["cells", "ANATOMY", 436, 441], ["tissues", "ANATOMY", 446, 453], ["host cell", "CELL", 152, 161], ["host cells", "CELL", 431, 441], ["tissues", "TISSUE", 446, 453], ["viral proteins", "PROTEIN", 81, 95], ["host cell proteins", "PROTEIN", 152, 170], ["infected host cells", "CELL_TYPE", 422, 441], ["these viral proteins", "PROBLEM", 75, 95], ["host cell proteins", "TREATMENT", 152, 170], ["proteomic technology", "TREATMENT", 240, 260], ["virus", "TREATMENT", 309, 314], ["different techniques", "TREATMENT", 338, 358], ["altered proteins in infected host cells and tissues", "PROBLEM", 402, 453], ["host cell", "OBSERVATION", 152, 161], ["infected host cells", "OBSERVATION", 422, 441]]], ["For example, Sun et al. [16] have identified 35 differentially expressed proteins in PK-15 cells infected with classical swine fever virus (CSFV) using two-dimensional polyacrylamide gel electrophoresis (2D PAGE) followed by matrix-assisted laser desorption-ionization time-of-flight tandem mass spectrometry (MALDI-TOF-MS/MS).", [["PK-15 cells", "ANATOMY", 85, 96], ["swine fever", "DISEASE", 121, 132], ["polyacrylamide", "CHEMICAL", 168, 182], ["PK-15 cells", "CELL", 85, 96], ["classical swine fever virus", "ORGANISM", 111, 138], ["CSFV", "ORGANISM", 140, 144], ["PK-15 cells", "CELL_LINE", 85, 96], ["swine fever virus", "SPECIES", 121, 138], ["classical swine fever virus", "SPECIES", 111, 138], ["CSFV", "SPECIES", 140, 144], ["Sun et al.", "TEST", 13, 23], ["PK", "TEST", 85, 87], ["classical swine fever virus", "PROBLEM", 111, 138], ["two-dimensional polyacrylamide gel electrophoresis", "TREATMENT", 152, 202], ["matrix-assisted laser desorption", "TREATMENT", 225, 257], ["ionization time", "TEST", 258, 273], ["flight tandem mass spectrometry", "TEST", 277, 308], ["MALDI", "TEST", 310, 315]]], ["In addition, two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) and MS/MS proteomic approaches have been applied to characterize protein changes occurring in host cells in response to porcine circovirus type 2 (PCV2) infection [17].", [["cells", "ANATOMY", 182, 187], ["infection", "DISEASE", 236, 245], ["host cells", "CELL", 177, 187], ["porcine circovirus type 2", "ORGANISM", 203, 228], ["PCV2", "ORGANISM", 230, 234], ["host cells", "CELL_TYPE", 177, 187], ["porcine circovirus", "SPECIES", 203, 221], ["porcine circovirus type 2 (PCV2)", "SPECIES", 203, 235], ["gel electrophoresis", "TEST", 53, 72], ["MS/MS proteomic approaches", "TREATMENT", 87, 113], ["protein changes", "PROBLEM", 148, 163], ["host cells", "PROBLEM", 177, 187], ["porcine circovirus type 2 (PCV2) infection", "PROBLEM", 203, 245], ["host cells", "OBSERVATION", 177, 187], ["porcine circovirus", "OBSERVATION", 203, 221]]], ["The same methods have also been studied for many other pathogenic animal viruses, including porcine reproductive and respiratory syndrome virus (PRRSV) [18], coronavirus infectious bronchitis virus (IBV) [19], severe acute respiratory syndrome-associated coronavirus (SARS-CoV) [20], and TGEV [21].", [["porcine reproductive and respiratory syndrome virus", "DISEASE", 92, 143], ["coronavirus infectious bronchitis virus", "DISEASE", 158, 197], ["acute respiratory syndrome-associated coronavirus (SARS-CoV)", "DISEASE", 217, 277], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 92, 143], ["PRRSV", "ORGANISM", 145, 150], ["coronavirus infectious bronchitis virus", "ORGANISM", 158, 197], ["IBV", "ORGANISM", 199, 202], ["severe acute respiratory syndrome-associated coronavirus", "ORGANISM", 210, 266], ["SARS-CoV", "ORGANISM", 268, 276], ["TGEV", "ORGANISM", 288, 292], ["porcine", "SPECIES", 92, 99], ["syndrome virus", "SPECIES", 129, 143], ["PRRSV", "SPECIES", 145, 150], ["coronavirus infectious bronchitis virus", "SPECIES", 158, 197], ["-associated coronavirus", "SPECIES", 243, 266], ["TGEV", "SPECIES", 288, 292], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 92, 143], ["PRRSV", "SPECIES", 145, 150], ["coronavirus infectious bronchitis virus", "SPECIES", 158, 197], ["IBV", "SPECIES", 199, 202], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 210, 266], ["SARS-CoV", "SPECIES", 268, 276], ["TGEV", "SPECIES", 288, 292], ["many other pathogenic animal viruses", "PROBLEM", 44, 80], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 92, 143], ["coronavirus infectious bronchitis virus", "PROBLEM", 158, 197], ["severe acute respiratory syndrome", "PROBLEM", 210, 243], ["associated coronavirus", "PROBLEM", 244, 266], ["viruses", "OBSERVATION", 73, 80], ["respiratory syndrome", "OBSERVATION", 117, 137], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["acute", "OBSERVATION_MODIFIER", 217, 222], ["respiratory syndrome", "OBSERVATION", 223, 243]]], ["However, these conventional approaches based on 2D gel electrophoresis are not suitable for detecting low abundance, hydrophobic, or very acidic/basic proteins.", [["acidic/basic proteins", "PROTEIN", 138, 159], ["2D gel electrophoresis", "TEST", 48, 70], ["low abundance", "PROBLEM", 102, 115], ["very acidic/basic proteins", "PROBLEM", 133, 159]]], ["On the other hand, the isobaric tags for relative and absolute quantitation (iTRAQ) technique, in association with liquid chromatograph (LC), is a more advanced method for proteomic research, and is capable of detecting a much larger number of proteins, even those with low abundance, in addition to identifying and quantifying the proteins simultaneously [22].", [["the isobaric tags", "TEST", 19, 36], ["proteomic research", "TEST", 172, 190]]], ["To this end, Lu et al. [23] previously used the iTRAQ method to identify 160 significantly altered proteins in pulmonary alveolar macrophages (PAMs) infected with PRRSV.", [["pulmonary alveolar macrophages", "ANATOMY", 111, 141], ["PAMs", "ANATOMY", 143, 147], ["pulmonary alveolar macrophages", "CELL", 111, 141], ["PAMs", "CELL", 143, 147], ["PRRSV", "ORGANISM", 163, 168], ["pulmonary alveolar macrophages", "CELL_TYPE", 111, 141], ["PAMs", "CELL_TYPE", 143, 147], ["PRRSV", "SPECIES", 163, 168], ["PRRSV", "SPECIES", 163, 168], ["the iTRAQ method", "TREATMENT", 44, 60], ["significantly altered proteins in pulmonary alveolar macrophages", "PROBLEM", 77, 141], ["PRRSV", "PROBLEM", 163, 168], ["pulmonary", "ANATOMY", 111, 120], ["alveolar macrophages", "OBSERVATION", 121, 141]]], ["Similarly, this method has been used to investigate influenza virus infection in primary human macrophages [24], human immunodeficiency virus 1 (HIV-1) infection in CD4+ T cells [25], and Epstein\u2013Barr virus (EBV) infection in nasopharyngeal carcinoma cell line [26].IntroductionHere, we report the first differential proteomic analysis of TGEV-infected and uninfected ST cells using iTRAQ labeling followed by 2D-LC-MS and bioinformatic analyses.", [["macrophages", "ANATOMY", 95, 106], ["CD4+ T cells", "ANATOMY", 165, 177], ["nasopharyngeal carcinoma cell line", "ANATOMY", 226, 260], ["ST cells", "ANATOMY", 368, 376], ["influenza virus infection", "DISEASE", 52, 77], ["human immunodeficiency virus", "DISEASE", 113, 141], ["infection", "DISEASE", 152, 161], ["Epstein\u2013Barr virus (EBV) infection", "DISEASE", 188, 222], ["nasopharyngeal carcinoma", "DISEASE", 226, 250], ["influenza virus", "ORGANISM", 52, 67], ["human", "ORGANISM", 89, 94], ["macrophages", "CELL", 95, 106], ["human immunodeficiency virus 1", "ORGANISM", 113, 143], ["HIV-1", "ORGANISM", 145, 150], ["CD4", "GENE_OR_GENE_PRODUCT", 165, 168], ["Epstein\u2013Barr virus", "ORGANISM", 188, 206], ["EBV", "ORGANISM", 208, 211], ["nasopharyngeal carcinoma cell line [26", "CELL", 226, 264], ["TGEV", "ORGANISM", 339, 343], ["ST cells", "CELL", 368, 376], ["primary human macrophages", "CELL_TYPE", 81, 106], ["CD4", "PROTEIN", 165, 168], ["T cells", "CELL_TYPE", 170, 177], ["nasopharyngeal carcinoma cell line", "CELL_LINE", 226, 260], ["uninfected ST cells", "CELL_TYPE", 357, 376], ["influenza virus", "SPECIES", 52, 67], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 113, 118], ["immunodeficiency virus 1", "SPECIES", 119, 143], ["HIV-1", "SPECIES", 145, 150], ["Barr virus", "SPECIES", 196, 206], ["influenza virus", "SPECIES", 52, 67], ["human", "SPECIES", 89, 94], ["human immunodeficiency virus 1", "SPECIES", 113, 143], ["HIV-1", "SPECIES", 145, 150], ["Epstein\u2013Barr virus", "SPECIES", 188, 206], ["EBV", "SPECIES", 208, 211], ["TGEV", "SPECIES", 339, 343], ["this method", "TREATMENT", 11, 22], ["influenza virus infection", "PROBLEM", 52, 77], ["human immunodeficiency virus", "PROBLEM", 113, 141], ["HIV", "TEST", 145, 148], ["infection", "PROBLEM", 152, 161], ["CD4", "TEST", 165, 168], ["T cells", "PROBLEM", 170, 177], ["Epstein\u2013Barr virus (EBV) infection in nasopharyngeal carcinoma cell line", "PROBLEM", 188, 260], ["TGEV", "PROBLEM", 339, 343], ["infected", "PROBLEM", 344, 352], ["uninfected ST cells", "PROBLEM", 357, 376], ["iTRAQ labeling", "TEST", 383, 397], ["bioinformatic analyses", "TEST", 423, 445], ["Barr virus", "OBSERVATION", 196, 206], ["nasopharyngeal", "ANATOMY", 226, 240], ["carcinoma cell line", "OBSERVATION", 241, 260]]], ["The proteomic data obtained in this study will help to enhance our understanding of the host response to TGEV infection, but also provide new insights on the mechanisms of disease onset.Cell culture and viral replication ::: Materials and MethodsST cells were obtained from the American Type Culture Collection (ATCC).", [["Cell", "ANATOMY", 186, 190], ["ST cells", "ANATOMY", 246, 254], ["TGEV infection", "DISEASE", 105, 119], ["TGEV", "ORGANISM", 105, 109], ["Cell", "CELL", 186, 190], ["ST cells", "CELL", 246, 254], ["ST cells", "CELL_TYPE", 246, 254], ["TGEV", "SPECIES", 105, 109], ["The proteomic data", "TEST", 0, 18], ["this study", "TEST", 31, 41], ["TGEV infection", "PROBLEM", 105, 119], ["disease onset", "PROBLEM", 172, 185], ["Cell culture", "TEST", 186, 198], ["MethodsST cells", "PROBLEM", 239, 254], ["infection", "OBSERVATION", 110, 119], ["disease", "OBSERVATION", 172, 179], ["viral replication", "OBSERVATION", 203, 220]]], ["The cells were cultured in high-glucose Dulbecco\u2019s modified Eagle\u2019s medium (DMEM; GIBCO, UK) containing 1% L-glutamine and 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) at 37\u00b0C in 5% CO2.", [["cells", "ANATOMY", 4, 9], ["fetal bovine serum", "ANATOMY", 127, 145], ["FBS", "ANATOMY", 147, 150], ["glucose", "CHEMICAL", 32, 39], ["L-glutamine", "CHEMICAL", 107, 118], ["CO2", "CHEMICAL", 187, 190], ["glucose", "CHEMICAL", 32, 39], ["L-glutamine", "CHEMICAL", 107, 118], ["CO2", "CHEMICAL", 187, 190], ["cells", "CELL", 4, 9], ["L-glutamine", "SIMPLE_CHEMICAL", 107, 118], ["bovine", "ORGANISM", 133, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["FBS", "ORGANISM_SUBSTANCE", 147, 150], ["Hyclone", "ORGANISM_SUBSTANCE", 153, 160], ["CO2", "SIMPLE_CHEMICAL", 187, 190], ["bovine", "SPECIES", 133, 139], ["The cells", "TEST", 0, 9], ["GIBCO", "TEST", 82, 87], ["1% L-glutamine", "TREATMENT", 104, 118], ["fetal bovine serum", "TEST", 127, 145]]], ["Culture medium was replaced two to three times per week.", [["Culture medium", "TEST", 0, 14]]], ["The TGEV TH-98 strain was isolated from a suburb of Harbin, Heilongjiang province, China.", [["TGEV TH-98", "CHEMICAL", 4, 14], ["TGEV", "ORGANISM", 4, 8], ["TH-98", "GENE_OR_GENE_PRODUCT", 9, 14], ["TGEV TH-98", "SPECIES", 4, 14], ["The TGEV TH", "TEST", 0, 11]]], ["The virus was propagated in ST cells and preserved at \u221270\u00b0C in our laboratory.TGEV infection ::: Materials and MethodsThe monolayer of confluent ST cells was dispersed with 0.25% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) and seeded in 6-cm cell culture flasks.", [["ST cells", "ANATOMY", 28, 36], ["monolayer", "ANATOMY", 122, 131], ["ST cells", "ANATOMY", 145, 153], ["cell", "ANATOMY", 255, 259], ["TGEV infection", "DISEASE", 78, 92], ["ethylenediaminetetraacetic acid", "CHEMICAL", 197, 228], ["EDTA", "CHEMICAL", 230, 234], ["ethylenediaminetetraacetic acid", "CHEMICAL", 197, 228], ["EDTA", "CHEMICAL", 230, 234], ["ST cells", "CELL", 28, 36], ["TGEV", "ORGANISM", 78, 82], ["monolayer", "CELL", 122, 131], ["confluent ST cells", "CELL", 135, 153], ["trypsin", "SIMPLE_CHEMICAL", 179, 186], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 197, 228], ["EDTA", "SIMPLE_CHEMICAL", 230, 234], ["ST cells", "CELL_TYPE", 28, 36], ["confluent ST cells", "CELL_LINE", 135, 153], ["TGEV", "SPECIES", 78, 82], ["TGEV", "SPECIES", 78, 82], ["The virus", "PROBLEM", 0, 9], ["TGEV infection", "PROBLEM", 78, 92], ["confluent ST cells", "PROBLEM", 135, 153], ["0.25% trypsin", "TREATMENT", 173, 186], ["0.02% ethylenediaminetetraacetic acid (EDTA", "TREATMENT", 191, 234], ["virus", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 83, 92], ["confluent", "OBSERVATION_MODIFIER", 135, 144], ["ST cells", "OBSERVATION", 145, 153], ["6-cm cell", "OBSERVATION_MODIFIER", 250, 259]]], ["After a 24 h incubation period, the culture medium was removed and the ST cells were washed with phosphate buffered saline (PBS, pH 7.4).", [["ST cells", "ANATOMY", 71, 79], ["phosphate", "CHEMICAL", 97, 106], ["phosphate", "CHEMICAL", 97, 106], ["ST cells", "CELL", 71, 79], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 97, 122], ["ST cells", "CELL_TYPE", 71, 79], ["the culture medium", "TEST", 32, 50], ["the ST cells", "TREATMENT", 67, 79], ["phosphate buffered saline", "TREATMENT", 97, 122], ["pH", "TEST", 129, 131]]], ["The cells were then infected with the TGEV TH-98 strain at a 50% tissue culture infectious dose (TCID50) of 1\u00d7103.53 viruses per well, with absorption for 2 h at 37\u00b0C. Maintenance medium (DMEM medium supplemented with 2% FBS) was then added to the cells.", [["cells", "ANATOMY", 4, 9], ["tissue", "ANATOMY", 65, 71], ["cells", "ANATOMY", 248, 253], ["TGEV TH-98", "CHEMICAL", 38, 48], ["cells", "CELL", 4, 9], ["TGEV", "ORGANISM", 38, 42], ["TH-98", "ORGANISM", 43, 48], ["tissue", "TISSUE", 65, 71], ["FBS", "ORGANISM_SUBSTANCE", 221, 224], ["cells", "CELL", 248, 253], ["TGEV TH-98", "SPECIES", 38, 48], ["the TGEV TH", "TEST", 34, 45], ["Maintenance medium (DMEM medium", "TREATMENT", 168, 199], ["2% FBS", "TREATMENT", 218, 224]]], ["A mock group of ST cells that were not infected with TGEV was used as a negative control for each of the following experiments.", [["ST cells", "ANATOMY", 16, 24], ["ST cells", "CELL", 16, 24], ["TGEV", "ORGANISM", 53, 57], ["ST cells", "CELL_LINE", 16, 24], ["TGEV", "SPECIES", 53, 57], ["ST cells", "PROBLEM", 16, 24], ["TGEV", "PROBLEM", 53, 57]]], ["Three replicates of virus-infected and mock-infected cultures with different passage numbers were prepared at each time point.", [["cultures", "ANATOMY", 53, 61], ["cultures", "CELL", 53, 61], ["virus", "PROBLEM", 20, 25], ["infected cultures", "PROBLEM", 44, 61], ["different passage numbers", "PROBLEM", 67, 92], ["virus", "OBSERVATION", 20, 25], ["infected", "OBSERVATION_MODIFIER", 26, 34]]], ["The morphological changes were observed under the light microscope at 24, 40, 48, and 64 hours post infection (hpi).Reverse transcription polymerase chain reaction (RT-PCR) and real time quantitative PCR (qRT-PCR) ::: Materials and MethodsTo determine the extent of TGEV infection, conventional RT-PCR and qRT-PCR assays were performed to detect the viral N gene.", [["infection", "DISEASE", 100, 109], ["TGEV infection", "DISEASE", 266, 280], ["TGEV", "ORGANISM", 266, 270], ["viral N gene", "DNA", 350, 362], ["TGEV", "SPECIES", 266, 270], ["the light microscope", "TEST", 46, 66], ["infection", "PROBLEM", 100, 109], ["Reverse transcription polymerase chain reaction", "PROBLEM", 116, 163], ["RT-PCR", "TEST", 165, 171], ["real time quantitative PCR", "TEST", 177, 203], ["qRT", "TEST", 205, 208], ["Methods", "TREATMENT", 232, 239], ["TGEV infection", "PROBLEM", 266, 280], ["conventional RT-PCR", "TEST", 282, 301], ["qRT-PCR assays", "TEST", 306, 320], ["infection", "OBSERVATION", 100, 109], ["TGEV", "OBSERVATION_MODIFIER", 266, 270], ["infection", "OBSERVATION", 271, 280]]], ["Monolayers of ST cells were infected with TGEV as described above.", [["Monolayers", "ANATOMY", 0, 10], ["ST cells", "ANATOMY", 14, 22], ["Monolayers", "CELL", 0, 10], ["ST cells", "CELL", 14, 22], ["TGEV", "ORGANISM", 42, 46], ["ST cells", "CELL_TYPE", 14, 22], ["TGEV", "SPECIES", 42, 46], ["ST cells", "PROBLEM", 14, 22], ["TGEV", "PROBLEM", 42, 46], ["ST cells", "ANATOMY", 14, 22], ["infected", "OBSERVATION", 28, 36]]], ["Cells were collected from 24 to 80 hpi at 8 h intervals, and the total RNA of the infected cells was extracted using Trizol (Invitrogen).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 91, 96], ["Cells", "CELL", 0, 5], ["cells", "CELL", 91, 96], ["infected cells", "CELL_TYPE", 82, 96], ["Cells", "TEST", 0, 5], ["the infected cells", "PROBLEM", 78, 96], ["Trizol (Invitrogen", "TREATMENT", 117, 135], ["infected cells", "OBSERVATION", 82, 96]]], ["RNA samples were reverse-transcribed using PrimeScript RT reagent Kit (Takara Bio, Dalian, China), according to the manufacturer\u2019s instructions.", [["samples", "ANATOMY", 4, 11], ["RNA samples", "TEST", 0, 11], ["PrimeScript RT reagent Kit", "TREATMENT", 43, 69]]], ["The RT reaction was incubated at 37\u00b0C for 15 min followed by 85\u00b0C for 5 s.", [["The RT reaction", "PROBLEM", 0, 15]]], ["A mixture of oligo dT primers and random 6 mers was used in the RT step.", [["oligo dT", "CHEMICAL", 13, 21], ["A mixture of oligo dT primers", "TREATMENT", 0, 29], ["random 6 mers", "TREATMENT", 34, 47]]], ["The cDNA was stored at \u221220\u00b0C until further use.Reverse transcription polymerase chain reaction (RT-PCR) and real time quantitative PCR (qRT-PCR) ::: Materials and MethodsPCR was performed for the TGEV N gene in a 25 \u00b5l reaction mixture containing 1 \u00b5l of the cDNA, 0.5 \u00b5l of each forward (F) and reverse (R) primer, 12.5 \u00b5l of Premix Taq (Takara Bio, Dalian, China), and 10.5 \u00b5l DEPC water, starting with a 5 min denaturation at 95 C followed by 32 cycles of 30 s denaturation at 95 C, 30 s annealing at 56 C, and 40 s extension at 72 C. A final extension step was carried out at 72 C for 10 min.", [["DEPC", "CHEMICAL", 379, 383], ["TGEV", "ORGANISM", 196, 200], ["cDNA", "DNA", 4, 8], ["TGEV N gene", "DNA", 196, 207], ["cDNA", "DNA", 259, 263], ["TGEV", "SPECIES", 196, 200], ["The cDNA", "TEST", 0, 8], ["Reverse transcription polymerase chain reaction", "PROBLEM", 47, 94], ["RT-PCR", "TEST", 96, 102], ["real time quantitative PCR", "TEST", 108, 134], ["qRT", "TEST", 136, 139], ["MethodsPCR", "TEST", 163, 173], ["a 25 \u00b5l reaction mixture", "TREATMENT", 211, 235], ["the cDNA", "TREATMENT", 255, 263], ["reverse (R) primer", "TREATMENT", 296, 314], ["Premix Taq", "TREATMENT", 327, 337], ["10.5 \u00b5l DEPC water", "TREATMENT", 371, 389], ["a 5 min denaturation", "TREATMENT", 405, 425], ["A final extension step", "TEST", 538, 560]]], ["RT-PCR products were resolved on a 15 g/L agarose gel.", [["agarose", "SIMPLE_CHEMICAL", 42, 49], ["RT-PCR products", "TREATMENT", 0, 15], ["a 15 g/L agarose gel", "TREATMENT", 33, 53], ["resolved", "OBSERVATION_MODIFIER", 21, 29]]], ["The following PCR primers were used in this study: TGEV N (F, 5\u2032-GAGCAGTGCCAAGCATTACCC-3\u2032 and R, 5\u2032-GACTTCTAT CTGGTCGCCATCTTC-3\u2032) and \u03b2-actin (F, 5\u2032-GCAAGGACCTCTACGCCAA-3\u2032 and R, 5\u2032-CTGGAAGGTGGACAGCGAG-3\u2032).Reverse transcription polymerase chain reaction (RT-PCR) and real time quantitative PCR (qRT-PCR) ::: Materials and MethodsThe mRNA expression level of the TGEV N gene was quantified using a SYBR Green assay on a Bio-Rad iQ5 real time PCR detection system as described previously [27].", [["TGEV", "ORGANISM", 51, 55], ["\u03b2-actin", "SIMPLE_CHEMICAL", 134, 141], ["TGEV N", "GENE_OR_GENE_PRODUCT", 362, 368], ["PCR primers", "DNA", 14, 25], ["\u03b2-actin", "DNA", 134, 141], ["TGEV N gene", "DNA", 362, 373], ["TGEV", "SPECIES", 51, 55], ["TGEV", "SPECIES", 362, 366], ["The following PCR primers", "TEST", 0, 25], ["this study", "TEST", 39, 49], ["TGEV", "TEST", 51, 55], ["F", "TEST", 59, 60], ["GAGCAGTGCCAAGCATTACCC", "TEST", 65, 86], ["R", "TEST", 94, 95], ["GACTTCTAT", "TEST", 100, 109], ["CTGGTCGCCATCTTC", "TEST", 110, 125], ["\u03b2-actin", "TEST", 134, 141], ["GCAAGGACCTCTACGCCAA", "TEST", 149, 168], ["R", "TEST", 176, 177], ["CTGGAAGGTGGACAGCGAG", "TEST", 182, 201], ["Reverse transcription polymerase chain reaction", "PROBLEM", 206, 253], ["RT-PCR", "TEST", 255, 261], ["real time quantitative PCR", "TEST", 267, 293], ["qRT", "TEST", 295, 298], ["Methods", "TREATMENT", 322, 329]]], ["We used the same primers listed above for qRT-PCR.", [["qRT", "DNA", 42, 45], ["the same primers", "TREATMENT", 8, 24]]], ["Reactions were carried out in 50 \u00b5l volumes containing 0.5 \u00b5l of 20 \u00d7 SYBR Green I, 2 \u00b5l of cDNA template, 1 \u00b5l of each F and R primer, 25 \u00b5l of 2 \u00d7 PCR buffer, and 20.5 \u00b5l DEPC water.", [["DEPC", "CHEMICAL", 173, 177], ["cDNA template", "DNA", 92, 105], ["cDNA template", "TREATMENT", 92, 105], ["R primer", "TEST", 126, 134]]], ["The cycling conditions were 94\u00b0C for 4 min, followed by 35 cycles of 94\u00b0C for 20 s, 60\u00b0C for 30 s, 72\u00b0C for 30 s, and then a final extension of 10 min at 72\u00b0C. The relative gene expression was determined with the 2(\u2212\u0394\u0394Ct) method [28], and the tests were performed in triplicate.Protein isolation, digestion, and labeling with iTRAQ reagents ::: Materials and MethodsFollowing ST cell infection, cells were collected at 48 and 64 hpi by centrifugation at 3,000 rpm for 5 min at 4\u00b0C, washed twice with PBS, and 1 mL of iTRAQ lysis solution (8 M urea, 1% (w/v) dithiothreitol (DTT)) containing protease inhibitor was added.", [["ST cell", "ANATOMY", 376, 383], ["cells", "ANATOMY", 395, 400], ["infection", "DISEASE", 384, 393], ["urea", "CHEMICAL", 543, 547], ["DTT", "CHEMICAL", 574, 577], ["urea", "CHEMICAL", 543, 547], ["dithiothreitol", "CHEMICAL", 558, 572], ["DTT", "CHEMICAL", 574, 577], ["MethodsFollowing ST cell", "CELL", 359, 383], ["cells", "CELL", 395, 400], ["urea", "SIMPLE_CHEMICAL", 543, 547], ["(w/v) dithiothreitol", "SIMPLE_CHEMICAL", 552, 572], ["DTT", "SIMPLE_CHEMICAL", 574, 577], ["The cycling conditions", "TEST", 0, 22], ["the tests", "TEST", 239, 248], ["Protein isolation", "TEST", 278, 295], ["digestion", "PROBLEM", 297, 306], ["MethodsFollowing ST cell infection", "PROBLEM", 359, 393], ["PBS", "TREATMENT", 500, 503], ["iTRAQ lysis solution", "TREATMENT", 517, 537], ["urea", "TEST", 543, 547], ["w/v) dithiothreitol (DTT)", "TREATMENT", 553, 578], ["protease inhibitor", "TREATMENT", 591, 609], ["cell infection", "OBSERVATION", 379, 393]]], ["Then, the cells were put in an ice bath and broken up by sonication.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["the cells", "TREATMENT", 6, 15], ["an ice bath", "TREATMENT", 28, 39]]], ["The solution was then mixed for 30 min at 4\u00b0C. The soluble protein fraction was harvested by centrifugation at 40,000 \u00d7 g for 30 min at 4\u00b0C and the debris was discarded.", [["C", "GENE_OR_GENE_PRODUCT", 138, 139], ["The solution", "TREATMENT", 0, 12], ["The soluble protein fraction", "TREATMENT", 47, 75], ["the debris", "PROBLEM", 144, 154], ["debris", "OBSERVATION", 148, 154]]], ["The protein concentration was determined with the Bradford protein assay (2-D Quant Kit, Bestbio, China).", [["The protein concentration", "TEST", 0, 25], ["the Bradford protein assay", "TEST", 46, 72]]], ["A 100 \u00b5g aliquot of protein from each sample was reduced, alkylated, and trypsin-digested as described in the iTRAQ protocol (AB Sciex, American), followed by labeling with the 4-plex iTRAQ Reagents Multiplex Kit according to the manufacturer\u2019s instructions (AB Sciex, American).", [["sample", "ANATOMY", 38, 44], ["trypsin", "SIMPLE_CHEMICAL", 73, 80], ["trypsin", "PROTEIN", 73, 80], ["A 100 \u00b5g aliquot of protein", "TREATMENT", 0, 27], ["trypsin", "TEST", 73, 80]]], ["Two virus-free samples at 48 h and 64 h were labeled with iTRAQ tags 114 and 115, while two TGEV-infected samples at 48 h and 64 h were labeled with tags 116 and 117.", [["samples", "ANATOMY", 15, 22], ["samples", "ANATOMY", 106, 113], ["TGEV", "ORGANISM", 92, 96], ["TGEV", "SPECIES", 92, 96], ["Two virus-free samples", "TEST", 0, 22], ["iTRAQ tags", "TEST", 58, 68], ["tags", "TEST", 149, 153], ["free", "OBSERVATION_MODIFIER", 10, 14]]], ["The labeled digests were then pooled, dried using a vacuum freeze drier (Christ RVC 2\u221225, Germany), and preserved at \u221220\u00b0C for later use.2D LC-MS/MS analysis ::: Materials and MethodsThe combined peptide mixtures were separated by reversed phase high-performance liquid chromatography (HPLC) (Ekspert ultraLC 100, AB Sciex, USA) on a Durashell-C18 reverse phase column (4.6 mm \u00d7 250 mm, 5 \u00b5m 100 \u00c5, Agela).", [["a vacuum freeze drier", "TREATMENT", 50, 71], ["Methods", "TREATMENT", 176, 183], ["The combined peptide mixtures", "TEST", 183, 212], ["HPLC", "TEST", 286, 290], ["Ekspert ultraLC", "TEST", 293, 308], ["a Durashell", "TEST", 332, 343]]], ["The mobile phases used were composed of 20 mM ammonium formate (pH 10) in water (labeled mobile phase A) and 20 mM ammonium formate (pH 10) in acetonitrile(ACN) (mobile phase B).", [["ammonium formate", "CHEMICAL", 46, 62], ["ammonium formate", "CHEMICAL", 115, 131], ["acetonitrile", "CHEMICAL", 143, 155], ["ACN", "CHEMICAL", 156, 159], ["ammonium formate", "CHEMICAL", 46, 62], ["ammonium formate", "CHEMICAL", 115, 131], ["acetonitrile", "CHEMICAL", 143, 155], ["ACN", "CHEMICAL", 156, 159], ["ammonium formate", "SIMPLE_CHEMICAL", 46, 62], ["water", "SIMPLE_CHEMICAL", 74, 79], ["ammonium formate", "SIMPLE_CHEMICAL", 115, 131], ["acetonitrile", "SIMPLE_CHEMICAL", 143, 155], ["ACN", "SIMPLE_CHEMICAL", 156, 159], ["20 mM ammonium formate", "TREATMENT", 40, 62], ["pH", "TEST", 64, 66], ["20 mM ammonium formate", "TEST", 109, 131], ["pH", "TEST", 133, 135]]], ["The flow rate was 0.8 mL/min, and the elutant was collected into 48 centrifuge tubes at each minute after the first 5 min.", [["The flow rate", "TEST", 0, 13], ["flow", "OBSERVATION_MODIFIER", 4, 8]]], ["Each aliquot was then dried by vacuum freezing.2D LC-MS/MS analysis ::: Materials and MethodsThe peptides were then analyzed with a nanoflow reversed-phase liquid chromatography-tandem mass spectrometry (nano-RPLC-MS/MS) system (TripleTOF 5600, AB Sciex, USA).", [["Each aliquot", "TREATMENT", 0, 12], ["a nanoflow reversed-phase liquid chromatography", "TEST", 130, 177], ["tandem mass spectrometry", "TEST", 178, 202], ["nano", "TEST", 204, 208], ["vacuum freezing", "OBSERVATION", 31, 46]]], ["The above 48 tubes were merged into 10 components dissolved in 2% ACN and 0.1% formic acid (FA), then centrifuged at 12,000 \u00d7 g for 10 min.", [["ACN", "CHEMICAL", 66, 69], ["formic acid", "CHEMICAL", 79, 90], ["FA", "CHEMICAL", 92, 94], ["ACN", "CHEMICAL", 66, 69], ["formic acid", "CHEMICAL", 79, 90], ["ACN", "SIMPLE_CHEMICAL", 66, 69], ["formic acid", "SIMPLE_CHEMICAL", 79, 90], ["FA", "SIMPLE_CHEMICAL", 92, 94], ["The above 48 tubes", "TREATMENT", 0, 18], ["2% ACN", "TREATMENT", 63, 69], ["0.1% formic acid (FA", "TREATMENT", 74, 94], ["tubes", "OBSERVATION", 13, 18]]], ["The supernatant (8 \u00b5l) was used for loading at a rate of 2 \u00b5l/min, with a separation rate of 0.3 \u00b5l/min.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant (8 \u00b5l)", "TREATMENT", 0, 22], ["a separation rate", "TEST", 72, 89]]], ["The mobile phase A used in this analysis was composed of 2% ACN and 0.2% FA, while mobile phase B was composed of 98% ACN and 0.1% FA.", [["ACN", "CHEMICAL", 60, 63], ["FA", "CHEMICAL", 73, 75], ["ACN", "CHEMICAL", 118, 121], ["FA", "CHEMICAL", 131, 133], ["ACN", "CHEMICAL", 60, 63], ["ACN", "CHEMICAL", 118, 121], ["ACN", "SIMPLE_CHEMICAL", 60, 63], ["FA", "SIMPLE_CHEMICAL", 73, 75], ["ACN", "SIMPLE_CHEMICAL", 118, 121], ["FA", "SIMPLE_CHEMICAL", 131, 133], ["this analysis", "TEST", 27, 40], ["mobile phase", "OBSERVATION_MODIFIER", 4, 16]]], ["The following MS parameters were utilized: source gas parameters (ion spray voltage: 2.3 kV, GS1\u22364, curtain gas: 30 or 35, DP: 100 or 80); TOF MS (m/z: 350\u20131250, accumulation time: 0.25 s); and product ion scan (IDA number: 30, m/z: 100\u20131500, accumulation time: 0.1 s, dynamic exclusion time: 25 s, rolling CE: enabled, adjust CE when using iTRAQ reagent: enabled, CES: 5).Data analysis and bioinformatics ::: Materials and MethodsProtein identification and quantification were performed with the ProteinPilot software (version 4.0, AB Sciex) using the Paragon algorithm.", [["The following MS parameters", "TEST", 0, 27], ["source gas parameters", "TEST", 43, 64], ["ion spray voltage", "TEST", 66, 83], ["kV", "TEST", 89, 91], ["GS1", "TEST", 93, 96], ["curtain gas", "TEST", 100, 111], ["DP", "TEST", 123, 125], ["TOF MS", "TEST", 139, 145], ["accumulation time", "TEST", 162, 179], ["product ion scan", "TEST", 194, 210], ["IDA number", "TEST", 212, 222], ["accumulation time", "TEST", 243, 260], ["dynamic exclusion time", "TEST", 269, 291], ["rolling CE", "TEST", 299, 309], ["CE", "TEST", 327, 329], ["iTRAQ reagent", "TEST", 341, 354], ["Data analysis", "TEST", 373, 386], ["MethodsProtein identification", "TEST", 424, 453], ["quantification", "TEST", 458, 472], ["the ProteinPilot software", "TEST", 493, 518], ["version", "TEST", 520, 527], ["the Paragon algorithm", "TEST", 549, 570]]], ["Each MS/MS spectrum was searched against a database of Sus scrofa protein sequences (NCBI nr, released in March 2011, downloaded from ftp://ftp.ncbi.nih.gov/genomes/Sus_scrofa/protein/).", [["Sus", "ORGANISM", 55, 58], ["Sus scrofa protein sequences", "DNA", 55, 83], ["Sus scrofa", "SPECIES", 55, 65], ["Sus scrofa", "SPECIES", 55, 65], ["Each MS/MS spectrum", "PROBLEM", 0, 19]]], ["The following search parameters were used: iTRAQ 4-plex (peptide labeled), cysteine alkylation with methyl methanethiosulfonate(MMTS), trypsin digestion, biological modifications allowed, a thorough search, a detected protein threshold of 95% confidence (unused Protscore \u22651.3), and a critical false discovery rate (FDR) of 1%.", [["cysteine", "CHEMICAL", 75, 83], ["methyl methanethiosulfonate", "CHEMICAL", 100, 127], ["MMTS", "CHEMICAL", 128, 132], ["cysteine", "CHEMICAL", 75, 83], ["methyl methanethiosulfonate", "CHEMICAL", 100, 127], ["MMTS", "CHEMICAL", 128, 132], ["4-plex", "SIMPLE_CHEMICAL", 49, 55], ["cysteine", "SIMPLE_CHEMICAL", 75, 83], ["methyl methanethiosulfonate", "SIMPLE_CHEMICAL", 100, 127], ["MMTS", "SIMPLE_CHEMICAL", 128, 132], ["trypsin", "SIMPLE_CHEMICAL", 135, 142], ["trypsin", "PROTEIN", 135, 142], ["iTRAQ 4-plex (peptide labeled)", "TREATMENT", 43, 73], ["cysteine alkylation", "TREATMENT", 75, 94], ["methyl methanethiosulfonate(MMTS)", "TREATMENT", 100, 133], ["trypsin digestion", "TREATMENT", 135, 152]]], ["The peptide and protein selection criteria for relative quantitation were performed as described previously, whereby only peptides unique for a given protein were considered [29].", [["relative quantitation", "TEST", 47, 68], ["protein selection", "OBSERVATION", 16, 33]]], ["In addition, proteins with an iTRAQ ratio higher than 20 or lower than 0.05 as well as proteins in reverse database were removed [30].Data analysis and bioinformatics ::: Materials and MethodsTo assign enriched Gene Ontology (GO) terms to the identified proteins, the differentially expressed proteins identified from iTRAQ experiments and all of the 4,112 measured proteins were classified based on their GO annotations using QuickGO (http://www.ebi.ac.uk/QuickGO/), with UniProt ID (http://www.uniprot.org/?tab=mapping) as the data source.", [["an iTRAQ ratio", "TEST", 27, 41], ["Data analysis", "TEST", 134, 147], ["Methods", "TREATMENT", 185, 192], ["iTRAQ experiments", "TEST", 318, 335], ["UniProt ID (http://www.uniprot.org/?tab=mapping", "TREATMENT", 473, 520]]], ["GO enrichment analysis of the differentially regulated proteins was evaluated using all of the 4,112 quantified proteins as background with hypergeometric distribution [31].", [["differentially regulated proteins", "PROTEIN", 30, 63], ["4,112 quantified proteins", "PROTEIN", 95, 120]]], ["Categories belonging to biological processes, molecular functions, and cellular components that were identified at a confidence level of 95% were included in the analysis.", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["a confidence level", "TEST", 115, 133], ["the analysis", "TEST", 158, 170], ["cellular components", "OBSERVATION", 71, 90]]], ["The protein-protein interaction network for a select group of proteins was analyzed using the STRING 9.1 database (http://string-db.org/).", [["protein-protein interaction network", "PROTEIN", 4, 39], ["The protein", "TEST", 0, 11]]], ["Network analysis was set at medium confidence (STRING score >0.4).Western blot analysis ::: Materials and MethodsFollowing ST cell infection with TGEV, the culture medium was removed after incubating for 48 h and 64 h; then, the cells were washed with cold PBS and collected after centrifugation at 3,000 rpm for 10 min.", [["ST cell", "ANATOMY", 123, 130], ["cells", "ANATOMY", 229, 234], ["infection", "DISEASE", 131, 140], ["ST cell", "CELL", 123, 130], ["TGEV", "ORGANISM", 146, 150], ["cells", "CELL", 229, 234], ["TGEV", "SPECIES", 146, 150], ["Network analysis", "TEST", 0, 16], ["STRING score", "TEST", 47, 59], ["Materials", "TREATMENT", 92, 101], ["Methods", "TREATMENT", 106, 113], ["ST cell infection", "PROBLEM", 123, 140], ["TGEV", "PROBLEM", 146, 150], ["the culture medium", "TEST", 152, 170], ["cold PBS", "TREATMENT", 252, 260], ["centrifugation", "TREATMENT", 281, 295], ["infection", "OBSERVATION", 131, 140]]], ["Cells were then lysed in RIPA lysis buffer with protease inhibitors (Applygen Technologies Inc., China).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["RIPA lysis buffer", "TREATMENT", 25, 42], ["protease inhibitors", "TREATMENT", 48, 67]]], ["Cellular debris was removed by centrifugation at 12,000 \u00d7 g for 5 min at 4\u00b0C, and the protein concentration was measured by Coomassie blue G250 staining.", [["Cellular debris", "ANATOMY", 0, 15], ["Coomassie blue", "CHEMICAL", 124, 138], ["Coomassie", "SIMPLE_CHEMICAL", 124, 133], ["Coomassie blue G250", "SPECIES", 124, 143], ["Cellular debris", "PROBLEM", 0, 15], ["the protein concentration", "TEST", 82, 107], ["debris", "OBSERVATION", 9, 15]]], ["An equal amount (20 \u00b5g) of cell lysate from each sample was separated using 10% SDS-PAGE and then transferred to polyvinyl difluoride (PVDF) membranes (Millipore, Bedford, USA).", [["cell lysate", "ANATOMY", 27, 38], ["sample", "ANATOMY", 49, 55], ["polyvinyl difluoride", "CHEMICAL", 113, 133], ["SDS", "CHEMICAL", 80, 83], ["polyvinyl difluoride", "CHEMICAL", 113, 133], ["PVDF", "CHEMICAL", 135, 139], ["cell lysate", "ORGANISM_SUBSTANCE", 27, 38], ["polyvinyl difluoride", "SIMPLE_CHEMICAL", 113, 133], ["cell lysate", "TREATMENT", 27, 38], ["10% SDS", "TREATMENT", 76, 83], ["polyvinyl difluoride (PVDF) membranes", "TREATMENT", 113, 150], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["amount", "OBSERVATION_MODIFIER", 9, 15]]], ["The PVDF membranes were then blocked with 5% (w/v) de-fatted milk powder dissolved in tris buffered saline and tween 20 (TBST) buffer (150 mM NaCl, 50 mM Tris, 0.05% Tween 20) for 1 h at 37\u00b0C. After blocking, membranes were incubated with anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mouse monoclonal antibody (1\u22363000; Western Biotechnology, China), anti-heat shock protein 90 alpha (Hsp90\u03b1/HSP90AA1) antibody (1\u2236300; Abcam, Cambridge, UK), anti-caspase 8 antibody (1\u2236300; Abcam, Cambridge, UK), or anti-transforming growth factor \u03b2 1 (TGF-\u03b21/TGFB1) antibody (1\u2236300; Abcam, Cambridge, UK) overnight at 4\u00b0C, followed by HRP-conjugated secondary antibody (1\u22365000; Western Biotechnology, China) for 1.5 h at 37\u00b0C. The membranes were then washed four times in TBST buffer for 5 min each time.", [["PVDF membranes", "ANATOMY", 4, 18], ["membranes", "ANATOMY", 209, 218], ["membranes", "ANATOMY", 724, 733], ["NaCl", "CHEMICAL", 142, 146], ["anti-glyceraldehyde 3-phosphate", "CHEMICAL", 239, 270], ["PVDF", "CHEMICAL", 4, 8], ["tris", "CHEMICAL", 86, 90], ["NaCl", "CHEMICAL", 142, 146], ["Tris", "CHEMICAL", 154, 158], ["Tween 20", "CHEMICAL", 166, 174], ["anti-glyceraldehyde 3-phosphate", "CHEMICAL", 239, 270], ["membranes", "CELLULAR_COMPONENT", 9, 18], ["milk", "ORGANISM", 61, 65], ["tris buffered saline", "SIMPLE_CHEMICAL", 86, 106], ["membranes", "CELLULAR_COMPONENT", 209, 218], ["anti-glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 239, 284], ["GAPDH", "GENE_OR_GENE_PRODUCT", 286, 291], ["mouse", "ORGANISM", 293, 298], ["anti-heat shock protein 90 alpha", "GENE_OR_GENE_PRODUCT", 359, 391], ["Hsp90\u03b1", "GENE_OR_GENE_PRODUCT", 393, 399], ["HSP90AA1", "GENE_OR_GENE_PRODUCT", 400, 408], ["Abcam", "GENE_OR_GENE_PRODUCT", 427, 432], ["UK", "GENE_OR_GENE_PRODUCT", 445, 447], ["anti-caspase 8 antibody", "GENE_OR_GENE_PRODUCT", 450, 473], ["Abcam", "GENE_OR_GENE_PRODUCT", 482, 487], ["UK", "GENE_OR_GENE_PRODUCT", 500, 502], ["anti-transforming growth factor \u03b2 1", "GENE_OR_GENE_PRODUCT", 508, 543], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 545, 551], ["TGFB1", "GENE_OR_GENE_PRODUCT", 552, 557], ["HRP", "SIMPLE_CHEMICAL", 628, 631], ["membranes", "CELLULAR_COMPONENT", 724, 733], ["anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mouse monoclonal antibody", "PROTEIN", 239, 318], ["1\u22363000", "PROTEIN", 320, 326], ["anti-heat shock protein 90 alpha (Hsp90\u03b1/HSP90AA1) antibody", "PROTEIN", 359, 418], ["1\u2236300", "PROTEIN", 420, 425], ["Abcam", "PROTEIN", 427, 432], ["anti-caspase 8 antibody", "PROTEIN", 450, 473], ["1\u2236300", "PROTEIN", 475, 480], ["Abcam", "PROTEIN", 482, 487], ["anti-transforming growth factor \u03b2 1 (TGF-\u03b21/TGFB1) antibody", "PROTEIN", 508, 567], ["HRP", "PROTEIN", 628, 631], ["mouse", "SPECIES", 293, 298], ["mouse", "SPECIES", 293, 298], ["The PVDF membranes", "TREATMENT", 0, 18], ["5% (w/v) de-fatted milk powder", "TREATMENT", 42, 72], ["tris buffered saline", "TREATMENT", 86, 106], ["50 mM Tris", "TREATMENT", 148, 158], ["anti-glyceraldehyde 3-phosphate dehydrogenase", "TEST", 239, 284], ["mouse monoclonal antibody", "TEST", 293, 318], ["anti-heat shock protein", "TEST", 359, 382], ["alpha", "TEST", 386, 391], ["Hsp90\u03b1", "TEST", 393, 399], ["HSP90AA1", "TEST", 400, 408], ["antibody", "TEST", 410, 418], ["Abcam", "TEST", 427, 432], ["anti-caspase 8 antibody", "TEST", 450, 473], ["Abcam", "TEST", 482, 487], ["anti-transforming growth factor", "TEST", 508, 539], ["TGF", "TEST", 545, 548], ["TGFB1", "TEST", 552, 557], ["antibody", "TEST", 559, 567], ["Abcam", "TEST", 576, 581], ["HRP", "TEST", 628, 631], ["PVDF membranes", "ANATOMY", 4, 18]]], ["Protein band detection was performed using ECL reagents (Applygen Technologies Inc., China), and the band intensities were analyzed using Labworks 4.6 software.Confirmation of TGEV infection in ST Cells ::: ResultsAfter introducing TGEV into the ST cells, we observed the induction of typical CPEs, including cell rounding, swelling, granular degeneration of the cytoplasm, cell detachment, and severely diseased cell morphology, from 40 to 64 h after inoculation (Figure 1 A\u2013D) compared to the non-infected control cells (Figure 1 E\u2013H).", [["ST Cells", "ANATOMY", 194, 202], ["ST cells", "ANATOMY", 246, 254], ["CPEs", "ANATOMY", 293, 297], ["cell", "ANATOMY", 309, 313], ["cytoplasm", "ANATOMY", 363, 372], ["cell", "ANATOMY", 374, 378], ["cell", "ANATOMY", 413, 417], ["cells", "ANATOMY", 516, 521], ["TGEV infection", "DISEASE", 176, 190], ["CPEs", "DISEASE", 293, 297], ["swelling", "DISEASE", 324, 332], ["TGEV", "ORGANISM", 176, 180], ["ST Cells", "CELL", 194, 202], ["TGEV", "ORGANISM", 232, 236], ["ST cells", "CELL", 246, 254], ["CPEs", "PATHOLOGICAL_FORMATION", 293, 297], ["cell", "CELL", 309, 313], ["cytoplasm", "ORGANISM_SUBSTANCE", 363, 372], ["cell", "CELL", 374, 378], ["cell", "CELL", 413, 417], ["cells", "CELL", 516, 521], ["ST cells", "CELL_TYPE", 246, 254], ["non-infected control cells", "CELL_TYPE", 495, 521], ["TGEV", "SPECIES", 176, 180], ["TGEV", "SPECIES", 232, 236], ["Protein band detection", "TEST", 0, 22], ["ECL reagents", "TEST", 43, 55], ["the band intensities", "TEST", 97, 117], ["TGEV infection", "PROBLEM", 176, 190], ["TGEV into the ST cells", "TREATMENT", 232, 254], ["typical CPEs", "PROBLEM", 285, 297], ["cell rounding", "PROBLEM", 309, 322], ["swelling", "PROBLEM", 324, 332], ["granular degeneration", "PROBLEM", 334, 355], ["the cytoplasm", "PROBLEM", 359, 372], ["cell detachment", "PROBLEM", 374, 389], ["severely diseased cell morphology", "PROBLEM", 395, 428], ["TGEV", "OBSERVATION_MODIFIER", 176, 180], ["infection", "OBSERVATION", 181, 190], ["swelling", "OBSERVATION", 324, 332], ["granular degeneration", "OBSERVATION", 334, 355], ["cytoplasm", "OBSERVATION_MODIFIER", 363, 372], ["cell detachment", "OBSERVATION", 374, 389], ["severely", "OBSERVATION_MODIFIER", 395, 403], ["diseased", "OBSERVATION_MODIFIER", 404, 412], ["cell morphology", "OBSERVATION", 413, 428]]], ["Virus infection at 48 and 64 h was also confirmed by RT-PCR detection of the viral N gene in the sample (Figure 2A).Dynamic changes in viral gene expression in infected cells ::: ResultsTo further identify the extent of TGEV infection, the mRNA expression levels of viral genes in infected cells were determined using qRT-PCR.", [["sample", "ANATOMY", 97, 103], ["cells", "ANATOMY", 169, 174], ["cells", "ANATOMY", 290, 295], ["Virus infection", "DISEASE", 0, 15], ["TGEV infection", "DISEASE", 220, 234], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 169, 174], ["TGEV", "ORGANISM", 220, 224], ["cells", "CELL", 290, 295], ["viral N gene", "DNA", 77, 89], ["infected cells", "CELL_TYPE", 160, 174], ["viral genes", "DNA", 266, 277], ["infected cells", "CELL_TYPE", 281, 295], ["TGEV", "SPECIES", 220, 224], ["Virus infection", "PROBLEM", 0, 15], ["RT", "TEST", 53, 55], ["PCR detection", "TEST", 56, 69], ["Dynamic changes in viral gene expression in infected cells", "PROBLEM", 116, 174], ["TGEV infection", "PROBLEM", 220, 234], ["viral genes in infected cells", "PROBLEM", 266, 295], ["qRT", "TEST", 318, 321], ["infection", "OBSERVATION", 6, 15], ["viral gene expression", "OBSERVATION", 135, 156], ["infected cells", "OBSERVATION", 160, 174], ["TGEV", "OBSERVATION_MODIFIER", 220, 224], ["infection", "OBSERVATION", 225, 234], ["viral genes", "OBSERVATION", 266, 277], ["infected cells", "OBSERVATION", 281, 295]]], ["Comparative threshold (Ct) cycle values in three independent experiments were calculated and the results indicated that the average Ct value for the TGEV N gene ranged from 25.2 to 27.5.", [["TGEV", "ORGANISM", 149, 153], ["TGEV N gene", "DNA", 149, 160], ["TGEV", "SPECIES", 149, 153], ["Comparative threshold", "TEST", 0, 21], ["Ct) cycle values", "TEST", 23, 39], ["the average Ct value", "TEST", 120, 140], ["the TGEV N gene", "TEST", 145, 160]]], ["Correspondingly, the average Ct value observed for the \u03b2-actin control gene ranged from 19.6 to 21.0.", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 55, 62], ["\u03b2-actin control gene", "DNA", 55, 75], ["the average Ct value", "TEST", 17, 37], ["the \u03b2-actin control gene", "TEST", 51, 75]]], ["The relative expression of TGEV N mRNA was calculated using the 2(\u2013\u0394\u0394CT) method [28], and the change in expression at each time point is indicated in Figure 2B.", [["TGEV N", "GENE_OR_GENE_PRODUCT", 27, 33], ["TGEV N mRNA", "RNA", 27, 38], ["TGEV", "SPECIES", 27, 31], ["TGEV N mRNA", "TEST", 27, 38]]], ["These data show that, following infection, the viral mRNA levels increased gradually over time, and reached a peak at 48 hpi.", [["infection", "DISEASE", 32, 41], ["viral mRNA", "RNA", 47, 57], ["These data", "TEST", 0, 10], ["infection", "PROBLEM", 32, 41], ["the viral mRNA levels", "TEST", 43, 64], ["infection", "OBSERVATION", 32, 41], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["gradually", "OBSERVATION_MODIFIER", 75, 84]]], ["Following this time point, the viral mRNA levels appear to decrease.Protein identification by MS ::: ResultsIn the infected ST cells, a total of 29,214 peptides and 4,364 proteins were detected (Table S1); however, only 4,112 proteins were quantified reliably (Table S2).", [["ST cells", "ANATOMY", 124, 132], ["ST cells", "CELL", 124, 132], ["viral mRNA", "RNA", 31, 41], ["infected ST cells", "CELL_TYPE", 115, 132], ["4,112 proteins", "PROTEIN", 220, 234], ["the viral mRNA levels", "TEST", 27, 48], ["the infected ST cells", "PROBLEM", 111, 132], ["viral mRNA", "OBSERVATION", 31, 41], ["decrease", "OBSERVATION_MODIFIER", 59, 67], ["infected", "OBSERVATION_MODIFIER", 115, 123], ["ST cells", "OBSERVATION", 124, 132]]], ["Notably, the abnormal proteins, such as the proteins with iTRAQ ratio higher than 20 or lower than 0.05, which are not quantifiable [30], were removed and only proteins with reasonable ratios across all channels were investigated further.", [["iTRAQ", "GENE_OR_GENE_PRODUCT", 58, 63], ["abnormal proteins", "PROTEIN", 13, 30], ["the abnormal proteins", "PROBLEM", 9, 30], ["the proteins", "TEST", 40, 52], ["iTRAQ ratio", "TEST", 58, 69], ["abnormal", "OBSERVATION_MODIFIER", 13, 21], ["proteins", "OBSERVATION", 22, 30]]], ["Figure 3A depicts the scatter plots for the log10 116/114 and log10 117/115 ratios in the iTRAQ experiment.", [["the scatter plots", "TEST", 18, 35], ["the log10", "TEST", 40, 49], ["scatter plots", "OBSERVATION", 22, 35], ["iTRAQ experiment", "OBSERVATION", 90, 106]]], ["Linear regression analysis showed that correlation (R2) was 0.58, with a p-value less than 0.05.", [["Linear regression analysis", "TEST", 0, 26], ["a p-value", "TEST", 71, 80]]], ["These results suggest that the alterations in protein abundance due to virus infection were near-linear dependency between the two time points.", [["infection", "DISEASE", 77, 86], ["the alterations in protein abundance", "PROBLEM", 27, 63], ["virus infection", "PROBLEM", 71, 86], ["linear dependency", "PROBLEM", 97, 114], ["linear", "OBSERVATION_MODIFIER", 97, 103], ["dependency", "OBSERVATION_MODIFIER", 104, 114]]], ["In order to identify the proteins that were significantly different at each time point (infected/uninfected) or between the different time points, we analyzed the distribution of ratios for the identified proteins as shown in the Figure 3B.", [["the proteins", "PROBLEM", 21, 33]]], ["For the distribution range of the differentially expressed proteins identified at 48 hpi, shown in Figure 3C, a ratio higher than 3.35 or lower than \u22121.35 was defined as a statistically significant difference in protein expression.", [["a ratio", "TEST", 110, 117], ["a statistically significant difference in protein expression", "PROBLEM", 170, 230], ["significant", "OBSERVATION_MODIFIER", 186, 197], ["difference", "OBSERVATION", 198, 208], ["protein expression", "OBSERVATION", 212, 230]]], ["At 64 hpi, a ratio higher than 4.55 or lower than \u22122.15 was defined as a statistically significant difference in protein expression.", [["a ratio", "TEST", 11, 18], ["a statistically significant difference in protein expression", "PROBLEM", 71, 131], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["difference", "OBSERVATION", 99, 109], ["protein expression", "OBSERVATION", 113, 131]]], ["According to analyses, the differentially expressed proteins identified were considered to show a significant upward or downward trend if their expression ratios were greater than 4.0 or less than 0.25 compared to the control group.Protein identification by MS ::: ResultsUsing the criterion listed above, the expression of 146 proteins was significantly changed at 48 hpi (95 upregulated and 51 downregulated), while 219 proteins were significantly changed at 64 hpi (172 upregulated and 47 downregulated).", [["146 proteins", "PROTEIN", 324, 336], ["a significant upward or downward trend", "PROBLEM", 96, 134], ["their expression ratios", "TEST", 138, 161], ["downward", "OBSERVATION_MODIFIER", 120, 128]]], ["Further, 72 proteins were identified to be significantly different between the two time points (54 upregulated and 18 downregulated), resulting in a total of 316 unique proteins being significantly altered during TGEV infection, including 162 predicted proteins (Table S3 and Table 1 (excluding the predicted proteins)).", [["TGEV infection", "DISEASE", 213, 227], ["TGEV", "ORGANISM", 213, 217], ["Table S3", "GENE_OR_GENE_PRODUCT", 263, 271], ["Table 1", "GENE_OR_GENE_PRODUCT", 276, 283], ["S3", "PROTEIN", 269, 271], ["Table 1", "PROTEIN", 276, 283], ["TGEV", "SPECIES", 213, 217], ["Further, 72 proteins", "TEST", 0, 20], ["unique proteins", "PROBLEM", 162, 177], ["TGEV infection", "PROBLEM", 213, 227], ["significantly different", "OBSERVATION_MODIFIER", 43, 66]]], ["Because the current pig genome database is poorly annotated compared to the human genome database, there were numerous proteins that were unassigned or uncharacterized, resulting in a large number of predicted proteins in our analysis.", [["pig", "ORGANISM", 20, 23], ["human", "ORGANISM", 76, 81], ["pig genome database", "DNA", 20, 39], ["human genome database", "DNA", 76, 97], ["pig", "SPECIES", 20, 23], ["human", "SPECIES", 76, 81], ["pig", "SPECIES", 20, 23], ["human", "SPECIES", 76, 81], ["the human genome database", "TEST", 72, 97], ["numerous proteins", "PROBLEM", 110, 127], ["our analysis", "TEST", 222, 234], ["numerous", "OBSERVATION_MODIFIER", 110, 118], ["proteins", "OBSERVATION", 119, 127], ["large", "OBSERVATION_MODIFIER", 184, 189]]], ["However, our ability to detect the unannotated proteins by MS demonstrates that they do existence in this species, and additional research concerning their function is warranted.GO enrichment analysis ::: ResultsBiological process-based enrichment analysis of the differentially expressed proteins revealed that six common GO terms were significantly enriched in this set of proteins (p<0.05).", [["ResultsBiological process", "TEST", 205, 230]]], ["Thus, it appears that in TGEV-infected ST cells at 48 and 64 hpi there are expression changes in proteins that are related to cell adhesion, neurological system processes, extracellular matrix organization, locomotion, cell junction organization, and cell-cell signaling.", [["ST cells", "ANATOMY", 39, 47], ["cell", "ANATOMY", 126, 130], ["neurological system", "ANATOMY", 141, 160], ["extracellular matrix", "ANATOMY", 172, 192], ["cell junction", "ANATOMY", 219, 232], ["cell", "ANATOMY", 251, 255], ["cell", "ANATOMY", 256, 260], ["TGEV", "ORGANISM", 25, 29], ["ST cells", "CELL", 39, 47], ["cell", "CELL", 126, 130], ["extracellular matrix", "CELLULAR_COMPONENT", 172, 192], ["cell junction", "CELLULAR_COMPONENT", 219, 232], ["cell", "CELL", 251, 255], ["cell", "CELL", 256, 260], ["TGEV-infected ST cells", "CELL_LINE", 25, 47], ["TGEV", "SPECIES", 25, 29], ["TGEV", "PROBLEM", 25, 29], ["infected ST cells", "PROBLEM", 30, 47], ["expression changes in proteins", "PROBLEM", 75, 105], ["cell adhesion", "PROBLEM", 126, 139], ["neurological system processes", "PROBLEM", 141, 170], ["extracellular matrix organization", "TEST", 172, 205], ["locomotion, cell junction organization", "TEST", 207, 245], ["cell-cell signaling", "PROBLEM", 251, 270], ["infected", "OBSERVATION_MODIFIER", 30, 38], ["cell adhesion", "OBSERVATION", 126, 139], ["cell junction", "OBSERVATION", 219, 232], ["cell-cell signaling", "OBSERVATION", 251, 270]]], ["Moreover, at the later time point, 64 hpi, our GO term analysis also indicated that a significant number of the differentially expressed proteins were related to cellular stress (p = 8.18E-4), generation of precursor metabolites and energy (p = 2.74E-3), cell motility (p = 6.71E-3), protein complex assembly (p = 4.69E-2), growth (p = 3.87E-2), developmental maturation (p = 1.53E-2), and immune system processes (p = 4.67E-2) (Table 2).GO enrichment analysis ::: ResultsTo further investigate the localization pattern of these differentially expressed genes, a cellular component-based enrichment analysis was performed.", [["cellular", "ANATOMY", 162, 170], ["cell", "ANATOMY", 255, 259], ["immune system", "ANATOMY", 390, 403], ["cellular", "ANATOMY", 563, 571], ["cellular", "CELL", 162, 170], ["cell", "CELL", 255, 259], ["6.71E-3", "GENE_OR_GENE_PRODUCT", 274, 281], ["cellular", "CELL", 563, 571], ["protein complex", "PROTEIN", 284, 299], ["differentially expressed genes", "DNA", 529, 559], ["our GO term analysis", "TEST", 43, 63], ["cellular stress", "TEST", 162, 177], ["generation of precursor metabolites", "PROBLEM", 193, 228], ["energy", "TEST", 233, 239], ["cell motility", "TEST", 255, 268], ["p", "TEST", 270, 271], ["protein complex", "TEST", 284, 299], ["p", "TEST", 310, 311], ["growth", "TEST", 324, 330], ["p", "TEST", 332, 333], ["developmental maturation", "PROBLEM", 346, 370], ["p", "TEST", 372, 373], ["a cellular component", "TEST", 561, 581], ["based enrichment analysis", "TEST", 582, 607], ["significant", "OBSERVATION_MODIFIER", 86, 97]]], ["At 48 hpi, we observed the significant enrichments in extracellular region (p = 1.29E-4), proteinaceous extracellular matrix (p = 1.62E-4), and extracellular space (p = 1.52E-2) (Table S4).", [["extracellular region", "ANATOMY", 54, 74], ["extracellular matrix", "ANATOMY", 104, 124], ["extracellular space", "ANATOMY", 144, 163], ["extracellular region", "CELLULAR_COMPONENT", 54, 74], ["extracellular matrix", "CELLULAR_COMPONENT", 104, 124], ["extracellular space", "CELLULAR_COMPONENT", 144, 163], ["extracellular region", "PROTEIN", 54, 74], ["the significant enrichments in extracellular region", "PROBLEM", 23, 74], ["proteinaceous extracellular matrix", "TEST", 90, 124], ["extracellular space", "TEST", 144, 163], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["enrichments", "OBSERVATION", 39, 50], ["extracellular", "ANATOMY_MODIFIER", 54, 67], ["region", "ANATOMY_MODIFIER", 68, 74], ["extracellular matrix", "ANATOMY", 104, 124], ["extracellular space", "ANATOMY", 144, 163]]], ["In addition, 37 differentially expressed proteins were also significantly enriched (p = 8.65E-3) in mitochondrion at 64 hpi (Table S5).GO enrichment analysis ::: ResultsThe final step of our GO enrichment analysis consisted of investigating the mechanistic role these genes play in the cell.", [["mitochondrion", "ANATOMY", 100, 113], ["cell", "ANATOMY", 286, 290], ["mitochondrion", "CELLULAR_COMPONENT", 100, 113], ["cell", "CELL", 286, 290], ["proteins", "TEST", 41, 49], ["our GO enrichment analysis", "TEST", 187, 213]]], ["To do so, we performed a molecular function-based enrichment analysis.", [["a molecular function", "TEST", 23, 43], ["based enrichment analysis", "TEST", 44, 69]]], ["This analysis showed that two GO terms, unfolded protein binding (p = 2.67E-2) and transmembrane transporter activity (p = 3.55E-2), were significantly enriched at 64 hpi (Table S5).", [["transmembrane transporter", "PROTEIN", 83, 108], ["This analysis", "TEST", 0, 13], ["unfolded protein binding", "PROBLEM", 40, 64], ["p", "TEST", 66, 67], ["transmembrane transporter activity", "TEST", 83, 117]]], ["Further GO analysis of the differentially expressed proteins between the two time points indicated that there were no significant enriched terms.Protein\u2013protein interaction analysis ::: ResultsIn order to understand the interactions between TGEV and host cell proteins, we further analyzed the differentially expressed proteins by searching the STRING 9.1 database (http://string-db.org/) for protein-protein interactions (Figure 4).", [["cell", "ANATOMY", 255, 259], ["TGEV", "ORGANISM", 241, 245], ["host cell", "CELL", 250, 259], ["TGEV and host cell proteins", "PROTEIN", 241, 268], ["http:", "PROTEIN", 366, 371], ["db.org", "PROTEIN", 380, 386], ["TGEV", "SPECIES", 241, 245], ["Further GO analysis", "TEST", 0, 19], ["significant enriched terms", "PROBLEM", 118, 144], ["TGEV and host cell proteins", "TREATMENT", 241, 268], ["the STRING", "TEST", 341, 351], ["http:", "TEST", 366, 371], ["no", "UNCERTAINTY", 115, 117], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["enriched terms", "OBSERVATION", 130, 144]]], ["In this STRING analysis, the interactions (edges) of the submitted proteins (nodes) were scored according to known and predicted protein-protein interactions.", [["this STRING analysis", "TEST", 3, 23]]], ["We created three protein network maps: one for proteins changed significantly at 48 hpi (30 nodes and 15 edges; Figure 4A), one for proteins changed significantly at 64 hpi (66 nodes and 70 edges; Figure 4B), and one for the proteins that were significantly changed when the viral infection was prolonged from 48 to 64 h (24 nodes and 9 edges; Figure 4C).", [["viral infection", "DISEASE", 275, 290], ["three protein network maps", "TEST", 11, 37], ["proteins", "TEST", 47, 55], ["nodes", "TEST", 92, 97], ["edges", "TEST", 105, 110], ["Figure 4A", "TEST", 112, 121], ["proteins", "TEST", 132, 140], ["nodes", "TEST", 177, 182], ["edges", "TEST", 190, 195], ["Figure 4B", "TEST", 197, 206], ["the proteins", "TEST", 221, 233], ["the viral infection", "PROBLEM", 271, 290], ["nodes", "TEST", 325, 330], ["edges", "TEST", 337, 342], ["viral", "OBSERVATION_MODIFIER", 275, 280], ["infection", "OBSERVATION", 281, 290]]], ["Notably, the protein network constructed for the 64 hpi time point is clearly much more extensive than the two other networks, and these protein-protein interactions suggest the existence of reported functional linkages.", [["the protein network", "TEST", 9, 28], ["these protein", "TEST", 131, 144], ["much more", "OBSERVATION_MODIFIER", 78, 87], ["functional linkages", "OBSERVATION", 200, 219]]], ["GO enrichment analysis for the STRING protein network at 64 hpi showed that several biological processes were significantly affected (p<0.05 based on the FDR correction) in this network, including the regulation of viral genome replication, the innate immune response, negative regulation of viral genome replication, positive and negative regulation of viral processes, and ATP biosynthetic processes (Table 3).", [["ATP", "CHEMICAL", 375, 378], ["ATP", "CHEMICAL", 375, 378], ["ATP", "SIMPLE_CHEMICAL", 375, 378], ["enrichment analysis", "TEST", 3, 22], ["the STRING protein network", "TEST", 27, 53], ["several biological processes", "PROBLEM", 76, 104], ["the FDR correction", "TREATMENT", 150, 168], ["viral genome replication", "TREATMENT", 215, 239], ["viral genome replication", "PROBLEM", 292, 316], ["viral processes", "PROBLEM", 354, 369], ["ATP biosynthetic processes", "PROBLEM", 375, 401], ["viral genome replication", "OBSERVATION", 215, 239], ["viral genome replication", "OBSERVATION", 292, 316], ["viral processes", "OBSERVATION", 354, 369]]], ["However, at 48 hpi, the most enriched biological process was related to cell recognition during phagocytosis(p = 8.02E-1).", [["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["cell recognition", "TEST", 72, 88], ["phagocytosis", "TEST", 96, 108]]], ["In Figure 4C, we have shown that the majority proteins in these protein networks, such as radical S-adenosyl methionine domain containing protein 2 (RSAD2), Mx dynamin-like GTPase 1 (Mx1), 2\u2032-5\u2032-oligoadenylate synthetase 1 (OAS1), Mx dynamin-like GTPase 2 (Mx2), are involved in the innate immune response.", [["methionine", "CHEMICAL", 109, 119], ["S-adenosyl methionine", "CHEMICAL", 98, 119], ["radical S-adenosyl methionine domain containing protein 2", "GENE_OR_GENE_PRODUCT", 90, 147], ["RSAD2", "GENE_OR_GENE_PRODUCT", 149, 154], ["Mx dynamin-like GTPase 1", "GENE_OR_GENE_PRODUCT", 157, 181], ["Mx1", "GENE_OR_GENE_PRODUCT", 183, 186], ["2\u2032-5\u2032-oligoadenylate synthetase 1", "GENE_OR_GENE_PRODUCT", 189, 222], ["OAS1", "GENE_OR_GENE_PRODUCT", 224, 228], ["Mx dynamin-like GTPase 2", "GENE_OR_GENE_PRODUCT", 231, 255], ["Mx2", "GENE_OR_GENE_PRODUCT", 257, 260], ["protein networks", "PROTEIN", 64, 80], ["radical S-adenosyl methionine domain containing protein 2", "PROTEIN", 90, 147], ["RSAD2", "PROTEIN", 149, 154], ["Mx dynamin-like GTPase 1", "PROTEIN", 157, 181], ["Mx1", "PROTEIN", 183, 186], ["2\u2032", "PROTEIN", 189, 191], ["5\u2032", "PROTEIN", 192, 194], ["oligoadenylate synthetase 1", "PROTEIN", 195, 222], ["OAS1", "PROTEIN", 224, 228], ["Mx dynamin", "PROTEIN", 231, 241], ["GTPase 2", "PROTEIN", 247, 255], ["Mx2", "PROTEIN", 257, 260], ["these protein networks", "TREATMENT", 58, 80], ["radical S-adenosyl methionine domain containing protein", "TREATMENT", 90, 145], ["Mx dynamin", "TREATMENT", 157, 167], ["oligoadenylate synthetase", "TREATMENT", 195, 220], ["Mx dynamin", "TREATMENT", 231, 241]]], ["These data suggest that some entirely different host proteins, interactions, or processes, including the immune response, were perturbed at these times during TGEV infection.Western blot confirmation of altered expression for three of the differentially expressed proteins ::: ResultsTo further confirm the proteomic data for three of the proteins, western blot analysis was performed to investigate the changes in the expression of HSP90\u03b1, caspase 8, and TGF-\u03b21.", [["TGEV infection", "DISEASE", 159, 173], ["TGEV", "ORGANISM", 159, 163], ["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 433, 439], ["caspase 8", "GENE_OR_GENE_PRODUCT", 441, 450], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 456, 462], ["HSP90\u03b1", "PROTEIN", 433, 439], ["caspase 8", "PROTEIN", 441, 450], ["TGF-\u03b21", "PROTEIN", 456, 462], ["TGEV", "SPECIES", 159, 163], ["These data", "TEST", 0, 10], ["TGEV infection", "PROBLEM", 159, 173], ["altered expression", "PROBLEM", 203, 221], ["the proteomic data", "TEST", 303, 321], ["the proteins", "TEST", 335, 347], ["western blot analysis", "TEST", 349, 370], ["HSP90\u03b1", "TEST", 433, 439], ["caspase", "TEST", 441, 448], ["TGF", "TEST", 456, 459], ["infection", "OBSERVATION", 164, 173]]], ["The proteins were selected based on three criteria: 1) the expression of the protein was increased or decreased during TGEV infection according to our proteomics data; 2) the protein is known to be relevant during viral infection; and 3) each protein analyzed needs to be involved in a special biological process as determined by our GO enrichment analysis [32].", [["infection", "DISEASE", 124, 133], ["viral infection", "DISEASE", 214, 229], ["TGEV", "ORGANISM", 119, 123], ["TGEV", "SPECIES", 119, 123], ["the protein", "PROBLEM", 73, 84], ["TGEV infection", "PROBLEM", 119, 133], ["our proteomics data", "TEST", 147, 166], ["the protein", "TEST", 171, 182], ["viral infection", "PROBLEM", 214, 229]]], ["HSP90\u03b1, caspase 8, and TGF-\u03b21 all filled these criteria and their protein expression was analyzed via western blot analysis of the cell lysate.", [["cell lysate", "ANATOMY", 131, 142], ["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 0, 6], ["caspase 8", "GENE_OR_GENE_PRODUCT", 8, 17], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 23, 29], ["cell", "CELL", 131, 135], ["HSP90\u03b1", "PROTEIN", 0, 6], ["caspase 8", "PROTEIN", 8, 17], ["TGF-\u03b21", "PROTEIN", 23, 29], ["HSP90\u03b1", "TEST", 0, 6], ["caspase", "TEST", 8, 15], ["TGF", "TEST", 23, 26], ["the cell lysate", "TEST", 127, 142], ["cell lysate", "OBSERVATION", 131, 142]]], ["As shown in Figure 5, the expression of HSP90\u03b1 was significantly downregulated in TGEV-infected cells at 64 hpi, while the expression of caspase-8 was upregulated from 48 to 64 hpi in these cells.", [["cells", "ANATOMY", 96, 101], ["cells", "ANATOMY", 190, 195], ["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 40, 46], ["TGEV", "ORGANISM", 82, 86], ["cells", "CELL", 96, 101], ["caspase-8", "GENE_OR_GENE_PRODUCT", 137, 146], ["cells", "CELL", 190, 195], ["HSP90\u03b1", "PROTEIN", 40, 46], ["caspase-8", "PROTEIN", 137, 146], ["TGEV", "SPECIES", 82, 86], ["HSP90\u03b1", "TEST", 40, 46], ["TGEV", "PROBLEM", 82, 86], ["infected cells", "PROBLEM", 87, 101], ["caspase", "TEST", 137, 144], ["infected cells", "OBSERVATION", 87, 101]]], ["The expression of TGF-\u03b21 was also significantly induced in TGEV-infected cells following infection.", [["cells", "ANATOMY", 73, 78], ["infection", "DISEASE", 89, 98], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 18, 24], ["TGEV", "ORGANISM", 59, 63], ["cells", "CELL", 73, 78], ["TGF-\u03b21", "PROTEIN", 18, 24], ["TGEV-infected cells", "CELL_TYPE", 59, 78], ["TGEV", "SPECIES", 59, 63], ["TGF", "TEST", 18, 21], ["TGEV", "PROBLEM", 59, 63], ["infected cells", "PROBLEM", 64, 78], ["infection", "PROBLEM", 89, 98], ["infected cells", "OBSERVATION", 64, 78], ["infection", "OBSERVATION", 89, 98]]], ["Thus, these results confirm the altered expression observed in the proteomic data for these three representative proteins during TGEV infection.DiscussionThe interactions between a virus and a host cell during a viral infection are complex, involving numerous genes and signaling pathways.", [["cell", "ANATOMY", 198, 202], ["TGEV infection", "DISEASE", 129, 143], ["viral infection", "DISEASE", 212, 227], ["TGEV", "ORGANISM", 129, 133], ["host cell", "CELL", 193, 202], ["TGEV", "SPECIES", 129, 133], ["the altered expression", "PROBLEM", 28, 50], ["TGEV infection", "PROBLEM", 129, 143], ["a virus", "PROBLEM", 179, 186], ["a host cell", "PROBLEM", 191, 202], ["a viral infection", "PROBLEM", 210, 227], ["infection", "OBSERVATION", 134, 143], ["host cell", "OBSERVATION", 193, 202], ["viral", "OBSERVATION_MODIFIER", 212, 217], ["infection", "OBSERVATION", 218, 227]]], ["ST cells are known to be sensitive to TGEV, resulting in increased viral multiplication and CPEs [15].", [["ST cells", "ANATOMY", 0, 8], ["ST cells", "CELL", 0, 8], ["TGEV", "ORGANISM", 38, 42], ["ST cells", "CELL_TYPE", 0, 8], ["TGEV", "SPECIES", 38, 42], ["ST cells", "PROBLEM", 0, 8], ["TGEV", "PROBLEM", 38, 42], ["increased viral multiplication", "PROBLEM", 57, 87], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["viral multiplication", "OBSERVATION", 67, 87]]], ["In order to better understand the interactions between the host proteome and TGEV, we adopted an iTRAQ quantitative proteomic approach to investigate the altered cellular proteins of the ST cells during TGEV infection in vitro.", [["cellular", "ANATOMY", 162, 170], ["ST cells", "ANATOMY", 187, 195], ["TGEV infection", "DISEASE", 203, 217], ["TGEV", "ORGANISM", 77, 81], ["cellular", "CELL", 162, 170], ["ST cells", "CELL", 187, 195], ["TGEV", "ORGANISM", 203, 207], ["cellular proteins", "PROTEIN", 162, 179], ["ST cells", "CELL_TYPE", 187, 195], ["TGEV", "SPECIES", 77, 81], ["TGEV", "SPECIES", 203, 207], ["an iTRAQ quantitative proteomic approach", "TREATMENT", 94, 134], ["the altered cellular proteins of the ST cells", "PROBLEM", 150, 195], ["TGEV infection", "PROBLEM", 203, 217], ["infection", "OBSERVATION", 208, 217]]], ["Compared with the 2-DE and 2D-DIGE methods often used, the 2D-LC-MS/MS method utilized here provides more quantitative and qualitative information about the proteins, and can also detect membrane proteins, hydrophobic proteins, higher molecular weight proteins, and low-abundance proteins, which are often missed by other methods. iTRAQ also has more advantages compared to isotope-coded affinity tags (ICAT) and stable isotope labeling by amino acids in cell culture (SILAC) methods, which both allow multiple labeling and quantitation of four to eight samples simultaneously with high sensitivity [22], [33], [34].", [["membrane", "ANATOMY", 187, 195], ["cell", "ANATOMY", 455, 459], ["samples", "ANATOMY", 554, 561], ["amino acids", "CHEMICAL", 440, 451], ["amino acids", "CHEMICAL", 440, 451], ["membrane", "CELLULAR_COMPONENT", 187, 195], ["amino acids", "AMINO_ACID", 440, 451], ["cell", "CELL", 455, 459], ["membrane proteins", "PROTEIN", 187, 204], ["hydrophobic proteins", "PROTEIN", 206, 226], ["higher molecular weight proteins", "PROTEIN", 228, 260], ["low-abundance proteins", "PROTEIN", 266, 288], ["membrane proteins", "PROBLEM", 187, 204], ["hydrophobic proteins", "PROBLEM", 206, 226], ["higher molecular weight proteins", "PROBLEM", 228, 260], ["low-abundance proteins", "PROBLEM", 266, 288], ["isotope", "TEST", 374, 381], ["amino acids", "TEST", 440, 451], ["cell culture", "TEST", 455, 467], ["low-abundance", "OBSERVATION_MODIFIER", 266, 279]]], ["Further, the iTRAQ technique has been widely used for quantitative proteomics, including protein expression analysis and biomarker identification [23]\u2013[26], [35].DiscussionPrior to proteomic analysis, we determined which time points to investigate following infection by observing the morphological changes and analyzing viral gene expression dynamics in the TGEV infected cells.", [["cells", "ANATOMY", 373, 378], ["infection", "DISEASE", 258, 267], ["[23]\u2013[26], [35]", "SIMPLE_CHEMICAL", 146, 161], ["TGEV", "ORGANISM", 359, 363], ["cells", "CELL", 373, 378], ["TGEV infected cells", "CELL_TYPE", 359, 378], ["TGEV", "SPECIES", 359, 363], ["the iTRAQ technique", "TREATMENT", 9, 28], ["quantitative proteomics", "TEST", 54, 77], ["protein expression analysis", "TEST", 89, 116], ["biomarker identification", "TEST", 121, 145], ["proteomic analysis", "TEST", 181, 199], ["infection", "PROBLEM", 258, 267], ["the morphological changes", "PROBLEM", 281, 306], ["analyzing viral gene expression dynamics", "PROBLEM", 311, 351], ["the TGEV infected cells", "PROBLEM", 355, 378], ["infection", "OBSERVATION", 258, 267], ["infected cells", "OBSERVATION", 364, 378]]], ["The results indicated that TGEV induced significant CPEs from 40 to 64 hpi in infected cells compared to the mock infected cells.", [["cells", "ANATOMY", 87, 92], ["cells", "ANATOMY", 123, 128], ["TGEV", "ORGANISM", 27, 31], ["CPEs", "PATHOLOGICAL_FORMATION", 52, 56], ["cells", "CELL", 87, 92], ["cells", "CELL", 123, 128], ["infected cells", "CELL_TYPE", 78, 92], ["mock infected cells", "CELL_TYPE", 109, 128], ["TGEV", "SPECIES", 27, 31], ["TGEV", "PROBLEM", 27, 31], ["significant CPEs", "PROBLEM", 40, 56], ["infected cells", "PROBLEM", 78, 92], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["infected cells", "OBSERVATION", 78, 92], ["infected cells", "OBSERVATION", 114, 128]]], ["At 40 hpi, less than 50% of the infected cells were morphologically altered, while at 48 hpi more than 80% infected cells showed rounding and granular degeneration.", [["cells", "ANATOMY", 41, 46], ["cells", "ANATOMY", 116, 121], ["cells", "CELL", 41, 46], ["cells", "CELL", 116, 121], ["infected cells", "CELL_TYPE", 32, 46], ["infected cells", "CELL_TYPE", 107, 121], ["granular degeneration", "PROBLEM", 142, 163], ["infected cells", "OBSERVATION", 32, 46], ["granular degeneration", "OBSERVATION", 142, 163]]], ["Further, the mRNA level of the viral N gene in ST cells continuously increased in the infected cells until 48 h, at which time we observed the highest viral replication level.", [["ST cells", "ANATOMY", 47, 55], ["cells", "ANATOMY", 95, 100], ["ST cells", "CELL", 47, 55], ["cells", "CELL", 95, 100], ["viral N gene", "DNA", 31, 43], ["ST cells", "CELL_TYPE", 47, 55], ["infected cells", "CELL_TYPE", 86, 100], ["the mRNA level", "TEST", 9, 23], ["the viral N gene in ST cells", "PROBLEM", 27, 55], ["the infected cells", "PROBLEM", 82, 100], ["the highest viral replication level", "PROBLEM", 139, 174], ["viral", "OBSERVATION", 31, 36], ["infected cells", "OBSERVATION", 86, 100], ["viral replication", "OBSERVATION", 151, 168]]], ["At 64 hpi, the morphological effects observed were much more pronounced, characterized by even more cellular rounding and detachment.", [["cellular", "ANATOMY", 100, 108], ["cellular", "CELL", 100, 108], ["detachment", "PROBLEM", 122, 132], ["more pronounced", "OBSERVATION_MODIFIER", 56, 71], ["more", "OBSERVATION_MODIFIER", 95, 99], ["cellular rounding", "OBSERVATION", 100, 117], ["detachment", "OBSERVATION", 122, 132]]], ["However, the mRNA levels of the viral N gene decreased rapidly from 48 to 64 h, a phenomenon we believe may be attributed to the host's immune response or a decrease in infected cell viability as the TGEV infection progressed.", [["cell", "ANATOMY", 178, 182], ["infection", "DISEASE", 205, 214], ["cell", "CELL", 178, 182], ["TGEV", "ORGANISM", 200, 204], ["viral N gene", "DNA", 32, 44], ["TGEV", "SPECIES", 200, 204], ["the mRNA levels", "TEST", 9, 24], ["the viral N gene", "TEST", 28, 44], ["the host's immune response", "PROBLEM", 125, 151], ["a decrease in infected cell viability", "PROBLEM", 155, 192], ["the TGEV infection", "PROBLEM", 196, 214], ["viral", "OBSERVATION", 32, 37], ["decreased", "OBSERVATION_MODIFIER", 45, 54], ["may be attributed to", "UNCERTAINTY", 104, 124], ["decrease", "OBSERVATION_MODIFIER", 157, 165], ["infected cell viability", "OBSERVATION", 169, 192], ["TGEV", "OBSERVATION_MODIFIER", 200, 204], ["infection", "OBSERVATION", 205, 214]]], ["Based on our qRT-PCR and CPE analyses, we choose to more deeply investigate the proteomic changes occurring in the TGEV-infected ST cells at 48 hpi and 64 hpi using a 4-plex iTRAQ analysis.DiscussionIn our analysis, we observed a statistically significant change in the expression of 316 proteins during TGEV infection in vitro.", [["ST cells", "ANATOMY", 129, 137], ["TGEV infection", "DISEASE", 304, 318], ["TGEV", "ORGANISM", 115, 119], ["ST cells", "CELL", 129, 137], ["TGEV", "ORGANISM", 304, 308], ["TGEV-infected ST cells", "CELL_LINE", 115, 137], ["316 proteins", "PROTEIN", 284, 296], ["TGEV", "SPECIES", 115, 119], ["TGEV", "SPECIES", 304, 308], ["our qRT-PCR", "TEST", 9, 20], ["CPE analyses", "TEST", 25, 37], ["the proteomic changes", "PROBLEM", 76, 97], ["infected ST cells", "PROBLEM", 120, 137], ["a 4-plex iTRAQ analysis", "TEST", 165, 188], ["our analysis", "TEST", 202, 214], ["a statistically significant change", "PROBLEM", 228, 262], ["TGEV infection in vitro", "PROBLEM", 304, 327], ["significant", "OBSERVATION_MODIFIER", 244, 255], ["change", "OBSERVATION", 256, 262], ["infection", "OBSERVATION", 309, 318]]], ["This number includes protein changes that were unique for a specific time point as well as those shared at these different time conditions.", [["protein changes", "PROBLEM", 21, 36]]], ["For example, the expression level of HSP90\u03b1 expression was unchanged at 48 hpi, but decreased at 64 hpi, making this change unique for the latter time point.", [["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 37, 43], ["HSP90\u03b1", "PROTEIN", 37, 43], ["HSP90\u03b1 expression", "TEST", 37, 54], ["unchanged", "OBSERVATION_MODIFIER", 59, 68]]], ["On the other hand, TGF-\u03b21 was observed to increase at both of the time points, and was thus labeled a shared protein change.", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 19, 25], ["TGF-\u03b21", "PROTEIN", 19, 25], ["TGF", "TEST", 19, 22], ["a shared protein change", "PROBLEM", 100, 123], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["protein change", "OBSERVATION", 109, 123]]], ["Moreover, the 316 altered proteins also includes proteins that changed from 48 hpi to 64 hpi, rather than one of these time points compared to non-infected cells.", [["cells", "ANATOMY", 156, 161], ["cells", "CELL", 156, 161], ["316 altered proteins", "PROTEIN", 14, 34], ["non-infected cells", "CELL_TYPE", 143, 161], ["proteins", "TEST", 49, 57], ["non-infected cells", "OBSERVATION", 143, 161]]], ["For example, mitochondrial aldehyde dehydrogenase 2 (ALDH2) and MHC class I antigen (PD1) were not changed at 48 or 64 hpi compared to the control group, but increased at 64 hpi compared with 48 hpi.", [["mitochondrial", "ANATOMY", 13, 26], ["aldehyde", "CHEMICAL", 27, 35], ["aldehyde", "CHEMICAL", 27, 35], ["mitochondrial", "CELLULAR_COMPONENT", 13, 26], ["aldehyde dehydrogenase 2", "GENE_OR_GENE_PRODUCT", 27, 51], ["ALDH2", "GENE_OR_GENE_PRODUCT", 53, 58], ["MHC class I antigen", "GENE_OR_GENE_PRODUCT", 64, 83], ["PD1", "GENE_OR_GENE_PRODUCT", 85, 88], ["mitochondrial aldehyde dehydrogenase 2", "PROTEIN", 13, 51], ["ALDH2", "PROTEIN", 53, 58], ["MHC class I antigen", "PROTEIN", 64, 83], ["PD1", "PROTEIN", 85, 88], ["mitochondrial aldehyde dehydrogenase", "TEST", 13, 49], ["mitochondrial", "OBSERVATION", 13, 26], ["aldehyde dehydrogenase", "OBSERVATION", 27, 49], ["increased", "OBSERVATION_MODIFIER", 158, 167]]], ["We also observed a larger proteomic shift at 64 hpi compared to the 48 hpi time point in the infected ST cells.DiscussionFurther, some proteins previously reported to play a role in virus-induced host cell death, such as caspase-8, caspase-3, caspase-9, and porcine aminopeptidase-N (pAPN) [36]\u2013[38], were also identified using this iTRAQ technique.", [["ST cells", "ANATOMY", 102, 110], ["cell", "ANATOMY", 201, 205], ["ST cells", "CELL", 102, 110], ["cell", "CELL", 201, 205], ["caspase-8", "GENE_OR_GENE_PRODUCT", 221, 230], ["caspase-3", "GENE_OR_GENE_PRODUCT", 232, 241], ["caspase-9", "GENE_OR_GENE_PRODUCT", 243, 252], ["porcine aminopeptidase-N", "SIMPLE_CHEMICAL", 258, 282], ["pAPN) [36]\u2013[38]", "SIMPLE_CHEMICAL", 284, 299], ["infected ST cells", "CELL_TYPE", 93, 110], ["caspase-8", "PROTEIN", 221, 230], ["caspase-3", "PROTEIN", 232, 241], ["caspase-9", "PROTEIN", 243, 252], ["a larger proteomic shift", "PROBLEM", 17, 41], ["the infected ST cells", "PROBLEM", 89, 110], ["host cell death", "PROBLEM", 196, 211], ["caspase", "TEST", 221, 228], ["caspase", "TREATMENT", 232, 239], ["caspase", "TREATMENT", 243, 250], ["porcine aminopeptidase-N (pAPN)", "TREATMENT", 258, 289], ["this iTRAQ technique", "TREATMENT", 328, 348], ["larger", "OBSERVATION_MODIFIER", 19, 25], ["infected", "OBSERVATION", 93, 101], ["ST cells", "OBSERVATION", 102, 110], ["host cell death", "OBSERVATION", 196, 211]]], ["These caspase proteins are known to be involved in TGEV-induced cell apoptosis processes, while pAPN is the cell receptor for TGEV.", [["cell", "ANATOMY", 64, 68], ["cell", "ANATOMY", 108, 112], ["caspase", "GENE_OR_GENE_PRODUCT", 6, 13], ["TGEV", "ORGANISM", 51, 55], ["cell", "CELL", 64, 68], ["pAPN", "GENE_OR_GENE_PRODUCT", 96, 100], ["cell", "CELL", 108, 112], ["TGEV", "ORGANISM", 126, 130], ["caspase proteins", "PROTEIN", 6, 22], ["pAPN", "PROTEIN", 96, 100], ["TGEV", "SPECIES", 51, 55], ["TGEV", "SPECIES", 126, 130], ["These caspase proteins", "TEST", 0, 22], ["TGEV", "PROBLEM", 51, 55], ["induced cell apoptosis processes", "PROBLEM", 56, 88], ["TGEV", "PROBLEM", 126, 130], ["induced cell apoptosis", "OBSERVATION", 56, 78]]], ["Our results indicate that TGEV infection caused significant upregulation of caspase-8 expression at two time points (approximately 7-fold at 48 hpi and 16-fold at 64 hpi) in the virus-infected ST cells, and this change was verified by western blotting analysis.", [["ST cells", "ANATOMY", 193, 201], ["TGEV infection", "DISEASE", 26, 40], ["TGEV", "ORGANISM", 26, 30], ["caspase-8", "GENE_OR_GENE_PRODUCT", 76, 85], ["ST cells", "CELL", 193, 201], ["caspase-8", "PROTEIN", 76, 85], ["ST cells", "CELL_TYPE", 193, 201], ["TGEV", "SPECIES", 26, 30], ["TGEV infection", "PROBLEM", 26, 40], ["caspase", "TEST", 76, 83], ["the virus", "PROBLEM", 174, 183], ["infected ST cells", "PROBLEM", 184, 201], ["blotting analysis", "TEST", 243, 260], ["TGEV", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 31, 40], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["upregulation", "OBSERVATION_MODIFIER", 60, 72], ["infected", "OBSERVATION_MODIFIER", 184, 192], ["ST cells", "OBSERVATION", 193, 201]]], ["However, the expression of caspase-3, caspase-9, and pAPN was not significantly altered, indicating that the pathways involving these genes are not altered or that other proteins are compensating for their lack of change.", [["caspase-3", "GENE_OR_GENE_PRODUCT", 27, 36], ["caspase-9", "GENE_OR_GENE_PRODUCT", 38, 47], ["pAPN", "GENE_OR_GENE_PRODUCT", 53, 57], ["caspase-3", "PROTEIN", 27, 36], ["caspase-9", "PROTEIN", 38, 47], ["pAPN", "PROTEIN", 53, 57], ["caspase", "TEST", 27, 34], ["caspase", "TEST", 38, 45]]], ["In this regard, we identified an additional 15 proteins involved in cell death pathways that had significantly altered expression levels (p = 4.46E-2) (Table S6), including melanoma differentiation associated protein-5 (MDA5), monocyte chemoattractant protein 1 (CCL2), thioredoxin- dependent peroxide reductase, mitochondrial (PRDX3), peroxiredoxin-2 (PRDX2), predicted protein CYR61 (CYR61), keratin, type II cytoskeletal 8 (KRT8), predicted bcl-2-like protein 13 (BCL2L13), predicted integrin alpha-5 isoform 1 (ITGA5), TGF-\u03b21, amyloid beta A4 protein (APP), clusterin (CLU), C\u2013C motif chemokine 5 (CCL5), heat shock 70 kDa protein 1B (HSPA1B), alpha-crystallin B chain (CRYAB), voltage-dependent anion-selective channel protein 1 (VDAC1), all of which, with the exception of PRDX2 and BCL2L13 were upregulated at one or two time points.", [["cell", "ANATOMY", 68, 72], ["melanoma", "ANATOMY", 173, 181], ["mitochondrial", "ANATOMY", 313, 326], ["peroxide", "CHEMICAL", 293, 301], ["cell", "CELL", 68, 72], ["4.46E-2", "GENE_OR_GENE_PRODUCT", 142, 149], ["Table S6", "GENE_OR_GENE_PRODUCT", 152, 160], ["melanoma differentiation associated protein-5", "GENE_OR_GENE_PRODUCT", 173, 218], ["MDA5", "GENE_OR_GENE_PRODUCT", 220, 224], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 227, 261], ["CCL2", "GENE_OR_GENE_PRODUCT", 263, 267], ["thioredoxin- dependent peroxide reductase", "GENE_OR_GENE_PRODUCT", 270, 311], ["mitochondrial", "CELLULAR_COMPONENT", 313, 326], ["PRDX3", "GENE_OR_GENE_PRODUCT", 328, 333], ["peroxiredoxin-2", "GENE_OR_GENE_PRODUCT", 336, 351], ["PRDX2", "GENE_OR_GENE_PRODUCT", 353, 358], ["CYR61", "GENE_OR_GENE_PRODUCT", 379, 384], ["CYR61", "GENE_OR_GENE_PRODUCT", 386, 391], ["keratin", "GENE_OR_GENE_PRODUCT", 394, 401], ["type II cytoskeletal 8", "GENE_OR_GENE_PRODUCT", 403, 425], ["KRT8", "GENE_OR_GENE_PRODUCT", 427, 431], ["bcl-2-like protein 13", "GENE_OR_GENE_PRODUCT", 444, 465], ["BCL2L13", "GENE_OR_GENE_PRODUCT", 467, 474], ["integrin alpha-5 isoform 1", "GENE_OR_GENE_PRODUCT", 487, 513], ["ITGA5", "GENE_OR_GENE_PRODUCT", 515, 520], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 523, 529], ["amyloid beta A4", "GENE_OR_GENE_PRODUCT", 531, 546], ["APP", "GENE_OR_GENE_PRODUCT", 556, 559], ["clusterin", "GENE_OR_GENE_PRODUCT", 562, 571], ["CLU", "GENE_OR_GENE_PRODUCT", 573, 576], ["C\u2013C motif chemokine 5", "GENE_OR_GENE_PRODUCT", 579, 600], ["CCL5", "GENE_OR_GENE_PRODUCT", 602, 606], ["heat shock 70 kDa protein 1B", "GENE_OR_GENE_PRODUCT", 609, 637], ["HSPA1B", "GENE_OR_GENE_PRODUCT", 639, 645], ["alpha-crystallin B chain", "GENE_OR_GENE_PRODUCT", 648, 672], ["CRYAB", "GENE_OR_GENE_PRODUCT", 674, 679], ["voltage-dependent anion-selective channel protein 1", "GENE_OR_GENE_PRODUCT", 682, 733], ["VDAC1", "GENE_OR_GENE_PRODUCT", 735, 740], ["PRDX2", "GENE_OR_GENE_PRODUCT", 779, 784], ["BCL2L13", "GENE_OR_GENE_PRODUCT", 789, 796], ["S6", "PROTEIN", 158, 160], ["melanoma differentiation associated protein-5", "PROTEIN", 173, 218], ["MDA5", "PROTEIN", 220, 224], ["monocyte chemoattractant protein 1", "PROTEIN", 227, 261], ["CCL2", "PROTEIN", 263, 267], ["thioredoxin- dependent peroxide reductase", "PROTEIN", 270, 311], ["PRDX3", "PROTEIN", 328, 333], ["peroxiredoxin-2", "PROTEIN", 336, 351], ["PRDX2", "PROTEIN", 353, 358], ["CYR61", "PROTEIN", 379, 384], ["CYR61", "PROTEIN", 386, 391], ["keratin", "PROTEIN", 394, 401], ["type II cytoskeletal 8", "PROTEIN", 403, 425], ["KRT8", "PROTEIN", 427, 431], ["bcl-2-like protein 13", "PROTEIN", 444, 465], ["BCL2L13", "PROTEIN", 467, 474], ["integrin alpha-5 isoform 1", "PROTEIN", 487, 513], ["ITGA5", "PROTEIN", 515, 520], ["TGF-\u03b21", "PROTEIN", 523, 529], ["amyloid beta A4 protein", "PROTEIN", 531, 554], ["APP", "PROTEIN", 556, 559], ["clusterin", "PROTEIN", 562, 571], ["CLU", "PROTEIN", 573, 576], ["C\u2013C motif chemokine 5", "PROTEIN", 579, 600], ["CCL5", "PROTEIN", 602, 606], ["heat shock 70 kDa protein 1B", "PROTEIN", 609, 637], ["HSPA1B", "PROTEIN", 639, 645], ["alpha-crystallin B chain", "PROTEIN", 648, 672], ["CRYAB", "PROTEIN", 674, 679], ["voltage-dependent anion-selective channel protein 1", "PROTEIN", 682, 733], ["VDAC1", "PROTEIN", 735, 740], ["PRDX2", "PROTEIN", 779, 784], ["BCL2L13", "PROTEIN", 789, 796], ["cell death pathways", "PROBLEM", 68, 87], ["significantly altered expression levels", "PROBLEM", 97, 136], ["p", "TEST", 138, 139], ["melanoma differentiation", "PROBLEM", 173, 197], ["protein", "TEST", 209, 216], ["MDA5", "TEST", 220, 224], ["monocyte chemoattractant protein", "TEST", 227, 259], ["CCL2", "TEST", 263, 267], ["thioredoxin", "TEST", 270, 281], ["dependent peroxide reductase", "PROBLEM", 283, 311], ["mitochondrial (PRDX3)", "TEST", 313, 334], ["peroxiredoxin", "TEST", 336, 349], ["CYR61", "TEST", 386, 391], ["keratin, type II cytoskeletal", "TEST", 394, 423], ["KRT8", "TEST", 427, 431], ["bcl", "TEST", 444, 447], ["protein", "TEST", 455, 462], ["BCL2L13", "TEST", 467, 474], ["integrin alpha", "TEST", 487, 501], ["isoform", "TEST", 504, 511], ["ITGA5", "TEST", 515, 520], ["TGF", "TEST", 523, 526], ["amyloid beta A4 protein", "TEST", 531, 554], ["APP", "TEST", 556, 559], ["clusterin (CLU", "TEST", 562, 576], ["C\u2013C motif chemokine", "TEST", 579, 598], ["CCL5", "TEST", 602, 606], ["heat shock", "TEST", 609, 619], ["protein 1B", "TEST", 627, 637], ["HSPA1B", "TEST", 639, 645], ["alpha-crystallin B chain", "TEST", 648, 672], ["CRYAB", "TEST", 674, 679], ["voltage", "TEST", 682, 689], ["PRDX2", "TREATMENT", 779, 784], ["BCL2L13", "TREATMENT", 789, 796], ["melanoma", "OBSERVATION", 173, 181]]], ["Regulation of cell death is known to be important for replication and pathogenesis in various coronaviruses [39], and we believe that further research on these proteins will lead to a better understanding of cell death regulation during TGEV infection.DiscussionIn order to determine what other processes, in addition to cell death, were affected by TGEV infection, we performed a GO enrichment analysis for the different temporal conditions.", [["cell", "ANATOMY", 14, 18], ["cell", "ANATOMY", 208, 212], ["cell", "ANATOMY", 321, 325], ["death", "DISEASE", 213, 218], ["TGEV infection", "DISEASE", 237, 251], ["death", "DISEASE", 326, 331], ["TGEV infection", "DISEASE", 350, 364], ["cell", "CELL", 14, 18], ["cell", "CELL", 208, 212], ["TGEV", "ORGANISM", 237, 241], ["cell", "CELL", 321, 325], ["TGEV", "ORGANISM", 350, 354], ["TGEV", "SPECIES", 237, 241], ["TGEV", "SPECIES", 350, 354], ["cell death", "PROBLEM", 14, 24], ["replication", "PROBLEM", 54, 65], ["pathogenesis in various coronaviruses", "PROBLEM", 70, 107], ["cell death regulation", "PROBLEM", 208, 229], ["TGEV infection", "PROBLEM", 237, 251], ["cell death", "PROBLEM", 321, 331], ["TGEV infection", "PROBLEM", 350, 364], ["a GO enrichment analysis", "TEST", 379, 403], ["the different temporal conditions", "PROBLEM", 408, 441], ["cell death", "OBSERVATION", 14, 24], ["infection", "OBSERVATION", 242, 251]]], ["This analysis indicated that six biological processes were significantly affected at 48 and 64 hpi, and the differentially expressed proteins involved in these processes were almost the same.", [["This analysis", "TEST", 0, 13], ["six biological processes", "PROBLEM", 29, 53]]], ["The large overlap between the two time points suggests that some of the same sets of host proteins or processes were disturbed at these times.", [["host proteins", "PROTEIN", 85, 98], ["large", "OBSERVATION_MODIFIER", 4, 9], ["overlap", "OBSERVATION", 10, 17]]], ["However, it is also likely that some processes were affected solely at one time point or the other.", [["is also likely", "UNCERTAINTY", 12, 26]]], ["At 48 hpi, serine/threonine-protein phosphatase PP1-beta-catalytic subunit (PPP1CB), scavenger receptor class B member 1 (SCARB1), transforming growth factor-beta-induced protein ig-h3 (TGFBI), and predicted inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) were uniquely altered, likely indicating changes in cell adhesion and/or cell-cell signaling processes.", [["cell", "ANATOMY", 313, 317], ["cell", "ANATOMY", 334, 338], ["cell", "ANATOMY", 339, 343], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 208, 236], ["serine", "CHEMICAL", 11, 17], ["threonine", "CHEMICAL", 18, 27], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 208, 236], ["serine", "AMINO_ACID", 11, 17], ["threonine", "AMINO_ACID", 18, 27], ["PP1-beta-catalytic subunit", "GENE_OR_GENE_PRODUCT", 48, 74], ["PPP1CB", "GENE_OR_GENE_PRODUCT", 76, 82], ["scavenger receptor class B member 1", "GENE_OR_GENE_PRODUCT", 85, 120], ["SCARB1", "GENE_OR_GENE_PRODUCT", 122, 128], ["transforming growth factor-beta", "GENE_OR_GENE_PRODUCT", 131, 162], ["ig-h3", "GENE_OR_GENE_PRODUCT", 179, 184], ["TGFBI", "GENE_OR_GENE_PRODUCT", 186, 191], ["inositol 1,4,5-trisphosphate receptor type 3", "GENE_OR_GENE_PRODUCT", 208, 252], ["ITPR3", "GENE_OR_GENE_PRODUCT", 254, 259], ["cell", "CELL", 313, 317], ["cell", "CELL", 334, 338], ["cell", "CELL", 339, 343], ["serine/threonine-protein phosphatase PP1-beta-catalytic subunit", "PROTEIN", 11, 74], ["PPP1CB", "PROTEIN", 76, 82], ["scavenger receptor class B member 1", "PROTEIN", 85, 120], ["SCARB1", "PROTEIN", 122, 128], ["transforming growth factor-beta-induced protein", "PROTEIN", 131, 178], ["ig", "PROTEIN", 179, 181], ["h3", "PROTEIN", 182, 184], ["TGFBI", "PROTEIN", 186, 191], ["inositol 1,4,5-trisphosphate receptor type 3", "PROTEIN", 208, 252], ["ITPR3", "PROTEIN", 254, 259], ["threonine", "TEST", 18, 27], ["phosphatase", "TEST", 36, 47], ["PP1", "TEST", 48, 51], ["beta", "TEST", 52, 56], ["catalytic subunit (PPP1CB)", "TREATMENT", 57, 83], ["transforming growth factor", "TEST", 131, 157], ["beta", "TEST", 158, 162], ["protein ig", "TEST", 171, 181], ["TGFBI", "TEST", 186, 191], ["inositol", "TEST", 208, 216], ["changes in cell adhesion", "PROBLEM", 302, 326], ["cell-cell signaling processes", "PROBLEM", 334, 363], ["likely indicating", "UNCERTAINTY", 284, 301], ["cell adhesion", "OBSERVATION", 313, 326], ["cell", "OBSERVATION", 339, 343], ["signaling processes", "OBSERVATION", 344, 363]]], ["At 64 hpi, on the other hand, calreticulin (CALR), predicted tumor- associated calcium signal transducer 2-like (TACSTD2), vascular cell adhesion molecule, galectin-3 (LGALS3), glutamate dehydrogenase 1 (GLUD1), and C\u2013X-C motif chemokine 16 (CXCL16) were uniquely changed, also indicating changes in cell adhesion and/or cell-cell signaling as well as extracellular matrix organization and locomotion.", [["tumor", "ANATOMY", 61, 66], ["cell", "ANATOMY", 300, 304], ["cell", "ANATOMY", 321, 325], ["cell", "ANATOMY", 326, 330], ["extracellular matrix", "ANATOMY", 352, 372], ["tumor", "DISEASE", 61, 66], ["calcium", "CHEMICAL", 79, 86], ["glutamate", "CHEMICAL", 177, 186], ["calcium", "CHEMICAL", 79, 86], ["glutamate", "CHEMICAL", 177, 186], ["calreticulin", "GENE_OR_GENE_PRODUCT", 30, 42], ["CALR", "GENE_OR_GENE_PRODUCT", 44, 48], ["tumor", "CANCER", 61, 66], ["calcium signal transducer 2-like", "GENE_OR_GENE_PRODUCT", 79, 111], ["TACSTD2", "GENE_OR_GENE_PRODUCT", 113, 120], ["vascular cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 123, 154], ["galectin-3", "GENE_OR_GENE_PRODUCT", 156, 166], ["LGALS3", "GENE_OR_GENE_PRODUCT", 168, 174], ["glutamate dehydrogenase 1", "GENE_OR_GENE_PRODUCT", 177, 202], ["GLUD1", "GENE_OR_GENE_PRODUCT", 204, 209], ["C\u2013X-C motif chemokine 16", "GENE_OR_GENE_PRODUCT", 216, 240], ["CXCL16", "GENE_OR_GENE_PRODUCT", 242, 248], ["cell", "CELL", 300, 304], ["cell", "CELL", 321, 325], ["cell", "CELL", 326, 330], ["extracellular matrix", "CELLULAR_COMPONENT", 352, 372], ["calreticulin", "PROTEIN", 30, 42], ["CALR", "PROTEIN", 44, 48], ["tumor- associated calcium signal transducer 2-like", "PROTEIN", 61, 111], ["TACSTD2", "PROTEIN", 113, 120], ["vascular cell adhesion molecule", "PROTEIN", 123, 154], ["galectin-3", "PROTEIN", 156, 166], ["LGALS3", "PROTEIN", 168, 174], ["glutamate dehydrogenase 1", "PROTEIN", 177, 202], ["GLUD1", "PROTEIN", 204, 209], ["C\u2013X", "PROTEIN", 216, 219], ["chemokine 16", "PROTEIN", 228, 240], ["CXCL16", "PROTEIN", 242, 248], ["predicted tumor", "PROBLEM", 51, 66], ["calcium signal transducer", "TEST", 79, 104], ["vascular cell adhesion molecule", "TEST", 123, 154], ["galectin", "TEST", 156, 164], ["LGALS3", "TEST", 168, 174], ["glutamate dehydrogenase", "TEST", 177, 200], ["GLUD1", "TEST", 204, 209], ["C\u2013X", "TEST", 216, 219], ["motif chemokine", "TEST", 222, 237], ["CXCL16", "TEST", 242, 248], ["changes in cell adhesion", "PROBLEM", 289, 313], ["cell-cell signaling", "PROBLEM", 321, 340], ["extracellular matrix organization", "TEST", 352, 385], ["tumor", "OBSERVATION", 61, 66], ["vascular cell", "ANATOMY", 123, 136], ["adhesion molecule", "OBSERVATION", 137, 154], ["cell adhesion", "OBSERVATION", 300, 313], ["cell signaling", "OBSERVATION", 326, 340], ["locomotion", "OBSERVATION_MODIFIER", 390, 400]]], ["We believe that these uniquely altered proteins reflect changes in specific/specialized processes at each time point that are tightly linked to the temporal changes observed in the host cell morphology and gene/protein expression after TGEV infection.DiscussionThe most significantly enriched GO category related to the differentially expressed proteins was stress, which included 12 differentially expressed proteins at 48 hpi and 27 different proteins at 64 hpi.", [["cell", "ANATOMY", 186, 190], ["TGEV infection", "DISEASE", 236, 250], ["host cell", "CELL", 181, 190], ["TGEV", "ORGANISM", 236, 240], ["TGEV", "SPECIES", 236, 240], ["these uniquely altered proteins", "PROBLEM", 16, 47], ["the temporal changes", "PROBLEM", 144, 164], ["gene/protein expression", "PROBLEM", 206, 229], ["TGEV infection", "PROBLEM", 236, 250], ["proteins", "TEST", 409, 417], ["altered", "OBSERVATION_MODIFIER", 31, 38], ["proteins", "OBSERVATION", 39, 47], ["temporal", "OBSERVATION_MODIFIER", 148, 156], ["changes", "OBSERVATION", 157, 164], ["host cell morphology", "OBSERVATION", 181, 201], ["protein expression", "OBSERVATION", 211, 229], ["infection", "OBSERVATION", 241, 250]]], ["The increased number of proteins association with this GO term at 48 hpi likely highlights the initial upregulation of the cellular stress response, while the higher number at 64 hpi indicates that the stress response to TGEV infection is likely more fully induced at this later stage.", [["cellular", "ANATOMY", 123, 131], ["infection", "DISEASE", 226, 235], ["cellular", "CELL", 123, 131], ["TGEV", "ORGANISM", 221, 225], ["TGEV", "SPECIES", 221, 225], ["the cellular stress response", "PROBLEM", 119, 147], ["the stress response", "PROBLEM", 198, 217], ["TGEV infection", "PROBLEM", 221, 235], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["cellular stress response", "OBSERVATION", 123, 147], ["infection", "OBSERVATION", 226, 235]]], ["HSPs, also known as stress proteins, are often involved in the cellular response to stress, influencing changes in the state or activity of the cell or organism.", [["cellular", "ANATOMY", 63, 71], ["cell", "ANATOMY", 144, 148], ["HSPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 63, 71], ["cell", "CELL", 144, 148], ["HSPs", "PROTEIN", 0, 4], ["stress proteins", "PROTEIN", 20, 35], ["HSPs", "PROBLEM", 0, 4], ["stress proteins", "PROBLEM", 20, 35], ["stress", "PROBLEM", 84, 90], ["influencing changes in the state", "PROBLEM", 92, 124], ["stress proteins", "OBSERVATION", 20, 35]]], ["HSP90, which has two isoforms (HSP90\u03b1 and HSP90\u03b2), is one of the most abundant molecular chaperones that is induced in response to cellular stress, and it functions to stabilize proteins involved in cell growth and anti-apoptotic signaling [40].", [["cellular", "ANATOMY", 131, 139], ["cell", "ANATOMY", 199, 203], ["HSP90", "GENE_OR_GENE_PRODUCT", 0, 5], ["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 31, 37], ["HSP90\u03b2", "GENE_OR_GENE_PRODUCT", 42, 48], ["cellular", "CELL", 131, 139], ["cell", "CELL", 199, 203], ["HSP90", "PROTEIN", 0, 5], ["HSP90\u03b1", "PROTEIN", 31, 37], ["HSP90\u03b2", "PROTEIN", 42, 48], ["molecular chaperones", "PROTEIN", 79, 99], ["HSP90", "TEST", 0, 5], ["HSP90", "TEST", 31, 36], ["HSP90\u03b2", "TEST", 42, 48], ["cellular stress", "PROBLEM", 131, 146], ["anti-apoptotic signaling", "TEST", 215, 239], ["cellular stress", "OBSERVATION", 131, 146]]], ["The expression of HSP90\u03b1 has been reported to play an important role in the replication of some viruses, such as Ebola virus (EBOV) [41], hepatitis C virus (HCV) [42], influenza virus [43], and Japanese encephalitis virus [44].", [["Ebola virus", "DISEASE", 113, 124], ["hepatitis C", "DISEASE", 138, 149], ["influenza virus", "DISEASE", 168, 183], ["Japanese encephalitis", "DISEASE", 194, 215], ["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 18, 24], ["Ebola virus", "ORGANISM", 113, 124], ["EBOV) [41],", "ORGANISM", 126, 137], ["hepatitis C virus", "ORGANISM", 138, 155], ["HCV) [42", "ORGANISM", 157, 165], ["influenza virus", "ORGANISM", 168, 183], ["Japanese encephalitis virus", "ORGANISM", 194, 221], ["HSP90\u03b1", "PROTEIN", 18, 24], ["Ebola virus", "SPECIES", 113, 124], ["hepatitis C virus", "SPECIES", 138, 155], ["influenza virus", "SPECIES", 168, 183], ["Japanese encephalitis virus", "SPECIES", 194, 221], ["Ebola virus", "SPECIES", 113, 124], ["EBOV", "SPECIES", 126, 130], ["hepatitis C virus", "SPECIES", 138, 155], ["HCV", "SPECIES", 157, 160], ["Japanese encephalitis virus", "SPECIES", 194, 221], ["HSP90", "TEST", 18, 23], ["some viruses", "PROBLEM", 91, 103], ["Ebola virus", "PROBLEM", 113, 124], ["hepatitis C virus (HCV)", "PROBLEM", 138, 161], ["influenza virus", "PROBLEM", 168, 183], ["Japanese encephalitis virus", "PROBLEM", 194, 221]]], ["On the other hand, the reduction of HSP90\u03b2 has been reported to decrease the correct assembly of human enterovirus 71 viral particles [40].", [["HSP90\u03b2", "GENE_OR_GENE_PRODUCT", 36, 42], ["human", "ORGANISM", 97, 102], ["enterovirus 71", "ORGANISM", 103, 117], ["HSP90\u03b2", "PROTEIN", 36, 42], ["human", "SPECIES", 97, 102], ["human enterovirus 71", "SPECIES", 97, 117], ["HSP90", "TEST", 36, 41], ["human enterovirus", "PROBLEM", 97, 114]]], ["In this study, HSP90\u03b1 and heat shock 90kD protein 1, beta (HSPCB/HSP90\u03b2) were significantly downregulated at 64 hpi in the TGEV-infected ST cells, but were unchanged at 48 hpi, indicating that they may play a similar role in TGEV infection.", [["ST cells", "ANATOMY", 137, 145], ["TGEV infection", "DISEASE", 225, 239], ["HSP90\u03b1", "GENE_OR_GENE_PRODUCT", 15, 21], ["heat shock 90kD protein 1", "GENE_OR_GENE_PRODUCT", 26, 51], ["beta (HSPCB/HSP90\u03b2", "GENE_OR_GENE_PRODUCT", 53, 71], ["TGEV", "ORGANISM", 123, 127], ["ST cells", "CELL", 137, 145], ["TGEV", "ORGANISM", 225, 229], ["HSP90\u03b1", "PROTEIN", 15, 21], ["heat shock 90kD protein 1", "PROTEIN", 26, 51], ["beta", "PROTEIN", 53, 57], ["HSPCB", "PROTEIN", 59, 64], ["HSP90\u03b2", "PROTEIN", 65, 71], ["TGEV-infected ST cells", "CELL_LINE", 123, 145], ["TGEV", "SPECIES", 123, 127], ["TGEV", "SPECIES", 225, 229], ["this study", "TEST", 3, 13], ["HSP90", "TEST", 15, 20], ["heat shock", "TEST", 26, 36], ["protein", "TEST", 42, 49], ["beta (HSPCB/HSP90", "TEST", 53, 70], ["the TGEV", "TEST", 119, 127], ["infected ST cells", "PROBLEM", 128, 145], ["TGEV infection", "PROBLEM", 225, 239], ["unchanged", "OBSERVATION_MODIFIER", 156, 165], ["TGEV", "OBSERVATION_MODIFIER", 225, 229], ["infection", "OBSERVATION", 230, 239]]], ["Interestingly, a member of the HSP70 protein family, heat shock 70 kDa protein 1B (HSPA1B), as well as mitochondrial 60 kDa heat shock protein (HSP60) were both upregulated in infected ST cells at 48 and/or 64 hpi.", [["mitochondrial", "ANATOMY", 103, 116], ["ST cells", "ANATOMY", 185, 193], ["HSP70", "GENE_OR_GENE_PRODUCT", 31, 36], ["heat shock 70 kDa protein 1B", "GENE_OR_GENE_PRODUCT", 53, 81], ["HSPA1B", "GENE_OR_GENE_PRODUCT", 83, 89], ["mitochondrial", "CELLULAR_COMPONENT", 103, 116], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 124, 142], ["HSP60", "GENE_OR_GENE_PRODUCT", 144, 149], ["ST cells", "CELL", 185, 193], ["HSP70 protein family", "PROTEIN", 31, 51], ["heat shock 70 kDa protein 1B", "PROTEIN", 53, 81], ["HSPA1B", "PROTEIN", 83, 89], ["mitochondrial 60 kDa heat shock protein", "PROTEIN", 103, 142], ["HSP60", "PROTEIN", 144, 149], ["infected ST cells", "CELL_TYPE", 176, 193], ["heat shock", "TEST", 53, 63], ["protein 1B", "TEST", 71, 81], ["HSPA1B", "TEST", 83, 89], ["mitochondrial 60 kDa heat shock protein", "TEST", 103, 142], ["HSP60", "TEST", 144, 149], ["infected ST cells", "PROBLEM", 176, 193]]], ["HSP60 is a mitochondrial chaperonin protein involved in protein folding and a number of extracellular immunomodulatory activities.", [["mitochondrial", "ANATOMY", 11, 24], ["extracellular", "ANATOMY", 88, 101], ["HSP60", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 11, 24], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 88, 101], ["HSP60", "PROTEIN", 0, 5], ["mitochondrial chaperonin protein", "PROTEIN", 11, 43], ["HSP60", "TEST", 0, 5], ["a mitochondrial chaperonin protein", "TREATMENT", 9, 43], ["protein folding", "PROBLEM", 56, 71], ["extracellular immunomodulatory activities", "TREATMENT", 88, 129], ["chaperonin protein", "OBSERVATION", 25, 43], ["protein folding", "OBSERVATION", 56, 71], ["extracellular immunomodulatory activities", "OBSERVATION", 88, 129]]], ["Elevated expression of HSP60 is associated with a number of inflammatory disorders [45].", [["HSP60", "GENE_OR_GENE_PRODUCT", 23, 28], ["HSP60", "PROTEIN", 23, 28], ["Elevated expression of HSP60", "PROBLEM", 0, 28], ["inflammatory disorders", "PROBLEM", 60, 82], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72]]], ["HSP70 plays an important role in multiple processes within cells, including protein translation, folding, intracellular trafficking, and degradation.", [["cells", "ANATOMY", 59, 64], ["intracellular", "ANATOMY", 106, 119], ["HSP70", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 59, 64], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["HSP70", "PROTEIN", 0, 5], ["protein translation", "TREATMENT", 76, 95], ["intracellular trafficking", "OBSERVATION", 106, 131]]], ["A previous study has revealed that HSP70 is involved in all steps of the viral life cycle, including replication, and is highly specific in regards to viral response, differing from one cell to another for any given virus type [46].", [["cell", "ANATOMY", 186, 190], ["HSP70", "GENE_OR_GENE_PRODUCT", 35, 40], ["cell", "CELL", 186, 190], ["HSP70", "PROTEIN", 35, 40], ["A previous study", "TEST", 0, 16], ["HSP70", "PROBLEM", 35, 40], ["viral response", "PROBLEM", 151, 165]]], ["For example, silencing HSP70 expression has been associated with an increase in viral protein levels, while an increase in HSP70 has been suspected to be the initial cellular response to protect against viral infection in rotavirus-infected cells [47].", [["cellular", "ANATOMY", 166, 174], ["cells", "ANATOMY", 241, 246], ["viral infection", "DISEASE", 203, 218], ["rotavirus-infected", "DISEASE", 222, 240], ["HSP70", "GENE_OR_GENE_PRODUCT", 23, 28], ["HSP70", "GENE_OR_GENE_PRODUCT", 123, 128], ["cellular", "CELL", 166, 174], ["rotavirus", "ORGANISM", 222, 231], ["cells", "CELL", 241, 246], ["HSP70", "PROTEIN", 23, 28], ["HSP70", "PROTEIN", 123, 128], ["rotavirus-infected cells", "CELL_TYPE", 222, 246], ["rotavirus", "SPECIES", 222, 231], ["silencing HSP70 expression", "PROBLEM", 13, 39], ["an increase in viral protein levels", "PROBLEM", 65, 100], ["an increase in HSP70", "PROBLEM", 108, 128], ["viral infection", "PROBLEM", 203, 218], ["rotavirus", "PROBLEM", 222, 231], ["infected cells", "PROBLEM", 232, 246], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["viral protein levels", "OBSERVATION", 80, 100], ["infection", "OBSERVATION", 209, 218]]], ["Further, a recent study showed that HSP70 is an essential host factor for the replication of PRRSV as the silence of HSP70 significantly reduced PRRSV replication [48].", [["HSP70", "GENE_OR_GENE_PRODUCT", 36, 41], ["PRRSV", "ORGANISM", 93, 98], ["HSP70", "GENE_OR_GENE_PRODUCT", 117, 122], ["HSP70", "PROTEIN", 36, 41], ["HSP70", "PROTEIN", 117, 122], ["PRRSV", "SPECIES", 93, 98], ["PRRSV", "SPECIES", 145, 150], ["a recent study", "TEST", 9, 23], ["HSP70", "TEST", 36, 41], ["PRRSV", "TREATMENT", 93, 98], ["HSP70", "TEST", 117, 122]]], ["Our results provide new experimental evidence relating the expression of HSP90, HSP70, and HSP60 to TGEV infection, and we speculate that these proteins play a potential role in TGEV replication.", [["TGEV infection", "DISEASE", 100, 114], ["HSP90", "GENE_OR_GENE_PRODUCT", 73, 78], ["HSP70", "GENE_OR_GENE_PRODUCT", 80, 85], ["HSP60", "GENE_OR_GENE_PRODUCT", 91, 96], ["TGEV", "ORGANISM", 100, 104], ["TGEV", "ORGANISM", 178, 182], ["HSP90", "PROTEIN", 73, 78], ["HSP70", "PROTEIN", 80, 85], ["HSP60", "PROTEIN", 91, 96], ["TGEV", "SPECIES", 100, 104], ["TGEV", "SPECIES", 178, 182], ["HSP90", "TEST", 73, 78], ["HSP70", "TEST", 80, 85], ["HSP60", "PROBLEM", 91, 96], ["TGEV infection", "PROBLEM", 100, 114], ["TGEV replication", "TREATMENT", 178, 194], ["infection", "OBSERVATION", 105, 114]]], ["Additional work is required to investigate the detailed role of these proteins during TGEV infection.DiscussionFurthermore, another significantly enriched GO process we observed that 11 significantly altered proteins was immune system processes.", [["TGEV infection", "DISEASE", 86, 100], ["TGEV", "ORGANISM", 86, 90], ["TGEV", "SPECIES", 86, 90], ["these proteins", "PROBLEM", 64, 78], ["TGEV infection", "PROBLEM", 86, 100], ["significantly altered proteins was immune system processes", "PROBLEM", 186, 244], ["infection", "OBSERVATION", 91, 100]]], ["Most of these proteins were significantly upregulated at 64 hpi in response to the viral infection, while some were first upregulated at 48 hpi, including CCL5 and TGF-\u03b21.", [["viral infection", "DISEASE", 83, 98], ["CCL5", "GENE_OR_GENE_PRODUCT", 155, 159], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 164, 170], ["CCL5", "PROTEIN", 155, 159], ["TGF-\u03b21", "PROTEIN", 164, 170], ["the viral infection", "PROBLEM", 79, 98], ["CCL5", "TEST", 155, 159], ["TGF", "TEST", 164, 167], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["infection", "OBSERVATION", 89, 98]]], ["Chemokines, such as CCL2, CCL5, and CXCL16, whose main function is macrophage recruitment and activation, are potentially involved in host-mediated immunopathology.", [["macrophage", "ANATOMY", 67, 77], ["immunopathology", "DISEASE", 148, 163], ["CCL2", "GENE_OR_GENE_PRODUCT", 20, 24], ["CCL5", "GENE_OR_GENE_PRODUCT", 26, 30], ["CXCL16", "GENE_OR_GENE_PRODUCT", 36, 42], ["macrophage", "CELL", 67, 77], ["Chemokines", "PROTEIN", 0, 10], ["CCL2", "PROTEIN", 20, 24], ["CCL5", "PROTEIN", 26, 30], ["CXCL16", "PROTEIN", 36, 42], ["Chemokines", "TEST", 0, 10], ["CCL2", "TEST", 20, 24], ["CCL5", "TEST", 26, 30], ["CXCL16", "TEST", 36, 42], ["macrophage recruitment", "OBSERVATION", 67, 89], ["immunopathology", "OBSERVATION", 148, 163]]], ["A recent study showed that coronavirus infection of transgenic mice expressing CCL2 led to a dysregulated immune response without effective virus clearance and enhanced death [49].", [["coronavirus infection", "DISEASE", 27, 48], ["death", "DISEASE", 169, 174], ["coronavirus", "ORGANISM", 27, 38], ["transgenic mice", "ORGANISM", 52, 67], ["CCL2", "GENE_OR_GENE_PRODUCT", 79, 83], ["CCL2", "PROTEIN", 79, 83], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["A recent study", "TEST", 0, 14], ["coronavirus infection of transgenic mice expressing CCL2", "PROBLEM", 27, 83], ["a dysregulated immune response", "PROBLEM", 91, 121], ["effective virus clearance", "PROBLEM", 130, 155], ["enhanced death", "PROBLEM", 160, 174], ["coronavirus", "OBSERVATION_MODIFIER", 27, 38], ["infection", "OBSERVATION", 39, 48]]], ["In additional, TGEV-infection can induce the expression of proinflammatory genes, including CCL2, CCL5, and probable ATP-dependent RNA helicase DDX58 (DDX58/RIG-1), in cell culture and in vivo in the absence of viral protein 7 [50].", [["cell culture", "ANATOMY", 168, 180], ["infection", "DISEASE", 20, 29], ["ATP", "CHEMICAL", 117, 120], ["ATP", "CHEMICAL", 117, 120], ["TGEV", "ORGANISM", 15, 19], ["CCL2", "GENE_OR_GENE_PRODUCT", 92, 96], ["CCL5", "GENE_OR_GENE_PRODUCT", 98, 102], ["ATP", "SIMPLE_CHEMICAL", 117, 120], ["DDX58", "GENE_OR_GENE_PRODUCT", 144, 149], ["DDX58/RIG-1", "GENE_OR_GENE_PRODUCT", 151, 162], ["cell culture", "CELL", 168, 180], ["proinflammatory genes", "DNA", 59, 80], ["CCL2", "PROTEIN", 92, 96], ["CCL5", "PROTEIN", 98, 102], ["ATP-dependent RNA helicase", "PROTEIN", 117, 143], ["DDX58", "PROTEIN", 144, 149], ["DDX58", "PROTEIN", 151, 156], ["RIG-1", "PROTEIN", 157, 162], ["viral protein 7", "PROTEIN", 211, 226], ["TGEV", "SPECIES", 15, 19], ["TGEV", "PROBLEM", 15, 19], ["infection", "PROBLEM", 20, 29], ["proinflammatory genes", "PROBLEM", 59, 80], ["CCL2", "TEST", 92, 96], ["CCL5", "TEST", 98, 102], ["ATP", "TEST", 117, 120], ["helicase DDX58", "TEST", 135, 149], ["DDX58", "TEST", 151, 156], ["RIG", "TEST", 157, 160], ["cell culture", "TEST", 168, 180], ["viral protein", "TEST", 211, 224], ["infection", "OBSERVATION", 20, 29], ["proinflammatory genes", "OBSERVATION", 59, 80]]], ["In this study, we observed an upregulation of CCL2, CCL5, CXCL16, TGF-\u03b21, and DDX58 expression.", [["CCL2", "GENE_OR_GENE_PRODUCT", 46, 50], ["CCL5", "GENE_OR_GENE_PRODUCT", 52, 56], ["CXCL16", "GENE_OR_GENE_PRODUCT", 58, 64], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 66, 72], ["DDX58", "GENE_OR_GENE_PRODUCT", 78, 83], ["CCL2", "PROTEIN", 46, 50], ["CCL5", "PROTEIN", 52, 56], ["CXCL16", "PROTEIN", 58, 64], ["DDX58", "PROTEIN", 78, 83], ["this study", "TEST", 3, 13], ["CCL2", "TEST", 46, 50], ["CCL5", "TEST", 52, 56], ["CXCL16", "TEST", 58, 64], ["TGF", "TEST", 66, 69], ["CCL2", "ANATOMY", 46, 50]]], ["TGF-\u03b21 is a multifunctional cytokine, secreted from various cells, and, in immunology, it regulates cellular proliferation, differentiation, and other cellular functions for a variety of cell types, especially regulatory T cells [51].", [["cells", "ANATOMY", 60, 65], ["cellular", "ANATOMY", 100, 108], ["cellular", "ANATOMY", 151, 159], ["cell", "ANATOMY", 187, 191], ["regulatory T cells", "ANATOMY", 210, 228], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 60, 65], ["cellular", "CELL", 100, 108], ["cellular", "CELL", 151, 159], ["cell", "CELL", 187, 191], ["T cells", "CELL", 221, 228], ["TGF-\u03b21", "PROTEIN", 0, 6], ["multifunctional cytokine", "PROTEIN", 12, 36], ["regulatory T cells", "CELL_TYPE", 210, 228], ["TGF", "TEST", 0, 3], ["a multifunctional cytokine", "PROBLEM", 10, 36], ["cellular proliferation", "OBSERVATION", 100, 122], ["cell types", "OBSERVATION", 187, 197]]], ["Some research has indicated that SARS-CoV papain-like protease (PLpro) increases TGF-\u03b21 mRNA expression and protein production in human promonocytes [52].", [["promonocytes", "ANATOMY", 136, 148], ["SARS-CoV papain-like protease", "GENE_OR_GENE_PRODUCT", 33, 62], ["PLpro", "SIMPLE_CHEMICAL", 64, 69], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 81, 87], ["human", "ORGANISM", 130, 135], ["SARS-CoV papain-like protease", "PROTEIN", 33, 62], ["PLpro", "PROTEIN", 64, 69], ["TGF-\u03b21 mRNA", "RNA", 81, 92], ["human", "SPECIES", 130, 135], ["SARS-CoV", "SPECIES", 33, 41], ["human", "SPECIES", 130, 135], ["SARS", "PROBLEM", 33, 37], ["CoV papain", "TREATMENT", 38, 48], ["protease (PLpro)", "TREATMENT", 54, 70], ["TGF", "TEST", 81, 84], ["protein production", "TEST", 108, 126]]], ["Further, Gomez-Laguna et al. [53] inferred that the upregulation of the TGF-\u03b2 may impair the host immune response during PRRSV infection by limiting the overproduction of proinflammatory cytokines necessary to decrease PRRSV replication.", [["PRRSV infection", "DISEASE", 121, 136], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 72, 77], ["PRRSV", "ORGANISM", 121, 126], ["PRRSV", "ORGANISM", 219, 224], ["TGF-\u03b2", "PROTEIN", 72, 77], ["proinflammatory cytokines", "PROTEIN", 171, 196], ["PRRSV", "SPECIES", 121, 126], ["PRRSV", "SPECIES", 219, 224], ["the TGF", "TEST", 68, 75], ["PRRSV infection", "PROBLEM", 121, 136], ["proinflammatory cytokines", "TREATMENT", 171, 196], ["PRRSV replication", "TREATMENT", 219, 236]]], ["In response to viral infection, DDX58 plays important roles in the recognition of RNA viruses in various cells, and has been identified as a candidate for a cytoplasmic viral dsRNA receptor [54].", [["cells", "ANATOMY", 105, 110], ["cytoplasmic", "ANATOMY", 157, 168], ["viral infection", "DISEASE", 15, 30], ["DDX58", "CHEMICAL", 32, 37], ["DDX58", "GENE_OR_GENE_PRODUCT", 32, 37], ["cells", "CELL", 105, 110], ["cytoplasmic", "ORGANISM_SUBSTANCE", 157, 168], ["DDX58", "PROTEIN", 32, 37], ["cytoplasmic viral dsRNA receptor", "PROTEIN", 157, 189], ["viral infection", "PROBLEM", 15, 30], ["RNA viruses in various cells", "PROBLEM", 82, 110], ["a cytoplasmic viral dsRNA receptor", "TREATMENT", 155, 189], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["RNA viruses", "OBSERVATION", 82, 93]]], ["Further, upregulation of this gene activates cells to produce type I interferons, which may increase the antiviral status of cells to protect against viral infection.", [["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 125, 130], ["viral infection", "DISEASE", 150, 165], ["cells", "CELL", 45, 50], ["type I interferons", "GENE_OR_GENE_PRODUCT", 62, 80], ["cells", "CELL", 125, 130], ["type I interferons", "PROTEIN", 62, 80], ["this gene activates cells", "TREATMENT", 25, 50], ["type I interferons", "TREATMENT", 62, 80], ["the antiviral status of cells", "TREATMENT", 101, 130], ["viral infection", "PROBLEM", 150, 165], ["infection", "OBSERVATION", 156, 165]]], ["In this regard, we found that interferon-inducible antiviral proteins, RSAD2, OAS1, were also upregulated in the period of late infection, suggesting that many of the proteins identified in this study are associated with inflammation, IFN activation, and the innate immune response.", [["infection", "DISEASE", 128, 137], ["inflammation", "DISEASE", 221, 233], ["interferon-inducible antiviral proteins", "GENE_OR_GENE_PRODUCT", 30, 69], ["RSAD2", "GENE_OR_GENE_PRODUCT", 71, 76], ["OAS1", "GENE_OR_GENE_PRODUCT", 78, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 235, 238], ["interferon", "PROTEIN", 30, 40], ["antiviral proteins", "PROTEIN", 51, 69], ["RSAD2", "PROTEIN", 71, 76], ["OAS1", "PROTEIN", 78, 82], ["IFN", "PROTEIN", 235, 238], ["interferon-inducible antiviral proteins", "PROBLEM", 30, 69], ["RSAD2", "TEST", 71, 76], ["late infection", "PROBLEM", 123, 137], ["the proteins", "PROBLEM", 163, 175], ["this study", "TEST", 190, 200], ["inflammation", "PROBLEM", 221, 233], ["IFN activation", "PROBLEM", 235, 249], ["antiviral proteins", "OBSERVATION", 51, 69], ["upregulated", "OBSERVATION_MODIFIER", 94, 105], ["late", "OBSERVATION_MODIFIER", 123, 127], ["infection", "OBSERVATION", 128, 137], ["associated with", "UNCERTAINTY", 205, 220], ["inflammation", "OBSERVATION", 221, 233]]], ["Increased expression of these proteins may help the virus enter the cell as well as potentially enhance TGEV replication or the host response against the virus, during the late stages of infection.DiscussionIn conclusion, we used the iTRAQ method to identify 316 significantly altered proteins in TGEV-infected ST cells.", [["cell", "ANATOMY", 68, 72], ["ST cells", "ANATOMY", 311, 319], ["infection", "DISEASE", 187, 196], ["cell", "CELL", 68, 72], ["TGEV", "ORGANISM", 104, 108], ["TGEV", "ORGANISM", 297, 301], ["ST cells", "CELL", 311, 319], ["TGEV-infected ST cells", "CELL_LINE", 297, 319], ["TGEV", "SPECIES", 104, 108], ["TGEV", "SPECIES", 297, 301], ["these proteins", "PROBLEM", 24, 38], ["TGEV replication", "TREATMENT", 104, 120], ["the virus", "PROBLEM", 150, 159], ["infection", "PROBLEM", 187, 196], ["the iTRAQ method", "TEST", 230, 246], ["significantly altered proteins in TGEV", "PROBLEM", 263, 301], ["infected ST cells", "PROBLEM", 302, 319], ["late stages", "OBSERVATION_MODIFIER", 172, 183], ["infection", "OBSERVATION", 187, 196], ["infected ST cells", "OBSERVATION", 302, 319]]], ["A larger number of protein expression changes occurred at 64 hpi compared to 48 hpi, indicating a larger shift in the proteome in the later stages of infection.", [["infection", "DISEASE", 150, 159], ["protein expression changes", "PROBLEM", 19, 45], ["a larger shift in the proteome", "PROBLEM", 96, 126], ["infection", "PROBLEM", 150, 159], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["protein expression", "OBSERVATION", 19, 37], ["larger", "OBSERVATION_MODIFIER", 98, 104], ["shift", "OBSERVATION", 105, 110], ["later stages", "OBSERVATION_MODIFIER", 134, 146], ["infection", "OBSERVATION", 150, 159]]], ["GO analysis of these differentially expressed proteins indicated that a number of diverse biological processes are affected.", [["diverse", "OBSERVATION_MODIFIER", 82, 89], ["biological processes", "OBSERVATION", 90, 110]]], ["In addition, many of the significant immune response related changes in protein expression we discovered are novel and, to our knowledge, have not been detected in previous proteome study.", [["the significant immune response", "PROBLEM", 21, 52], ["changes in protein expression", "PROBLEM", 61, 90], ["previous proteome study", "TEST", 164, 187], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["immune response", "OBSERVATION", 37, 52], ["protein expression", "OBSERVATION", 72, 90]]], ["Results from this study complement the previous proteomics data obtained concerning the host response to a viral infection, and further facilitates a better understanding of the pathogenic mechanisms of TGEV infection and molecular responses of host cells to this virus.", [["cells", "ANATOMY", 250, 255], ["viral infection", "DISEASE", 107, 122], ["infection", "DISEASE", 208, 217], ["TGEV", "ORGANISM", 203, 207], ["host cells", "CELL", 245, 255], ["host cells", "CELL_TYPE", 245, 255], ["TGEV", "SPECIES", 203, 207], ["this study complement", "TEST", 13, 34], ["the previous proteomics data", "TEST", 35, 63], ["a viral infection", "PROBLEM", 105, 122], ["TGEV infection", "PROBLEM", 203, 217], ["host cells", "PROBLEM", 245, 255], ["this virus", "PROBLEM", 259, 269], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122], ["host cells", "OBSERVATION", 245, 255]]]], "PMC7335940": [["IntroductionCovid-19 was confirmed as a widespread pandemic over Europe as of March 2020, affecting many industrial sectors.", [["IntroductionCovid", "TEST", 0, 17], ["widespread", "OBSERVATION_MODIFIER", 40, 50], ["pandemic", "OBSERVATION", 51, 59], ["industrial sectors", "OBSERVATION", 105, 123]]], ["The first coronavirus cases were reported in Italy on January 30, 2020.", [["coronavirus", "ORGANISM", 10, 21]]], ["The lockdown imposed the temporary closure of non-essential shops and businesses.", [["the temporary closure of non-essential shops", "TREATMENT", 21, 65], ["temporary closure", "OBSERVATION", 25, 42], ["non-essential shops", "OBSERVATION", 46, 65]]], ["For the UK, the government announced a state of lockdown on March 23 to close all but essential businesses.", [["businesses", "OBSERVATION", 96, 106]]], ["People were only allowed to go outside for shopping, basic necessities, health reasons, and one form of exercise a day, or work if it was deemed \u2018essential\u2019, such as firefighters, police, electricity provision, etc.IntroductionBelgium faced the highest per-capita COVID-19 death rate in Europe [1].", [["death", "DISEASE", 273, 278], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Stricter measures issued on March 17 ordered the closure of non-essential shops, prohibited non-essential travel, and banned all gatherings.", [["the closure of non-essential shops", "TREATMENT", 45, 79], ["non-essential shops", "OBSERVATION", 60, 79], ["non-essential travel", "OBSERVATION", 92, 112]]], ["In contrast, the Netherlands adopted less-restrictive measures to get the virus under control as much as possible.", [["less-restrictive measures", "TREATMENT", 37, 62], ["the virus under control", "TREATMENT", 70, 93]]], ["All large-scale public events and gatherings were banned, schools and day care centres were closed, and people were required to self-distance and to work from home wherever possible.", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["large", "OBSERVATION_MODIFIER", 4, 9], ["-scale", "OBSERVATION_MODIFIER", 9, 15]]], ["The measures were limited to recommendations for people with symptoms of respiratory infection and people over 70 to isolate themselves.IntroductionThis paper shows how different containment measures taken by European countries in response to COVID-19 reshaped the electricity consumption profile in these countries.", [["respiratory", "ANATOMY", 73, 84], ["respiratory infection", "DISEASE", 73, 94], ["COVID-19", "CHEMICAL", 243, 251], ["COVID-19", "CHEMICAL", 243, 251], ["people", "ORGANISM", 49, 55], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 49, 55], ["people", "SPECIES", 99, 105], ["symptoms", "PROBLEM", 61, 69], ["respiratory infection", "PROBLEM", 73, 94], ["COVID", "TEST", 243, 248], ["respiratory", "ANATOMY", 73, 84], ["infection", "OBSERVATION", 85, 94], ["different", "OBSERVATION_MODIFIER", 169, 178], ["containment", "OBSERVATION_MODIFIER", 179, 190]]], ["The results show that the change in peoples\u2019 activities in countries with different approaches is reflected in consumption profiles.Electricity consumption change amid the COVID-19 pandemicThe procedures implemented by the European governments to deal with the COVID-19 emergency have drastically changed peoples\u2019 habits and activities at the national level.", [["the COVID", "TEST", 168, 177], ["the COVID", "TREATMENT", 257, 266], ["change", "OBSERVATION_MODIFIER", 26, 32]]], ["This change in behaviour is reflected in the electricity systems, in particular in terms of changes in electricity consumption profiles.", [["This change in behaviour", "PROBLEM", 0, 24], ["electricity consumption", "OBSERVATION", 103, 126]]], ["This is illustrated in Fig. 1by comparing the electricity consumption profiles of Spain, Italy, Belgium, and the UK, all countries with population containment measures, with the Netherlands as a country with less restrictive measures, and Sweden which did not impose a lockdown.Electricity consumption change amid the COVID-19 pandemicThe comparisons are between a week after the pandemic had been announced, and a reference week from 2019.", [["population containment measures", "TREATMENT", 136, 167], ["less restrictive measures", "TREATMENT", 208, 233], ["the COVID", "TEST", 314, 323], ["less restrictive", "OBSERVATION_MODIFIER", 208, 224]]], ["The electricity demand is not only influenced by the day of the week and the time of the day, but it is also affected by weather changes.", [["electricity demand", "OBSERVATION", 4, 22]]], ["However, there are other factors which affect the demand, hence the comparisons cannot be perfect.Electricity consumption change amid the COVID-19 pandemicIn Fig. 1, the grey line shows the trend in total national electricity demand for the second week of April (i.e. 6\u201313 April 2020) and the blue line shows the demand for a reference week in 2019.", [["the COVID", "TEST", 134, 143], ["pandemicIn Fig", "TREATMENT", 147, 161], ["the grey line", "TEST", 166, 179], ["the blue line", "TREATMENT", 289, 302], ["grey line", "OBSERVATION", 170, 179], ["blue line", "OBSERVATION", 293, 302]]], ["A comparison of consumption profiles clearly shows that for all countries except Sweden, the national demand was reduced after the pandemic was declared.", [["A comparison of consumption profiles", "TEST", 0, 36]]], ["The state of alarm decreed by the governments and the gradual restriction on activities to deal with the COVID-19 pandemic have led to a considerable reduction in electricity demand.", [["the gradual restriction on activities", "TREATMENT", 50, 87], ["the COVID", "TREATMENT", 101, 110], ["a considerable reduction in electricity demand", "PROBLEM", 135, 181], ["considerable", "OBSERVATION_MODIFIER", 137, 149], ["reduction", "OBSERVATION_MODIFIER", 150, 159], ["electricity demand", "OBSERVATION", 163, 181]]], ["This is a direct consequence of population containment measures, and the closure of public and industrial centres as a means to curb the pandemic.Electricity consumption change amid the COVID-19 pandemicDuring the lockdown, there has been an increase in domestic demand as people have been spending more time at home.", [["people", "ORGANISM", 273, 279], ["people", "SPECIES", 273, 279], ["population containment measures", "TREATMENT", 32, 63], ["the COVID", "TEST", 182, 191], ["population", "OBSERVATION_MODIFIER", 32, 42], ["containment", "OBSERVATION", 43, 54], ["closure", "OBSERVATION_MODIFIER", 73, 80], ["increase", "OBSERVATION_MODIFIER", 242, 250], ["domestic demand", "OBSERVATION", 254, 269]]], ["However, as businesses have been shrinking their activities, the reduction in commercial and industrial demand has been far greater than the increase in domestic demand.", [["the reduction", "TREATMENT", 61, 74], ["reduction", "OBSERVATION_MODIFIER", 65, 74], ["increase", "OBSERVATION_MODIFIER", 141, 149], ["domestic demand", "OBSERVATION", 153, 168]]], ["In the case of Belgium, Elia, the Belgian transmission system operator, reported that the drop was more noticeable for consumers connected to the distribution grid compared to Elia\u2019s 149 industrial customers connected directly to the high-voltage grid [2].Electricity consumption change amid the COVID-19 pandemicFor Netherlands, remote working, the ban on public events and gatherings, and reduced activities have lowered the daily consumption.", [["the drop", "PROBLEM", 86, 94], ["Elia", "TEST", 176, 180]]], ["However, the usual evening peak remained, indicating that normal evening activities were still going on.", [["normal", "OBSERVATION", 58, 64]]], ["For Thursday evening and the subsequent long weekend, the consumption was even greater than for the reference week of 2019.Electricity consumption change amid the COVID-19 pandemicTo better compare the change in demand for the countries considered, a Demand Variation Index (DVI) is defined as follows, which presents the average reduction of demand compared to a reference period:(1)DVI=\u2211i=1nPtiold-Ptinewn\u00d7Pold-\u00d7100where Ptinew is the demand for time ti, Ptiold is the demand for the same time of a previous reference period, n is the number of recorded demands, and Pold- is the average demand during the previous reference period.Electricity consumption change amid the COVID-19 pandemic", [["the COVID", "TEST", 159, 168], ["a Demand Variation Index", "TEST", 249, 273], ["the COVID", "TEST", 670, 679]]]], "b0efe964a79591d17204c076f174aef315976cc9": [["UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company. populations, the US has 47X the number of cases and 79X the number of deaths.", [["cardiovascular", "ANATOMY", 132, 146], ["cardiovascular disease", "DISEASE", 132, 154], ["deaths", "DISEASE", 515, 521], ["cardiovascular", "ANATOMICAL_SYSTEM", 132, 146], ["Women", "SPECIES", 184, 189], ["inflammatory markers", "PROBLEM", 107, 127], ["cardiovascular disease", "PROBLEM", 132, 154], ["the US", "TEST", 458, 464], ["inflammatory", "OBSERVATION", 107, 119], ["cardiovascular disease", "OBSERVATION", 132, 154]]]], "PMC7370308": [["There are a lot of \u201csnakeoil salespeople\u201d and fraudsters out there, but universitiesare well-trusted and ideally placed to make a genuine difference.Be persistent (and polite) when dealingwith peopleinternally and externally.", [["persistent", "OBSERVATION_MODIFIER", 152, 162]]], ["You willbe surprisedby the number of people and organizations who want\u2014and areable\u2014to help you.", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43]]]], "804b3849f49f81c261bd5d738a47d2766ee87fd9": [["IntroductionMitigation of the ongoing COVID-19 pandemic requires reliable and accessible laboratory diagnostic services.", [["the ongoing COVID", "TEST", 26, 43]]], ["The specific diagnosis of SARS-CoV-2 infection relies on molecular methods, especially on RT-PCR, although other technologies including serologic immunoassays are emerging 1,2 .", [["SARS", "DISEASE", 26, 30], ["infection", "DISEASE", 37, 46], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV-2", "SPECIES", 26, 36], ["SARS", "PROBLEM", 26, 30], ["CoV", "PROBLEM", 31, 34], ["2 infection", "PROBLEM", 35, 46], ["molecular methods", "TEST", 57, 74], ["RT-PCR", "TEST", 90, 96], ["other technologies", "TEST", 107, 125], ["serologic immunoassays", "TEST", 136, 158]]], ["The first methods for SARS-CoV-2 detection were laboratory developed RT-PCR tests (LDTs), one of the first methods published was described by Corman et al. 3 .", [["SARS-CoV", "SPECIES", 22, 30], ["SARS", "TEST", 22, 26], ["RT-PCR tests", "TEST", 69, 81], ["LDTs", "TEST", 83, 87]]], ["Roche Molecular Systems (Branchburg, NJ, USA) cobas\u00ae SARS-Cov-2 test was the first commercial test to get EUA from FDA on March 12 2020.", [["Branchburg", "TEST", 25, 35], ["Cov", "TEST", 58, 61]]], ["Both LDTs and commercial tests have been set up in a high time pressure.", [["Both LDTs", "TEST", 0, 9], ["commercial tests", "TEST", 14, 30]]], ["Therefore, it is of great importance to evaluate the tests in clinical laboratory settings.", [["the tests", "TEST", 49, 58]]], ["In this study we evaluated the performance of one LDT and two commercial tests, namely cobas\u00ae SARS-CoV-2 (Roche) and recently CE/IVD marked Amplidiag\u00ae COVID-19 (Mobidiag, Espoo, Finland), for the detection of SARS-CoV-2 RNA in respiratory specimens.SpecimensAltogether 237 respiratory tract specimens referred to Helsinki University Hospital Laboratory (HUS Diagnostic Center, HUSLAB), Department of Virology and Immunology, Finland were included in this study.", [["respiratory specimens", "ANATOMY", 227, 248], ["respiratory tract specimens", "ANATOMY", 273, 300], ["HUS", "DISEASE", 354, 357], ["Roche", "ORGANISM", 106, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 209, 219], ["respiratory specimens", "CANCER", 227, 248], ["SARS-CoV-2 RNA", "RNA", 209, 223], ["SARS-CoV", "SPECIES", 209, 217], ["this study", "TEST", 3, 13], ["two commercial tests", "TEST", 58, 78], ["cobas", "TEST", 87, 92], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["CE", "TEST", 126, 128], ["IVD", "PROBLEM", 129, 132], ["COVID", "TEST", 151, 156], ["the detection", "TEST", 192, 205], ["SARS", "PROBLEM", 209, 213], ["CoV", "TEST", 214, 217], ["respiratory specimens", "TEST", 227, 248], ["Specimens", "TEST", 249, 258], ["respiratory tract specimens", "TEST", 273, 300], ["this study", "TEST", 450, 460], ["respiratory", "ANATOMY", 227, 238]]], ["54 specimens collected from patients with respiratory symptoms in 2018-2020 were used to verify analytical specificity of the tests.", [["specimens", "ANATOMY", 3, 12], ["respiratory", "ANATOMY", 42, 53], ["respiratory symptoms", "DISEASE", 42, 62], ["specimens", "CANCER", 3, 12], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["respiratory symptoms", "PROBLEM", 42, 62], ["the tests", "TEST", 122, 131]]], ["The specimens from 2020 were negative for SARS-CoV-2 RNA by the LDT.", [["specimens", "ANATOMY", 4, 13], ["SARS", "DISEASE", 42, 46], ["specimens", "CANCER", 4, 13], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["SARS-CoV-2 RNA", "RNA", 42, 56], ["SARS-CoV", "SPECIES", 42, 50], ["The specimens", "TEST", 0, 13], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50]]], ["183 specimens collected from suspected COVID-19 patients in 2020 were studied with all three methods to compare the performance of the tests in detecting SARS-CoV-2 RNA.", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["patients", "ORGANISM", 48, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["SARS-CoV-2 RNA", "RNA", 154, 168], ["patients", "SPECIES", 48, 56], ["SARS-CoV", "SPECIES", 154, 162], ["specimens", "TEST", 4, 13], ["suspected COVID", "TEST", 29, 44], ["the tests", "TEST", 131, 140], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162]]], ["Although most of the specimens tested were nasopharyngeal swabs, also oropharyngeal and nasal swabs were included due to the global shortage of the swab sticks needed for nasopharyngeal sampling.", [["specimens", "ANATOMY", 21, 30], ["nasopharyngeal swabs", "ANATOMY", 43, 63], ["oropharyngeal", "ANATOMY", 70, 83], ["nasal swabs", "ANATOMY", 88, 99], ["swab", "ANATOMY", 148, 152], ["nasopharyngeal", "ANATOMY", 171, 185], ["specimens", "CANCER", 21, 30], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 43, 63], ["oropharyngeal", "ORGANISM_SUBDIVISION", 70, 83], ["nasal swabs", "ORGANISM_SUBSTANCE", 88, 99], ["nasopharyngeal", "ORGAN", 171, 185], ["the specimens", "TEST", 17, 30], ["nasopharyngeal swabs", "TEST", 43, 63], ["oropharyngeal and nasal swabs", "TEST", 70, 99], ["the swab sticks", "TEST", 144, 159], ["nasopharyngeal sampling", "TREATMENT", 171, 194], ["nasopharyngeal", "ANATOMY", 43, 57], ["oropharyngeal", "ANATOMY", 70, 83], ["nasal", "ANATOMY", 88, 93]]], ["The specimens were collected either in Copan UTM (Copan, Brescia, Italy) or in tubes containing 0.9% saline due to the global shortage of Copan UTM tubes.", [["specimens", "ANATOMY", 4, 13], ["saline", "SIMPLE_CHEMICAL", 101, 107], ["The specimens", "TEST", 0, 13], ["tubes", "TREATMENT", 79, 84], ["0.9% saline", "TREATMENT", 96, 107], ["Copan UTM tubes", "TREATMENT", 138, 153]]], ["The suitability of the 0.9% saline tubes as alternative to viral transport media for SARS-CoV-2 testing has been shown before 5 .SpecimensThe specimens (n=183) deployed to compare the performance of the three studied RT-PCR methods comprised of two sets of specimens collected within two time frames.", [["Specimens", "ANATOMY", 129, 138], ["specimens", "ANATOMY", 142, 151], ["specimens", "ANATOMY", 257, 266], ["SARS", "DISEASE", 85, 89], ["SARS-CoV", "SPECIES", 85, 93], ["the 0.9% saline tubes", "TREATMENT", 19, 40], ["viral transport media", "TREATMENT", 59, 80], ["SARS", "PROBLEM", 85, 89], ["CoV-2 testing", "TEST", 90, 103], ["Specimens", "TEST", 129, 138], ["The specimens", "TEST", 138, 151], ["PCR methods", "TEST", 220, 231], ["specimens", "TEST", 257, 266]]], ["The first set of specimens (n=37) was part of the material used for the initial verification of cobas\u00ae SARS-CoV-2/Amplidiag\u00ae COVID-19 tests.", [["specimens", "ANATOMY", 17, 26], ["specimens", "TEST", 17, 26], ["cobas", "TEST", 96, 101], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["Amplidiag\u00ae COVID", "TREATMENT", 114, 130]]], ["These specimens were collected between March 5 and March 18, 2020, and the SARS-CoV-2 positive specimens (n=18) represent virus strains from the early epidemic.", [["specimens", "ANATOMY", 6, 15], ["specimens", "ANATOMY", 95, 104], ["specimens", "CANCER", 6, 15], ["SARS-CoV", "SPECIES", 75, 83], ["These specimens", "TEST", 0, 15], ["the SARS", "TEST", 71, 79], ["CoV", "TEST", 80, 83], ["virus strains", "PROBLEM", 122, 135], ["virus strains", "OBSERVATION", 122, 135], ["early", "OBSERVATION_MODIFIER", 145, 150], ["epidemic", "OBSERVATION_MODIFIER", 151, 159]]], ["The second set of specimens (n=146) were collected between May 4 and May 8 2020, and the positive specimens (n=90) thus represent strains from a declining phase of the epidemic in Finland.", [["specimens", "ANATOMY", 18, 27], ["specimens", "ANATOMY", 98, 107], ["specimens", "TEST", 18, 27], ["the positive specimens", "TEST", 85, 107], ["strains", "PROBLEM", 130, 137], ["declining", "OBSERVATION_MODIFIER", 145, 154], ["epidemic", "OBSERVATION_MODIFIER", 168, 176]]], ["Specimens were stored at -20 \u00b0C/-70 \u00b0C after initial analysis and were thawn upon analysis.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["initial analysis", "TEST", 45, 61], ["analysis", "TEST", 82, 90]]], ["Specimens were not thawn more than twice before RT-PCR.SpecimensIn addition, QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study proficiency samples (Glasgow, Scotland, UK) were used to evaluate the performance of the methods.SpecimensInactivation and lysing of the specimens All specimens were inactivated in a biosafety cabinet in a biosafety level 2 laboratory that has a negative pressure.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "ANATOMY", 234, 243], ["specimens", "ANATOMY", 274, 283], ["specimens", "ANATOMY", 288, 297], ["Specimens", "TEST", 0, 9], ["RT-PCR", "TEST", 48, 54], ["the specimens", "TEST", 270, 283], ["All specimens", "TEST", 284, 297], ["negative pressure", "OBSERVATION", 383, 400]]], ["At the beginning of the epidemic FFP3 mask, protective glasses and protective clothing were worn during working in the laboratory.", [["the epidemic FFP3 mask", "TREATMENT", 20, 42], ["protective glasses", "TREATMENT", 44, 62], ["protective clothing", "TREATMENT", 67, 86]]], ["Later in the epidemic visor and surgical mask replaced the FFP3 masks and protective glasses.Laboratory developed test (LDT), HUSLABThe possible SARS-CoV-2 in the specimen was inactivated by adding 250 \u00b5l of MagNA Pure Lysis/Binding Buffer (Roche Diagnostics GmbH, Mannheim, Germany) to 250 \u00b5l of patient specimen.", [["specimen", "ANATOMY", 163, 171], ["specimen", "ANATOMY", 305, 313], ["patient", "ORGANISM", 297, 304], ["patient", "SPECIES", 297, 304], ["SARS-CoV", "SPECIES", 145, 153], ["surgical mask", "TREATMENT", 32, 45], ["the FFP3 masks", "TREATMENT", 55, 69], ["protective glasses", "TREATMENT", 74, 92], ["test", "TEST", 114, 118], ["LDT", "TEST", 120, 123], ["HUSLABThe", "TEST", 126, 135], ["SARS", "PROBLEM", 145, 149], ["CoV", "TEST", 150, 153], ["MagNA Pure Lysis", "TREATMENT", 208, 224], ["patient specimen", "TEST", 297, 313], ["surgical mask", "OBSERVATION", 32, 45], ["protective glasses", "OBSERVATION", 74, 92]]], ["Lysates were incubated for a minimum of 10 minutes before processed further.Cobas\u00ae SARS-CoV-2If needed, the specimens were first equilibrated to room temperature, after which the possible SARS-CoV-2 in the specimen was inactivated by adding 350 \u00b5l of MagNA Pure Lysis/Binding Buffer (Roche Diagnostics GmbH, Mannheim, Germany) to 350 \u00b5l of patient specimen.", [["Lysates", "ANATOMY", 0, 7], ["specimens", "ANATOMY", 108, 117], ["specimen", "ANATOMY", 206, 214], ["specimen", "ANATOMY", 348, 356], ["SARS", "DISEASE", 188, 192], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Cobas\u00ae", "SIMPLE_CHEMICAL", 76, 82], ["specimens", "CELL", 108, 117], ["patient", "ORGANISM", 340, 347], ["patient", "SPECIES", 340, 347], ["Lysates", "TEST", 0, 7], ["Cobas\u00ae SARS", "PROBLEM", 76, 87], ["the specimens", "TEST", 104, 117], ["SARS", "PROBLEM", 188, 192], ["CoV", "TEST", 193, 196], ["MagNA Pure Lysis", "TREATMENT", 251, 267], ["patient specimen", "TEST", 340, 356]]], ["Lysates were incubated for a minimum of 10 minutes before processed further.Amplidiag\u00ae COVID-19The possible SARS-CoV-2 in the specimen was inactivated either by adding 600 \u00b5l of the specimen to an eNAT-tube (Copan) or 360 \u00b5l to an mNAT-tube (Mobidiag). eNAT tubes were incubated for a minimum of 30 minutes and mNAT-tubes for a minimum of 5 minutes before processed further.Laboratory developed test (LDT), HUSLABThe real-time LDT SARS-CoV-2 RT-PCR used in this study is a modification of the method published by Corman et al. 3 .", [["Lysates", "ANATOMY", 0, 7], ["specimen", "ANATOMY", 126, 134], ["specimen", "ANATOMY", 182, 190], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["specimen", "CANCER", 126, 134], ["eNAT-tube", "TISSUE", 197, 206], ["mNAT-tube", "TISSUE", 231, 240], ["SARS-CoV-2", "DNA", 108, 118], ["Lysates", "TEST", 0, 7], ["Amplidiag\u00ae COVID", "TREATMENT", 76, 92], ["SARS", "PROBLEM", 108, 112], ["CoV", "TEST", 113, 116], ["an eNAT-tube (Copan)", "TREATMENT", 194, 214], ["an mNAT-tube (Mobidiag)", "TREATMENT", 228, 251], ["eNAT tubes", "TREATMENT", 253, 263], ["mNAT-tubes", "TREATMENT", 311, 321], ["test", "TEST", 395, 399], ["LDT", "TEST", 401, 404], ["HUSLABThe", "TEST", 407, 416], ["LDT SARS", "TEST", 427, 435], ["CoV", "TEST", 436, 439], ["PCR", "TEST", 445, 448], ["this study", "TEST", 457, 467], ["tube", "OBSERVATION", 202, 206], ["tube", "OBSERVATION", 236, 240], ["NAT tubes", "OBSERVATION", 254, 263], ["tubes", "OBSERVATION", 316, 321]]], ["The test is suitable for detection of SARS-CoV-2 RNA from sputum, nasopharyngeal/tracheal aspirates, nasal, nasopharyngeal and oropharyngeal swab specimens and faeces.", [["sputum", "ANATOMY", 58, 64], ["nasopharyngeal", "ANATOMY", 66, 80], ["tracheal aspirates", "ANATOMY", 81, 99], ["nasal", "ANATOMY", 101, 106], ["nasopharyngeal", "ANATOMY", 108, 122], ["oropharyngeal swab specimens", "ANATOMY", 127, 155], ["faeces", "ANATOMY", 160, 166], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["sputum", "ORGANISM_SUBSTANCE", 58, 64], ["nasopharyngeal", "CANCER", 66, 80], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 81, 99], ["nasal", "ORGANISM_SUBDIVISION", 101, 106], ["nasopharyngeal", "CANCER", 108, 122], ["oropharyngeal swab specimens", "ORGANISM_SUBSTANCE", 127, 155], ["faeces", "ORGANISM_SUBSTANCE", 160, 166], ["SARS-CoV-2 RNA", "RNA", 38, 52], ["SARS-CoV", "SPECIES", 38, 46], ["The test", "TEST", 0, 8], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["sputum", "TEST", 58, 64], ["nasopharyngeal/tracheal aspirates", "TEST", 66, 99], ["nasal, nasopharyngeal and oropharyngeal swab specimens", "TEST", 101, 155], ["nasopharyngeal", "ANATOMY", 66, 80], ["tracheal", "ANATOMY", 81, 89], ["aspirates", "OBSERVATION", 90, 99], ["nasal", "ANATOMY", 101, 106], ["nasopharyngeal", "ANATOMY", 108, 122], ["oropharyngeal", "ANATOMY", 127, 140]]], ["Initially, all target genes (E, RdRP and N) were included in the diagnostic assay.", [["target genes", "DNA", 15, 27], ["E", "DNA", 29, 30], ["RdRP", "DNA", 32, 36], ["N", "DNA", 41, 42], ["RdRP and N)", "TREATMENT", 32, 43], ["the diagnostic assay", "TEST", 61, 81]]], ["In addition, a PCR for beta-globin gene 6Cobas SARS-CoV-2 testThe cobas\u00ae SARS-CoV-2 test (Roche Molecular Systems) is a qualitative test for fully automated cobas\u00ae 6800/8800 platforms.", [["beta-globin", "GENE_OR_GENE_PRODUCT", 23, 34], ["beta-globin gene", "DNA", 23, 39], ["SARS-CoV", "SPECIES", 73, 81], ["a PCR", "TEST", 13, 18], ["beta-globin gene", "TEST", 23, 39], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["The cobas\u00ae SARS", "TEST", 62, 77], ["CoV", "TEST", 78, 81], ["a qualitative test", "TEST", 118, 136]]], ["The test is validated to detect SARS-CoV-2 RNA from nasal, nasopharyngeal and oropharyngeal swab specimens.", [["nasal", "ANATOMY", 52, 57], ["nasopharyngeal", "ANATOMY", 59, 73], ["oropharyngeal swab specimens", "ANATOMY", 78, 106], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["nasal", "ORGANISM_SUBDIVISION", 52, 57], ["nasopharyngeal", "CANCER", 59, 73], ["oropharyngeal swab specimens", "CANCER", 78, 106], ["SARS-CoV-2 RNA", "RNA", 32, 46], ["SARS-CoV", "SPECIES", 32, 40], ["The test", "TEST", 0, 8], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["nasal, nasopharyngeal and oropharyngeal swab specimens", "TEST", 52, 106], ["nasal", "ANATOMY", 52, 57], ["nasopharyngeal", "ANATOMY", 59, 73], ["oropharyngeal swab", "ANATOMY", 78, 96]]], ["The test amplifies two SARS-CoV-2 targets: orf1ab (Target 1), which is specific for SARS-CoV-2 and a conserved region of the E-gene (Target 2), which is pan-Sarbeco specific and detects also SARS-CoV and other Sarbecoviruses currently unknown to infect humans.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["orf1ab (Target 1", "GENE_OR_GENE_PRODUCT", 43, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 94], ["Target 2", "GENE_OR_GENE_PRODUCT", 133, 141], ["SARS-CoV", "ORGANISM", 191, 199], ["humans", "ORGANISM", 253, 259], ["SARS-CoV-2 targets", "DNA", 23, 41], ["orf1ab", "DNA", 43, 49], ["Target 1", "DNA", 51, 59], ["SARS-CoV-2", "DNA", 84, 94], ["E-gene", "DNA", 125, 131], ["Target 2", "DNA", 133, 141], ["humans", "SPECIES", 253, 259], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 191, 199], ["humans", "SPECIES", 253, 259], ["The test", "TEST", 0, 8], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["SARS", "PROBLEM", 191, 195], ["other Sarbecoviruses", "PROBLEM", 204, 224]]], ["In addition, the test includes an internal RNA-control (IC), which is added to the specimens before extraction.", [["specimens", "ANATOMY", 83, 92], ["the test", "TEST", 13, 21], ["an internal RNA-control (IC)", "TREATMENT", 31, 59], ["extraction", "TREATMENT", 100, 110]]], ["The test includes also positive and negative controls, which are processed the same way as the samples.Cobas SARS-CoV-2 test8 600 \u00b5l of specimen lysate was subjected to cobas\u00ae 6800 system.", [["samples", "ANATOMY", 95, 102], ["specimen lysate", "ANATOMY", 136, 151], ["The test", "TEST", 0, 8], ["Cobas SARS", "TEST", 103, 113], ["CoV", "TEST", 114, 117], ["specimen lysate", "TEST", 136, 151]]], ["Testing was performed according to the manufacturer's instructions apart from the inactivation step.Amplidiag COVID-19 testThe Amplidiag\u00ae COVID-19 test (Mobidiag) is a qualitative test for the detection of SARS-CoV-2 RNA in nasopharyngeal specimens.", [["nasopharyngeal specimens", "ANATOMY", 224, 248], ["SARS", "DISEASE", 206, 210], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 206, 216], ["nasopharyngeal specimens", "CANCER", 224, 248], ["Amplidiag\u00ae COVID-19 test", "DNA", 127, 151], ["SARS-CoV-2 RNA", "RNA", 206, 220], ["SARS-CoV", "SPECIES", 206, 214], ["Testing", "TEST", 0, 7], ["the inactivation step", "PROBLEM", 78, 99], ["Amplidiag COVID", "TEST", 100, 115], ["a qualitative test", "TEST", 166, 184], ["the detection", "TEST", 189, 202], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214], ["nasopharyngeal specimens", "TEST", 224, 248], ["nasopharyngeal", "ANATOMY", 224, 238]]], ["The test amplifies two SARS-CoV-2 targets: orf1ab and N-gene, which are both specific for SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["orf1ab", "GENE_OR_GENE_PRODUCT", 43, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["SARS-CoV-2 targets", "DNA", 23, 41], ["orf1ab and N-gene", "DNA", 43, 60], ["SARS-CoV", "SPECIES", 90, 98], ["The test", "TEST", 0, 8], ["orf1ab", "TREATMENT", 43, 49]]], ["In addition, the test amplifies the human RNase P gene (RP), which serves as a sampling control.", [["human", "ORGANISM", 36, 41], ["RNase P", "GENE_OR_GENE_PRODUCT", 42, 49], ["human RNase P gene", "DNA", 36, 54], ["RP", "DNA", 56, 58], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["the test", "TEST", 13, 21], ["a sampling control", "TREATMENT", 77, 95]]], ["The test includes positive and negative control.Amplidiag COVID-19 testeNAT or mNAT tubes were subjected to Amplidiag\u00ae Easy system, which extracts nucleic acids and does the PCR setup.", [["mNAT tubes", "ANATOMY", 79, 89], ["nucleic acids", "CHEMICAL", 147, 160], ["mNAT tubes", "ORGANISM_SUBSTANCE", 79, 89], ["The test", "TEST", 0, 8], ["Amplidiag COVID", "TREATMENT", 48, 63], ["mNAT tubes", "TREATMENT", 79, 89], ["nucleic acids", "TEST", 147, 160], ["the PCR setup", "TREATMENT", 170, 183]]], ["The PCR plate was then transferred to a real time PCR-machine (CFX-96, Bio-Rad, Hercules, CA, USA), which contains the Amplidiag\u00ae Analyzer software.", [["The PCR plate", "TEST", 0, 13], ["CFX", "TEST", 63, 66], ["Bio", "TEST", 71, 74], ["Hercules", "TEST", 80, 88]]], ["Testing was performed according to the manufacturer's instructions, apart from the specimen type (validated only for nasopharyngeal specimens) and inactivation step with eNAT-tubes.", [["specimen", "ANATOMY", 83, 91], ["nasopharyngeal specimens", "ANATOMY", 117, 141], ["nasopharyngeal specimens", "CANCER", 117, 141], ["eNAT", "PROTEIN", 170, 174], ["Testing", "TEST", 0, 7], ["the specimen type", "TEST", 79, 96], ["nasopharyngeal specimens", "TEST", 117, 141], ["eNAT-tubes", "TREATMENT", 170, 180], ["tubes", "OBSERVATION", 175, 180]]], ["Verification of the performance of all three studied methods on specimens collected to Copan UTM versus 0.9 % saline and using eNAT versus mNAT in the lysing/inactivation step with Amplidiag COVID-19 test When the epidemic started, the specimens were collected to Copan UTM tubes (3 ml), but later to tubes containing 1.5 ml of 0.9% saline, because of the global shortage in supply of the Copan tubes.", [["specimens", "ANATOMY", 64, 73], ["specimens", "ANATOMY", 236, 245], ["mNAT", "CHEMICAL", 139, 143], ["saline", "SIMPLE_CHEMICAL", 110, 116], ["mNAT", "SIMPLE_CHEMICAL", 139, 143], ["saline", "SIMPLE_CHEMICAL", 333, 339], ["specimens", "TEST", 64, 73], ["Copan UTM", "TREATMENT", 87, 96], ["0.9 % saline", "TREATMENT", 104, 116], ["eNAT", "TREATMENT", 127, 131], ["mNAT", "TREATMENT", 139, 143], ["the lysing/inactivation step", "TREATMENT", 147, 175], ["Amplidiag COVID", "TREATMENT", 181, 196], ["the specimens", "TEST", 232, 245], ["Copan UTM tubes", "TREATMENT", 264, 279], ["0.9% saline", "TREATMENT", 328, 339], ["the Copan tubes", "TREATMENT", 385, 400], ["global", "OBSERVATION_MODIFIER", 356, 362], ["shortage", "OBSERVATION_MODIFIER", 363, 371], ["Copan tubes", "OBSERVATION", 389, 400]]], ["A patient specimen known to contain SARS-CoV-2 RNA originally collected to Copan tube was diluted to pooled Copan-collected negative specimen. (ii).", [["specimen", "ANATOMY", 10, 18], ["specimen", "ANATOMY", 133, 141], ["SARS", "DISEASE", 36, 40], ["patient", "ORGANISM", 2, 9], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["Copan tube", "TISSUE", 75, 85], ["SARS-CoV-2 RNA", "RNA", 36, 50], ["patient", "SPECIES", 2, 9], ["A patient specimen", "TEST", 0, 18], ["SARS", "PROBLEM", 36, 40], ["CoV-2 RNA", "TREATMENT", 41, 50], ["Copan tube", "TREATMENT", 75, 85], ["SARS", "OBSERVATION", 36, 40]]], ["A patient specimen known to contain SARS-CoV-2 RNA originally collected to 0.9% saline was diluted to pooled 0.9% saline-collected negative specimen.", [["specimen", "ANATOMY", 10, 18], ["specimen", "ANATOMY", 140, 148], ["SARS", "DISEASE", 36, 40], ["patient", "ORGANISM", 2, 9], ["saline", "SIMPLE_CHEMICAL", 80, 86], ["saline", "SIMPLE_CHEMICAL", 114, 120], ["SARS-CoV-2 RNA", "RNA", 36, 50], ["patient", "SPECIES", 2, 9], ["A patient specimen", "TEST", 0, 18], ["SARS", "PROBLEM", 36, 40], ["CoV-2 RNA", "TREATMENT", 41, 50], ["saline", "TREATMENT", 80, 86], ["SARS", "OBSERVATION", 36, 40]]], ["The ct-value for SARS-CoV-2 detection by RT-PCR was around 24 for both the Copan-collected and saline-collected original positive specimens.", [["specimens", "ANATOMY", 130, 139], ["SARS", "DISEASE", 17, 21], ["saline", "SIMPLE_CHEMICAL", 95, 101], ["SARS-CoV", "SPECIES", 17, 25], ["The ct-value", "TEST", 0, 12], ["SARS", "PROBLEM", 17, 21], ["CoV", "TEST", 22, 25], ["RT-PCR", "TEST", 41, 47], ["the Copan", "TEST", 71, 80], ["saline", "TREATMENT", 95, 101], ["positive specimens", "OBSERVATION", 121, 139]]], ["A dilution series of 1:10 -1:100000 for both specimens (in Copan UTM or saline) in respective specimen pools were constructed and analyzed with all three studied methods.Amplidiag COVID-19 testDue to the shortage of the eNAT tubes a change to mNAT tubes was necessary.Amplidiag COVID-19 testThis change was evaluated with a small number of specimens.", [["specimens", "ANATOMY", 45, 54], ["specimen", "ANATOMY", 94, 102], ["specimens", "ANATOMY", 340, 349], ["saline", "SIMPLE_CHEMICAL", 72, 78], ["COVID-19 test", "DNA", 278, 291], ["A dilution series", "TEST", 0, 17], ["specimens", "TEST", 45, 54], ["saline", "TREATMENT", 72, 78], ["Amplidiag COVID", "TREATMENT", 170, 185], ["the eNAT tubes", "TREATMENT", 216, 230], ["mNAT tubes", "TREATMENT", 243, 253], ["Amplidiag COVID", "TREATMENT", 268, 283], ["tubes", "OBSERVATION", 225, 230], ["tubes", "OBSERVATION", 248, 253], ["small", "OBSERVATION_MODIFIER", 324, 329]]], ["Eleven specimens defined positive by the cobas\u00ae test were inactivated/lysed in parallel by pipetting the specimen to an mNAT and eNAT tube and analyzed in the same PCR run.Analytical specificityThe analytical specificity of the tests was studied by analyzing patient specimens containing other respiratory viruses.", [["specimens", "ANATOMY", 7, 16], ["specimen", "ANATOMY", 105, 113], ["specimens", "ANATOMY", 267, 276], ["respiratory viruses", "DISEASE", 294, 313], ["cobas\u00ae", "ORGANISM", 41, 47], ["eNAT tube", "TISSUE", 129, 138], ["patient", "ORGANISM", 259, 266], ["mNAT", "DNA", 120, 124], ["patient", "SPECIES", 259, 266], ["Eleven specimens", "TEST", 0, 16], ["the cobas\u00ae test", "TEST", 37, 52], ["an mNAT and eNAT tube", "TREATMENT", 117, 138], ["Analytical specificity", "TEST", 172, 194], ["the tests", "TEST", 224, 233], ["analyzing patient specimens", "TEST", 249, 276], ["other respiratory viruses", "PROBLEM", 288, 313], ["tube", "OBSERVATION", 134, 138], ["respiratory viruses", "OBSERVATION", 294, 313]]], ["Altogether 54 specimens were included, but not all samples were run with all three methods.", [["specimens", "ANATOMY", 14, 23], ["samples", "ANATOMY", 51, 58], ["specimens", "CANCER", 14, 23], ["Altogether 54 specimens", "TEST", 0, 23]]], ["Some of the specimens contained several viruses (n=11).", [["specimens", "ANATOMY", 12, 21], ["the specimens", "TEST", 8, 21], ["several viruses", "PROBLEM", 32, 47], ["several", "OBSERVATION_MODIFIER", 32, 39], ["viruses", "OBSERVATION_MODIFIER", 40, 47]]], ["In four specimens, the presence of a respiratory virus nucleic acid was defined by xTAG RVP Fast (Luminex Diagnostics, Toronto, Canada) assay, and in 50 specimens by the Allplex Respiratory Panel 1/2/3 (Seegene, Seoul, Republic of Korea).", [["specimens", "ANATOMY", 8, 17], ["specimens", "ANATOMY", 153, 162], ["nucleic acid", "CHEMICAL", 55, 67], ["a respiratory virus nucleic acid", "PROBLEM", 35, 67], ["Respiratory Panel", "TEST", 178, 195], ["respiratory virus", "OBSERVATION", 37, 54]]], ["The specimens were chosen to contain moderate to high concentrations of viral nucleic acids (ct-value <30 for specimens by Seegene test or high mean fluorescence intensity for Luminex test).", [["specimens", "ANATOMY", 4, 13], ["specimens", "ANATOMY", 110, 119], ["nucleic acids", "CHEMICAL", 78, 91], ["The specimens", "TEST", 0, 13], ["viral nucleic acids", "TEST", 72, 91], ["ct-value", "TEST", 93, 101], ["Seegene test", "TEST", 123, 135], ["Luminex test", "TEST", 176, 188], ["moderate", "OBSERVATION_MODIFIER", 37, 45]]], ["The specimens were collected during 2018-2020 representing recent virus strains in Finland.", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["The specimens", "TEST", 0, 13], ["recent virus strains", "PROBLEM", 59, 79], ["virus strains", "OBSERVATION", 66, 79]]], ["The specimens are described in Table 1 .Analytical specificityStatistical methods sided 95% confidence intervals (CI) were calculated with an on-line MEDCALC\u00ae tool (https://www.medcalc.org/calc/diagnostic_test.php).", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["Analytical specificity", "TEST", 40, 62], ["CI", "TEST", 114, 116]]], ["The overall agreement of the evaluated assays was evaluated by the kappa value, which was calculated (including two-sided 95% CI) with an on-line QuickCalcs tool (https://www.graphpad.com/quickcalcs/kappa1/).", [["the evaluated assays", "TEST", 25, 45], ["an on-line QuickCalcs tool", "TEST", 135, 161]]], ["Kappa values were interpreted as follows: No agreement (< 0), slight agreement (0-0.20), fair agreement (0.21-0.40), moderate agreement (0.41-0.60), substantial agreement (0.61-0.80), and almost perfect agreement (0.81-1).", [["Kappa", "GENE_OR_GENE_PRODUCT", 0, 5], ["Kappa values", "TEST", 0, 12]]], ["All values were calculated relative to the reference standard, which was established as the result obtained by two of the three studied methods.Analytical specificityThe significance of the difference of the ct values obtained by Amplidiag\u00ae test from eNAT vs mNAT tubes was estimated by two tailed students T-test.", [["All values", "TEST", 0, 10], ["Analytical specificity", "TEST", 144, 166], ["the ct values", "TEST", 204, 217], ["Amplidiag\u00ae test", "TEST", 230, 245], ["mNAT tubes", "TREATMENT", 259, 269]]], ["P-value < 0.05 was considered significant.ResultsClinical performance of the evaluated assays Altogether, 183 specimens were analyzed by all three evaluated methods.", [["specimens", "ANATOMY", 110, 119], ["P", "TEST", 0, 1], ["the evaluated assays", "TEST", 73, 93], ["specimens", "TEST", 110, 119]]], ["One specimen gave an invalid result by cobas\u00ae SARS-Cov-2 test (0.5%), two specimens had an incorrect amount of specimen lysate in LDT and were therefore considered invalid (1.1%), and 10 specimens gave failed results by Amplidiag\u00ae COVID-19 test (5.5%).", [["specimen", "ANATOMY", 4, 12], ["specimens", "ANATOMY", 74, 83], ["specimen lysate", "ANATOMY", 111, 126], ["specimens", "ANATOMY", 187, 196], ["One specimen", "TEST", 0, 12], ["cobas\u00ae SARS", "TEST", 39, 50], ["Cov-2 test", "TEST", 51, 61], ["two specimens", "TEST", 70, 83], ["specimen lysate", "TEST", 111, 126], ["LDT", "TEST", 130, 133], ["Amplidiag\u00ae COVID", "TEST", 220, 236]]], ["The failed/invalid specimens were excluded from the agreement analysis.", [["specimens", "ANATOMY", 19, 28], ["specimens", "CANCER", 19, 28], ["The failed/invalid specimens", "PROBLEM", 0, 28], ["the agreement analysis", "TEST", 48, 70]]], ["In relation to the reference standard the positive percent agreement (PPA) was highest for cobas\u00ae test (100%), followed by Amplidiag\u00ae test (98.9%) and the LDT (98.9%).", [["cobas\u00ae test", "TEST", 91, 102], ["Amplidiag\u00ae test", "TEST", 123, 138], ["the LDT", "TEST", 151, 158]]], ["Negative percent agreement (NPA) was lowest for cobas\u00ae test (89.4%), followed by Amplidiag\u00ae test (98.8%) and the best specificity value was obtained for LDT (100%).", [["cobas\u00ae test", "TEST", 48, 59], ["Amplidiag\u00ae test", "TEST", 81, 96], ["LDT", "TEST", 153, 156]]], ["The overall agreement as defined by kappa-value was excellent for all studied tests ( (Table 3) .ResultsPerformance comparison of the evaluated methods on specimens collected to Copan UTM versus 0.9 % saline Two independent dilution series of two positive specimens were constructed to 0.9% saline and copan UTM in respiratory specimen matrix to verify that specimens collected to Copan and saline perform at the same level with the evaluated methods.", [["specimens", "ANATOMY", 155, 164], ["specimens", "ANATOMY", 256, 265], ["respiratory specimen matrix", "ANATOMY", 315, 342], ["specimens", "ANATOMY", 358, 367], ["Copan", "CHEMICAL", 381, 386], ["saline", "SIMPLE_CHEMICAL", 201, 207], ["saline", "SIMPLE_CHEMICAL", 291, 297], ["Copan", "SIMPLE_CHEMICAL", 381, 386], ["saline", "SIMPLE_CHEMICAL", 391, 397], ["all studied tests", "TEST", 66, 83], ["specimens", "TEST", 155, 164], ["Copan UTM", "TREATMENT", 178, 187], ["0.9 % saline", "TREATMENT", 195, 207], ["0.9% saline", "TREATMENT", 286, 297], ["copan", "TREATMENT", 302, 307], ["respiratory specimen matrix", "TREATMENT", 315, 342], ["specimens", "TEST", 358, 367], ["Copan", "TREATMENT", 381, 386], ["saline", "TREATMENT", 391, 397]]], ["The results indicate similar performance of all three methods independent of the collection media used (Table 4 and Figure 1 ).", [["the collection media", "TREATMENT", 77, 97]]], ["However, the data suggest higher overall sensitivity for the cobas\u00ae test as the (Table 5 ).", [["the data", "TEST", 9, 17], ["the cobas\u00ae test", "TEST", 57, 72]]], ["However, the test identified correctly another sample containing SARS-CoV-2 RNA 2.3 log10 copies/ml.", [["sample", "ANATOMY", 47, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 65, 75], ["SARS-CoV-2 RNA", "RNA", 65, 79], ["SARS-CoV", "SPECIES", 65, 73], ["the test", "TEST", 9, 17], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73]]], ["Amplidiag\u00ae test reported four samples as failed because the EQA samples lack human RNase P target needed for valid negative results with the test.Analytical specificityNone of the studied SARS-CoV-2 tests gave positive result from patient specimens containing other respiratory viruses (Table 1) .Discrepant analysesAltogether, there were 12 discrepant results.", [["samples", "ANATOMY", 30, 37], ["specimens", "ANATOMY", 239, 248], ["SARS", "DISEASE", 188, 192], ["respiratory viruses", "DISEASE", 266, 285], ["human", "ORGANISM", 77, 82], ["RNase", "GENE_OR_GENE_PRODUCT", 83, 88], ["SARS-CoV-2", "ORGANISM", 188, 198], ["patient", "ORGANISM", 231, 238], ["human RNase P target", "DNA", 77, 97], ["human", "SPECIES", 77, 82], ["patient", "SPECIES", 231, 238], ["human", "SPECIES", 77, 82], ["SARS-CoV", "SPECIES", 188, 196], ["Amplidiag\u00ae test", "TEST", 0, 15], ["the EQA samples", "TEST", 56, 71], ["the test", "TEST", 137, 145], ["Analytical specificity", "TEST", 146, 168], ["the studied SARS", "TEST", 176, 192], ["CoV-2 tests", "TEST", 193, 204], ["positive result", "PROBLEM", 210, 225], ["patient specimens", "TEST", 231, 248], ["other respiratory viruses", "PROBLEM", 260, 285], ["Discrepant analyses", "TEST", 297, 316], ["respiratory viruses", "OBSERVATION", 266, 285]]], ["In one specimen, which only gave a positive result with Amplidiag\u00ae the positive signal was obtained for the orf1ab target with ct value of 40.8.", [["specimen", "ANATOMY", 7, 15], ["Amplidiag\u00ae", "SIMPLE_CHEMICAL", 56, 66], ["the orf1ab target", "TEST", 104, 121], ["ct value", "TEST", 127, 135]]], ["However, in the amplification curve provided by Amplidiag\u00ae analyzer software no specific amplification could be seen.", [["the amplification curve", "TEST", 12, 35]]], ["Instead of the expected logarithmic rise in the fluorescence signal, only a slow rise in background signal was seen (data not shown).", [["the fluorescence signal", "TEST", 44, 67], ["a slow rise in background signal", "PROBLEM", 74, 106], ["logarithmic", "OBSERVATION_MODIFIER", 24, 35], ["rise", "OBSERVATION_MODIFIER", 36, 40], ["slow", "OBSERVATION_MODIFIER", 76, 80], ["rise", "OBSERVATION_MODIFIER", 81, 85]]], ["For 1 specimen a positive result was obtained with cobas\u00ae and Amplidiag\u00ae tests, but a negative result with LDT.", [["specimen", "ANATOMY", 6, 14], ["cobas\u00ae", "SIMPLE_CHEMICAL", 51, 57], ["Amplidiag\u00ae tests", "TEST", 62, 78], ["LDT", "TEST", 107, 110]]], ["In one specimen positive results were obtained for cobas\u00ae test and LDT, while the Amplidiag\u00ae test gave a negative result.", [["specimen", "ANATOMY", 7, 15], ["cobas\u00ae test", "TEST", 51, 62], ["LDT", "TEST", 67, 70], ["the Amplidiag\u00ae test", "TEST", 78, 97]]], ["In that case the specimen had gone through 2 freeze-thaw cycles before it was analyzed by Amplidiag\u00ae test, but only one or none when analyzed by cobas\u00ae or LTD tests, respectively.", [["specimen", "ANATOMY", 17, 25], ["cobas\u00ae", "SIMPLE_CHEMICAL", 145, 151], ["Amplidiag\u00ae test", "TEST", 90, 105], ["LTD tests", "TEST", 155, 164]]], ["In 9 specimens a positive result was obtained only by cobas\u00ae test.", [["specimens", "ANATOMY", 5, 14]]], ["However, positive result was obtained for two specimens, when rerun with the new Amplidiag\u00ae COVID-19 software version.", [["specimens", "ANATOMY", 46, 55], ["two specimens", "TEST", 42, 55], ["the new Amplidiag\u00ae COVID", "TREATMENT", 73, 97]]], ["In all 9 specimens positive signal was obtained for both amplification targets of the test, but the ct values were high, >30 for 8/9 specimens.", [["specimens", "ANATOMY", 9, 18], ["specimens", "ANATOMY", 133, 142], ["the test", "TEST", 82, 90], ["the ct values", "TEST", 96, 109]]], ["(Table 6B )DiscussionIn general, all tested assays performed adequately.", [["all tested assays", "TEST", 33, 50]]], ["Both the time from sample to result and hands-on time per sample were shortest for cobas\u00ae test.", [["cobas\u00ae test", "TEST", 83, 94], ["hands", "ANATOMY", 40, 45]]], ["The cobas\u00ae and Amplidiag\u00ae assays allow for an automatic transfer of the results to the laboratory information system.", [["cobas\u00ae", "SIMPLE_CHEMICAL", 4, 10], ["Amplidiag\u00ae assays", "TEST", 15, 32]]], ["On the other hand, both LDT and Amplidag\u00ae allow for the evaluation of the actual amplification curves, which is very important for the quality assurance of the results, especially when the tests have been set up in a straining timetable.DiscussionOf the three RT-PCR methods evaluated in this study, cobas\u00ae SARS-CoV-2 test showed the best overall performance for the detection of SARS-CoV-2 RNA in clinical respiratory specimens.", [["respiratory specimens", "ANATOMY", 407, 428], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 380, 390], ["SARS-CoV-2 RNA", "RNA", 380, 394], ["SARS-CoV", "SPECIES", 380, 388], ["the evaluation", "TEST", 52, 66], ["the actual amplification curves", "TEST", 70, 101], ["the tests", "TEST", 185, 194], ["PCR methods", "TEST", 263, 274], ["this study", "TEST", 288, 298], ["cobas\u00ae SARS", "TEST", 300, 311], ["CoV-2 test", "TEST", 312, 322], ["the detection", "TEST", 363, 376], ["SARS", "PROBLEM", 380, 384], ["CoV", "TEST", 385, 388], ["clinical respiratory specimens", "TEST", 398, 428], ["respiratory", "ANATOMY", 407, 418]]], ["In the absence of a gold standard, the reference value was created as a consensus of two methods.", [["the reference value", "TEST", 35, 54]]], ["The agreement between the different methods tested was excellent.", [["the different methods", "TEST", 22, 43]]], ["However, the positive percent agreement was highest for cobas\u00ae SARS-CoV-2 test (100%), while its negative percent agreement was the lowest (89.4%).", [["cobas", "TEST", 56, 61], ["SARS", "TEST", 63, 67], ["CoV-2 test", "TEST", 68, 78]]], ["All the specimens positive only with cobas\u00ae SARS-Cov-2 test had high ct-values (>30), with one exception, where ct-values of 28.6 (orf1) and 29.1 (E-gene) were obtained.", [["specimens", "ANATOMY", 8, 17], ["E-gene", "DNA", 147, 153], ["All the specimens", "TEST", 0, 17], ["cobas\u00ae SARS", "TEST", 37, 48], ["Cov", "TEST", 49, 52], ["high ct", "TEST", 64, 71], ["ct-values", "TEST", 112, 121], ["orf1", "TEST", 131, 135]]], ["The dilution series conducted for specimens collected in Copan UTM vs. 0.9% saline, however, suggests significantly higher sensitivity for the cobas\u00ae assay in comparison with the other two assays and the low NPA value may well be due to the same reason.", [["specimens", "ANATOMY", 34, 43], ["saline", "SIMPLE_CHEMICAL", 76, 82], ["The dilution series", "TEST", 0, 19], ["specimens", "TEST", 34, 43], ["Copan UTM", "TREATMENT", 57, 66], ["0.9% saline", "TREATMENT", 71, 82], ["the cobas\u00ae assay", "TEST", 139, 155], ["the other two assays", "TEST", 175, 195], ["the low NPA value", "PROBLEM", 200, 217]]], ["Previous studies also suggest high sensitivity for the cobas\u00ae SARS-CoV-2 test 8, 9 .", [["Previous studies", "TEST", 0, 16], ["high sensitivity", "PROBLEM", 30, 46], ["the cobas\u00ae SARS", "TEST", 51, 66], ["CoV-2 test", "TEST", 67, 77], ["high sensitivity", "OBSERVATION_MODIFIER", 30, 46]]], ["The second commercial test evaluated, the Amplidiag\u00ae COVID-19 test obtained same PPA (98.9%) as LDT, but lower NPA (98.8% vs. 100% respectively).", [["PPA", "CHEMICAL", 81, 84], ["NPA", "CHEMICAL", 111, 114], ["The second commercial test", "TEST", 0, 26], ["the Amplidiag\u00ae COVID", "TEST", 38, 58], ["PPA", "TEST", 81, 84], ["LDT", "TEST", 96, 99], ["lower NPA", "TEST", 105, 114]]], ["There was one specimen that was positive by Amplidiag\u00ae COVID-19 test only, which seemed to be a false positive by interpretation of the amplification curve of the positive target (orf1ab).", [["specimen", "ANATOMY", 14, 22], ["orf1ab", "PROTEIN", 180, 186], ["Amplidiag\u00ae COVID", "TEST", 44, 60], ["a false positive", "PROBLEM", 94, 110], ["the amplification curve", "TEST", 132, 155]]], ["This specimen was negative by the new Amplidiag\u00ae software version, which did not give any false interpretation of negative results in this study.", [["specimen", "ANATOMY", 5, 13], ["This specimen", "TEST", 0, 13], ["this study", "TEST", 134, 144]]], ["However, it seems that what is gained in specificity is lost in sensitivity: With the new software version three specimens positive by the old version gave negative results, even though specific amplification from the orf1ab target could be seen.", [["specimens", "ANATOMY", 113, 122], ["orf1ab", "GENE_OR_GENE_PRODUCT", 218, 224], ["orf1ab target", "DNA", 218, 231], ["new", "OBSERVATION_MODIFIER", 86, 89]]], ["All things considered, Amplidiag\u00ae test seems to perform on the same par with LDT, apart from the relatively high failure rate with Amplidiag\u00ae test (5.5%).", [["Amplidiag\u00ae test", "TEST", 23, 38], ["the relatively high failure rate", "PROBLEM", 93, 125], ["Amplidiag\u00ae test", "TEST", 131, 146], ["high", "OBSERVATION_MODIFIER", 108, 112], ["failure", "OBSERVATION", 113, 120]]], ["The comparison of results from eNAT tubes versus mNAT tubes suggests that the Amplidiag\u00ae test is for some reason less sensitive (later ct value) for the sampling control (RNase P gene) from mNAT tubes.", [["eNAT tubes", "MULTI-TISSUE_STRUCTURE", 31, 41], ["RNase P", "GENE_OR_GENE_PRODUCT", 171, 178], ["RNase P gene", "DNA", 171, 183], ["eNAT tubes", "TREATMENT", 31, 41], ["mNAT tubes", "TREATMENT", 49, 59], ["the Amplidiag\u00ae test", "TEST", 74, 93], ["ct value", "TEST", 135, 143], ["the sampling control (RNase P gene", "TREATMENT", 149, 183], ["mNAT tubes", "TREATMENT", 190, 200], ["tubes", "OBSERVATION", 195, 200]]], ["The difference in obtained ct values was greater for RNase P gene (~2 ct cycles) than for the specific virus targets (<1 ct cycle).", [["RNase P", "GENE_OR_GENE_PRODUCT", 53, 60], ["RNase P gene", "DNA", 53, 65], ["ct values", "TEST", 27, 36], ["RNase P gene (~2 ct cycles", "TREATMENT", 53, 79], ["the specific virus targets", "TEST", 90, 116]]], ["This was also observed in the rising failure percent (from 3.8 % to 8.4%, data not shown) when the change to mNAT tubes was implemented.We analyzed the QCMD 2020 Coronavirus Outbreak Preparedness EQA PilotStudy with all the evaluated methods available in our laboratory.", [["mNAT tubes", "TREATMENT", 109, 119], ["rising", "OBSERVATION_MODIFIER", 30, 36], ["failure", "OBSERVATION", 37, 44], ["tubes", "OBSERVATION", 114, 119]]], ["The cobas\u00ae test and LDT identified all samples correctly.", [["samples", "ANATOMY", 39, 46], ["The cobas\u00ae test", "TEST", 0, 15]]], ["Amplidiag\u00ae missed repeatedly one specimen with dPCR reference value of 3.3 log10 copies/ml, although it correctly identified another sample with dPCR reference value of 2.3 log10 copies/ml.", [["specimen", "ANATOMY", 33, 41], ["sample", "ANATOMY", 133, 139], ["dPCR reference value", "TEST", 47, 67], ["dPCR reference value", "TEST", 145, 165]]], ["In addition, Amplidiag\u00ae test yielded a failed test result for 4 samples, as these samples lacked human RNase P target needed for a valid negative result with the test.", [["samples", "ANATOMY", 64, 71], ["samples", "ANATOMY", 82, 89], ["human", "ORGANISM", 97, 102], ["RNase", "GENE_OR_GENE_PRODUCT", 103, 108], ["human RNase P target", "DNA", 97, 117], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["Amplidiag\u00ae test", "TEST", 13, 28], ["these samples", "TEST", 76, 89], ["the test", "TEST", 158, 166]]], ["The lack of correct matrix in EQA samples is a major drawback in general.", [["matrix", "ANATOMY", 20, 26], ["matrix", "CELLULAR_COMPONENT", 20, 26], ["EQA samples", "TEST", 30, 41], ["correct matrix", "OBSERVATION_MODIFIER", 12, 26]]], ["The performance of the test identifying the target virus may be very different in the correct matrix in comparison to virus alone.", [["matrix", "ANATOMY", 94, 100], ["matrix", "CELLULAR_COMPONENT", 94, 100], ["the test", "TEST", 19, 27], ["the target virus", "PROBLEM", 40, 56]]], ["Human nucleic acids, if not yielding a false positive result in a PCR, may take force from the amplification reaction (e.g. if primers and/or probe have binding sites in human genome or transcriptome).", [["nucleic acids", "CHEMICAL", 6, 19], ["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 170, 175], ["binding sites", "DNA", 153, 166], ["human genome", "DNA", 170, 182], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 170, 175], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 170, 175], ["Human nucleic acids", "TEST", 0, 19], ["a false positive result", "PROBLEM", 37, 60], ["a PCR", "TEST", 64, 69], ["the amplification reaction", "PROBLEM", 91, 117], ["primers", "PROBLEM", 127, 134], ["binding sites", "PROBLEM", 153, 166]]], ["For example, the LDT amplifies virus positive specimens without human matrix more efficiently than specimens with human matrix included (data not shown).We analyzed the QCMD 2020 Coronavirus Outbreak Preparedness EQA PilotIt is common that RNA-viruses accumulate mutations at high frequency since RNA-polymerase lacks proofreading activity.", [["specimens", "ANATOMY", 46, 55], ["matrix", "ANATOMY", 70, 76], ["specimens", "ANATOMY", 99, 108], ["human", "ORGANISM", 64, 69], ["matrix", "CELLULAR_COMPONENT", 70, 76], ["human", "ORGANISM", 114, 119], ["RNA-polymerase", "PROTEIN", 297, 311], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 114, 119], ["the LDT amplifies virus positive specimens", "PROBLEM", 13, 55], ["human matrix", "PROBLEM", 64, 76], ["human matrix", "TEST", 114, 126], ["viruses accumulate mutations", "PROBLEM", 244, 272]]], ["Indeed, there is evidence that also SARS-CoV-2 is evolving during time and mutations may occur in the target area of molecular tests used.We analyzed the QCMD 2020 Coronavirus Outbreak Preparedness EQA PilotA previous report suggests that a mutation has already occurred in the target region of the cobas\u00ae SARS-CoV-2 E-gene test 10 .", [["SARS", "DISEASE", 36, 40], ["cobas\u00ae", "CHEMICAL", 299, 305], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 306, 316], ["cobas\u00ae", "DNA", 299, 305], ["SARS-CoV-2 E-gene test 10", "DNA", 306, 331], ["SARS", "PROBLEM", 36, 40], ["mutations", "PROBLEM", 75, 84], ["molecular tests", "TEST", 117, 132], ["a mutation", "PROBLEM", 239, 249], ["SARS", "TEST", 306, 310], ["CoV", "TEST", 311, 314], ["cobas\u00ae", "ANATOMY", 299, 305]]], ["In this study, all specimens gave a positive signal for both target genes by cobas\u00ae test.", [["specimens", "ANATOMY", 19, 28], ["specimens", "CANCER", 19, 28], ["target genes", "DNA", 61, 73], ["this study", "TEST", 3, 13], ["all specimens", "TEST", 15, 28], ["cobas\u00ae test", "TEST", 77, 88]]], ["Fortunately, the test uses a dual target approach, which means that the mutation proposed to be in the target area of the cobas\u00ae E-gene test does not compromise correct results.", [["cobas\u00ae E", "GENE_OR_GENE_PRODUCT", 122, 130], ["cobas\u00ae E-gene", "DNA", 122, 135], ["the test", "TEST", 13, 21], ["a dual target approach", "TREATMENT", 27, 49], ["the mutation", "PROBLEM", 68, 80]]], ["This highlights the importance of a dual target approach 11-13 .", [["a dual target approach", "TEST", 34, 56]]], ["Many countries are now (in July 2020) moving from lock-down to \"test, trace and isolate\" strategy in their COVID-19 mitigation, which requires a large capacity for sensitive and reliable SARS-CoV-2 laboratory testing.", [["a large capacity", "TEST", 143, 159], ["CoV", "TEST", 192, 195], ["laboratory testing", "TEST", 198, 216]]], ["Clinical laboratories need to be prepared for uninterrupted high-throughput testing during the coming months.", [["Clinical laboratories", "TEST", 0, 21]]], ["In order to achieve this, laboratories need to deploy optional testing methods for the event of breakage in instrumentation, as well as prepare for the ongoing global shortage in testing supplies.We analyzed the QCMD 2020 Coronavirus Outbreak Preparedness EQA PilotTherefore, it is of critical importance for clinical laboratories to maintain several simultaneous platforms in their SARS-CoV-2 nucleic acid testing, and continuously monitor the performance of the assays used.", [["breakage", "DISEASE", 96, 104], ["nucleic acid", "CHEMICAL", 394, 406], ["optional testing methods", "TEST", 54, 78], ["breakage in instrumentation", "TREATMENT", 96, 123], ["clinical laboratories", "TEST", 309, 330], ["their SARS", "TEST", 377, 387], ["CoV", "TEST", 388, 391], ["nucleic acid testing", "TEST", 394, 414], ["the assays", "TEST", 460, 470], ["breakage", "OBSERVATION", 96, 104], ["instrumentation", "OBSERVATION", 108, 123]]], ["Table 2 The positive percent agreement (PPA), negative percent agreement (NPA) and concordance of the evaluated assays relative to the reference values (\"consensus result\" was used as a reference value and was defined as the result obtained by at least two of the three studied methods).", [["the evaluated assays", "TEST", 98, 118]]], ["The specimen had gone through two freezing-thawing cycles when anal yzed by Amplidiag\u00ae and only one with cobas\u00ae test and non with LDT", [["specimen", "ANATOMY", 4, 12], ["anal", "ANATOMY", 63, 67], ["Amplidiag\u00ae", "CHEMICAL", 76, 86], ["anal", "ORGANISM_SUBDIVISION", 63, 67], ["The specimen", "TEST", 0, 12], ["cobas\u00ae test", "TEST", 105, 116], ["anal", "ANATOMY", 63, 67]]]], "2a342bddeca93a319539fa01061776543e38a88f": [["Samples were collected from 441 individual wild birds of 42 species, including both migratory and resident species (Table 1) .", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Fecal samples and oropharyngeal swabs were collected from live birds that had been caught primarily for ringing purposes (8) and from dead wildfowl and corvids provided by licensed shooters.", [["Fecal samples", "ANATOMY", 0, 13], ["oropharyngeal swabs", "ANATOMY", 18, 37], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 18, 37], ["Fecal samples", "TEST", 0, 13], ["oropharyngeal swabs", "TEST", 18, 37], ["oropharyngeal", "ANATOMY", 18, 31]]], ["Biometric data and information concerning the location where birds had been trapped or shot were recorded (8) .", [["birds", "ORGANISM", 61, 66], ["Biometric data", "TEST", 0, 14]]], ["Samples were placed in virus transport media (Eagle minimum essential medium supplemented with 10% fetal calf serum, penicillin, and streptomycin [10,000 units penicillin, 10 \u00b5g streptomycin/mL] and amphotericin B [250 \u00b5g/ mL]); samples collected from the same wild bird species or genus were pooled in groups of 5 and frozen at -80\u00b0C until required.The StudyViral RNA was extracted from pooled fecal samples and pooled oropharyngeal swabs by using a QIAamp Viral RNA Mini Kit (QIAGEN, Crawley, UK) following the manufacturer's instructions.", [["Samples", "ANATOMY", 0, 7], ["fetal calf serum", "ANATOMY", 99, 115], ["samples", "ANATOMY", 229, 236], ["fecal samples", "ANATOMY", 395, 408], ["oropharyngeal swabs", "ANATOMY", 420, 439], ["penicillin", "CHEMICAL", 117, 127], ["streptomycin", "CHEMICAL", 133, 145], ["penicillin", "CHEMICAL", 160, 170], ["streptomycin", "CHEMICAL", 178, 190], ["amphotericin B", "CHEMICAL", 199, 213], ["penicillin", "CHEMICAL", 117, 127], ["streptomycin", "CHEMICAL", 133, 145], ["penicillin", "CHEMICAL", 160, 170], ["streptomycin", "CHEMICAL", 178, 190], ["amphotericin B", "CHEMICAL", 199, 213], ["calf", "ORGANISM", 105, 109], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["penicillin", "SIMPLE_CHEMICAL", 117, 127], ["streptomycin", "SIMPLE_CHEMICAL", 133, 145], ["penicillin", "SIMPLE_CHEMICAL", 160, 170], ["streptomycin", "SIMPLE_CHEMICAL", 178, 190], ["amphotericin B", "SIMPLE_CHEMICAL", 199, 213], ["fecal samples", "ORGANISM_SUBSTANCE", 395, 408], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 420, 439], ["StudyViral RNA", "RNA", 354, 368], ["calf", "SPECIES", 105, 109], ["Samples", "TEST", 0, 7], ["virus transport media", "TREATMENT", 23, 44], ["10% fetal calf serum", "TREATMENT", 95, 115], ["penicillin", "TREATMENT", 117, 127], ["streptomycin", "TREATMENT", 133, 145], ["penicillin", "TREATMENT", 160, 170], ["streptomycin", "TREATMENT", 178, 190], ["amphotericin B", "TREATMENT", 199, 213], ["The StudyViral RNA", "TEST", 350, 368], ["pooled fecal samples", "TEST", 388, 408], ["pooled oropharyngeal swabs", "TEST", 413, 439], ["a QIAamp", "TEST", 449, 457]]], ["Reverse transcription-PCR was used to detect avian coronaviruses as previously described (9) .", [["avian coronaviruses", "ORGANISM", 45, 64], ["avian coronaviruses", "SPECIES", 45, 64], ["Reverse transcription-PCR", "TEST", 0, 25], ["avian coronaviruses", "PROBLEM", 45, 64]]], ["The primers UTR41+ (5\u2032-ATGTCTATCGCCAGGGAAATGTC-3\u2032) and UTR11-(5\u2032-GCTCTAACTCTATACTAGCCTA-3\u2032) targeted the 3\u2032 untranslated region (UTR) of the coronavirus genome, which is highly conserved among all known types of IBV (9) .", [["UTR11-(5\u2032-GCTCTAACTCTATACTAGCCTA-3\u2032", "GENE_OR_GENE_PRODUCT", 55, 90], ["coronavirus", "ORGANISM", 141, 152], ["IBV", "ORGANISM", 212, 215], ["primers UTR41", "DNA", 4, 17], ["3\u2032 untranslated region", "DNA", 105, 127], ["UTR", "DNA", 129, 132], ["coronavirus genome", "DNA", 141, 159], ["coronavirus", "SPECIES", 141, 152], ["IBV", "SPECIES", 212, 215], ["The primers UTR41", "TEST", 0, 17], ["ATGTCTATCGCCAGGGAAATGTC", "TEST", 23, 46], ["UTR11", "TEST", 55, 60], ["5\u2032-GCTCTAACTCTATACTAGCCTA", "TEST", 62, 87], ["the coronavirus genome", "PROBLEM", 137, 159], ["coronavirus genome", "OBSERVATION", 141, 159]]], ["This procedure was followed by use of a heminested PCR with the same forward primer but the reverse primer UTR hemi-(5\u2032-CTTAAACTAAAATTTAGCTCTTCC-3\u2032) under the same reaction conditions as the initial PCR, which had an expected product size of 214 bp.", [["forward primer", "DNA", 69, 83], ["reverse primer UTR", "DNA", 92, 110], ["This procedure", "TREATMENT", 0, 14], ["a heminested PCR", "TREATMENT", 38, 54], ["5\u2032-CTTAAACTAAAATTTAGCTCTTCC", "TEST", 117, 144], ["the initial PCR", "TEST", 187, 202], ["bp", "TEST", 246, 248], ["size", "OBSERVATION_MODIFIER", 234, 238]]], ["PCR products were purified by using a commercial purification kit (QIAquick PCR Purification Kit; QIAGEN) according to the manufacturer's instructions and were sequenced commercially (Cogenics, Essex, UK) as recommended by the manufacturer (ABI 3730xl DNA Analyser; Applied Biosystems, Warrington, UK).", [["DNA", "CELLULAR_COMPONENT", 252, 255], ["PCR products", "TREATMENT", 0, 12], ["a commercial purification kit", "TREATMENT", 36, 65], ["ABI", "TEST", 241, 244]]], ["Nucleotide sequences derived from this study have been deposited in the GenBank sequence database under accession nos.", [["Nucleotide sequences", "TEST", 0, 20], ["this study", "TEST", 34, 44]]], ["FJ490193-FJ490199.The StudySequences were aligned with previously published coronavirus sequences obtained from GenBank by using the Clustal program within the MEGA 4.0 package (10) (online Appendix Figure, available from www.cdc.gov/EID/ content/15/7/1091-appF.htm).", [["FJ490193-FJ490199", "CHEMICAL", 0, 17], ["FJ490193-FJ490199", "CHEMICAL", 0, 17], ["coronavirus", "ORGANISM", 76, 87], ["coronavirus sequences", "DNA", 76, 97], ["previously published coronavirus sequences", "PROBLEM", 55, 97]]], ["Phylogenetic analyses were conducted in MEGA 4.0.", [["Phylogenetic analyses", "TEST", 0, 21]]], ["Phylogenies were estimated by using a minimum-evolution method (11) , and evolutionary distances were computed by using the Tamura-Nei method (12) .", [["Phylogenies", "TEST", 0, 11]]], ["Phylogenetic trees were drawn to scale; branch lengths in the same units as those of the evolutionary distances were used to infer the phylogenetic tree.", [["Phylogenetic trees", "PROBLEM", 0, 18], ["branch", "OBSERVATION_MODIFIER", 40, 46], ["lengths", "OBSERVATION_MODIFIER", 47, 54], ["phylogenetic tree", "OBSERVATION", 135, 152]]], ["Bootstrap analysis using 1,000 repetitions provided support for individual nodes (13) .The StudyAnimal-level prevalences and confidence limits, based on pooled samples, were estimated by using a pooled prev- alence calculator (www.ausvet.com.au/pprev).", [["Bootstrap analysis", "TEST", 0, 18], ["individual nodes", "PROBLEM", 64, 80], ["pooled samples", "TEST", 153, 167], ["a pooled prev- alence calculator", "TREATMENT", 193, 225], ["nodes", "OBSERVATION", 75, 80]]], ["Generalized linear modeling was used to calculate maximum-likelihood estimates of prevalence and confidence limits (14) .The StudyCoronavirus RNA was detected in 7 fecal sample pools (Table 2) , giving an individual animal-level prevalence estimate of 1.6% (95% confidence interval 0.7-3.1).", [["fecal sample", "ANATOMY", 164, 176], ["StudyCoronavirus RNA", "RNA", 125, 145], ["Generalized linear modeling", "PROBLEM", 0, 27], ["The StudyCoronavirus RNA", "TEST", 121, 145], ["interval", "TEST", 273, 281], ["linear", "OBSERVATION_MODIFIER", 12, 18]]], ["Of the pools with positive results for coronavirus, 4 were collected from ducks (designated Anas/UK/p20/2005, Anas/UK/ p33/2005, Anas/UK/p42/2005 and Anas/UK/p71/2005; Table 2 ).", [["coronavirus", "ORGANISM", 39, 50], ["ducks", "ORGANISM", 74, 79], ["Anas", "ORGANISM", 92, 96], ["UK", "GENE_OR_GENE_PRODUCT", 97, 99], ["Anas", "ORGANISM", 110, 114], ["UK", "GENE_OR_GENE_PRODUCT", 115, 117], ["Anas", "ORGANISM", 129, 133], ["UK", "GENE_OR_GENE_PRODUCT", 134, 136], ["Anas", "ORGANISM", 150, 154], ["ducks", "SPECIES", 74, 79], ["Anas/UK/p20/2005, Anas/UK/ p33/2005, Anas/UK/p42/2005 and Anas/UK/p71/2005", "SPECIES", 92, 166], ["coronavirus", "PROBLEM", 39, 50], ["Anas", "TEST", 110, 114], ["Anas", "TEST", 129, 133]]], ["Another pool contained samples from whooper swans (Cygnus cygnus) (whooper swan/UK/p3/2005), 1 consisted of samples from red knots (Calidris canutus) (red knot/UK/p60/2006), and 1 contained samples from Eurasian oystercatchers (Haematopus ostralegus) (oystercatcher/UK/p17/2006).", [["samples", "ANATOMY", 23, 30], ["samples", "ANATOMY", 108, 115], ["samples", "ANATOMY", 190, 197], ["swans", "ORGANISM_SUBDIVISION", 44, 49], ["Cygnus cygnus", "ORGANISM", 51, 64], ["Calidris canutus", "ORGANISM", 132, 148], ["Haematopus ostralegus", "ORGANISM", 228, 249], ["Cygnus cygnus", "SPECIES", 51, 64], ["Calidris canutus", "SPECIES", 132, 148], ["Haematopus ostralegus", "SPECIES", 228, 249], ["whooper swans", "SPECIES", 36, 49], ["Cygnus cygnus", "SPECIES", 51, 64], ["whooper swan/UK/p3/2005)", "SPECIES", 67, 91], ["red knots", "SPECIES", 121, 130], ["Calidris canutus", "SPECIES", 132, 148], ["red knot/UK/p60/2006)", "SPECIES", 151, 172], ["Eurasian oystercatchers", "SPECIES", 203, 226], ["Haematopus ostralegus", "SPECIES", 228, 249], ["whooper swans", "TEST", 36, 49], ["red knots", "TEST", 121, 130], ["Eurasian oystercatchers", "TEST", 203, 226], ["red knots", "OBSERVATION", 121, 130]]], ["PCR-positive pools were from birds sampled in estuarine, salt marsh, or standing water habitats ( Table 2 ).", [["PCR", "TEST", 0, 3], ["positive pools", "PROBLEM", 4, 18], ["standing water habitats", "TREATMENT", 72, 95], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["pools", "OBSERVATION_MODIFIER", 13, 18]]], ["All birds appeared to be healthy.", [["birds", "ORGANISM", 4, 9]]], ["All pooled oropharyngeal samples were PCR negative.The StudyPhylogenetic analyses were based on a final usable sequence of 146 nt after removal of primer sites (online Appendix Figure) .", [["oropharyngeal samples", "ANATOMY", 11, 32], ["oropharyngeal samples", "CANCER", 11, 32], ["primer sites", "DNA", 147, 159], ["All pooled oropharyngeal samples", "TEST", 0, 32], ["PCR", "TEST", 38, 41], ["The StudyPhylogenetic analyses", "TEST", 51, 81], ["removal of primer sites", "TREATMENT", 136, 159], ["oropharyngeal", "ANATOMY", 11, 24], ["Appendix", "ANATOMY", 168, 176]]], ["Nucleotide distances between coronavirus sequences derived from this study were 0.0%-15.6%.", [["coronavirus", "ORGANISM", 29, 40], ["coronavirus sequences", "DNA", 29, 50], ["Nucleotide distances between coronavirus sequences", "PROBLEM", 0, 50], ["this study", "TEST", 64, 74]]], ["Sequences detected in 3 pooled duck samples and a sequence derived from a pool of whooper swan samples clustered with sequence from an IBV H120 (Massachusetts) vaccine strain.", [["samples", "ANATOMY", 36, 43], ["samples", "ANATOMY", 95, 102], ["duck", "ORGANISM", 31, 35], ["duck", "SPECIES", 31, 35], ["IBV H120", "SPECIES", 135, 143], ["Sequences", "TEST", 0, 9], ["a sequence", "TEST", 48, 58], ["whooper swan samples", "TREATMENT", 82, 102], ["sequence", "TEST", 118, 126], ["an IBV H120 (Massachusetts) vaccine strain", "TREATMENT", 132, 174]]], ["Sequences within this cluster were relatively homogenous with low within-group distance values (0.0%-2.8%).The StudyWithin this cluster, bootstrap support for the individual nodes was relatively low (Figure) .", [["nodes", "MULTI-TISSUE_STRUCTURE", 174, 179], ["bootstrap support", "TREATMENT", 137, 154], ["the individual nodes", "PROBLEM", 159, 179], ["homogenous", "OBSERVATION_MODIFIER", 46, 56], ["low", "OBSERVATION_MODIFIER", 62, 65], ["nodes", "OBSERVATION", 174, 179], ["low", "OBSERVATION_MODIFIER", 195, 198]]], ["Coronavirus sequences detected in red knots clustered with a previously described goose coronavirus; divergence at the nucleotide level was 2.0%.", [["goose coronavirus", "DISEASE", 82, 99], ["nucleotide", "CHEMICAL", 119, 129], ["goose coronavirus", "ORGANISM", 82, 99], ["Coronavirus sequences", "DNA", 0, 21], ["goose coronavirus", "SPECIES", 82, 99], ["goose coronavirus", "SPECIES", 82, 99], ["Coronavirus sequences", "TEST", 0, 21], ["red knots", "PROBLEM", 34, 43], ["a previously described goose coronavirus", "PROBLEM", 59, 99], ["the nucleotide level", "TEST", 115, 135], ["goose coronavirus", "OBSERVATION", 82, 99]]], ["Sequences from viruses detected in samples from Eurasian oystercatchers and ducks clustered with sequence from a published duck coronavirus (7) .", [["samples", "ANATOMY", 35, 42], ["oystercatchers", "ANATOMY", 57, 71], ["duck coronavirus", "DISEASE", 123, 139], ["ducks", "ORGANISM", 76, 81], ["duck coronavirus", "ORGANISM", 123, 139], ["ducks", "SPECIES", 76, 81], ["duck coronavirus", "SPECIES", 123, 139], ["Eurasian oystercatchers", "SPECIES", 48, 71], ["duck coronavirus", "SPECIES", 123, 139], ["Sequences from viruses", "TEST", 0, 22], ["Eurasian oystercatchers", "TEST", 48, 71], ["a published duck coronavirus", "TEST", 111, 139]]], ["The sequence from Eurasian oystercatchers was identical to that of the published duck coronavirus; distance values within this cluster were 0.0%-1.0%.ConclusionsAlthough samples were collected from wild bird populations comprising 46 species of wild birds from numerous and diverse habitats, coronavirus RNA was detected only in wildfowl (Anseriforms) and waders (Charadriiformes).", [["samples", "ANATOMY", 170, 177], ["duck coronavirus", "DISEASE", 81, 97], ["duck coronavirus", "ORGANISM", 81, 97], ["samples", "CANCER", 170, 177], ["coronavirus", "ORGANISM", 292, 303], ["coronavirus RNA", "RNA", 292, 307], ["duck coronavirus", "SPECIES", 81, 97], ["Eurasian oystercatchers", "SPECIES", 18, 41], ["duck coronavirus", "SPECIES", 81, 97], ["coronavirus", "SPECIES", 292, 303], ["distance values", "TEST", 99, 114], ["this cluster", "TEST", 122, 134], ["samples", "TEST", 170, 177], ["wild bird populations", "PROBLEM", 198, 219], ["wild birds from numerous and diverse habitats", "PROBLEM", 245, 290], ["coronavirus RNA", "PROBLEM", 292, 307], ["coronavirus RNA", "OBSERVATION", 292, 307]]], ["Coronaviruses have been detected previously in wildfowl species, rock doves, wild peafowl, and some passerine species (4-7).", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["rock doves", "ORGANISM", 65, 75], ["Coronaviruses", "PROTEIN", 0, 13], ["Coronaviruses", "PROBLEM", 0, 13], ["some passerine species", "PROBLEM", 95, 117]]], ["All wild birds from which coronaviruses were detected in this study appeared to be healthy.", [["birds", "ORGANISM", 9, 14], ["coronaviruses", "ORGANISM", 26, 39], ["coronaviruses", "PROBLEM", 26, 39], ["this study", "TEST", 57, 67]]], ["Although IBV is recognized primarily as a respiratory agent, it has been demonstrated that certain strains are able to replicate in the chicken intestine without obvious clinical disease (15) .ConclusionsPhylogenetic analysis showed that coronavirus sequences detected by this study were genetically diverse.", [["respiratory", "ANATOMY", 42, 53], ["intestine", "ANATOMY", 144, 153], ["IBV", "ORGANISM", 9, 12], ["chicken", "ORGANISM", 136, 143], ["intestine", "ORGAN", 144, 153], ["coronavirus", "ORGANISM", 238, 249], ["coronavirus sequences", "DNA", 238, 259], ["chicken", "SPECIES", 136, 143], ["IBV", "SPECIES", 9, 12], ["chicken", "SPECIES", 136, 143], ["IBV", "PROBLEM", 9, 12], ["a respiratory agent", "TREATMENT", 40, 59], ["certain strains", "PROBLEM", 91, 106], ["obvious clinical disease", "PROBLEM", 162, 186], ["Phylogenetic analysis", "TEST", 204, 225], ["coronavirus sequences", "TEST", 238, 259], ["this study", "TEST", 272, 282], ["IBV", "OBSERVATION", 9, 12], ["intestine", "ANATOMY", 144, 153], ["without", "UNCERTAINTY", 154, 161]]], ["Virus sequences from 3 pools of fecal samples from ducks and whooper swans shared high nucleotide sequence identity with sequence from the IBV H120 vaccine strain, which is commonly used for the vaccination of commercial chickens worldwide.", [["fecal samples", "ANATOMY", 32, 45], ["nucleotide", "CHEMICAL", 87, 97], ["nucleotide", "CHEMICAL", 87, 97], ["fecal samples", "ORGANISM_SUBSTANCE", 32, 45], ["ducks", "ORGANISM", 51, 56], ["IBV H120 vaccine", "ORGANISM", 139, 155], ["chickens", "ORGANISM", 221, 229], ["ducks", "SPECIES", 51, 56], ["IBV H120 vaccine", "SPECIES", 139, 155], ["chickens", "SPECIES", 221, 229], ["whooper swans", "SPECIES", 61, 74], ["IBV H120 vaccine strain", "SPECIES", 139, 162], ["chickens", "SPECIES", 221, 229], ["Virus sequences", "TEST", 0, 15], ["fecal samples", "TEST", 32, 45], ["whooper swans", "PROBLEM", 61, 74], ["high nucleotide sequence identity", "PROBLEM", 82, 115], ["the IBV H120 vaccine strain", "TREATMENT", 135, 162], ["commercial chickens worldwide", "TREATMENT", 210, 239]]], ["Coronaviruses sharing a high degree of identity with the IBV H120 vaccine strain have been detected previously in healthy, unvaccinated, domestic peafowl and as well as wild peafowl in China (4,5).", [["IBV H120 vaccine", "ORGANISM", 57, 73], ["IBV H120 vaccine", "SPECIES", 57, 73], ["IBV H120", "SPECIES", 57, 65], ["Coronaviruses", "PROBLEM", 0, 13], ["the IBV H120 vaccine strain", "TREATMENT", 53, 80], ["high degree", "OBSERVATION_MODIFIER", 24, 35]]], ["These vi- It would be useful to determine the number and genome position of accessory genes of the coronaviruses detected in wild birds and to compare them with those of IBV.", [["coronaviruses", "ORGANISM", 99, 112], ["birds", "ORGANISM", 130, 135], ["IBV", "ORGANISM", 170, 173], ["accessory genes", "DNA", 76, 91], ["IBV", "SPECIES", 170, 173], ["the coronaviruses", "PROBLEM", 95, 112], ["IBV", "TREATMENT", 170, 173], ["accessory genes", "OBSERVATION", 76, 91], ["coronaviruses", "OBSERVATION", 99, 112]]], ["More detailed genetic characterization of the viruses detected including, for example, the S1 spike gene, is also needed.", [["S1", "GENE_OR_GENE_PRODUCT", 91, 93], ["S1 spike gene", "DNA", 91, 104], ["the viruses", "PROBLEM", 42, 53], ["viruses", "OBSERVATION", 46, 53]]], ["The detection of coronaviruses that appear to be related to IBV in wild migratory birds raises interesting questions as to their role in the transmission, dissemination, and evolution of IBV strains.", [["coronaviruses", "ORGANISM", 17, 30], ["IBV", "ORGANISM", 60, 63], ["birds", "ORGANISM", 82, 87], ["IBV", "ORGANISM", 187, 190], ["IBV", "SPECIES", 60, 63], ["IBV", "SPECIES", 187, 190], ["The detection", "TEST", 0, 13], ["coronaviruses", "PROBLEM", 17, 30], ["IBV", "PROBLEM", 60, 63], ["IBV strains", "PROBLEM", 187, 198], ["coronaviruses", "OBSERVATION", 17, 30], ["appear to be related to", "UNCERTAINTY", 36, 59], ["IBV", "OBSERVATION", 60, 63], ["IBV strains", "OBSERVATION", 187, 198]]], ["Minimum-evolution tree (11) of coronaviruses based on a 146-bp fragment of the 3\u2032 untranslated region of infectious bronchitis virus (IBV).", [["infectious bronchitis", "DISEASE", 105, 126], ["infectious bronchitis virus", "ORGANISM", 105, 132], ["IBV", "ORGANISM", 134, 137], ["146-bp fragment", "DNA", 56, 71], ["3\u2032 untranslated region", "DNA", 79, 101], ["infectious bronchitis virus", "SPECIES", 105, 132], ["infectious bronchitis virus", "SPECIES", 105, 132], ["IBV", "SPECIES", 134, 137], ["coronaviruses", "PROBLEM", 31, 44], ["a 146-bp fragment", "TREATMENT", 54, 71], ["infectious bronchitis virus", "PROBLEM", 105, 132], ["tree", "OBSERVATION_MODIFIER", 18, 22], ["infectious", "OBSERVATION_MODIFIER", 105, 115], ["bronchitis", "OBSERVATION", 116, 126]]], ["Evolutionary distances were computed by using the Tamura-Nei method (12) and are in the units of the number of base substitutions per site.", [["base substitutions", "OBSERVATION", 111, 129]]], ["Coronaviruses detected in wild birds by this study are denoted with an asterisk.", [["Coronaviruses", "PROBLEM", 0, 13], ["this study", "TEST", 40, 50]]], ["Previously published coronavirus sequences from different sources were included for comparative purposes.", [["coronavirus", "ORGANISM", 21, 32], ["coronavirus sequences", "DNA", 21, 42], ["Previously published coronavirus sequences", "PROBLEM", 0, 42], ["comparative purposes", "TEST", 84, 104]]], ["The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1,000 replicates) is shown next to the branches (13) .", [["the bootstrap test", "TEST", 85, 103], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["replicate trees", "OBSERVATION", 18, 33], ["branches", "ANATOMY_MODIFIER", 144, 152]]], ["The tree is drawn to scale; branch lengths are in the same units as those of the evolutionary distances used to infer the phylogenetic tree.", [["tree", "OBSERVATION_MODIFIER", 4, 8], ["branch", "OBSERVATION_MODIFIER", 28, 34], ["lengths", "OBSERVATION_MODIFIER", 35, 42], ["phylogenetic tree", "OBSERVATION", 122, 139]]], ["Phylogenetic analyses were conducted in MEGA4 (10).", [["Phylogenetic analyses", "TEST", 0, 21]]], ["CoV, coronavirus.", [["CoV", "ORGANISM", 0, 3], ["coronavirus", "ORGANISM", 5, 16], ["coronavirus", "SPECIES", 5, 16], ["CoV", "SPECIES", 0, 3], ["CoV", "PROBLEM", 0, 3], ["coronavirus", "PROBLEM", 5, 16], ["coronavirus", "OBSERVATION", 5, 16]]], ["Scale bar indicates nucleotide substitutions per site.", [["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 20, 30], ["nucleotide substitutions per site", "PROBLEM", 20, 53], ["nucleotide substitutions", "OBSERVATION", 20, 44]]]], "PMC6635749": [["INTRODUCTIONMicroglia are highly specialized and dynamic cellular components of the central nervous system (CNS) originating from embryonic precursors in the yolk sac, comprising approximately 10% of the total glial cell number in the adult brain (Ginhoux et al., 2010; Labzin, Heneka, & Latz, 2017; Li & Barres, 2017).", [["cellular components", "ANATOMY", 57, 76], ["central nervous system", "ANATOMY", 84, 106], ["CNS", "ANATOMY", 108, 111], ["embryonic precursors", "ANATOMY", 130, 150], ["yolk sac", "ANATOMY", 158, 166], ["glial cell", "ANATOMY", 210, 220], ["brain", "ANATOMY", 241, 246], ["cellular", "CELL", 57, 65], ["central nervous system", "ANATOMICAL_SYSTEM", 84, 106], ["CNS", "ANATOMICAL_SYSTEM", 108, 111], ["embryonic precursors", "ANATOMICAL_SYSTEM", 130, 150], ["yolk sac", "MULTI-TISSUE_STRUCTURE", 158, 166], ["glial cell", "CELL", 210, 220], ["brain", "ORGAN", 241, 246], ["embryonic precursors", "CELL_TYPE", 130, 150], ["embryonic precursors in the yolk sac", "PROBLEM", 130, 166], ["highly", "OBSERVATION_MODIFIER", 26, 32], ["dynamic cellular components", "OBSERVATION", 49, 76], ["central", "ANATOMY_MODIFIER", 84, 91], ["nervous system", "ANATOMY", 92, 106], ["CNS", "ANATOMY", 108, 111], ["embryonic precursors", "OBSERVATION", 130, 150], ["yolk sac", "ANATOMY", 158, 166], ["approximately", "OBSERVATION_MODIFIER", 179, 192], ["10%", "OBSERVATION_MODIFIER", 193, 196], ["total", "OBSERVATION_MODIFIER", 204, 209], ["glial cell number", "OBSERVATION", 210, 227], ["adult", "ANATOMY_MODIFIER", 235, 240], ["brain", "ANATOMY", 241, 246]]], ["Microglia have traditionally been considered to be in a resting and quiescent state in physiological conditions.", [["Microglia", "ANATOMY", 0, 9], ["Microglia", "CELL", 0, 9], ["Microglia", "CELL_TYPE", 0, 9]]], ["With the advent of elegant two/multiple photon microscopy image techniques, genetic and molecular targeting tools, we now appreciate that in normal conditions microglia have a ramified morphology, are maintained by diverse signals from neurons and can continuously move their dendrites, which allows for constant active screening of the surrounding microenvironment (Kierdorf & Prinz, 2017; Nimmerjahn, Kirchhoff, & Helmchen, 2005).INTRODUCTIONMicroglia are long\u2010lived cells with a relatively low turnover.", [["microglia", "ANATOMY", 159, 168], ["neurons", "ANATOMY", 236, 243], ["dendrites", "ANATOMY", 276, 285], ["cells", "ANATOMY", 469, 474], ["microglia", "CELL", 159, 168], ["neurons", "CELL", 236, 243], ["dendrites", "CELLULAR_COMPONENT", 276, 285], ["cells", "CELL", 469, 474], ["microglia", "CELL_TYPE", 159, 168], ["long\u2010lived cells", "CELL_TYPE", 458, 474], ["multiple photon microscopy image techniques", "TEST", 31, 74], ["genetic and molecular targeting tools", "PROBLEM", 76, 113], ["Nimmerjahn", "TREATMENT", 391, 401], ["long\u2010lived cells", "PROBLEM", 458, 474], ["a relatively low turnover", "PROBLEM", 480, 505], ["long\u2010lived cells", "OBSERVATION", 458, 474], ["relatively", "OBSERVATION_MODIFIER", 482, 492], ["low turnover", "OBSERVATION", 493, 505]]], ["By genetically labeling microglia in pathogen\u2010free mice it was recently determined that microglia can survive during the whole lifespan of an animal, and can thus exert crucial long\u2010lasting influences on neurodegenerative disorders (Fuger et al., 2017).", [["microglia", "ANATOMY", 24, 33], ["microglia", "ANATOMY", 88, 97], ["neurodegenerative disorders", "DISEASE", 204, 231], ["microglia", "CELL", 24, 33], ["mice", "ORGANISM", 51, 55], ["microglia", "CELL", 88, 97], ["microglia", "CELL_TYPE", 24, 33], ["microglia", "CELL_TYPE", 88, 97], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["neurodegenerative disorders", "PROBLEM", 204, 231]]], ["However, it is well documented that microglia can be self\u2010regulated without contribution from peripheral myeloid cells and their turnover is tightly controlled by the coupling of apoptosis, with approximately 1% murine microglia dying in 1 day and the whole population of cells renewing several times throughout life (Askew et al., 2017; Tay et al., 2017).", [["microglia", "ANATOMY", 36, 45], ["peripheral myeloid cells", "ANATOMY", 94, 118], ["microglia", "ANATOMY", 219, 228], ["cells", "ANATOMY", 272, 277], ["microglia", "CELL", 36, 45], ["peripheral myeloid cells", "CELL", 94, 118], ["murine", "ORGANISM", 212, 218], ["microglia", "CELL", 219, 228], ["cells", "CELL", 272, 277], ["microglia", "CELL_TYPE", 36, 45], ["peripheral myeloid cells", "CELL_TYPE", 94, 118], ["murine", "SPECIES", 212, 218], ["peripheral myeloid cells", "PROBLEM", 94, 118], ["apoptosis", "PROBLEM", 179, 188], ["peripheral", "ANATOMY_MODIFIER", 94, 104], ["myeloid cells", "OBSERVATION", 105, 118], ["apoptosis", "OBSERVATION", 179, 188]]], ["Although significant species differences in microglial biology such as microglial density were noted, this finding also concords with observations in humans, a recent study highlighting that more than 96% of human microglia can be slowly renewed throughout life (Reu et al., 2017).INTRODUCTIONMicroglial cells are believed to play multifunctional roles in both inflammatory and physiological contexts (Grabert et al., 2016; Thompson & Tsirka, 2017).", [["microglial", "ANATOMY", 44, 54], ["microglial", "ANATOMY", 71, 81], ["microglia", "ANATOMY", 214, 223], ["INTRODUCTIONMicroglial cells", "ANATOMY", 281, 309], ["microglial", "CELL", 44, 54], ["microglial", "CELL", 71, 81], ["humans", "ORGANISM", 150, 156], ["human", "ORGANISM", 208, 213], ["microglia", "CELL", 214, 223], ["INTRODUCTIONMicroglial cells", "CELL", 281, 309], ["human microglia", "CELL_TYPE", 208, 223], ["INTRODUCTIONMicroglial cells", "CELL_TYPE", 281, 309], ["humans", "SPECIES", 150, 156], ["human", "SPECIES", 208, 213], ["humans", "SPECIES", 150, 156], ["human", "SPECIES", 208, 213], ["significant species differences", "PROBLEM", 9, 40], ["microglial density", "PROBLEM", 71, 89], ["a recent study", "TEST", 158, 172], ["INTRODUCTIONMicroglial cells", "PROBLEM", 281, 309], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["species", "OBSERVATION", 21, 28], ["microglial density", "OBSERVATION", 71, 89], ["inflammatory", "OBSERVATION_MODIFIER", 361, 373]]], ["In the healthy brain microglia efficiently monitor CNS homeostasis and have a marked impact on neural development.", [["brain microglia", "ANATOMY", 15, 30], ["CNS", "ANATOMY", 51, 54], ["neural", "ANATOMY", 95, 101], ["brain microglia", "CELL", 15, 30], ["CNS", "ANATOMICAL_SYSTEM", 51, 54], ["microglia", "CELL_TYPE", 21, 30], ["CNS homeostasis", "PROBLEM", 51, 66], ["a marked impact on neural development", "PROBLEM", 76, 113], ["brain microglia", "ANATOMY", 15, 30], ["marked", "OBSERVATION_MODIFIER", 78, 84]]], ["In order to actively survey the CNS they have recently been demonstrated to require the proper activity of tandem\u2010pore domain halothane\u2010inhibited K+ channel 1, which is the main K+ channel expressed in microglial cells (Madry et al., 2017).", [["CNS", "ANATOMY", 32, 35], ["microglial cells", "ANATOMY", 202, 218], ["K", "CHEMICAL", 146, 147], ["K", "CHEMICAL", 178, 179], ["K+", "CHEMICAL", 146, 148], ["K+", "CHEMICAL", 178, 180], ["CNS", "ANATOMICAL_SYSTEM", 32, 35], ["K+ channel 1", "GENE_OR_GENE_PRODUCT", 146, 158], ["K+", "SIMPLE_CHEMICAL", 178, 180], ["microglial cells", "CELL", 202, 218], ["tandem\u2010pore domain", "PROTEIN", 107, 125], ["halothane\u2010inhibited K+ channel 1", "PROTEIN", 126, 158], ["K+ channel", "PROTEIN", 178, 188], ["microglial cells", "CELL_TYPE", 202, 218], ["microglial cells", "OBSERVATION", 202, 218]]], ["In several pathological conditions such as epilepsy, single\u2010cell RNA sequencing of hippocampal microglia indicated that microglia undergo dramatically transcriptomic alterations (more than 2,000 differentially expressed genes) and immunological activation during early time points, particularly regarding mitochondrial activity and metabolic pathways (Bosco et al., 2018).", [["hippocampal microglia", "ANATOMY", 83, 104], ["microglia", "ANATOMY", 120, 129], ["mitochondrial", "ANATOMY", 305, 318], ["epilepsy", "DISEASE", 43, 51], ["hippocampal microglia", "CELL", 83, 104], ["microglia", "CELL", 120, 129], ["mitochondrial", "CELLULAR_COMPONENT", 305, 318], ["hippocampal microglia", "CELL_TYPE", 83, 104], ["microglia", "CELL_TYPE", 120, 129], ["several pathological conditions", "PROBLEM", 3, 34], ["epilepsy", "PROBLEM", 43, 51], ["single\u2010cell RNA sequencing of hippocampal microglia", "PROBLEM", 53, 104], ["dramatically transcriptomic alterations", "PROBLEM", 138, 177], ["immunological activation", "PROBLEM", 231, 255], ["several", "OBSERVATION_MODIFIER", 3, 10], ["pathological", "OBSERVATION", 11, 23], ["hippocampal", "ANATOMY", 83, 94]]], ["As such they play an indispensable role in the inflammatory cascade.", [["the inflammatory cascade", "TREATMENT", 43, 67], ["inflammatory cascade", "OBSERVATION", 47, 67]]], ["Some studies based on comprehensive single cell RNA sequencing experiments have reported that microglia do not vary considerably in the whole brain (Keren\u2010Shaul et al., 2017; Matcovitch\u2010Natan et al., 2016).", [["microglia", "ANATOMY", 94, 103], ["brain", "ANATOMY", 142, 147], ["cell", "CELL", 43, 47], ["microglia", "CELL", 94, 103], ["brain", "ORGAN", 142, 147], ["microglia", "CELL_TYPE", 94, 103], ["Some studies", "TEST", 0, 12], ["comprehensive single cell RNA sequencing experiments", "TEST", 22, 74], ["whole brain", "ANATOMY", 136, 147]]], ["However, a recent study provides further novel evidence that CD11b+ microglia in the circumventricular regions are actually maintained in the activated state even during physiological conditions (Takagi, Furube, Nakano, Morita, & Miyata, 2017).", [["CD11b+ microglia", "ANATOMY", 61, 77], ["circumventricular regions", "ANATOMY", 85, 110], ["CD11b", "GENE_OR_GENE_PRODUCT", 61, 66], ["circumventricular regions", "MULTI-TISSUE_STRUCTURE", 85, 110], ["CD11b", "PROTEIN", 61, 66], ["microglia", "CELL_TYPE", 68, 77], ["a recent study", "TEST", 9, 23], ["CD11b+ microglia in the circumventricular regions", "PROBLEM", 61, 110], ["CD11b", "OBSERVATION", 61, 66], ["microglia", "OBSERVATION", 68, 77], ["circumventricular", "ANATOMY_MODIFIER", 85, 102], ["regions", "ANATOMY_MODIFIER", 103, 110]]], ["Microglia in this specific region not only display the amoeboid morphology rather than the ramified form, but also express high protein levels of activation markers in the healthy mouse brain (Takagi et al., 2017).INTRODUCTIONThis recent report is consistent with the view that while microglia are uniformly distributed throughout the CNS they appear to perform characteristic functions in specific regions (De Biase et al., 2017; Marshall, Deleyrolle, Reynolds, Steindler, & Laywell, 2014).", [["Microglia", "ANATOMY", 0, 9], ["brain", "ANATOMY", 186, 191], ["microglia", "ANATOMY", 284, 293], ["CNS", "ANATOMY", 335, 338], ["Microglia", "CELL", 0, 9], ["mouse", "ORGANISM", 180, 185], ["brain", "ORGAN", 186, 191], ["microglia", "CELL", 284, 293], ["CNS", "ANATOMICAL_SYSTEM", 335, 338], ["Microglia", "CELL_TYPE", 0, 9], ["activation markers", "PROTEIN", 146, 164], ["microglia", "CELL_TYPE", 284, 293], ["mouse", "SPECIES", 180, 185], ["mouse", "SPECIES", 180, 185], ["high protein levels of activation markers", "PROBLEM", 123, 164], ["amoeboid morphology", "OBSERVATION", 55, 74], ["brain", "ANATOMY", 186, 191], ["consistent with", "UNCERTAINTY", 248, 263], ["microglia", "OBSERVATION", 284, 293], ["CNS", "ANATOMY", 335, 338]]], ["Indeed, genome\u2010wide transcriptional studies have reported that the bio\u2010energetic and immunoregulatory functions of microglia varied considerably in different anatomical regions, evidenced by cerebellar and cortical microglia displaying distinct gene expression profiles under steady\u2010state conditions (Grabert et al., 2016).", [["microglia", "ANATOMY", 115, 124], ["cerebellar", "ANATOMY", 191, 201], ["cortical microglia", "ANATOMY", 206, 224], ["microglia", "CELL", 115, 124], ["cerebellar", "CELL", 191, 201], ["cortical microglia", "CELL", 206, 224], ["microglia", "CELL_TYPE", 115, 124], ["cerebellar and cortical microglia", "CELL_TYPE", 191, 224], ["genome\u2010wide transcriptional studies", "TEST", 8, 43], ["the bio\u2010energetic and immunoregulatory functions of microglia", "PROBLEM", 63, 124], ["cerebellar and cortical microglia", "PROBLEM", 191, 224], ["microglia varied", "OBSERVATION", 115, 131], ["anatomical", "ANATOMY_MODIFIER", 158, 168], ["cerebellar", "ANATOMY", 191, 201], ["cortical microglia", "OBSERVATION", 206, 224], ["gene expression", "OBSERVATION", 245, 260]]], ["More specifically, a recent study provides convincing evidence of an epigenetic mechanism involved in the clearance activity of microglia that differs regionally in the adult brain (Ayata et al., 2018).", [["microglia", "ANATOMY", 128, 137], ["brain", "ANATOMY", 175, 180], ["microglia", "CELL", 128, 137], ["brain", "ORGAN", 175, 180], ["microglia", "CELL_TYPE", 128, 137], ["a recent study", "TEST", 19, 33], ["an epigenetic mechanism", "PROBLEM", 66, 89], ["convincing evidence of", "UNCERTAINTY", 43, 65], ["epigenetic mechanism", "OBSERVATION", 69, 89], ["adult", "ANATOMY_MODIFIER", 169, 174], ["brain", "ANATOMY", 175, 180]]], ["Variations in microglial profiles may also depend on the specific diseases states (Mastroeni et al., 2017), significantly altered transcripts having been reported in the hippocampus of Alzheimer's disease (AD) and in the substantia nigra of Parkinson's disease (PD), respectively (Mastroeni et al., 2017).INTRODUCTIONIt is now well accepted that alterations in microglial activity and dysregulated microglial\u2010induced neuroinflammation have dual effects on many neurological diseases (Du et al., 2017; Salter & Stevens, 2017).", [["microglial", "ANATOMY", 14, 24], ["hippocampus", "ANATOMY", 170, 181], ["substantia nigra", "ANATOMY", 221, 237], ["microglial", "ANATOMY", 361, 371], ["neurological", "ANATOMY", 461, 473], ["Alzheimer's disease", "DISEASE", 185, 204], ["AD", "DISEASE", 206, 208], ["Parkinson's disease", "DISEASE", 241, 260], ["PD", "DISEASE", 262, 264], ["neuroinflammation", "DISEASE", 417, 434], ["neurological diseases", "DISEASE", 461, 482], ["microglial", "CELL", 14, 24], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 170, 181], ["microglial", "CELL", 361, 371], ["Variations in microglial profiles", "PROBLEM", 0, 33], ["the specific diseases states", "PROBLEM", 53, 81], ["significantly altered transcripts", "PROBLEM", 108, 141], ["Alzheimer's disease", "PROBLEM", 185, 204], ["Parkinson's disease", "PROBLEM", 241, 260], ["dysregulated microglial\u2010induced neuroinflammation", "PROBLEM", 385, 434], ["many neurological diseases", "PROBLEM", 456, 482], ["microglial profiles", "OBSERVATION", 14, 33], ["hippocampus", "ANATOMY", 170, 181], ["Alzheimer", "OBSERVATION", 185, 194], ["substantia nigra", "ANATOMY", 221, 237], ["Parkinson's disease", "OBSERVATION", 241, 260], ["microglial activity", "OBSERVATION", 361, 380]]], ["Although the microglial field is intensively researched at present, less is still known about how microglia can be precisely targeted for optimal therapeutic efficacy.", [["microglial field", "ANATOMY", 13, 29], ["microglia", "ANATOMY", 98, 107], ["microglial", "CELL", 13, 23], ["microglia", "CELL", 98, 107], ["microglia", "CELL_TYPE", 98, 107], ["microglial", "OBSERVATION_MODIFIER", 13, 23]]], ["The concept of glial replacement therapy using progenitors has recently been proposed (Cartier, Lewis, Zhang, & Rossi, 2014; Shen, Li, Bao, & Wang, 2017; Srivastava, Bulte, Walczak, & Janowski, 2017).", [["glial", "ANATOMY", 15, 20], ["progenitors", "ANATOMY", 47, 58], ["glial", "CELL", 15, 20], ["progenitors", "CELL", 47, 58], ["progenitors", "CELL_TYPE", 47, 58], ["glial replacement therapy", "TREATMENT", 15, 40], ["glial replacement", "OBSERVATION", 15, 32]]], ["In this review we will introduce and discuss a new experimental paradigm to specifically control the excessive activation of microglia in vivo using fully differentiated and pre\u2010activated cells, and provide a rationale for its translation into clinical practice.MULTI\u2010TASKING MICROGLIA: A FRIEND FOR BRAIN HOMEOSTASISMicroglia can perform diverse functions to maintain overall tissue integrity during steady\u2010state conditions (Colonna & Butovsky, 2017; Kabba et al., 2017; Mosser, Baptista, Arnoux, & Audinat, 2017; Prinz, Erny, & Hagemeyer, 2017).", [["microglia", "ANATOMY", 125, 134], ["cells", "ANATOMY", 188, 193], ["tissue", "ANATOMY", 377, 383], ["microglia", "CELL", 125, 134], ["cells", "CELL", 188, 193], ["tissue", "TISSUE", 377, 383], ["microglia", "CELL_TYPE", 125, 134], ["pre\u2010activated cells", "CELL_LINE", 174, 193], ["a new experimental paradigm", "TREATMENT", 45, 72], ["fully differentiated and pre\u2010activated cells", "PROBLEM", 149, 193], ["BRAIN HOMEOSTASISMicroglia", "TREATMENT", 300, 326], ["diverse functions", "TREATMENT", 339, 356]]], ["Indeed, a growing body of evidence convincingly demonstrates that microglia are recognized for acting as \u201cbusy bees\u201d and maintain an expanding array of functions during both early brain development and adult homeostasis (Figure 1).", [["microglia", "ANATOMY", 66, 75], ["brain", "ANATOMY", 180, 185], ["microglia", "CELL", 66, 75], ["brain", "ORGAN", 180, 185], ["microglia", "CELL_TYPE", 66, 75], ["microglia", "OBSERVATION", 66, 75], ["brain", "ANATOMY", 180, 185]]], ["In particular, microglia can secrete a broad range of protective neurotrophic substances such as brain\u2010derived neurotrophic factor (BDNF), vascular endothelial growth factor, neuronal growth factor (NGF), insulin\u2010like growth factor\u20101 (IGF\u20101), platelet\u2010derived growth factors and transforming growth factor\u2010\u03b2 (TGF\u2010\u03b2) (Butovsky et al., 2014; Parkhurst et al., 2013; Shibata & Suzuki, 2017; Wlodarczyk et al., 2017), thus ensuring appropriate neuronal network development and maintenance as well as enhancing memory and learning (Molteni & Rossetti, 2017; Parkhurst et al., 2013).", [["microglia", "ANATOMY", 15, 24], ["neuronal network", "ANATOMY", 440, 456], ["microglia", "CELL", 15, 24], ["brain\u2010derived neurotrophic factor", "GENE_OR_GENE_PRODUCT", 97, 130], ["BDNF", "GENE_OR_GENE_PRODUCT", 132, 136], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 139, 173], ["neuronal growth factor", "GENE_OR_GENE_PRODUCT", 175, 197], ["NGF", "GENE_OR_GENE_PRODUCT", 199, 202], ["insulin\u2010like growth factor\u20101", "GENE_OR_GENE_PRODUCT", 205, 233], ["IGF\u20101", "GENE_OR_GENE_PRODUCT", 235, 240], ["platelet\u2010derived growth factors", "GENE_OR_GENE_PRODUCT", 243, 274], ["transforming growth factor\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 279, 307], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 309, 314], ["neuronal network", "MULTI-TISSUE_STRUCTURE", 440, 456], ["microglia", "CELL_TYPE", 15, 24], ["brain\u2010derived neurotrophic factor", "PROTEIN", 97, 130], ["BDNF", "PROTEIN", 132, 136], ["vascular endothelial growth factor", "PROTEIN", 139, 173], ["neuronal growth factor", "PROTEIN", 175, 197], ["NGF", "PROTEIN", 199, 202], ["insulin\u2010like growth factor\u20101", "PROTEIN", 205, 233], ["IGF\u20101", "PROTEIN", 235, 240], ["platelet\u2010derived growth factors", "PROTEIN", 243, 274], ["transforming growth factor\u2010\u03b2", "PROTEIN", 279, 307], ["TGF\u2010\u03b2", "PROTEIN", 309, 314], ["protective neurotrophic substances", "TREATMENT", 54, 88], ["vascular endothelial growth factor", "PROBLEM", 139, 173], ["neuronal growth factor", "PROBLEM", 175, 197], ["NGF", "TEST", 199, 202], ["insulin\u2010like growth factor\u20101", "PROBLEM", 205, 233], ["IGF", "TEST", 235, 238], ["platelet\u2010derived growth factors", "PROBLEM", 243, 274], ["transforming growth factor\u2010\u03b2", "TEST", 279, 307], ["neurotrophic substances", "OBSERVATION", 65, 88], ["vascular endothelial", "ANATOMY", 139, 159]]], ["There is a widespread consensus that microglia are also in active intimate contact with neighboring neuronal and non\u2010neuronal cells, thereby regulating neuronal proliferation, migration and differentiation and refining the neural circuits (Frost & Schafer, 2016; Mosser et al., 2017).MULTI\u2010TASKING MICROGLIA: A FRIEND FOR BRAIN HOMEOSTASISIn order to perform these above\u2010mentioned functions a diverse array of receptors including TAM receptors, glutamate receptors, and purinergic receptors are used by microglia to efficiently communicate with other cells (Fourgeaud et al., 2016; York, Bernier, & MacVicar, 2017).", [["microglia", "ANATOMY", 37, 46], ["neuronal", "ANATOMY", 100, 108], ["non\u2010neuronal cells", "ANATOMY", 113, 131], ["neuronal", "ANATOMY", 152, 160], ["neural", "ANATOMY", 223, 229], ["microglia", "ANATOMY", 503, 512], ["cells", "ANATOMY", 551, 556], ["TAM", "CHEMICAL", 430, 433], ["glutamate", "CHEMICAL", 445, 454], ["TAM", "CHEMICAL", 430, 433], ["glutamate", "CHEMICAL", 445, 454], ["microglia", "CELL", 37, 46], ["neuronal", "CELL", 100, 108], ["non\u2010neuronal cells", "CELL", 113, 131], ["neuronal", "CELL", 152, 160], ["TAM receptors", "GENE_OR_GENE_PRODUCT", 430, 443], ["glutamate receptors", "GENE_OR_GENE_PRODUCT", 445, 464], ["microglia", "CELL", 503, 512], ["cells", "CELL", 551, 556], ["microglia", "CELL_TYPE", 37, 46], ["neuronal and non\u2010neuronal cells", "CELL_TYPE", 100, 131], ["TAM receptors", "PROTEIN", 430, 443], ["glutamate receptors", "PROTEIN", 445, 464], ["purinergic receptors", "PROTEIN", 470, 490], ["microglia", "CELL_TYPE", 503, 512], ["neighboring neuronal and non\u2010neuronal cells", "PROBLEM", 88, 131], ["regulating neuronal proliferation", "PROBLEM", 141, 174], ["a diverse array of receptors", "TREATMENT", 391, 419], ["TAM receptors", "TREATMENT", 430, 443], ["glutamate receptors", "TREATMENT", 445, 464], ["purinergic receptors", "TREATMENT", 470, 490], ["widespread", "OBSERVATION_MODIFIER", 11, 21], ["microglia", "OBSERVATION", 37, 46], ["active", "OBSERVATION_MODIFIER", 59, 65], ["non\u2010neuronal cells", "OBSERVATION", 113, 131], ["neuronal proliferation", "OBSERVATION", 152, 174], ["migration", "OBSERVATION_MODIFIER", 176, 185], ["neural circuits", "ANATOMY", 223, 238]]], ["Among these complex systems the CX3CL1/CX3CR1 and CD200\u2010CD200R axes play key roles in microglia\u2013neuron contact (Eyo & Wu, 2013; Kierdorf & Prinz, 2017; Limatola & Ransohoff, 2014; Mecca, Giambanco, Donato, & Arcuri, 2018).", [["microglia\u2013neuron contact", "ANATOMY", 86, 110], ["CX3CL1", "GENE_OR_GENE_PRODUCT", 32, 38], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 39, 45], ["CD200", "GENE_OR_GENE_PRODUCT", 50, 55], ["CD200R", "GENE_OR_GENE_PRODUCT", 56, 62], ["CX3CL1", "PROTEIN", 32, 38], ["CX3CR1", "PROTEIN", 39, 45], ["CD200", "PROTEIN", 50, 55], ["CD200R", "PROTEIN", 56, 62], ["the CX3CL1", "TEST", 28, 38], ["CX3CR1", "TEST", 39, 45], ["CD200", "TEST", 50, 55], ["Mecca", "TREATMENT", 180, 185]]], ["Indeed, the CX3CR1\u2212/\u2212 mouse exhibited profound alterations in both morphology and connectivity of the mature newborn hippocampal granule neurons (Bolos et al., 2017).", [["hippocampal granule neurons", "ANATOMY", 117, 144], ["CX3CR1\u2212", "GENE_OR_GENE_PRODUCT", 12, 19], ["hippocampal granule neurons", "CELL", 117, 144], ["CX3CR1\u2212", "PROTEIN", 12, 19], ["mature newborn hippocampal granule neurons", "CELL_TYPE", 102, 144], ["mouse", "SPECIES", 22, 27], ["mouse", "SPECIES", 22, 27], ["the CX3CR1\u2212", "TEST", 8, 19], ["profound alterations", "PROBLEM", 38, 58], ["profound", "OBSERVATION_MODIFIER", 38, 46], ["alterations", "OBSERVATION", 47, 58], ["both morphology", "OBSERVATION_MODIFIER", 62, 77], ["mature", "OBSERVATION_MODIFIER", 102, 108], ["newborn hippocampal", "OBSERVATION", 109, 128], ["granule neurons", "OBSERVATION", 129, 144]]], ["The CD200\u2212/\u2212 mouse exhibits an activated microglial phenotype accompanied by high expression of CD11b and CD45 (Hoek et al., 2000).", [["microglial", "ANATOMY", 41, 51], ["CD200\u2212", "GENE_OR_GENE_PRODUCT", 4, 10], ["mouse", "ORGANISM", 13, 18], ["microglial", "CELL", 41, 51], ["CD11b", "GENE_OR_GENE_PRODUCT", 96, 101], ["CD45", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD200\u2212", "PROTEIN", 4, 10], ["CD11b", "PROTEIN", 96, 101], ["CD45", "PROTEIN", 106, 110], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["an activated microglial phenotype", "PROBLEM", 28, 61], ["microglial phenotype", "OBSERVATION", 41, 61], ["high expression", "OBSERVATION_MODIFIER", 77, 92]]], ["Concurrently, microglia are critically involved in neural repair through phagocytic scavenging, such as clearing dead tissues, ingesting plaques, and apoptotic cells (Michell\u2010Robinson et al., 2015).MULTI\u2010TASKING MICROGLIA: A FRIEND FOR BRAIN HOMEOSTASISFurthermore, microglia participate in synaptogenesis by producing neurotrophic substances, such as BDNF, as well as eliminating excessive presynaptic and postsynaptic elements through synaptic pruning via the activation of the complement pathway (Masuda & Prinz, 2016; Sominsky, De Luca, & Spencer, 2017; Stevens et al., 2007; Um, 2017).", [["microglia", "ANATOMY", 14, 23], ["neural", "ANATOMY", 51, 57], ["tissues", "ANATOMY", 118, 125], ["plaques", "ANATOMY", 137, 144], ["cells", "ANATOMY", 160, 165], ["microglia", "ANATOMY", 266, 275], ["presynaptic", "ANATOMY", 391, 402], ["synaptic", "ANATOMY", 437, 445], ["microglia", "CELL", 14, 23], ["neural", "TISSUE", 51, 57], ["tissues", "TISSUE", 118, 125], ["cells", "CELL", 160, 165], ["microglia", "CELL", 266, 275], ["BDNF", "GENE_OR_GENE_PRODUCT", 352, 356], ["microglia", "CELL_TYPE", 14, 23], ["apoptotic cells", "CELL_TYPE", 150, 165], ["microglia", "CELL_TYPE", 266, 275], ["BDNF", "PROTEIN", 352, 356], ["neural repair", "TREATMENT", 51, 64], ["phagocytic scavenging", "TEST", 73, 94], ["clearing dead tissues", "PROBLEM", 104, 125], ["ingesting plaques", "PROBLEM", 127, 144], ["excessive presynaptic and postsynaptic elements", "TREATMENT", 381, 428], ["synaptic pruning", "TREATMENT", 437, 453], ["neural repair", "OBSERVATION", 51, 64], ["phagocytic scavenging", "OBSERVATION", 73, 94], ["plaques", "OBSERVATION", 137, 144], ["apoptotic cells", "OBSERVATION", 150, 165], ["postsynaptic elements", "OBSERVATION", 407, 428]]], ["In addition to the complement\u2010mediated mechanism, astrocyte\u2010derived interleukin (IL)\u201033 is also physiologically required to maintain synapse homeostasis by modulating microglial synapse engulfment (Vainchtein et al., 2018).", [["synapse", "ANATOMY", 133, 140], ["microglial synapse", "ANATOMY", 167, 185], ["interleukin (IL)\u201033", "GENE_OR_GENE_PRODUCT", 68, 87], ["synapse", "CELLULAR_COMPONENT", 133, 140], ["microglial synapse", "CELLULAR_COMPONENT", 167, 185], ["astrocyte\u2010derived interleukin (IL)\u201033", "PROTEIN", 50, 87], ["the complement\u2010mediated mechanism", "PROBLEM", 15, 48], ["astrocyte\u2010derived interleukin (IL)", "TREATMENT", 50, 84], ["microglial synapse engulfment", "OBSERVATION", 167, 196]]], ["Microglia are involved in regulating and shaping both excitatory and inhibitory synapses, such as \u03b3\u2010aminobutyric acid\u2010expressing and glycinergic synapses (Cantaut\u2010Belarif et al., 2017; Um, 2017).", [["Microglia", "ANATOMY", 0, 9], ["inhibitory synapses", "ANATOMY", 69, 88], ["Microglia", "CELL", 0, 9], ["\u03b3\u2010aminobutyric acid\u2010expressing", "GENE_OR_GENE_PRODUCT", 98, 128], ["Microglia", "CELL_TYPE", 0, 9], ["Microglia", "PROBLEM", 0, 9], ["inhibitory synapses", "TREATMENT", 69, 88], ["\u03b3\u2010aminobutyric acid\u2010expressing", "TREATMENT", 98, 128], ["glycinergic synapses", "OBSERVATION", 133, 153]]], ["Conversely, early evidence obtained from CX3CR1 gene\u2010deleted mice indicated that reduced numbers of microglial cells during brain development could impair the processes of synaptic pruning, resulting in a significantly higher density of dendritic spines and immature synapses (Paolicelli et al., 2011; Shibata & Suzuki, 2017).", [["microglial cells", "ANATOMY", 100, 116], ["brain", "ANATOMY", 124, 129], ["synaptic", "ANATOMY", 172, 180], ["dendritic spines", "ANATOMY", 237, 253], ["synapses", "ANATOMY", 267, 275], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 41, 47], ["mice", "ORGANISM", 61, 65], ["microglial cells", "CELL", 100, 116], ["brain", "ORGAN", 124, 129], ["dendritic spines", "CELLULAR_COMPONENT", 237, 253], ["CX3CR1", "PROTEIN", 41, 47], ["microglial cells", "CELL_TYPE", 100, 116], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["reduced numbers of microglial cells", "PROBLEM", 81, 116], ["synaptic pruning", "PROBLEM", 172, 188], ["a significantly higher density of dendritic spines", "PROBLEM", 203, 253], ["immature synapses", "PROBLEM", 258, 275], ["reduced", "OBSERVATION_MODIFIER", 81, 88], ["microglial cells", "OBSERVATION", 100, 116], ["synaptic pruning", "OBSERVATION", 172, 188], ["significantly", "OBSERVATION_MODIFIER", 205, 218], ["higher", "OBSERVATION_MODIFIER", 219, 225], ["density", "OBSERVATION_MODIFIER", 226, 233], ["dendritic spines", "OBSERVATION", 237, 253], ["immature synapses", "OBSERVATION", 258, 275]]], ["During adult neurogenesis, microglia actively contribute to regulate the dynamics, maintenance, and functions of synapses of adult\u2010born neurons (Reshef et al., 2017).MULTI\u2010TASKING MICROGLIA: A FRIEND FOR BRAIN HOMEOSTASISIn addition to their well\u2010described immunological roles, newly emerging neurobiological functions of microglia are currently being recognized and studied.", [["microglia", "ANATOMY", 27, 36], ["synapses", "ANATOMY", 113, 121], ["adult\u2010born neurons", "ANATOMY", 125, 143], ["microglia", "ANATOMY", 322, 331], ["microglia", "CELL", 27, 36], ["adult\u2010born neurons", "CELL", 125, 143], ["microglia", "CELL", 322, 331], ["microglia", "CELL_TYPE", 27, 36], ["adult\u2010born neurons", "CELL_TYPE", 125, 143], ["microglia", "CELL_TYPE", 322, 331], ["microglia", "ANATOMY", 322, 331]]], ["It has been recently determined that a subpopulation of transiently activated microglia, identified in early postnatal white matter region, can directly contribute to the maintenance of oligodendrocyte progenitor numbers and subsequent myelinogenesis in the mouse, since a decreased oligodendrocyte progenitor number was noted following injection of the selective colony\u2010stimulating factor 1 receptor (CSF\u20101R) inhibitor BLZ945 that effectively depletes microglia (Hagemeyer et al., 2017).", [["microglia", "ANATOMY", 78, 87], ["white matter region", "ANATOMY", 119, 138], ["oligodendrocyte progenitor", "ANATOMY", 186, 212], ["oligodendrocyte progenitor", "ANATOMY", 283, 309], ["microglia", "ANATOMY", 453, 462], ["BLZ945", "CHEMICAL", 420, 426], ["BLZ945", "CHEMICAL", 420, 426], ["microglia", "CELL", 78, 87], ["oligodendrocyte progenitor", "CELL", 186, 212], ["mouse", "ORGANISM", 258, 263], ["oligodendrocyte progenitor", "CELL", 283, 309], ["selective colony\u2010stimulating factor 1 receptor", "GENE_OR_GENE_PRODUCT", 354, 400], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 402, 408], ["BLZ945", "SIMPLE_CHEMICAL", 420, 426], ["microglia", "CELL", 453, 462], ["microglia", "CELL_TYPE", 78, 87], ["selective colony\u2010stimulating factor 1 receptor", "PROTEIN", 354, 400], ["CSF\u20101R", "PROTEIN", 402, 408], ["microglia", "CELL_TYPE", 453, 462], ["mouse", "SPECIES", 258, 263], ["mouse", "SPECIES", 258, 263], ["transiently activated microglia", "PROBLEM", 56, 87], ["early postnatal white matter region", "PROBLEM", 103, 138], ["subsequent myelinogenesis in the mouse", "PROBLEM", 225, 263], ["a decreased oligodendrocyte progenitor number", "PROBLEM", 271, 316], ["the selective colony\u2010stimulating factor", "TREATMENT", 350, 389], ["receptor (CSF\u20101R) inhibitor", "TREATMENT", 392, 419], ["subpopulation", "OBSERVATION_MODIFIER", 39, 52], ["transiently", "OBSERVATION_MODIFIER", 56, 67], ["activated microglia", "OBSERVATION", 68, 87], ["early", "OBSERVATION_MODIFIER", 103, 108], ["postnatal", "OBSERVATION_MODIFIER", 109, 118], ["white matter", "OBSERVATION", 119, 131], ["oligodendrocyte progenitor", "OBSERVATION", 186, 212], ["decreased", "OBSERVATION_MODIFIER", 273, 282], ["oligodendrocyte progenitor", "OBSERVATION", 283, 309]]], ["Other recent observations provide evidence that microglia actively regulate neurovascular homeostasis, such as forming new blood vessels and the vascular branching of the retina and hindbrain (Arcuri, Mecca, Bianchi, Giambanco, & Donato, 2017; Brandenburg et al., 2016; Dudvarski Stankovic, Teodorczyk, Ploen, Zipp, & Schmidt, 2016; Zhao, Eyo, Murugan, & Wu, 2018).", [["microglia", "ANATOMY", 48, 57], ["neurovascular", "ANATOMY", 76, 89], ["blood vessels", "ANATOMY", 123, 136], ["vascular", "ANATOMY", 145, 153], ["retina", "ANATOMY", 171, 177], ["hindbrain", "ANATOMY", 182, 191], ["microglia", "CELL", 48, 57], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 76, 89], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 123, 136], ["vascular", "MULTI-TISSUE_STRUCTURE", 145, 153], ["retina", "MULTI-TISSUE_STRUCTURE", 171, 177], ["hindbrain", "MULTI-TISSUE_STRUCTURE", 182, 191], ["microglia", "CELL_TYPE", 48, 57], ["neurovascular homeostasis", "PROBLEM", 76, 101], ["new blood vessels", "PROBLEM", 119, 136], ["Teodorczyk", "TREATMENT", 291, 301], ["Ploen", "TREATMENT", 303, 308], ["vessels", "ANATOMY", 129, 136], ["vascular", "ANATOMY", 145, 153], ["branching", "ANATOMY_MODIFIER", 154, 163], ["retina", "ANATOMY", 171, 177], ["hindbrain", "ANATOMY", 182, 191]]], ["In a historical perspective remarkable progress has been made in deciphering many aspects of microglial biology.", [["microglial", "ANATOMY", 93, 103], ["microglial", "CELL", 93, 103]]], ["Further in vivo studies are still warranted to characterize and explore the versatile features of microglia.THE ROLE OF MICROGLIA IN NEUROLOGICAL DISEASES: FRIEND OR FOE?Apart from beneficial roles in the development of CNS, microglia can be widely involved in various types of neurological disorders, including stroke (Guruswamy & ElAli, 2017; Kronenberg et al., 2017), multiple sclerosis (MS) (Bogie, Stinissen, & Hendriks, 2014; Luo et al., 2017), AD (Hansen, Hanson, & Sheng, 2017; Sarlus & Heneka, 2017), PD (Subramaniam & Federoff, 2017), sleep disorders (Nadjar, Wigren, & Tremblay, 2017), amyotrophic lateral sclerosis (ALS) (Geloso et al., 2017; Liu & Wang, 2017), Huntington's disease (H. M. Yang, Yang, Huang, Tang, & Guo, 2017), epilepsy (Eyo, Murugan, & Wu, 2017; Zhao, Liao, et al., 2018), gliomas (Hambardzumyan, Gutmann, & Kettenmann, 2016; Schiffer, Mellai, Bovio, & Annovazzi, 2017), Prion diseases (Aguzzi & Zhu, 2017; Obst, Simon, Mancuso, & Gomez\u2010Nicola, 2017), psychiatric disorders (Mondelli, Vernon, Turkheimer, Dazzan, & Pariante, 2017; Prinz & Priller, 2014; Setiawan et al., 2018; Singhal & Baune, 2017), neuropathic pain (Inoue & Tsuda, 2018; Peng et al., 2016), adrenomyeloneuropathy (Gong et al., 2017), and traumatic brain injury (Donat, Scott, Gentleman, & Sastre, 2017).", [["microglia", "ANATOMY", 98, 107], ["CNS", "ANATOMY", 220, 223], ["microglia", "ANATOMY", 225, 234], ["neurological", "ANATOMY", 278, 290], ["gliomas", "ANATOMY", 804, 811], ["brain", "ANATOMY", 1248, 1253], ["neurological disorders", "DISEASE", 278, 300], ["stroke", "DISEASE", 312, 318], ["multiple sclerosis", "DISEASE", 371, 389], ["MS", "DISEASE", 391, 393], ["AD", "DISEASE", 451, 453], ["PD", "DISEASE", 510, 512], ["sleep disorders", "DISEASE", 545, 560], ["amyotrophic lateral sclerosis", "DISEASE", 597, 626], ["ALS", "DISEASE", 628, 631], ["Huntington's disease", "DISEASE", 674, 694], ["epilepsy", "DISEASE", 741, 749], ["gliomas", "DISEASE", 804, 811], ["Prion diseases", "DISEASE", 902, 916], ["psychiatric disorders", "DISEASE", 983, 1004], ["neuropathic pain", "DISEASE", 1132, 1148], ["adrenomyeloneuropathy", "DISEASE", 1191, 1212], ["traumatic brain injury", "DISEASE", 1238, 1260], ["microglia", "CELL", 98, 107], ["CNS", "ANATOMICAL_SYSTEM", 220, 223], ["microglia", "CELL", 225, 234], ["amyotrophic lateral sclerosis", "CANCER", 597, 626], ["gliomas", "CANCER", 804, 811], ["brain", "ORGAN", 1248, 1253], ["microglia", "CELL_TYPE", 98, 107], ["microglia", "CELL_TYPE", 225, 234], ["Further in vivo studies", "TEST", 0, 23], ["microglia", "PROBLEM", 98, 107], ["neurological disorders", "PROBLEM", 278, 300], ["stroke", "PROBLEM", 312, 318], ["multiple sclerosis (MS)", "PROBLEM", 371, 394], ["sleep disorders", "PROBLEM", 545, 560], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 597, 632], ["Huntington's disease", "PROBLEM", 674, 694], ["epilepsy", "PROBLEM", 741, 749], ["gliomas", "PROBLEM", 804, 811], ["Mellai", "TREATMENT", 867, 873], ["psychiatric disorders", "PROBLEM", 983, 1004], ["neuropathic pain", "PROBLEM", 1132, 1148], ["traumatic brain injury", "PROBLEM", 1238, 1260], ["microglia", "OBSERVATION", 98, 107], ["beneficial", "OBSERVATION_MODIFIER", 181, 191], ["CNS", "ANATOMY", 220, 223], ["neurological disorders", "OBSERVATION", 278, 300], ["multiple", "OBSERVATION_MODIFIER", 371, 379], ["sclerosis", "OBSERVATION", 380, 389], ["amyotrophic", "OBSERVATION", 597, 608], ["lateral", "ANATOMY_MODIFIER", 609, 616], ["sclerosis", "OBSERVATION", 617, 626], ["gliomas", "ANATOMY", 804, 811], ["neuropathic", "ANATOMY", 1132, 1143], ["traumatic", "OBSERVATION", 1238, 1247], ["brain", "ANATOMY", 1248, 1253], ["injury", "OBSERVATION", 1254, 1260]]], ["In general, microglia can be rapidly activated depending upon different stimulatory contexts and environmental changes through diverse molecular and cellular programs, subsequently transforming into the activated state and enhancing the expression of the Toll\u2010like receptors which sensitively bind microbial structures (Arcuri et al., 2017).THE ROLE OF MICROGLIA IN NEUROLOGICAL DISEASES: FRIEND OR FOE?In addition to these morphological changes, activated microglia can acquire an altered gene expression pattern toward functionally distinct phenotypes.", [["microglia", "ANATOMY", 12, 21], ["cellular", "ANATOMY", 149, 157], ["microglia", "ANATOMY", 457, 466], ["microglia", "CELL", 12, 21], ["cellular", "CELL", 149, 157], ["Toll\u2010like receptors", "GENE_OR_GENE_PRODUCT", 255, 274], ["microglia", "CELL", 457, 466], ["microglia", "CELL_TYPE", 12, 21], ["Toll\u2010like receptors", "PROTEIN", 255, 274], ["activated microglia", "CELL_TYPE", 447, 466], ["these morphological changes", "PROBLEM", 418, 445], ["activated microglia", "PROBLEM", 447, 466], ["an altered gene expression pattern", "PROBLEM", 479, 513], ["functionally distinct phenotypes", "PROBLEM", 521, 553], ["activated microglia", "OBSERVATION", 447, 466], ["distinct phenotypes", "OBSERVATION", 534, 553]]], ["Once provoked, microglia produce pro\u2010inflammatory cytokines and chemokines, such as IL\u20101, IL\u20106, IL\u201023, interferon gamma\u2010\u03b3 (IFN\u2010\u03b3), CC chemokine ligand 2 (CCL2) and tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) (Natoli et al., 2017; Nicolas et al., 2017; Smith, Das, Ray, & Banik, 2012), which are toxic to neighboring neurons and other glial cells such as astrocytes and oligodendrocytes.", [["microglia", "ANATOMY", 15, 24], ["neurons", "ANATOMY", 304, 311], ["glial cells", "ANATOMY", 322, 333], ["astrocytes", "ANATOMY", 342, 352], ["oligodendrocytes", "ANATOMY", 357, 373], ["necrosis", "DISEASE", 170, 178], ["microglia", "CELL", 15, 24], ["IL\u20101", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 90, 94], ["IL\u201023", "GENE_OR_GENE_PRODUCT", 96, 101], ["interferon gamma\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 103, 121], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 123, 128], ["CC chemokine ligand 2", "GENE_OR_GENE_PRODUCT", 131, 152], ["CCL2", "GENE_OR_GENE_PRODUCT", 154, 158], ["tumor necrosis factor\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 164, 187], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 189, 194], ["neurons", "CELL", 304, 311], ["glial cells", "CELL", 322, 333], ["astrocytes", "CELL", 342, 352], ["oligodendrocytes", "CELL", 357, 373], ["microglia", "CELL_TYPE", 15, 24], ["pro\u2010inflammatory cytokines", "PROTEIN", 33, 59], ["chemokines", "PROTEIN", 64, 74], ["IL\u20101", "PROTEIN", 84, 88], ["IL\u20106", "PROTEIN", 90, 94], ["IL\u201023", "PROTEIN", 96, 101], ["interferon gamma\u2010\u03b3", "PROTEIN", 103, 121], ["IFN\u2010\u03b3", "PROTEIN", 123, 128], ["CC chemokine ligand 2", "PROTEIN", 131, 152], ["CCL2", "PROTEIN", 154, 158], ["tumor necrosis factor\u2010\u03b1", "PROTEIN", 164, 187], ["TNF\u2010\u03b1", "PROTEIN", 189, 194], ["neighboring neurons", "CELL_TYPE", 292, 311], ["glial cells", "CELL_TYPE", 322, 333], ["astrocytes", "CELL_TYPE", 342, 352], ["oligodendrocytes", "CELL_TYPE", 357, 373], ["pro\u2010inflammatory cytokines", "TREATMENT", 33, 59], ["chemokines", "TEST", 64, 74], ["IL\u2010", "TREATMENT", 84, 87], ["interferon gamma\u2010\u03b3", "TREATMENT", 103, 121], ["CC chemokine ligand", "TEST", 131, 150], ["CCL2", "TEST", 154, 158], ["tumor necrosis factor\u2010\u03b1", "TEST", 164, 187], ["TNF", "TEST", 189, 192], ["toxic to neighboring neurons", "PROBLEM", 283, 311], ["other glial cells", "PROBLEM", 316, 333], ["oligodendrocytes", "PROBLEM", 357, 373], ["tumor necrosis", "OBSERVATION", 164, 178], ["Ray", "ANATOMY", 252, 255], ["glial cells", "OBSERVATION", 322, 333]]], ["Nevertheless, activated microglia are more than simply destructive, it being widely recognized that immunoregulatory microglia are required for regulating brain repair and regeneration by secreting anti\u2010inflammatory factors, such as IL\u20104, IL\u201010, IL\u201013, and TGF\u2010\u03b2 (Cherry, Olschowka, & O'Banion, 2014; X. Jin & Yamashita, 2016).THE ROLE OF MICROGLIA IN NEUROLOGICAL DISEASES: FRIEND OR FOE?Despite that microglia are necessary for repairing the CNS in normal conditions, activated microglia suppress the processes of brain repair by inhibiting the differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes via distinct mechanisms including heat shock protein 60 production, NO\u2010dependent oxidative damage and TNF\u2010\u03b1 signaling (Li, Zhang, et al., 2017; Pang et al., 2010).", [["microglia", "ANATOMY", 24, 33], ["microglia", "ANATOMY", 117, 126], ["brain", "ANATOMY", 155, 160], ["microglia", "ANATOMY", 402, 411], ["CNS", "ANATOMY", 444, 447], ["microglia", "ANATOMY", 480, 489], ["brain", "ANATOMY", 516, 521], ["oligodendrocyte precursor cells", "ANATOMY", 566, 597], ["oligodendrocytes", "ANATOMY", 615, 631], ["NO", "CHEMICAL", 700, 702], ["NO", "CHEMICAL", 700, 702], ["microglia", "CELL", 24, 33], ["microglia", "CELL", 117, 126], ["brain", "ORGAN", 155, 160], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 233, 237], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 239, 244], ["IL\u201013", "GENE_OR_GENE_PRODUCT", 246, 251], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 257, 262], ["microglia", "CELL", 402, 411], ["CNS", "ANATOMICAL_SYSTEM", 444, 447], ["microglia", "CELL", 480, 489], ["brain", "ORGAN", 516, 521], ["oligodendrocyte precursor cells", "CELL", 566, 597], ["oligodendrocytes", "CELL", 615, 631], ["heat shock protein 60", "GENE_OR_GENE_PRODUCT", 666, 687], ["NO\u2010", "SIMPLE_CHEMICAL", 700, 703], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 734, 739], ["activated microglia", "CELL_TYPE", 14, 33], ["immunoregulatory microglia", "CELL_TYPE", 100, 126], ["anti\u2010inflammatory factors", "PROTEIN", 198, 223], ["IL\u20104", "PROTEIN", 233, 237], ["IL\u201010", "PROTEIN", 239, 244], ["IL\u201013", "PROTEIN", 246, 251], ["TGF", "PROTEIN", 257, 260], ["microglia", "CELL_TYPE", 402, 411], ["activated microglia", "CELL_TYPE", 470, 489], ["oligodendrocyte precursor cells", "CELL_TYPE", 566, 597], ["myelinating oligodendrocytes", "CELL_TYPE", 603, 631], ["heat shock protein 60", "PROTEIN", 666, 687], ["TNF", "PROTEIN", 734, 737], ["activated microglia", "PROBLEM", 14, 33], ["immunoregulatory microglia", "PROBLEM", 100, 126], ["brain repair", "TREATMENT", 155, 167], ["secreting anti\u2010inflammatory factors", "PROBLEM", 188, 223], ["brain repair", "TREATMENT", 516, 528], ["oligodendrocyte precursor cells", "PROBLEM", 566, 597], ["myelinating oligodendrocytes", "PROBLEM", 603, 631], ["heat shock protein", "TEST", 666, 684], ["\u2010dependent oxidative damage", "PROBLEM", 702, 729], ["microglia", "OBSERVATION", 24, 33], ["more than simply destructive", "OBSERVATION_MODIFIER", 38, 66], ["immunoregulatory microglia", "OBSERVATION", 100, 126], ["brain", "ANATOMY", 155, 160], ["repair", "OBSERVATION", 161, 167], ["CNS", "ANATOMY", 444, 447], ["normal conditions", "OBSERVATION", 451, 468], ["brain", "ANATOMY", 516, 521], ["repair", "OBSERVATION", 522, 528], ["oxidative damage", "OBSERVATION", 713, 729]]], ["Following pathological alterations, extracellular adenosine triphosphate, a source of energy metabolism, produced by dead and injured neurons can in turn activate microglia via purinergic receptors (Liu & Wang, 2017).", [["extracellular", "ANATOMY", 36, 49], ["neurons", "ANATOMY", 134, 141], ["microglia", "ANATOMY", 163, 172], ["adenosine", "CHEMICAL", 50, 59], ["triphosphate", "CHEMICAL", 60, 72], ["adenosine triphosphate", "CHEMICAL", 50, 72], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 49], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 50, 72], ["neurons", "CELL", 134, 141], ["microglia", "CELL", 163, 172], ["injured neurons", "CELL_TYPE", 126, 141], ["microglia", "CELL_TYPE", 163, 172], ["purinergic receptors", "PROTEIN", 177, 197], ["pathological alterations", "PROBLEM", 10, 34], ["extracellular adenosine triphosphate", "TREATMENT", 36, 72], ["energy metabolism", "PROBLEM", 86, 103], ["dead and injured neurons", "PROBLEM", 117, 141], ["adenosine triphosphate", "OBSERVATION", 50, 72]]], ["Excessive activation of microglia can induce mitochondrial damage and decrease mitochondrial oxygen consumption depending on the degree of their activity, thus influencing total brain energy metabolism and exacerbating disease states (Ghosh, Castillo, Frias, & Swanson, 2017).", [["microglia", "ANATOMY", 24, 33], ["mitochondrial", "ANATOMY", 45, 58], ["mitochondrial", "ANATOMY", 79, 92], ["brain", "ANATOMY", 178, 183], ["mitochondrial damage", "DISEASE", 45, 65], ["oxygen", "CHEMICAL", 93, 99], ["oxygen", "CHEMICAL", 93, 99], ["microglia", "CELL", 24, 33], ["mitochondrial", "CELLULAR_COMPONENT", 45, 58], ["mitochondrial", "CELLULAR_COMPONENT", 79, 92], ["oxygen", "SIMPLE_CHEMICAL", 93, 99], ["brain", "ORGAN", 178, 183], ["microglia", "CELL_TYPE", 24, 33], ["Excessive activation of microglia", "PROBLEM", 0, 33], ["mitochondrial damage", "PROBLEM", 45, 65], ["mitochondrial oxygen consumption", "TREATMENT", 79, 111], ["influencing total brain energy metabolism", "PROBLEM", 160, 201], ["exacerbating disease states", "PROBLEM", 206, 233], ["microglia", "OBSERVATION", 24, 33], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["mitochondrial oxygen consumption", "OBSERVATION", 79, 111]]], ["Activated microglia can also be viewed as a major source of reactive oxidative stress through the release of reactive oxygen species and reactive nitrogen species, which cause oxidative damage to neurons and exacerbate the inflammatory cascade.THE ROLE OF MICROGLIA IN NEUROLOGICAL DISEASES: FRIEND OR FOE?Moreover, excessively activated microglia have detrimental effects on neurogenesis, contribute to neuronal death and aggravate long\u2010term neurological deficits by hindering axonal regeneration (Kitayama, Ueno, Itakura, & Yamashita, 2011; Papageorgiou et al., 2016; Rodriguez et al., 2017).", [["microglia", "ANATOMY", 10, 19], ["neurons", "ANATOMY", 196, 203], ["microglia", "ANATOMY", 338, 347], ["neuronal", "ANATOMY", 404, 412], ["neurological", "ANATOMY", 443, 455], ["axonal", "ANATOMY", 478, 484], ["oxygen", "CHEMICAL", 118, 124], ["neuronal death", "DISEASE", 404, 418], ["neurological deficits", "DISEASE", 443, 464], ["oxygen", "CHEMICAL", 118, 124], ["nitrogen", "CHEMICAL", 146, 154], ["microglia", "CELL", 10, 19], ["reactive oxygen species", "SIMPLE_CHEMICAL", 109, 132], ["reactive nitrogen species", "SIMPLE_CHEMICAL", 137, 162], ["neurons", "CELL", 196, 203], ["microglia", "CELL", 338, 347], ["neuronal", "CELL", 404, 412], ["axonal", "MULTI-TISSUE_STRUCTURE", 478, 484], ["microglia", "CELL_TYPE", 10, 19], ["microglia", "CELL_TYPE", 338, 347], ["reactive oxidative stress", "PROBLEM", 60, 85], ["reactive oxygen species", "PROBLEM", 109, 132], ["reactive nitrogen species", "PROBLEM", 137, 162], ["oxidative damage to neurons", "PROBLEM", 176, 203], ["the inflammatory cascade", "PROBLEM", 219, 243], ["excessively activated microglia", "PROBLEM", 316, 347], ["neuronal death", "PROBLEM", 404, 418], ["aggravate long\u2010term neurological deficits", "PROBLEM", 423, 464], ["hindering axonal regeneration", "PROBLEM", 468, 497], ["microglia", "OBSERVATION", 10, 19], ["reactive oxidative stress", "OBSERVATION", 60, 85], ["reactive", "OBSERVATION_MODIFIER", 109, 117], ["oxygen species", "OBSERVATION", 118, 132], ["reactive nitrogen species", "OBSERVATION", 137, 162], ["inflammatory cascade", "OBSERVATION", 223, 243], ["neuronal death", "OBSERVATION", 404, 418], ["axonal regeneration", "OBSERVATION", 478, 497]]], ["In vivo, microglia may even have a functional interaction with peripherally derived immune cells in the circulation in healthy subjects (Kanegawa et al., 2016).", [["microglia", "ANATOMY", 9, 18], ["immune cells", "ANATOMY", 84, 96], ["microglia", "CELL", 9, 18], ["peripherally derived immune cells", "CELL", 63, 96], ["microglia", "CELL_TYPE", 9, 18], ["peripherally derived immune cells", "CELL_TYPE", 63, 96], ["immune cells", "OBSERVATION", 84, 96], ["circulation", "ANATOMY", 104, 115]]], ["A recent exciting study has reported that activation of microglia plays a central role in inducing neurotoxic reactive astrocytes through production of IL\u20101\u03b1, TNF, and C1q.", [["microglia", "ANATOMY", 56, 65], ["astrocytes", "ANATOMY", 119, 129], ["neurotoxic", "DISEASE", 99, 109], ["microglia", "CELL", 56, 65], ["astrocytes", "CELL", 119, 129], ["IL\u20101\u03b1", "GENE_OR_GENE_PRODUCT", 152, 157], ["TNF", "GENE_OR_GENE_PRODUCT", 159, 162], ["C1q", "GENE_OR_GENE_PRODUCT", 168, 171], ["microglia", "CELL_TYPE", 56, 65], ["neurotoxic reactive astrocytes", "CELL_TYPE", 99, 129], ["IL\u20101\u03b1", "PROTEIN", 152, 157], ["TNF", "PROTEIN", 159, 162], ["C1q", "PROTEIN", 168, 171], ["A recent exciting study", "TEST", 0, 23], ["neurotoxic reactive astrocytes", "PROBLEM", 99, 129], ["TNF", "TEST", 159, 162], ["microglia", "ANATOMY", 56, 65], ["neurotoxic", "OBSERVATION_MODIFIER", 99, 109], ["reactive astrocytes", "OBSERVATION", 110, 129], ["TNF", "ANATOMY", 159, 162]]], ["The reactive astrocytes induced by activated microglia, termed A1, lose their homeostatic functions and consequently contribute to the death of neurons and differentiated oligodendrocytes (Liddelow et al., 2017).", [["astrocytes", "ANATOMY", 13, 23], ["microglia", "ANATOMY", 45, 54], ["neurons", "ANATOMY", 144, 151], ["oligodendrocytes", "ANATOMY", 171, 187], ["death", "DISEASE", 135, 140], ["astrocytes", "CELL", 13, 23], ["microglia", "CELL", 45, 54], ["A1", "GENE_OR_GENE_PRODUCT", 63, 65], ["neurons", "CELL", 144, 151], ["oligodendrocytes", "CELL", 171, 187], ["reactive astrocytes", "CELL_TYPE", 4, 23], ["activated microglia", "CELL_TYPE", 35, 54], ["A1", "PROTEIN", 63, 65], ["neurons", "CELL_TYPE", 144, 151], ["differentiated oligodendrocytes", "CELL_TYPE", 156, 187], ["The reactive astrocytes", "PROBLEM", 0, 23], ["the death of neurons", "PROBLEM", 131, 151], ["reactive astrocytes", "OBSERVATION", 4, 23], ["activated microglia", "OBSERVATION", 35, 54]]], ["In addition, activated microglia have been shown to inhibit anti\u2010inflammatory TGF\u2010\u03b2 signaling by downregulating TGF\u2010\u03b2\u2010regulated gene expression and this prolongs chronic microglial dysfunction, partly through the NF\u2010\u03baB signaling pathway (Affram, Mitchell, & Symes, 2017).", [["microglia", "ANATOMY", 23, 32], ["microglial", "ANATOMY", 170, 180], ["microglia", "CELL", 23, 32], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["TGF\u2010", "GENE_OR_GENE_PRODUCT", 112, 116], ["microglial", "CELL", 170, 180], ["NF\u2010\u03baB", "GENE_OR_GENE_PRODUCT", 213, 218], ["activated microglia", "CELL_TYPE", 13, 32], ["TGF\u2010\u03b2", "PROTEIN", 78, 83], ["TGF", "PROTEIN", 112, 115], ["NF\u2010\u03baB", "PROTEIN", 213, 218], ["anti\u2010inflammatory TGF", "TREATMENT", 60, 81], ["this prolongs chronic microglial dysfunction", "PROBLEM", 148, 192], ["microglial dysfunction", "OBSERVATION", 170, 192]]], ["In this way microglial cells may prevent a return to normal homeostatic function.", [["microglial cells", "ANATOMY", 12, 28], ["microglial cells", "CELL", 12, 28], ["microglial cells", "CELL_TYPE", 12, 28], ["microglial cells", "OBSERVATION", 12, 28], ["homeostatic function", "OBSERVATION", 60, 80]]], ["Conversely, if chronic inflammation mediated by persistent dysfunction of microglia remains after injury, this could lead to further extensive tissue damage, neuronal loss and cognitive deficits (Donat et al., 2017).", [["microglia", "ANATOMY", 74, 83], ["tissue", "ANATOMY", 143, 149], ["neuronal", "ANATOMY", 158, 166], ["inflammation", "DISEASE", 23, 35], ["tissue damage", "DISEASE", 143, 156], ["neuronal loss", "DISEASE", 158, 171], ["cognitive deficits", "DISEASE", 176, 194], ["microglia", "CELL", 74, 83], ["tissue", "TISSUE", 143, 149], ["neuronal", "CELL", 158, 166], ["microglia", "CELL_TYPE", 74, 83], ["chronic inflammation", "PROBLEM", 15, 35], ["persistent dysfunction of microglia", "PROBLEM", 48, 83], ["injury", "PROBLEM", 98, 104], ["further extensive tissue damage", "PROBLEM", 125, 156], ["neuronal loss", "PROBLEM", 158, 171], ["cognitive deficits", "PROBLEM", 176, 194], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["inflammation", "OBSERVATION", 23, 35], ["persistent", "OBSERVATION_MODIFIER", 48, 58], ["dysfunction", "OBSERVATION", 59, 70], ["extensive", "OBSERVATION_MODIFIER", 133, 142], ["tissue", "ANATOMY", 143, 149], ["damage", "OBSERVATION", 150, 156], ["neuronal loss", "OBSERVATION", 158, 171]]], ["In summary, although microglia are essential for the development and normal function of the CNS, dysregulated microglia contribute to disease severity in various neurological pathologies.SUBSETS OF MICROGLIA: MORE THAN PRO\u2010INFLAMMATORY AND IMMUNOREGULATORYSimilar to macrophages in the periphery and other organs, microglia exhibit differential activation states generally associated with pro\u2010inflammatory or immunoregulatory functions (Mecha, Carrillo\u2010Salinas, Feliu, Mestre, & Guaza, 2016).", [["microglia", "ANATOMY", 21, 30], ["CNS", "ANATOMY", 92, 95], ["microglia", "ANATOMY", 110, 119], ["neurological", "ANATOMY", 162, 174], ["macrophages", "ANATOMY", 267, 278], ["periphery", "ANATOMY", 286, 295], ["organs", "ANATOMY", 306, 312], ["microglia", "ANATOMY", 314, 323], ["neurological pathologies", "DISEASE", 162, 186], ["microglia", "CELL", 21, 30], ["CNS", "ANATOMICAL_SYSTEM", 92, 95], ["microglia", "CELL", 110, 119], ["macrophages", "CELL", 267, 278], ["organs", "ORGAN", 306, 312], ["microglia", "CELL", 314, 323], ["microglia", "CELL_TYPE", 21, 30], ["microglia", "CELL_TYPE", 110, 119], ["macrophages", "CELL_TYPE", 267, 278], ["microglia", "CELL_TYPE", 314, 323], ["dysregulated microglia", "PROBLEM", 97, 119], ["disease severity in various neurological pathologies", "PROBLEM", 134, 186], ["INFLAMMATORY AND IMMUNOREGULATORYSimilar to macrophages in the periphery and other organs", "PROBLEM", 223, 312], ["differential activation states", "PROBLEM", 332, 362], ["immunoregulatory functions", "PROBLEM", 409, 435], ["Mecha", "TEST", 437, 442], ["normal", "OBSERVATION", 69, 75], ["CNS", "ANATOMY", 92, 95], ["dysregulated microglia", "OBSERVATION", 97, 119], ["macrophages", "OBSERVATION", 267, 278], ["periphery", "ANATOMY_MODIFIER", 286, 295], ["organs", "ANATOMY", 306, 312], ["microglia", "OBSERVATION", 314, 323]]], ["The former contribute to neuroinflammation and neuronal injury through secretion of pro\u2010inflammatory and neurotoxic mediators, whereas the latter exert crucial influences on tissue repair through production of anti\u2010inflammatory cytokines (Tang & Le, 2016).", [["neuronal", "ANATOMY", 47, 55], ["tissue", "ANATOMY", 174, 180], ["neuroinflammation", "DISEASE", 25, 42], ["neuronal injury", "DISEASE", 47, 62], ["neurotoxic", "DISEASE", 105, 115], ["neuronal", "CELL", 47, 55], ["tissue", "TISSUE", 174, 180], ["anti\u2010inflammatory cytokines", "PROTEIN", 210, 237], ["neuroinflammation", "PROBLEM", 25, 42], ["neuronal injury", "PROBLEM", 47, 62], ["secretion of pro\u2010inflammatory and neurotoxic mediators", "PROBLEM", 71, 125], ["tissue repair", "TREATMENT", 174, 187], ["anti\u2010inflammatory cytokines", "TREATMENT", 210, 237], ["neuroinflammation", "OBSERVATION", 25, 42], ["neuronal injury", "OBSERVATION", 47, 62], ["crucial", "OBSERVATION_MODIFIER", 152, 159], ["tissue repair", "OBSERVATION", 174, 187]]], ["We have argued that it is functional states and not in vitro induced surface marker expression phenotypes that should be used to describe activated myeloid cells (Mills, Harris, & Ley, 2015), and the classification of M1 and M2 functionally polarized states for microglia is now considered less valid (Ransohoff, 2016).", [["surface", "ANATOMY", 69, 76], ["myeloid cells", "ANATOMY", 148, 161], ["microglia", "ANATOMY", 262, 271], ["myeloid cells", "CELL", 148, 161], ["Mills", "CELL", 163, 168], ["M1", "CELL", 218, 220], ["microglia", "CELL", 262, 271], ["myeloid cells", "CELL_TYPE", 148, 161], ["microglia", "CELL_TYPE", 262, 271], ["expression phenotypes", "PROBLEM", 84, 105], ["activated myeloid cells", "PROBLEM", 138, 161], ["microglia", "PROBLEM", 262, 271], ["myeloid cells", "OBSERVATION", 148, 161], ["M1", "ANATOMY", 218, 220]]], ["Despite this conceptual development, at least nine subgroups of macrophage activation states based on transcriptome\u2010based network analysis have been proposed (Xue et al., 2014).", [["macrophage", "ANATOMY", 64, 74], ["macrophage", "CELL", 64, 74], ["macrophage activation", "OBSERVATION", 64, 85]]], ["It has been mostly ignored that novel subpopulations of macrophages such as CD169+ macrophages and T cell receptor positive (TCR+) macrophages may play different roles during specific conditions (Chavez\u2010Galan, Olleros, Vesin, & Garcia, 2015).SUBSETS OF MICROGLIA: MORE THAN PRO\u2010INFLAMMATORY AND IMMUNOREGULATORYWe are beginning to recognize that activated microglia are also quite plastic cells that may differentiate into a plethora of subsets and perform various functions in response to different stimuli and environmental changes such as obesity, diet, alcohol, and even the host microbiota (Chunchai, Chattipakorn, & Chattipakorn, 2017; Erny et al., 2015; Hanamsagar & Bilbo, 2017; Henriques et al., 2017; Johnson, 2015; Mathys et al., 2017; Menzel et al., 2017).", [["macrophages", "ANATOMY", 56, 67], ["CD169+ macrophages", "ANATOMY", 76, 94], ["T cell receptor positive (TCR+) macrophages", "ANATOMY", 99, 142], ["microglia", "ANATOMY", 356, 365], ["cells", "ANATOMY", 389, 394], ["obesity", "DISEASE", 542, 549], ["alcohol", "CHEMICAL", 557, 564], ["alcohol", "CHEMICAL", 557, 564], ["macrophages", "CELL", 56, 67], ["CD169", "GENE_OR_GENE_PRODUCT", 76, 81], ["macrophages", "CELL", 83, 94], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 99, 114], ["TCR", "GENE_OR_GENE_PRODUCT", 125, 128], ["microglia", "CELL", 356, 365], ["plastic cells", "CELL", 381, 394], ["alcohol", "SIMPLE_CHEMICAL", 557, 564], ["macrophages", "CELL_TYPE", 56, 67], ["CD169+ macrophages", "CELL_TYPE", 76, 94], ["T cell receptor positive (TCR+) macrophages", "CELL_TYPE", 99, 142], ["activated microglia", "CELL_TYPE", 346, 365], ["macrophages", "PROBLEM", 56, 67], ["CD169", "TEST", 76, 81], ["macrophages", "PROBLEM", 83, 94], ["T cell receptor", "TEST", 99, 114], ["macrophages", "PROBLEM", 131, 142], ["INFLAMMATORY AND IMMUNOREGULATORYWe", "PROBLEM", 278, 313], ["activated microglia", "PROBLEM", 346, 365], ["different stimuli", "PROBLEM", 490, 507], ["environmental changes", "PROBLEM", 512, 533], ["obesity", "PROBLEM", 542, 549], ["subpopulations", "OBSERVATION_MODIFIER", 38, 52], ["macrophages", "OBSERVATION", 56, 67], ["macrophages", "ANATOMY", 83, 94]]], ["In support of this, it has recently been reported that microglia can even respond to microbial challenges during embryogenesis, and that the absent status of a microbiome has a quite different impact on both age\u2010 and sex\u2010specific microglial gene expression (Thion et al., 2017).", [["microglia", "ANATOMY", 55, 64], ["microglia", "CELL", 55, 64], ["microglial", "CELL", 230, 240], ["microglia", "CELL_TYPE", 55, 64], ["microbial challenges", "TREATMENT", 85, 105]]], ["Furthermore, emerging data have indicated that mixed activation states are evident in later active lesions of MS whereby the activated microglia did not express purinergic receptor P2RY12, which is a novel and specific marker for homeostatic microglia (Zrzavy et al., 2017).", [["lesions", "ANATOMY", 99, 106], ["microglia", "ANATOMY", 135, 144], ["microglia", "ANATOMY", 242, 251], ["MS", "DISEASE", 110, 112], ["lesions", "PATHOLOGICAL_FORMATION", 99, 106], ["microglia", "CELL", 135, 144], ["P2RY12", "GENE_OR_GENE_PRODUCT", 181, 187], ["microglia", "CELL", 242, 251], ["activated microglia", "CELL_TYPE", 125, 144], ["P2RY12", "PROTEIN", 181, 187], ["homeostatic microglia", "CELL_TYPE", 230, 251], ["mixed activation states", "PROBLEM", 47, 70], ["later active lesions of MS", "PROBLEM", 86, 112], ["active", "OBSERVATION_MODIFIER", 92, 98], ["lesions", "OBSERVATION", 99, 106]]], ["Microglial cells may also display distinct activation patterns in the setting of AD, recently evidenced by different morphological properties between plaque\u2010associated and plaque\u2010distinct microglia using three\u2010dimensional cell analysis in an AD animal model (Plescher et al., 2018).SUBSETS OF MICROGLIA: MORE THAN PRO\u2010INFLAMMATORY AND IMMUNOREGULATORYNewly emerging phenotypes of microglia continue to be described and investigated.", [["Microglial cells", "ANATOMY", 0, 16], ["plaque\u2010distinct microglia", "ANATOMY", 172, 197], ["cell", "ANATOMY", 222, 226], ["microglia", "ANATOMY", 380, 389], ["AD", "DISEASE", 81, 83], ["Microglial cells", "CELL", 0, 16], ["plaque\u2010associated", "CELL", 150, 167], ["plaque\u2010distinct microglia", "CELL", 172, 197], ["cell", "CELL", 222, 226], ["microglia", "CELL", 380, 389], ["Microglial cells", "CELL_TYPE", 0, 16], ["plaque\u2010associated and plaque\u2010distinct microglia", "CELL_LINE", 150, 197], ["microglia", "CELL_TYPE", 380, 389], ["Microglial cells", "TEST", 0, 16], ["distinct activation patterns", "PROBLEM", 34, 62], ["AD", "PROBLEM", 81, 83], ["plaque\u2010associated and plaque\u2010distinct microglia", "PROBLEM", 150, 197], ["three\u2010dimensional cell analysis", "TEST", 204, 235], ["INFLAMMATORY AND IMMUNOREGULATORYNewly emerging phenotypes of microglia", "PROBLEM", 318, 389], ["distinct", "OBSERVATION_MODIFIER", 34, 42], ["activation patterns", "OBSERVATION", 43, 62], ["different", "OBSERVATION_MODIFIER", 107, 116], ["morphological properties", "OBSERVATION_MODIFIER", 117, 141], ["plaque\u2010distinct microglia", "OBSERVATION", 172, 197], ["three\u2010dimensional cell", "OBSERVATION", 204, 226], ["microglia", "OBSERVATION", 380, 389]]], ["Specifically, the existence of disease\u2010associated microglia during pathological states, for example in the APP\u2010PS1 mouse and the CX3CR1 knockout mouse, has been indicated at the ultrastructural level by transmission electron microscopy (Bisht, Sharma, Lecours, et al., 2016).", [["disease\u2010associated microglia", "ANATOMY", 31, 59], ["microglia", "CELL", 50, 59], ["APP", "GENE_OR_GENE_PRODUCT", 107, 110], ["PS1", "GENE_OR_GENE_PRODUCT", 111, 114], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 129, 135], ["mouse", "ORGANISM", 145, 150], ["disease\u2010associated microglia", "CELL_TYPE", 31, 59], ["APP", "PROTEIN", 107, 110], ["PS1", "PROTEIN", 111, 114], ["CX3CR1", "PROTEIN", 129, 135], ["mouse", "SPECIES", 115, 120], ["mouse", "SPECIES", 145, 150], ["mouse", "SPECIES", 115, 120], ["mouse", "SPECIES", 145, 150], ["disease\u2010associated microglia during pathological states", "PROBLEM", 31, 86], ["electron microscopy", "TEST", 216, 235], ["disease\u2010associated", "OBSERVATION_MODIFIER", 31, 49], ["microglia", "OBSERVATION", 50, 59], ["CX3CR1", "OBSERVATION", 129, 135], ["knockout mouse", "OBSERVATION", 136, 150]]], ["Even though such disease\u2010associated microglia express microglial markers, such as CD11b, IBA1, and TREM2, this specific subset of cells has been suggested to be strikingly different from normal microglia since they exhibit signs of oxidative stress and transpire to be phagocytically hyperactive with highly ramified processes during pathological states.", [["microglia", "ANATOMY", 36, 45], ["microglial", "ANATOMY", 54, 64], ["cells", "ANATOMY", 130, 135], ["microglia", "ANATOMY", 194, 203], ["microglia", "CELL", 36, 45], ["microglial", "CELL", 54, 64], ["CD11b", "GENE_OR_GENE_PRODUCT", 82, 87], ["IBA1", "GENE_OR_GENE_PRODUCT", 89, 93], ["TREM2", "GENE_OR_GENE_PRODUCT", 99, 104], ["cells", "CELL", 130, 135], ["microglia", "CELL", 194, 203], ["disease\u2010associated microglia", "CELL_TYPE", 17, 45], ["microglial markers", "PROTEIN", 54, 72], ["CD11b", "PROTEIN", 82, 87], ["IBA1", "PROTEIN", 89, 93], ["TREM2", "PROTEIN", 99, 104], ["microglia", "CELL_TYPE", 194, 203], ["microglial markers", "TEST", 54, 72], ["CD11b", "TEST", 82, 87], ["IBA1", "TEST", 89, 93], ["TREM2", "PROBLEM", 99, 104], ["oxidative stress", "PROBLEM", 232, 248], ["phagocytically hyperactive", "PROBLEM", 269, 295], ["microglial markers", "OBSERVATION", 54, 72], ["normal microglia", "OBSERVATION", 187, 203], ["oxidative stress", "OBSERVATION", 232, 248]]], ["Such disease\u2010associated microglia can also cause abnormal interactions with synapses and lead to cognitive decline and learning deficits (Bisht, Sharma, Lacoste, & Tremblay, 2016; Bisht, Sharma, Lecours, et al., 2016).", [["microglia", "ANATOMY", 24, 33], ["synapses", "ANATOMY", 76, 84], ["cognitive decline and learning deficits", "DISEASE", 97, 136], ["microglia", "CELL", 24, 33], ["disease\u2010associated microglia", "CELL_TYPE", 5, 33], ["Such disease\u2010associated microglia", "PROBLEM", 0, 33], ["abnormal interactions with synapses", "PROBLEM", 49, 84], ["cognitive decline", "PROBLEM", 97, 114], ["learning deficits", "PROBLEM", 119, 136]]], ["Interestingly, another unique neonatal white matter\u2010associated CD11c+ microglial subset has been described that specifically contributes to myelination and neurogenesis during postnatal brain development by producing neuroprotective IGF1.", [["neonatal white matter\u2010associated CD11c+ microglial", "ANATOMY", 30, 80], ["brain", "ANATOMY", 186, 191], ["CD11c", "GENE_OR_GENE_PRODUCT", 63, 68], ["brain", "ORGAN", 186, 191], ["IGF1", "GENE_OR_GENE_PRODUCT", 233, 237], ["neonatal white matter\u2010associated CD11c+ microglial subset", "CELL_TYPE", 30, 87], ["IGF1", "PROTEIN", 233, 237], ["microglial subset", "PROBLEM", 70, 87], ["myelination", "PROBLEM", 140, 151], ["neurogenesis", "PROBLEM", 156, 168], ["CD11c", "OBSERVATION", 63, 68], ["microglial subset", "OBSERVATION", 70, 87]]], ["Although these repopulating CD11c+ microglia were evident following genetic adult microglial depletion using CX3CR1CreER iDTR mice, the newly repopulated CD11c+ microglia did not exhibit a neurogenic gene expression profile characteristic of the neonatal CD11c+ microglial subset (Bennett & Barres, 2017; Wlodarczyk et al., 2017).", [["CD11c+ microglia", "ANATOMY", 28, 44], ["CD11c+ microglia", "ANATOMY", 154, 170], ["neonatal CD11c+ microglial", "ANATOMY", 246, 272], ["CD11c", "GENE_OR_GENE_PRODUCT", 28, 33], ["microglia", "CELL", 35, 44], ["microglial", "CELL", 82, 92], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 109, 115], ["CreER", "GENE_OR_GENE_PRODUCT", 115, 120], ["CD11c", "GENE_OR_GENE_PRODUCT", 154, 159], ["CD11c", "GENE_OR_GENE_PRODUCT", 255, 260], ["CD11c", "PROTEIN", 28, 33], ["microglia", "CELL_TYPE", 35, 44], ["CD11c", "PROTEIN", 154, 159], ["microglia", "CELL_TYPE", 161, 170], ["CD11c", "PROTEIN", 255, 260], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["microglia", "PROBLEM", 35, 44], ["genetic adult microglial depletion", "PROBLEM", 68, 102], ["CX3CR", "TEST", 109, 114], ["a neurogenic gene expression profile", "PROBLEM", 187, 223], ["repopulating", "OBSERVATION_MODIFIER", 15, 27], ["CD11c", "OBSERVATION", 28, 33], ["microglia", "OBSERVATION", 35, 44], ["microglial depletion", "OBSERVATION", 82, 102], ["repopulated CD11c", "OBSERVATION", 142, 159], ["neurogenic", "OBSERVATION", 189, 199]]], ["Consistently, the same research group also determined that CD11c+ microglia and CD11c\u2212 microglia have different roles in the contexts of cuprizone\u2010induced demyelination, experimental autoimmune encephalomyelitis (EAE) and neuromyelitis optica\u2010like disease models (Wlodarczyk et al., 2015).SUBSETS OF MICROGLIA: MORE THAN PRO\u2010INFLAMMATORY AND IMMUNOREGULATORYMoreover, another unique type of disease\u2010associated microglia has been discovered in AD mice (through using massively parallel single\u2010cell RNA sequencing) that perform protective functions by restricting progression in neurodegenerative diseases (Keren\u2010Shaul et al., 2017).", [["CD11c+ microglia", "ANATOMY", 59, 75], ["CD11c\u2212 microglia", "ANATOMY", 80, 96], ["disease\u2010associated microglia", "ANATOMY", 391, 419], ["demyelination", "DISEASE", 155, 168], ["autoimmune encephalomyelitis", "DISEASE", 183, 211], ["EAE", "DISEASE", 213, 216], ["neuromyelitis optica\u2010like disease", "DISEASE", 222, 255], ["AD", "DISEASE", 443, 445], ["neurodegenerative diseases", "DISEASE", 577, 603], ["CD11c", "GENE_OR_GENE_PRODUCT", 59, 64], ["microglia", "CELL", 66, 75], ["CD11c\u2212 microglia", "GENE_OR_GENE_PRODUCT", 80, 96], ["microglia", "CELL", 410, 419], ["AD mice", "ORGANISM", 443, 450], ["CD11c", "PROTEIN", 59, 64], ["microglia", "CELL_TYPE", 66, 75], ["CD11c\u2212 microglia", "CELL_TYPE", 80, 96], ["disease\u2010associated microglia", "CELL_TYPE", 391, 419], ["mice", "SPECIES", 446, 450], ["mice", "SPECIES", 446, 450], ["CD11c", "TEST", 59, 64], ["microglia", "PROBLEM", 66, 75], ["CD11c\u2212 microglia", "PROBLEM", 80, 96], ["cuprizone\u2010induced demyelination", "PROBLEM", 137, 168], ["experimental autoimmune encephalomyelitis", "PROBLEM", 170, 211], ["neuromyelitis optica\u2010like disease models", "PROBLEM", 222, 262], ["disease\u2010associated microglia", "PROBLEM", 391, 419], ["massively parallel single\u2010cell RNA sequencing", "TREATMENT", 466, 511], ["neurodegenerative diseases", "PROBLEM", 577, 603], ["CD11c", "OBSERVATION", 59, 64], ["cuprizone\u2010induced", "OBSERVATION_MODIFIER", 137, 154], ["demyelination", "OBSERVATION", 155, 168], ["autoimmune encephalomyelitis", "OBSERVATION", 183, 211], ["disease\u2010associated microglia", "OBSERVATION", 391, 419], ["progression", "OBSERVATION_MODIFIER", 562, 573], ["neurodegenerative diseases", "OBSERVATION", 577, 603]]], ["TREM2 is a receptor for the activation of disease\u2010associated microglia and the TREM2 signaling pathway has been considered as a common microglial activation pathway in several neurodegenerative conditions and aging (Deczkowska et al., 2018; Krasemann et al., 2017).", [["disease\u2010associated microglia", "ANATOMY", 42, 70], ["microglial", "ANATOMY", 135, 145], ["neurodegenerative conditions", "DISEASE", 176, 204], ["TREM2", "GENE_OR_GENE_PRODUCT", 0, 5], ["microglia", "CELL", 61, 70], ["TREM2", "GENE_OR_GENE_PRODUCT", 79, 84], ["microglial", "CELL", 135, 145], ["TREM2", "PROTEIN", 0, 5], ["disease\u2010associated microglia", "CELL_TYPE", 42, 70], ["TREM2", "PROTEIN", 79, 84], ["disease\u2010associated microglia", "PROBLEM", 42, 70], ["the TREM2 signaling pathway", "PROBLEM", 75, 102], ["a common microglial activation pathway", "PROBLEM", 126, 164], ["several neurodegenerative conditions", "PROBLEM", 168, 204], ["several", "OBSERVATION_MODIFIER", 168, 175], ["neurodegenerative conditions", "OBSERVATION", 176, 204]]], ["Compared with normal microglia the disease\u2010associated microglia progressively increase lipid metabolism and expression of phagocytic genes, and are specifically localized around AD plaques, thereby engulfing neurotoxic proteins and protecting against neurodegenerative diseases (Keren\u2010Shaul et al., 2017).", [["microglia", "ANATOMY", 21, 30], ["microglia", "ANATOMY", 54, 63], ["AD plaques", "ANATOMY", 178, 188], ["neurotoxic", "DISEASE", 208, 218], ["neurodegenerative diseases", "DISEASE", 251, 277], ["microglia", "CELL", 21, 30], ["microglia", "CELL", 54, 63], ["lipid", "SIMPLE_CHEMICAL", 87, 92], ["normal microglia", "CELL_TYPE", 14, 30], ["disease\u2010associated microglia", "CELL_TYPE", 35, 63], ["phagocytic genes", "DNA", 122, 138], ["neurotoxic proteins", "PROTEIN", 208, 227], ["lipid metabolism", "PROBLEM", 87, 103], ["phagocytic genes", "PROBLEM", 122, 138], ["AD plaques", "PROBLEM", 178, 188], ["engulfing neurotoxic proteins", "PROBLEM", 198, 227], ["neurodegenerative diseases", "PROBLEM", 251, 277], ["normal microglia", "OBSERVATION", 14, 30], ["disease\u2010associated microglia", "OBSERVATION", 35, 63], ["progressively", "OBSERVATION_MODIFIER", 64, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["lipid metabolism", "OBSERVATION", 87, 103], ["phagocytic genes", "OBSERVATION", 122, 138], ["plaques", "OBSERVATION", 181, 188], ["engulfing", "OBSERVATION_MODIFIER", 198, 207], ["neurotoxic proteins", "OBSERVATION", 208, 227]]], ["However, recent discoveries using unbiased weighted co\u2010expression network analysis have shed light on another distinct pro\u2010inflammatory subpopulation of disease\u2010associated microglia in the context of AD (Rangaraju et al., 2018).SUBSETS OF MICROGLIA: MORE THAN PRO\u2010INFLAMMATORY AND IMMUNOREGULATORYCurrently, it is still unknown whether other disease\u2010associated microglia subsets in different neurological disorders exist or not, or indeed whether specific subtypes are common to several neurological disease states.", [["microglia", "ANATOMY", 172, 181], ["microglia", "ANATOMY", 361, 370], ["neurological", "ANATOMY", 392, 404], ["neurological", "ANATOMY", 487, 499], ["AD", "DISEASE", 200, 202], ["neurological disorders", "DISEASE", 392, 414], ["neurological disease", "DISEASE", 487, 507], ["microglia", "CELL", 172, 181], ["microglia", "CELL", 361, 370], ["disease\u2010associated microglia", "CELL_TYPE", 153, 181], ["disease\u2010associated microglia subsets", "CELL_TYPE", 342, 378], ["unbiased weighted co\u2010expression network analysis", "TEST", 34, 82], ["disease\u2010associated microglia", "PROBLEM", 153, 181], ["INFLAMMATORY AND IMMUNOREGULATORYCurrently", "PROBLEM", 264, 306], ["other disease\u2010associated microglia subsets", "PROBLEM", 336, 378], ["different neurological disorders", "PROBLEM", 382, 414], ["several neurological disease states", "PROBLEM", 479, 514], ["disease\u2010associated microglia", "OBSERVATION", 153, 181], ["microglia subsets", "OBSERVATION", 361, 378]]], ["However, we are optimistic that further studies employing comprehensive combined transcriptome, proteomic and metabolomic approaches will define a wider spectrum of microglia subsets in different neurological disorders and facilitate targeting microglia with unprecedented precision (Haimon et al., 2018; Rangaraju et al., 2018).", [["microglia", "ANATOMY", 165, 174], ["neurological", "ANATOMY", 196, 208], ["microglia", "ANATOMY", 244, 253], ["neurological disorders", "DISEASE", 196, 218], ["microglia subsets", "CELL", 165, 182], ["microglia", "CELL", 244, 253], ["microglia subsets", "CELL_TYPE", 165, 182], ["microglia", "CELL_TYPE", 244, 253], ["further studies", "TEST", 32, 47], ["microglia subsets", "PROBLEM", 165, 182], ["different neurological disorders", "PROBLEM", 186, 218], ["microglia subsets", "OBSERVATION", 165, 182]]], ["Thus further studies are warranted to characterize the scope of intrinsic mechanisms of disease\u2010associated microglia during diverse disease conditions.DEPLETING MICROGLIA IN DISEASES: THE FRIEND IN NEED MAY NOT ALWAYS BE DESIRABLE INDEEDA novel CX3CR1CreER R26Confetti multiple reporter system has been used to demonstrate that microglia can regulate their cell number by clonally forming a cluster at the site of local injury (Madore, Baufeld, & Butovsky, 2017; Tay et al., 2017).", [["microglia", "ANATOMY", 107, 116], ["microglia", "ANATOMY", 328, 337], ["cell", "ANATOMY", 357, 361], ["microglia", "CELL", 107, 116], ["microglia", "CELL", 328, 337], ["cell", "CELL", 357, 361], ["disease\u2010associated microglia", "CELL_TYPE", 88, 116], ["CX3CR1CreER", "PROTEIN", 245, 256], ["microglia", "CELL_TYPE", 328, 337], ["further studies", "TEST", 5, 20], ["disease\u2010associated microglia during diverse disease conditions", "PROBLEM", 88, 150], ["local injury", "PROBLEM", 414, 426], ["disease\u2010associated microglia", "OBSERVATION", 88, 116], ["MICROGLIA", "OBSERVATION", 161, 170], ["local", "OBSERVATION_MODIFIER", 414, 419], ["injury", "OBSERVATION", 420, 426]]], ["As described above, reactive microglia can lead to tissue damage, exacerbate deleterious effects and potentially contribute to neurodegeneration (Leyns & Holtzman, 2017).", [["microglia", "ANATOMY", 29, 38], ["tissue", "ANATOMY", 51, 57], ["tissue damage", "DISEASE", 51, 64], ["neurodegeneration", "DISEASE", 127, 144], ["microglia", "CELL", 29, 38], ["tissue", "TISSUE", 51, 57], ["reactive microglia", "CELL_TYPE", 20, 38], ["reactive microglia", "PROBLEM", 20, 38], ["tissue damage", "PROBLEM", 51, 64], ["deleterious effects", "PROBLEM", 77, 96], ["neurodegeneration", "PROBLEM", 127, 144], ["reactive microglia", "OBSERVATION", 20, 38], ["neurodegeneration", "OBSERVATION", 127, 144]]], ["As it follows that microglia play a central role in many neurological disorders (Salter & Stevens, 2017; Wendeln et al., 2018), then microglia\u2010directed therapy, including specific microglia depletion strategies, can be regarded as a promising immunotherapy for neurological diseases (Du et al., 2017; Feng et al., 2017; Rice et al., 2015).", [["microglia", "ANATOMY", 19, 28], ["neurological", "ANATOMY", 57, 69], ["microglia", "ANATOMY", 180, 189], ["neurological", "ANATOMY", 261, 273], ["neurological disorders", "DISEASE", 57, 79], ["neurological diseases", "DISEASE", 261, 282], ["microglia", "CELL", 19, 28], ["microglia", "CELL", 180, 189], ["microglia", "CELL_TYPE", 19, 28], ["many neurological disorders", "PROBLEM", 52, 79], ["microglia\u2010directed therapy", "TREATMENT", 133, 159], ["specific microglia depletion strategies", "TREATMENT", 171, 210], ["a promising immunotherapy", "TREATMENT", 231, 256], ["neurological diseases", "PROBLEM", 261, 282], ["microglia depletion", "OBSERVATION", 180, 199]]], ["In order to specifically deplete microglia in an injured CNS, many approaches including pharmacological inhibition (e.g. targeting the CSF\u2010R1 receptor with PLX5562) and genetic targeting have been developed (Waisman, Ginhoux, Greter, & Bruttger, 2015), and we have previously reviewed the outcomes of these approaches (Han, Harris, & Zhang, 2017; Lund, Pieber, & Harris, 2017).DEPLETING MICROGLIA IN DISEASES: THE FRIEND IN NEED MAY NOT ALWAYS BE DESIRABLE INDEEDIn support of the hypothesis, microglial depletion has thus led to a broad range of positive and neuroprotective outcomes in distinct disease conditions by reducing neuroinflammation (Table 1): ameliorating EAE (Heppner et al., 2005; Lassmann & Bradl, 2017; Nissen, Thompson, West, & Tsirka, 2018); enhancing remyelination in the cuprizone demyelination model (Beckmann et al., 2018); attenuating neurological https://www.google.se/search?q=abnormalities&spell=1&sa=X&ved=0ahUKEwi38NK94bfYAhUMMJoKHSPtDHEQvwUIJCgA and brain edema in two stroke mouse models (Li, Li, et al., 2017); reducing mRNA levels of proinflammatory cytokines such as IL\u20101\u03b2 and TNF\u2010\u03b1 induced by peripheral lipopolysaccharide injection after microglial depletion (Xie et al., 2017); or acute binge ethanol withdrawal with little negative effects on behavioral functions (Walter & Crews, 2017).", [["microglia", "ANATOMY", 33, 42], ["CNS", "ANATOMY", 57, 60], ["microglial", "ANATOMY", 493, 503], ["brain edema", "ANATOMY", 981, 992], ["microglial", "ANATOMY", 1175, 1185], ["neuroinflammation", "DISEASE", 628, 645], ["EAE", "DISEASE", 670, 673], ["cuprizone", "CHEMICAL", 793, 802], ["demyelination", "DISEASE", 803, 816], ["brain edema", "DISEASE", 981, 992], ["stroke", "DISEASE", 1000, 1006], ["Li", "CHEMICAL", 1021, 1023], ["lipopolysaccharide", "CHEMICAL", 1140, 1158], ["ethanol", "CHEMICAL", 1231, 1238], ["cuprizone", "CHEMICAL", 793, 802], ["ethanol", "CHEMICAL", 1231, 1238], ["microglia", "CELL", 33, 42], ["CNS", "ANATOMICAL_SYSTEM", 57, 60], ["CSF\u2010R1 receptor", "GENE_OR_GENE_PRODUCT", 135, 150], ["PLX5562", "GENE_OR_GENE_PRODUCT", 156, 163], ["microglial", "CELL", 493, 503], ["brain edema", "PATHOLOGICAL_FORMATION", 981, 992], ["mouse", "ORGANISM", 1007, 1012], ["IL\u20101\u03b2", "GENE_OR_GENE_PRODUCT", 1102, 1107], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 1112, 1117], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 1140, 1158], ["microglial", "CELL", 1175, 1185], ["ethanol", "SIMPLE_CHEMICAL", 1231, 1238], ["microglia", "CELL_TYPE", 33, 42], ["CSF\u2010R1 receptor", "PROTEIN", 135, 150], ["PLX5562", "PROTEIN", 156, 163], ["proinflammatory cytokines", "PROTEIN", 1068, 1093], ["IL\u20101\u03b2", "PROTEIN", 1102, 1107], ["TNF\u2010\u03b1", "PROTEIN", 1112, 1117], ["mouse", "SPECIES", 1007, 1012], ["mouse", "SPECIES", 1007, 1012], ["pharmacological inhibition", "TREATMENT", 88, 114], ["the CSF", "TEST", 131, 138], ["the hypothesis", "PROBLEM", 477, 491], ["microglial depletion", "PROBLEM", 493, 513], ["distinct disease conditions", "PROBLEM", 588, 615], ["Nissen", "TREATMENT", 721, 727], ["enhancing remyelination", "PROBLEM", 762, 785], ["attenuating neurological https://www.google.se/search?q=abnormalities&spell=1&sa=X&ved=0ahUKEwi38NK94bfYAhUMMJoKHSPtDHEQvwUIJCgA", "PROBLEM", 848, 976], ["brain edema", "PROBLEM", 981, 992], ["two stroke mouse models", "PROBLEM", 996, 1019], ["proinflammatory cytokines", "PROBLEM", 1068, 1093], ["IL\u2010", "TREATMENT", 1102, 1105], ["TNF", "PROBLEM", 1112, 1115], ["peripheral lipopolysaccharide injection", "TREATMENT", 1129, 1168], ["microglial depletion", "PROBLEM", 1175, 1195], ["acute binge ethanol withdrawal", "PROBLEM", 1219, 1249], ["deplete microglia", "OBSERVATION", 25, 42], ["CNS", "ANATOMY", 57, 60], ["MICROGLIA", "OBSERVATION", 387, 396], ["microglial depletion", "OBSERVATION", 493, 513], ["brain", "ANATOMY", 981, 986], ["edema", "OBSERVATION", 987, 992], ["peripheral lipopolysaccharide", "ANATOMY", 1129, 1158], ["acute", "OBSERVATION_MODIFIER", 1219, 1224]]], ["In one of our previous studies, we have indicated that cranial irradiation can cause transient accumulation of microglial cells followed by persistent inflammation and pronounced expression of IL\u20101\u03b2 and CCL2 in the hippocampus (Han et al., 2016).", [["cranial", "ANATOMY", 55, 62], ["microglial cells", "ANATOMY", 111, 127], ["hippocampus", "ANATOMY", 215, 226], ["inflammation", "DISEASE", 151, 163], ["cranial", "ORGAN", 55, 62], ["microglial cells", "CELL", 111, 127], ["IL\u20101\u03b2", "GENE_OR_GENE_PRODUCT", 193, 198], ["CCL2", "GENE_OR_GENE_PRODUCT", 203, 207], ["hippocampus", "ORGAN", 215, 226], ["microglial cells", "CELL_TYPE", 111, 127], ["IL\u20101\u03b2", "PROTEIN", 193, 198], ["CCL2", "PROTEIN", 203, 207], ["our previous studies", "TEST", 10, 30], ["cranial irradiation", "TREATMENT", 55, 74], ["transient accumulation of microglial cells", "PROBLEM", 85, 127], ["persistent inflammation", "PROBLEM", 140, 163], ["IL\u2010", "TREATMENT", 193, 196], ["cranial", "ANATOMY", 55, 62], ["irradiation", "OBSERVATION", 63, 74], ["microglial cells", "OBSERVATION", 111, 127], ["persistent", "OBSERVATION_MODIFIER", 140, 150], ["inflammation", "OBSERVATION", 151, 163], ["pronounced", "OBSERVATION_MODIFIER", 168, 178], ["hippocampus", "ANATOMY", 215, 226]]], ["Indeed, neuroinflammation induced by activated resident microglia as well as infiltrating monocytes plays a pivotal role in hippocampal\u2010dependent severe cognitive dysfunction after both acute and long\u2010term irradiation (Feng et al., 2016) and microglial depletion can ameliorate these cranial radiation\u2010induced cognitive deficits (Acharya et al., 2016).", [["microglia", "ANATOMY", 56, 65], ["infiltrating monocytes", "ANATOMY", 77, 99], ["microglial", "ANATOMY", 242, 252], ["cranial", "ANATOMY", 284, 291], ["neuroinflammation", "DISEASE", 8, 25], ["cognitive dysfunction", "DISEASE", 153, 174], ["cognitive deficits", "DISEASE", 310, 328], ["microglia", "CELL", 56, 65], ["monocytes", "CELL", 90, 99], ["microglial", "CELL", 242, 252], ["activated resident microglia", "CELL_TYPE", 37, 65], ["infiltrating monocytes", "CELL_TYPE", 77, 99], ["neuroinflammation", "PROBLEM", 8, 25], ["infiltrating monocytes", "PROBLEM", 77, 99], ["hippocampal\u2010dependent severe cognitive dysfunction", "PROBLEM", 124, 174], ["long\u2010term irradiation", "TREATMENT", 196, 217], ["microglial depletion", "PROBLEM", 242, 262], ["these cranial radiation\u2010induced cognitive deficits", "PROBLEM", 278, 328], ["infiltrating monocytes", "OBSERVATION", 77, 99], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["cognitive dysfunction", "OBSERVATION", 153, 174], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["microglial depletion", "OBSERVATION", 242, 262], ["cranial", "ANATOMY", 284, 291]]], ["Confirmed in another study, PLX5662\u2010mediated depletion can lead to protection from loss of dendritic spines, reduction of CD11b+Ly6G\u2212Ly6Chi monocytes in the blood, inhibition of monocyte accumulation and ultimately prevention of radiation\u2010induced cognitive https://www.google.se/search?q=abnormalities&spell=1&sa=X&ved=0ahUKEwjGqt_3grnYAhXnApoKHQ77AlIQvwUIJCgA (Feng et al., 2016).", [["dendritic spines", "ANATOMY", 91, 107], ["CD11b+Ly6G\u2212Ly6Chi monocytes", "ANATOMY", 122, 149], ["blood", "ANATOMY", 157, 162], ["monocyte", "ANATOMY", 178, 186], ["PLX5662", "CHEMICAL", 28, 35], ["PLX5662", "CHEMICAL", 28, 35], ["PLX5662", "SIMPLE_CHEMICAL", 28, 35], ["dendritic spines", "MULTI-TISSUE_STRUCTURE", 91, 107], ["CD11b", "GENE_OR_GENE_PRODUCT", 122, 127], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["monocyte", "CELL", 178, 186], ["PLX5662", "PROTEIN", 28, 35], ["CD11b", "PROTEIN", 122, 127], ["Ly6G\u2212Ly6Chi monocytes", "CELL_LINE", 128, 149], ["another study", "TEST", 13, 26], ["mediated depletion", "PROBLEM", 36, 54], ["loss of dendritic spines", "PROBLEM", 83, 107], ["CD11", "TEST", 122, 126], ["the blood", "TEST", 153, 162], ["monocyte accumulation", "PROBLEM", 178, 199], ["radiation\u2010induced cognitive https://www.google.se/search?q=abnormalities&spell=1&sa=X&ved=0ahUKEwjGqt_3grnYAhXnApoKHQ77AlIQvwUIJCgA", "PROBLEM", 229, 360], ["dendritic spines", "OBSERVATION", 91, 107], ["blood", "ANATOMY", 157, 162], ["monocyte accumulation", "OBSERVATION", 178, 199]]], ["Furthermore, PLX5562 treatment can also alleviate two different forms of Charcot\u2013Marie\u2013Tooth disease by reducing neuropathic features, axonal damage and promoting hindlimb grip strength (Klein et al., 2015; Scherer, 2015).", [["axonal", "ANATOMY", 135, 141], ["hindlimb", "ANATOMY", 163, 171], ["PLX5562", "CHEMICAL", 13, 20], ["Charcot\u2013Marie\u2013Tooth disease", "DISEASE", 73, 100], ["axonal damage", "DISEASE", 135, 148], ["PLX5562", "CHEMICAL", 13, 20], ["PLX5562", "SIMPLE_CHEMICAL", 13, 20], ["axonal", "MULTI-TISSUE_STRUCTURE", 135, 141], ["hindlimb", "ORGANISM_SUBDIVISION", 163, 171], ["grip", "ORGANISM_SUBDIVISION", 172, 176], ["PLX5562 treatment", "TREATMENT", 13, 30], ["Tooth disease", "PROBLEM", 87, 100], ["reducing neuropathic features", "PROBLEM", 104, 133], ["axonal damage", "PROBLEM", 135, 148], ["Charcot", "OBSERVATION", 73, 80], ["Tooth", "ANATOMY", 87, 92], ["disease", "OBSERVATION", 93, 100], ["neuropathic", "OBSERVATION_MODIFIER", 113, 124], ["axonal damage", "OBSERVATION", 135, 148], ["hindlimb", "ANATOMY", 163, 171]]], ["One more study showed that microglial depletion by PLX5562 treatment prevented the symptom of catatonia in structural myelin protein Cnp\u2212/\u2212 mouse by reducing neuroinflammation and neurodegeneration (Janova et al., 2017).DEPLETING MICROGLIA IN DISEASES: THE FRIEND IN NEED MAY NOT ALWAYS BE DESIRABLE INDEEDEliminating microglia in AD mice also provided beneficial outcomes including reduced neuronal loss, improvement of memory functions and partially preventing the progression of AD pathology, but had little effects on amyloid levels and plaque loads (Asai et al., 2015; Dagher et al., 2015; Olmos\u2010Alonso et al., 2016; Spangenberg et al., 2016).", [["microglial", "ANATOMY", 27, 37], ["neuronal", "ANATOMY", 391, 399], ["plaque", "ANATOMY", 541, 547], ["PLX5562", "CHEMICAL", 51, 58], ["catatonia", "DISEASE", 94, 103], ["neuroinflammation", "DISEASE", 158, 175], ["neurodegeneration", "DISEASE", 180, 197], ["AD", "DISEASE", 331, 333], ["neuronal loss", "DISEASE", 391, 404], ["AD", "DISEASE", 482, 484], ["PLX5562", "CHEMICAL", 51, 58], ["microglial", "CELL", 27, 37], ["PLX5562", "SIMPLE_CHEMICAL", 51, 58], ["myelin", "GENE_OR_GENE_PRODUCT", 118, 124], ["Cnp\u2212", "GENE_OR_GENE_PRODUCT", 133, 137], ["microglia", "CELL", 318, 327], ["mice", "ORGANISM", 334, 338], ["neuronal", "CELL", 391, 399], ["amyloid", "GENE_OR_GENE_PRODUCT", 522, 529], ["plaque", "PATHOLOGICAL_FORMATION", 541, 547], ["Cnp\u2212", "PROTEIN", 133, 137], ["microglia", "CELL_TYPE", 318, 327], ["mouse", "SPECIES", 140, 145], ["mice", "SPECIES", 334, 338], ["mouse", "SPECIES", 140, 145], ["mice", "SPECIES", 334, 338], ["One more study", "TEST", 0, 14], ["microglial depletion", "PROBLEM", 27, 47], ["PLX5562 treatment", "TREATMENT", 51, 68], ["the symptom", "PROBLEM", 79, 90], ["catatonia", "PROBLEM", 94, 103], ["reducing neuroinflammation", "PROBLEM", 149, 175], ["neurodegeneration", "PROBLEM", 180, 197], ["reduced neuronal loss", "PROBLEM", 383, 404], ["AD pathology", "PROBLEM", 482, 494], ["amyloid levels", "PROBLEM", 522, 536], ["microglial depletion", "OBSERVATION", 27, 47], ["catatonia", "OBSERVATION", 94, 103], ["neuroinflammation", "OBSERVATION", 158, 175], ["MICROGLIA", "OBSERVATION", 230, 239], ["neuronal loss", "OBSERVATION", 391, 404]]], ["One recent study has indicated that microglial depletion in the CX3CR1CreER DTR transgenic mouse can lead to enlargement of A\u03b2 plaques and may cause extensive neurite damage (Zhao, Hu, Tsai, Li, & Gan, 2017).", [["microglial", "ANATOMY", 36, 46], ["A\u03b2 plaques", "ANATOMY", 124, 134], ["neurite", "ANATOMY", 159, 166], ["enlargement of A\u03b2 plaques", "DISEASE", 109, 134], ["neurite damage", "DISEASE", 159, 173], ["microglial", "CELL", 36, 46], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 64, 70], ["CreER", "GENE_OR_GENE_PRODUCT", 70, 75], ["DTR", "GENE_OR_GENE_PRODUCT", 76, 79], ["mouse", "ORGANISM", 91, 96], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 124, 126], ["DTR", "PROTEIN", 76, 79], ["mouse", "SPECIES", 91, 96], ["mouse", "SPECIES", 91, 96], ["One recent study", "TEST", 0, 16], ["microglial depletion", "PROBLEM", 36, 56], ["the CX3CR", "TEST", 60, 69], ["enlargement of A\u03b2 plaques", "PROBLEM", 109, 134], ["extensive neurite damage", "PROBLEM", 149, 173], ["microglial depletion", "OBSERVATION", 36, 56], ["enlargement", "OBSERVATION_MODIFIER", 109, 120], ["plaques", "OBSERVATION", 127, 134], ["may cause", "UNCERTAINTY", 139, 148], ["extensive", "OBSERVATION_MODIFIER", 149, 158], ["neurite damage", "OBSERVATION", 159, 173]]], ["However, early long\u2010term pharmacologically microglial depletion could finally inhibit plaque deposition and amyloid formation in the 5XFAD mouse model of AD, together with a relatively low level of soluble fibrillar oligomers in the brain (Sosna et al., 2018).", [["plaque", "ANATOMY", 86, 92], ["brain", "ANATOMY", 233, 238], ["AD", "DISEASE", 154, 156], ["microglial", "CELL", 43, 53], ["plaque", "PATHOLOGICAL_FORMATION", 86, 92], ["amyloid", "SIMPLE_CHEMICAL", 108, 115], ["mouse", "ORGANISM", 139, 144], ["fibrillar oligomers", "GENE_OR_GENE_PRODUCT", 206, 225], ["brain", "ORGAN", 233, 238], ["mouse", "SPECIES", 139, 144], ["mouse", "SPECIES", 139, 144], ["early long\u2010term pharmacologically microglial depletion", "PROBLEM", 9, 63], ["plaque deposition", "PROBLEM", 86, 103], ["amyloid formation", "PROBLEM", 108, 125], ["a relatively low level of soluble fibrillar oligomers in the brain", "PROBLEM", 172, 238], ["early", "OBSERVATION_MODIFIER", 9, 14], ["long\u2010term", "OBSERVATION_MODIFIER", 15, 24], ["pharmacologically", "OBSERVATION_MODIFIER", 25, 42], ["microglial depletion", "OBSERVATION", 43, 63], ["plaque", "OBSERVATION_MODIFIER", 86, 92], ["deposition", "OBSERVATION_MODIFIER", 93, 103], ["amyloid formation", "OBSERVATION", 108, 125], ["relatively", "OBSERVATION_MODIFIER", 174, 184], ["low", "OBSERVATION_MODIFIER", 185, 188], ["soluble fibrillar oligomers", "OBSERVATION", 198, 225], ["brain", "ANATOMY", 233, 238]]], ["Furthermore, the administration of GW2580 (tyrosine kinase inhibitor) orally can regulate inflammation of both the CNS and peripheral nervous systems in the ALS animal model, attenuating motoneuronal cell death, slowing disease progression and extending life expectancy (Martinez\u2010Muriana et al., 2016).", [["CNS", "ANATOMY", 115, 118], ["peripheral nervous systems", "ANATOMY", 123, 149], ["motoneuronal cell", "ANATOMY", 187, 204], ["GW2580", "CHEMICAL", 35, 41], ["tyrosine", "CHEMICAL", 43, 51], ["ALS", "DISEASE", 157, 160], ["death", "DISEASE", 205, 210], ["GW2580", "CHEMICAL", 35, 41], ["tyrosine", "CHEMICAL", 43, 51], ["GW2580", "SIMPLE_CHEMICAL", 35, 41], ["tyrosine kinase inhibitor", "SIMPLE_CHEMICAL", 43, 68], ["CNS", "ANATOMICAL_SYSTEM", 115, 118], ["peripheral nervous systems", "ANATOMICAL_SYSTEM", 123, 149], ["motoneuronal cell", "CELL", 187, 204], ["the administration of GW2580 (tyrosine kinase inhibitor", "TREATMENT", 13, 68], ["inflammation of both the CNS and peripheral nervous systems", "PROBLEM", 90, 149], ["attenuating motoneuronal cell death", "PROBLEM", 175, 210], ["slowing disease progression", "PROBLEM", 212, 239], ["inflammation", "OBSERVATION", 90, 102], ["CNS", "ANATOMY", 115, 118], ["peripheral", "ANATOMY_MODIFIER", 123, 133], ["nervous", "ANATOMY", 134, 141], ["attenuating", "OBSERVATION_MODIFIER", 175, 186], ["motoneuronal cell death", "OBSERVATION", 187, 210], ["slowing", "OBSERVATION_MODIFIER", 212, 219]]], ["However, this has not been confirmed in other studies using different approaches to deplete microglia (Gowing et al., 2008; Spiller et al., 2018).", [["microglia", "ANATOMY", 92, 101], ["microglia", "CELL", 92, 101], ["microglia", "CELL_TYPE", 92, 101], ["other studies", "TEST", 40, 53]]], ["A beneficial outcome of microglial depletion is also evident in neuropathic pain by reducing the expression of pro\u2010inflammatory cytokines (Lee, Shi, Fan, West, & Zhang, 2018), which was also confirmed in another study (Wang, Mao, Wu, & Wang, 2018).DEPLETING MICROGLIA IN DISEASES: THE FRIEND IN NEED MAY NOT ALWAYS BE DESIRABLE INDEEDDespite this intensive research, microglia depletion as a treatment paradigm is still in its infancy.", [["microglial", "ANATOMY", 24, 34], ["microglia", "ANATOMY", 367, 376], ["neuropathic pain", "DISEASE", 64, 80], ["microglial", "CELL", 24, 34], ["microglia", "CELL", 367, 376], ["pro\u2010inflammatory cytokines", "PROTEIN", 111, 137], ["microglial depletion", "PROBLEM", 24, 44], ["neuropathic pain", "PROBLEM", 64, 80], ["microglia depletion", "PROBLEM", 367, 386], ["a treatment paradigm", "TREATMENT", 390, 410], ["microglial depletion", "OBSERVATION", 24, 44], ["neuropathic", "OBSERVATION_MODIFIER", 64, 75], ["pain", "OBSERVATION", 76, 80], ["MICROGLIA", "OBSERVATION", 258, 267], ["microglia depletion", "OBSERVATION", 367, 386]]], ["It is also of importance to note the differences of microglia activation in different types of disease processes.", [["microglia", "ANATOMY", 52, 61], ["microglia", "CELL", 52, 61], ["microglia", "CELL_TYPE", 52, 61], ["microglia activation", "PROBLEM", 52, 72], ["disease processes", "PROBLEM", 95, 112], ["different types", "OBSERVATION_MODIFIER", 76, 91], ["disease", "OBSERVATION", 95, 102]]], ["On the basis of the above results, some critical issues need further investigation.", [["some critical issues", "PROBLEM", 35, 55], ["further investigation", "TEST", 61, 82]]], ["For example, microglial elimination has been shown to exacerbate brain neurotoxicity in the contexts of brain ischemia, PD and coronavirus encephalitis (Jin et al., 2017; Szalay et al., 2016; Wheeler, Sariol, Meyerholz, & Perlman, 2018; Yang et al., 2018).", [["microglial", "ANATOMY", 13, 23], ["brain", "ANATOMY", 65, 70], ["brain", "ANATOMY", 104, 109], ["brain neurotoxicity", "DISEASE", 65, 84], ["brain ischemia", "DISEASE", 104, 118], ["PD", "DISEASE", 120, 122], ["coronavirus encephalitis", "DISEASE", 127, 151], ["microglial", "CELL", 13, 23], ["brain", "ORGAN", 65, 70], ["brain", "ORGAN", 104, 109], ["microglial elimination", "PROBLEM", 13, 35], ["brain neurotoxicity", "PROBLEM", 65, 84], ["brain ischemia", "PROBLEM", 104, 118], ["PD", "PROBLEM", 120, 122], ["coronavirus encephalitis", "PROBLEM", 127, 151], ["brain", "ANATOMY", 65, 70], ["neurotoxicity", "OBSERVATION", 71, 84], ["brain", "ANATOMY", 104, 109], ["ischemia", "OBSERVATION", 110, 118], ["coronavirus encephalitis", "OBSERVATION", 127, 151]]], ["Most microglial depletion studies have been performed using CSF\u20101R inhibitors several weeks before inducing the animal disease models.", [["microglial", "ANATOMY", 5, 15], ["microglial", "CELL", 5, 15], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 60, 66], ["Most microglial depletion studies", "TEST", 0, 33], ["CSF\u20101R inhibitors", "TREATMENT", 60, 77], ["the animal disease models", "PROBLEM", 108, 133]]], ["However, it is more reasonable from a clinical perspective to deplete the activated microglial cells after disease onset.", [["microglial cells", "ANATOMY", 84, 100], ["microglial cells", "CELL", 84, 100], ["activated microglial cells", "CELL_TYPE", 74, 100], ["the activated microglial cells", "PROBLEM", 70, 100], ["disease onset", "PROBLEM", 107, 120], ["microglial cells", "OBSERVATION", 84, 100]]], ["Furthermore, current research findings employing CSF\u20101R kinase inhibitors (including PLX3397, PLX5562, GW2580, and BLZ945) might target multiple cell populations other than microglia (e.g. meningeal, perivascular and choroid plexus macrophages and microglial progenitor cells) (Yang et al., 2018).", [["cell", "ANATOMY", 145, 149], ["microglia", "ANATOMY", 173, 182], ["meningeal", "ANATOMY", 189, 198], ["perivascular", "ANATOMY", 200, 212], ["choroid plexus macrophages", "ANATOMY", 217, 243], ["microglial progenitor cells", "ANATOMY", 248, 275], ["PLX3397", "CHEMICAL", 85, 92], ["PLX5562", "CHEMICAL", 94, 101], ["GW2580", "CHEMICAL", 103, 109], ["BLZ945", "CHEMICAL", 115, 121], ["PLX3397", "CHEMICAL", 85, 92], ["PLX5562", "CHEMICAL", 94, 101], ["GW2580", "CHEMICAL", 103, 109], ["BLZ945", "CHEMICAL", 115, 121], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 49, 55], ["PLX3397", "SIMPLE_CHEMICAL", 85, 92], ["PLX5562", "SIMPLE_CHEMICAL", 94, 101], ["GW2580", "SIMPLE_CHEMICAL", 103, 109], ["BLZ", "SIMPLE_CHEMICAL", 115, 118], ["cell populations", "CELL", 145, 161], ["microglia", "CELL", 173, 182], ["meningeal", "CELL", 189, 198], ["perivascular", "CELL", 200, 212], ["choroid plexus macrophages", "CELL", 217, 243], ["microglial progenitor cells", "CELL", 248, 275], ["microglia", "CELL_TYPE", 173, 182], ["meningeal, perivascular and choroid plexus macrophages", "CELL_TYPE", 189, 243], ["microglial progenitor cells", "CELL_TYPE", 248, 275], ["CSF\u20101R kinase inhibitors", "TEST", 49, 73], ["BLZ", "TEST", 115, 118], ["multiple cell populations", "PROBLEM", 136, 161], ["microglia (e.g. meningeal, perivascular and choroid plexus macrophages", "PROBLEM", 173, 243], ["multiple", "OBSERVATION_MODIFIER", 136, 144], ["cell populations", "OBSERVATION", 145, 161], ["meningeal", "ANATOMY", 189, 198], ["perivascular", "ANATOMY_MODIFIER", 200, 212], ["choroid plexus", "ANATOMY", 217, 231], ["microglial progenitor cells", "OBSERVATION", 248, 275]]], ["Cautious interpretation of pure microglial depletion effects using systemic delivery of current available CSF\u20101R inhibitors is thus warranted.", [["microglial", "ANATOMY", 32, 42], ["microglial", "CELL", 32, 42], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 106, 112], ["pure microglial depletion effects", "TREATMENT", 27, 60], ["systemic delivery", "TREATMENT", 67, 84], ["current available CSF\u20101R inhibitors", "TREATMENT", 88, 123], ["microglial depletion", "OBSERVATION", 32, 52]]], ["Indeed, recent studies have reported that CSF\u20101R inhibition can deplete IBA+ macrophages in the kidney (Chalmers et al., 2017).", [["IBA+ macrophages", "ANATOMY", 72, 88], ["kidney", "ANATOMY", 96, 102], ["IBA", "CHEMICAL", 72, 75], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 42, 48], ["IBA", "GENE_OR_GENE_PRODUCT", 72, 75], ["macrophages", "CELL", 77, 88], ["kidney", "ORGAN", 96, 102], ["CSF\u20101R", "PROTEIN", 42, 48], ["IBA", "PROTEIN", 72, 75], ["macrophages", "CELL_TYPE", 77, 88], ["recent studies", "TEST", 8, 22], ["CSF\u20101R inhibition", "TEST", 42, 59], ["macrophages in the kidney", "PROBLEM", 77, 102], ["macrophages", "OBSERVATION", 77, 88], ["kidney", "ANATOMY", 96, 102]]], ["In addition, CSF\u20101R inhibition can robustly decline the actions of nerve\u2010associated macrophages in the periphery (Klein et al., 2015).", [["macrophages", "ANATOMY", 84, 95], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 13, 19], ["nerve\u2010associated macrophages", "CELL", 67, 95], ["CSF", "PROTEIN", 13, 16], ["nerve\u2010associated macrophages", "CELL_TYPE", 67, 95], ["CSF\u20101R inhibition", "TEST", 13, 30], ["nerve\u2010associated macrophages", "PROBLEM", 67, 95], ["nerve\u2010associated macrophages", "OBSERVATION", 67, 95], ["periphery", "ANATOMY_MODIFIER", 103, 112]]], ["However, several studies have identified some potential markers that are exclusively expressed in microglia including Tmem119, P2RY12, Siglec\u2010H and Sal1, permitting distinction of resident microglia from other myeloid cells (Bennett et al., 2016; Butovsky et al., 2014; Buttgereit et al., 2016; Konishi et al., 2017).", [["microglia", "ANATOMY", 98, 107], ["microglia", "ANATOMY", 189, 198], ["myeloid cells", "ANATOMY", 210, 223], ["microglia", "CELL", 98, 107], ["Tmem119", "GENE_OR_GENE_PRODUCT", 118, 125], ["P2RY12", "GENE_OR_GENE_PRODUCT", 127, 133], ["Siglec\u2010H", "GENE_OR_GENE_PRODUCT", 135, 143], ["Sal1", "GENE_OR_GENE_PRODUCT", 148, 152], ["microglia", "CELL", 189, 198], ["myeloid cells", "CELL", 210, 223], ["microglia", "CELL_TYPE", 98, 107], ["Tmem119", "PROTEIN", 118, 125], ["P2RY12", "PROTEIN", 127, 133], ["Siglec\u2010H", "PROTEIN", 135, 143], ["Sal1", "PROTEIN", 148, 152], ["resident microglia", "CELL_TYPE", 180, 198], ["myeloid cells", "CELL_TYPE", 210, 223], ["several studies", "TEST", 9, 24], ["Tmem119", "TEST", 118, 125], ["P2RY12", "TEST", 127, 133], ["myeloid cells", "OBSERVATION", 210, 223]]], ["These markers, together with the Cre/loxP technology, may make it possible to deplete microglia with exquisite precision in the near future.DEPLETING MICROGLIA IN DISEASES: THE FRIEND IN NEED MAY NOT ALWAYS BE DESIRABLE INDEEDLast but not the least, the potential side\u2010effects of microglial depletion is another crucial aspect to be considered.", [["microglia", "ANATOMY", 86, 95], ["microglial", "ANATOMY", 280, 290], ["Cre", "GENE_OR_GENE_PRODUCT", 33, 36], ["microglia", "CELL", 86, 95], ["microglial", "CELL", 280, 290], ["microglia", "CELL_TYPE", 86, 95], ["These markers", "TEST", 0, 13], ["the Cre/loxP technology", "TREATMENT", 29, 52], ["microglial depletion", "PROBLEM", 280, 300], ["MICROGLIA", "OBSERVATION", 150, 159], ["microglial depletion", "OBSERVATION", 280, 300]]], ["Under non\u2010sterile conditions the depletion of microglia might induce at least a transient immunodeficiency that could be harmful both with respect to CNS infection and also in disrupting normal CNS homeostatic functionality in unaffected brain areas.", [["microglia", "ANATOMY", 46, 55], ["CNS", "ANATOMY", 150, 153], ["CNS", "ANATOMY", 194, 197], ["brain areas", "ANATOMY", 238, 249], ["immunodeficiency", "DISEASE", 90, 106], ["infection", "DISEASE", 154, 163], ["microglia", "CELL", 46, 55], ["CNS", "ANATOMICAL_SYSTEM", 150, 153], ["CNS", "ANATOMICAL_SYSTEM", 194, 197], ["brain areas", "MULTI-TISSUE_STRUCTURE", 238, 249], ["microglia", "CELL_TYPE", 46, 55], ["microglia", "PROBLEM", 46, 55], ["a transient immunodeficiency", "PROBLEM", 78, 106], ["CNS infection", "PROBLEM", 150, 163], ["depletion of microglia", "OBSERVATION", 33, 55], ["transient", "OBSERVATION_MODIFIER", 80, 89], ["immunodeficiency", "OBSERVATION", 90, 106], ["CNS", "ANATOMY", 150, 153], ["infection", "OBSERVATION", 154, 163], ["normal CNS homeostatic functionality", "OBSERVATION", 187, 223], ["brain", "ANATOMY", 238, 243]]], ["Indeed, the removal of immunomodulatory microglia producing and responding to TGF\u2010\u03b2 could be expected to be a traumatic event in itself.", [["microglia", "ANATOMY", 40, 49], ["microglia", "CELL", 40, 49], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["immunomodulatory microglia", "CELL_TYPE", 23, 49], ["TGF\u2010\u03b2", "PROTEIN", 78, 83], ["the removal", "TREATMENT", 8, 19], ["immunomodulatory microglia", "PROBLEM", 23, 49], ["a traumatic event", "PROBLEM", 108, 125], ["immunomodulatory microglia", "OBSERVATION", 23, 49], ["traumatic", "OBSERVATION", 110, 119]]], ["The selective replacement of dysfunctional or aberrantly activated microglia in affected areas would thus be the most efficient approach.", [["microglia", "ANATOMY", 67, 76], ["microglia", "CELL", 67, 76], ["microglia", "CELL_TYPE", 67, 76], ["The selective replacement", "TREATMENT", 0, 25], ["dysfunctional or aberrantly activated microglia in affected areas", "PROBLEM", 29, 94], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["replacement", "OBSERVATION", 14, 25], ["dysfunctional", "OBSERVATION_MODIFIER", 29, 42], ["aberrantly", "OBSERVATION_MODIFIER", 46, 56], ["activated", "OBSERVATION_MODIFIER", 57, 66], ["microglia", "OBSERVATION_MODIFIER", 67, 76]]], ["Most studies have indicated that no obvious behavioral consequences in adult mice following microglial depletion, despite extensive neuronal loss in the brain (Dagher et al., 2015; Elmore, Lee, West, & Green, 2015; Elmore et al., 2014; Rice et al., 2017).", [["microglial", "ANATOMY", 92, 102], ["neuronal", "ANATOMY", 132, 140], ["brain", "ANATOMY", 153, 158], ["neuronal loss", "DISEASE", 132, 145], ["mice", "ORGANISM", 77, 81], ["microglial", "CELL", 92, 102], ["neuronal", "CELL", 132, 140], ["brain", "ORGAN", 153, 158], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["Most studies", "TEST", 0, 12], ["obvious behavioral consequences", "PROBLEM", 36, 67], ["microglial depletion", "PROBLEM", 92, 112], ["extensive neuronal loss in the brain", "PROBLEM", 122, 158], ["no obvious", "UNCERTAINTY", 33, 43], ["microglial depletion", "OBSERVATION", 92, 112], ["extensive", "OBSERVATION_MODIFIER", 122, 131], ["neuronal loss", "OBSERVATION", 132, 145], ["brain", "ANATOMY", 153, 158]]], ["Microglial depletion in the adult wide\u2010type C57BL/6 mouse does not influence BDNF expression, the response of astrocytes and leukocyte infiltration in the experimental setting of PD (Yang et al., 2018).", [["Microglial", "ANATOMY", 0, 10], ["astrocytes", "ANATOMY", 110, 120], ["leukocyte", "ANATOMY", 125, 134], ["PD", "DISEASE", 179, 181], ["Microglial", "CELL", 0, 10], ["C57BL/6 mouse", "ORGANISM", 44, 57], ["BDNF", "GENE_OR_GENE_PRODUCT", 77, 81], ["astrocytes", "CELL", 110, 120], ["leukocyte", "CELL", 125, 134], ["BDNF", "PROTEIN", 77, 81], ["astrocytes", "CELL_TYPE", 110, 120], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 52, 57], ["Microglial depletion", "PROBLEM", 0, 20], ["astrocytes", "PROBLEM", 110, 120], ["leukocyte infiltration", "PROBLEM", 125, 147], ["PD", "PROBLEM", 179, 181], ["depletion", "OBSERVATION", 11, 20], ["astrocytes", "ANATOMY", 110, 120], ["leukocyte infiltration", "OBSERVATION", 125, 147]]], ["By contrast, neonatal microglial depletion during early life using pharmacological strategies can have a persistent impact on related motivated behavioral domains during adulthood (Nelson & Lenz, 2017).", [["microglial", "ANATOMY", 22, 32], ["microglial", "CELL", 22, 32], ["neonatal microglial depletion", "PROBLEM", 13, 42], ["pharmacological strategies", "TREATMENT", 67, 93], ["microglial depletion", "OBSERVATION", 22, 42], ["persistent", "OBSERVATION_MODIFIER", 105, 115]]], ["Furthermore, new tools to specifically deplete microglia by utilizing genetic approaches are in great demand.", [["microglia", "ANATOMY", 47, 56], ["microglia", "CELL", 47, 56], ["microglia", "CELL_TYPE", 47, 56], ["genetic approaches", "TREATMENT", 70, 88], ["great demand", "OBSERVATION", 96, 108]]], ["In a recent study, we have indicated that microglia can be efficiently depleted through the administration of tamoxifen in both CX3CR1CreER DTA and CX3CR1CreER DTR transgenic mice (Figure 2a) (Lund et al., 2018).", [["microglia", "ANATOMY", 42, 51], ["tamoxifen", "CHEMICAL", 110, 119], ["tamoxifen", "CHEMICAL", 110, 119], ["microglia", "CELL", 42, 51], ["tamoxifen", "SIMPLE_CHEMICAL", 110, 119], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 148, 154], ["DTR", "GENE_OR_GENE_PRODUCT", 160, 163], ["microglia", "CELL_TYPE", 42, 51], ["DTR", "PROTEIN", 160, 163], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["a recent study", "TEST", 3, 17], ["tamoxifen", "TREATMENT", 110, 119], ["CX3CR", "TEST", 148, 153]]], ["This system thus allows for depletion of microglia at different disease stages by controlling the timing of tamoxifen provision.MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSBasic and clinical research demonstrates that suppressing the immune response by depleting autoreactive immune cells may re\u2010establish the immune balance (Wraith, 2017).", [["microglia", "ANATOMY", 41, 50], ["immune cells", "ANATOMY", 306, 318], ["tamoxifen", "CHEMICAL", 108, 117], ["tamoxifen", "CHEMICAL", 108, 117], ["microglia", "CELL", 41, 50], ["tamoxifen", "SIMPLE_CHEMICAL", 108, 117], ["autoreactive immune cells", "CELL", 293, 318], ["microglia", "CELL_TYPE", 41, 50], ["autoreactive immune cells", "CELL_TYPE", 293, 318], ["depletion", "PROBLEM", 28, 37], ["microglia at different disease stages", "PROBLEM", 41, 78], ["tamoxifen provision", "TREATMENT", 108, 127], ["NEW CELLS", "PROBLEM", 180, 189], ["depleting autoreactive immune cells", "TREATMENT", 283, 318], ["microglia", "OBSERVATION", 41, 50], ["NEW CELLS", "OBSERVATION", 180, 189], ["autoreactive immune cells", "OBSERVATION", 293, 318]]], ["Taking MS for example, monoclonal antibodies (including Rituximab and Ocrelizumab) that selectively target and deplete CD20+ B cells have been approved for the treatment of MS (Greenfield & Hauser, 2017; Hauser et al., 2017; Sabatino, Zamvil, & Hauser, 2018; Salzer et al., 2016).", [["CD20+ B cells", "ANATOMY", 119, 132], ["Rituximab", "CHEMICAL", 56, 65], ["Ocrelizumab", "CHEMICAL", 70, 81], ["MS", "DISEASE", 173, 175], ["Ocrelizumab", "CHEMICAL", 70, 81], ["Rituximab", "SIMPLE_CHEMICAL", 56, 65], ["Ocrelizumab", "SIMPLE_CHEMICAL", 70, 81], ["CD20", "GENE_OR_GENE_PRODUCT", 119, 123], ["monoclonal antibodies", "PROTEIN", 23, 44], ["CD20", "PROTEIN", 119, 123], ["B cells", "CELL_TYPE", 125, 132], ["monoclonal antibodies", "TREATMENT", 23, 44], ["Rituximab", "TREATMENT", 56, 65], ["Ocrelizumab", "TREATMENT", 70, 81]]], ["Our colleagues have demonstrated that relapsing\u2013remitting MS patients with Rituximab as the initial treatment have better relapse control and tolerability in comparison with other disease\u2010modifying drugs (Granqvist et al., 2018; Spelman, Frisell, Piehl, & Hillert, 2017).", [["MS", "DISEASE", 58, 60], ["Rituximab", "CHEMICAL", 75, 84], ["patients", "ORGANISM", 61, 69], ["Rituximab", "SIMPLE_CHEMICAL", 75, 84], ["patients", "SPECIES", 61, 69], ["Rituximab", "TREATMENT", 75, 84], ["the initial treatment", "TREATMENT", 88, 109]]], ["Available MS treatments mainly resolve the peripheral inflammation but further specific and effective cell\u2010depletion therapies still represent a highly unmet medical need, especially in chronic disease states.MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSDue to the self\u2010renewal ability of microglia, following microglial depletion by pharmacological therapies or genetic targeting the empty CNS niche can be entirely repopulated within a relatively short period without serious side\u2010effects (Elmore et al., 2015; Han et al., 2017; Varvel et al., 2012).", [["microglia", "ANATOMY", 318, 327], ["microglial", "ANATOMY", 339, 349], ["CNS niche", "ANATOMY", 420, 429], ["peripheral inflammation", "DISEASE", 43, 66], ["microglia", "CELL", 318, 327], ["microglial", "CELL", 339, 349], ["microglia", "CELL_TYPE", 318, 327], ["Available MS treatments", "TREATMENT", 0, 23], ["the peripheral inflammation", "PROBLEM", 39, 66], ["effective cell\u2010depletion therapies", "TREATMENT", 92, 126], ["chronic disease states", "PROBLEM", 186, 208], ["microglia", "PROBLEM", 318, 327], ["microglial depletion", "TREATMENT", 339, 359], ["pharmacological therapies", "TREATMENT", 363, 388], ["peripheral", "ANATOMY_MODIFIER", 43, 53], ["inflammation", "OBSERVATION", 54, 66], ["chronic", "OBSERVATION_MODIFIER", 186, 193], ["disease", "OBSERVATION", 194, 201], ["microglial depletion", "OBSERVATION", 339, 359]]], ["In a previous pioneering study, Elmore and colleagues indicated that rapid repopulation of microglial cells can be noted after administration of the selective CSF\u20101R inhibitor PLX3397 (Elmore et al., 2014).", [["microglial cells", "ANATOMY", 91, 107], ["PLX3397", "CHEMICAL", 176, 183], ["PLX3397", "CHEMICAL", 176, 183], ["microglial cells", "CELL", 91, 107], ["CSF\u20101R", "GENE_OR_GENE_PRODUCT", 159, 165], ["PLX3397", "SIMPLE_CHEMICAL", 176, 183], ["microglial cells", "CELL_TYPE", 91, 107], ["a previous pioneering study", "TEST", 3, 30], ["rapid repopulation of microglial cells", "PROBLEM", 69, 107], ["the selective CSF\u20101R inhibitor", "TREATMENT", 145, 175], ["rapid", "OBSERVATION_MODIFIER", 69, 74], ["repopulation", "OBSERVATION_MODIFIER", 75, 87], ["microglial cells", "OBSERVATION", 91, 107]]], ["They claimed that following cessation of PLX3397 treatment the newly repopulated cells did not arise from bone marrow\u2010derived cells, but instead from local nestin+ microglial progenitor cells in the brain parenchyma (Figure 2b) (Elmore et al., 2014).", [["cells", "ANATOMY", 81, 86], ["bone marrow\u2010derived cells", "ANATOMY", 106, 131], ["nestin+ microglial progenitor cells", "ANATOMY", 156, 191], ["brain parenchyma", "ANATOMY", 199, 215], ["PLX3397", "CHEMICAL", 41, 48], ["PLX3397", "CHEMICAL", 41, 48], ["PLX3397", "SIMPLE_CHEMICAL", 41, 48], ["cells", "CELL", 81, 86], ["bone marrow\u2010derived cells", "CELL", 106, 131], ["nestin", "GENE_OR_GENE_PRODUCT", 156, 162], ["microglial progenitor cells", "CELL", 164, 191], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 199, 215], ["bone marrow\u2010derived cells", "CELL_TYPE", 106, 131], ["nestin", "PROTEIN", 156, 162], ["microglial progenitor cells", "CELL_TYPE", 164, 191], ["PLX3397 treatment", "TREATMENT", 41, 58], ["the newly repopulated cells", "PROBLEM", 59, 86], ["bone marrow\u2010derived cells", "PROBLEM", 106, 131], ["local nestin", "TEST", 150, 162], ["repopulated cells", "OBSERVATION", 69, 86], ["bone", "ANATOMY", 106, 110], ["microglial progenitor cells", "OBSERVATION", 164, 191], ["brain", "ANATOMY", 199, 204], ["parenchyma", "ANATOMY_MODIFIER", 205, 215]]], ["However, Bruttger et al demonstrated that following partial depletion (80%) in the CX3CR1CreER iDTR mouse, microglia proliferate by themselves rather than from nestin+ microglial progenitor cells to finally refill the niche (Figure 2d) (Bruttger et al., 2015; Jakel & Dimou, 2017).", [["microglia", "ANATOMY", 107, 116], ["nestin+ microglial progenitor cells", "ANATOMY", 160, 195], ["niche", "ANATOMY", 218, 223], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 83, 89], ["mouse", "ORGANISM", 100, 105], ["microglia", "CELL", 107, 116], ["nestin", "GENE_OR_GENE_PRODUCT", 160, 166], ["microglial progenitor cells", "CELL", 168, 195], ["CX3CR1CreER iDTR mouse", "CELL_LINE", 83, 105], ["microglia", "CELL_TYPE", 107, 116], ["nestin", "PROTEIN", 160, 166], ["microglial progenitor cells", "CELL_TYPE", 168, 195], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 100, 105], ["partial depletion", "PROBLEM", 52, 69], ["the CX3CR", "TEST", 79, 88], ["nestin+ microglial progenitor cells", "TREATMENT", 160, 195], ["partial", "OBSERVATION_MODIFIER", 52, 59], ["depletion", "OBSERVATION", 60, 69], ["microglia proliferate", "OBSERVATION", 107, 128], ["microglial progenitor cells", "OBSERVATION", 168, 195]]], ["This mechanism has received further support (Askew et al., 2017) including using elegant fate\u2010mapping approaches, single\u2010cell RNA sequencing and parabiosis (Huang, Xu, Xiong, Sun, et al., 2018).MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSThe recruitment of circulating precursors does not contribute to the resident microglial pool in the healthy CNS (Ajami, Bennett, Krieger, McNagny, & Rossi, 2011; Mildner et al., 2007).", [["microglial pool", "ANATOMY", 346, 361], ["CNS", "ANATOMY", 377, 380], ["microglial", "CELL", 346, 356], ["CNS", "ANATOMICAL_SYSTEM", 377, 380], ["further support", "TREATMENT", 28, 43], ["elegant fate\u2010mapping approaches", "TREATMENT", 81, 112], ["NEW CELLS", "OBSERVATION", 246, 255]]], ["However, contradictory findings have been reported by using the CD11b\u2010HSVTK transgenic mouse in which circulating monocytes have the ability to potentially replace the adult CNS myeloid niche after microglial depletion (Figure 2c) (Varvel et al., 2012) and the newly engrafted peripheral cells have a unique functional phenotype compared with resident microglia (Cronk et al., 2018).MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSBy contrast, two repopulating origins following microglial depletion in the retina have been described (Huang, Xu, Xiong, Qin, et al., 2018).", [["monocytes", "ANATOMY", 114, 123], ["CNS myeloid niche", "ANATOMY", 174, 191], ["microglial", "ANATOMY", 198, 208], ["peripheral cells", "ANATOMY", 277, 293], ["microglia", "ANATOMY", 352, 361], ["microglial", "ANATOMY", 505, 515], ["retina", "ANATOMY", 533, 539], ["CD11b", "GENE_OR_GENE_PRODUCT", 64, 69], ["HSVTK", "GENE_OR_GENE_PRODUCT", 70, 75], ["mouse", "ORGANISM", 87, 92], ["monocytes", "CELL", 114, 123], ["CNS myeloid niche", "CELL", 174, 191], ["microglial", "CELL", 198, 208], ["peripheral cells", "CELL", 277, 293], ["microglia", "CELL", 352, 361], ["microglial", "CELL", 505, 515], ["retina", "MULTI-TISSUE_STRUCTURE", 533, 539], ["CD11b", "PROTEIN", 64, 69], ["HSVTK", "PROTEIN", 70, 75], ["circulating monocytes", "CELL_TYPE", 102, 123], ["engrafted peripheral cells", "CELL_TYPE", 267, 293], ["resident microglia", "CELL_TYPE", 343, 361], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["HSVTK transgenic mouse", "PROBLEM", 70, 92], ["microglial depletion", "PROBLEM", 198, 218], ["the newly engrafted peripheral cells", "PROBLEM", 257, 293], ["microglial depletion in the retina", "PROBLEM", 505, 539], ["CNS myeloid", "ANATOMY", 174, 185], ["microglial depletion", "OBSERVATION", 198, 218], ["peripheral cells", "OBSERVATION", 277, 293], ["functional phenotype", "OBSERVATION", 308, 328], ["NEW CELLS", "OBSERVATION", 435, 444], ["microglial depletion", "OBSERVATION", 505, 525], ["retina", "ANATOMY", 533, 539]]], ["One is the resident central\u2010emerging microglia in the optic nerve and the other is the extra\u2010retinal periphery\u2010emerging microglia from the ciliary body/iris (Huang, Xu, Xiong, Qin, et al., 2018).", [["microglia", "ANATOMY", 37, 46], ["optic nerve", "ANATOMY", 54, 65], ["extra\u2010retinal periphery\u2010emerging microglia", "ANATOMY", 87, 129], ["ciliary body", "ANATOMY", 139, 151], ["iris", "ANATOMY", 152, 156], ["microglia", "CELL", 37, 46], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 54, 65], ["microglia", "CELL", 120, 129], ["ciliary body", "TISSUE", 139, 151], ["iris", "ORGAN", 152, 156], ["resident central\u2010emerging microglia", "CELL_TYPE", 11, 46], ["extra\u2010retinal periphery\u2010emerging microglia", "CELL_TYPE", 87, 129], ["central\u2010emerging", "OBSERVATION_MODIFIER", 20, 36], ["microglia", "OBSERVATION", 37, 46], ["optic nerve", "ANATOMY", 54, 65], ["extra\u2010retinal", "ANATOMY_MODIFIER", 87, 100], ["microglia", "OBSERVATION", 120, 129], ["ciliary body", "ANATOMY", 139, 151], ["iris", "ANATOMY", 152, 156]]], ["Two distinct resources including peripheral macrophages could also contribute to robust microglial regeneration independently of irradiation (Cronk et al., 2018).", [["peripheral macrophages", "ANATOMY", 33, 55], ["microglial", "ANATOMY", 88, 98], ["peripheral macrophages", "CELL", 33, 55], ["microglial", "CELL", 88, 98], ["peripheral macrophages", "CELL_TYPE", 33, 55], ["peripheral macrophages", "PROBLEM", 33, 55], ["robust microglial regeneration", "PROBLEM", 81, 111], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["resources", "OBSERVATION", 13, 22], ["peripheral", "ANATOMY_MODIFIER", 33, 43], ["macrophages", "ANATOMY", 44, 55], ["could also contribute to", "UNCERTAINTY", 56, 80], ["robust", "OBSERVATION_MODIFIER", 81, 87], ["microglial regeneration", "OBSERVATION", 88, 111], ["irradiation", "OBSERVATION_MODIFIER", 129, 140]]], ["However, intrinsic regulatory mechanisms that mediate the replacement of microglia\u2010like cells after selective depletion are not yet fully understood.MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSOne recent study provided novel evidence that CX3CR1 signaling may actively regulate microglial compensation in the retina since CX3CR1\u2212/\u2212 deficient mice had significantly lower numbers of repopulated microglial during early recovery when compared to CX3CR1 signaling\u2010sufficient mice (Zhang et al., 2018).", [["microglia\u2010like cells", "ANATOMY", 73, 93], ["microglial", "ANATOMY", 308, 318], ["retina", "ANATOMY", 339, 345], ["microglial", "ANATOMY", 424, 434], ["microglia\u2010like cells", "CELL", 73, 93], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 269, 275], ["microglial", "CELL", 308, 318], ["retina", "MULTI-TISSUE_STRUCTURE", 339, 345], ["CX3CR1\u2212", "GENE_OR_GENE_PRODUCT", 352, 359], ["\u2212", "GENE_OR_GENE_PRODUCT", 360, 361], ["microglial", "CELL", 424, 434], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 474, 480], ["mice", "ORGANISM", 502, 506], ["microglia\u2010like cells", "CELL_TYPE", 73, 93], ["CX3CR1", "PROTEIN", 269, 275], ["CX3CR1", "PROTEIN", 474, 480], ["mice", "SPECIES", 372, 376], ["mice", "SPECIES", 502, 506], ["mice", "SPECIES", 372, 376], ["intrinsic regulatory mechanisms", "PROBLEM", 9, 40], ["the replacement of microglia\u2010like cells", "TREATMENT", 54, 93], ["selective depletion", "TREATMENT", 100, 119], ["recent study", "TEST", 227, 239], ["CX3CR1 signaling", "PROBLEM", 269, 285], ["microglial compensation in the retina", "PROBLEM", 308, 345], ["CX3CR1\u2212", "TEST", 352, 359], ["replacement", "OBSERVATION_MODIFIER", 58, 69], ["microglia\u2010like cells", "OBSERVATION", 73, 93], ["microglial compensation", "OBSERVATION", 308, 331], ["retina", "ANATOMY", 339, 345], ["lower", "OBSERVATION_MODIFIER", 395, 400], ["numbers", "OBSERVATION_MODIFIER", 401, 408], ["repopulated microglial", "OBSERVATION", 412, 434]]], ["Furthermore, we have recently demonstrated that CNS repopulated monocytes required TGF\u2010\u03b2 signaling to colonize the functional microglial niche following microglia depletion in the CX3CR1CreER DTA transgenic mouse model (Figure 2a) (Lund et al., 2018).", [["CNS", "ANATOMY", 48, 51], ["monocytes", "ANATOMY", 64, 73], ["microglial niche", "ANATOMY", 126, 142], ["microglia", "ANATOMY", 153, 162], ["monocytes", "CELL", 64, 73], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 83, 88], ["microglial niche", "CELL", 126, 142], ["microglia", "CELL", 153, 162], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 180, 186], ["CreER", "GENE_OR_GENE_PRODUCT", 186, 191], ["mouse", "ORGANISM", 207, 212], ["CNS repopulated monocytes", "CELL_TYPE", 48, 73], ["TGF\u2010\u03b2", "PROTEIN", 83, 88], ["microglia", "CELL_TYPE", 153, 162], ["CX3CR1", "PROTEIN", 180, 186], ["CreER", "PROTEIN", 186, 191], ["mouse", "SPECIES", 207, 212], ["mouse", "SPECIES", 207, 212], ["CNS repopulated monocytes", "PROBLEM", 48, 73], ["TGF", "TREATMENT", 83, 86], ["microglia depletion", "PROBLEM", 153, 172], ["CNS", "ANATOMY", 48, 51], ["repopulated monocytes", "OBSERVATION", 52, 73], ["functional microglial", "OBSERVATION", 115, 136], ["microglia depletion", "OBSERVATION", 153, 172]]], ["Specific TGF\u2010\u03b2 signaling deficiency on the new microglia\u2010like cells led to development of progressive motor disease similar to ALS\u2010like symptoms (Lund et al., 2018).MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSIn this context, the next critical question is whether the newly engrafted microglia\u2010like cells including local hyperproliferation and/or bone marrow\u2010derived cells could completely adapt the embryonically seeded microglial phenotypes and functions.", [["microglia\u2010like cells", "ANATOMY", 47, 67], ["microglia\u2010like cells", "ANATOMY", 314, 334], ["bone marrow\u2010derived cells", "ANATOMY", 377, 402], ["microglial", "ANATOMY", 451, 461], ["motor disease", "DISEASE", 102, 115], ["ALS", "DISEASE", 127, 130], ["TGF\u2010\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["microglia\u2010like cells", "CELL", 47, 67], ["microglia\u2010like cells", "CELL", 314, 334], ["bone marrow\u2010derived cells", "CELL", 377, 402], ["microglial", "CELL", 451, 461], ["TGF\u2010\u03b2", "PROTEIN", 9, 14], ["microglia\u2010like cells", "CELL_TYPE", 47, 67], ["microglia\u2010like cells", "CELL_TYPE", 314, 334], ["bone marrow\u2010derived cells", "CELL_TYPE", 377, 402], ["Specific TGF", "TEST", 0, 12], ["signaling deficiency", "PROBLEM", 15, 35], ["the new microglia\u2010like cells", "PROBLEM", 39, 67], ["progressive motor disease", "PROBLEM", 90, 115], ["ALS\u2010like symptoms", "PROBLEM", 127, 144], ["the newly engrafted microglia\u2010like cells", "PROBLEM", 294, 334], ["local hyperproliferation", "PROBLEM", 345, 369], ["bone marrow\u2010derived cells", "PROBLEM", 377, 402], ["signaling deficiency", "OBSERVATION", 15, 35], ["new", "OBSERVATION_MODIFIER", 43, 46], ["microglia\u2010like cells", "OBSERVATION", 47, 67], ["progressive", "OBSERVATION_MODIFIER", 90, 101], ["motor disease", "OBSERVATION", 102, 115], ["local", "OBSERVATION_MODIFIER", 345, 350], ["hyperproliferation", "OBSERVATION", 351, 369], ["bone", "ANATOMY", 377, 381], ["microglial phenotypes", "OBSERVATION", 451, 472]]], ["Even though they are numerically and morphologically different from embryonically seeded microglia, the newly repopulated cells can still perform the same general functions as resident microglia including constantly surveying the microenvironment and appropriately responding to the acute events (Varvel et al., 2012; Zhang et al., 2018).", [["microglia", "ANATOMY", 89, 98], ["cells", "ANATOMY", 122, 127], ["microglia", "ANATOMY", 185, 194], ["microglia", "CELL", 89, 98], ["cells", "CELL", 122, 127], ["microglia", "CELL", 185, 194], ["embryonically seeded microglia", "CELL_LINE", 68, 98], ["resident microglia", "CELL_TYPE", 176, 194], ["embryonically seeded microglia", "PROBLEM", 68, 98], ["the newly repopulated cells", "PROBLEM", 100, 127], ["the acute events", "PROBLEM", 279, 295], ["morphologically", "OBSERVATION_MODIFIER", 37, 52], ["different", "OBSERVATION_MODIFIER", 53, 62], ["seeded microglia", "OBSERVATION", 82, 98], ["repopulated cells", "OBSERVATION", 110, 127]]], ["Additionally, embryonically seeded microglia and the newly repopulated cells may respond differently to environmental stimuli, as evidenced by two distinct cell types showing differential motilities in response to laser burn injury in vivo (Cronk et al., 2018).", [["microglia", "ANATOMY", 35, 44], ["cells", "ANATOMY", 71, 76], ["cell", "ANATOMY", 156, 160], ["burn injury", "DISEASE", 220, 231], ["microglia", "CELL", 35, 44], ["cells", "CELL", 71, 76], ["cell", "CELL", 156, 160], ["embryonically seeded microglia", "CELL_LINE", 14, 44], ["newly repopulated cells", "CELL_TYPE", 53, 76], ["embryonically seeded microglia", "PROBLEM", 14, 44], ["environmental stimuli", "TEST", 104, 125], ["two distinct cell types", "PROBLEM", 143, 166], ["differential motilities", "PROBLEM", 175, 198], ["laser burn injury", "PROBLEM", 214, 231], ["seeded microglia", "OBSERVATION", 28, 44], ["repopulated cells", "OBSERVATION", 59, 76], ["distinct cell types", "OBSERVATION", 147, 166], ["laser burn", "OBSERVATION", 214, 224]]], ["Using RNA sequencing it was determined that the gene profiles of fully repopulated microglia had been little influenced by administration of PLX5622 because no inflammatory related genes were up\u2010regulated or down\u2010regulated during depletion and repopulation processes (Huang, Xu, Xiong, Qin, et al., 2018).", [["microglia", "ANATOMY", 83, 92], ["PLX5622", "CHEMICAL", 141, 148], ["PLX5622", "CHEMICAL", 141, 148], ["microglia", "CELL", 83, 92], ["PLX5622", "SIMPLE_CHEMICAL", 141, 148], ["microglia", "CELL_TYPE", 83, 92], ["inflammatory related genes", "DNA", 160, 186], ["RNA sequencing", "TEST", 6, 20], ["PLX5622", "TREATMENT", 141, 148], ["inflammatory related genes", "PROBLEM", 160, 186], ["inflammatory", "OBSERVATION", 160, 172]]], ["Consistent with this idea, Elmore and colleagues determined that repopulated microglia have relatively larger cell bodies than do resident microglia.", [["microglia", "ANATOMY", 77, 86], ["cell bodies", "ANATOMY", 110, 121], ["microglia", "ANATOMY", 139, 148], ["microglia", "CELL", 77, 86], ["cell bodies", "CELLULAR_COMPONENT", 110, 121], ["microglia", "CELL", 139, 148], ["repopulated microglia", "CELL_TYPE", 65, 86], ["resident microglia", "CELL_TYPE", 130, 148], ["repopulated microglia", "PROBLEM", 65, 86], ["repopulated microglia", "OBSERVATION", 65, 86], ["larger", "OBSERVATION_MODIFIER", 103, 109], ["cell bodies", "OBSERVATION", 110, 121], ["microglia", "OBSERVATION", 139, 148]]], ["These two types of microglial cells shared the same level of mRNA gene expression as well as similar responses to lipopolysaccharide stimulation (Elmore et al., 2015).", [["microglial cells", "ANATOMY", 19, 35], ["lipopolysaccharide", "CHEMICAL", 114, 132], ["microglial cells", "CELL", 19, 35], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 114, 132], ["microglial cells", "CELL_TYPE", 19, 35], ["microglial cells", "PROBLEM", 19, 35], ["lipopolysaccharide stimulation", "TREATMENT", 114, 144], ["microglial cells", "OBSERVATION", 19, 35]]], ["Furthermore, mice with repopulated microglia did not exhibit any cognitive or behavioral https://www.google.se/search?biw=1280&bih=615&q=abnormalities&spell=1&sa=X&ved=0ahUKEwihtbSN1bLYAhUEQZoKHUVwCk4QvwUIJCgA (Elmore et al., 2015).MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDSMore interestingly, the same research group further reported that repopulated microglia have the ability to largely resolve the pro\u2010inflammatory response and promote functional recovery after brain damage by replacing the active and highly swollen microglia with normal ramified microglia, downregulating the expression of reactive microglial markers and reducing the levels of inflammatory\u2010related genes (Rice et al., 2017).", [["microglia", "ANATOMY", 35, 44], ["microglia", "ANATOMY", 384, 393], ["brain", "ANATOMY", 498, 503], ["microglia", "ANATOMY", 554, 563], ["microglia", "ANATOMY", 585, 594], ["microglial", "ANATOMY", 638, 648], ["brain damage", "DISEASE", 498, 510], ["mice", "ORGANISM", 13, 17], ["microglia", "CELL", 35, 44], ["microglia", "CELL", 384, 393], ["brain", "ORGAN", 498, 503], ["microglia", "CELL", 554, 563], ["microglia", "CELL", 585, 594], ["microglial", "CELL", 638, 648], ["repopulated microglia", "CELL_TYPE", 23, 44], ["repopulated microglia", "CELL_TYPE", 372, 393], ["microglia", "CELL_TYPE", 554, 563], ["normal ramified microglia", "CELL_TYPE", 569, 594], ["microglial markers", "PROTEIN", 638, 656], ["inflammatory\u2010related genes", "DNA", 684, 710], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["brain damage", "PROBLEM", 498, 510], ["the active and highly swollen microglia", "PROBLEM", 524, 563], ["reactive microglial markers", "PROBLEM", 629, 656], ["inflammatory\u2010related genes", "PROBLEM", 684, 710], ["NEW", "OBSERVATION_MODIFIER", 284, 287], ["active", "OBSERVATION_MODIFIER", 528, 534], ["highly", "OBSERVATION_MODIFIER", 539, 545], ["swollen", "OBSERVATION", 546, 553], ["ramified microglia", "OBSERVATION", 576, 594], ["reactive microglial markers", "OBSERVATION", 629, 656], ["inflammatory", "OBSERVATION_MODIFIER", 684, 696]]], ["Furthermore, peripherally derived microglia\u2010like cells remained transcriptionally and functionally distinct from microglia arising through local proliferation (Cronk et al., 2018).", [["peripherally derived microglia\u2010like cells", "ANATOMY", 13, 54], ["microglia", "ANATOMY", 113, 122], ["microglia\u2010like cells", "CELL", 34, 54], ["microglia", "CELL", 113, 122], ["microglia\u2010like cells", "CELL_TYPE", 34, 54], ["microglia", "CELL_TYPE", 113, 122], ["peripherally derived microglia\u2010like cells", "PROBLEM", 13, 54], ["peripherally", "ANATOMY_MODIFIER", 13, 25], ["microglia\u2010like cells", "OBSERVATION", 34, 54], ["microglia", "OBSERVATION_MODIFIER", 113, 122], ["local", "OBSERVATION_MODIFIER", 139, 144], ["proliferation", "OBSERVATION_MODIFIER", 145, 158]]], ["Further evaluations are needed to confirm if overall brain function can be affected by mixed engrafted microglia\u2010like cells during diverse neurological disease models.ENFORCED MICROGLIAL REPOPULATION: A NEW PROSPECT FOR FIXING A DYSFUNCTIONAL NICHESo microglial depletion can lead to natural repopulation of the empty niche through either (a) hyperproliferation of remaining microglia, (b) stimulation of microglial precursors, or (c) infiltrating of monocytes from the circulation.", [["brain", "ANATOMY", 53, 58], ["microglia\u2010like cells", "ANATOMY", 103, 123], ["neurological", "ANATOMY", 139, 151], ["niche", "ANATOMY", 318, 323], ["microglia", "ANATOMY", 375, 384], ["microglial precursors", "ANATOMY", 405, 426], ["monocytes", "ANATOMY", 451, 460], ["neurological disease", "DISEASE", 139, 159], ["brain", "ORGAN", 53, 58], ["microglia\u2010like cells", "CELL", 103, 123], ["microglia", "CELL", 375, 384], ["microglial", "CELL", 405, 415], ["monocytes", "CELL", 451, 460], ["mixed engrafted microglia\u2010like cells", "CELL_LINE", 87, 123], ["microglia", "CELL_TYPE", 375, 384], ["microglial precursors", "CELL_TYPE", 405, 426], ["monocytes", "CELL_TYPE", 451, 460], ["Further evaluations", "TEST", 0, 19], ["mixed engrafted microglia\u2010like cells", "PROBLEM", 87, 123], ["diverse neurological disease models", "PROBLEM", 131, 166], ["A DYSFUNCTIONAL NICHESo microglial depletion", "TREATMENT", 227, 271], ["natural repopulation", "TREATMENT", 284, 304], ["a) hyperproliferation of remaining microglia", "PROBLEM", 340, 384], ["microglial precursors", "PROBLEM", 405, 426], ["(c) infiltrating of monocytes", "PROBLEM", 431, 460], ["microglia\u2010like cells", "OBSERVATION", 103, 123], ["neurological disease", "OBSERVATION", 139, 159], ["MICROGLIAL REPOPULATION", "OBSERVATION", 176, 199], ["microglial depletion", "OBSERVATION", 251, 271], ["empty niche", "OBSERVATION", 312, 323], ["remaining microglia", "OBSERVATION", 365, 384], ["monocytes", "OBSERVATION", 451, 460], ["circulation", "ANATOMY", 470, 481]]], ["An interesting aspect of myeloid cell repopulation with peripheral monocytes is that transcriptomic analyses reveal different outcomes in different tissues (Guilliams & Scott, 2017).", [["myeloid cell", "ANATOMY", 25, 37], ["peripheral monocytes", "ANATOMY", 56, 76], ["tissues", "ANATOMY", 148, 155], ["myeloid cell", "CELL", 25, 37], ["peripheral monocytes", "CELL", 56, 76], ["tissues", "TISSUE", 148, 155], ["peripheral monocytes", "CELL_TYPE", 56, 76], ["myeloid cell repopulation", "PROBLEM", 25, 50], ["peripheral monocytes", "PROBLEM", 56, 76], ["transcriptomic analyses", "TEST", 85, 108], ["different outcomes in different tissues", "PROBLEM", 116, 155], ["myeloid cell repopulation", "OBSERVATION", 25, 50], ["peripheral monocytes", "OBSERVATION", 56, 76], ["different", "OBSERVATION_MODIFIER", 116, 125], ["outcomes", "OBSERVATION_MODIFIER", 126, 134], ["different tissues", "OBSERVATION_MODIFIER", 138, 155]]], ["Monocytes can thus replace Kupffer cells in the liver (Scott et al., 2016) and alveolar macrophages in the lung (van de Laar et al., 2016) with almost identical cellular phenotypes, while in the CNS bone marrow monocyte\u2010derived microglia only become microglia\u2010like cells, retaining more than 2,000 differentially expressed genes compared to resident microglia (Cronk et al., 2018).", [["Monocytes", "ANATOMY", 0, 9], ["Kupffer cells", "ANATOMY", 27, 40], ["liver", "ANATOMY", 48, 53], ["alveolar macrophages", "ANATOMY", 79, 99], ["lung", "ANATOMY", 107, 111], ["cellular", "ANATOMY", 161, 169], ["CNS bone marrow monocyte\u2010derived microglia", "ANATOMY", 195, 237], ["microglia\u2010like cells", "ANATOMY", 250, 270], ["microglia", "ANATOMY", 350, 359], ["Monocytes", "CELL", 0, 9], ["Kupffer cells", "CELL", 27, 40], ["liver", "ORGAN", 48, 53], ["alveolar macrophages", "CELL", 79, 99], ["lung", "ORGAN", 107, 111], ["cellular", "CELL", 161, 169], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 199, 210], ["microglia", "CELL", 228, 237], ["microglia\u2010like cells", "CELL", 250, 270], ["microglia", "CELL", 350, 359], ["Monocytes", "CELL_TYPE", 0, 9], ["Kupffer cells", "CELL_TYPE", 27, 40], ["alveolar macrophages", "CELL_TYPE", 79, 99], ["CNS bone marrow monocyte\u2010derived microglia", "CELL_TYPE", 195, 237], ["microglia\u2010like cells", "CELL_TYPE", 250, 270], ["resident microglia", "CELL_TYPE", 341, 359], ["Monocytes", "TEST", 0, 9], ["alveolar macrophages in the lung", "PROBLEM", 79, 111], ["almost identical cellular phenotypes", "PROBLEM", 144, 180], ["microglia\u2010like cells", "PROBLEM", 250, 270], ["Kupffer cells", "OBSERVATION", 27, 40], ["liver", "ANATOMY", 48, 53], ["alveolar", "ANATOMY", 79, 87], ["macrophages", "OBSERVATION", 88, 99], ["lung", "ANATOMY", 107, 111], ["cellular phenotypes", "OBSERVATION", 161, 180], ["CNS", "ANATOMY", 195, 198], ["bone marrow", "ANATOMY", 199, 210], ["microglia\u2010like cells", "OBSERVATION", 250, 270]]], ["It is currently unknown why the CNS should differ in this respect to other tissues, but indicates that environmental cues must be tissue\u2010specific and of varied instructional consequence in different tissues (Bennett et al., 2018).", [["CNS", "ANATOMY", 32, 35], ["tissues", "ANATOMY", 75, 82], ["tissues", "ANATOMY", 199, 206], ["CNS", "ANATOMICAL_SYSTEM", 32, 35], ["tissues", "TISSUE", 75, 82], ["tissues", "TISSUE", 199, 206]]], ["It is also apparent that the repopulation process is tightly regulated, cells only occupying available tissue niches and the repopulation process (through either surviving microglia proliferation or monocyte infiltration) being halted through as yet undetermined mechanisms once the tissue is full.", [["cells", "ANATOMY", 72, 77], ["tissue niches", "ANATOMY", 103, 116], ["microglia", "ANATOMY", 172, 181], ["monocyte", "ANATOMY", 199, 207], ["tissue", "ANATOMY", 283, 289], ["cells", "CELL", 72, 77], ["tissue", "TISSUE", 103, 109], ["microglia", "CELL", 172, 181], ["monocyte", "CELL", 199, 207], ["tissue", "TISSUE", 283, 289], ["microglia", "CELL_TYPE", 172, 181], ["the repopulation process", "PROBLEM", 25, 49], ["the repopulation process", "TREATMENT", 121, 145], ["surviving microglia proliferation", "PROBLEM", 162, 195], ["monocyte infiltration", "PROBLEM", 199, 220], ["repopulation", "OBSERVATION", 29, 41], ["repopulation process", "OBSERVATION", 125, 145], ["microglia proliferation", "OBSERVATION", 172, 195], ["monocyte infiltration", "OBSERVATION", 199, 220], ["full", "OBSERVATION", 293, 297]]], ["In certain studies an \u201covershoot\u201d of repopulating cell numbers appears to be adjusted through selective loss of cells so that a homeostatic numerical occupancy is achieved.", [["cell", "ANATOMY", 50, 54], ["cells", "ANATOMY", 112, 117], ["cell", "CELL", 50, 54], ["cells", "CELL", 112, 117], ["certain studies", "TEST", 3, 18], ["repopulating cell numbers", "TEST", 37, 62], ["selective loss of cells", "PROBLEM", 94, 117], ["a homeostatic numerical occupancy", "PROBLEM", 126, 159], ["repopulating cell", "OBSERVATION", 37, 54], ["numerical occupancy", "OBSERVATION", 140, 159]]], ["The important concept herein is that myeloid cell niches can be both efficiently depleted of resident cells and that repopulating cells can occupy the available niche with partial or total restoration of normal homeostatic functionality.ENFORCED MICROGLIAL REPOPULATION: A NEW PROSPECT FOR FIXING A DYSFUNCTIONAL NICHEMicroglial repopulation can arise from either bone marrow\u2010derived elements or local self\u2010renewal proliferation to replenish the empty niche in the CNS, which can be therapeutically targeted (Varvel et al., 2012; Waisman et al., 2015).", [["myeloid cell niches", "ANATOMY", 37, 56], ["cells", "ANATOMY", 102, 107], ["cells", "ANATOMY", 130, 135], ["bone", "ANATOMY", 364, 368], ["CNS", "ANATOMY", 465, 468], ["myeloid cell", "CELL", 37, 49], ["cells", "CELL", 102, 107], ["cells", "CELL", 130, 135], ["bone", "TISSUE", 364, 368], ["CNS", "ANATOMICAL_SYSTEM", 465, 468], ["resident cells", "CELL_TYPE", 93, 107], ["repopulating cells", "CELL_TYPE", 117, 135], ["bone marrow\u2010derived elements", "DNA", 364, 392], ["myeloid cell niches", "PROBLEM", 37, 56], ["repopulating cells", "PROBLEM", 117, 135], ["A DYSFUNCTIONAL NICHEMicroglial repopulation", "TREATMENT", 297, 341], ["bone marrow\u2010derived elements", "PROBLEM", 364, 392], ["local self\u2010renewal proliferation", "PROBLEM", 396, 428], ["myeloid cell niches", "OBSERVATION", 37, 56], ["repopulating cells", "OBSERVATION", 117, 135], ["normal homeostatic functionality", "OBSERVATION", 204, 236], ["MICROGLIAL REPOPULATION", "OBSERVATION", 246, 269], ["bone", "ANATOMY", 364, 368], ["empty niche", "OBSERVATION", 446, 457], ["CNS", "ANATOMY", 465, 468]]], ["It is also important to note that the therapeutic outcomes of the newly derived microglia can be fundamentally different during these two processes, as evidenced by recent data indicating that bone marrow\u2010derived microglia are functionally distinct from yolk sac\u2010derived microglia (Cronk et al., 2018).", [["microglia", "ANATOMY", 80, 89], ["bone marrow\u2010derived microglia", "ANATOMY", 193, 222], ["yolk sac\u2010derived microglia", "ANATOMY", 254, 280], ["microglia", "CELL", 80, 89], ["bone marrow\u2010derived microglia", "CELL", 193, 222], ["yolk sac\u2010derived microglia", "CELL", 254, 280], ["microglia", "CELL_TYPE", 80, 89], ["bone marrow\u2010derived microglia", "CELL_TYPE", 193, 222], ["yolk sac\u2010derived microglia", "CELL_TYPE", 254, 280], ["the newly derived microglia", "PROBLEM", 62, 89], ["bone marrow\u2010derived microglia", "PROBLEM", 193, 222], ["bone", "ANATOMY", 193, 197], ["marrow\u2010derived microglia", "OBSERVATION", 198, 222]]], ["It follows that there might be specific advantages depending on the disease state.", [["the disease state", "PROBLEM", 64, 81]]], ["For example, if microglia are genetically dysfunctional, then self\u2010proliferation following depletion will not help.", [["microglia", "ANATOMY", 16, 25], ["microglia", "CELL", 16, 25], ["microglia", "CELL_TYPE", 16, 25], ["microglia", "PROBLEM", 16, 25]]], ["If the dysfunction extends to all myeloid cells (e.g. TREM2 in Nasu\u2010Hakola disease, ALS, and X\u2010linked adrenoleukodystrophy) then even repopulation by infiltrating monocytes will also not be beneficial.", [["myeloid cells", "ANATOMY", 34, 47], ["monocytes", "ANATOMY", 163, 172], ["Hakola disease", "DISEASE", 68, 82], ["ALS", "DISEASE", 84, 87], ["adrenoleukodystrophy", "DISEASE", 102, 122], ["myeloid cells", "CELL", 34, 47], ["Hakola", "GENE_OR_GENE_PRODUCT", 68, 74], ["monocytes", "CELL", 163, 172], ["myeloid cells", "CELL_TYPE", 34, 47], ["TREM2", "PROTEIN", 54, 59], ["infiltrating monocytes", "CELL_TYPE", 150, 172], ["the dysfunction", "PROBLEM", 3, 18], ["Hakola disease", "PROBLEM", 68, 82], ["ALS", "PROBLEM", 84, 87], ["X\u2010linked adrenoleukodystrophy", "PROBLEM", 93, 122], ["infiltrating monocytes", "PROBLEM", 150, 172], ["dysfunction", "OBSERVATION", 7, 18], ["myeloid cells", "OBSERVATION", 34, 47], ["infiltrating monocytes", "OBSERVATION", 150, 172]]], ["As monocyte\u2010derived repopulating cells would have a potentially different response to systemic stimuli compared to normal repopulating microglia, this is also an issue to contemplate.", [["monocyte\u2010derived repopulating cells", "ANATOMY", 3, 38], ["microglia", "ANATOMY", 135, 144], ["monocyte\u2010derived repopulating cells", "CELL", 3, 38], ["microglia", "CELL", 135, 144], ["monocyte\u2010derived repopulating cells", "CELL_TYPE", 3, 38], ["normal repopulating microglia", "CELL_TYPE", 115, 144], ["monocyte\u2010derived repopulating cells", "TREATMENT", 3, 38], ["systemic stimuli", "TEST", 86, 102], ["repopulating cells", "OBSERVATION", 20, 38], ["systemic stimuli", "OBSERVATION", 86, 102], ["repopulating microglia", "OBSERVATION", 122, 144]]], ["In contrast, it has been shown that bone marrow\u2010derived cells are much more efficient in clearing amyloid beta deposits compared to their endogenous counterparts (Kawanishi et al., 2018; Simard, Soulet, Gowing, Julien, & Rivest, 2006) and so monocyte repopulation would potentially be more efficient in AD.ENFORCED MICROGLIAL REPOPULATION: A NEW PROSPECT FOR FIXING A DYSFUNCTIONAL NICHEA final scenario is enforced repopulation of pre\u2010defined myeloid cell through adoptive transfer.", [["bone marrow\u2010derived cells", "ANATOMY", 36, 61], ["monocyte", "ANATOMY", 242, 250], ["myeloid cell", "ANATOMY", 444, 456], ["AD", "DISEASE", 303, 305], ["bone marrow\u2010derived cells", "CELL", 36, 61], ["amyloid beta", "GENE_OR_GENE_PRODUCT", 98, 110], ["monocyte", "CELL", 242, 250], ["myeloid cell", "CELL", 444, 456], ["bone marrow\u2010derived cells", "CELL_TYPE", 36, 61], ["amyloid beta", "PROTEIN", 98, 110], ["pre\u2010defined myeloid cell", "CELL_TYPE", 432, 456], ["bone marrow\u2010derived cells", "PROBLEM", 36, 61], ["clearing amyloid beta deposits", "PROBLEM", 89, 119], ["monocyte repopulation", "TREATMENT", 242, 263], ["A DYSFUNCTIONAL NICHEA final scenario", "TREATMENT", 366, 403], ["adoptive transfer", "TREATMENT", 465, 482], ["bone", "ANATOMY", 36, 40], ["marrow\u2010derived cells", "OBSERVATION", 41, 61], ["clearing", "OBSERVATION_MODIFIER", 89, 97], ["amyloid beta deposits", "OBSERVATION", 98, 119], ["MICROGLIAL REPOPULATION", "OBSERVATION", 315, 338], ["myeloid cell", "OBSERVATION", 444, 456]]], ["Natural microglia are excluded from this scenario, but blood\u2010derived monocytes or bone marrow\u2010derived macrophages, either unactivated, pre\u2010activated or genetically modified, have potential, as do stem cell\u2010derived myeloid cells.", [["microglia", "ANATOMY", 8, 17], ["monocytes", "ANATOMY", 69, 78], ["bone marrow\u2010derived macrophages", "ANATOMY", 82, 113], ["stem cell\u2010derived myeloid cells", "ANATOMY", 196, 227], ["microglia", "CELL", 8, 17], ["monocytes", "CELL", 69, 78], ["bone marrow\u2010derived macrophages", "CELL", 82, 113], ["stem", "CELL", 196, 200], ["myeloid cells", "CELL", 214, 227], ["Natural microglia", "CELL_TYPE", 0, 17], ["blood\u2010derived monocytes", "CELL_TYPE", 55, 78], ["bone marrow\u2010derived macrophages", "CELL_TYPE", 82, 113], ["stem cell\u2010derived myeloid cells", "CELL_TYPE", 196, 227], ["Natural microglia", "PROBLEM", 0, 17], ["blood\u2010derived monocytes", "PROBLEM", 55, 78], ["bone marrow\u2010derived macrophages", "PROBLEM", 82, 113], ["microglia", "OBSERVATION", 8, 17], ["bone", "ANATOMY", 82, 86], ["marrow\u2010derived macrophages", "OBSERVATION", 87, 113], ["myeloid cells", "OBSERVATION", 214, 227]]], ["In order to successfully generate a sufficient source of renewable microglia\u2010like cells, several different protocols using cultured human inducible pluripotent stem cells (hiPSCs) have been recently established (Abud et al., 2017; Pocock & Piers, 2018).", [["microglia\u2010like cells", "ANATOMY", 67, 87], ["pluripotent stem cells", "ANATOMY", 148, 170], ["hiPSCs", "ANATOMY", 172, 178], ["microglia\u2010like cells", "CELL", 67, 87], ["human", "ORGANISM", 132, 137], ["inducible pluripotent stem cells", "CELL", 138, 170], ["hiPSCs", "CELL", 172, 178], ["renewable microglia\u2010like cells", "CELL_LINE", 57, 87], ["cultured human inducible pluripotent stem cells", "CELL_LINE", 123, 170], ["hiPSCs", "CELL_LINE", 172, 178], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["renewable microglia\u2010like cells", "TREATMENT", 57, 87], ["several different protocols", "TREATMENT", 89, 116], ["cultured human inducible pluripotent stem cells", "TREATMENT", 123, 170], ["microglia\u2010like cells", "OBSERVATION", 67, 87], ["pluripotent stem cells", "OBSERVATION", 148, 170]]], ["Specifically, hiPSCs are cultured with neuroglia differentiation media by supplement of CSF1 and IL\u201034 to differentiate into Tmem119+/P2RY12+ microglia\u2010like cells that perform phagocytic functions (Muffat et al., 2016).", [["hiPSCs", "ANATOMY", 14, 20], ["neuroglia", "ANATOMY", 39, 48], ["Tmem119+/P2RY12+ microglia\u2010like cells", "ANATOMY", 125, 162], ["hiPSCs", "CELL", 14, 20], ["neuroglia", "CELL", 39, 48], ["CSF1", "GENE_OR_GENE_PRODUCT", 88, 92], ["IL\u201034", "GENE_OR_GENE_PRODUCT", 97, 102], ["Tmem119", "GENE_OR_GENE_PRODUCT", 125, 132], ["P2RY12", "GENE_OR_GENE_PRODUCT", 134, 140], ["hiPSCs", "CELL_TYPE", 14, 20], ["CSF1", "PROTEIN", 88, 92], ["IL\u201034", "PROTEIN", 97, 102], ["Tmem119+/P2RY12+ microglia\u2010like cells", "CELL_LINE", 125, 162], ["CSF1 and IL\u2010", "TEST", 88, 100], ["Tmem119", "TEST", 125, 132], ["microglia\u2010like cells", "PROBLEM", 142, 162], ["phagocytic functions", "TEST", 176, 196]]], ["Another well\u2010characterized method has been used to differentiate human and murine hiPSCs into microglia\u2010like cells through a hematopoietic progenitor\u2010like intermediate stage by adding defined factors and then co\u2010culturing with astrocytes (Pandya et al., 2017).", [["hiPSCs", "ANATOMY", 82, 88], ["microglia\u2010like cells", "ANATOMY", 94, 114], ["hematopoietic progenitor\u2010like", "ANATOMY", 125, 154], ["astrocytes", "ANATOMY", 227, 237], ["human", "ORGANISM", 65, 70], ["murine", "ORGANISM", 75, 81], ["hiPSCs", "CELL", 82, 88], ["microglia\u2010like cells", "CELL", 94, 114], ["astrocytes", "CELL", 227, 237], ["human and murine hiPSCs", "CELL_LINE", 65, 88], ["microglia\u2010like cells", "CELL_TYPE", 94, 114], ["astrocytes", "CELL_TYPE", 227, 237], ["human", "SPECIES", 65, 70], ["murine", "SPECIES", 75, 81], ["human", "SPECIES", 65, 70], ["microglia\u2010like cells", "PROBLEM", 94, 114], ["murine hiPSCs", "OBSERVATION", 75, 88], ["hematopoietic", "ANATOMY", 125, 138]]], ["A recently developed protocol for the derivation of microglia\u2010like cells from human monocytes could be the adoptive cell of most practical and functional relevance (Sellgren et al., 2017).ENFORCED MICROGLIAL REPOPULATION: A NEW PROSPECT FOR FIXING A DYSFUNCTIONAL NICHEConsidering that we have demonstrated the beneficial action of adoptively transferred immunomodulatory macrophages to prevent pathogenesis in settings of both Type 1 Diabetes (Parsa et al., 2012) and EAE (Zhang, Lund, Mia, Parsa, & Harris, 2014) and that other researchers have consequently successfully therapeutically employed our protocol in settings of spinal cord injury (Ma et al., 2015) and in wound healing (Riabov et al., 2017) then conceptually an initial transfer of immunomodulatory macrophages (either stimulated or gene\u2010modified) to halt the neuroinflammatory process could then be followed by transfer of microglia\u2010like cells.", [["microglia\u2010like cells", "ANATOMY", 52, 72], ["monocytes", "ANATOMY", 84, 93], ["cell", "ANATOMY", 116, 120], ["macrophages", "ANATOMY", 372, 383], ["spinal cord", "ANATOMY", 626, 637], ["wound", "ANATOMY", 670, 675], ["macrophages", "ANATOMY", 764, 775], ["microglia\u2010like cells", "ANATOMY", 889, 909], ["Type 1 Diabetes", "DISEASE", 428, 443], ["EAE", "DISEASE", 469, 472], ["cord injury", "DISEASE", 633, 644], ["microglia\u2010like cells", "CELL", 52, 72], ["human", "ORGANISM", 78, 83], ["monocytes", "CELL", 84, 93], ["cell", "CELL", 116, 120], ["macrophages", "CELL", 372, 383], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 626, 637], ["wound", "PATHOLOGICAL_FORMATION", 670, 675], ["macrophages", "CELL", 764, 775], ["microglia\u2010like cells", "CELL", 889, 909], ["microglia\u2010like cells", "CELL_LINE", 52, 72], ["human monocytes", "CELL_TYPE", 78, 93], ["immunomodulatory macrophages", "CELL_TYPE", 355, 383], ["immunomodulatory macrophages", "CELL_TYPE", 747, 775], ["microglia\u2010like cells", "CELL_TYPE", 889, 909], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["microglia\u2010like cells", "PROBLEM", 52, 72], ["human monocytes", "PROBLEM", 78, 93], ["immunomodulatory macrophages", "TREATMENT", 355, 383], ["pathogenesis", "PROBLEM", 395, 407], ["Type 1 Diabetes", "PROBLEM", 428, 443], ["EAE", "PROBLEM", 469, 472], ["our protocol", "TREATMENT", 598, 610], ["spinal cord injury", "PROBLEM", 626, 644], ["wound healing", "PROBLEM", 670, 683], ["immunomodulatory macrophages", "TREATMENT", 747, 775], ["the neuroinflammatory process", "PROBLEM", 821, 850], ["microglia\u2010like cells", "PROBLEM", 889, 909], ["microglia\u2010like cells", "OBSERVATION", 52, 72], ["MICROGLIAL REPOPULATION", "OBSERVATION", 197, 220], ["Diabetes", "OBSERVATION", 435, 443], ["spinal cord", "ANATOMY", 626, 637], ["injury", "OBSERVATION", 638, 644], ["wound", "ANATOMY", 670, 675], ["healing", "OBSERVATION_MODIFIER", 676, 683], ["immunomodulatory macrophages", "OBSERVATION", 747, 775], ["neuroinflammatory", "OBSERVATION", 825, 842]]], ["These approaches may provide a potential novel therapeutic angle for a wide array of neurological disorders and we currently actively explore this potential.ENFORCED MICROGLIAL REPOPULATION: A NEW PROSPECT FOR FIXING A DYSFUNCTIONAL NICHEWe thus propose that an immunotherapy protocol comprising total microglial ablation followed by the immediate enforced repopulation of the available niche through the adoptive transfer of myeloid cells could be considered as a means of replacing dysfunctional microglia in neurodegenerative states such as ALS and AD (Figure 3).CONCLUDING REMARKSEnforced microglia depletion and repopulation with fully differentiated cells, termed microglia\u2010replacement therapy, has great potential as an intervention in many neurological disease states.", [["neurological", "ANATOMY", 85, 97], ["microglial", "ANATOMY", 302, 312], ["niche", "ANATOMY", 387, 392], ["myeloid cells", "ANATOMY", 426, 439], ["microglia", "ANATOMY", 498, 507], ["cells", "ANATOMY", 656, 661], ["neurological", "ANATOMY", 748, 760], ["neurological disorders", "DISEASE", 85, 107], ["neurodegenerative states", "DISEASE", 511, 535], ["ALS", "DISEASE", 544, 547], ["AD", "DISEASE", 552, 554], ["neurological disease", "DISEASE", 748, 768], ["microglial", "CELL", 302, 312], ["myeloid cells", "CELL", 426, 439], ["microglia", "CELL", 498, 507], ["microglia", "CELL", 593, 602], ["cells", "CELL", 656, 661], ["myeloid cells", "CELL_TYPE", 426, 439], ["microglia", "CELL_TYPE", 498, 507], ["differentiated cells", "CELL_TYPE", 641, 661], ["neurological disorders", "PROBLEM", 85, 107], ["an immunotherapy protocol", "TREATMENT", 259, 284], ["total microglial ablation", "TREATMENT", 296, 321], ["myeloid cells", "PROBLEM", 426, 439], ["dysfunctional microglia in neurodegenerative states", "PROBLEM", 484, 535], ["ALS", "PROBLEM", 544, 547], ["REMARKSEnforced microglia depletion", "TREATMENT", 577, 612], ["repopulation", "TREATMENT", 617, 629], ["fully differentiated cells", "PROBLEM", 635, 661], ["termed microglia\u2010replacement therapy", "TREATMENT", 663, 699], ["an intervention", "TREATMENT", 724, 739], ["many neurological disease states", "PROBLEM", 743, 775], ["MICROGLIAL REPOPULATION", "OBSERVATION", 166, 189], ["myeloid cells", "OBSERVATION", 426, 439], ["dysfunctional microglia", "OBSERVATION", 484, 507], ["microglia depletion", "OBSERVATION", 593, 612], ["microglia\u2010replacement therapy", "OBSERVATION", 670, 699], ["neurological disease", "OBSERVATION", 748, 768]]], ["Optimization of timing between depletion and repopulation, long\u2010term effects on CNS homeostasis and long\u2010term therapeutic efficacy in preclinical models will provide a solid rationale for clinical translation.CONFLICT OF INTERESTThe authors declare that there are no conflicts of interest.", [["CNS", "ANATOMY", 80, 83], ["CNS", "ANATOMICAL_SYSTEM", 80, 83], ["timing between depletion", "TREATMENT", 16, 40], ["repopulation", "TREATMENT", 45, 57], ["CNS homeostasis", "TREATMENT", 80, 95], ["a solid rationale", "TREATMENT", 166, 183], ["no", "UNCERTAINTY", 264, 266]]]]}